Substition treatment in European prisons:  a study of policies and practices of substitution treatment in prisons in 18 European countries. by Stover, Heino et al.
 
 
   
SUBSTITUTION TREATMENT IN 
EUROPEAN PRISONS 
A study of policies and practies of substitution in prisons  
in 18 European countries 
Heino Stöver, Laetitia C. Hennebel  
and Joris Casselmann  
 
Cranstoun Drug Services Publishing 2004 
This project was partly funded by the European Commission. Neither 
the European Commission nor any person acting on its behalf is liable 
for the use of information contained in this report. 
   
Copyright © 2004.  
All rights reserved. 
No part of this book may be reproduced or utilized in any form or by any means, electronic or 
mechanical, including photocopying and recording, or by any information storage or retrieval 
system, without permission in writing from the publisher. Quotation is authorised providing the 
source is acknowledged. 
Printed in Germany. 
Publisher: 
The European Network of Drug Services in Prison (ENDSP) 
Cranstoun Drug Services 
4th floor Broadway House 
112-134 The Broadway 
Wimbledon, London, SW19 1RL 
United Kingdom 
Tel: +44-208-5438333 
Fax: +44-208-5434348 
e-mail: info@cranstoun.org.uk 
http://www.cranstoun.org 
Bibliotheks- und Informationssystem der  
Carl von Ossietzy Universität Oldenburg (BIS) – Verlag 
Postfach 2541 
26015 Oldenburg 
Germany 
e-mail: verlag@bis.uni-oldenburg.de 
http://www.bis.uni-oldenburg.de/bisverlag/bisverl.html 
Also appears as volume 11 of the series “Gesundheitsförderung im Justizvollzug” (Health Pro-
motion in Prisons) edited by Jutta Jacob and Heino Stöver. 
Distribution: 
The European Network of Drug Services in Prison (ENDSP) 
Hosted by Cranstoun Drug Services (details above). If you would like to request further copies 
of this report, please contact Vikky Bullock (vbullock@cranstoun.org.uk) at the above address. 
Copies are priced at €25 / £18.  
http://www.endipp.net 
Printed in Germany, May 2004. 
ISBN: 1 902114 09 4 
ISBN 3-8142-0925-7 
Contents 
Executive Summary 5 
Acknowledgements 11 
List of Tables  15 
Introduction 17 
PART I: Review of the situation 19 
A. General Introduction 21 
B. Basic Concepts and Definitions 27 
C. Literature Review 29 
PART II: Methodology 45 
PART III: Findings 63 
A. Country Reports 65 
Austria 65 
Belgium 88 
Czech Republic 105 
Denmark 119 
Finland  137 
France  152 
Germany 178 
Greece  220 
Ireland  228 
Italy  256 
Luxembourg 276 
The Netherlands 285 
Poland  306 
Portugal  326 
Scotland 345 
Slovenia  369 
Spain  383 
Sweden  396 
B. Emerging Issues 409 
C. The need to treat women separately in substitution 
treatment 435 
PART IV: Conclusions & Recommendations 451 
A. Conclusions 453 
B. Recommendations 473 
C. Prevention and treatment of blood-borne-viruses (HIV 
and Hepatitis) within Substitution Treatment in Prisons 481 
References 483 
Appendices 503 
A.  Interview Schedule for Prisoners 505 
B.  Interview Schedule for Professionals 508 
C.  Research Protocol and Ethical Issues 512 
D.  Useful Websites 514 
E. Authors 516 
 
Executive Summary 
Aims 
Compared to services offered in the community, access to substitution treat-
ment in prisons is inadequate in many countries across Europe. This study 
uncovers obstacles to the introduction of substitution treatment and explores 
limitations that prisoners encounter when attempting to access services. The 
objectives of the research were (i) to conduct a literature review on substitu-
tion treatment in prisons, (ii) to elaborate an inventory of substitution policy 
and practice in prisons, (iii) to provide an overview of the national and 
regional developments of health care standards (iv) to raise issues related to 
the interruption or continuation of substitution treatment from the commu-
nity into the prison setting, (v) to initiate an exchange of information 
between medical doctors and health care workers in prisons (vi) to identify 
‘good practice’ in the field of substitution treatment. 
Methodology 
Research was conducted over 18 months, from December 2002 to May 2004. 
This involved: (i) The collection of general data at the national level 
(through literature review, library searches, consultation of ministerial docu-
ments) and (ii) field trips in which interviews were conducted in two prisons 
per country with prison staff, doctors, nurses and focus groups of prisoners. 
As an explorative study, qualitative methods were employed, providing in-
depth insights into individual experiences and sensitive areas. Prisoners’ 
views on service provision constitute a major element of this study. Prison 
visits took place in 33 prisons in 17 countries (15 EU-Member States, as of 
1st May 2004, except Luxembourg, plus Czech Republic, Poland and 
Slovenia) with 184 prisoners (132 men, 52 women) in 33 focus groups. 
Results 
In common with the evolution of substitution treatment in the community, 
the service was first made available in prisons for inmates with HIV/AIDs, 
other infectious diseases and, in the case of women, those who were preg-
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nant. Though these constraints have largely vanished, with substitution treat-
ment now offered to a broad cross-section of prisoners, provision still lags 
behind the standards of substitution treatment in the community. A treatment 
gap persists between those requiring substitution treatment and those receiv-
ing it and, in most of the countries studied, coverage is patchy. Heterogene-
ous and inconsistent regulations and treatment modalities appear throughout 
Europe, sometimes even within one country. Nevertheless, compared to pre-
vious research, this study illustrates that the scope of substitution treatment 
has extended across Europe: it is now only Greece and Sweden who do not 
offer treatment in prisons. 
In most countries, substitution treatment is most likely to be discontinued 
when entering prison. The reasons for this include: (i) a basic drug free ori-
entation in prison, (ii) the perception of methadone (or any other substitution 
drug) as a psychoactive drug that is unsuitable for therapy, (iii) a lack of 
understanding of dependence as a chronic disease, (iv) limited resources and 
expertise. Prisoners also demonstrated resistance due to: (i) a lack of under-
standing of the nature of substitution treatment; prison sentences are often 
viewed as a drug free time with an expectation of withdrawal and subsequent 
relapse upon release, (ii) prisoners want to hide their drug use (one reason 
being that they fear prejudice and disadvantageous treatment if seen as a 
drug user), which is an impossibility if they are receiving treatment. 
Across the board, a consensus surrounding the need to continue substitution 
treatment that had already been started in the community was apparent. 
However, this depended on the time spent in treatment in the community and 
the length of sentence that the prisoner faced. The initiation of substitution 
treatment within prison proved much more problematic. When it occurred, 
treatment arranged immediately upon admission or in the run up to release. 
In some countries, substitution treatment is formally limited to a period of 
between 6 to 12 months. Elsewhere, such restrictions apply informally but 
are not codified in official guidelines or regulations. In other countries, no 
time limits exist and substitution treatment is offered on an individual basis. 
In Spain and Austria, substitution is standard practice. Psychosocial care is 
seen as an integral part of treatment and a vital compliment to medical care. 
However, such support is rarely provided. 
As much variety exists in relation to methods of detoxification, both across 
Europe and within individual countries. Reductions in dosage tend to fluctu-
ate from prison to prison with schemes lasting from between 7 days and four 
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weeks. The use of benzodiazepines is beginning to enter the prison system 
and constitutes an additional problem due to the intensified dependence, 
severe syndromes and difficulties in detoxification involved. 
Research indicated that the average substitute dose varied considerably in 
prisons (from 30 to 70 mg). In contrast to community practice, many be-
lieved that low doses were sufficient on the basis that 100% intake was guar-
anteed and that the amount of other drugs used is significantly lower in 
prison.  
The provision of information concerning substitution treatment, drug-use and 
prison policy was seen to be lacking in many prisons. Frequently, prisoners 
didn’t understand the goals being pursued through substitution treatment, nor 
why specific drugs or treatment methods (exclusion criteria etc.) were 
employed. This raises serious issues about the extent to which prisoners can 
be said to have given informed consent. 
Although it is hard to secure anonymity and confidentiality within the prison 
context, attempts have been made to administer substitution drugs in a way 
that protects prisoners, either by putting all patients together in one wing or 
delivering substitution drugs discreetly with other pharmaceuticals. Excep-
tions were found in which prisoners complained of public identification of 
those on treatment. 
In several countries, specific training for doctors is not required, preventing 
professionals from responding to a fast changing treatment environment and 
making necessary improvements. With most staff learning on the job, addi-
tional training would be welcomed. It was reported that some training pro-
grammes focus on drugs and drug treatment in the community and are not 
targeted towards the prison setting. 
Conclusions 
Prisons systems were found to be slow in responding to epidemics of viral 
infectious diseases (such as HIV and Hepatitis) and injection drug use. Sub-
stitution treatment was seen as a response to the dangers encountered by opi-
ate dependent inmates as it can reduce (i) heroin use, drug injection and nee-
dle sharing, (ii) participation in the prison-based drug trade, (iii) opiate 
related mortality soon after release from prison. It can lead to (iii) increased 
participation in drug treatment following release from prison, (iv) a signifi-
cant reduction in serious drug charges. Offenders participating in substitution 
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treatment displayed lower readmission rates overall. More broadly, the 
prison system benefits through a reduction in withdrawal symptoms upon 
admission, a restricted drug trade and increased productivity among prison-
ers. The existing studies indicate that continuity of care is required to main-
tain any benefits acquired. 
In order to ensure universal levels of care (i) a major expansion of mainte-
nance is needed in many countries to meet the needs of prisoners (ii) sub-
stantial efforts have to be made to improve the quality of services and (iii) 
better links and continuity of care are needed between prisons and the range 
of community based services.  
The research indicates that the goal of achieving a drug free state for all 
patients jeopardises the achievement of other important objectives – HIV/ 
Hepatitis infection, prevention of overdose, relapse after release etc. – which 
should be afforded greater priority as policy objectives. 
Low and high threshold programmes should be considered, emphasising 
harm reduction goals (e.g. prevention of relapse after release, prevention of 
infectious diseases), where high threshold programmes would be equipped 
with additional means and resources (e.g. psycho-social care and support) 
and would require greater commitment and engagement. The specific treat-
ment needs of women must be met according to the complexity and severity 
of the drug use of women admitted to prisons. 
Ongoing contributions from patients are valuable in order to improve the 
quality of health care; most prisoners have had previous, personal experience 
of prison health care and substitution treatment inside prison and in the 
community (either detoxification or maintenance). They are willing and able 
to make substantial and valuable comments on the service delivery.  
In many countries, health care is not monitored adequately; only rough esti-
mates on the scope and quality of substitution treatment are available. In 
almost all countries visited, there was a lack of evaluation in which the needs 
of the patients were taken into consideration as well as the views of the ser-
vice providers. For any improvements to be seen, additional work must be 
done on patients’ needs, service provision and enhanced links with commu-
nity services. 
On a positive note, examples of good practice were found in relation to 
(i) guidelines on clinical management and the treatment of substance use, 
(ii) structures for substitution treatment e.g. regular meetings between social 
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workers, nurses, doctors and psychologists, (iii) networking with community 
substitution treatment services. On the basis of these findings, recommenda-
tions for improvements in the quality of substitution treatment have been 
elaborated. 
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Introduction 
Forty years after the introduction of substitution treatment for opiate depend-
ent persons its implementation is often far from adequate. Especially in pri-
son settings in Europe the availability, the implementation, clinical manage-
ment and the evaluation of substitution treatment for opiate dependent 
persons are often deficient. This is one of the reasons why this study of the 
situation in prisons in 18 European countries is important. As there is a 
wealth of scientific evidence that shows effectiveness of substitution treat-
ment both in the community and in prison, we are focusing on the obstacles 
to introduce this treatment and the limitations of its access for prisoners, so 
that this group can benefit from medical and social improvements adequa-
tely. 
We would like to stress two peculiar aspects of the study right from the start. 
First, although in almost each of the eighteen countries two prisons were 
visited, it is not a comparative study. The inmates and the substitution treat-
ment for opiate dependent persons differ not only from one country to 
another, but also from one region to another, from one prison to another and 
from one prison physician to another. It is therefore not really possible to 
compare the collected data on a country level or any other level. What we 
tried to do is to involve as much as possible different settings (such as male 
and female prisons, youth prisons, prisons in big cities and in small commu-
nities, etc.) in order to be able to describe the very different ways of functio-
ning in relation to substitution treatment for opiate drug users in a prison set-
ting in a reasonable number of European countries. 
Secondly, the most original aspect of the study is the fact that, besides offi-
cial data and interviews of key persons, inmates themselves were intervie-
wed in focus groups. We consider this as an often forgotten sound in the 
concerts of policy, practice and research. 
Our report starts with the objectives of the study, followed by a chapter on 
basic terminology and the applied methodology. Then the results of the study 
are summarised in the literature review, the country reports presented in 
alphabetical order, followed by emerging issues, conclusions and recom-
mendations and ending up with a reference list and some relevant appen-
dices. 
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This study is only a first general overview, a kind of base line study realised 
in a very short time. For all of these reasons it calls for further in-depth 
research in the future. 
May 2004 Heino Stöver, Bremen (Germany)  
Laetitia C. Hennebel, Brussels (Belgium)  
 Joris Casselman, Leuven (Belgium) 
PART I : 
Review oft the Situation 

A. General Introduction 
1 Background information 
There is a consensus among many experts and committees (Gezondheidsraad 
2002, 22) that the greatest possible use can and must be made of detention 
periods to motivate drug users to continue or start to work on their drug use 
and dependence. The central aims of detention are to enable inmates to 
increase their social and individual competence in order to overcome either 
the drug dependence or to develop coping strategies which are harm minimi-
zed either in an individual or social meaning. The prison service can support 
this process by offering (new) opportunities. The provision of health care, 
either a continuity of care or the initiation of treatment, which can be conti-
nued following the individual’s release are central elements in the recovery 
and stabilization process. We know that while many drug users get into con-
tact for the first time with health services while in prison, others try to conti-
nue their treatment started outside. However, it should be recognized that the 
opportunities for treating drug users with the aim of cure and causal therapy 
are very limited in penitentiary settings. The limitations are inherent to the 
nature of detention, the dominance of security aspects, the duration of deten-
tion, the scope and accessibility of treatment facilities, the coercive and con-
trol oriented setting, and the nature of dependence itself.  
So, any opportunities should be fully exploited. In most countries the peni-
tentiary and treatment policies are primarily focussed on abstinence so that 
not all opportunities (e.g. harm reduction and stabilization) are exploited 
adequately.  
Substitution treatment is a treatment which unifies cure and care elements. It 
is a cure for opioid dependence in that it blocks the craving and allows drug 
dependents to lead a normal life with a substitute drug. The treatment is a 
care for those not yet or not at all capable and willing to pursue the goal of 
abstinence, but who try to avoid the damaging effects for themselves and 
their social environment deriving from their drug dependency. Stabilisation 
and improvement of the individual’s health and quality of life is one key 
element in the treatment with substitution treatment within the wider concept 
of risk reduction. 
Substitution treatment is one of the most widespread drug treatments for opi-
ate dependent persons in the EU and Norway. According to the EMCDDA 
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(2003) the substitution treatment has seen a 34% increase in availability. 
Some 400,000 people now receive substitution treatment in the 16 countries. 
Over 60% (around 250,000) of these treatments places are found in Spain, 
France and Italy. 
But still access to substitution treatment for opiate dependent prisoners is 
very limited and it is clear that in many countries prisoners do not have the 
same or even similar health services available as those outside the prison 
system. So, experts are analysing a special need for further development of 
substitution services within the prison system of different countries (Farrell 
et al., 2001, 31; Casselman, Meuwissen, Opdebeeck, 2003) and demanding 
extra efforts to attain this objective of equivalent health care (Buning, 2001, 
216). 
This study “Substitution Treatment In European Prisons” looks at the proce-
dures and problems of substitution treatment in prisons. It acknowledges that 
there is an overall need to bring about consistency in the management of in-
mates who are on substitution treatment when admitted to and released from 
prison in order to strengthen their health, and to ensure that the provision of 
substitution programmes is managed safely, securely and continuously. 
Substitution treatment in prison can only be understood in the broader sense 
of the treatment facilities outside in the community and in the light of regio-
nal and/or national law and regulations. Prison medical services and conse-
quently substitution treatments reflect the legal and professional situation 
outside within their organizational boundaries. Substitution treatment in 
Europe is a very heterogeneous issue. There are many different views of the 
impact and the value of substitution treatment, the way it is integrated in the 
drug treatment services (detoxification and/or maintenance), the way it is 
used as baseline for ongoing treatments. Furthermore, medical care in prison 
is provided by many different agencies and systems and approaches (either 
under the auspices of the Ministry of Health or the Ministry of Justice). Dif-
ferent values and concepts make it difficult to compare the provision of sub-
stitution treatment in Europe. We are far from giving advice or recipes for 
substitution treatment in prisons. But on the other hand, substitution treat-
ment has been well analysed in the research and over a period of time, has 
been well-documented and international bodies have formulated their views 
both of prison-based medical services in general and substitution treatment 
specifically (see the chapter ‘literature review’). 
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2  The principle of ‘equivalence’ in international guidelines and 
recommendations 
While the United Nations has stated that persons “deprived of liberty” have 
all other rights retained, and most countries are signatories to this conven-
tion1, the realities of prison life, and death, are grim. Disease transmission in 
prison, and the impact on the general community provides ample reason to 
consider the public health implications of mass incarceration. A number of 
studies have identified disparities between services inside and outside of pri-
son, in the fields of diabetes (MacFarlane, 1996), mental health (Hargreaves, 
1997) and drug and alcohol treatment. There are a variety of international 
recommendations that include the principle of equivalence as a basic suppo-
sition for the treatment and care of drug using prisoners. This principle 
means that prisoners should have access to the same medical and health care 
services as outside prison, and that the professional standards of care and 
cure provided outside should be applied in prisons. Prisoners and all detained 
persons have the right to the highest attainable standard of physical and 
mental health. They are not sentenced to insufficient medical care, but to a 
loss of freedom. The principle of equivalence serves as a baseline in discus-
sing health care services for drug users in prisons, either for treatment of 
their drug use or for the prevention of drug-related harm, such as infectious 
diseases.  
The Joint United Nations Programme in HIV/AIDS (UNAIDS) clearly sta-
tes: ‘With regard to effective HIV/AIDS prevention and care programmes, 
prisoners have a right to be provided the basic standard of medical care 
available in the community. But in reality, few prisons provide adequate 
HIV/AIDS prevention and care programmes comparable to the outside si-
tuation. Neither prisoners nor prison staff are provided adequate information 
and education concerning how to avoid becoming infected. Nor do prisoners 
have the access to the means of prevention that are available on the outside. 
This would include condoms, bleach for disinfecting needles, and needle 
exchange programmes, which are available in the community.’ 
The European Council also clearly stated for HIV/AIDS policy that all poli-
tical actors regarding AIDS should be in alignment with the guidelines of the 
WHO as well as with the principle of equality along the recommendation 
No. R (93) 6 by the European Council (see Appendix A5): prisoners should 
                                                          
1  Standard Minimum Rules for the Treatment of Prisoners: 
http://www.unhchr.ch/html/menu3/b/h_comp34.htm 
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be offered the same medical treatment and psychological care as other mem-
bers of society.  
Although in some countries the principle of equivalence of care and provi-
sion for the continuity of care is explicitly formulated in official government 
papers (for Ireland, Department of Justice 1994, in: Dillon 2000, Irish Prison 
Service 2000), in practice health care provision equivalent to that available 
in the community is hardly achieved – at least for drug using inmates (for 
Ireland: Dillon 2000; for the UK: Turnbull 2000, 102). O’Brien & Stevens 
(1997) found in their European study on the ‘Implementation of International 
Guidelines on HIV/AIDS in Prisons of the European Union’ that WHO gui-
delines on HIV/AIDS in prisons (1993) are not being uniformly applied in 
prisons in EU member states. “In general, the principal of equivalence bet-
ween HIV services in prison and in the community is not applied. In parti-
cular, many of the WHO recommendations on HIV/AIDS in prisons are not 
implemented”. 
One reason for that, according to Dillon (2000, 38), is that different govern-
ment departments are responsible for the care of drug users in the commu-
nity and for drug users in prison: ‘This situation creates inherent problems 
for the continuity of care of drug users. Despite on-going commitments, the 
principle of equivalence does not prevail within the Irish prison system in its 
care of drug users.’ Furthermore, some HIV-prevention measures are highly 
politically loaded, cannot be introduced due to resistance of staff, or are per-
ceived as inadequate for the prison setting (e.g. needle exchange). 
In the European Union there appears to be gaps in adequate provision of 
treatment, care and prevention as Stevens (1998) and Bollini (1997)2 point 
out. WHO/UNAIDS (1997) confirmed this in a study of 23 prison systems in 
20 European countries, representing 387 000 prisoners. It was pointed out 
that: 
                                                          
2  Bollini 1997 suggests to install demonstration projects to implement the WHO guidelines 
on HIV/AIDS in prison as example: These pilot projects should be supervised and co-ordi-
nated by UNAIDS or WHO (p. 12): ‘The presence of international organisations would 
provide symbolic and scientific authority to the program, and would ensure effective dis-
semination of its results. It is important to stress that harm reduction projects in the parti-
cipating countries should not necessarily be the same, but should respond to the current 
needs of each partner. Each project should implement, and duly evaluate, one aspect of 
WHO Guidelines ....’. 
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− in most prisons, information is provided for prisoners and staff;  
− condoms are distributed in 18 of 23 systems; 
− disinfectants are available in 11 systems and methadone treatment in one 
way or the other in only 9 systems. 
3 Substitution treatment as acknowledged and effectively  
proven therapy  
Substitution treatment in its different forms has established itself as a widely 
accepted harm reduction and treatment measure for opiate dependent indivi-
duals in the community (Council of Europe, 2001). Its effectiveness in terms 
of desirable treatment outcomes can be concluded from a decisive body of 
research (Farrell et al., 2001; see also the chapter ‘Literature Review’).  
If methadone is perceived more as a “psychoactive drug” than as a “thera-
peutic drug” as it is the case in some countries and settings (e.g. prisons), this 
view and perception causes consequences in terms of general acceptance and 
understanding of substitution treatment as a therapy. Viewed as a ‘psychoac-
tive drug’ it can more easily be subordinated under public order policies. 
Taking comparably the acknowledged treatment against diabetes, nobody 
would doubt the usefulness and continuation of proven therapies like giving 
insulin while the concerned are at the admission to prison. As substitution 
treatment varies considerably throughout European prisons, problem areas 
need to be identified, such as 
− Different concepts of substitution treatment,  
− Different medications, 
− Different forms of psycho-social care, etc. 
4 Increase Access to and Availability of treatment for drug users 
The EU Action Plan on Drugs 2000-2004 (CORDROGUE 32 7/6/00) calls 
on Member States to find strategies to increase access to and availability of 
services for drug users who are at risk of severe health damage, drug-related 
infectious diseases and deaths, in order to reduce individual and public 
health risks. One of the priorities of the work plan 2003 of the Programme of 
Community action in the field of public health (2003-2008) (2003/C 62/06, 
Decision No. 1786/2002/EG) is to develop strategies to reduce health ine-
qualities in the Community (2.1.2). Taking prisons as part of the community 
inequalities can clearly be identified. The questions are: 
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− How can more drug users benefit from new treatment options? 
− What are ‘Good Practice’ models that could be identified? 
− Which problems at the interface of community/prison can be solved and 
in which way? 
B. Basic Concepts and Definitions 
Within the context of the activities of the ‘European Network on Drug Ser-
vices in Prisons’ (ENDSP), Cranstoun Drug Services has managed a research 
project on ‘Substitution Treatment in European Prisons’ over a period of 
18 months in 18 countries (the 15 EU Western countries, the Czech Repub-
lic, Slovenia and Poland) starting in December 2002 and finishing in 
May 2004. 
The study results will be presented at the 8th European Conference on Drug 
and HIV/AIDS Services in Prison inJuly 2005 in Budapest, Hungary. 
The researchers were Dr. Heino Stöver (University of Bremen, Germany) 
and Laetitia Hennebel (ENDSP/Cranstoun Drug Services, U.K.). Professor 
Joris Casselman (Catholic University of Leuven, Belgium) acted as scientific 
peer-reviewer. 
The study was carried out with the support of the ENDSP’s national contacts 
(see acknowledgments). 
1 Objectives 
The general objective of the research was to conduct a study of substitution 
treatment in prisons in 18 European countries. 
The research had the following specific objectives: 
− Conduct a literature review on substitution treatment in prisons; 
− Elaborate an inventory of the substitution policy and practice in prisons; 
− Provide an overview of the national and regional developments of health 
care standards with regard to substitution treatment in prisons; 
− Point out issues related to cessation and continuation of substitution treat-
ment prescription from the community into the prison setting; 
− Initialise an exchange of information of medical doctors and health care 
workers in charge of prison health care services; and 
− Identify ‘Good Practice’ of substitution treatment offered in prisons. 
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2 Structure of the report 
The Executive Summary is presented at the very beginning of the report. 
The first PART includes 3 chapters. The first chapter introduces the research 
by stating the rationale behind conducting such a research project, the con-
text of the research, as well as its objectives. The reader will find information 
and feedback all through the report on the different set objectives. The sec-
ond chapter presents the large literature review that was conducted. Basic 
concepts (and definitions) that are used throughout the report, are presented 
in the third chapter. 
The methodology is covered entirely in the second PART. 
PART three presents the findings. Country reports for the 18 countries are 
presented in an alphabetical order in the first chapter, followed by emerging 
issues in the second chapter. This latter presents important issues shared in 
the various visited countries. In a third chapter we are stressing the need to 
treat women separately in substitution treatment. 
Conclusions and recommendations are presented in the fourth PART includ-
ing an outline on prevention and treatment of blood-borne-viruses (HIV and 
Hepatitis) within substitution treatment in prisons. 
Although each country report has a list of references referring to the country 
described, all references, across all the chapters, are presented in alphabetic 
order at the end of the report. 
C. Literature Review 
1 Introduction 
In its different forms, substitution treatment has established itself as a widely 
accepted harm reduction and treatment measure for opiate dependent indi-
viduals in the community (Council of Europe 2001). In terms of desirable 
treatment, its effectiveness in outcomes can be concluded from a decisive 
body of research (Farrell et al. 2001). Most of the scientific research work 
has been done on methadone; newly authorized substitution substances, like 
buprenorphine, have only been studied in the last years.  
A different situation is encountered when looking at substitute prescription 
in penal institutions: Different goals are formulated (e.g. abstinence-orienta-
tion vs. harm reduction); different values and characteristics are connoted to 
substitution drugs (methadone within a hedonistic rather than pharmaceutical 
concept), security aspects have to be acknowledged (supervision of intake to 
avoid selling the substitute), the different doctor-patient relationship has to 
be recognised (namely, the loss of free choice of the doctor) and, finally, 
structural conditions of the prison setting as such have to be looked at (such 
as the impossibility of escaping the prison drug scene). Finally, opposing ar-
guments are to be found among the views of professionals, prison health 
authorities and politicians. In 1996, DeClerck, the Belgian Minister of Jus-
tice, summed up the grounds for a negative position on substitution treatment 
in prisons: 
− “Methadone treatment should have diminished criminal behaviour. The 
fact that the user ended up in prison is proof that his treatment failed; 
− The supply of heroin in prison is limited and irregular, therefore use will 
diminish anyway; 
− Users of other drugs (cocaine, amphetamines) also have to detoxify. To 
offer substitution to one group, but not to another would be unfair; 
− The large numbers of heroin users entering the prison system preclude the 
necessary psychological and social follow-up; 
− In society, methadone is being used as a tool to lower the threshold of 
treatment. In prison, there is no need for such a tool”. 
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In many countries, the issue of substitution treatment in prisons remains 
highly controversial. As it is practiced in only a very limited number of pris-
ons over the world, the amount of research conducted in this area is also of a 
very limited nature.  
Programme. As most of the research has taken place in the United States, it 
is problematic to adapt the results and conclusions to European conditions. 
Even in the case of successful treatment programmes, the positive effects 
seem to disappear over the longer term if they are not succeeded by adequate 
follow-up care. But, methadone maintenance programmes in penal institu-
tions which are intended to prevent addicts from relapsing to the use of ille-
gal drugs and/or consequently to crime are promising (Gezondhedsraad 
2002). 
2 Results of previous literature review 
The existing investigations on substitution treatment in prisons comprise: a 
small number of controlled trials (Dolan et al., 2002); evaluation studies of 
the provision in prisons (Schultze, 2001; McGuigan, 1995; Boguna, 1997; 
Keppler, 1995); feasibility studies and reviews (Dolan and Wodak, 1996; 
Pearson and Lipton, 1999); examinations of the different modes of substitu-
tion treatment found in either individual or in a number of prisons (e.g. de-
toxification, pre-release, short-term and maintenance) (Michel and Maguet, 
2003) studies on the diverse criteria relevant to evaluating the quality of the 
outcomes/the national protocols (Hannifin 1997) or highlighting certain 
aspects of ST (for instance “overdose”, see Tracqui et al. 1998). 
One of the most important reviews of existing literature has been done by 
Kate Dolan and Alex Wodak in their ‘International review of methadone 
provision in prisons’, (1996). Here they reviewed the ‘rationale, current 
international implementation and evidence of the effectiveness of methadone 
provision to inmates’ (p. 85). Our review focuses on data that was generated 
after their review process but, nevertheless, it is worth presenting some of 
their key findings in brief: 
− Significant reductions in sharing injection equipment have been docu-
mented for among a group of incarcerated intravenous drug users in Spain 
who, along with a control group, participated in a prison based methadone 
programme (Marco, 1995).  
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− In an array of studies, correctional staff perceived prison methadone main-
tenance treatment (PMMT) to have reduced anxiety amongst prisoners, 
causing inmates in PMMT to be less irritable, anxious and easier to 
manage (Gorta, 1992; Herzog, 1993; Magura et al., 1993).  
− Participants of a drug reduction scheme in Scotland, involving prescrip-
tion of opiates, including methadone, who were accommodated in a sepa-
rate unit were seen to have used fewer drugs than a control group 
(Shewan et al., 1994). However, since only two thirds received methadone 
it is not possible to single out its specific impact. 
− No conflicts between treated and untreated were reported by Herzog 
explicitly (1993).  
− Inmates in PMMT in New South Wales reported decreases in drug use, 
drug-related prison violence, crime following release (Bertram & Gorta, 
1990a) and considered PMMT to be more effective at preventing HIV in 
prison than in the community (Bertram & Gorta, 1990b).  
− Methadone based detoxification of heroin dependent prison entrants in 
Switzerland was found to reduce tension and facilitate custodial manage-
ment (Herzog, 1993).  
− In several studies (Bertram, 1991; Gorta, 1987; Wale & Gorta, 1987), 
negative side-effects of PMMT often feared by prison staff, such as stand-
over tactics or a black market for methadone, were reported not have 
occurred.  
− Herzog (1993) found that 7% of urine samples of PMMT receiving 
inmates in Switzerland tested positive for heroin and 20% for benzodi-
azepines. Bertram (1991) reported positive urine samples from inmates in 
New South Wales to be more likely to contain benzodiazepines than mor-
phine whilst Gorta (1992) found the majority of samples (90%) to be clear 
of non-prescribed drugs.  
− Sometimes correctional staff were found to feel ambivalent or negative 
towards PMMT (Magura et al., 1993). Sometimes this was also the case 
for inmates (Rosenblum et al., 1991). In New South Wales, prison staff 
frequently lacked an understanding of the aims and objectives of PMMT 
(Hume & Gorta, 1988). 
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3 Most recent review 
Taking the review from Dolan & Wodak (1996) as a basis to 1995, an exten-
sive literature review has been carried out of studies appearing between 1995 
and 2003. These studies, on the effects of the divergent practices of substi-
tute prescribing in penal institutions, also reflect the development of ST in 
prisons since the mid-nineties:  
− ST has become more widespread in many countries,  
− Prison policy and administration are looking for standards and protocols 
and are reviewing the progress 
− Access and treatment modalities have changed substantially,  
− Additional substitution drugs are prescribed (buprenorphine etc.). 
We have accessed an array of sources, such as libraries, internet, experts and 
data bases. In the following, the core findings of the revised studies will be 
structured and presented according to the criteria described below whilst 
considering the scientific integrity, validity and impact on practical discus-
sions.  
4 Literature review of substitution treatment in prison 
In the following, the existing literature on substitution treatment in prisons is 
examined and divided according to the following criteria:  
A) Patterns of drug use and related risk behaviours (e.g. needle sharing) 
B) Social status related issues (e.g. housing, education/qualification and 
employment) and treatment outcome and development on and after 
release  
C) Inmates’ subjective perspectives and experiences towards prison based 
substitution treatment (e.g. prisoners’ perception of treatment) 
D) Issues associated with control of inmates (e.g. management of opiate 
dependent inmates) 
E) Pharmacological Studies 
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A) Patterns of drug use and related risk behaviours  
(e.g. needle sharing) 
1) On the basis of retrospective reports, Dolan et al. (1998) investigated 
whether methadone maintenance treatment (MMT) reduces injecting risk 
behaviour and, consequently, the transmission of blood-borne viral infec-
tions among inmates in prisons in New South Wales (Australia). For this 
purpose, in 1993, structured interviews were carried out with 185 injecting 
drug users who had been imprisoned in New South Wales within the last two 
years and had recently been released. Participants were recruited at different 
drugs treatment agencies and services dealing with injecting drug users. 
According to the type of drug treatment received while in prison, respon-
dents, who shared corresponding demographic variables, were allocated to 
group I-III as follows: 105 to the ‘standard care group’ (I: Drug and alcohol 
counselling), 32 to the ‘time-limited methadone group’ (II: Prescription of 
methadone on a restricted level regarding dose and duration) and 48 to the 
‘methadone-maintained group’ (III: Prescription of doses of methadone over 
60 mg for the whole duration of imprisonment). The results revealed that, 
significantly, members of group III were least likely to report injecting her-
oin, sharing syringes and scored lowest on the HIV Risk-taking scale whilst 
imprisoned. Even though, non-significantly, they were also least likely to 
have injected any drug in prison. The present study is the first to provide 
evidence that MMT can reduce injecting risk behaviour in penal institutions. 
However, Dolan et al. stress the crucial point that, for MMT to be effective, 
a moderately high dose of methadone, prescribed for the entire period of im-
prisonment, is decisive. Consequently, and with regard to the known impact 
of adequate MMT on HIV incidence and prevalence rates among injecting 
drug users in the community (Ward et al., 1992), the authors draw the con-
clusion that the risk of the transmission of HIV and other blood-borne 
viruses amongst prisoners might also be attenuated. Along these lines, the 
authors strongly emphasise the fundamental role of prison MMT Pro-
grammes, particularly when considering the extreme lack of other harm 
reduction measures across penal institutions, such as syringe exchange pro-
grammes. Concerning the limitations of their study – differing doses of 
methadone prescribed in group III, retrospective reports, no randomised allo-
cation of participants to the three groups and lack of equal group sizes – 
Dolan et al. (1998) recommend future research into the form of prospective, 
randomised studies with objective outcome measures, to optimally evaluate 
the effectiveness of MMT in prison. 
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2) According to the recommendations (discussed above), Dolan et al. (2002) 
measured the impact of prison based methadone maintenance treatment on 
prevalence and frequency of heroin injecting, incidence of HIV and hepatitis 
C and the shared use of injecting equipment. They conducted a two-group, 
pre-post randomised controlled trial with 382 inmates in a New South Wales 
prison in Australia. Both groups, the MMT and the control group, consisted 
of 191 inmates. The results of this study demonstrated that MMT provision 
in a prison healthcare setting was effective in reducing heroin use, drug 
injection and syringe sharing among incarcerated heroin users. There were 
equal numbers of hepatitis C Virus (HCV) seroconversions (four subjects in 
both groups seroconverted to HCV; no one seroconverted to HIV). The au-
thors recommend that PMMT should be made available to all prisoners with 
heroin use problems throughout their period of imprisonment. These results 
are consistent with the methadone literature on prison-based substitution 
treatment in other countries (Johnson et al. 2001). 
3) With the aim of comparing the prevalence of drug use and injection risk-
taking amongst incarcerated and community methadone maintenance pa-
tients in New South Wales, Australia, Darke et al. (1998) conducted struc-
tured interviews with 100 prison inmates and 183 community methadone 
maintenance patients. Inmates were recruited in two urban and three rural 
prisons and had to be enrolled in a prison MMT programme for at least six 
months. The comparison group was recruited in the community and also had 
to have taken part in a community methadone maintenance programme for 
six months or longer. Drug use and injection behaviours were examined with 
regard to the 6 months preceding the interview. According to the results, 
community participants were significantly more likely than their prison 
counterparts to have injected a drug (84 vs. 44%), to have used heroin (72 vs. 
38%) and to have done so more regularly (20 vs. 4.5 days median). Even 
though the frequency of heroin use and drug injecting amongst the prison 
group was decisively lower, incarcerated patients were significantly more 
likely to have engaged in highly risky injecting behaviour, e.g. to have bor-
rowed (32 vs. 15%) and lent (35 vs. 21%) injecting equipment. The differ-
ences in drug use patterns between the two groups were explained in terms 
of the widespread access of community drug users, not only to drugs but also 
to sterile injecting equipment, and the scarcity of both in prisons. The au-
thors emphasise that they had not intended to evaluate the effectiveness of 
prison methadone maintenance prescription (regarding the reduction of 
injecting and injecting risk behaviours), which had been done elsewhere  
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(e.g. Dolan et al., 1996), but to demonstrate the impact of the setting, i.e. the 
peculiarities of the prison environment compared to the community environ-
ment. They point out that, in prison, and even more so in the community, 
methadone substitution can be expected to solve the problem of drug use and 
injecting risk behaviour but could certainly attenuate both. They highlight 
the need for a harm reduction combination, i.e. methadone maintenance and 
injecting equipment exchange, to be available in prisons. The advantages of 
this study were that it dealt with participants who were still incarcerated 
rather than using retrospective reports and that it included control group 
interviews. 
4) On the basis of the conviction, that methadone maintenance treatment 
represents an adequate treatment option – especially for individuals with 
certain physical and psychological indications – and that MMT started in the 
community should not be interrupted at the point of incarceration, the Cata-
lan (Spain) Ministries of Health and Justice initiated a pilot programme of 
methadone maintenance prescription in a male prison in Barcelona. The 
intention was to evaluate the efficacy of programmes of this sort; their ability 
to prevent MMT interruption, the transmission of infectious diseases and the 
reduction of opiate use. The findings were presented in a report by Mourino 
(1994), Generalitat de Catalunya (Ministry of Justice): 123 incarcerated opi-
ate users participated in a 5month methadone maintenance programme in the 
Barcelonan prison. Included were: Opiate users already in MMT prior to 
incarceration (the majority of participants); users who, due to psychotic con-
ditions, were not able to withdraw and those with infections, such as HIV 
and AIDS. All participants were male, most of Spanish and some of other 
Caucasian origin, on average 30 years old and all opiate users since the age 
of 17. The average prison methadone dose was 58 mg. Over the course of the 
programme, the incidence of sharing syringes, as well as injecting in general, 
reduced significantly. However, it is crucial to emphasise that this trend was 
only marked when the entire treatment duration exceeded six months. 
15 participants had concomitant use of drugs, mostly of heroin. Concomitant 
opiate use was significantly more frequent among individuals who were pre-
scribed less than 50mg than those who received more than 50mg, pointing to 
the importance of a sufficiently high dosage. Both inferences, the necessity 
of a sufficiently high dose of methadone and an adequate length of treatment, 
have also been emphasised by Dolan et al. (1998). The programme was 
completed by 60 participants. No one finished prematurely voluntarily; only 
ue to release, transferral or death. According to the author, the high retention 
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rate offers the possibility of getting inmates in touch with general medical 
services. Moreover, he points to the value of therapeutic outcome studies in 
the context of ‘daily treatment’ rather than under ‘controlled laboratory con-
ditions’. Still, Mourino criticises the limited duration of the programme, as 
reducing the possibility of generalising the findings, as opposed to pro-
grammes which are not time limited (e.g. Magura et al., 1993; KEEP on 
Rikers Island, New York/United States of America, see B2). Finally, regard-
ing the social and health related aspects of the findings, he argues for substi-
tution treatment to be accompanied by psychosocial care. 
5) With the purpose of evaluating the efficacy of prison based MMT, and 
ultimately to inform policymakers, the Addiction Research Centre, a re-
search branch of the Correctional Service Canada, compared the release out-
come of offenders who participated in a prison based MMT programme with 
the outcome of inmates who did not. (Lists of offenders receiving MMT 
were obtained by relevant health care representatives in different Canadian 
prisons). The experimental group was comprised of 303 inmates who were 
included on the basis of having received prison based MMT between 1996 
and 1999. The 215 controls were matched in most key characteristics but 
were slightly older and had a slightly lower criminal history risk. The inclu-
sion criterion was being a known heroin user, which was measured using 
urine analysis and through a questionnaire that offenders had to complete 
upon admission to prison. In order to be in the position to carry out a follow-
up, only people who were released were included. Release outcome meas-
ures were: Time spent in the community before readmission to jail and 
institutional misconduct before and after MMT initiation, at a rate per month 
for the experimental group, and before and after the positive urine analysis 
for the control group, also at a rate per month. The analysis of the results 
revealed a significant reduction in ‘serious drugs charges’ when comparing 
‘before and after MMT initiation’. Even though it was found that MMT par-
ticipants were readmitted at a lower, more gradual rate, than the controls, this 
difference was not statistically significant. The authors recommend addi-
tional research to address issues such as continuation of treatment in the 
community and other community safety benefits. 
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B)  Social status related issues (e.g. housing, education/qualification  
and employment) and treatment outcome, development on and  
after release 
1) Johnson et al. (2001; see also D1 below) analysed the effects of institu-
tional methadone maintenance treatment on release outcome and institutional 
behaviour, especially regarding drug offences, in Canadian prisons. The 
study compares PMMT participants to a group of incarcerated heroin users. 
Amongst other things the readmission rates of the two groups were exam-
ined. Offenders participating in PMMT had lower readmission rates and 
were readmitted at a slower rate than the Non-MMT group. Within a 
12 month period, the Non-MMT group was 28% more likely than the MMT 
group to be returned to custody. “In terms of institutional behaviour, the 
MMT group had a reduced rate of serious drug related institutional charges 
following initiation of the MMT. This likely indicates a decrease in drug 
seeking and drug taking behaviour among MMT offenders in comparison to 
Non-MMT offenders after MMT initiation” [*Reference needed?]. This 
study clearly indicates that participation in an institutional MMT programme 
had a beneficial effect on outcome after release. 
2) To evaluate the effectiveness of KEEP, an MMT programme for inmates 
at Rikers Island prison in New York, Magura et al. (1993) used a longitudi-
nal follow-up design. They compared post-release outcomes of KEEP par-
ticipants and inmates, who had detoxified from heroin at Rikers. Effective-
ness was defined in terms of whether the programme led heroin dependent 
offenders into long-term community drug treatment, thus breaking the cycle 
of illicit drug use and criminal recidivism. Similar to the Catalan programme 
(Mourino, 1994, A4) described above, KEEP represents an opportunity to 
prevent the disruption of methadone substitution treatment initiated prior to 
incarceration. The inclusion criteria for KEEP were to be medically diag-
nosed as a narcotics addict and to be serving a sentence not longer than a 
year. The experimental group consisted of 308 randomly sampled, predomi-
nantly black and Hispanic heroin users, who had not already received MMT 
in the community. They were maintained on a daily methadone dose of 
30 mg. Most participants, of whom a significant majority was male, were 
daily heroin and/or cocaine injectors. The 138 systematically sampled con-
trols matched the study group in most characteristics and differences were 
statistically adjusted. Of the total participants, 250 were re-interviewed at a 
median of 6.5 months after release from prison. The dependent variables 
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were represented by “show” and retention rates at community drug treatment 
programmes after release. 85% of KEEP participants, versus 37% of con-
trols, had applied for some sort of drug treatment after release, both primar-
ily for MMT. At the time of the follow-up interviews, 27% and 9% respec-
tively were still enrolled, again, mainly in MMT programmes. Both group 
differences were significant. Consequently, the authors concluded that KEEP 
has been proven to have a modestly beneficial impact on routing untreated, 
criminally involved heroin dependent individuals into community drug 
treatment. However, administrative and organisational as well as individual 
obstacles should also be considered as barriers to treatment. Regarding 
relapse into drug use and crime after discharge from prison no group differ-
ences were found – 88% of KEEP and 85% of control participants returned 
to heroin and/or cocaine use. Consequently, the authors point out, the fre-
quently concurrent crack and cocaine use of many diagnosed opiate addicts 
is not addressed sufficiently with MMT and thus reduces success outcome 
rates. As before, one obstacle to success may be the comparatively low 
methadone dose (see, for example, Mourino, 1994, B3; Dolan et al., 1998, 
A1; Bellin et al., 1999). Moreover, in order not to relapse into crime, people 
need both alternative financial sources to survive on and appropriate ac-
commodation options. Overall, the authors suggest considering long-term 
drug treatment, instead of incarceration for drug dependent offenders, for at 
least the duration of the respective prison sentences. 
3) Bellin et al. (1999) identified inmates accepting high dose (median dose of 
70 mg; 1,423 inmates) and low dose methadone therapy (median dose of 
30 mg; 1.371 inmates) between 1996 and 1997 in New York’s Correctional 
system. In order to assess the impact of dosage on the criminal recidivism 
rate, the duration between release to the community and re-incarceration was 
measured. They found that individuals discharged on high dose methadone 
were less likely to return to jail than those on low dose, with a median re-
incarceration time of 253 and 187 days respectively. While a fixed higher 
dose demonstrably reduced recidivism, the authors recommend routine 
methadone plasma level monitoring to adjust doses to achieve “blocking 
dose plasma levels” both in the community and in prison. 
4) Sibbald (2002) evaluated the effects of expanding methadone maintenance 
inside federal Canadian prisons. The Canadian prison policy regarding 
methadone prescription developed from 1998, when all those prisoners 
receiving methadone in the community were permitted to continue the treat-
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ment, to 1999, when under certain circumstances severely addicted prisoners 
were prescribed methadone, to 2000 when MMT was offered to any prisoner 
with an opiate addiction. It was found that, after a year, 41% of inmates who 
were receiving MMT were readmitted to prison, compared with 58% of 
addicted inmates who were not on the programme. 
5) In France, this result was confirmed by Levasseur et al. (2002), who 
showed that re-incarceration is less likely among inmates who receive main-
tenance treatment while incarcerated. Inmates who received maintenance 
treatment while incarcerated had less than half the likelihood of re-incarcera-
tion than those who only detoxify (19% vs. 39%). 
6) Crowley (1999) analysed the drug detoxification unit at Mountjoy Prison 
in Dublin/Ireland. Detoxification consists of a 10-day methadone detoxifica-
tion programme and a 6-week intensive rehabilitation module. Approxi-
mately 67% participants were drug free in the training unit and, in addition, 
an estimated further 35% remained drug free in the community or in another 
prison. In a follow up, after 12 months, the relapse rate was 78% compared 
to approximately 90% in other in-patient detoxification programmes. The 
author reports a high death rate after release (3 out of 4 deaths after release 
have been drug related). Crowley suggests that it is likely that many on the 
detoxification programme would have been treated more appropriately under 
a maintenance programme. The survey showed that 87 out of 479 committals 
were receiving methadone maintenance in the community, with treatment 
stopped on admission. 
C)  Subjective experiences of inmates participating  
in a substitution programme 
1) In his qualitative retrospective investigation Hughes (2000) explored drug 
injectors’ views and experiences of substitute prescribing inside English pri-
sons. Besides 17 in-depth interviews small group discussions with a further 
7 participants were conducted. Of the total 24 participants, 6 were female 
and 18 male with a mean age of 27 and 23 years respectively. Respondents 
were recruited in two North Eastern English cities with the aid of drugs 
agencies and snowballing. Participants had previously injected drugs – 
mainly heroin – for between nine months and 19 years and had spent time in 
custody on between one and 18 occasions. As a key finding, Hughes identi-
fied the heterogeneity of experiences that participants reported regarding 
substitute prescribing in prison; highlighting the inconsistencies in prescrib-
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ing practices. The inconsistencies ranged from no treatment, over the pre-
scription of painkillers and sedatives, to the prescription of methadone and 
lofexidine and were understood to depend on prison specific practices rather 
than on injectors’ self-identified treatment needs. Even though many partici-
pants regarded receiving no treatment as problematic, especially regarding 
withdrawal effects, advantages were also mentioned such as much shorter 
withdrawals and not having to withdraw from methadone subsequently. The 
sole prescription of psychotropic drugs was commonly perceived as being 
inadequate in managing withdrawals. Short courses of methadone detoxifi-
cation were frequently experienced as too short, with doses reducing too 
quickly. More adequate prescribing practices were reported when respon-
dents had been detoxified with lofexidine. None of the interviewed drug 
users had had experiences with methadone maintenance in prison. According 
to participants, the frequently experienced disruption of methadone mainte-
nance treatment, initiated in the community, not only resulted in physical and 
psychological problems and risks but also in increases in intravenous drug 
use, sharing of injecting equipment and, subsequently, in the spread of in-
fectious diseases. In the concluding discussion, the author emphasises the 
crucial contribution of qualitative research. Hughes points to the views and 
experiences of those affected as representing useful and reliable accounts 
(Neale, 1998), offering a rich source of data from which policies and prac-
tices can be examined. Furthermore, he regards respondents’ statements 
regarding inadequacies in substitute prescribing treatment in prisons as evi-
dence for both the self-identified needs of imprisoned drug users’ and 
‘Health Care Standards’ (HM Prison Service, 1996; Reed and Lyne, 1997) 
often not being met. Restrictive prescription, leading to an increase in infec-
tion-related risk behaviours, has also been reported in quantitative studies 
(e.g. Shewan et al., 1994). Finally, he highlights the fact that the views of 
some drug injectors concur with national (HM Inspectorate of Prisons for 
England and Wales, 1996) and British Medical Association, 1997) and inter-
national (World Health Organization, 1993 and Council of Europe, 1995) 
recommendations that promote consistent health care policies and practices 
including methadone maintenance treatment inside and outside prison. 
2) In a study of drug use and treatment in prison after release, BMRB Inter-
national (2001), 227 men were interviewed who had recently been released 
in England and Wales. 22% were placed on a substitution detoxification pro-
gramme during their last sentence (approximately 2/3 said that the detoxifi-
cation programme they have been in lasted 1-2 weeks). The views of the 
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prisoners indicate that the detoxification programmes could be improved in 
so far as “it could last longer” (most frequently mentioned suggestion by 
36%) and “should give sleeping tablets” (21%). 18% rated their programme 
participation as ‘very beneficial’. 39% as ‘fairly beneficial’, 24% as ‘not 
very beneficial’ and 18% as ‘not at all beneficial’. 
D)  Control related issues 
1) As already described in B1, Johnson et al. (2001) investigated the impact 
of prison-based methadone maintenance treatment on release outcome and 
institutional behaviour, especially regarding drug offences, in Canadian pris-
ons. PMMT participants were compared to a group of incarcerated heroin 
users. As well as outcome results, the institutional behaviour of the two 
groups has been studied, i.e. whether MMT while incarcerated resulted in 
any desirable effects. Offenders involved in PMMT showed a decrease in 
drug charges over time, while offenders in the comparison group showed an 
increase. With regard to segregation periods, the MMT group spent less time 
in involuntary segregation than the Non-MMT group, both before and after 
the initiation of MMT. The authors conclude, cautiously, that methadone 
serves to calm disruptive institutional behaviour (p. 30). “More importantly, 
it was demonstrated that there was a decrease for MMT offenders, relative to 
Non-MMT offenders, in behaviours related to activity in the drug subcul-
ture.”  
Johnson et al. (2001) looked at the impact of PMMT on institutional behav-
iour explicitly, i.e. inmates’ behaviour while incarcerated. However, some 
studies, which focused on other variables associated with prison-based 
methadone maintenance treatment or on institutional behaviour, also found a 
desirable impact of PMMT on the “management of inmates” as outlined 
below.  
This favourable impact was also reported by Mourino (1994), in the study 
described above (see A4), of a 5 month, PMMT programme in a Barcelona 
prison. Contrary to expectations, the programme did not cause any pressure 
within the prison social structure nor did non-dependent inmates demand 
access. Quite the reverse was the case; prison officers reported a reduced rate 
of conflicts amongst participating inmates. 
Similar results were found by Magura et al (1993) in their evaluation of 
KEEP, a MMT programme for inmates at Riker’s island prison in New York 
(see B2). Neither the diversionary effects of methadone, violence and secu-
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rity breaches, which the prison personnel anticipated as negative side effects 
of KEEP, took place. Quite the opposite was reported, prison staff even per-
ceived KEEP participants to be easier to handle than non-participants. 
Kaufmann et al. (1998) evaluated the project KOST, which is concerned 
with the prescription of heroin rather than methadone, in a Swiss prison. 
However, it is still worth mentioning that, throughout the study, neither 
medical and social complications nor security related problems, such as vio-
lence or stealing of heroin, were registered. 
E)  Pharmacological Studies 
1) With the aim of comparing the effectiveness and suitability of methadone 
with lofexidine in prison based opiate detoxification treatment, Howells et al. 
(2002) conducted the first, and to date, only randomised double blind con-
trolled trial in this area. In the UK, many of the 30,000 detoxifications from 
opiate dependence per year are methadone assisted. However, the disadvan-
tages of methadone are the potentially fatal outcome of overdoses, which 
have occurred a few times in prison settings (Cairns et al., 1996; Dyer, 1999) 
and some prisoners’ dislike of it as a detoxification medication (e.g. Hughes, 
2000; Dolan & Wodak, 1996). According to the authors, Lofexidine – an 
alpha2-adrenergic agonist – as opposed to methadone – an opiate derivative 
– is less dangerous and causes fewer side effects (Washton et al., 1983 and 
Cairns et al. (1996). The study was carried out in accordance with GCP 
(Good Clinical Practice) and ethical standards. The investigated variables 
were the relative efficacy, side effect profiles and participant acceptability. 
68 inmates, recently admitted to a southern English prison for male remand 
and short-term prisoners, who met the DSM-IV criteria for opiate depend-
ence and induced withdrawal and were younger than 55 years old, were ran-
domised to receive either methadone or lofexidine for 10 days. 36 patients 
were allocated to the methadone group and 32 received lofexidine. Recent 
typical daily drug use corresponded between the two groups. Regarding the 
outcome measures, neither withdrawal severity in the beginning and over the 
course of the trial nor the number of treatment completers resulted in signifi-
cant group differences. Nonetheless, it is worth mentioning that 87.5% ver-
sus 70% completed the methadone and the lofexidine detoxification respec-
tively. Moreover, more lofexidine than methadone patients showed a 
hypotensive side effect: Whereas 12.7% of the lofexidine group showed a 
sitting systolic blood pressure below 90mmHg this applied to only 8% of the 
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methadone group. The authors recommend future research into the optimal 
treatment duration for both medications in terms of highest retention rates. In 
this context, the reasons for the longer retention rates within the methadone 
group should also be examined. While the authors view lofexidine as a suit-
able alternative detoxification medication, the subjective preferences and 
self-perceived needs of dependent opiate users detoxifying from drugs in a 
prison setting are crucial in this context (e.g. Hughes, 2000 described below). 
F)  Organisation of care in substitution treatment 
Michel/Maguet (2003) looked at substitution treatment modalities in French 
prisons. Their starting point was the observation that care practices vary con-
siderable from one institution to the other and that both patients and teams of 
healthcare professionals have frequently expressed their dissatisfaction with 
the way substitution treatment is organised. Alongside their literature review, 
they assessed practices of health care with regard to substitution treatment in 
22 institutions (that were representative, at a national level, in terms of size, 
type and geographical distribution). Furthermore, they interviewed prison 
staff in 3 penal institutions (10 people in each, from prison governor to 
prison guard) and prisoners in 7 prisons. 
They found a varying practice in substitution treatment; commenting that 
each prison has a different scheme and that the organisational choices that 
have been made are due largely to the capabilities of the healthcare teams 
and material circumstances rather than the needs of the prisoners. They also 
discovered misunderstandings of substitution treatment, which were often 
being linked to detoxification treatments. 
With regard to access to care, or day-to-day organisation of treatment provi-
sion, the prisoners reported perceiving substitution treatment as arbitrary. In 
addition, they express their dissatisfaction with the lack of confidentiality. 
Finally, the authors elaborated recommendations for the improvement of 
treatment programmes and modalities.  
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5 Conclusions 
Regarding the variety of substitution drugs appropriate for the treatment of 
opiate dependent individuals, research is carried out on the type of drug 
(either methadone, lofexidine and buprenorphine) most suitable to the differ-
ent needs of the patients. At this moment, it can only be concluded that more 
research is needed into the advantages and disadvantages of different medi-
cations with regard to dosage, treatment duration and retention rate of 
patients.  
Studies focussing on drug use and related risk behaviours (e.g. needle shar-
ing) showed that methadone maintenance treatment (MMT) can reduce 
injecting risk behaviour in penal institutions. One crucial point is that, for 
MMT to be effective, a moderately high dose of methadone must be pre-
scribed and the prescription must last for the entire period of imprisonment. 
Moreover, MMT provision was shown to be effective in reducing heroin use, 
drug injection and syringe sharing. A sufficiently high dosage (more than 
50 mg) also seems to be important for an increase in the retention rate, which 
then can be used for additional health care services. The initiation of MMT 
also contributes to a significant reduction in serious drug charges and in 
behaviour related to activities in the drug subculture. Offenders participating 
in MMT had lower readmission rates and were readmitted at a slower rate 
than Non-MMT patients. There is evidence that continued MMT in prison 
has a beneficial impact on transferring prisoners into drug treatment after 
release. 
Research into the subjective experiences of inmates participating in substitu-
tion programmes reveals the heterogeneity of prescription practices in pris-
ons. In particular, short courses of methadone detoxifications were fre-
quently experienced as insufficient and inadequate. Most striking was the 
inconsistency in methadone maintenance prescription inside prison com-
pared to the community. Notably, the disruption of treatment when entering 
the institution often leads to physical and psychological problems and 
increases the risk of intravenous drug use and sharing of injection equip-
ment. Finally, more research is needed into prescription practices in Euro-
pean prisons. 
PART II: 
Methodology

General 
This chapter presents the methodology that was used to collect information 
on substitution treatment across prisons in 18 different countries. It is in-
tended to be as clear and concise as possible so that other researchers can 
replicate the same research with the same methodology. 
This chapter contains the following: 
1. The identification, role and importance of national contacts; 
2. The procedure adopted to conduct the literature review; 
3. The methodology used for collection of national data; 
4. The process of conducting the qualitative study (via field visits); 
5. Analysis and report writing 
6. Ethical issues; 
7. The role of the Scientific Committees. 
The research project was conducted over a period of 18 months, from 
December 2002 to May 2004. The study was divided into 3 parts, each last-
ing approximately 6 months: the first part focused on the identification of the 
national contacts, preparation of the methodology and undertaking of the lit-
erature review; the second focused on the field visits and the third focused on 
data analysis and report writing. 
Please note that all information in this report is presented in alphabetic order 
by country. 
1 National Contacts 
The first step of the project was the identification of national contacts. Since 
mid 1990s, Cranstoun Drug Services has been managing the European Net-
work of Drug Services in Prison (ENDSP)1. Within that context, key indi-
                                                          
1  Cranstoun Drug Services has managed the European Network of Drug Services in Prisons 
(ENDSP) thanks to funding from the European Commission to carry out activities through-
out the European Union. ENDSP, along with its more recently established sister network, 
the Central and Eastern European Network of Drug Services in Prisons (CEENDSP, Janu-
ary 2003), have been leading activities in the promotion of drug and infection prevention 
services in prisons within the enlarged European Union. As of July 2004, the two networks 
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viduals working in governmental and/or non-governmental institutions have 
been involved in the network. The majority of national contacts were 
ENDSP (and CEENDSP) representatives as well as key individuals working 
in the national prison service. 
These individuals were contacted and were asked if they were interested and 
would like to be involved in the ‘Substitution Treatment in European Pris-
ons’ research project. They were asked to: 
− Collect comprehensive information on substitution treatment in their 
respective countries (at the general/ community level and at the prison 
level). 
− If requested, provide support to the researcher to enable them to under-
stand key information in languages they do not speak. 
− Identify national experts, NGOs, and others to be interviewed during the 
qualitative part of the project (via the field visit). 
− Facilitate the organisation of the field visit, further to the field visits’ 
requirements and proposed agenda as sent in an appendix to the national 
contact. 
− Assist the researcher during the field visit. 
− Provide availability and support for issues that may arise during the 
research. 
− Prior to publication, provide comments and feedback on the country 
report. 
Each national contact had a direct contact with the designated researcher. 
Each researcher was appointed 9 countries. 
National contacts provided key support by advising on the procedures 
needed to obtain official authorisation to conduct the research in the various 
prisons and in underlining cultural issues.  
Thanks to their role and important involvement, authorisation for the 
research was obtained in all countries but Luxembourg, where a national 
contact was not identified successfully and where direct contact with the 
Ministry did not result in authorisation.  
                                                                                                                            
will join with the European Network on HIV and Hepatitis Prevention in Prison to under-
take an ambitious three-year work plan throughout the 27 European countries. 
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The following national contacts confirmed their interest, involvement and 
provided great support with the research project. It must be underlined that it 
is likely that, without their contribution, the research project could not have 
been carried out. 
Table 1 List of National contacts used as facilitators and advisors for the research 
Austria Alfred Steinacher, Ministry of Justice, Prison Director 
Belgium Sven Todts, Ministry of Justice, Drug Coordinator 
Czech Republic Jan Sochurek, Ministry of Justice, coordinator for Prison Service of the 
Czech Republic 
Jiri Richter, NGO Sananim, Director 
Denmark Alette Reventlow, Ministry of Justice, Senior Advisor 
Finland Leena Arpo, Ministry of Justice, Chief Medical Officer of the Prison 
Administration 
France Saadia Yakoub, Centre Hospitalier Sainte-Anne, Maison d'Arrêt de la 
Santé, Psychologist 
Germany Heino Stöver, University of Bremen, Researcher 
Greece Anna Tsiboukli, Educational Psychologist, Kethea, Director  
Italy Dario Foa, ASL Ministry of Health, In charge of the operative unit in 
Prison 
Susanna Falchini, ASL Ministry of Health, in charge of the operative unit 
in Prison 
Ireland Enda Dooley, Irish Prison Service, director of prison health care 
Francis Nangle-Connor, Co-ordinator of Nursing – Health Care Direc-
torate 
The Netherlands Jan Flikkema, Ministry of Justice, Senior policy advisor prison policy-
development 
Poland Marek Bujak / Marzena Ksel, Healthcare Department, Polish Prison 
Service 
Maria Salivonenko, International Projects' Co-ordinator, MONAR NGO 
Portugal Maria Estrela da Graça de Pinho Campinos Poças, Prison administration 
Service, Ministry of Justice, Director of Health Care Office 
Slovenia Joze Hren, Ministry of Health, Government Office for Drugs, Counsellor 
to the Director 
Borut Bah, Association for Harm Reduction Stigma, Director 
Spain Graciela Silvosa Rodriguez, Delegation to the Government for the ‘Plan 
National on Drugs’, Director of the Service for Prison Programmes 
Julian Sanz Sanz, Ministry of Interior, Directorate General of Prison 
Services, Head of Drug use service 
Sweden Åke Farbring, Swedish Prison and Probation Administration, Pro-
gramme Inspector 
U.K., Scotland Karen Norrie, Scottish Prison Service, Addictions Advisor 
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2 Literature review 
The literature review focused on peer-reviewed journals and published 
reports from all over the world. Different forms of studies have been inte-
grated into the study and analysed: 
− (Randomized), controlled trials,  
− Evaluation studies of the provision of substitution treatment in prisons 
− Feasibility studies and reviews, examining the different modes of substitu-
tion treatment (e.g. detoxification, pre-release, short-term and mainte-
nance) found in either individual or in a number of prisons,  
− Studies concentrating on the different criteria relevant to evaluate the 
quality of the outcomes/the national protocols or highlighting certain 
aspects of ST (for instance “overdose”). 
Following the review of Dolan, Wodak & Hall (1996) of substitution treat-
ment until 1996, our review focuses on data that has been generated after 
their review process. 
3 Collection of national data 
The research involved collecting national data and qualitative data. The 
methodology used for the qualitative data is described below. 
National data was collected with the support of the national contact and on-
going examination of research reports, national governmental and non-gov-
ernmental websites. This included general information on substitution treat-
ment, in the community and prisons, as legislation, protocols, agreements, 
and procedures of the treatment itself. The national Reitox reports, from the 
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) 
website, were used widely. 
4 qualitative methods (field visits) 
Qualitative data was collected through interviews conducted during the field 
visits and organised with the support of the national contact.  
a) Interests of qualitative methods 
Staff involved in and prisoners receiving substitution treatment were inter-
viewed using qualitative methodology: this provides in-depth insight into 
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individual experiences and views in sensitive areas. Qualitative methods 
have proven to be suitable to public health studies and complex contexts as 
well as to charting the differing views of those involved. The researchers 
believed that qualitative methods were the most suitable for this explorative 
study. The choice of a qualitative approach reflects the fact that substitution 
treatment in prisons is a controversial issue in many countries and requires a 
sensitive approach. Indeed, qualitative methods are a relevant and useful 
research tool to reach a deep understanding of the phenomenon of substitu-
tion treatment in prisons, as well as to evaluate it from the perspective of 
those involved in it. By using qualitative methods, the researchers felt able to 
immerse themselves in the context and to understand participants’ experi-
ences, views and opinions better. Researchers felt that experiences, percep-
tions, attitudes and suggestions of all groups involved in substitution treat-
ment (patients/inmates, professionals and individuals in charge of substitu-
tion treatment at the prison administration) should be given an adequate 
forum for discussion. 
Importantly, the application of qualitative methods to this area of research 
and the scope of the study is unprecedented. 
This research is not comparative or representative in any way. Instead, we 
used qualitative data to look at the subjective experiences of a limited num-
ber of individuals interviewed on a specific date.  
We used several forms of interviews:  
− qualitative one-to-one in-depth interviewing; a key means of carrying out 
research on sensitive topics (such as illicit drugs), with professionals and 
some prisoners who had refused to attend a focus group 
− focus group, non-directive (free associations) and stimulated by open 
questions, resulting in narrative statements from prisoners 
− group discussions, stimulating an open debate about various aspects of a 
specific topic (i.e. substitution treatment) with professionals . 
The interview setting differed according to the venues available. In each 
case, the researchers gained assurance that the venues were suitable for the 
interviewees. When meeting prisoners, prison officers remained outside the 
room to ensure confidentiality. Anonymity was also ensured. No record of 
the names of the prisoners or the staff was kept. The researcher tried to 
maintain a balance between facilitating the emergence of new themes and 
insights whilst ensuring that the interview schedule was covered. During 
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focus groups or group discussions, the group dynamics were managed and 
kept in mind. Prisoners tended to use the interview situation to refer to their 
own cases and interests. Again, this had to be balanced with the interview 
schedule and the interest in raising new themes. 
The researchers were not concerned with testing pre-existing hypothesis: the 
focus was put on gaining new knowledge, experiences and perceptions of 
different groups involved in specific health interventions. The aim was to 
compose a broad view of different professionals and people concerned with 
substitution treatment. 
Prison visits took place in 33 prisons with 184 prisoners (132 men, 52 
women) in 33 focus groups out of 17 countries. But, within these 17 coun-
tries there is a total of 1,318 prisons with a total population of 435,202 pris-
oners. Taking this background into consideration, it becomes evident that 
this study only offers snapshots of the modalities of substitution treatment in 
European prisons. Considering the heterogeneity of substitution treatment 
programmes across European prisons, the findings provide a limited basis for 
comparison. Clearly, due to a limitation in resources, all the prisons in each 
country could not be visited.  
Moreover, the descriptions obtained during the field visits do not generate a 
generalised picture of a country. Instead, they reflect the subjective experi-
ence of some individuals involved with substitution treatment and reflect 
some specific practices in different prisons and countries. Prisoners’ partici-
pation was selective and arbitrary. Therefore, conclusions in terms of possi-
ble generalisations must be drawn very carefully. With this in mind, key 
problems and issues have been identified in several prisons, allowing for 
conclusions and recommendations which, hopefully, can be used to improve 
treatment access, modalities, and public health across the prison sector. 
b) Procedure 
(i)  Interview schedules 
 Prior to any interview or focus group, the researcher briefed each 
participant on the goal and expected outcomes of the research as 
well as the ethical issues involved. 
 Two lists of interview schedules (composed of open-ended ques-
tions) were drawn and used: one with the prisoners and one with 
professionals. (see Appendix 1+2 for the interview schedules)  
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(ii)  Pilot study 
 To ensure the validity and reliability of the interview schedules, a 
pilot study was organised and conducted in a prison. The research-
ers discussed and revised the interview schedules further to this 
pilot study. As a result, alterations were made to apparatus used. No 
findings from this pilot study were integrated in the final report; the 
pilot study was used only for methodological purpose. 
(iii)  Tape-recorder 
 In the majority of the countries, interviews with prisoners were 
tape-recorded having obtained authorisation from the prison or 
relevant Ministry and the responsible staff members. Interviews 
with other participants were either tape-recorded or notes were 
taken. Any names of participants, as well as other data that may 
lead to their identification of, have been left out in order to avoid 
retrieval of information given. 
(iv)  Linguistic issues 
 Researchers conducted interviews and focus groups mainly in Eng-
lish but also in the language of the interviewees. The researchers 
carried out interviews in German, French and Spanish but used neu-
tral and freelance interpreters for countries in which they did not 
speak the native language. Neutral, freelance interpreters were used 
in Italy, Poland, Portugal, the Czech Republic and Slovenia. 
c) Time 
The field visits, across 17 countries, were conducted between March 2003 
and May 2004. Each visit lasted for between 3 to 7 days, depending on the 
geographical location of the prisons and the agenda prepared by the national 
contact. The field visits extended to 7 days in Eastern European countries 
where a double research agenda was conducted (as explained under ‘Scien-
tific Committees’ below). 
d)  The Setting 
(i)  The countries 
 The research took place in 18 different countries: the 15 Member 
States of the European Union, Poland, the Czech Republic and Slo-
venia. The countries, 15 Western European member states and three 
Eastern European countries, were chosen on the basis of the 
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national contact’s involvement in Cranstoun’s networks as well as 
the interest they expressed for the research project. 
 Each researcher was in charge of 9 countries. The distribution of 
the countries between researchers was made according to linguistic 
knowledge as well as previous experience in and knowledge of the 
country and prison system. 
 Dr. Heino Stöver was in charge of and conducted the field visits in 
Austria, Denmark, Germany, Greece, Ireland, The Netherlands, 
Poland and Sweden and supervised the visit in Finland, which was 
conducted by Ms. Jutta Engelhardt (Mainline, Amsterdam/The 
Netherlands). 
 Laetitia Hennebel was in charge of and conducted the field visits in 
Belgium, the Czech Republic, France, Italy, Portugal, Slovenia, 
Spain, and the United Kingdom. Luxembourg was not visited (due 
to the lack of authorisation) but a country report was drawn up on 
the basis of national data. Hence, the methodology used for Luxem-
bourg was altered in order to include information on that country 
and to write a country report. 
(ii) Prisons 
 Two prisons were selected in each country, with the exception of 
Sweden and Greece where, as no substitution treatment is available 
in the prison setting, the researcher chose to visit only one prison.  
 The prisons were chosen on the basis of discussion and advise from 
national contacts. 
 Requirements for the field visits included visiting two prisons in 
each country (resources and time constraints prevented researchers 
from visiting more prisons), visiting prisons that differ in their geo-
graphical location, their type (remand/sentenced, men/women, juve-
nile/adults) and their approach and practise of substitution treat-
ment.
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d) The Sample 
The sample was made up of sample A: prisoners and professionals working 
in prison, and sample B: key individuals within governmental and non-gov-
ernmental institutions located outside of the prison. 
All participants in the study volunteered to take part. An explanation of the 
study’s approach to issues of confidentiality, anonymity, informed consent 
and the right to withdraw were presented to participants (as stated in Appen-
dix 3 Research Protocol and ethical issues). The ethical code of conduct was 
consistently and rigorously adhered to. 
Sample A 
Researchers interviewed prisoners with a history of illegal drug use (any 
drugs, poly-drug use being frequent) and professionals working in prison and 
concerned with substitution treatment. National contacts invited prison staff 
and prisoners to take part in the research. 
Usually, the national contact identified a key individual in each prison to 
take charge of organising the visit for the research. The researchers had pre-
viously provided the national contact with the field visit requirements and 
criteria to follow when inviting professionals and prisoners to take part in the 
research. It was underlined that the participation was on a voluntary basis. 
The confidentiality and anonymity aspects of the participation were also 
underlined. 
(i) Prisoners  
The research focused on prisoners with a history of illegal drug use and 
experiences in substitution treatment, inside prison and/or outside in the 
community. They were identified by the prison staff.  
Prisoners were, in general, approached by a member of staff from the psy-
cho-social-medical team. According to the researcher’s criteria, prisoners 
were contacted who (i) were on a substitution treatment, (ii) had been on a 
substitution treatment, and/or (iii) could have benefited from a substitution 
treatment but for various reasons, never received such treatment. Researchers 
underlined that the ideal was to have a group with prisoners with different 
experiences. Once identified, prisoners were invited to take part in the focus 
group on a voluntary basis.  
Prisoners were interviewed through focus groups (i. e. a group interview) 
that lasted for approximately 60-90 minutes. Permission to conduct focus 
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groups was obtained from the prison governor and/or the Ministry of Justice. 
One focus group with 2 to 8 prisoners was conducted in each prison with the 
sole presence of the researcher (accompanied by an interpreter when appli-
cable). 
Prisoners expressed no objections to taking part in a focus group except in 
France where, apart from 2 prisoners, the others wished to be interviewed 
alone. The methodology was thus adapted in that country in order to respect 
the cultural differences and to give a voice to French prisoners even on one-
to-one basis. 
In total, 33 focus groups in 33 prisons across 17 countries were conducted; 
reaching a total number of 184 prisoners. 
(ii) Professionals working in prison 
On the basis of the researcher’s requirements, the national contact identified 
and invited professionals working in the prison and concerned with substitu-
tion treatment. Like prisoners, participants were briefed on the research goals 
and outcomes and ethical issues were underlined. 
Information from prison staff involved in substitution treatment was obtained 
through interviews (on a one-to-one basis or with several individuals). This 
method was chosen because it elicits subjective opinions, allowing respon-
dents to speak in their own words, covering issues that may not have been 
covered in a more pre-structured way (such as through written questionnaire) 
and thus providing added insight and depth to the data obtained. 
Those prison staff interviewed in each prison were the drug treatment team 
(medical doctor, psychiatrist, nurse) the psycho-social team (psychiatrist, 
psychologist, social worker, pedagogue, …), guards, management team and 
the governor and/or deputy governor. 
The staff concerned with substitution treatment were interviewed for ap-
proximately 30 to 60 minutes, mostly on a one-to-one basis or in a group 
according to their preference and to the situation. 
Sample B 
In each country, key individuals within governmental and non-governmental 
institutions, located outside of the prison, were also interviewed. National 
contacts provided advice and guidance to the researchers as to who they 
should interview at the national level. They also facilitated most of the inter-
views.  
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In order to acquire a more general picture of substitution treatment in each 
country, researchers interviewed the Ministries in charge of the prison sys-
tem (Ministry of Justice or of Interior) as well as, when applicable, the Min-
istry of Health. Various key individuals from ministries or other bodies con-
cerned with substitution treatment in prisons (like health care management, 
training management, probation service, through care service, judge) were 
thus interviewed to gather information on the national procedure of substitu-
tion treatment in prisons.  
Some key national experts on substitution treatment in prisons, as well as 
key NGOs representatives, were also interviewed to collect national infor-
mation on substitution treatment in prisons. 
Participants were interviewed for approximately 30 to 90 minutes, on a one-
to-one basis or in a group according to their preference and to the situation. 
5 Analysis and report writing 
Analysis was conducted using quotations in order to generate categories (for 
the findings chapter), which serve as a differentiation of broader topics 
already set up in the interview schedules. This was intended to create a struc-
ture that would provide a better explanation of substitution treatment from 
various perspectives. As a contents analysis, it aims at bringing together the 
different subjective views of those involved in the study. The categories 
were identified inductively, through a process of reading and re-reading 
interview scripts, allowing careful understanding of interviewees’ quotes, 
excerpts of which are used throughout this report as examples of the themes 
and patterns that emerged through the analysis process (Dillon, 2001). On 
the basis of this analysis, the findings are presented in Part III in two chap-
ters. Chapter one presents (in alphabetic order) a country report for each vis-
ited country. Laetitia Hennebel, with the support of respective national con-
tacts, wrote the country reports on Belgium, Czech Republic, France, Italy, 
Luxembourg, Portugal, Slovenia, Spain, and United Kingdom. Heino Stöver, 
with the support of respective national contacts, wrote the country reports on 
Austria, Denmark, Finland (via Jutta Engelhardt), Germany, Greece, Ireland, 
the Netherlands, Poland and Sweden. 
Chapter two covers emerging issues across the 18 countries. 
The analysis and findings are further presented in the conclusion and rec-
ommendations chapters in Part IV of the report. 
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6 Ethical Issues 
Throughout the conduct of the research study, the ethical code of conduct for 
the completion of social science research was vigorously pursued. 
Researchers explained the purpose of the research to each participant and 
stated participants’ rights: participation was voluntary, confidential, anony-
mous, and participants had the right to withdraw from the research at any 
time. (see Appendix 3 for Research Protocol and ethical issues). 
7 Scientific Committees 
The ‘Substitution Treatment in European Prisons’ (STEP) Scientific Com-
mittee was made up of Joris Casselman, acting as the scientific peer-
reviewer and as chair of this Committee, and the two researchers, Dr. Heino 
Stöver and Laetitia Hennebel.  
The Scientific Advisory Group (SAG), see below, was an extension of the 
research Committee. The STEP research team worked closely with 
Dr. Morag MacDonald (UCE, Birmingham, England) who had carried out 
studies, on behalf of CEENDSP and Cranstoun Drug Services, in 10 Eastern 
European countries on the ‘Provision of Services in prisons’1. As well as a 
general cooperation and an exchange of information on drug services in pris-
ons, a close collaboration between the two research projects was developed 
for the three countries that both research projects shared: the Czech Repub-
lic, Poland and Slovenia.  
The STEP researchers conducted the field visits in these three common 
countries for STEP, and also on behalf of CEENDSP/ Dr MacDonald’s 
research, using the list of open-ended questions for both. A pilot study and 
various meetings between the three researchers, with their respective scienti-
fic peer-reviewers, were held to ensure the validity and potential for replica-
tion of the methodology and to test the research instruments. 
A scientific advisory group (SAG) for both research projects (STEP and 
CEENDSP) was set up as an important prerequisite for the success and 
scientific quality of the whole study. This involved: the three researchers 
                                                          
1  This research, published in July 2004, is entitled “A Study of Existing Drug Services and 
Strategies. Operating in Prisons in Ten Countries from Central and Eastern Europe”. 
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(Hennebel, Stöver and MacDonald), Professor Joris Casselman, Roy 
Walmsley, Dr. Karlheinz Keppler and Professor Johannes Feest. 
Meetings with Professors Casselman and Walmsley were held regularly with 
the three researchers (Hennebel, Stöver and MacDonald) to discuss the 
researchers’ progress and the scientific validity of their findings. 
Professor Joris Casselman was designated as the scientific peer-reviewer and 
co-author of the STEP research. Although he did not conduct any field visits 
himself, he was present and involved in the research project intensively 
throughout the project. 
Roy Walmsley, from the “International Centre for Prison Studies”, King’s 
College London (England), was designated as the scientific peer-reviewer 
and general advisor for the CEENDSP research, conducted by Dr. MacDo-
nald. 
Two additional experts from the field of substitution treatment in prisons 
were part of the SAG, in the capacity of scientific advisors. They did not 
take part in any meetings but were consulted: 
− Dr. Karlheinz Keppler, medical doctor in the Women’s prison of Vechta 
in Lower-Saxony (Germany), acted as a medical advisor for all relevant 
questions of medical details on substitution treatment. 
− Professor Dr. Johannes Feest, criminologist from the University of Bre-
men (Germany) and director of the “Archive for Penal Studies in Bremen, 
Germany”, provided support by making contacts and delivering relevant 
literature for the research. 
  
PART III: 
Findings 
  
  
A. Country Reports 
Austria1 
1 General data:  
drug use, substitution treatment and prison population 
1.1 Number of drug users (EMCDDA data) 
In Austria, the number of “problematic drug users”, defined as those who 
frequently use “hard drugs” (predominantly opiates and cocaine) with poly-
valent drug using patterns, is about 20-30 000 (ÖBIG 2003). This marks a 
slight increase over the last ten years. 
Spirig and Ess-Dietz (2001) point out that there is no systematic data collec-
tion about drug use in Austrian prisons. The profile and drug use of inmates 
has changed over the years. During the mid 80s, the number of people physi-
cally dependent on opiates, at the time of incarceration, was approximately 
10%. Today, a prudent estimate would be around 20%. The result of the last 
representative survey (Spirig and Schmied, 1999) revealed that: 15% of men, 
6% of women and 8% of juveniles were found to be consuming intrave-
nously during their sentence. During their sentence, 3% of both women and 
men as well as 25% of juveniles consume intravenously for the first time 
during their sentence. If the numbers of regular users and occasional users 
are aggregated, the total is estimated at 50%. If the consumption of other 
psychotropic substances, such as medicine or alcohol, is taken into consid-
eration, the majority of inmates are supposed to be drug users. The patterns 
of use are changing over time, polyvalent drug use is widespread. 
                                                          
1  The field visit, conducted by Heino Stöver, was facilitated by Alfred Steinacher, Ministry 
of Justice of Austria, who also provided national-general information and support with the 
finalisation of this country report. 
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1.2 Substitution treatment  
1.2.1 Historical and legal background  
In 2003, 6 423 persons were in substitution treatment 891 for the first time 
(ÖBIG, 2003), of whom were 68 receiving substitution treatment for the first 
time. In general, the number of patients in substitution programmes is con-
stantly on the rise (ÖBIG, 2003, 25). 
WHO guidelines and European Council Recommendation (No.R(93)6)2 pro-
vide the basic principles on which the Austrian prison health care system is 
based. The principle of equality must be followed: inmates should be offered 
the same medical and psychological treatments that are available to other 
members of society. In the Austrian penal system, this principle is only par-
tially fulfilled. 
The medical care of inmates in prison is organized by The Ministry of Jus-
tice and provided by internal medical services. Needs assessments for drug 
users are done, by a doctor, upon their admittance to prison. The guidelines 
for this assessment are provided by both the Ministry of Justice (e.g. substi-
tution programmes) and individual prison guidelines and concepts. Accord-
ing to Spirig and Ess-Dietz (2001) the structure of drug services is divided 
into three main areas: 
Abstinence Oriented Care  
The court can order appropriate measures of care to be given to dependent 
delinquents (§ 22 StGB (Strafgesetzbuch). The measures can also be exe-
cuted upon the request of the inmates, on a voluntary basis (§ 68a Strafvoll-
zugsgesetz/StVG). There are specialized areas for these treatments in five 
prisons. In Vienna, the Favoriten Prison specialises in caring for addicts. 
Substitution 
Spirig and Schmied (2003) point out that, according to the decree of The 
Ministry of Justice, substitution treatment must be available, as standard 
practice in every prison. “The decision is made by the prison doctor. It is 
recommended to maintain an existing substitution but at the same time a step 
by step reduction. In special cases it is also possible for the inmates to get 
                                                          
2  „Gefängnis und kriminologische Aspekte der Kontrolle von übertragbaren Krankheiten 
inklusive AIDS im Gefängnis.“ 
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into a substitution programme during the sentence or before release.” (Spirig 
and Schmied, 2003, p. 25) 
Drugfree wings 
Drug free zones have the dual purpose of providing treatment to dependent 
inmates as well as to protecting non-dependent inmates. After positive re-
sults from the ‘Drugfree Zone’ in the Hirtenberg Prison (piloted since 1995), 
other drug free wings were created in four additional prisons. According to 
the Ministry of Justice, today about 600 places in controlled drug free areas 
are available. (Bundesministerium für Justiz, 2001) 
The concept is based on voluntary cooperation: by signing a contract, 
through which the inmates commit themselves to follow certain rules (e.g. 
alcohol and drug abstinence, regular urine testing), they can enter the drug 
free zone. Violations (e.g. positive urine testing) or non-conformation to the 
rules is sanctioned with the removal of certain privileges (having cell doors 
opened during the day, having access to a telephone, reduction of controlled 
visits, permission to go out of the prison, etc.). (Spirig, 2000) 
Drug treatment targets all three of these methods with varying degrees of 
cooperation from external institutions.  
Substitution Treatment in general3 
In 1987, guidelines for substitution treatment were laid down for the first 
time in the “Decree on Oral Substitution Treatment of Intravenous Drug 
Addicts” (“Substitution Decree”), based on the Narcotic Drugs Act (NDA). 
In 1998, a decree was issued by the Federal Ministry of Labour, Health and 
Social Affairs (FMLHSA)4, in which guidelines for substitution treatment in 
Austria were specified, and, in the revised Narcotic Substances Act (NSA)of 
January 1998, the legal admissibility of substitution treatment was made ex-
plicit..The ‘ultima-ratio-principle’, stating that substitution drugs could only 
be prescribed on medical grounds and if other drugs were not sufficient for 
the intended purpose, was no longer binding. As substitution treatment had 
                                                          
3  The following chapter is based on: Sabine Haas, Klarissa Guzei, Elisabeth Tüscherl, 
Marion Weigl,, Austrian Health Institute (ÖBIG), Report on the Drug Situation in Austria, 
Vienna, 2001.  
4  Erlass des Bundesministeriums für soziale Sicherheit und Generationen, Orale Substitu-
tionsbehandlung von Suchtkranken, GZ 21.551/6-VIII/B/12/98, Wien, June 1998. 
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become an important form of therapy, it was included in the range of 
“health-related measures” targeting drug misuse as defined in the Act (Art 11 
of the NSA). 
When the NSA entered into force, the “Substitution Decree” (see above) was 
also amended on according to the experience and knowledge gathered which 
enabled relevant indicators to be specified more easily.  
All over Austria, substitution treatment has become an integral part of avail-
able drug services. The indicators for substitution treatment have been 
changed over time. Under the amended version of the “Substitution Decree”, 
issued in 1998 by the Federal Ministry of Labour, Health and Social Affairs 
(FMLHSA), pregnant women, patients with HIV infections and people ad-
dicted to opiates for over one year have been included in the primary target 
groups for substitution treatment. 
In the decree, with the exception of pregnant women, methadone continues 
to be defined as the substance of choice. In recent years, a diversification in 
prescribed substitution drugs has occurred: prolonged-action morphine and 
buprenorphine are used as well. In 2003, an analysis of substances used for 
first-time substitution patients showed that prolonged-action morphine was 
the drug most often prescribed followed by methadone and, shortly after, 
buprenorphine5. The decree also remarks that substitution treatment for peo-
ple under 20 should be administered sparingly, with the option of abstinence 
treatment considered thoroughly. 
Regarding organisation and monitoring, the decree stated that: 
− The relevant diagnosis shall be made by doctors familiar with the problem 
of addiction, i.e. psychiatrists (and neurologists) or other physicians with 
special experience or knowledge in the field of addiction treatment. 
− Generally, the substitution substances will be available on submitting a 
long-term, narcotic drug prescription, valid for a maximum period of one 
month. 
− In the course of substitution therapy, the head physician must carry out 
regular examinations such as health checks and urine analyses. 
On the basis of these general prerequisites, a number of organisational 
structures for substitution treatment were developed by the Provinces. 
                                                          
5  Personal communication with Dr. Sabine Haas, ÖBIG, Vienna, Austria. 
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1.2.2 Substitution treatment in prisons  
On 28th of February 2002, 531 prisoners were in substitution treatment. This 
is approximately 7.5% of all inmates. 410 detainees received methadone, 
115 received retarded morphine and 6 others were given oral opiates. This 
marks another increase in comparison with recent years (i.e. 335 detainees, 
or 5% of all inmates, in 2001. Spirig & Schmied, 2003, p. 11). 
According to the Ministry of Justice (Bundesministerium, 2002, p. 28), sub-
stitution treatment is available in all prisons in Austria and is not limited to 
the length of the sentence. With regard to prisons, the Federal Ministry of 
Justice issued a decree stipulating that it will be possible for prisoners in any 
penal institution to continue substitution treatment initiated before impris-
onment. Now, it is solely up to the physicians or psychiatrists to decide 
whether or not to continue the substitution treatment of a prisoner whilst, in 
the past, this decision also depended on the term of imprisonment. In indi-
vidual cases, inmates may also start a new substitution therapy during 
imprisonment or before they are released (Melnitzky et al., 1998). Prisons 
focusing on substitution treatment include the Penal Institutions of Josefstadt 
(Vienna, see field visit), with a capacity for 100 patients, Innsbruck, Favor-
iten (Vienna) and the prison of Eisenstadt. In this prison, a special unit for 
methadone patients was opened for 15 inmates. Its aim is to reduce the 
methadone dosage step by step, but this is not a prerequisite. Participation in 
individual or group therapies is obligatory. Having reduced the methadone 
dose, a transfer to other prisons with more specific drug therapeutic re-
sources (Wien Favoriten, or drug free zone) is possible and planned. 
Random urine analyses and alcohol control tests are taken. The advantages 
for the inmates are that the cell doors are left open more often, with access to 
tea kitchen and other rooms, which in turn plays a role in facilitating and 
accompanying the steps to release (Bundesministerium für Justiz, 2002, 
p. 13).  
As of 1 June 1999, substitution treatment was complemented by support 
from the penal Institution of Stein with a special ward for a maximum of 
50 patients. The number of prisoners undergoing substitution treatment has 
risen continuously, from approximately 50 persons in 1990 to more than 
500 in 2002. In most cases, methadone is administered. “The substitution 
programmes must be handled by medical doctors who are trained in drug 
treatment. Additional specialists are consulted when needed. The costs of 
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(external) medical care are paid by the Ministry of Justice because inmates 
are not insured.” (Spirig and Ess-Dietz, 2001).  
According to the Ministry of Justice (Bundesministerium, 2002, p. 28), sub-
stitution treatment focuses mainly on HIV-positive inmates, those with a 
serious opiate case history and some inmates with a high risk of overdose on 
release. 
1.3 Prison Population  
Table 3 Data on the prison situation in Austria. (Source: King’s College London, Interna-
tional Centre for Prison Studies, Prison Brief for Austria) 
Country  AUSTRIA 
Ministry responsible  Ministry of Justice 
Prison administration  Prison Administration 
Contact address  Museumstrasse 7, A-1016 VIENNA, Austria 
Telephone / fax / website  tel:   +43 1 52 152 2216 fax:  +43 1 52 152 2727 or 2822 
Head of prison administration  
(and title)  Michael Neider Director General 
Prison population total  
(including pre-trial detainees / 
remand prisoners)  
8,114 at 10.11.2003 (national prison administration)  
Prison population rate  
(per 100,000 of national population) 
100  
based on an estimated national 
population of 8.09 million at November 
2003 (from Council of Europe figures)   
Pre-trial detainees / remand 
prisoners  
(percentage of prison population)  
26.8%  (1.9.2003 – national prison administration)  
Female prisoners  
(percentage of prison population)  5.7%    (1.7.2003)  
Juveniles / minors / young prisoners 
incl. definition (percentage of prison 
population)  
2.5%    (1.7.2003 – under 18)  
Foreign prisoners 
(percentage of prison population)  
33.0%  (1.9.2002 – Council of Europe Annual Penal 
Statistics)  
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Number of establishments / institu-
tions  
29 
  
Official capacity of prison system  8,022     (10.11.2003)  
Occupancy level (based on official 
capacity)  101.1% (10.11.2003)  
Recent prison population trend 
(year, prison population total, prison 
population rate)  
1992      6,913      (87) 
1995      6,180      (77) 
1998      6,962      (86) 
2001      6,915      (85) 
2 The field visits  
2.1 Prison of Hirtenberg 
2.1.1 Description of the prison 
The prison of Hirtenberg, some 30 m southwest of Vienna, is a prison for 
sentenced prisoners and holds 329 inmates, of which approximately 30 were 
in substitution treatment at the time of the visit. The prison drug service 
became well-known when the first drug free-zone was established in 1995 
(Steinacher, 2000; Bundesministerium für Justiz, 2002). Today, about  
65-80% inmates participate in the programme. 
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2.1.2 Goals and practical procedures of substitution treatment  
Substitution drugs are allocated by nurses and by prison officers during the 
week-end. The intake is supervised and the drug is diluted in water. In most 
cases, the initial dosage of the substitution drug is set by remand prisons  
(e.g. Vienna Josefstadt, see below) and is adopted in the prison setting.  
According to the psychologist, some prisoners wish to change their substitu-
tion drug from methadone to retarded morphine (e.g. Substitol®). Those who 
await a longer sentence often wish to reduce their dosage (down to 10 or 
20 mg), but stop at this certain stage. This minimal dosage is often perceived 
as a form of security. 
Patients in substitution treatment are led to the medical ward in the morning 
where they give their names. The nurse confirms the identity against a pho-
tograph of each patient before allocating the monthly prescription. Substitu-
tion treatment is oriented towards the specific needs of the patients and 
whether they want to stay on the treatment or reduce it. At the time of the 
visit (July 2003), The average dosage was 70 mg and urinalyses were taken 
once a month. The results are not communicated to the security staff of the 
prison and the medical unit does have access to the results of the urinalyses 
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conducted by the security staff (e.g. before leave). No connection has been 
made between cannabis use and substitution treatment. 
The prison offers work for almost 90% of the inmates in 14 undertakings 
(e.g. market garden, waste separation; locksmithery). The exception for in-
mates being undergoing substitution treatment is that they are not allowed to 
work machines (for which they need a special machine license). This is the 
only work area that substitution patients are excluded from. 
The prison staff expressed that there is a changeover possible from the 
methadone programme to the drug free zone, which is talked about during 
the admission interview. The drug free zone is supposed to be a protected 
zone, in which inmates can get distance from drug related talks and habits. 
According the external psychologist, being in substitution treatment is not a 
taboo but is perceived to be normal treatment for sick people. 
Psychosocial care is provided, within a methadone group that meets every 
Wednesday, with a psychologist from a therapy institution near Vienna 
(Schweizer Haus Hadersdorf). The group is attended by 7-8 inmates regu-
larly. Following this, a group is offered for those having problems with co-
medication (e.g. benzodiazepines). The external psychologist offers one-to-
one interviews. The person in charge of psychological care within the prison 
stays in close contact with the external psychologist. 
 The social worker of the prison hosts a monthly group on the topic “Impris-
onment and Addiction” which, according to her, is attended by more partici-
pants from the drug free zone. 
Once a month, everyone involved in the substitution programme meets (psy-
chiatrist, external psychologist, social worker). This has to be seen as a cen-
tral forum in which case studies are discussed. This meeting is confidential 
and all views are brought together to avoid playing the prison staff off 
against the external psychologist. From the beginning, conflicts have been 
overcome and a cooperative atmosphere has developed. 
2.2 Prison of ‘Wien Josefstadt’ (Vienna) 
2.2.1 Description of the prison  
The prison of ‘Wien Josefstadt’, located in the centre of Vienna, is the cen-
tral remand prison (also sentenced prisoners) in Austria and holds approxi-
mately 1 100 inmates, of whom 130-150 are in substitution treatment. On 
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average, the inmates stay in remand for between 3 and 4 months. Care for 
the drug users is provided by the Forensic Drug Ambulance of the University 
Clinic for Psychiatry of the General Hospital in Vienna (AKH Wien). 
2.2.2 Goals and practical procedures in the provision of substitution 
treatment  
According to a physician, substitution treatment was introduced in 1991, 
mainly as a continuation of the treatment in the community. The nurses see 
the connection between the increase in people on prescription outside and the 
number of inmates being admitted to prisons within a programme of substi-
tution treatment.  
Nurses report that substitution treatment is no longer a topic of conflict 
among the personnel. Only a few staff do not like to work with inmates in a 
substitution programme. The nurses feel there has been a remarkable process 
of normalisation in the last few years but that additional education remains 
necessary for the staff members. 
“… we had a lot less then, ... about 50 or 60 people who´d been put on sub-
stitution treatment outside, and we continued it here. Of course, not everyone 
thinks its a good idea. We still get that today, not many, but there are still 
some who’re against it. Well that was worse then, especially when it came to 
letting them have jobs.” (A nurse) 
For the staff especially, the nurses’ substitution treatment contributes to a 
quieter everyday life in prison and enables the prisoners to lead a normal life: 
“The nights quietened down right away … The sick bay was really quite at 
night and we just had the three in, the first ones were all admitted. But when 
it started escalating on the outside, we got more and more coming in here. 
Now, I’d admit I’m for methadone … It makes the mornings that much eas-
ier, – I wouldn’t have thought so before, but now I always tell our staff: the 
ones on methadone can work just like normal. They get their tranquilisers 
and other stuff as well. You can treat them as normal” (A nurse) 
The nurses had to gather experience in finding a mode of delivery that satis-
fied all needs: 
“... We used to get them all over to the sick bay, and they all got their metha-
done at the same time. They were all swapping and changing – like a mad-
house, it was! Oh, and we had Heptadone-cubicles set up, to supervise them 
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better, but that didn’t help, so then we got a trolley with locking compart-
ments for all the different units. And a registered nurse goes round early to 
all the different units, with a warder, and dispenses it in the medical room.” 
(A nurse). 
The staff of the medical unit emphasized how important it is to provide suf-
ficient supervision: 
“On average, there are 150 people in the programme. The warder comes 
with the methadone, then they all come in here and bring something with 
them to drink. ... They’re very well behaved, you know, I’m always amazed 
how good they are here. …Last year we had a lot who were vomiting after-
wards in the cells. You do need to keep an eye on them.” (Two nurses) 
Substitution treatment is seen by the physicians as a crook to enable patients 
to participate in life. But, some of the patients think that they do not need a 
crook any longer and experience relapses because they want to get rid off the 
support too early or too fast. 
“You always have to bear in mind that methadone is a medicine, a substitute. 
If you’re doing it right, it’s a support, – a support you don’t want to let go of 
while you still need it. That’s my way of thinking. But you always get a lot of 
people, methadone users included, who think: first I’ll switch to methadone, 
then I won’t take anything, then I’ll get a completely new life and then I’ll be 
fine. And when it doesn’t work, because they haven’t learnt to cope with 
frustration, then they crack up. If they can’t cope with boredom, or hassles, 
or anger – how are they going to stay clean?” (A doctor) 
Furthermore, substitution treatment is acknowledged as having stabilizing 
effects; the physicians stress the fact that drug users are experiencing often 
extreme fluctuations between drug consumption and withdrawal. This is seen 
as a “yo-yo-effect”, which is seen as problematic for the users in terms of a 
negative health impact. 
In the beginning, with little experience, prescriptions were simply continued. 
But, through the use of methadone, and its use to combat withdrawal ache, 
the nights in the admission unit became calmer. The nurses report “horror 
nights” from before the introduction of methadone due to inmates having 
pain on withdrawal. Since the mid 90s, nurses see an increase in inmates 
being admitted with a multiple drug use (including benzodiazepines and 
alcohol). 
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The details of the continuation of the prescription are discussed with the ex-
ternal pharmacy on the basis of what the inmate said: 
“When the prisoner gets here he simply tells us he’s on methadone mainte-
nance, or whatever. Then we get the details from the chemist where his pre-
scription is registered, because they’re the ones who know the details.” 
The reduction steps are taken in 5 mg steps. The dosage has to be confirmed 
in the pharmacy where the monthly prescription has to be placed. According 
to physicians, the dosage reported by most inmates is correct.  
For various reasons, the strategy of the physicians is to change-over from 
retarded morphine (Morphine hydrochlorid) to methadone. It is said that it is 
easier to handle (the possibility of misuse is high) and enables the treatment 
team to control the intake of methadone. Only in exceptional cases (e.g. 
HIV-positive inmates) or in cases of medical incompatibility (which counts 
for 2-3 persons) is it inappropriate. 
“Before you could get Substidol® regularly, we tried to introduce it – and 
then when it came on the market, we didn’t need to anymore. But ... it’s not a 
problem. Anyone coming in now gets put on methadone. ... Or what might 
happen is, we put them on methadone, and if they react badly to it, they get 
taken off again … You always get 2 or 3 in here with a physical intolerance, 
or HIV, who can’t take it…Well with methadone in liquid form, that’s easy to 
supervise. I suppose you can always fiddle something, but not many people 
want to swallow something someone else has spit out.” 
The nurses are supporting this view on the basis of their daily experience. 
“... We can only do that as an exception to the rule, when there are really 
valid medical reasons. If a patient reacts badly to methadone, then we switch 
them over. And we’ve learned the hard way: everything that hasn’t been 
mixed with liquid gets collected up immediately. We had one person who 
horded it for a week and took it all at once. He only survived because he got 
first aid quickly. The risk of misuse is very high.” (Two nurses) 
The retarded morphine is available in capsules containing pellets, which can 
not be dissolved in liquids, because they are embedded in a wax film. It is 
possible to hide pellets in the mouth and, although the patient has to drink 
afterwards, it is supposed to be less safe than methadone.  
“Substidol® is a form of morphine, so it doesn’t have the same effect as 
methadone, and people prefer it and react better. Methadone tends to make 
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some people groggy or depressed, or they swell up ... It doesn’t have those 
side effects. On the other hand, methadone helps people to stay off drugs 
better. It’s a different substance and has slightly different effects from the 
heroin they’re addicted to. So methadone has a more stabilizing effect than 
Substidol® ... perhaps because it lasts longer and works in a different way. 
Morphine is much more like heroin, so you run a greater risk of not just sub-
stituting, but getting back on the needle again.” (A doctor) 
The physician also reported that another reason is that the experience of 
morphine is supposed to be too close to the euphoric effects known from the 
use of the original substance (e.g. heroin). The drug user’s internal distance 
to their previous use is supposed to be bigger with methadone than with 
morphine, which is closer in its effect to heroin. So, this is a therapeutic rea-
son not to continue the prescription of morphine. It is reported that the 
change-over sometimes leads to conflicts with the inmates, who often insist 
on their preferred substitution drug. 
Only very few patients receive retarded morphine: 
“Maybe 1 or 2% Substidol®. It isn’t really a big thing here – we have to be 
much more restrictive with it because of the risks. So we only use it when we 
can’t avoid it.” 
The average dose of methadone is 60 mg. Urinalyses are taken occasionally 
on the basis suspicion but not as a tool for therapy.  
“What can you do if you catch someone out? It’s just not worth imposing 
restrictions, if you can’t do anything about them ... You’re only making life 
difficult for yourself.” (A doctor) 
According to the physicians, it is possible to see when an inmate is topping 
up the substitution drug with other drugs. The aim is that inmates feel able to 
report their use of other drugs and a degree of frankness is achieved in com-
munication with the inmates. 
The doctors don’t work with treatment contracts, because they can’t take 
away the substance someone needs as a possible consequence. 
“Some people do [work with written agreements), but I’ve always found 
having a personal relationship is the best option, because you’re always 
going to have to talk things over anyway, whether they’ve signed something 
or not. ... They all sign. It doesn’t mean much; – as long as someone’s be-
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having themselves, they don’t need the lecture, and if not, well you’ve got to 
talk to them anyway.” (A doctor) 
The intake of the prescription drugs is either done in the ambulance or on the 
wards within a specially locked carriage. On the wards, a member of the 
security staff accompanies the nurse. The intake is supervised through visual 
control: the inmates have to say a few words afterwards. Intoxicated inmates 
will be identified easily in the delivery of methadone. 
Co-medication drugs which are prescribed are anti-depressants, neuroleptics. 
If an inmate is prescribed benzodiazepines this is reduced consequently. 
Physicians state that detoxification is a drawn-out process which is done in 
small steps of reduction and which can last several months. It is aimed to 
give inmates an awareness of the harmfulness of the benzodiazepines. The 
steps of reduction are taken following individual talks between physician and 
patient. The process of reduction of benzodiazepines is supposed to be a very 
painful treatment. According to the doctors, women need a longer period of 
reduction than men. A mono-dependency from the substitution drug is 
achieved. 
“No, we cut it right back, but not all at once. We start with a big cut and 
then phase down slowly. If someone comes in who’s on 10 tablets, then he 
gets 4, plus one of something else, like neuroleptics or anti-depressants, just 
to break the fall. Then we reduce gradually in really small steps, – from 
50 mg to 30, then 15. Really slow, so they don’t get the feeling they’re miss-
ing something, or else they’d run straight out for a fill-up when they’re 
released. That’s the danger if you’re too drastic. I like them to understand 
what I’m doing, and why. I want people to really understand that there’s a 
valid medical reason for all this. That they understand what a mess they’re 
really in. Of course, you always get the ones who say, – I was taking X on 
the outside, I need X now. I can’t make do with 4. Its really our goal to get 
them off benzodiazepam. To get them off addiction full stop. Which is a very 
long, difficult process. I don’t think there’s anywhere you can come down off 
benzodiazepam as slowly as here. That’s one of our big advantages.” 
(A doctor) 
It is also possible that inmates will be taken into prescription before release 
as a “starting point” and a form of relapse prevention (approx. 5 inmates). 
“We do actually start people on methadone from scratch. It depends on the 
person’s character, and how badly addicted they are – how bad the need is 
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and whether their first impulse when they get out is to fulfil that need. Other 
things we consider are the length of sentence and the momentary situation.” 
(A doctor) 
Once a year, all physicians working in penal institutions come together and 
discuss relevant topics. 
If the drug users are on leave (e.g. week-end) they receive single doses pre-
scriptions, which allow them to take the substitution drug under control in 
the pharmacy (the supervision of intake is noted on the prescription). 
According to the nurses, information is lacking for wardens on the nature 
and character of substitution treatment and this could contribute to a better 
understanding of prisoners: 
“These days, some of the staff, some of the workshops take people who are 
on methadone, and they’re quite satisfied with them. Only a few don’t want 
them. I don’t think there’s enough done about combatting prejudice, – that’s 
what I told the director, too. One officer even said he thought people ought 
to be better informed, so it wouldn’t scare them off so much. Well, some 
officers make the effort, and some just don’t want to know. I’ve already 
talked to the officers in charge of allocating jobs, and tried to get more 
allotted, because the ones who only take methadone are much more clear 
headed than the ones who take all this other stuff. Officers who’ve worked 
with them know that’s true. But people still call them names: the tox brigade, 
and stuff.” 
Psychosocial care and support (self help/peer groups from inside and out-
side) is offered and inmates are able to access social workers when they are 
in need. Furthermore, the association “PASS” is caring for the transfer of 
inmates to therapeutic institutions (e.g. Schweizer Haus Hadersdorf, accord-
ing to §39 SGG). 
2.2.3 Views of prisoners  
A focus group with inmates was held with four prisoners who all had long 
drug use histories and long prison careers (several stays in prison between 
1.5 and 9 years and methadone doses between 45 mg and 120 mg metha-
done). They confirmed the fact that the prescription is continued once they 
get arrested: 
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“I’ve been in the substitution programme 8 years, outside and in. It has 
always gone fine. I didn’t have my prescription on me when I got arrested – 
but I was in the programme, so I am here too. When you’re in, you’re in.” 
(A prisoner) 
Prisoners complained that they all got methadone instead of retarded mor-
phine (as they got in the community).  
“... I get Kapanol®. If possible, I think people should get what they were 
having on the outside. I was put on Kapanol® for a good reason.” (A pris-
oner) 
The change-over is seen as an additional health burden. The reason for this 
change-over is that it has been shown that methadone is easier to handle. But 
the needs of the prisoners are not adequately addressed. In that respect, the 
substitution treatment reflects the needs of the system more than the patients. 
Substitution treatment modalities change considerable from prison to prison. 
“Every prison’s different. Dr. Y., who we used to have here, he was all for 
soft drugs. He used to say: ‘We’re winning if we can get them off GBH and 
on to Breaking and Entering. ‘He was all for Kapanol®, he said it was much 
less harmful. And Dr. X., you’ll meet him, he’s carried things on much the 
same.” (A prisoner) 
The dependency of the inmates on the doctors was emphasized by an inmate: 
“You’re totally dependent on them, – and they’re holding the reins. You get 
the feeling they just give you whatever they’ve got in stock at the moment. 
They don’t care about the side effects, or whether or not it’s good for you.” 
(A prisoner) 
Discrimination is present through the fact that the word “HEPTA” (for Hep-
tanol, forerunner of methadone) is noted beside their cell door so that every-
one knows that a drug user is living inside the cell. The prisoners think that 
this label as “Giftler” (drug user) is leading to prejudices against them.  
As the methadone is given out at 7.30, everyone knows who gets methadone. 
Different forms of treatment are noticed between drug users receiving 
methadone and non-drug users. The prisoners feel that the staff are not very 
well informed about drug addiction and other related topics. The prescription 
of co-medication (like benzodiacepines) is felt to be dependent on the par-
ticular doctor. The prisoners complain that, apart from methadone, there is 
not an extended psycho-social care for them. Group meetings are notably ab-
 81 
 
sent and access to work and qualification is less, although this is also possi-
ble when in substitution treatment: 
“I got my school-leaving exam (in Z.) and trained as a cook while I was in 
the methadone programme.” (A prisoner) 
2.3 Prison of Stein 
2.3.1 Description of the prison  
The prison of Stein (“Justizanstalt Stein”) is a high security prison for sen-
tenced prisoners located in the province of Lower Austria, not far from the 
Czech border. By June 2002, 677 inmates had been incarcerated, there is a 
total capacity of 730 places. The number of staff is about 315. 103 inmates 
receive substitution treatment (37 methadone and 63 retarded morphine e.g. 
Substitol®, 3 buprenorphine). 44 of the substitution patients are taken to-
gether on a special ward (V3) which has less restrictions. The Stein prison is 
the prison with the highest number of steady and long-term substitute pro-
grammes in Austria. 
More and more the prison of Stein is designated to “problematic inmates”: 
a high proportion of lifers (75), a high prevalence of alcohol and drug users, 
a high percentage of migrants (28%), mentally ill persons, self harm and sui-
cidal persons. A concept “Inmates against drugs” has been implemented 
here, intervening on two levels: Security measures to detect drug use and 
trafficking and demand reduction and care specific measures. 
In the admission phase, inmates are allocated to one of the following catego-
ries: 
− Drug free zone 
− Abstinence-oriented therapy 
− Drug users 
− Substitutions treatment unit 
The latter is focused on inmates already integrated into a methadone pro-
gramme in the community as well as inmates who are eligible for this pro-
gramme because they are long-term drug addicts. A treatment contract has to 
be signed, group therapy is offered and a transfer to the drug free areas, 
having finalized the substitution treatment is possible. There is a capacity for 
45 inmates. 
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2.3.2 Goals and practical procedures of substitution treatment  
In Stein, the number of patients in substitution treatment has increased con-
siderably in the past decade. 
“The number of people on substitution has escalated so much that we get a 
lot for substitution in here too.” (A nurse) 
Furthermore, the people in charge are well aware of the fact that prison mir-
rors the external situation and that health care has to deal with the develop-
ments in the community: 
“We mirror the situation in the outside world. There’s nothing in here that 
hasn’t come in from there! – Some of the staff think I’m experimenting, but 
I’m just keeping up with the drugs scene outside. I’d be the first to criticise 
benzodiazepam, but we’ve got people coming in here with a whole range of 
diseases, especially psychological ones, – people with massive panic disor-
ders, who’ve been on prescription for it for years. You try taking them off it 
in a prison environment like we´ve got here! Clinically it would look better, 
but it would make for tougher living conditions.” (A doctor) 
The doctor’s view of addiction (as a chronic relapsing disease) is essential 
for the treatment and the modalities of it: 
“But if you work in methadone maintenance, you just have to accept that 
relapse is part of the illness. You need to work at a good doctor/client rela-
tionship. And that means you need to be in contact with the people. And 
some of them don’t like you keeping tabs on them, and some won’t accept 
treatment from a woman doctor ... But I’ve got my limits too and I refuse to 
work outside the legal boundaries. You’ve got to have supervision – even if 
its not very strict – you’ve got to stay inside the limits of the law. And you’ve 
got to remember that substitution isn’t obligator – its the state that’s under 
obligation to provide this option for the really serious cases. And don’t for-
get that people are always going to reach out more for things to ease pain 
and frustration in a prison atmosphere. And that means turning to drugs, be-
cause ’t’s just so much more brutal in here. And you can’t stop drugs getting 
into prisons, – no way. There was an experiment in America where every-
thing was completely sealed off, and the staff and inmates all suffered from 
psychological decompensation. You just can’t do it.  
I think you need to concentrate mostly on cooperation, – but keep tabs on 
them too. You’ve got to know what’s happening with the chronic cases and 
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the relapse risks. It doesn’t mean rejecting the maintenance programme out 
of hand.” (A doctor) 
In most cases, the dosage from the remand prison is continued and the physi-
cian adjusts the dosage. 
At 7 o’clock, the substitution drug is handed out to the prisoners. They have 
to swallow the dosage and to drink some water afterwards. Again, metha-
done is perceived to be safer than other drugs (see above).  
”We dispense methadone and Substidol every day at 7 am. The prisoners are 
brought up, the nurse breaks open the capsules and tips them into a mug. A 
warder watches while the prisoner swallows it and checks their mouth 
afterwards to see its all gone. And then the next one, and so on. The same 
with methadone. After they drink it, they have to say something, so you can 
check if they’ve swallowed or not.” (A nurse) 
A special facility has been constructed for reasons of safety and supervision 
and to enable staff to talk to every prisoner individually: 
“There’s this room, and the cubicle is for the prisoner. Here’s the table 
where we put the Substidol, and there’s the opening in the cubicle so they 
can take it. The warder sits here on the left and checks the prisoners’ 
mouths. The other prisoners wait in the corridor, only one comes in at a 
time. The cubicle door locks automatically when they shut it, and when 
they’re finished they can just open it and leave.” (A nurse) 
“They really prefer Substidol, or Mundadol too. But they get more 
methadone now, – that’s the way Dr. XY. prefers it – and we prefer 
methadone, because its easier to dispense. With Substidol you never know if 
they’ve still got it stuck behind their teeth … they get it in a mug. The 
capsules are opened and the granules are tipped into a mug of liquid, then 
they drink that. But the granules don’t actually dissolve first.” (A nurse) 
If inmates are on leave, they will be given the substitution drug for up to 
3 days with the same allocation upon release, when the drug is given for  
1-2 days whilst the patient looks for a doctor in the community. 
The average dosage is 72 mg (for the 37 methadone patients at the time of 
visit). Here too, the number of inmates in substitution treatment has been 
risen sharply in the last years (from 25 patients in mid 2000 to more than 
100 three years later). This is explained by the parallel increase substitution 
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treatment use in community and in remand prisons (especially Vienna Josef-
stadt, see above). 
The nurses regard substitution treatment as a sort of privilege and there is 
more contact with the doctors and the other professional personnel. 
Urinalyses are taken 1-2 times a month (under visual control with mirrors), 
the positive cannabis results do not lead to exclusion from the substitution 
programme but, if they test positive for urine controls on a regular basis, this 
then may lead to dosage reduction: 
”If someone’s urine tests positive for cannabis, then they have to go and see 
the specialist. He talks it over with them and they usually get a second 
chance. ... But if it keeps on happening, if their urine regularly tests positive, 
well, – they aren’t taken off maintenance, but then the dosage gets reduced.” 
(A nurse) 
The doctor uses their discretion in the use of urine controls depending on the 
personal circumstances and abilities: 
“I’m not for keeping tabs on people in the maintenance programme when 
they’re outside, – except if its someone with a driving license who’s working 
as a driver, for example. Someone who’s stabilized and working in a respon-
sible position should get regular urine checks. 
Otherwise it’s not so important, more a question of ethics. In here its a dif-
ferent story of course, – I’m not against checks – its not as though I’d stop 
someone’s methadone treatment if they had a relapse, – its more about good 
communication. I get more and more people coming to me who say: I’ve re-
lapsed, – my urine’s going to test positive, so you’ll find out anyway. Which 
brings us straight to the point: we don’t only talk over the negative aspects, 
but about whether the dosage is high enough, whether they’re getting the 
right drug. A lot of them wouldn´t come to me, wouldn’t say anything other-
wise, so this way I can reassess the dosage, find out what they’re using on 
the side, and so on.” (A doctor) 
If someone is topping up drugs and is detected, they will be sent to the spe-
cialist: 
“If the specialist’s on duty, then they have to go and see him straight away. 
And if the substitution specialist isn’t there they have to see the GP at the 
prison hospital, or the psychiatrist. There’s almost always a specialist on 
duty here. And there’s always one on call.” (A nurse) 
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Reduction steps are often requested before release. The reduction scheme is 
different according to individual needs and abilities. 
If someone shows signs of drug abuse during his sentence, it is also possible 
to start a substitution treatment: 
“Sometimes we start people on maintenance here too. If a prisoner ap-
proaches us with an ongoing drug problem, we can get the substitution 
treatment specialist to have a look at him to see if he needs to be on mainte-
nance. It only needs a quick urine test and a check for symptoms. If there are 
needle marks or a positive urine test, then the prisoner can be put in the pro-
gramme.” (A nurse) 
For the doctor, it is not relevant whether or not somebody gets into the prison 
on a prescription but withdrawal symptoms and drug consumption signs are 
to be observed in the prison: 
“When someone comes to see me, they’re already motivated enough to have 
made an appointment for their drug problems. Then I have to decide if this is 
just a tactic to get medication to ease withdrawal. So I do a urine test, I look 
for needle marks. Basically I have to make an on-the-spot diagnosis; ’'ts ob-
vious if someone’s having really extreme withdrawal problems. People used 
to get lost in the system – they’d be sitting there on their own with massive 
withdrawal symptoms. Our screening’s much better now – during admission 
for example ... or if someone’s already been in a maintenance programme 
and fits the criteria – positive urine test and so on. Then they can get into the 
programme. No problem.” (A doctor) 
Reduction in the substitution drug dosage are possible at any time: 
“… you can reduce anytime you want, it happens quite a lot. Usually just 
before release. One or two months before ... Of course, the long haul ones 
don’t do that so much. They get an appointment with the specialist and he 
reduces their dose week by week.” (A nurse) 
The head physician leads a group for prisoners in substitution treatment and 
with drug problems in general. Benzodiazepines are seen as a big problem in 
this group because the strategy is to reduce the dosages (as 80% of those 
coming from remand prisons still have a prescription of those drugs). Fur-
thermore, a psychologist is offers group and single sessions. 
There are regular group discussions between doctor and inmates on the sub-
stitution ward: 
86 
 
“The group discussions aren’t only about therapeutic solutions for addiction 
problems. We talk about anything that comes up, – personal problems, – 
situation on the ward – anything that needs looking into. For example, we’ve 
got a washing machine in our department now. Or, that the outdoor yard 
stays open till lock-in. Just things that need discussing.” (A doctor) 
2.3  The views of prisoners  
The focus group consisted of four prisoners with different length of sen-
tences (from 3 months to life), with various periods in prisons before. Partly, 
they were prescribed methadone, partly retarded morphine. All of them ap-
preciated the continuation of substitution treatment. From their own experi-
ence of other regimes in which treatment was stopped, this had aggravated 
their situation and had not helped.. Substitution treatment is regarded as a 
form of security. According to those receiving retarded morphine, metha-
done does have the effect of making people depressive, feeble, and does not 
give any pleasure at all. Morphine is perceived to be good in physical re-
spects and stimulating in terms of libido. But these effects vanish after some 
months and a feeling of functioning normally follows. The advantages and 
disadvantages of the substitution drugs have been discussed.  
Q: How does Substidol work differently from methadone? 
‘It varies. In my case, methadone made me groggy. I couldn’t think straight. 
I didn’t want to do anything. Not sex either.’ 
‘I went from 90 mg of methadone to 600 mg of substidol. I react better to 
Substidol. I’m back to normal now. I don’t want to be high anymore, just 
normal.’ 
Q: Can you confirm that it gives you a buzz during the first three weeks, then 
eases off? 
Yeah, the first three weeks, then it gradually eases off. Now I can live quite 
normally’ 
Inmates reported both a change-over from retarded morphine to methadone 
and vice versa. 
The inmates complained about the reduction of co-medication (e.g. benzodi-
azepines). Furthermore, they feel that there is not enough psycho-social care 
related staff to talk to. There is only one psychologist for the whole ward, 
who is overextended and a chaplain. They also feel resentment and discrimi-
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nation from the staff regarding working facilities, and that there is a rough 
distinction between drug users and non-drug users (“Giftler” und “Nicht-
Giftler”). So, consequently, more education is demanded for the staff about 
drug and addiction issues. 
3 Summing up 
Due to a decree from The Ministry of Justice, substitution treatment must be 
available in every prison and is supposed to be standard procedure. The 
number of prisoners receiving substitution treatment has steadily increased in 
recent years. The visit to the two prisons confirmed this trend. There was 
almost no discussion about the continuation of treatment. Additionally, a 
surprisingly high number of patients receive substitution treatment for the 
first time whilst in prison. In all three prisons, the atmosphere was basically 
positive towards substitution treatment. In discussions with prisoners, nurses 
and doctors it became clear that treatment modalities were relatively clear 
and that prisoners views were acknowledged and integrated in the treatment 
process. As an example, negotiation about dosage was possible and the deci-
sions in favour of detoxification or maintenance were acknowledged as part 
of the doctor-patient relationship. 
Nevertheless there were a few conflicts around the treatment process. Obvi-
ously, different policies and practices were applied regarding the substitution 
drugs of retarded morphine, which was judged differently by doctors in 
remand prison and in sentenced prison. If these drugs are prescribed in the 
community, they are replaced by methadone, which is seen as pharmacologi-
cally superior and easier to handle in terms of control and supervision of 
intake. 
In addition, the prescription of benzodiazepines was a subject of debate. As 
these drugs are very widespread in the community, doctors in the remand 
prison prescribe and do not immediately reduce them but as part of a (longer) 
detoxification process whereas, in other prisons, these substances are only 
prescribed rarely. This leads to misunderstandings, as the prisoners them-
selves are usually unaware of the dangerousness of the drug. Prisoners men-
tioned the lack of adequate psycho-social care. 
  
Belgium1 
1 General data:  
drug use, substitution treatment and prison population 
1.1 Number of drug users (and type of drugs used) 
There are an estimated 30,000 drug users in the country, a doctor reported. 
Currently, there is an estimated number of 7,000 persons in substitution 
treatment in 2001/2002 (EMCDDA, 2003). 
Approximately 50% of prisoners are drug users (Todts and Hariga, unpublis-
hed). 
There are 224 drug-using prisoners on substitution treatment in prison, com-
pared to 122 in 2002 (Todts, unpublished). 219 of them are on a methadone 
treatment. The mean dosage was 36.8 mg, varying from 1 to 205 mg. The 
mean age of patients was 32.8 years old. Substitution treatment is delivered 
in detoxification as well as maintenance programme.  
Although the alcohol related problems are a much bigger problem than any 
other drug-related problem (a doctor reported), the most commonly used illi-
cit psychoactive substances are in order of frequency of use cannabis, syn-
thetic drugs, heroin and cocaine. (Reitox Belgium, 2002) 
The treatment section (health care) in prisons is part of the responsibilities of 
the National Prison Administration, Ministry of Justice. 
                                                          
1  The field visit, conducted by Laetitia Hennebel, was facilitated by Sven Todts, Ministry of 
Justice, who also provided national-general information and support with the finalisation of 
this country report. Special thanks again to Sven Todts for his availability, support and 
great expertise. 
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1.2 Substitution treatment 
Data comes from an on-going review of research reports, websites and laws/ 
regulations, as well as from interviews conducted during the field visit2. 
1.2.1 Historical and legal background 
The law of 21/02/1921 known as the ‘drug law’ prohibited any doctor from 
maintaining dependence by prescribing medicine. The royal decree of 1930 
lists the substances concerned by the drug law. Article 23 states that any 
physician who ‘starts, maintains or aggravates a pre-existing dependence’ 
will be prosecuted. From 1982 and on, most of the provincial medical com-
missions published guidelines on prescribing narcotics. The 1975 law was a 
revision of the 1921 drug law and was aimed at refining the list of substances 
and increasing the government’s control system to ‘fight drugs’. It stated that 
doctors ‘can be punished if they abuse their authority to prescribe, deliver or 
administer any product that can establish, maintain or aggravate dependence’ 
(no need to prove a pre-established dependence). (Todts, unpublished) 
The first doctors to provide substitution treatment did so in the mid-nineteen 
seventies and in the form of methadone, bezitramide and dextromoramide. 
Deaths by overdose from topping up methadone with medication in the 
1980s (Reisinger & Picard, 1996) resulted in the prosecution of doctors pre-
scribing substitution treatment (not the treatment banning). Dr. Baudour and 
Dr. Nystrom were both sentenced for the prescription of methadone and 
bezitramide respectively.3 4  
                                                          
2  Interviews were conducted at the national level with: 
– The Drug Co-ordinator, Ministry of Justice. 
– The Director General of the Directorate General Execution of Sentences and Measures, 
Ministry of Justice.. 
– The medical doctor director of Penitentiary Health Service at the Ministry of Justice 
– The inspector of medical services for the prisons located in the French area of Belgium, 
Ministry of Justice. 
– The co-ordinator of Psychosocial Service for Prisons, Ministry of Justice. 
– The director of Modus Vivendi, NGO. 
3  Corr. Brussel, 16 februari 1984, J.Proc., 2 maart 1984, 25-33. 
4  Brussel, 7 november 1985, J.T., 1986, 371. 
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A legal battle started between the Belgian Medical Association (BMA)5 and 
doctors united in the ‘Initiative Déontologique Médicale’ (IDM) – Medical 
Deontological Initiative. Indeed, in 1986, the national council named the 
BMA and the judicial authorities responsible in judging what constitutes 
abuse (as the drug law does not define ‘abuse’). Facing a growing epidemic 
of drug use and HIV, despite the legal conflict, doctors prescribed bezitra-
mide, methadone and buprenorphine. The legal battle concluded in 1993 
with the State Council (a Court with the authority to verify the legality of 
directives) reviewing the BMA’s directives and supporting doctors’ rights to 
prescribe substitution treatment. (Todts, unpublished) 
A consensus conference on substitution treatment was held in Brussels in 
October 1994 (a follow-up of the Consensus conference was organised in 
2000 and put forward a few additional recommendations) (Pelc, 2004). The 
consensus statement of 1994 acknowledged two substances for treatment: 
methadone and buprenorphine; and rejected bezitramide for a lack of scienti-
fic evidence. Although the statement underlines that substitution treatment 
should be provided to persons 18 years old or older who have used heroin for 
at least one year, specialised doctors are allowed to administer such treat-
ment to anyone further to careful examination. The statement emphasises 
that methadone, if adequately provided, is safe and effective; effective to re-
duce heroin use, HIV-Hepatitis risk behaviours, and criminal behaviour, and 
to improve, social and professional skills. The statement claims that the daily 
dose of methadone – taken in an oral form - should start at 30 or 40 mg and 
eventually increase or decrease according to the individual’s needs. Metha-
done treatment may be provided with or without a set duration. Short-term 
detoxification goes from 3 weeks to 3 months. Occasionally topping up the 
methadone treatment does not imply termination of the treatment. Finally, 
the statement underlines the importance of providing psychosocial care and 
support along with the substitution treatment. 
On 1st October 2002 the drug law of 1921 was altered to include substitution 
treatment on a maintenance basis (Law of 22 August 2002). This law effecti-
vely states that substitution treatment is legal. (Todts, unpublished) 
                                                          
5  Each doctor practising medicine in Belgium must be a member of the Belgian Medical 
Association (BMA). The BMA has provincial councils and one national council and has 
disciplinary authority over its members. 
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The Royal Decree of 19 March 2004, published on 30 April 2004, defines 
the two substances to be used as a substitution treatment: methadone and 
buprenorphine. It also states that only medical doctors trained in substitution 
treatment can deliver this treatment; they must adopt a multi-disciplinary 
approach and must keep a medical record for every patient on the treatment. 
The decree differentiates between doctors who ‘habitually’ prescribe substi-
tution treatment, who must be able to prove they have an expertise within 
substitution treatment, and other doctors, who are allowed to prescribe once 
registered with a specialised organisation or network. A registration of pati-
ents on substitution treatment is set through the insurance companies. This 
Royal Decree establishes a legal framework for the provision of substitution 
treatment. (Todts, unpublished) 
Geographical differences 
There is a tendency in Belgium for geographical differences in the provision 
of treatment to occur due to the country’s structure and the way health care 
to drug users is managed for. Prisons are managed at the federal level by the 
Ministry of Justice, but Belgium’s communities have autonomous compe-
tence. 
At the moment, in the community, substitution treatment is offered at the 
level of MASS/MSOC in certain ambulatory centres and by a GP (private 
office). It was reported that the Flemish-speaking part of Belgium had been 
more reluctant and cautious in providing substitution treatment in the com-
munity and in prison, where the psychiatrist is generally in charge of the 
treatment. The French-speaking part of Belgium had been more in favour 
and ahead of the Flemish part, largely due to the influence of the ‘Initiative 
Déontologique Médicale’ (Medical Deontological Initiative). Generally, in 
the French community, the GP provides substitution treatment in the com-
munity and in prison. 
1.2.2 Substitution treatment in prison 
The two substances offered as part of a substitution treatment in prison are 
methadone and buprenorphine.  
At first, substitution treatment was available in prisons on a limited basis. 
The BMA recommended providing the treatment mainly on a detoxification 
basis. Detoxification could also be conducted with the use of medications, 
such as benzodiazepines and neuroleptics. Substitution treatment on a main-
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tenance basis was recommended for vulnerable groups, such as pregnant 
women, prisoners positive for HIV or hepatitis, and short-term incarceration 
(less than one year). Initiation of substitution treatment in prison was excep-
tional. A prisoner on substitution treatment was to continue his/her treatment 
if transferred to another prison. (Reitox National Report, 2002)6 
Although BMA made recommendations, substitution treatment in prison was 
the sole responsibility of the prison’s doctor. 7 Nevertheless, in prisons, ther-
apy choices are not only guided by doctors’ personal insights, but often also 
by prison traditions and beliefs as expressed by the management and other 
stake holders, including drug free-oriented co-operators from specialised 
NGOs (Todts, unpublished). 
The BMA no longer recommends detoxification. Although the guiding text 
is still the circular letter of December 2000, interpretations of what is allo-
wed have been broadened, especially further to Todts’s ‘advice’ on bupre-
norphine and methadone written in 2002. The methadone advice was signed 
by the Head of Health Service in prison and the Head of Psychosocial ser-
vice in prison. In the near future, it is to be expected that possibilities of sub-
stitution treatment will broaden further and be available to a higher number 
of patients. (Todts, interviewed) 
The Ministry of Justice provides health care in prison. All treatment and 
medication costs are paid by the Ministry of Justice. 
Methadone has been the main substitution treatment provided in prisons, as 
buprenorphine has been reimbursed in the whole country only since August 
2003. This change may impact on the type of substitution treatment provided 
in the country in and out of prison (although this still has not happened by 
May 2004).  
There is no contract between the prisoner and the doctor regarding substitu-
tion treatment provision, although this was at the time of the visit under dis-
                                                          
6  Ministerial circular number 1722 of 18 December 2000 relative to the integral approach of 
drug use in penitentiary establishments (‘Circulaire ministérielle n° 1722 du 18 décembre 
2000 relative à l’approche intégrale de la problématique de la drogue dans les établisse-
ments pénitentiaires’). 
7  Tijdschrift Nationale Raad Orde van Geneesheren, september 1996, vol. V nr. 73, 24, 
geciteerd in: Van Mol, F., Gezondheid en detentie, Brussel, Penitentiaire gezondheids-
dienst, 80. 
 93 
 
cussion as a plan to hold a contract was being drawn, further to some pris-
ons, like Ypres Prison, asking for (or using ‘unofficially’) such a contract. 
The provision of methadone in prison is provided by a local pharmacist 
(instead of a central one), meaning that one day per week (the same day 
every week, at the same time) the same person from the prison (either the 
psychiatrist or GP in charge of substitution treatment) goes to the pharmacist 
to get the doses for all prisoners for one week. All doses are prepared for 
daily use and are labelled with the name of the prisoner. Methadone is only 
provided in liquid form. (Todts, unpublished) 
Upon arrival at the prison, a prisoner on substitution treatment in the com-
munity informs the prison of his/her doctor in the community. Once the trace 
is confirmed, substitution treatment is usually provided following the provi-
sion in the community. Usually, new entrants are not provided with metha-
done within the first 24 hours since their drug intake is unknown. 
In case of transfer, although the computerised system allows information on 
prisoners to be transferred easily from one prison to the other, it was reported 
that a prisoner on maintenance transferred to a prison where substitution 
treatment is only provided on a detoxification basis, is very likely to receive 
substitution treatment on a detoxification basis (and not maintenance). 
A liaison with a community centre or a doctor that provides substitution 
treatment must be organised prior to release for the prisoner to be able to 
continue his/ her treatment once released. (Todts, unpublished) 
The Prison Health Service has the right to advise doctors to provide substi-
tution treatment. Doctors have the right to 'therapeutic freedom', allowing 
them to choose or reject available therapies. This may lead to some prisoners 
not receiving substitution treatment because the doctor does not agree with 
such a treatment for ethical reasons. 
Geographical differences 
The geographical differences mentioned earlier have been illustrated in the 
field visit as – at the time of the visit – substitution treatment in the prison 
located in the Flemish part of the country was managed by psychiatrists; 
whereas substitution treatment in the prison located in the French part of the 
country was managed by a GP. 
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Generally speaking, in prison, doctors in charge of substitution treatment are 
either the GP or the psychiatrist. Each prison has a convention defining who 
is in charge of the treatment. GPs belong to the Medical service for Prisons 
at the Ministry of Justice, whereas psychiatrists belong to the Psychosocial 
Service for Prisons at the Ministry of Justice. Either the GP or the psychia-
trist is to prescribe substitution treatment within the same prison. Although 
GPs do not draw ‘expertise reports’ on prisoners for the Ministry of Justice, 
some psychiatrists do. A psychiatrist is not allowed to provide clinical con-
sultancy and conduct expertise within the same establishment. However, this 
may not be clear to all prisoners who may be somewhat reluctant to consult.  
Psychosocial support and staff training 
‘It is stated that psychosocial counselling and assistance to patients are fac-
tors improving the results of methadone treatment’ (Reitox National Report, 
2002, pg. 87). 
However, it was reported that in general no proper psychosocial treatment is 
offered to prisoners due to a lack of resources. Psychologists must also pro-
vide the Ministry of Justice with reports on the prisoner including referrals 
and links with the community regarding housing, jobs and health care. 
There tends to be more external psychosocial services in the North part of 
Belgium, although the situation is problematic in the North and South part as 
financial means lack to fund such services. 
Regarding training offered to medical staff in charge of the substitution 
treatment, it was reported that the Health Service has trained its staff exten-
sively on substitution treatment. 
1.3 Prison Population 
Table 4 Data on the prison situation in Belgium (Source: King’s College London, Interna-
tional Centre for Prison Studies, Prison Brief for Belgium). 
Country  BELGIUM 
Ministry responsible of Prisons Ministry of Justice 
Prison administration  Directorate General of the Penitentiary Admini-stration
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Head of prison administration  
(and title)  
Gisleen van Belle  
Director General 
Prison population total  
(including pre-trial detainees / 
remand prisoners)  
8,764 at 1.9.2001 (Council of Europe Annual Penal 
Statistics)  
9,245 at 1/3/2004 (Ministry of Justice) 
Prison population rate  
(per 100,000 of national population)  
85 based on an estimated national po-
pulation of 10.28 million at mid-2001 
(from Council of Europe figures)  
89.3 (based on a population of 
10,355,844 on 1/1/2003, National In-
stitute Statistics), Ministry of Justice  
Pre-trial detainees / remand prisoners  
(percentage of prison population)  
22.9%  (1.9.2001 – plus 18.5% convicted but sen-
tence unconfirmed) 
39%      (N=3,614 out of 9,245) (1/3/2004, Ministry 
of Justice) 
Female prisoners  
(percentage of prison population)  
4.1%    (1.9.2000)  
3.9% (N=362 out of 9,258) (30/12/2003), Ministry 
of Justice 
Juveniles / minors / young prisoners 
incl. definition (percentage of prison 
population)  
1.1%    (1.9.2000 – under 18)  
Special youth courts are competent for offences 
committed by youths. 
Foreign prisoners 
(percentage of prison population)  
40.4%  (1.9.2000)  
42.5 % (30/12/2000) – Ministry of Justice 
Number of establishments / instituti-
ons  32 (2002)  
Official capacity of prison system  6,896   (1.9.2001) 
8,092   (14/11/2003), Ministry of Justice 
Occupancy level (based on official 
capacity)  
127.1% (1.9.2001) 
114.2%  (9,245 out of 8,092) (1/3/2004, Ministry of 
Justice) 
Recent prison population trend 
(year, prison population total, prison 
population rate)  
1992     7,116     (71) 
1995     7,561     (75) 
1998     8,271     (81) 
2004     9,245 (1/3/2004, Ministry of Justice) 
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2 The field visits8 
Time frame. The field visit took place from 13 to 18 June 2003. 
Location. Visits were conducted in two prisons: Jamioulx Prison and Ghent 
Prison. 
 
 
Map of prisons in Belgium 
Visits were conducted in two prisons: one in the French speaking area of 
Belgium, where the medical doctor is in charge of substitution treatment, and 
one in the Flemish speaking are of Belgium, where the psychiatrist is in 
                                                          
8  Methodology. Interviews were conducted with the hereunder mentioned individuals and 
focus groups (tape-recorded with consent) with the prisoners. The researcher conducted all 
interviews/ focus groups on her own, accompanied by a freelance and neutral interpreter in 
Ghent Prison, Flemish speaking area. All participants were briefed and told about ethical 
issues. 
Jamioulx Prison 
Ghent Prison 
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charge of substitution treatment, illustrating the differences between the 
North and the South of Belgium as reported above. 
2.1 Jamioulx Prison9 
2.1.1 Description of the prison 
Jamioulx prison is located in the city of Charleroi, situated in Wallonia, the 
French speaking part of Belgium. Charleroi has a high level of criminality 
and unemployment. 
Jamioulx prison is a male, remand prison, holding approximately 400 priso-
ners for a capacity of 269 (31/12/2003, Ministry of Justice), some of which 
are sentenced prisoners. The majority are in a closed detention with some 
prisoners in half-open detention. It was reported that the prison faces serious 
drug use (legal and illegal on the black market) inside the prison on a daily 
basis. 
The prison was built in an L structure, the main surveillance point being 
located at the extremity (not the centre), posing practical issues and mana-
gement difficulties to the penitentiary staff. 
2.1.2 Goals and practical procedures 
Substitution treatment was initiated in Jamioulx Prison by the doctor, a gen-
eral practitioner (GP) who has been working for years on the drugs field in 
the community. It was reported that substitution treatment has been running 
for about 5 years in the prison. Resistance and obstacles from the prison staff 
were first felt at the implementation of substitution treatment in the prison, 
but substitution treatment is now a well-established programme managed by 
the medical team (GPs). Substitution treatment is offered as a continuation of 
what the patient received in the community (either detoxification or mainte-
nance programme) or is initiated in the prison, further to the doctors’ thera-
peutic freedom. 
                                                          
9  Interviews were conducted with: 
– A medical doctor (GP) and doctor in charge. 
– The physiotherapist. 
– A security officer working in the medical centre. 
– Security officers and a guard head of section. 
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The medical team said that out the 400 prisoners, 40 are on methadone 
treatment, receiving an average dose of 22 mg of methadone per day. It was 
reported that the maximum dose a prisoner has received in the prison is 
110 mg of methadone. It was also reported that prisoners are given 10% less 
of the dose given in the community because the medical team feels that pris-
oners are better looked after in prison and can report their needs more easily 
than outside.  
At the time of the visit, June 2003, methadone was the only substitution 
treatment provided. Buprenorphine has only been reimbursed in Belgium 
since August 2003, and was therefore not offered at the time of the visit. The 
GP reported that methadone is well managed and known by the medical 
doctors and the prisoners, contrarily to buprenorphine. The medical staff 
reported transferring a French prisoner who received buprenorphine treat-
ment in France to a methadone programme when he was incarcerated at 
Jamioulx Prison successfully. 
The medical team said they estimate that 10 out of the 40 prisoners on 
methadone treatment have no real motivation to stop drugs, 10 are going 
through a difficult time but do not use illegal drugs, 5 have a real motivation 
to become drug free, and the others are unstable. 20 out of the 40 prisoners 
on methadone were known from the community drug services before being 
incarcerated.  
The medical team said that substitution treatment, provided on an individual 
basis, offers prisoners a chance to get off drugs if they are motivated to 
become drug free and to acquire stability. A security guard stated that sub-
stitution treatment is useful only for some prisoners, but is used as another 
drug (for consumption or for traffic) by others. 
Difficulties linked to substitution treatment reported by the medical staff 
were: (i) thefts of methadone in the prison pharmacy (although the stolen 
items are often quickly found), (ii) medical doctors are not informed of pris-
oners’ release; the file of the prisoner disappears from the prison screen, and 
(iii) overdoses due to alcohol and benzodiazepines from the black market 
topped up with methadone. However, the use of methadone has meant a 
decrease of the consumption of prescribed, legal drugs.  
The medical team reported that drug-using prisoners with no treatment from 
the community or other prison are offered (i) analgesics (e.g. codeine), neu-
roleptics (e.g. triapridal), benzodiazepines (e.g. valium) towards detoxifica-
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tion, given in the evening (although dependence on these legal drugs is 
common), or (ii) methadone treatment, known and requested by many priso-
ners. 
Drug-using prisoners who are new entrants at the prison and who claim they 
received substitution treatment outside tend to ask to continue substitution 
treatment in prison. A trace with their situation in the community is establis-
hed, and if needed, half of the dose of what they received outside is given if 
the individual is going through withdrawal and the trace could not be esta-
blished right the way. 
Substitution treatment is provided to prisoners every day, in the morning 
around 7.00 am or earlier if the prisoner is awaken earlier. When receiving 
his dose, the prisoner signs a receipt document. Methadone is prescribed 
once a week. The GP is in charge of receiving the substitution treatments, 
once a week from the local area pharmacist who always provides it to the 
same designated, person in charge every week on the same day of the week 
and at the same time. 
It was reported that no urine analysis are conducted for prisoners on substi-
tution treatment because this would imply a ‘control’ role from the medical 
team and control and treatment are seen as incompatible. Instead ‘trust’, 
better communication (asking prisoners about their drug use) and patients’ 
competences and responsibilities in substitution treatment are encouraged.  
The medical team and the psychosocial team10 do not work together. At 
Jamioulx Prison the psychosocial team plays no or very little role in substi-
tution treatment. The medical team said they are not informed of the psycho-
social aspect of prisoners by the psychosocial team. The psychiatrist (in 
charge of the psychosocial team) is in charge of the psychiatric wing and 
looks after abusers, mentally and physically ill prisoners (around 20 to 25 of 
them). 
The GP doctor reported that he believes that the psychosocial team and the 
‘Directorate General Execution of Sentences and Measures’ do not hold a 
negative perception of substitution treatment and of prisoners on substitution 
treatment. However, some prisoners believe that if they stop taking metha-
done, they will acquire conditional freedom earlier. 
                                                          
10  The psychosocial team focuses on providing the Ministry of Justice an expertise report and 
provides psycho-social support, when sufficient time and staff resources. 
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It was reported that although it is obvious to all prisoners and prison staff 
which prisoners take substitution treatment, not hiding who is on substitution 
treatment helps to de-stigmatise substitution treatment and drug users and 
encourages communication about the topic. 
It was found that the medical team works closely with prison staff, especially 
security guards working in the medical centre, holding meetings, and trying 
to work closely together. 
2.2 Ghent Prison11 
2.2.1 Description of the prison 
Ghent Prison is located in the city of Ghent, situated in the Flemish speaking 
part of Belgium. The building is in a star-like shape, surveillance being 
located at the centre, enabling easy control and surveillance. 
Ghent Prison is a remand prison, with some 40 sentenced prisoners and 
60 ‘internés’ (i.e. individuals declared not responsible for their acts because 
of psychiatric problems)12. The prison holds 315 prisoners (time of field 
visit) for a capacity of 283 (31/12/2003, Ministry of Justice). The majority 
are male prisoners located in 3 wings. 33 female prisoners (capacity for 42), 
on remand or sentenced for at least 5 years, are located in an attached but 
separated wing. 
The prison counts 220 staff of which 180 are prison guards, 4 psychologists, 
3 social workers, 3 psychiatrists, 5 nurses, and 4 GPs (who provide 2 types 
of consultations per day: to new entrants and to current prisoners). 
2.2.2 Goals and practical procedures 
The substitution treatment programme, as methadone, had only been running 
for a couple of months at the time of the visit. Methadone became available 
                                                          
11  Interviews were conducted with: 
– The governor 
– A psychiatrist 
– A psychologist 
– A nurse 
12  ‘Internés’ should be sent to therapeutic settings, but one third remains in prison. Recently, 
a number of forensic psychiatric units have been set up in general psychiatric hospitals for 
medium security ‘internés’. 
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further to the initiative of a psychiatrist. Previously, it was reported, no sub-
stitution treatment was offered at all, mainly due to a doctor reluctance and 
opposition to the provision of methadone in prison. At the time of the visit, 
buprenorphine was not offered as it was not reimbursed and not a known 
treatment, increasing doctors’ reluctance to provide it. 
It was reported that the 3 psychiatrists at the Ghent Prison are in charge of 
prescribing substitution treatment, and decide together to provide substitu-
tion treatment or not, on a detoxification or maintenance basis. Two of them 
deliver methadone to prisoners. A psychiatrist stated that he tends to conti-
nue the treatment that the prisoner has received in the community and works 
on an individual approach. He also said that methadone treatment in prison 
can be initiated in prison but is rarely done. It was reported that substitution 
treatment is equally offered as maintenance and as detoxification to the cur-
rent 3 prisoners on methadone; detoxification may go over a period of 5 to 
6 weeks.  
At the time of field visit the medical staff reported that 3 prisoners were on 
methadone treatment. The maximum dose that has been given at the prison is 
80-90 mg. 
It was reported that the governor of the prison is not asked for permission to 
implement and provide substitution treatment but he is debriefed on decisi-
ons and practises used in the prison. 
The medical team stated that methadone is ordered from a local pharmacist 
and delivered every week on the same day, same time and to the same doctor 
in charge of collecting the treatment. They also said that prisoners receive 
their liquid dose of methadone daily at 5-6 pm at the medical centre, where 
no prison officers are present. All treatments (methadone and other) are dis-
tributed to all prisoners at the same time and place.  
The psychologist reported that she is not automatically informed of which 
prisoners take substitution treatment, but she is told by prisoners. The psy-
chiatrists may also inform her if perceived as relevant, and she might report 
specific issues linked to substitution treatment (individual topping up, or 
going through withdrawal, etc.) to the psychiatrist if needed. 
It was reported that prisoners do not want to be identified as drug users as 
they fear the judicial authorities to be informed of their drug use, and as a 
result to obtain a more severe sentence.  
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2.3 Prisoners’ experiences 
Focus groups and interview were conducted with prisoners: 
− A focus group with 3 prisoners – Jamioulx Prison  
− A focus group with 6 male prisoners - Ghent Prison 
− An interview with one female prisoner - Ghent Prison 
Prisoners stated that methadone has helped them in many ways. 
‘Substitution treatment… it is a spare wheel.’ 
‘Methadone, for us, it is good to reduce the dose.’ 
‘I have been taking in prison methadone for 4 years, it has greatly helped 
me, in the sense that it has allows me to reduce the violence that is within 
me.’ 
‘Why do they take methadone? Because we must live our days, find stability 
in prison.’ 
‘I take methadone here in prison to calm me down, to do my sentence. But I 
am sure that once I am released, I will not want to hear about methadone 
anymore, because I do not want to be dependent. I have done 9 treatments 
and I think that now I am 30 years old and I am getting tired of it all.’ 
However, some prisoners reported viewing methadone as another drug or 
taking it on the black market. 
‘The pleasure I get from taking drugs is such that despite all that is offered 
to us to become drugs free, I do not want to stop (…) it is clear that I prefer 
methadone considering its purity and the kick it gives.’ 
‘I know some people who take methadone (…) they put in a spoon and inject 
it. For them it is the same [as illegal drugs] and that is drugs that they do 
not pay. It is free.’ 
‘Receiving methadone doesn’t help us. I was drugs free for 7 years and rea-
lised that I felt better when I take nothing. (…) Taking methadone in prison 
is bad because it incites my desire [of drugs].’ 
‘At first I couldn’t have methadone because the prison where I was did not 
prescribe methadone at the time. So I smuggled some in from the black mar-
ket.’ 
Prisoners reported side-effects of methadone. 
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‘I don’t like methadone anyway because when we need to detox from metha-
done, it is terrible.’ 
‘I came in here [prison], and I said that I was on methadone. It was still in 
my urine, so they couldn’t deny it. It [methadone] was just not to think; it 
wasn’t because I was ill. It was just because it had the same effect or almost 
than heroin. It’s even worse actually. The withdrawal from heroin, that lasts 
for 3-5 days. The withdrawal from methadone, that’s 1 month (…). It’s eas-
ier to stop heroin, you know you will suffer for 5 days. If you take medicine 
or methadone, you know you are going to suffer for longer. I asked to stop 
[methadone] within 20 days. I was on 40 mg and within 20 days, I stopped. 
So 2 per day. Here, in prison, it’s better than outside. Outside, you suffer. 
Here, you don’t feel it because you are busy, you don’t think about it. But 
outside, you think about it and you know that you can have some [drugs] out-
side.’ 
‘A heroin user will stop heroin, will be sick for 10 days. A methadone user, 
he will stop methadone and that might last for 25 days, 1 month. When we 
stop methadone directly or even progressively, the problem is to get a nor-
mal sleeping pattern, that is 4 to 6 hours of sleep, it will take us 2 to 
4 months. Meaning that the bloke that stops methadone will sleep very, very 
poorly for 2 to 4 months and these 2 to 4 months can be critical and often 
people do not dare to stop because they apprehend that’. 
‘I was fed up with methadone (…) I felt even more down in fact.’ 
‘For 2 months I was ok, I felt nothing. I felt ok in the morning, but after-
wards, I felt it: my legs, my arms, my whole body was in pain. I drank 
methadone and 15 minutes later I was alive again. It’s like a plant that needs 
water. You live like a plant, that’s it, no other way, that’s the reality.’ 
‘When I took [methadone] I didn’t think. Now my mind is working again. 
When you take methadone you have no feelings even towards your partner. It 
changes all. I have noticed. Even dreams, when I took methadone I stopped 
dreaming, I did not want sex, did not want this or that. Now that I no longer 
take methadone, all comes back, all feelings come back.’ 
It was reported that methadone is helpful and has various advantages but 
does not solve the problematic issue solely. Prisoners’ needs were mainly 
about talking and wanting an individual approach allowing for more discus-
sion (to be listened to and to talk to). 
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‘The individual who decreases the dose needs to talk. The person in treat-
ment, if s/he does not talk, then the therapy is wrong. So it is nice to get pre-
scribed methadone, but it does not solve the problem.’ 
3 Summing up 
Recently, in the community and in prison, a lot of changes concerning sub-
stitution treatment at the legislative level as well as the practical level have 
occurred. Old practises favouring detoxification with methadone are still in 
place, but means to increase the availability and offer of substitution treat-
ment in and out of prison have been set. 
Development within prisons may occur at different paces in different regions 
and prisons of the country, although it was reported that within one year 
(between the time of the visit and the publication of the report) progress 
occurred in the prisons visited. 
Prisoners’ perceptions of substitution treatment were often mixed, as some 
stated that methadone was a key progress in the treatment of drug users, but 
also was ‘worse’ than heroin to detox from. Prisoners also stated that psy-
chosocial support was lacking: more of it and more dialogue between prison-
ers and prison and medical staff may help them all to understand substitution 
treatment (purpose and functioning) better. 
The doctors’ ‘battle’ to prescribe substitution treatment to drug users in and 
out of prison remains part of the history and may explain the reluctance of 
some doctors to prescribe the treatment or to still offer it on a maintenance 
basis, when a legal framework now exists supporting variety in the practise 
and response to individual needs. 
  
The Czech Republic1 2 
1 General data:  
drug use, substitution treatment and prison population 
1.1 Drug use 
The number of drug users is estimated to be between 35 000 and 37 5003. In 
9 Czech centres, 463 patients were registered on methadone and between 
500 to 700 patients were on buprenorphine treatment (Reitox Czech Repub-
lic, 2002). 
In 2001, prisons reported that 38.5 % of prisoners were registered as drug 
users. This trend has increased through the years (from a level of 22.5% in 
1998). Prison specialists estimated that the number of drug users in prison 
today is approximately 46% (Sochurek and Slukova, 2003). 
While the number of experimental and recreational drug users has been 
increasing in the Czech Republic (especially in relation to cannabis and 
ecstasy), the number of problem drug users (i.e. heroin and pervitin users) 
has stabilised (Reitox Czech Republic, 2002). 
The most commonly used psychoactive substances are marijuana and pervi-
tin or heroin4 (Reitox Czech Republic, 2002). Pervitin is a type of ampheta-
mine, used intravenously. Pervitin causes faster thought, movement, a good 
mood, feelings of greater creativity and relaxation. But, in the long term, it 
                                                          
1  The field visit, conducted by Laetitia Hennebel, was facilitated by Jan Sochurek, Prison 
Service Administration, and Jiri Richter, SANANIM NGO; both also provided national 
information and support with the finalisation of this country report. 
2  Terminology: in the Czech Republic cells are often called rooms. Guards are also called 
‘uniform staff’. Type A prisoner is on the lowest security regime, whereas type D prisoner 
is on the highest security regime. 
3  In 2002, among the 35-37 500 problem drug users, approximately 30 000 were injectors, 
13 500 users of heroin and 21 800 users of pervitin (Reitox Czech Republic, 2003). 
4  16% (1 150 000) of Czech citizens have used illicit drugs, mainly cannabis and hashish. 
4% of Czech citizens aged 15-64 have used the party drug ecstasy at least once in their life. 
Less than 1% of the population have used other drugs such as heroin, pervitin, cocaine or 
LSD (Reitox Czech Republic, 2002). 
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may also cause psychological dependence and has side effects such as indu-
cing a state of psychosis, hallucinations, or manic disorders.  
The national prevalence of 
− HIV/AIDS is 0.01% in the general population, 0.05% among intravenous 
drug users (IDUs) 
− TB is 1.5/10 000 in the general population, unknown among IDUs 
− Hepatitis is 5-7% in the general population, cca 10% in the IDUs, VHC 
cca 0,5% in the general population, 35% in IDUs, estimating that one in 
3 intravenously drug user is infected with Hep C. 
(Source: Reitox Czech Republic, 2002) 
In all prisons in the Czech Republic, health care is covered by the Prison 
Service’s own staff (medical doctors, nurses and specialists) and thus falls 
under the Ministry of Justice’s umbrella. Services that are not available in 
prison are contracted out to specialised or general hospital units. Health insu-
rance covers preventative care and medication. Therefore, according to the 
Czech law 169/1999 on the Execution of Penalty of Imprisonment, prisoners 
have the right to insurance. 
1.2 Substitution treatment 
Data comes from an on-going review of research reports, websites and laws/ 
regulations of the Czech Republic, as well as from interviews conducted 
during the field visit5. 
                                                          
5  Interviews conducted at the national level with: 
– Head of the department for special treatment with prisoners, Prison Administration Ser-
vice, Ministry of Justice. 
– An officer from the Prison Administration Service, the person in charge of social work-
ers for juveniles and adults and the link with the Probation in all prisons in the Czech 
Republic. 
– The Director and Head of the Probation and Mediation Services, Ministry of Justice. 
– A psychiatrist, the prison hospital located in Prague. 
– A psychiatrist M.D., Academia Medica Pragensis. 
– A pedagogue and therapist, Pudane Ruce (NGO), Brno. 
– A psychologist and psycho-therapeutic trainer, Pudane Ruce (NGO). 
– A social worker, SANANIM (NGO). 
– The Executive Director, SANANIM (NGO) and chairman of A.N.O. (umbrella associa-
tion for NGOs). 
– A social worker, LAXUS (NGO). 
 107 
 
1.2.1 Historical and legal background 
The Ministry of Health sets the rules for substitution treatment in the com-
munity. 
Since the 1970s, Diolan® (containing ethylmorphine) and Temgesic® (that 
is low dosage of buprenorphine) were the two mostly used substitution sub-
stances. In 1992, methadone was introduced following the initiative of 
Dr. Jirí Presl (Head Physician of a drop-in centre) for the most problematic 
patients who had been unsuccessful with other types of treatment. Although 
Dr. Presl was authorised by the Ministry of Health of the Czech and Slovak 
Federal Republic to provide substitution treatment as a one-year pilot, the 
programme was not renewed. In 1997, following an increase in heroin use 
and public pressure, a second pilot programme – offering methadone to 
20 patients – was carried out under the supervision of the Ministry of Health 
in the Department of Addiction Treatment of 1st Medical Faculty. On the 
back of a positive evaluation (results indicated better mental and physical 
health, as well as a reduction of recidivism), this programme was kept open 
and new treatment programmes were progressively opened all through the 
country. Indeed, the Criminal Code changed in April 1998. At the same time, 
the House of Representatives adopted a complimentary resolution – focusing 
on the treatment component of the drug policy – which resulted in an 
increase in treatment capacity. In 1999, the Ministry of Health set up a 
working group that presented ‘Substitution Treatment Standards’, an educa-
tional program for health professionals, and a ‘Substitution Treatment Reg-
ister’. In May 2000, 7 new substitution programmes were opened in new 
areas of the country. Through substitution treatment, health professionals 
have managed to attract Romany opiate users. Waiting lists or geographical 
differences in the number of treatments offered are problematic for users 
who wish to engage into treatment (Reitox Czech Republic, 2002). 
At the beginning of 2001, the National Institute of Drug Control (SÚKL) 
registered buprenorphine (Subutex®) as a medicine in the Czech legislation. 
Unlike methadone, doctors have no obligation to report buprenorphine use to 
the register. Buprenorphine is not paid by health insurance and must there-
fore be fully paid by the patient. (Reitox Czech Republic, 2002) Since 
1 September 2003 buprenorphine was moved from “free” prescription to 
opiate prescription, meaning that ‘any doctor’, with or without specializa-
tion, is allowed to prescribe it. However, the doctor must fulfil some ‘guide-
lines’ for the manipulation, such as keeping the medicine in a safe box, 
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making precise registration, etc. The idea behind these guidelines was to 
minimise the risks of substances on the black market and false prescriptions. 
In 2002, 463 patients were treated in 9 substitution programmes: 105 of them 
were in treatment for the first time in their lives. Within the same year, 
213 completed their treatment. In 2001, it was estimated that 40% of drug 
users (about 17 000 people) came in contact with treatment services (Reitox 
Czech Republic, 2002) with an increase to 59% in 2002 (Reitox Czech 
Republic, 2003). An NGO reported that the University Hospital has a capac-
ity for 20 substitution patients but, maybe due to the low prevalence of her-
oin use, is not full at present. However, the low number of heroin users in 
treatment is partly due to the limited availability of substitution treatment in 
the Czech Republic. Indeed, in 2002 professional reported that the number of 
opiate users in a substitution treatment was, and remains, inadequate. With 
approximately 1 000 people on substitution treatment, only 7% of opiate 
users are being reached. Across the European Union, the average treatment 
level is 30% (Reitox Czech Republic, 2003). 
It was reported that, since buprenorphine is available, there has been an 
increase in the prescription of buprenorphine in outpatient clinics of psy-
chiatrists and general practitioners. (Executive Director, NGO). The govern-
ment provides financial support to non-profit, NGO centres that provide the 
substitution treatment. 22 centres reported providing buprenorphine. How-
ever, GPs outside these centres also prescribe (Psychiatrist, Academia 
Medica Progensis). 
In 2001, 167 drug-related deaths were identified, of which 39 were due to 
Rohypnol®, 30 with opiates, 27 with benzodiazepines other than Rohypnol® 
and 3 with methadone and other drugs (Reitox Czech Republic, 2002). 
1.2.2 Substitution treatment in prison 
Prisons have focused on abstinence-oriented programmes for drug users and 
do not offer substitution treatment. It was reported that the prison offers a 
different environment than in the community, where conditions for absti-
nence can be arranged (prison staff). Drug users and substitution treatment 
tend to be seen negatively by prison staff who are not in favour of such 
treatment (NGOs). 
Nevertheless, the prison administration reported that the provision of substi-
tution treatment in prison was currently being discussed. NGOs concurred 
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that it was being debated very carefully but added that, due to the prison 
management’s reluctance, it was not part of broader discussions. 
Further to the initiative of a psychiatrist working at the Prison Hospital in 
Prague, prisoners (Czech, foreigners, on remand or sentenced, female or 
male) may get substitution treatment on a short-term, detoxification basis 
with buprenorphine. The psychiatrist reported that prisoners often say that 
the only time they have abstained from drugs was whilst in prison. There-
fore, the use of substitution as a maintenance treatment seems inappropriate 
at the moment (which does not mean that the situation may not change). Per-
sonally, she is not in favour of methadone. 
Buprenorphine is provided in the medical centre by skilled medical staff. 
Prisoners must take the pill (sub-lingual) in front of the staff and remain 
there until the pill has melted. The dose decreases (every day or every other 
day), usually starting at 4mg and ending at 0.4mg. The detoxification usually 
covers a period of up to 10 days, although it may vary according to the doc-
tor’s decision. On weekends, the hospital staff go to the cells to deliver 
buprenorphine. It was reported that, from June to September 2003, 40 pati-
ents have received buprenorphine in the prison hospital. 
The doctor stated she was satisfied with the treatment but was not in favour 
of methadone treatment as it was seen as more risky for overdoses. Staff are 
pleased with prisoners being quieter and more manageable. Prior to the pro-
vision of the treatment, meetings were organised to decide on the most suita-
ble and secure way to provide buprenorphine. 
Financial support for buprenorphine treatment has come from the Prison 
Service Headquarters. The medication is collected at a general pharmacy in 
the community. 
The doctor stated that obstacles to implementing and developing the provi-
sion of this treatment are due to beliefs and prejudices from colleagues and 
prison administration. 
1.2.3 Psychosocial support and staff training 
Buprenorphine, widely available in the country, is prescribed by GPs but, as 
it is not linked to any specific programme, there is no follow-up. Many GPs 
do not follow the guidelines, e.g. double prescription, or provide no reports 
(Psychiatrist, Academia Medica Progensis). 
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Information on complimentary psycho-social support in prison is lacking due 
to the fact that substitution treatment is only offered on detoxification basis. 
All prison staff are trained (induction and on-going) by the Institute of Edu-
cation of the Prison Service. No specific training on substitution treatment 
was mentioned. 
1.3 Prison Population 
Table 5  Data on the prison situation in the Czech Republic (Source: King’s College Lon-
don, International Centre for Prison Studies, Prison Brief for the Czech Republic) 
Country  CZECH REPUBLIC 
Ministry responsible  Ministry of Justice 
Prison administration  Prison Service of the Czech Republic 
Contact address  Soudni 1672/1a, P.O. Box 3, CZ-14067 PRAGUE 4, Czech Republic 
Telephone / fax / website  
tel:  +42 02 6103 4405 
fax: +42 02 4140 9072 
url:  www.vscr.cz 
Head of prison administration Kamila Meclova, Director General 
Prison population total (includ-
ing pre-trial detainees / remand 
prisoners)  
17 429 at 16.1.2004 (national prison administration web-
site)  
Prison population rate (per 
100,000 of national popula-
tion)  
171 (based on an estimated national population of 10.20 
million at January 2004 from Council of Europe figures)   
Pre-trial detainees / remand 
prisoners (percentage of prison 
population)  
19.6%   (16.1.2004) 
Female prisoners (percentage 
of prison population)  4.2%     (16.1.2004) 
Juveniles / minors / young 
prisoners, incl. Definition (per-
centage of prison population)  
1.2%     (31.10.2003 – under 18) 
Foreign prisoners (percentage 
of prison population)  9.9%     (31.12.2003) 
Number of establishments / 
institutions  35          (2003)  
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Official capacity of prison sys-
tem  
17 634 (1.9.2002 – Council of Europe Annual Penal Sta-
tistics)  
Occupancy level (based on 
official capacity)  95.6% (1.9.2002)  
Recent prison population trend 
(year, prison population total, 
prison population rate)  
1992      12 730      (123) 
1995      18 753      (181) 
1998      21 560      (209) 
2001      21 538      (210) 
2 The field visits6 
Time frame. The field visit took place from 8 to 15 September 2003. 
Location. Visits were conducted in two prisons: Opava prison and Pribram 
Prison. 
 
                                                          
6  Methodology: Interviews were conducted with the individuals and focus groups listed 
below (tape-recorded with consent) and with the prisoners. The researcher conducted all 
interviews and focus groups accompanied by a freelance and neutral interpreter in both pri-
sons. All participants were briefed and told about ethical issues. 
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2.1 Opava Prison7 
2.1.1 Description of the prison 
Opava prison is located in Opava city (see map above). The prison consists 
of 2 buildings: one was formerly part of the Justice Palace and the other be-
longed to the army. The first building of the prison was founded in 1888 and 
the second part in the mid-1940s. 
At the time of the visit, Opava prison held 365 prisoners with a capacity for 
399, of all security types. The prison is intended for juveniles (capacity of 
65), women (capacity of 91), and men (capacity of 190). 34 prisoners were 
on remand and the others sentenced. 
The prison has approximately 307 members of staff of which 187 are prison 
guards. There is a shortage of doctors and lawyers. 
Since 1999, the prison has had a Specialised Drug Treatment Unit (capacity 
of 26) for women with alcohol, drug and game dependence. These women 
have either volunteered to do the treatment or are on a Court Order. Prison-
ers on this unit reported that they wanted to abstain from using drugs and 
that they found the treatment unit very good and supportive. ‘I’m quite happy 
with the quality of the therapy. I’m really happy that we have a separate the-
rapist for ourselves we can talk to normally, who’s easy to talk to and who 
tries really hard to help us in what we are doing’ 
2.1.2 Goals and practical procedures 
No substitution treatment is offered in this prison. It was reported that sub-
stitution treatment is not favoured as it is seen as a continuation of addiction. 
The staff reported that information from the press states that addiction lasts 
longer with substitution treatment and that it takes longer for prisoners to be 
sentenced. Substitution treatment is thus seen as unsuitable for prisoners. It 
                                                          
7  Data from interviews conducted with: 
– The Governor. 
– A pedagogue, psychologist and the head of the department in the juveniles area 
– The doctor (GP). 
– The psychotherapist in the Specialised Drug Treatment Unit. 
– A psychologist and pedagogue in the Specialised Drug Treatment Unit. 
– The Security Guard and the sub-chief. 
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was reported that it is rare to see women going through withdrawal in prison 
as they usually have already gone through detoxification.  
However, it was reported that prison staff tend to lack expertise on drugs, 
their effects and withdrawals. Prisoners fear asking for further support on 
drug related issues and withdrawals as they are scared of being trapped in the 
care-security ‘battle’, becoming an item for security rather than for care. 
Some prisoners continue using drugs while in prison, managing withdrawals 
‘thanks to’ illegal drugs. Prisoners are extremely reluctant to admit to any 
drug use or withdrawals due to the lack of standard procedures for legal sup-
port (Chief Executive, NGO). 
It was stated that the prison management is thinking about setting up a sub-
stitution treatment centre for prisoners who were on substitution treatment in 
the community, prior to incarceration, but this is only an idea. 
2.2 Pribram Prison8 
2.2.1 Description of the prison 
Pribram Prison is located about 30 minutes drive from Prague (see map 
above). The prison is surrounded by closed uranium mines. Formerly, the 
prison was a labour camp, built in 1953 for convicts who worked in the 
mines. 
The prison employs approximately 300, staff of which 159 are prison guards. 
Pribram prison is a male prison, holding 596 prisoners with a capacity for 
684 of all security types (A, B, C and D), with a majority of high security 
prisoners. 
The Specialised Drug Treatment Unit, created in October 2002, has a team 
of 12 staff and a capacity for 32 men (there were 21 prisoners at the time of 
the study), who have volunteered to do the treatment. None are on a Court 
Order. Treatment focuses on psycho-social interventions. Prisoners tend to 
                                                          
8  Data coming from interviews were those conducted with: 
– The Governor, the first deputy and an officer in charge. 
– The team at the Specialised Unit, i.e. social worker, pedagogue, therapist, education-
therapist, educator, psychologist and the head of the whole department (who is psy-
chologist). 
– The Head of nurses. 
– The Head of guards. 
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stay in the unit for 6 to 12 months and are then transferred to the Drugs Free 
Unit, where the length of stay is unlimited and where the focus is on activi-
ties (education, workshops, work). 
‘It would be good to know the beginnings, what triggers the drug use, that's 
the basis, something to start with. Then the other thing that would be nice to 
talk about is, what is ahead of me, getting some feedback on the progress I’m 
making, because right now at the moment there's no feedback, and I would 
like to know what the progress is. Also I would like to know what I’m going 
to do after release, how to manage the situation once out of prison.’ (Pris-
oner) 
2.2.2 Goals and practical procedures 
No substitution treatment is offered in this prison. 
It was reported that the prison philosophy is abstinence, which is successful 
because of its isolation from the community. Moreover, prisoners come from 
a remand prison and have thus already gone through withdrawal. 
An officer stated that providing substitution treatment is seen as an easy way 
to ‘keep prisoners on drugs and make them calmer’. However, he claimed 
that pressure is felt to introduce substitution treatment in prison. He said that 
whilst he is not in favour of substitution treatment for non-heavy drug users, 
he is for heavy drug users. He reported that methadone was portrayed as a 
good thing and should be introduced. He said that the information provided 
on drug use in prisons was false; as a result all arguments lost credibility. 
2.3 Views of Prisoners 
Three focus groups were conducted with: 
− One group of 8 juveniles prisoners, aged 16 to 22 
− One group of 6 women, aged 22 to 27, in the Specialised Drug Treatment 
Unit 
− One group of 8 male prisoners, aged 22 to 26. 6 came from the Speciali-
sed Drug Treatment Unit and 2 from the Drugs Free Unit. 
Prisoners who took part in the research started using drugs at ages between 
14 to 16 and reported having used pervitin and heroin by injection, mari-
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juana, LSD, and various legal pills. Juveniles have mainly used marijuana 
and glue, but sometimes LSD and mushrooms as well. 
Prisoners confirmed the absence of substitution treatment in prison. 
‘Here in prison it’s almost out of the question. You don’t get any treatment 
for withdrawals, the doctors know that you can’t die so they just let you 
crawl on the floor. Outside it's different, because you get treated in a differ-
ent way, you get some substitution.’ 
However, some prisoners had experienced buprenorphine or methadone be-
fore incarceration, sometimes through a doctor, sometimes on the black mar-
ket. 
‘I used to take methadone and while I was on methadone I was not doing 
heroine, at the beginning I was not doing any other drug, but then gradually 
I started taking pervitin and some other drugs that I was combining it with 
and I stopped the methadone because I got into jail.’ 
‘Subutex® is basically a substitution for when there is no heroine available, 
so with heroine you take it and you have euphoria and with Subutex® you 
take it, but you don't have the pain and you don’t feel sick.’ 
Prisoners reported going through withdrawal when arrested. Some received 
buprenorphine whilst at the hospital, guarded by the police. 
‘(Buprenorphine) lasted for 3 days. First, I started out with a dose of four, 
then gradually went down to one. It helped because alone I wouldn’t have 
been able to go through it. The detox was bearable, the length was ok. I still 
had pains afterwards, but it was not as bad as if I was going through it with-
out medication. They [the medical team] don’t give methadone because 
that’s a long-term treatment, so they substitute that with buprenorphine.’ 
Several prisoners reported going through withdrawal with no substitution 
treatment, especially with high levels of pervitin in their blood. Withdrawing 
from pervitin, they stated, was sometimes not painful. 
‘I was taken to a hospital in Prague, but I had too much pervitin in my sys-
tem, and they [medical team] wouldn’t accept me so I was then left alone ... 
then the next day I was taken to a doctor who gave me some pills, but I don’t 
remember, I felt really sick, I was screaming, throwing up, I don’t recollect 
all that much from that period. (…) I couldn’t sleep for over a month.’ 
‘I didn’t go through detox [with medication] because I was on detox many 
times before and finally they [medical team] didn’t accept me, so I was 
going through withdrawal on remand without any pills. Going through detox 
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without pills is not as long as going through detox with pills, it went much 
faster. Although I had reverse sleeping order for about a month, the detox 
itself was not that long. I was in great pain and it was very unpleasant but it 
didn’t last long. I don’t have the experience with heroin where you cannot 
sleep, but I had problems with pervitin, and withdrawal from pervitin is the 
opposite of heroin. You sleep a lot and you tend to eat a lot.’ ‘[Pervitin] is a 
mental, psychological addiction. So the withdrawal is different. There's a 
chance that you may have a psychosis and for that you need a doctor 
around. But that depends on the person. I have taken pervitin quite heavily 
for the past 7 years, being on it, every single day, taking a few doses a day, 
and for me all I needed was just to sleep it through and eat a lot. I was OK, 
but there are cases of people who take the drug only for 2 years and they just 
go crazy, when they go through withdrawal.’ 
Prisoners reported that buprenorphine is prescribed more than methadone 
and is perceived as more appropriate for fast detoxification: 
‘In Prague it is very common that doctors prescribe Subutex®. Methadone is 
really long term, I needed to get clean very quick because I was going to jail, 
so I wanted to take Subutex®. Doctors prescribe Subutex® because it’s 
faster. Methadone is a long term treatment and it's basically going from one 
addiction to another. So if you want to become clean, there's no reason to 
take methadone.’ 
Prisoners who had received buprenorphine, stated they were satisfied with 
the treatment: 
‘(…) Subutex®, it’s the best of all the medications because it’s really quick, 
it takes you from the opium-based drugs to taking nothing very quickly and 
you feel a minimum of the withdrawal effect. It’s a really good drug, very 
efficient.’ 
Prison administration and staff frequently stated that drugs do not circulate 
widely and are not problematic in prison. However, some prisoners disa-
greed: 
‘There is so much stuff today. You can buy it anywhere. You can buy drugs 
anywhere today. You just go out behind the gate here at the prison and 
somebody is offering you something. It’s not so common in prison but you 
can smuggle an elephant into the prison. When you get something, double 
the price.’ 
Prisoners stated that substitution treatment should be offered to help them go 
through withdrawal for a period set according to individual needs. They also 
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claimed that substitution treatment should then be linked to support services 
such as therapy and psycho-social work. 
3 Summing up 
Throughout the Czech Republic, the provision of substitution treatment is 
inadequate and its provision ad hoc in terms of quantity, quality and geo-
graphical coverage. The demand from drug users tends to be low: this is 
partly due to the fact that the main illicit drug used is Pervitin (stimulant 
type), partly due to the lack of treatment on offer and partly due to the fear of 
being labelled as a drug user since makes prisoners’ lives more difficult. 
Only buprenorphine is offered, on a short-term detoxification basis at the 
Prison Hospital, to prisoners going through withdrawal due to opiate use. 
Although the doctor in charge of such ‘treatment’ is satisfied, the number of 
individuals benefiting from such care is extremely limited. Moreover, the 
lack of treatment options may neglect the needs of certain prisoners as indi-
viduals respond differently to methadone and to buprenorphine. 
In the case of pervitin users, some prisoners have had no or little physical 
withdrawal effects whereas some heroin users experienced intense ‘cold tur-
key’. Nevertheless, the health needs of opiate users should not be left in the 
shadow of pervitin users (who outnumber the opiate users) whose needs are 
different. 
Drug treatment in prison focuses on psycho-social interventions. At best, pri-
soners are offered the chance to go through a Drugs Free Unit or Specialised 
Drug Treatment Unit. The intervention programmes tend to focus on activi-
ties (workshops, education, sports), resulting in the need for information and 
active personal work, on the effects of drugs on mental and physical health, 
as well as in-depth therapy (going back as far as the source of the use of 
drugs). 
As drug use in prison (and the community) is heterogeneous and varies 
greatly from one place to the other. Quality monitoring of drug use in prison 
would be useful to acquire a better knowledge and understanding of the drug 
use in prison and prisoners’ needs. 
With further involvement from NGOs in prisons, greater expertise and sup-
port to prisoners and prison staff could be provided, enabling prisons to 
respond to their needs. Cooperation with experts and expert groups from the 
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community may play a key role in the prison setting, increasing satisfaction, 
well-being and motivation of both prisoners and professionals. In this way, 
improved understanding, management and treatment of drug issues could be 
acquired. 
  
Denmark1 
1 General data:  
drug use, substitution treatment and prison population 
1.1 Number of drug users 
According to Christensen (2003), the number of heavy intravenous drug 
users in Denmark is estimated to be 14 0002 (an average from the range of 
12 752-15 248), corresponding to 0.26% of the population3. This estimate 
was confirmed by a capture/recapture analysis in Copenhagen where two 
registers, the National Board of Health register from 1996 onwards and the 
hospital based National Health Care Register, were combined with the Mini-
stry of Justice register of drug related crime.4 
According to Christensen (2003), the prevalence of drug users in all Danish 
prisons is calculated once a year. Drug users are defined as those who have 
taken any illegal drugs (including hashish) more than a few times within the 
half a year before admission. In 2000, 38% (1316 inmates; 37% among male 
prisoners, 52% of female prisoners) were drug users, a figure that has been 
rising from 22% in 1980 to 27% in 1990. The number of “hard drug users”, 
defined by the habitual use of drugs other than hashish, was 689 (20% of all 
prisoners, a figure that has risen from 10% in 1991). Retzmann (2003) 
reports figures, from a study on alcohol and drug use among clients of penal 
institutions and resocialisation services, that 56% of all the clients of those 
services were drug dependent (14% opioid dependence). 50% of all inmates 
were drug users prior to their incarceration (alcohol and illegal drugs). 
                                                          
1  The field visit in Denmark (16-19 June 2003), conducted by Heino Stöver, was facilitated 
by Alette Reventlow, Ministry of Justice of Denmark, who also provided national-general 
information and support with the finalisation of this country report. 
2  Approximately half of them situated in the area of Copenhagen. 
3  According to the National Board of Health, (Drug situation in Denmark 2003), the number 
of “heavy” drug users is estimated to 25 000, including 6 000 users of cannabis. The num-
ber of opioid addicts is thus estimated to about 19 000, corresponding to 0.35% of the 
population. 
4  See also EMCDDA statistics “Estimated number of problem drug users in EU-Member 
States 1995-2001”, www.emcdda.int.org (20.6.03). 
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The mean age of drug users has risen slowly from 29 years in 1991 to 
31years in 1999. 25% of drug users were injecting drugs (IDUs) compared to 
8,8% of all prisoners. According to the Department of Prisons and Probation, 
the figures of drug use should only be considered as estimates, due to the 
methodology used to collect the data. 
1.2 Substitution treatment  
1.2.1 Historical and legal background  
The national focal point published information that in 1999, 4 398 drug users 
had been in substitution programmes (4 298 in methadone-based and 10 in 
buprenorphine-based programmes). This accounts for a coverage rate of  
27-34% of all estimated drug users (12 752-15 248). The only indication for 
substitution treatment is dependency on opioids (Opiate Dependence-ICD-
10, Kramp et al. 2003, P. 139). Methadone maintenance treatment is sup-
posed to be a key strategy for risk reduction for Danish intravenous drug 
users. In a regulation released in 1995”5, substitution treatment was been 
centralised at county level by local authorities (13 local communities exist in 
Denmark). 
“Before this date, all general practitioners were allowed to prescribe 
methadone for drug-misuse treatments. But then there was a lot of political 
rumour about this area. It was recognized that quite a lot of drug misusers 
were found dead on streets. And it was believed – not really proved – that it 
was due to a fairly liberal prescription of methadone to too many people. 
And so the right wing party in parliament decided that should be regulated. 
And the doctors, all of us who were engaged in this problem, we were happy 
that it was put down in the law that, when you treat drug misusers by sub-
stitution, it should be part of a social treatment too. So it was taken away 
from the GPs and put into those local ‘amt-clinics’ (local communities). The 
doctors that are employed by the ‘amt’ are not practising doctors, they are 
employed in the local area just to do this job, to do the medical part of the 
social treatment for the drug misuser. It was a good law and we are happy 
that it’s put down.” (A doctor) 
The treatment is carried out in special drug treatment clinics which provide a 
multi-sectoral treatment, with medical and psycho-social parts. Medical 
                                                          
5  Legislation on Methadone Treatment, ‘Lov om sygehusvæsenet’. 
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doctors outside these facilities are not allowed to prescribe substitution 
drugs. 
“Part of the philosophy is that the treatment of drug misusers is a multi-
sectoral treatment. 
The main part is social, the medical part is only a minor one and is only 
something to keep individuals in the position of having social treatments. 
And the social treatment is the job and responsibility of the social worker” 
(A doctor) 
According to Christensen (2003), the number of clients treated with metha-
done for more than five months a year increased from 3 376 in 1996 to 4 498 
in 1999 and to 5 077 in 2003 (National Board of Health), corresponding to 
25% of the estimated population of heavy drug users. This increase was due 
both to an increased treatment capacity and an increase in the number of 
drug users. Besides methadone treatment, pilot studies with buprenorphine 
were initiated in 1998 and have been positively evaluated. 
1.2.2 Substitution treatment in prisons 
Prisoners can apply for placement in drug free units and can receive detoxi-
fication treatment. The drug free units are segregated from the rest of the 
prison and, to enter, the prisoners have to sign a contract to remain drug free, 
to have regular urine tests and to cooperate with prison personnel. In ex-
change, the prisoners have better conditions for leave and other advantages. 
Methadone maintenance treatment is generally available in all prisons and is 
continued when initiated before admission to prison. If a drug user has been 
integrated in a substitution programme in the community (the clinics) his 
dosage will be continued without problem. The principle of equivalence of 
health care standards and services is well known and guideline for policy and 
practice. 
“So, when someone comes in we ask the prisoner: may we contact your 
clinic? And they are very happy that we contact because then they are sure 
that their methadone treatment is continued. We ask the clinic: ‘when did 
this person have its last dose, was it given under supervision, or was it a 
home arrangement and when was the man last in the clinic and what is your 
opinion of having this man back when he comes out of prison’. And I’d say 
that nearly all clinics in Denmark say: ‘when he comes back we take him 
again’. There are some areas in Denmark where there are some problems. 
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When they go into prison, get sentenced, they say: ‘now he is in the legal 
system, it’s not part of our business, so when he comes back they have to 
apply to have that man back’. And we do apply. But we tell them: ‘according 
to the law of 1st of January 1996 you have to take him, there is nobody else 
who is allowed to take this man in methadone treatments. He should be in a 
local clinic in that amts (local community – the authors) area.” 
If somebody is not known to the county clinics and shows symptoms of 
craving anyway, the patient will be treated and if he serves a short term sen-
tence he will receive his/her substitution drug. According to the medical 
doctor interviewed, substitution prescriptions are done on an individual 
basis, the dosage received in the community treatment programme are taken 
as a basis. There is no time limit for the duration of the substitution pro-
gramme. 
In 1998, 232 persons (6.5% of all prisoners) were in methadone treatment in 
prisons. In 2003, at the time of the visit, there were approximately 300. Since 
then, the number has risen considerably. Since the beginning of 2004, the 
Department of Prison and Probation has reported once a month to the 
National Board of Health with the number of inmates who have been in sub-
stitution treatment during that particular month. As of May 2004, about 500 
inmates were in substitution treatment. The figures are supposed to be reli-
able. 
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1.3 Prison Population  
Table 6 Data on the prison situation in Denmark (Source: King’s College London, Interna-
tional Centre for Prison Studies, Prison Brief for Denmark) 
Country  DENMARK 
Ministry responsible  Ministry of Justice 
Prison administration  Department of Prisons and Probation 
Contact address  Strandgade 100, DK-1401 COPENHAGEN K, Denmark 
Telephone / fax / website  
tel:  +45 32 68 4000 
fax: +45 32 68 4050 
url:  www.kriminalforsorgen.dk/ info/ 
krim_uk/index.html 
Head of prison administration (and title)  William Rentzmann Director General 
Prison population total  
(including pre-trial detainees / remand prisoners)  
3,908 at 25.11.2003 (national prison admini-
stration)  
Prison population rate  
(per 100,000 of national population)  
72  
based on an estimated national population of 
5.4 million at November 2003 (from Council of 
Europe figures)  
Pre-trial detainees / remand prisoners  
(percentage of prison population)  
29.3% 1.9.2003 - including convicted but 
unsentenced)  
Female prisoners  
(percentage of prison population)  4.7%   (1.9.2002)  
Juveniles / minors / young prisoners  
incl. definition (percentage of prison population)  0.3%   (1.9.2002 - under 18)  
Foreign prisoners 
(percentage of prison population)  16.3% (1.9.2002)  
Number of establishments / institutions  56 (2000)  
Official capacity of prison system  3,893 (25.11.2003)  
Occupancy level (based on official capacity)  100.4% (25.11.2003)  
Recent prison population trend 
(year, prison population total, prison population 
rate)  
1992      3,406      (66) 
1995      3,438      (66) 
1998      3,413      (64) 
2001      3,150      (59) 
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2 The field visits 
The field visit in Denmark (16-19 June 2003), conducted by Heino Stöver, 
was facilitated by Alette Reventlow, Ministry of Justice of Denmark, senior 
advisor, who also provided national and general information and support 
with the finalisation of this country report. Two prisons were visited: the 
main one in Copenhagen (Vaestre Faengsel) and the state prison of Vrid-
sløselille (out of the centre of Copenhagen). 
In both prisons I talked to nurses, focus groups and social workers and pro-
bation officers. In addition, I held a meeting with Dr. Knud Christensen, 
chief medical doctor of the prisons of Copenhagen, and Peter Ege, medical 
doctor and head of the Drug Addiction Service in the city of Copenhagen. 
Finally, there was a meeting with Dr. Christian Hvidt (Specialinstitutionen 
Forchhammersvej) from an institution of problematic drug users, mostly 
with methadone infectious diseases. 
 125 
 
 
  
126 
 
2.1 Vaestre Faengsel  
2.1.1 Description of the prison  
Vaestre Faengsel is part of the Copenhagen prisons, and is the largest local 
prison of the Prison and Probation Service, with a total capacity of 530 in-
mates. The Copenhagen prisons function mainly as local prison for the 
metropolitain Copenhagen area and consist of two prisons located in the 
centre. 
Vaestre Faengsel was erected in 1895 and considerably enlarged in 1918. 
The prison is a cross-shaped, panoptic cell prison of four storeys and has a 
capacity of 439 inmates. It contains a hospital with 36 beds, and a women’s 
unit with space for 30 inmates (Ministry of Justice 1998). 
2.1.2 Goals and practical procedures of substitution treatment 
Substitution treatment has a long history in Danish prisons and has been seen 
as helpful to the reintegration process.. Consequently, from the very begin-
ning, substitution treatment in prisons has been designed as through care and 
continuous prescription (see Schuller & Stöver, 1988). 
In Vaestre Faengsel, methadone has already been prescribed since the 80s. 
Dr. Stuip, the chief medical doctor was already prescribing methadone in 
1988 on three levels: 
− Detoxification 
− Bridging treatment (sentence not longer than 12 months) 
− Methadone maintenance prescription (individual dosage) 
The Council on Alcohol and Narcotics (Alkohol- og Narkotikarådet) recom-
mended substitution treatment in its Methadone Guidelines, 1988, for per-
sons imprisoned no longer than 12 months (see Metadonretningslinier, 
Alkohol- og Narkotikarådet, 1988) 
The dosages given in the community treatment centres serve as a basis for 
the decision about dosages in prisons: 
“When we (the doctors, the nurses, the social-workers) have good contact to 
the drug misuser then you speak to the man as a man, not as a convict. And 
when you give the man the impression: ‘I’d like to hear how you do feel 
about the dose of methadone or Subutex® is that ok to you?’ And when he 
says ‘No, I still feel I have some problems, then we increase a bit, then we go 
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from 80 to 90 or to 100 mg. Then we let a fortnight go and then we talk 
again. 
Sometimes even they come to us: ‘I have a bit too much.’ Then there are 
some other drug misusers who only wish to have so much methadone that 
they are sleeping all the time, then we have to decide, he will not go further 
than 140, 150 mg. 
Even if he still has some problems at that dose, we’ll not exceed the dose. In 
some clinics they have gone up for 200 mg, for 300 mg. When they come into 
this business then I’m telling them that beyond 150/160 that’s cosmetic. The 
prison doctors decide where to put the level. We have the patients and we 
decide where to end up. That’s our responsibility. If the social worker is tel-
ling us: you better go a bit up because he is telling me that he is not doing 
well. We listen to him, we listen to the guards and we talk to the man ‘should 
we go up? And he is happy.’ So we try at least – some social workers will 
say that I am painting too nice a picture of our doings some guards will tell 
the same, – and some social workers will say: doctors are very tough, it’s 
impossible to speak with them – but we try to have some kind of multi deci-
sional treatment.” 
Although, in Denmark, a through prescription of substitution treatment is 
done in those cases where inmates are know to a community-based treatment 
clinic, the goal of drug treatment in general is for patients to become drug 
free. As a chief probation officer said: 
“And when we agree and the social workers and the doctors agree then the 
person gets methadone. But of course it is the goal that people are drug-free. 
Some of the prisoners are not very motivated, maybe they are drug-addicts 
for many years and maybe it‘s not up for them right now to start to be drug-
free, but its our goal. And it is the social worker’s goal though. Try to get 
treatment.” 
If an inmate has to be referred to another prison, they are given an accompa-
nying letter: 
“So if he is here we continue with methadone; and if he gets a sentence 
about 4 months then he will leave this remand house and go for a state 
prison outside. Then, the doctors from there will have the papers from this 
place, the prisoners has to accept that we send it to the doctor. And if he 
does accept us sending the papers to the other doctor then we won’t give it to 
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the other doctor. But normally they agree. Sometimes they think: with the 
next doctor we can have a higher dose – so they do not allow us.” (A doctor) 
Generally, an oral or written permission (which has to be signed by the 
inmate), is necessary when information is handed from one doctor or clinic 
to another: 
“An allowance given by an inmate – patient to doctor – is good enough. Of 
course, the doctor has to write a paper: ‘the patient has given permission to 
me to contact the clinic.’ This should be written before he phones to the cli-
nic. We haven’t been accused yet that we do not use written permission. But 
in some cases the clinics are asking for written permission and then we fax 
one to the clinic. We have formula where the man is putting his name under-
neath and we send it to the clinic.” (A doctor) 
In Vaestre Faengsel, approximately one fourth of the prison population are 
supposed to be opiate users (approximately 120 out of 530). 70-80% of the 
inmates are drug users. The number of inmates in substitution treatment has 
risen considerably, from 10-15 patients in 1991, to 103 inmates in June 2003. 
At the time of the visit, urinalyses had not been carried out on a large scale. 
Cannabis is not seen as a reason to stop substitution treatment. The policy is 
to talk to inmates and to observe them. Since 1st July 2004, mandatory urine 
testing has been introduced by law6. This is part of the Government’s general 
policy to intensify the fight against drugs in and outside prison. 
The chief medical doctor applies a restricted prescribing policy with regard 
to benzodiazepines. He refused to prescribe substances of that category; now 
a common practice among physicians outside prison. 
The probation service and the social worker involved have to organize the 
continuation of the treatment at time of admission to the prison and at time 
of release after his or her sentence: “Because we can’t give methadone here 
if people don’t get it when they get out.”  
Apart from the continuation of substitution treatments, inmates can also start 
such a treatment whilst in prison: 
“We have the possibility to start a substitution treatment. If someone comes 
in and takes heroin, they get normally 16 days, then they can talk to the 
social worker and then they can come with a plan to start a treatment of sub-
                                                          
6  lov om ændring af lov om euforiserende stoffer og straffuldbyrdelsesloven. 
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stitution. And we have many prisoners who can start this here. Then we write 
to the centre outside. Having left, they go to the centre and can continue. The 
nurses talk to the people who come in and I tell them about the possibility of 
treatment in the jail. It depends how long they have to stay here, and maybe, 
if they are interested, they can start after one or two days.” (A doctor) 
For the staff, substitution treatment is seen as a normal treatment and the 
benefit, in terms of better conditions for the prison management, is seen 
widely. 
“I don’t think it’s very controversial because, here in Vaestre Faengsel, they 
were used to people getting methadone because a lot of prisoners get metha-
done. So, I think it’s very common to the staff. In some respects, it’s a good 
thing because it is less problematic with the prisoners, less violence, les 
problems.” (A probation officer) 
The medical and the social part of the substitution treatment take confidenti-
ality as an important point in the treatment process; it is not clear to the staff 
who is getting substitution drugs or not: 
“… actually it’s a little bit strange. They make a secret of who is on metha-
done. The social workers don’t know if the person in trouble is on metha-
done …They are very strict about confidentiality ... Sometimes it gives prob-
lems because the social workers don’t know what’s going on – but that’s the 
way it is and we have to respect that.” (A probation officer) 
Prisoners on home leave are given a dosage for two days and, after release, 
the prescription is continued by the community clinic. A positive urine test, 
either before or after the leave, will lead to a ban on home leave for up to ten 
weeks. 
In selected cases, there are financial reasons to prescribe buprenorphine only: 
“The reason why Subutex® it not used is that it costs ten times as much as 
methadone. …If someone wants to get out of drugs, out of methadone, out of 
substitution then we can give Subutex® in selected cases. And if inmates 
come from outside and tell us: we had Subutex® in this clinic then we say ok, 
we continue with Subutex®. We have a fund for medicine of about 1 million 
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DK’s; out of this we pay about 4-500 000 DK on methadone7. And if al that l 
should be converted to Subutex® ... so we try to be in between.” (A nurse)  
The central role of the nurse within substitution treatment is pointed out by 
the staff. They see the inmates on a day-to-day-basis: 
“The nurses know the patients, they go around with the doctors. Those the 
nurses who have been here for several years, not the new nurses. The doc-
tors have to prescribe the drugs, the doctors go to the nurses and ask for 
information on the patient.” (A doctor) 
Substitution treatment in the community is seen as an appropriate and neces-
sary treatment for drug users, and its success has been proven in the past: 
“.... they get very restless in the jail and people cut themselves and eat some 
glass and things from the radio and from the bed to get out of the cells. That 
we do not have any more. That is what is better now and that there is some 
opportunity for treatment in the jail.” (A nurse) 
In Vaestre Faengsel, and in other Danish prisons, “KRIS Denmark” is an 
NGO offering active support for inmates. This organization is paid by the 
government and works in most of the prisons in the area of Copenhagen. The 
association consists of ex-prisoners and ex-addicts and their basic approach 
is peer support. For them, it is important to look at who is bringing the mes-
sage across. And it’s different and more convincing when it comes from one 
of the peer group: 
“We try to focus on the individual. Usually we can look to the addicts, talk, 
whatever, get some connection, and we can say some pretty clear things to 
them, because we are former criminals they will accept it, they won’t accept 
it from others.” (An NGO staff member) 
The chief probation officer, responsible for the whole drug treatment facili-
ties, agreed: 
“It’s important to work with former criminals and drug-addicts because they 
may get the best connections with some of our prisoners, because it earns a 
lot of respect among the prisoners to meet someone who actually got out of 
the drug-addiction and out of criminal behaviour … It’s something quite new 
                                                          
7  This seems to be a bit exaggerated; Vestre Fængsel is paid 823.314 kr for medicine. As 
methadone is cheap, it seems unlikely that 50% of their budget is used for this kind of 
medicine. 
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to work with former criminals … They come here and have motivation 
groups and talk to the prisoners three times a week and a lot of the prisoners 
who did not have motivation group go ... So we are very happy about this 
cooperation, we hope to have the people from ... five times a week.” (A pro-
bation officer) 
The representative of Kris Denmark explained the benefit of employing for-
mer addicts and criminals in prison work. The policy approach of KRIS 
Denmark is drug free oriented: 
“They are all drug free orientated. We have connection with different treat-
ment centres in Denmark ... we can always get them a place if they want, but 
it’s our experience that those who want to be drug-free – that it’s not that big 
a deal getting out of drugs ... The problem is that you eventually start 
again.” (NGO staff member) 
Substitution treatment is only regarded as useful in the form of detoxifica-
tion: 
“… There is a lot of methadone in the prisons, that’s the problem. It’s 
harder to get out of methadone than to get out of heroin…[Methadone is 
given out] much too easily. Anything more than 14 ml is pure nonsense. Lots 
of people get 18 ml, ... 14 ml is more than enough to keep the ... pattern … 
making it much worse than it is ... It’s given out much too lightly, it’s a hard 
drug ... it seems they should take more care about methadone and do more 
about keeping drugs out of the prisons.” (NGO staff member) 
On the other hand, the representative of KRIS saw the problem of reducing 
methadone and at, the same time, not being able to successfully reduce the 
supply: 
“When I speak with anyone they always say: ‘I’m taking methadone so that I 
don’t get in trouble. On the other side: if the prison takes away the metha-
done that will bring the people big trouble. They’ll have to buy heroin and 
that will give big trouble. So you can’t just remove methadone without mak-
ing sure that Heroin doesn’t come in. That’s difficult.” (NGO staff member) 
2.1.3 Views of prisoners  
Four prisoners were invited to attend the focus group. Prisoners talked 
frankly about the substitution treatment they are in. One prisoner complained 
about the time at which methadone is dispensed: 
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“... normally, outside, they give liquid and in here they give tablets. I don’t 
know if it’s the same but normally I have some problems when I go from 
tablets to liquid. They give it with juice. And if you have a stomach pain or 
something then it’s cleaner with a tablet. They come in and give you the 
methadone before you are getting your breakfast.” (Prisoner) 
In addition, the lack of confidentiality is criticized, though it is recognised 
that the identity of substitution treatment patients is hard to hide within the 
prison setting: 
“… when they come with the nurse, they carry all the tablets in a small box. 
Of course, some other people- who don’t like people who take drug – can 
see, you cannot hide, so sometimes you get problems, people call you junkies 
or something like that. For my case I don’t care … normally you don’t care 
if there are some other people who take drugs.” (Prisoner)  
Prisoners expressed their doubts about whether there was confidentiality in 
relation to methadone provision: 
“I think it’s in all our papers and there is a medicine card in the office of the 
guards and so the guard can see what one gets. You also have this card 
inside the rooms in the closet, the doctors is only coming once a week so the 
guards are giving the medicine in place of the doctor.” (Prisoner) 
The prisoners state that there is an important psychological component in 
relation to the optimal dosage and form of substitution drug: 
“They say that tablets stay longer in the body, but sometimes it depends on 
your mind, if you focus in the morning already: it stays in the body for 24 to 
36 hours … it’s in the mind, you don’t get stoned. It’s only the first week or 
14 days when you start getting it ...” (Prisoner) 
The prisoners also confirm that they are able to negotiate the dosage with the 
doctors and, during the continuation of their prescription, the results are 
communicated with the treatment centres outside: 
“… but then they contact your centre, they have to give the same when you 
come out. Normally it’s no problem for the centre, it’s more a problem 
here.” (Prisoner) 
According to the inmates interviewed, the cooperation with the treatment 
centres outside is seen as very efficient. But, in the case of benzodiazepine 
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prescription – prescribed in drug clinics but not by the prison doctor, differ-
ences are marked: 
“I went in and out four times – it worked. It’s only with methadone like out-
side. If you got benzos, you don’t get it here. In the clinic they prescribe, but 
not here. It’s pretty bad. If you are used to a lot of benzos and you come in 
you can get cold turkey. [Q: Would you like to have access to Benzos?] Yes, 
of course, if you get it outside every day and don’t get it in here you get a lot 
of problems. Q: Do you understand the reason why doctors do not prescribe 
Benzos in here?] They do in the community, in the clinic, but not here … 
I think they could do that. I don’t know what the problem is.” (Prisoner)  
The prisoners negotiate with nurses about new substitution drugs (e.g. bu-
prenorphine) and, in doing so, discover new treatment options for them-
selves: 
“I talked to the nurses, they can also give us Subutex® in here. Then we 
have to make a withdrawal … I go down with methadone, I get sick on it, I 
get about 8 mg Subutex®, that’s not enough, but 12 mg was enough and they 
took one away each day and the dose has gone down. I think it was much 
better because I tried to go down to zero methadone … I had never heard 
before that you could get Subutex® when you are on methadone. I wanted to 
get rid of the methadone and they said to me: ‘yes we can do that.’ That’s 
new to me. I didn’t think that before, I didn’t think it would work. When you 
go from methadone to Subutex® you have to go down to four, and I waited 
for two hours, check my body and then you can take Subutex®. They start 
with 8 mg. Then they go to 12 and then they take one away every day to zero 
again. If I had done it the other way I would not sleep for one month.” 
(Prisoner) 
The prisoners in a substitution treatment also face negative views from other 
inmates: 
“… not all of them but, if you take drugs they call us junkies, people like us 
are nothing. They can try to make it more serious for people who want to be 
clean from drugs.” (Prisoner) 
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2.2 Vridsløselille State Prison 
2.2.1 Description of the prison 
The Vridsløselille State Prison was built in 1859 as a cellular confinement 
prison. The prison is star-shaped with four three-storied wings. Since July 
2004, it has become one of 6 closed prisons in Denmark with a capacity of 
222 places. The prison admits men over 23 years old from metropolitan 
Copenhagen, Zealand and Bornholm, who have to be committed to a closed 
prison (convicted of robbery, drug offences, homicide and other serious 
assault offences; see Ministry of Justice 1998, p. 70). 
2.2.2 Goals and practical procedures of substitution treatment 
Out of a total population of 240, there are 22 inmates in the substitution pro-
gramme – 10 receive methadone, twelve receive buprenorphine, the first 
choice is buprenorphine which, according to the nurses, is supposed to have 
milder effects. The inmates are given enough of the substitution drug for a 
few days when they are on home leave. 
According to the inmates and nurses, there are some drug addicted inmates 
who, for various reasons, don’t want to get into the substitution programme. 
One reason is that they want to hide their status as drug users to avoid the 
negative picture that staff and maybe other inmates might have of them. 
Another reason is that the community service brought in a drug free oriented 
treatment programme, ‘Kongens 0’, which is now used by 30 inmates. The 
target group for the treatment are inmates who are drug addicts and who 
want to become drug-free and who, after becoming acquainted with the 
contents of the treatment, sincerely wish to participate in the programme. 
The inmates come from both the Vridsløselille State Prison and from the 
other state and local prisons of the Prison and Probation Service. In connec-
tion with referral of inmates to the unit, there are, in principle, no restrictions 
concerning the length of the inmate’s residual sentence. It is assumed, 
though, that the primary target group are inmates who can be released for 
continued treatment outside the prison after completion of their treatment in 
the unit. The stay in a treatment unit is on average about 4 months. In some 
cases, the stay may be longer (Stöver, 2002). The substitution programme 
has to be seen in the context of enlarged treatment facilities in the prison. It 
is possible for the inmates in the substitution treatment to move over to the 
drug free oriented treatment of Kongens 0. 
According to the nurse and some inmates, the staff now regard the substitu-
tion treatment as very normal. This is due to the long history of that form of 
treatment and the enhanced education and training of the staff members: 
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“It has changed in the last 10-15 years. To be a guard in prison needs a long 
education. 20 years ago, the guards were very exciting about substitution 
treatment and so on. It changed, now you have paedagogical education ... we 
also have a lot of women guards ... that also means, you are using more talk, 
not power, talk, talk, talk … Addiction is called a disease now. We think in 
another way when we see drug users now.” (A nurse) 
Regarding dosage, nurses recognize a change in that the inmates themselves 
now try to reduce the dosage. 
“… earlier it was as much as possible, today it’s more normal that people 
come to us and say ‘Can we get down from 100 mg to 80 mg’, its quite com-
mon that people come and say I’m trying to get rid of methadone, that’s a 
change.” (A nurse) 
Regarding the correct dosage, the nurses point out that a prison setting with 
high control measures does not allow a high level of consumption of other 
drugs and this influences the dosage of methadone. Moreover, the nurse 
pointed to the importance of integration of the inmate’s wishes: 
“Our experience is that it is not necessary to give more than 100 mg; some 
people say they don’t take anything else ... But they normally admit a maxi-
mum of about 60 mg and then they can stop thinking about drugs. But I think 
you get the best result if you let the patient decide which level is best for 
them.” (A nurse) 
The nurses state that, in the substitution programme, there aren’t that many 
urine controls. The consumption of cannabis does not have negative effects 
on the methadone treatment. The nurses claim to see the inmates every day 
and say they would recognize additional drug use is it were present: 
“We had control but we stopped it 3 years ago. We found that the consensus 
between us and the inmates was very important. If some of the inmates have 
some problems with side-abuse they will come to us. We don’t need control. 
From the results of all these urine-tests, very few are positive. So I think they 
have a very low side-use in prison. … Earlier, when we took urine-tests, then 
they didn’t take drugs for the last 4 days or so and you didn’t know how 
much they use. They take some kind of stuff and they know how to handle it.” 
(A nurse) 
Psycho-social care, connected to the substitution treatment, is not requested 
by the inmates; they state that it is more for inmates who are in substitution 
programme for shorter periods but not for inmates in the programme for 
more than ten years. 
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2.2.3 Views of prisoners  
Two prisoners were able to attend the focus group. 
Again, the prisoners stressed the importance of confidentiality in methadone 
provision. In Vridsløselille, the inmates receive their methadone at 7.30 in 
the morning. This can be noticed by other prisoners who might envy their 
allowance: 
“We get methadone to become normal and to be able to go to work. But 
some other inmates don’t believe that.” (A prisoner) 
But for prisoners, it is also possible to go to the medical unit at 8.00 o’clock 
and then receive their methadone when other inmates, who are ill, attend the 
unit as well. In this context, it becomes less obvious. 
Some prisoners report from experiences in other prisons receiving metha-
done and see that it was sometimes not that easy to get it when entering 
prison: “To lose the prescription was easy, but not to get it.” 
3 Summing up 
In Denmark, substitution treatment is seen as a valuable treatment of opiate 
addiction. The treatment is organised by special drug clinics on a local level. 
The cooperation and communication with the prisons seem to work 
smoothly, so that the interface of community/prisons/community works 
without any problems. The continuation of substitution treatment for drug 
users is guaranteed when entering prison and on release. For the drug users, 
negotiations about dosage, appropriate substitution drug or the start of a sub-
stitution drug is possible. A perception of the value of acknowledging 
patient’s needs was expressed by several interviewees. In particular, two 
topics were discussed intensively: 
− the use and/or prescription of Benzodiazepines 
− the more general problem of how to guarantee confidentiality in the provi-
sion of substitution treatment, on an every day basis. 
  
Finland1 
1 General data:  
drug use, substitution treatment and prison population 
1.1 Number of drug users  
In 1999, according to EMCDDA figures, Finland reported the number pf 
problem drug users to be 12,550 (EMCDDA, 2003). Most are poly-drug 
users, including benzodiazepines and alcohol (Arpo, 2001). Finland ranks 
among the countries with lower lowest rate – 0.2-04% – of problem opiate 
users per 100 000 population. Koski-Jänes, Mäki & Jungner (2004) point out 
that substance misuse is common in most offender populations. It has been 
estimated that about 80% of prisoners have serious problems with alcohol 
and other drugs. Compared to 1988, when about 2% of prisoners had been 
convicted for drug offences, the figure rose to 16% and to 19% in 2002. In 
1995, in a study of four prisons, about one third of the inmates admitted drug 
use whilst in prison. 
1.2 Substitution treatment 
1.2.1 Historical and legal background 
Finland has a long history of a treatment oriented response, to crime in gen-
eral and particularly to problematic alcohol and drug use, both in the com-
munity and in prison. Drug services have increased in the last decade due to 
the recent increase in drug use: Almost all prisons have drug free wards and 
most open institutions are essentially drug free (Koski-Jänes, Mäki & Jung-
ner, 2004), even relapse treatment programmes have been implemented in all 
prisons for those prisoners who have relapsed during the institution’s drug 
treatment programmes (see Silvennoinen). 
                                                          
1  The field visit, conducted by Jutta Engelhardt (Mainline Amsterdam, The Netherlands), 
was facilitated by Leena Arpo, Chief Medical Officer of the Prison Administration, who 
also provided national-general information and support with the finalisation of this country 
report. The study visit took place from June 2-5, 2003. 
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After the consumption of illicit drugs increased in the 1990s, substitution 
treatment was initiated in Finland in 1997, in both the community and in 
prison. Before this period of political unrest and reformation in the neigh-
bouring countries of the former Soviet Union, the primary addiction in Fin-
land was alcohol addiction. ‘Illicit’ drug use of e.g. cannabis, amphetamines, 
or opiates was not considered a major health risk in Finnish society. 
In 1997, the Ministry of Social Affairs and Health reacted to the new devel-
opments and the increase of illicit drug use in the country with a new regula-
tion on treatment. The discussion of substitution treatment was controversial 
but implemented even against public and political opposition. It was decided 
that a limitation to a few urban sites was sensible, as research was necessary 
in order to collect enough national data on substitution treatment. Treatment 
was thus only started in a few, large hospitals in the urban area of Helsinki. 
Shortly after the first implementation, many advocates for substitution treat-
ment requested numerical enlargement of the programme and geographical 
extension to other parts of the country. Since 1999, the number of care units 
providing substitution treatment has been enlarged greatly. In June 2003, 
110 units such as hospitals, health centres, addiction clinics and prisons pro-
vide substitution treatment with both methadone and buprenorphine. 
As Finland’s authorities fully embrace the WHO guidelines on equal treat-
ment, in and outside of penitentiaries, substitution treatment was provided in 
prison right from its introduction to the Finnish health system in 1997. The 
first decree of the Ministry of Social Affairs and Health limited treatment to 
the need of new inmates to be granted the continuation of treatment when 
facing incarceration. In April 2002, the legal situation changed when the 
Ministry of Social Affairs and Health issued a new decree2, after which, the 
Chief Medical Officer of the Prison Administration released a communiqué3 
in which authorised medical staff in prisons could start substitution treatment 
for certain prisoners under specific circumstances. However, the practice is 
little known and only tentatively embraced by medical staff in prison. Conse-
quently, neither medical staff in detention facilities nor prisoners entering 
prison, without being on treatment before, seriously consider the possibilities 
of starting ST behind bars. 
                                                          
2  No. 289/2002 of April 15, 2002. 
3  Communiqué No.5/442/2002 of September 2002. 
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The political debate about the usefulness and necessity of substitution treat-
ment in Finland has lost its force. Research data, collected during the last 
6 years of implementation, proves that substitution treatment can have the 
following positive effects on public health policy as well as the health status 
of the individual in treatment: 
− Reducing risk-behaviour, leading to public health problems such as an 
HIV-/HCV-epidemic 
− Linking the addicted person to existing treatment services 
− Reducing criminal activity procuring illicit drugs  
− Breaking the cycle of addictive behaviour when used as a detoxification 
treatment  
However, these positive research results do not hinder the controversial 
political debate covering the general aims and the regulations underlying the 
day-to-day implementation of substitution treatment. As in many other Euro-
pean countries, treatment issues such as access criteria, links to other treat-
ment regimes and national uniformity of the treatment are still the subject of 
controversy. 
Practical procedures 
When introduced in 1997, the general aim of substitution treatment was 
withdrawal from opium addiction in all cases. All treatments required a treat-
ment plan. This plan was developed by professionals, specifying medical and 
psychosocial care received by the patient along with the medicinal treatment 
of the substitution drug. Treatment plans are still required today. However, 
in the June 2000 Decree on the treatment of opium addicts (607/2000), the 
aim of the treatment has been specified and broadened by the Ministry of 
Social Affairs and Health. Now substitution treatment does not only aim at 
withdrawal in all cases, its aims are threefold: 
− detoxification 
− substitution 
− maintenance 
Detoxification treatment is defined as care in which the care period does not 
exceed one month and which aims at a drug-free lifestyle using buprenor-
phine or methadone for the transitional period only. 
Substitution treatment is defined as medicinal care in which the care period 
exceeds one month and which aims at a drug-free lifestyle after a maximum 
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of five years. The treatment plan for substitution treatment can be divided 
into the following phases: 
1. Attachment phase: 6 months 
2. Rehabilitation phase: 6 months - 1 year 
3. Stabilisation phase: 1-4 years 
4. Detachment phase: 4-5 years 
Substitution treatment can only be started after previous treatment attempts, 
with approved care practices and procedures for curing the patient’s opium 
addiction, have not been successful. 
Maintenance treatment is defined as rehabilitative care of opium users, 
where the care period exceeds one month and where stress is put on harm 
reduction and the improvement of the patient’s quality of life. Maintenance 
treatment can only be started with patients with a special need for the reduc-
tion of harm caused by opium use. Maintenance treatment is chosen if it is 
not probable that the individual’s drug use pattern can be ended through sub-
stitution treatment. Maintenance treatment aims at preventing the spread of 
communicable diseases and other public health hazards, at binding the client 
to existing health services and at improving the patient’s quality of life. It 
also aims at preparing the patient for a more ambitious rehabilitative substi-
tution treatment (Yrjö and Tourunen 2002). 
The Finnish government is still working on unified national guidelines with 
regard to access criteria. Due to the fact that, in the past, only a few univer-
sity hospital wards were allowed to grant access to therapy, the need to de-
velop and publish national access guidelines arose at a comparatively late 
stage. The following general rules are handled as guidelines for the start of 
treatment for patients outside prison. Patients need to meet the following 
profile in order to be granted access to treatment: 
− To be officially diagnosed with an active opium addiction after having 
received a referral to an assessment from a social welfare, health care or 
substance abuse service unit 
− To be able to prove a previous attempt to cure the addiction with appro-
ved practices and procedures. 
Once accepted into treatment – which can, due to the limited amount of 
treatment places and too much demand, take more than a year – the patient 
needs to pass the commencement phase which includes an in-patient period 
of up to one week. Prior to this period, the patient has the chance to discuss 
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with his/her doctor whether substitution is provided in the form of metha-
done or buprenorphine treatment (both authorised). On the other hand, the 
decision of whether detoxification, substitution or maintenance treatment 
will be implemented remains fully in the hands of the medical professional. 
With regard to the qualification of those medical staff that can start substitu-
tion treatment, today’s criteria are defined as follows. The treatment can be 
started 
“if the doctor responsible for the activity has special qualifications in addic-
tion medicine 
OR  
if the unit has been involved in continuing treatment before 
OR  
if the staff has acquired the theoretical and practical knowledge needed to 
carry out treatment.”4 
This means that a large number of physicians outside prison qualify for 
evaluating patients or for having the responsibility to continue the patients’ 
substitution treatment. For health care units in prison, an exception was sta-
ted in the Communiqué of September 6th, 2002: 
“Exceptionally, it may come up that the evaluation and possibility of starting 
opium treatment during a patient’s stay in prison should be considered. In 
these cases, the prisoner may be sent to an ambulatory or hospital unit out-
side prison. The person may also have already been accepted for treatment, 
with the support of opium, but be waiting for it to start upon arrival in pri-
son. In such cases, care should be taken that getting into prison is not an 
obstacle, unless there are medical reasons for abstaining from starting the 
treatment. Evaluation and starting treatment can also be done in a hospital 
unit of the prison service, after the Chief Medical Officer has agreed and the 
provincial government has been informed 30 days in advance of starting the 
treatment.”5 
                                                          
4  Communiqué 5/442/3002 on Treatment of patients dependent on opioids with certain 
medicines, September 6, 2002. p. 1. 
5  ibid. p. 2. 
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However, as most doctors and medical staff in prison are not aware of the 
changes in the legislation, namely that treatment can be started in prison, 
little information is passed on to prisoners who might qualify for starting 
substitution treatment in prison. This development is quietly welcomed by 
those aware of the legal changes, as medical staff in prison fear a wave of 
substitution treatment requests once prisoners become widely aware of their 
new opportunities. 
The treatment plan, to be developed prior to the start of the substitution 
treatment, officially needs to include alternative treatment methods next to 
the medicinal substitution with methadone or buprenorphine. Psychosocial 
care and relapse prevention seminars are two additional pillars on which 
addiction treatment should rely. Officially, once a patient participates in sub-
stitution treatment, the participation in psychosocial care activities is obli-
gatory. For example, the treatment contract for Subutex substitution treat-
ment in Hämeenlinna Prison Hospital is quoted as stating: “1. Most impor-
tant in treatment is psychosocial treatment, which is supported by opioid 
treatment”.6 
However, in most locations where substitution treatment is provided – in and 
outside of prison – there is no or very little psychosocial care activity in 
which patients can enrol. None of those prisoners interviewed during the 
study visit reported being actively enrolled and obliged to participate in a 
psychosocial support program, such as a conversational support group or 
motivational training to break their addictive behaviour. Some of the inpa-
tient clinics make use of the Narcotics Anonymous (NA) meetings, utilising 
their principles of recognition and relapse prevention as a support group for 
their patients. Some prison facilities, such as Mikkeli remand Prison, have 
developed their own, elaborate system of relapse treatment programmes and 
motivational seminars which are, however the exception rather than the rule 
in Finnish penitentiaries (Riittinen). A nation-wide program is to be develo-
ped according to new legislation and in combination with the new national 
access criteria. 
Infection with a chronic incurable disease such as HCV, HIV, or TB does not 
necessarily ease the way into substitution treatment for injection drug users. 
Access criteria are more often determined by the assessment procedure men-
tioned above; in which medical professionals determine the motivation and 
                                                          
6  See Annex 3. 
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the medical necessity needed to reach the aim of detoxification, substitution 
or maintenance treatment. However, most intravenous drugs users infected 
with HIV qualify for an amelioration of their quality of life and therefore, if 
their medical record is made know to the substitution treatment specialist 
evaluating their application, they are granted access to substitution or main-
tenance treatment. 
1.2.2 Substitution treatment in prisons 
The scope of substitution treatment in the Finnish prison system is numeri-
cally very small. In the 14 Finnish prisons in which substitution treatment is 
provided, a total number of 116 prisoners have been treated from 1998 to the 
end of May 2003 (e.g. in 2001: 45 prisoners, 10 received methadone, 
12 Subutex®). The rate of prisoners receiving substitution treatment has 
increased since its introduction in 1997. All of them were enrolled in the 
treatment programme before entering the penitentiary and might have been 
released again after having served relatively short sentences, from 3-6 months, 
for defaulting on fines. In most cases, treatment lasted until release and was 
continued outside by the local health centre, the regional hospital or other 
institutions authorised to distribute substitution medication. The continuation 
of substitution treatment is in line with the basic principle for substitution 
treatment, issued by the Prison Administration (Health Care)7 which states: 
“… opioid treatment which has been started in accordance with the decree 
and based on a treatment plan must not be interrupted suddenly due to the 
fact that the patient gets into prison or is transferred to another institution. 
Thus, it must be possible to continue the treatment in all prisons and prison 
hospitals, as well as during transfers between institutions and short leaves 
from prison.” (p. 1) 
Substitution treatment can be started in prison but, usually, it is not due to 
difficulties in the connection to outside programmes for the continuation of 
treatment. 
The daily practice of distributing substitution drugs in prison takes the pri-
vacy rights of the patient into account. There are no specific substitution 
treatment units in Finnish penitentiaries nor is the diagnosis of drug addic-
tion made public to wardens or other inmates. During the week, the dosage is 
                                                          
7  Communiqué 5/442/3002 on Treatment of patients dependent on opioids with certain 
medicines, September 6, 2002. 
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given to the patient in the prison health care unit under direct observation 
whereas prison officers distribute the medication on the weekends when 
hospital units are closed. Although a maximum degree of confidentiality is 
attempted by the prison administration, most imprisoned interviewees 
reported difficulties with fellow prisoners who knew about their substitution 
treatment demanding to receive a share of the desired opiates. To counteract 
this development, prison administrations have developed an intricate system 
of direct observed therapy in which inmates receive their medication under 
supervision. Methadone is distributed in liquid form whereas buprenorphine 
is slipped on the patient’s tongue in pill form, the mouth being checked care-
fully by staff after the dissolving period. Urine tests are taken regularly to 
make sure that inmates in treatment do not top up their daily dose with illicit 
drugs and there are regular checks for injection marks. If a patient has shown 
cooperation and no incidents have occurred, he or she might qualify for the 
maximum of 8 daily doses at a time in order to spend a leave period uninter-
rupted and independently. 
In case of a referral to another penitentiary, medical dossiers and information 
about the dosage are communicated between medical staff of the different 
institutions. So far, only one incident has been reported in which the patient 
was denied the continuation of treatment after being transferred by a prison 
doctor strongly opposed to substitution treatment in general. The patient was 
immediately resent to the prison of departure where her treatment was conti-
nued. The medical employee refusing to distribute substitution treatment 
received an official reprimand by the Ministry of Justice stating that the dis-
continuation of treatment did not fall within his authority. This centralised 
approach, and the awareness that substitution treatment is generally percei-
ved as medical treatment, seems to prevent discontinuation in prison or a 
major change in dosage for the individual prisoner. 
Relying on the treatment plan, set up by the medical officials who started 
substitution treatment after the intricate phase of assessment, medical staff in 
prison fill in an official protocol recording the day-to-day implementation of 
the treatment during the patient’s stay in prison.8 In this chart, the daily 
developments towards the (ultimate) aims set in the treatment plan are 
monitored and the individual’s progress is recorded. These documents are 
                                                          
8  See annex 4. 
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passed on to medical staff taking over the supervision of the individual after 
transferral to another institution or release from prison. 
If the weekly random urine test is positive, according to the Prison Admini-
stration’s issued communiqué (5/442/3002) “the continuation, intensification 
or tapering down of the medication is considered individually in each case in 
co-operation with the unit which has started or continued the treatment be-
fore the imprisonment. When necessary, the treatment decision is discussed 
with the doctor responsible for treatment in prison. Essential changes in the 
treatment shall be reported to the Chief Medical Officer. Refusal to give a 
urine sample or other non-compliance to the treatment plan agreed upon is 
to be considered as a breach of the treatment agreement.” (p. 1) 
In order to guarantee continuity of care and eased communication between 
prison and ongoing treatment centre n the community, the patient’s written 
consent is required. 
Controversial issues among staff are (i) suspicion of misuse of methadone or 
buprenorphine, (ii) the double bind of giving out drugs when, at the same 
time, prisoners are told not to use drugs, (iii) prisoners’ inability to work un-
der substitution treatment. Regarding the latter, it was mentioned that some 
staff members assumed that patients will fall asleep during work. However, 
this is a matter of providing the right dose. The employers should not know 
who is in what type of health treatment. 
According to the interviewees there is no involvement of outside agencies 
(like NGOs) in substitution treatment, but there is close cooperation with 
doctors in the community. 
1.3 Prison Population  
Table 7 Data on the prison situation in Finland (Source: King’s College London, Interna-
tional Centre for Prison Studies, Prison Brief for Finland) 
Country  FINLAND 
Ministry responsible  Ministry of Justice 
Prison administration  Department of Prison Administration 
Contact address  P O Box 319, Albertinkatu 25, FIN-00181 Helsinki, Finland 
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Telephone / fax / website  
tel: +358 9 1601 
fax: +358 9 1608 8556 or 8410 
url: www.vn.fi/om/suomi/vaho/summay.htm 
Head of prison administration  
(and title)  
Markku Salminen  
Director General 
Prison population total  
(including pre-trial detainees / 
remand prisoners)  
3 719 (15.4.2004, national prison administration)  
Prison population rate  
(per 100,000 of national population) 
71 based on an estimated national 
population of 5.22 million in April 2004 
(from Council of Europe figures)  
 
Pre-trial detainees / remand 
prisoners  
(percentage of prison population)  
12.7%  (15.4.2004, not including 104 remand 
prisoners in police establishments)  
Female prisoners  
(percentage of prison population)  5.6%    (15.4.2004)  
Juveniles / minors / young prisoners 
incl. definition (percentage of prison 
population)  
0.2%    (15.4.2004 – under 18)  
Foreign prisoners 
(percentage of prison population)  7.9%    (15.4.2004)  
Number of establishments / institu-
tions  
37 (2004 – 16 closed prisons, 5 open prisons, 14 open 
prison units (including 4 labour colonies), 2 prison 
hospitals of which one is a psychriatric hospital)  
Official capacity of prison system  3 473    (15.4.2004)  
Occupancy level (based on official 
capacity)  107.1% (5.4.2004)  
Recent prison population trend 
(year, prison population total, prison 
population rate)  
1992      3 295      (65) 
1995      3 018      (59) 
1998      2 569      (50) 
2001      3 040      (59) 
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2 The field visits  
In addition to the interviews held in the two penitentiaries, further informa-
tion was collected through interviews in the Ministry of Justice (interviews 
with Leena Arpo, Chief Medical Officer of the prison administration), in 
Järvenpää Addiction Hospital and in Munkkisaari substitution therapy clinic 
(Pekka Tuomola, head of drug and mental health work of the Helsinki Dea-
coness Institute, Dr. Outi Kuikanmäki, head of substitution therapy clinic) 
and service centre for HIV infected drug addicts. In the Ministry, Senior 
Medical Officer Terhi Hermanson was willing to provide information on the 
historical and legal development underlying the introduction of substitution 
treatment and harm reduction methods in Finland, as well as the current 
political debate on financing and implementation of substitution treatment.  
In Järvenpää Addiction Hospital, a part of the non-profit private A-clinic 
foundation, information was provided by Jouni Tourunen and a staff member 
of the day-care clinic. The former is mostly involved in researching the 
development of substitution treatment in the face of the typical addiction 
patterns encountered in Finland, whereas, the latter was able to provide in-
formation on the day-to-day practice of treating in-patients for both acute 
withdrawal symptoms as well as long-term addictive problems. 
In Munkkisaari substitution therapy clinic, the urban Helsinki institute, three 
employees took the time to relate the scope and daily practice of treating 
opiate using patients with methadone and Subutex, in operation since 2000. 
42 of the approximately 200 patients who were on substitution treatment are 
HIV-infected drug users relying on the services offered by the institution – 
such as a day-care ward, a dormitory, individual and group therapy, as well 
as medical and social services. 
2.1 Vantaa prison  
2.1.1 Description of the prison 
Vantaa prison is a closed prison, mainly for male remand prisoners, with a 
few places for women and some sentenced prisoners. In 2002, the average 
population was 155 men and 12 women. It has a drug free unit for 60 men. It 
is situated just outside of Helsinki’s city boundaries. In this facility, the psy-
chiatrist, Aulikki Ahlgrén, and a nurse responsible for distribution of the 
substitution medication were interviewed as well as two male prisoners on 
treatment. 
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2.2 Hämeenlinna Prison  
2.2.1 Description of the prison 
This is the main institution for women prisoners. Hämeenlinna is a closed 
prison, in which both remand (female) prisoners and sentenced prisoners are 
held. It is close to the city of Hämeenlinna, some 100 km from Helsinki. 
In November 2003, it held 172 men and 131 women with a staffing capacity 
of 223. 
In Hämeenlinna Prison, the chief physician, Päivi Viitanen, and the nurse 
responsible for the pharmacy were able to provide information on the daily 
distribution practices and experiences in the institution. This information was 
supplemented by information given by one male prisoner, interviewed indi-
vidually, and three female prisoners, interviewed as a focus group. 
2.3 The views of prisoners in both prisons 
No problems have been reported concerning discontinuation or change of 
dosage; communication channels between the outside agencies and the 
medical staff inside of prison facilities seem to be well established and func-
tion satisfactory for all parties involved. 
Prisoners interviewed during the study visit did not report any complications 
or arbitrary dose change by medical staff in the penitentiaries or the police 
cells, where they were kept before being placed in remand prisons. They also 
reported being encouraged to keep in contact with the medical staff outside 
whilst being imprisoned in order to avoid treatment gaps after release. This is 
also advantageous as a means to avoid mental isolation and to communicate 
a prepared release procedure rather than a return into the well-known drug 
scene that might endanger the continuation of substitution treatment through 
additional illicit drug use. Though confidentiality is attempted by the prison 
administration, most imprisoned interviewees reported difficulties with those 
fellow prisoners who knew about their substitution treatment demanding to 
receive a share of the desired opiates. In addition, there is the difficulty of 
dispensing the substitution drug on weekends by staff members, which 
informs them of who is in substitution treatment. 
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3 Summing up 
So far, Finnish substitution treatment in prisons runs on a rather small scale. 
This is due to the nature of the introduction of substitution treatment into the 
Finnish health system and the fact that the treatment could only be started by 
a few renown university clinics in the urban area of Helsinki. Medical staff 
in prison began implementing treatment plans that were decided by staff out-
side the prison system. In September 2002, the legal situation changed when 
the Ministry of Justice gave permission to medical staff in prisons to start 
substitution treatment under specific circumstances. However, prison doctors 
who were qualified for starting treatment were anxious to take on this 
responsibility, as they feared a wave of requests from the prison population 
that would be larger than they could handle. Consequently, no treatment has 
been started inside prison yet and the number of prisoners enrolled in sub-
stitution treatment can easily be monitored. 
Of the three forms of substitution treatment determined in federal regula-
tions, most inmates are enrolled as ‘substitution’ or ‘maintenance’ patients. 
For patients that only qualify for detoxification treatment, imprisonment is 
usually postponed until the detoxification process has been completed suc-
cessfully. ‘Substitution’ treatment patients – supposed to overcome their 
addictive behaviour by medicinal aid within a maximum of 5 years – differ 
from ‘maintenance’ patients for whom the reduction of harm and the impro-
vement of their quality of life stand in the foreground of the treatment. In 
practice, however, substitution treatment received is in most cases closer to 
permanent maintenance than to substitution treatment aiming at opiate with-
drawal, as defined in the official Decree. 
Substitution is provided in the form of liquid methadone or buprenorphine 
whilst Subutex® pills are the preferred drug by most patients in treatment. 
Many of the Finnish drug users seem to have an undefined fear of a surplus 
addiction to methadone without having experienced the effects of the sub-
stitute. 
Imprisonment and transfers to other prisons, as well as the release procedu-
res, seem well organised in the Finnish prison system. Active cooperation 
and good communication between the external health services handing out 
substitution medication and the internal medical units in prison prevent pati-
ents from experiencing long periods without medication or an unexpected 
change in their dosage. Keeping in touch with the external health unit, 
responsible for the substitution treatment during incarceration, guarantees the 
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continuation of treatment after release. If patients ask for a raise in their do-
sage, prison staff are more likely to be conservative than outside health units, 
this can lead to complaints by prisoners to their external supervisors during 
their incarceration. 
Every patient that enters substitution treatment receives a treatment plan by 
the medical unit, assessing the patient’s record and granting access. This 
treatment plan includes an alternative treatment scheme in addition to the 
medicinal substitution. Psychosocial care, motivational seminars and relapse 
prevention programmes, as well as re-integration programmes into society, 
are part of this treatment scheme. However, most prisoners interviewed dur-
ing the visit to Finland stated that extra medicinal treatment offers were 
scarce, inside as well as outside of prison. 
There are no special substitution units in Finnish prisons. On weekdays, pri-
soners on substitution take their daily dose under supervision at the medical 
unit whereas, on weekends, they receive their medication from wardens 
when pharmacies and medical units are closed. A maximum degree of confi-
dentiality is granted to the individuals but usually fellow inmates are well 
aware of the special daily medical treatment. Urine tests and checks for 
injection marks are a regular routine for participants in the substitution treat-
ment. Topping up with illegal drugs usually leads to intensified care and 
supervision but, so far, has not yet led to the expulsion of any patient from 
the substitution treatment. 
The Finnish substitution treatment in prison is still young and small in scope. 
Its quality can be regarded as high due to the fact that patients and doctors 
alike are satisfied with the legal framework and the organisational set-up. 
Drug users pledge for more access possibilities and warmly welcome the op-
portunity to start substitution treatment in prison once the necessary changes 
legislation are communicated openly and implemented in all Finnish peni-
tentiaries. Medical staff will have to get used to the responsibility of evalua-
ting addiction files and to granting access to substitution therapy. This could 
mean that many of the prison doctors will have to follow vocational training 
in order to obtain more expertise in the field and that more staff will be nee-
ded to implement the therapy for a greater number of patients.  
Two further developments can be welcomed: the fact that the Finnish gov-
ernment is attempting to unify the access criteria to treatment as well as the 
attempt to stress the importance of extra medicinal treatment and the devel-
opment of a national curriculum of these activities for all institutions pro-
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viding substitution treatment. Both, the guidelines for access criteria and the 
curriculum of extra medicinal treatment, need to be regulated for the whole 
country if randomisation of access and discrepancy in quality of treatment is 
to be avoided when the program is enlarged in the near future. 
  
France1 
1 General data:  
drug use, substitution treatment and prison population 
1.1 Drug use 
The two most frequently used psychoactive substances in France are alcohol 
and cannabis, followed by cocaine, LSD, ecstasy, heroine and to a lesser 
extent amphetamines. Most of the drug users are poly-drugs users. (Reitox 
France, 2001). 
The number of drug users is estimated to be 120-180,000. About 100,000 are 
on a substitution treatment: 82,000 on Subutex® (that is approximately 80% 
of the total) and the rest on methadone. These figures are given by the labo-
ratory.2 (Interview with the Ministry of Health) 
In the community, 70,000 people were on a substitution treatment (Subutex® 
or methadone) in 1999, increasing to 92,000 in 2001 (80,000 on Subutex® 
and 12,000 on methadone). (Figures from the Ministry of Health) 
In prison, in 1999, there was a total of 1 653 prisoners on substitution treat-
ment for a population of 50,041 prisoners (3,3%). Out of these 1 653, 272 
were on methadone and 1 381 on subutex®. These figures increased in 2001 
to 2 548 prisoners in substitution treatment for a population of 47,311 priso-
ners (5,4%), with 366 on methadone and 2 182 on subutex®. (Figures deli-
vered to the Ministry of Health from each prison of the country on a given 
date, Ministry of Health) 
There was a total of approximately 60,000 prisoners for the whole of France 
prior to July 2004 (at the time of the field visit) for a total of 168 prisons in 
France (France Metropolitan and French overseas departments (DOM), 
excluding half open prisons). (The Ministry of Health) 
                                                          
1  The field visit, conducted by Laetitia Hennebel, was facilitated by Saadia Yakoub, psy-
chologist, who gave great support in the preparation phase and actual field visit. Special 
thanks to Laurent Michel, Pierre Lamothe, and Frédéric Meunier for their support. 
2  It must be taken into account that some (a minority) of these prescriptions/ treatments are 
misused, sold on the black market, or prescribed twice for the same patient. 
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1.2 Substitution treatment 
Data comes from an on-going review of research reports, websites and laws/ 
regulations, as well as from interviews conducted during the field visit3. 
1.2.1 Historical and legal background 
Health care in prison is under the management of the Ministry of Health 
further to the 1994 reform, as stated by the law of 18 January 1994 (law 
number 94-43). From that date prisoners’ health care depends on the Minis-
try of Health and the public hospital service, and no longer to the peniten-
tiary administration. Clinicians are employed by the Ministry of Health and 
attached to a public hospital, but practise in a prison. This law also sets that 
drug-using prisoners are to be cared for by the UCSA and the SMPR. The 
circular of 8 December 1994 (inter-ministerial circular of application of the 
law of 18 January 1994) sets an objective ‘to ensure equivalence of care to 
prisoners as it is provided in the community’. 
A UCSA is a ‘Unité de Consultations et de Soins Ambulatoires’ or Ambula-
tory Health Care Consultation Units. A SMPR is a ‘Service médico-psycho-
logique régional’ or Regional Medical-psychological services that were 
created through the decree of 14 March 1986. SMPRs are in charge of psy-
chiatric care in prison and are attached to a public health hospital but imple-
mented in a prison. The staff team usually comprises psychiatrists, psycholo-
gists, nurses, educators and social workers. Some SMPRs benefit from a 
CSST. A CSST is a ‘Centre Spécialisé de Soins aux Toxicomanes’ or a Spe-
cialised Health Care Centres for Drug Users in prisons. CSST are managed 
by the doctor in charge of the SMPR. The circular of 3 November 1987 
specifies the CSST modalities. 
There are around 168 prisons in France (Metropolitan France and French 
overseas departments (DOM), excluding half open prisons). Each prison has 
a UCSA but only 26 prisons have a SMPR, of which 16 have a CSST. Sub-
stitution treatments are normally offered through a UCSA or SMPR. Pres-
cription rarely occurs in a CSST. Treatments and health care frameworks 
                                                          
3  Interviews were conducted at the national level with: 
– The department (Ministry) of Health, 
– an administrator at the DR, Regional Prison Administration, 
– the ex-president of the MILDT, and 
– a clinical psychologist and president of ANIT. 
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vary tremendously all through the country. (Fatome, 2001; Michel & Ma-
guet, 2003) 
French sanitary authorities remained reluctant towards substitution treat-
ments for a long time (Fatome et al, 2001). However, since the end of the 
1990s they have been involved in the promotion of these treatments, as 
abstinence is no longer seen as the only possible response to opiate depend-
ency. 
In the community, substitution treatments with methadone were first offered 
in 1973 on an experimental basis and limited for over twenty years to appro-
ximately 50 patients at a time. Treatment to drug dependents focused on psy-
chological support and detoxification. 
The spread of HIV/Aids and Hepatitis infections, brought forward a harm 
reduction policy. In 1984 some GPs in the community already prescribed 
Temgesic® (low dosage of buprenorphine) (Courty, 2001). This resulted in a 
number of doctors being prosecuted in 1992 for prescribing Temgesic®. 
The circular n°72 of 9 November 1993 of the Secretary of State of Health, 
permitted the enlargement of the number of places which provide methadone 
treatment in health care centres to 250. This was further developed with the 
circular of the Ministry of Health n° 14 of 7 March 1994 on harm reduction 
and increase of methadone treatment offers to 1000. However, the conditions 
for the centres and for the patients were very restrictive. 
1995 was an important year regarding substitution treatment. The circular 
n° 4 of 11 January 1995 relative to the Ministry of Health generalises metha-
done programmes to all aggregated CSST. The circular n° 29 of 31 March 
1995 (Circular DGS/SP3/95 relative to substitution treatment for opiate de-
pendents) authorises the introduction of Subutex into the market for ‘major 
opiate pharmaco-dependences within the frame of a medical, social and psy-
chological structure and support’. This circular clarifies the structure within 
which substitution treatments must be offered and sets that ‘heath care of 
drug users now includes substitution treatment and is part of public health 
policy’. It also underlines that buprenorphine and methadone are to be used 
for major opiate pharmaco-dependency. Methadone no longer has an expe-
rimental status. 
The circular DGS/DH n°96-239 of 3 April 1996 focuses on the ‘improve-
ment of access to substitution treatment’. It sets a limit for the conditions of 
financing of aggregated centres, restricts budgets for urine tests, and limits 
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evaluation means of the clinical efficacy of treatment. This circular also sets 
the prescription modalities for buprenorphine, which are almost the opposite 
of methadone. Any doctor is allowed to prescribe buprenorphine, without 
preliminary urine tests, controls or check-ups. Even though doctors are advi-
sed to prescribe for 7 days, it is possible to prescribe for 28 days at once. 
The circular health-justice of 5 December 1996 states the health care organi-
sations through the ‘fight’ against HIV infection in prison (circular DGS/ 
DH/DAP n° 739) and that initiation or continuation of substitution treatment 
are allowed in prison with buprenorphine or methadone. ‘A health care inte-
grating the whole of the problems of dependence must be proposed in prison. 
In particular, for drug dependent, a substitution treatment with methadone 
or Subutex can be continued or initiated’. 
In the community and in prison, methadone is offered in a heavily controlled 
structure. Methadone is offered in a more restricted and controlled environ-
ment because of the risk of overdose. Patients must undergo a certain num-
ber of major constraints at the beginning of the programme, such as urine 
tests, daily visits to the aggregated centre, prescription for 7 days maximum. 
The treatment could only be initiated by a specialised doctor, contrary to 
buprenorphine that is available at pharmacists since the beginning of 1996 
and can be initiated by any doctor. This meant that there was a significant 
difference of access to buprenorphine and methadone treatment. The circular 
DGS/DHOS n° 57/2002 of 30 January 2002 concerns the modalities of 
methadone prescription and aims at re-balancing its accessibility. The circu-
lar allows any doctor practising in a health care centre or hospital to initialise 
methadone treatment. This brings progress in regard to methadone and 
allows UCSA doctors and psychiatrists in prison to initialise this treatment. 
The law n°2002-1487 of 20 December 2002 transfers the funding of CSST to 
the Social Security (Assurance Maladie) renovating the social and medico-
social actions. The decree n° 2003-160 of 26 February 2003 redefines the 
CSST missions setting the minimal conditions of the organisation and func-
tioning of the CSST. 
1.2.2 Substitution treatment in prison 
Substitution treatment has been a useful tool for the health care and treat-
ment of opiate dependents. A 5 year delay existed between the provision of 
substitution treatment in the community and in prison. The attitudes were: 
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(i) we are no dealers, (ii) a drug that replaces another one, (iii) abstinence is 
possible in prison (interview with the ex-president of the MILDT). 
Although misuse exists, different studies have shown that substitution treat-
ments allow access to medical and social structures, contribute to improving 
the health state of drug users and are part of harm (infections) reduction in 
prison. (Stankoff & Dhérot, 2000; Fatome et al, 2001) It was reported that 
buprenorphine progressed rapidly because the prescription framework was 
easy, however, around 10-15% of all patients in a substitution treatment traf-
fic Subutex®. Although only a minority misuse buprenorphine, traffic is a 
problem (interview with the ex-president of the MILDT). 
However, it was reported that access to treatments (continuation or initiation) 
is not guaranteed in prison due to the disparity of practise and care from one 
prison and region to the other. Furthermore, the psychosocial support is often 
lacking, protocols are not always respected due to a lack of staff (such as 
having staff to monitor the provision and distribution of substitution treat-
ment). Detoxification seems to be the most common response to treatment of 
drug users. Diversity of health care offer is not guaranteed in all prisons. 
(Stankoff & Dhérot, 2000) The Ministry of Health when interviewed repor-
ted that all regions of France do not benefit from a similar medical team. 
Some areas are ‘deserted’ and lack psychiatrists. 
Michel & Maguet (2003) also reported a great heterogeneity between pris-
ons. They also underlined the importance of training and information and put 
forward 13 recommendations for substitution treatment in prison. Michel & 
Maguet’s study was authorised and supported by both the Ministry of Justice 
and the Ministry of Health. The report of the study was distributed in every 
single prison of the country as a guide and support to the provision of sub-
stitution treatment. 
Stankoff & Dhérot (2000) further reported that a number of doctors refuse to 
prescribe substitution treatment in prison (as it occurs in the community). 
Contrary to the community, the prisoner cannot visit another doctor or health 
care centre. This refusal has further negative consequences when a treatment 
was initiated in the community and could be continued in prison. Staff’s 
reluctance to provide substitution treatments are linked to the difficulty in 
assimilating these treatments to medical treatments. Furthermore, the lack of 
information on the release date is sometimes used as a justification for refu-
sing to provide the treatment. Some doctors question the end-goal and possi-
ble risks of a long-term substitution treatment. 
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1.3 Prison Population 
Table 8:  Data on the prison situation in France (Source: King’s College London, Interna-
tional Centre for Prison Studies, Prison Brief for France) 
Country  FRANCE 
Ministry responsible  Ministere de la Justice 
Prison administration  French Prison Service 
Contact address  DAP/SCERI 13 Place Vendome, 75042 Paris, France 
Telephone / fax / website  
tel:   +33 1 49 96 28 15 
fax:  +33 1 49 96 28 80 
url:   www.justice.gouv.fr/minister/sceri 
Head of prison administration (and 
title)  Didier Lallement, Director of the Prison Administration 
Prison population total (including pre-
trial detainees / remand prisoners)  
55,382 at 1.4.2003 in metropolitan France (Ministry of 
Justice)  
Prison population rate (per 100,000 of 
national population)  
93 based on an estimated national population of 59.70 
million at April 2003 (from Council of Europe figures)   
Pre-trial detainees / remand prisoners 
(percentage of prison population)  38.3%  (1.4.2003)  
Female prisoners (percentage of prison 
population)  3.9%    (1.4.2003)  
Juveniles / minors / young prisoners 
incl. definition (percentage of prison 
population)  
1.4%    (1.4.2003 – under 18)  
Foreign prisoners (percentage of prison 
population)  21.4%  (1.4.2003)  
Number of establishments / institutions 185       (2002)  
Official capacity of prison system  45,881  (1.4.2003)  
Occupancy level (based on official 
capacity)  120.7% (1.4.2003)  
Recent prison population trend (year, 
prison population total, prison 
population rate)  
1992     48,113 in metropolitan France     (84) 
1995     51,623 in metropolitan France     (89) 
1998     50,744 in metropolitan France     (86) 
2001     46,376 in metropolitan France     (78) 
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There was a total of approximately 60,000 prisoners for the whole of France 
at the time of the field visit for a total of 168 prisons in France (France 
Metropolitan and French overseas departments (DOM), excluding half open 
prisons) (The Ministry of Health). 
2 The field visits 4 
Time frame: The field visit took place from 28 to 30 April 2004 in the Paris 
area and 25 to 26 May 2004 in the Lyon area. 
Location: Visits were conducted in two prisons: The Yvelines Prison (Bois 
d’Arcy) and Lyon Prison. 
Map of France 
                                                          
4  Methodology: Interviews were conducted with the individuals listed below as well as focus 
groups and interviews with the prisoners. No tape-recorder was used. The researcher con-
ducted all interviews/ focus groups on her own. All participants were briefed and told 
about ethical issues. 
The 
Yvelines  
Prison 
(Bois 
d’Arcy) – 
suburb of 
Paris 
Lyon Prison
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2.1 The Yvelines Prison (Bois d’Arcy)5 
2.1.1 Description of the prison 
The Yvelines prison (Bois d’Arcy) is located in the suburb of Paris, just 
south of Versailles. The area is known for having level of delinquencies, 
partly linked to social housing complexes in the area, and to bordering a 
large city. 
The prison, built in 1980, in the shape of a star, is a remand male prison. 
However, 40% of the prisoners are sentenced, waiting to be transferred to 
sentenced prisons, which is resulting in a late or no transfer. 
The prison has a capacity of 512, at the visit, approximately 850 prisoners 
(of which approximately 30 were juveniles). From 1980 to 1990, the prison 
was overcrowded and over-used holding approximately 1 000 prisoners on a 
given day, at one time reaching a maximum of 1 500 prisoners. This prison 
has thus aged very rapidly and faces maintenance issues. 
The prison has approximately 265 guards per week, of which, the governor 
reported, half are in their training scheme and thus there is a high turnover 
and guards have little experience. 
The prison has a UCSA, as well as a SMPR and CSST (managed by the 
Ministry of Health), attached to the hospital Mignot and to the hospital Char-
cot à Plaisir respectively. The SMPR-CSST counts 5 psychiatrists full-time, 
5 psychologists (4 full-time), 10 nurses (4 full-time), 2 head of nurses, 2 me-
dical secretaries, and 1 social worker. 
                                                          
5  Data from interviews were those conducted with: 
– The governor of the prison, 
– a magistrate (juge d’application des peines), 
– a psychiatrist (SMPR/ CSST) and head of CSST and SMPR, 
– the head of nurse/ health care (SMPR), 
– a nurse (SMPR), 
– a clinical psychologist (SMPR), 
– a social worker (SMPR), 
– a social worker, SPIP (Probation Services), Ministry of Justice, Prison Administration, 
– the head of guards, 
– a guard (SMPR unit), 
– a social worker, CAAT, NGO. 
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2.1.2 Goals and practical procedures 
Upon entry to the prison, the prisoner is seen by the UCSA as soon as possi-
ble (usually within 24 to 48 hours of arrival, except when arriving over the 
week-end) and then by the SMPR/CSST. The UCSA informs the SMPR-
CSST in case anything ‘specific’ needs to be ‘treated’. The SMPR-CSST 
may be informed by the UCSA, guards or SPIP (Probation and Insertion 
Services) if the prisoner says or reports something peculiar or alarming 
requiring further SMPR-CSST care. There is no auto-description or identifi-
cation to SMPR-CSST in order to avoid abuse, except through written 
request asking to see a specialist. Usually, after such a written request, the 
prisoner is attended by a psychologist, psychiatrist or nurse depending on the 
request. Patients on a specific treatment (psychiatric or drugs, like substitu-
tion treatment) are followed on individual cases by the SMPR-CSST. 
At the time of the visit 35 prisoners were receiving a substitution treatment: 
11 were on methadone (syrup) and 24 on buprenorphine (tablet or pill).  
The Ministry of Health reported the following figures:  
− no individual on methadone or buprenorphine in 1999 
− 17 on buprenorphine and 3 on methadone in 2001 
− 21 on buprenorphine and 15 on methadone in 2004 
(figures provided by the prison on a given day in November 1999, December 
2001 and February 2004). 
Substitution treatment is entirely managed by the SMPR-CSST. UCSA focu-
ses on somatic issues. The two departments liaise when needed. Collabora-
tion between the medical services and with the prison and prison administra-
tion was reported as working well (direction of the prison, prison and medi-
cal staff). 
Substitution treatment in the prison was offered further to the initiative of 
one of the psychiatrists and head of SMPR in post since November 2000, 
and after discussion with the staff for initiation of substitution treatment. 
Previously, the post was occupied by a psychiatrist who was not in favour of 
substitution treatment: she considered substitution treatment as a ‘one drug 
replacing another one’. Prior to 2001 no substitution treatment was offered in 
prison. At the end of 2000, beginning of 2001, continuation of a treatment 
started outside was put into practise. At the end of 2002, beginning of 2003, 
initiation of treatment was put into practise. 
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The prison staff viewed substitution treatment negatively and would say 
‘Rave party at the SMPR’ when talking about the availability of substitution 
treatment. The SMPR organised information group sessions on substitution 
treatment that were provided to every single guard working at the prison. 
This contributed to a change of attitude and to substitution treatment being 
considered as a medical treatment. 
The methadone is delivered to the prison by a laboratory located outside the 
prison in small bottles of dosage 60, 40, 20, 10 and 5 mg and are kept in a 
safe box (as set by the law) in the medical centre. The taste is bitter but sugar 
is added for the taste, and also to make injection impossible. Buprenorphine 
is delivered in tablets of 0.4, 2 and 8 mg. 
Methadone has the reputation of being a safer treatment, but it was reported 
that this is a false idea. This idea comes from the fact that it is provided 
within a supervised team and centre (CSST). 
When prescribing either treatment, the psychiatrist attempts to put the priso-
ner in a health care perspective and starting a clinical approach by talking 
about the treatment, liaising with the psychosocial team, and discussing fol-
low-up at release. The goal of substitution treatment is also to offer a harm 
reduction measure, better reinsertion after release and possibly abstinence. 
Deliveries for buprenorphine and methadone are different. Prisoners on a 
buprenorphine treatment must visit the SMPR during the first one to two 
weeks of treatment. They are taught about the sub-lingual intake, which is 
supervised, as well as the benefits and risks of buprenorphine. Doses of 
buprenorphine can be easily and quickly increased, but the average dose is 
8 to 10 mg. After these first weeks, the prisoner receives the buprenorphine 
treatment by hand twice a week (for daily intake) along with other medicine. 
Some prisoners choose to get their treatment delivered to their cell by a nurse 
(as it can be done for any medical treatment) or get it at the SMPR twice a 
week. Others visit the SMPR continue visiting the SMPR every day to 
receive their treatment. They may do so if they are unstable, if they need a 
daily contact with the medical centre, if they wish to increase discretion 
about their treatment and decrease the chances of being bullied or victim of 
racket. They may also do so in order to stay in close contact with the SMPR. 
However, it was underlined that substitution treatment must allow patients to 
gain certain autonomy. 
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For the delivery of methadone, any individual on methadone must visit the 
SMPR every single day to receive his treatment. The intake is supervised as 
according to the law. The delivery is between 8.30 am and 12.00 am. The 
SMPR guard notifies the respective guards to send to the SMPR the concer-
ned prisoners by groups (or all at once) in the morning at 8.30 am, 9.45 am, 
or 11.45 am. Although the treatment is not divulgated to any prison staff, it 
was reported that it is relatively easy to ‘guess’ that a prisoner sent to the 
SMPR on every single day is on a methadone treatment (prisoners, and 
guards). However, this did not raise any particular questions of confidential-
ity. It was reported that although respecting confidentiality and ethical con-
duct is done at its best, like it is done outside, it cannot be done at 100% in a 
prison setting. A guard stated that when enquiring about a particular priso-
ner, they are told it is confidential information (‘medical secret’). As a result 
they cannot be warned about or understand better certain prisoners with par-
ticular behaviours. 
Guards are not involved in health care. Their job is security and because of 
medical secret are not informed about health care of prisoners. A guard 
reported that there was a lack of doctors and punctuality from the medical 
team. Some difficulties have occurred when a prisoner has not been called 
for treatment (omission or error). The guards said that substitution treatment 
is perceived as a medical treatment in which the most obvious effect was to 
soothe and calm the prison environment for drug users. A guard said that 
some prisoners told them that they had been on a substitution treatment from 
the beginning; others talked about it when they discussed things with the 
guards. 
A social worker reported that sex offenders are highly stigmatised in prison; 
drug users are much less so. Moreover, there are a lot of conflicts related to 
drugs, mostly related to issues at the pre-incarceration stage. This may ex-
plain the fear of some prisoners of being identified or stigmatised as a drug 
user. 
When a methadone treatment is initiated, the starting dose for methadone is 
usually 15 to 30 mg. Initiation and maintenance are both offered at the prison 
according to individual needs. When delivering a methadone treatment, the 
psychiatrist makes sure the treatment can be continued after released, in 
order to avoid the brutal interruption of treatment. 
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The psychiatrist reported that prison is not the best place to end a substitution 
treatment (methadone or buprenorphine), because of the high level of stress 
and anxiety, and high risk of overdoses after release. 
Some prisoners are usually offered to transfer to a methadone treatment: 
− when they have been misusing buprenorphine, sniffing or injecting it 
− they have a ‘drug-use’-relation to the substance 
− they could still benefit from a substitution treatment 
When transferring from buprenorphine to methadone, the prisoner must wait 
for 48 hours after the last intake of buprenorphine before receiving the new 
treatment. After 48 hours 20 to 30 mg of methadone is given; no withdrawals 
can occur with such a dose. The average dose of methadone is 60 to 80 mg, 
although there is great variability from one patient to the other. Patients with 
a fast absorption may need to take methadone two times per day. 
Over weekends, buprenorphine is delivered prior to the weekend, whereas 
the prisoner must go to the SMPR for methadone, which is delivered by a 
nurse. A doctor is always on duty on Saturdays. For Sundays, the nurse man-
ages alone. In case of emergencies in the absence of medical staff (Sundays 
and every day after 6.00 pm), the prison is linked to ‘ERIC’ (i.e. rapid crisis 
intervention team), a medical psychiatric team that intervenes only in case of 
emergencies. They intervene for any prisoner and are linked to the Charcot 
hospital in Plaisir. ERIC may also be warned in case there is a likely proba-
bility for an emergency. 
There is no contract or consent form for substitution treatment but some 
written information and warning about misuse. 
The SMPR is entitled to conduct urine tests on prisoners who are on a sub-
stitution treatment. This is not conducted towards punitive measures. Urine 
tests are conducted: 
− before starting a new treatment. 
− When continuing a treatment. Confirmation of methadone treatment tends 
to be easily obtained since methadone is offered within a very supervised 
frame, which is not the case for buprenorphine. 
− as an assessment or check up when needed for medical reasons. 
− on prisoners who deny to the psychiatrist that they are using various drugs 
in prison; this use is obvious to the psychiatrist. The test allows the doctor 
to make the prisoner face his intake and remove any chance of denial. 
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In case of topping up the substitution treatment is not necessarily removed, 
but may be if it is supported medically. Otherwise, the treatment may be 
changed (transfer to buprenorphine or methadone, dose) and the relation pri-
soner with the psychosocial support is likely to be increased further. 
Nurses provide do the follow-up of the psychiatrist’s tasks, conduct assess-
ment such as for pre-release. Relaxation is also offered at the prison by a 
nurse. SMPR nurses work on the four different axis: ‘addictology’, general 
psychiatry, juveniles and sex offenders. 
Advantages and disadvantages 
The different interviewees reported that substitution treatment has various 
advantages and disadvantages. 
In general, thanks to substitution treatment,  
− Self-harm and overdoses in prison have largely decreased since the intro-
duction of substitution treatment. 
− there is a better ‘prise en charge’ (follow up) of drug users 
− doctors feel less or no longer helpless with drug users and more accept to 
treat them 
− the prisoner can ‘enter’ a therapeutic and care approach. 
− Abstinence and detoxification have been reached by some prisoners 
− Drug users have been identified 
− a health care system was set up and offered to drug users 
− prisoners take care of some personal issues themselves, such as making 
sure their social security is in order 
In general, because of substitution treatment, there is a new traffic, although 
other licit medicines largely generate the black market. Substitution treat-
ment is viewed by some as a substance (a drug) rather than a treatment, 
which relates to the idea that substitution treatment is just replacing one drug 
with another one. Prisoners still hold the idea that to consult a psychiatrist is 
especially for deep psychiatric disorders. As a result they are not keen to 
consult. Finally, substitution treatment brings no solution to the withdrawal 
and craving effect, which is partly psychological: users must still grieve their 
drug use. 
A magistrate reported that she considered a prisoner on substitution treat-
ment as someone who is better, taking care of himself and who has entered a 
health care approach. Other judges may see a prisoner on substitution treat-
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ment negatively, as someone who is still using. She further stated that sub-
stitution treatment needs to be provided with psycho-medico-social support, 
often lacking among doctors who simply prescribe. She also said that one 
must take advantage of prison as a moment when a health care team has 
access to the drug users in order to offer them support through specialists, 
and also to link up with health care and treatment. However, a full follow-up 
(prise en charge), although better than it was previously, is still often lack-
ing. 
Medically, buprenorphine offers clear advantages that methadone does not 
have: 
− the use is flexible, 
− there is less risk of overdose, and no risk of overdose with high doses of 
buprenorphine taken on its own, 
− stocking is easy (tablets) and easier than bottles, 
− delivery is easy (twice a week) and does not require a high number of 
staff, 
− weekly (but twice a week if unstable) doctor consultation is acceptable to 
a still-using prisoner, who would not consult every day, 
− the treatment is good even for heavy-users. 
Medically, the disadvantages of buprenorphine are: 
− sub-lingual intake is difficult and time consuming. The supervision of the 
intake is difficult, 
− The taste is unpleasant, 
− The context and frame of the provision is not the best fit and is too lax, 
− The effect is not euphoric – when taken properly – and may not appeal to 
some drug users in search of some euphoria. This results in topping up or 
misusing. 
Medically, the advantages of methadone are: 
− Easy intake (drinkable solution), that is time effective, 
− Does not generate a traffic and is not misused, 
− Any individual on methadone ends up in a health care environment, which 
offers support, supervision, guidance, 
− It is appropriate for those who have misused buprenorphine, 
− Produces a certain euphoric effect (similar to morphine) and some pleas-
ure related to the intake. 
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Medically, the disadvantages of methadone are: 
− because of this euphoric effect, the withdrawal and craving effects are 
stronger with methadone, 
− it is very bad for the teeth, 
− and a single dose of 1 mg per kg may be lethal for any “naïve” patient, 
Guards reported that prisoners on a substitution treatment are stabilised 
much faster than when receiving any other type of treatment. There would be 
a lot more incidents in prison without the treatment. The movement of priso-
ners to the SMPR does not have a great impact on the rest of the prison and 
does not impede other activities. 
Substitution treatment plays a trigger role and brings the individual within a 
treatment and health care environment. To be really efficient, substitution 
treatment must be provided along with support and supervision. 
There are still some negative attitudes or perceptions of substitution treat-
ment although it only applies to buprenorphine which is seen as toxic. Be-
cause of the highly supervised environment for methadone, this latter is seen 
as a medical treatment. Going from buprenorphine to methadone is seen as a 
therapeutic progress by some staff. 
The biggest disadvantage of substitution treatment is the new traffic it has 
generated. The governor reported that the negative aspect of substitution 
treatment is the traffic of buprenorphine; nevertheless it is worth providing 
such treatment. ‘With a global ‘prise en charge’ (follow up), it is a success-
ful.’ 
Misuse of buprenorphine sniffed or injected is common, as it is out of prison. 
10 to 20% of drug users on a buprenorphine treatment inject Subutex®. 
There are some corrupt doctors outside (and in prison) who give more than 
one prescription per medical consultation. Some individuals get Subutex® 
only to do traffic and deal and have no intention of engaging in a health 
treatment. These people make up the minority of those prescribing or recei-
ving a buprenorphine prescription, but ‘they have messed up the whole 
French system’ (a doctor). 
The starches present in the substance – when injected – are toxic and are 
likely to cause abscess, which may result in the need for amputation. 
Suboxone treatment (i.e. buprenorphine with Naloxone) is offered in the 
United States and Australia. This treatment presents no advantages to injec-
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tors and is thus not (or much less) misused. The unavailability of this treat-
ment in Europe remains unexplained by all interviewees. 
Drug users tend to remain dependent, if not on the substance, then on the 
gesture. It is therefore not surprising that they continue their use in whatever 
way possible. Moreover, when sniffing or injecting buprenorphine, users 
report getting a kick and euphoric state. This misuse results in an increased 
number of prisoners being transferred to methadone treatment. 
Guards reported that there is drug traffic inside the prison and ‘it is not a 
taboo topic’. They said that some prisoners get prescribed medicine to sell it. 
Guards feel they cannot control everything in prison and cannot fight back 
endlessly. 
The need of support, supervision, frame and ‘prise en charge’ (follow up) 
was underlined by all participants in the study as being a key part of the suc-
cess of the treatment. 
Psychosocial support and training 
Psychosocial support is delivered through the psychosocial team at the 
SMPR and the social workers from SPIP or NGOs collaborating with the 
prison. The SMPR psychosocial team tries to offer support to drug users via 
group sessions that focus on the body image, expression of emotions, sensa-
tions of the body (like pains), natural relaxation (offered by a nurse), self-
esteem. The majority of prisoners do not follow a therapy. Prisoners who 
have started a substitution treatment outside usually have gone through a 
proper ‘prise en charge’ (follow up). Drug users on substitution treatment are 
not accessible on an individual basis immediately after incarceration, unless 
they have had a therapeutic care previously or while outside. They tend to be 
closed and it is easier to first talk about administrative issues to ‘break the 
ice’. They eventually open up to talk about more personal issues. Each indi-
vidual is different and requires a different type of psychological support. 
Social workers focus on social, employment and family aspects but do not 
neglect medico-psycho issues and, if needed, liaise with appropriate indivi-
duals. They also work on the preparation for release and throughcare with 
outside centres. 
The SPIP social worker must make sure that sentences are applied, and that 
reinsertion is possible. 
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It was reported that there is a need for a better structure and access to health 
care, with a real ‘prise en charge’ (follow up) (quantitative and qualitative). 
For prisoners who must wait 2 months before the ‘prise en charge’, this is 
not adequate and is likely to result in relapses (in and/or out of prison). 
All staff (especially under the justice umbrella) stated their training was too 
short and did not cover important issues about drugs. It was reported that 
training for staff is insufficient regarding to substitution treatment. Training 
for medical staff, such as doctors, was reported as being very important. 
Specialisation is equally important, but it was reported that ideally there 
must be a rotation among the nurses as ‘the specialisation enriches the poly-
valence’: a nurse can be specialised but must also know general health care. 
2.2 Prison of Lyon 
2.2.1 Description of the prison6 
The prison of Lyon is located in the centre of Lyon. The prison comprises 
two buildings linked by a tunnel. St Joseph was built in 1830, and St Paul 
was built in 1860. The SMPR with a CSST is located in the St Paul building, 
where most of the interviews were conducted. 
The prison is a remand male prison, with a separate section for female priso-
ners in the St Joseph building. Approximately 40% of the prisoners are sen-
tenced. This is due to their waiting to be transferred to sentenced prisons. 
The governor reported that the prison has a capacity of 361. The number of 
prisoners has been approximately: 
− in 1999: 500 prisoners 
− in 2000: 600 prisoners 
                                                          
6  Data from interviews were those conducted with: 
– The governor of the prison  
– The psychiatrist and head of CSST and SMPR 
– Psychiatrists (CSST) 
– A psychologist (CSST) 
– The Head of nurses (SMPR/CSST) with a specialisation in mental health 
– A nurse (SMPR/CSST) 
– An educator (CSST) 
– A GP (UCSA) 
– A social worker 
– The pharmacist 
– Guards (SMPR) 
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− in 2001: 700 prisoners 
− in 2002: 800 prisoners 
− in 2004: 1000 prisoners 
The prison has been overcrowded for several years. It was reported that the 
prison is in a poor ‘physical’ state due to its old structure and overcrowding. 
The number of staff is approximately 380 (guards and administrative staff) 
since 1999. There are approximately 1 guard per 60 prisoners. 
The prison has a UCSA (with 12 nurses, 2 GPs, 2 physiotherapists, a dentist, 
a specialised doctor, administrative staff), as well as a SMPR and CSST 
(managed by the Ministry of Health), attached to the hospital Le Vinatier, 
that manages substitution treatment. The SMPR-CSST counts 1 psycholo-
gist, 1 GP (Public Health), 1 specialised GP, 2 educators, 1 administrative 
staff (CSST), and nurses and psychiatrists (SMPR). 
The UCSA and SMPR/CSST are located in two different parts/ buildings of 
the prison, resulting in less contact and communication between the two 
centres. 
2.2.2 Goals and practical procedures 
Upon entry to the prison, the prisoner is seen by the UCSA as soon as possi-
ble and then by the SMPR/CSST, SPIP (Probation and Insertion Services), 
etc.  
The two substances provided as substitution treatment are buprenorphine and 
methadone. 
The Ministry of Health reported the following figures: 
− 45 on buprenorphine and 3 on methadone in 1999 
− 53 on buprenorphine and 3 on methadone in 2001 
− 62 on buprenorphine and 12 on methadone in 2004 
(figures provided by the prison of Lyon on a given day in November 1999, 
December 2001 and February 2004). 
The pharmacist, located in the prison (which is actually not statutory), prepa-
res prisoners’ medical treatment which are placed in individual boxes with 
the prisoner’s name and cell number. The procedure is: the doctor prescribes, 
the pharmacist prepares and the nurse fetches the treatment from the phar-
macist and delivers it. Each prescription form is duplicated so that both the 
pharmacist and the prisoner have a copy. A copy is kept in the prisoner’s 
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medical file (for the doctor’s use). The prescription form cannot be falsified. 
Pharmacists verify the association of prescribed medicine, the doses and 
mode of use. If they perceive a problem, they directly contact the prescribing 
doctor. Once a month, they present a report taking bearings of the treatments 
prescribed. The prescription is valid for 28 days for buprenorphine and 
7 days for methadone. 
The maximal dose of buprenorphine allowed by the pharmacist is 16 mg 
(2 times 8 mg), although 16 mg should be exceptional as doses in prison 
should be less. The pharmacist recommends buprenorphine doses of 8 mg. 
The pharmacist said that detoxification with buprenorphine or methadone is 
not frequent in prison. 
At first, buprenorphine is distributed at the SMPR/CSST by nurses who 
control the intake. After the first 2 weeks of treatment (or sometimes earlier), 
the same two guards accompany one nurse to prisoners’ cells for the distri-
bution of buprenorphine. Buprenorphine is delivered either every day, once a 
week or twice a week (it varies on individual basis). It is delivered on Mon-
days and/or Fridays at noon. No pressure or conflicts from prisoners during 
the distribution of buprenorphine were reported as rules are clearly establis-
hed. However, conflicts arise from a lack of follow-up; for instance, the 
prescription is not renewed on time, which results in the prisoner being 
unsatisfied as, it was stated, they often take their treatment for granted. 
During the weekend and bank holiday, two nurses work from 8.30 am to 
5.30 pm. There is no medical staff at night. Medical services may be called 
for emergency cases. The medical staff stated that the offer (i.e. having 
medical staff overnight or a doctor during the weekend) would create the 
demand. 
A nurse reported that substitution treatment is ‘health care’ and, therefore, 
should be delivered within the SMPR setting. He further stated that he felt he 
had a lot of pressure from prisoners who want buprenorphine. He stated that 
the follow-up and therapeutic approach as part of the treatment is often 
lacking. ‘I don’t feel I am a health care worker, I don’t feel I am helping 
people.’ He also said that the diversity of practise, ethics and perception of 
substitution treatment within the medical team is problematic as a coherent, 
structured framework of practise should be in place. For instance, it was 
reported that if a nurse refuses to give a buprenorphine pill that the prisoner 
says he has lost, the doctor might accept to replace this ‘lost’ pill underlying 
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the trust relationship. The nurse said that the prisoner took advantage of the 
situation. 
It was reported that within the same prison some doctors are in favour of a 
reduction of the dose towards abstinence, whereas others are in favour of 
maintenance treatment. A psychiatrist said that each doctor should be free to 
choose and offer the health care approach he supports. Diversity of medical 
practise among doctors within the same penitentiary establishment increases 
the prisoner’s range of choice of doctor and treatment. No precise protocol 
exists for the prison, permitting a certain freedom of practise. 
Doctors reported that some prisoners were often keen on reducing the dose 
too rapidly. The end-goal of substitution treatment does not have to be ab-
solute abstinence, unlike an antibiotic. 
Guards reported that buprenorphine facilitates withdrawal, which is difficult 
to go through for the prisoner but also for the guard. The prison environment 
has become calmer thanks to substitution treatment. However, buprenor-
phine is valuable and is often swapped for other products on the black mar-
ket. A guard stated that she felt substitution treatment (especially, buprenor-
phine) is prescribed too easily and doses are frequently maintained. The gov-
ernor stated that the disadvantage with substitution treatment (especially 
Subutex®) is the risk of being used on the black market and thus being part 
of traffic or the racket associated with it. 
The situation is very different with methadone, where few problems and con-
flicts arise. Indeed, methadone is provided at the SMPR under close supervi-
sion, due to the possible fatal risks linked to the substance intake. The priso-
ner must take methadone in front of the nurse. There is a general willingness 
to decrease the dose of methadone. It was said that methadone is especially 
recommended for those who misuse buprenorphine, cannot manage the 
intake on their own or need close supervision. 
The main problem with methadone is the continuation of the treatment once 
the prisoner is released as not many doctors prescribe methadone outside, 
due to the compulsory urine tests, daily intake and close supervision. Fur-
thermore, many doctors are reluctant to prescribe methadone due to the pos-
sible fatal risks. Moreover, although 3 medical centres based in Lyon outside 
of prison accept to continue methadone for released prisoners, many prison-
ers refuse to visit the centre on a daily basis, a doctor reported. ‘Daily visits 
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work well in prison, but not outside’. One outside, released prisoners are also 
more reluctant to adhere to urine tests. 
In prison, the starting dose of methadone is on average 20 mg. The maximal 
dose is normally 110 mg. The pharmacist stated that it is easier to adapt the 
dose with methadone than buprenorphine because of its liquid form. One 
bottle contains a dose of 5 mg to 60 mg. Prisoners’ doses of methadone at 
the time of the visit were 10, 20, 50, 60, 65, 85 g. The pharmacists do not 
intervene with methadone doses as they perceive methadone as less proble-
matic due to its distribution in a more supervised and individualised appro-
ach. 
Substitution treatment is rarely initiated in prison for the very first time. 
Usually, most prisoners have had, at some point, a substitution treatment 
(buprenorphine and/or methadone) prior to incarceration. The ‘appropriate’ 
dose is set according to past history and discussion between the doctor and 
patient. 
Urine tests are conducted regularly with prisoners on methadone. Nurses 
may also recommend conducting a urine test on prisoners they suspect have 
topped up their treatment. The purpose is medical, not security. If any illicit 
drugs are found in the urine, the doctor will engage in a discussion with the 
prisoner and will not expulse him from the treatment. 
Overall, medical staff’s feelings about substitution treatment were mixed. 
Many criticised it, especially buprenorphine, due to the lack of supervision 
and global therapeutic approach. The traffic is also problematic and questi-
ons their role as doctor and ‘curer’. Nevertheless, they acknowledged that it 
is a tool to get a contact with a drug-using prisoner, even though a minority 
of prisoners on substitution treatment are truly willing to engage in a thera-
peutic work. They further said that substitution treatment has reduced self-
harm in prison, prevents HIV and hepatitis infections, and helps drug-using 
prisoners’ through withdrawal and possibly towards reaching abstinence. 
Psychosocial support and staff training 
There was no particular mention of psychosocial support or staff training. 
The psychologist stated that psychosocial support is provided to prisoners on 
substitution treatment. They often need a surrounding to ‘reconstruct’ them-
selves and their identity (other than that of a ‘drug user’), manage ‘psycholo-
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gical’ withdrawal symptoms; psychosocial support tries to help them in that 
sense. 
Many doctors stated that a global therapeutic approach should be offered to 
prisoners on substitution treatment. They also said that they often had lear-
ned about drugs and substitution treatment while working, which is not 
always appropriate. 
2.3 Views of prisoners 
A total of 6 male prisoners were interviewed. At the Prison des Yvelines, 
two together and two on an individual basis. At the Prison of Lyon, two on 
an individual basis. 
Most of the prisoners disagreed to be interviewed in a group. Although a 
focus group was planned with 5 to 6 prisoners, only 2 showed up. They 
agreed to be interviewed together. They said they did not care about being 
seen and identified as a drug user. 
Prisoners explained they did not take the treatment as advised to. 
‘I have asked to stop Subutex® because I ended up having a stock of subu-
tex® because I was taking only half of one pill. I asked to stop subutex® 
until I no longer had any stock. Then I asked to continue the treatment and 
decrease until complete detox. But the doctor refused because he said that I 
had asked to stop the treatment. I should have asked to stop temporarily.’ 
Prisoners reported misusing buprenorphine in prison. When buprenorphine is 
associated to the substance and misused, it loses its treatment value. It beco-
mes another drug and falls into the ‘love-hate’ relationship other prisoners 
reported in other countries when talking about methadone treatment. Recei-
ving substitution treatment in a supervised and appropriate health care 
scheme increases prisoners’ satisfaction. 
‘Subutex® did not work for me because it tempts me and reminds me of her-
oin. Subutex® replaces heroin for a moment, and then becomes similar to 
heroin. I took a lot of Subutex® but never sub-lingual, always sniffed.’ 
‘I injected Subutex® a few times, which is a problem because we then do not 
get out of the drugs field and drugs pattern.’ 
‘I took Subutex® for 2 to 3 years but it’s awful, disgusting. It has no effect. I 
used to take a lot of it. I had high doses. I took it on the black market, 
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through ‘magouille’ [dirty tricks]. It was the same as injecting other drugs, 
the same perspective and environment. Now I’m on methadone (since 2-3 
weeks) on 80 mg. I tried methadone once before on the black market. Now I 
get a syrup that I must drink in front of the nurse. It is efficient; it works. 
There are no risks of ‘magouille’. I must wait a few days with methadone to 
feel the effect. You don’t get a kick with methadone ‘ça ne défonce pas. (…) 
I only see the psychiatrist, no psychologist. I have been here for 1 month. 
The system is efficient. The medical centre is very good. There are a lot of 
doctors who do not know about drugs and do not want to do anything (or do 
not want to tackle) drug issues. (…) I do not need anything like psycho-
medico-social support. It goes well physically and psychologically. I have no 
special needs. Psychologically, I get support from the psychiatrist, who 
knows about drugs and addictions (even better than doctors outside).’ 
Needs for psychological support was important and lacking to some prison-
ers 
‘I only see the psychiatrist in prison. I also have a contact with an external 
centre ‘CEDAT’. The ‘prise en charge’ (follow up) in prison is good. Howe-
ver, there is a need for more social workers, psychologists, people to talk to. 
I have not seen one yet.’ 
The need to attend the SMPR daily for methadone provision may not be 
clear to all patients, although prisoners were satisfied with the SMPR ser-
vice. 
‘I mind being woken up every morning to go to the SMPR. I want to attend 
the mass on Sundays but I must go to the SMPR at the same time. I want to 
be allowed to receive methadone on the Saturday for the Sunday.’  
‘The SMPR is good and provide good support and health care. The people 
there are professionals and know what they do.’ 
When taken properly, prisoners reported being satisfied with the treatment. 
‘I feel good with methadone. I no longer am dependent on drugs psychologi-
cally and I am a lot calmer. When I am released, I don’t want to be depend-
ent on drugs. But it’s harder and more stressful outside with the family, and 
all.’ 
Prisoners reported getting no discrimination from the guards. 
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‘Guards must know or have suspicions about why the prisoner goes to the 
medical centre every day, but I get no discrimination.’ 
Confidentiality was not reported as being problematic either. 
‘Confidentiality is not a problem. It all depends on who you share your cell 
with.’ 
3 Summing up 
Substitution treatment is delivered in prison under the management of the 
Ministry of Health. Although the treatment has been allowed in and out of 
prison for approximately 10 years, in practice, the treatment has been offered 
in prison more recently. Sometimes, the treatment is not offered due to a 
doctor’ s own convictions, or due to a lack of resources (especially for 
methadone) or lack of SMPR-CSST. 
Any prisoner is considered and talked about as a patient (not prisoner) by the 
UCSA and SMPR-CSST. Substitution treatment is considered to be a medi-
cal treatment, successful in the stabilisation and treatment of drug users, and 
especially successful if provided within a thorough psychosocial-medico 
support and health care. 
Buprenorphine is misused by users and some doctors who prescribe it too 
lightly in the community. Buprenorphine is misused through injection or 
sniffing in prison as prisoners receive their treatment for one week. This 
results in buprenorphine being considered as ‘just another drug’ or a toxic 
substance. On the contrary, methadone is provided in a closed, supervised 
environment on a daily basis. Prisoners, who were motivated to tackle their 
drug use, preferred a supervised health care environment and a medicine that 
they did not remind them of drugs. 
It must be underlined that out of the 168 prisons in France, only 26 have a 
SMPR, of which 16 have a CSST. Although the structure SMPR-CSST in 
prison seems to bring a lot of support for drug treatment to the prison staff, 
medical staff and prisoners, there is a clear disparity of the availability of 
such structure in the French prisons. Substitution treatment is provided diffe-
rently across the country: there is great disparity among the different prisons 
and from one doctor to the other. 
Moreover, although France seems to be exemplary in terms of the health care 
management and structure in prison, as well as the way substitution treat-
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ment is considered (as a medical treatment), it was emphasised that substitu-
tion treatment should be offered with more psychosocial and therapeutic 
support, which is often lacking in prison. Some doctors questioned the end-
goal and meaning of substitution treatment without such global therapeutic 
structure. 
  
Germany1 
1 General data:  
Drug use, substitution treatment and prison population 
1.1 Number of drug users 
According to EMCCDA (2003), the number of problematic drug users is 
171 242. The use of opiates lifetime prevalence) is considerably low, 1.4% 
of the age group 18-59, though this does mark a slight increase in compari-
son with 0.9% in 2000. Lifetime prevalence of cocaine is much higher: 
3.0%. The prevalence of cocaine use in the age group 18-24, 3.9%, has 
increased fivefold when compared to a level of 0.8% in 1980 (Die Drogen-
beauftragte der Bundesregierung, 2004, 60f). According to the Robert-Koch 
Institute in Berlin, approximately 9% of all HIV cases are accounted for by 
intravenous drug users. Hepatitis C is most widespread in the population of 
drug users, according to the different populations studied, 60-90% of drug 
users are infected with HCV. 
1.2 Substitution treatment 
1.2.1 Historical and legal background 2  
Although the first, experimental methadone programme was carried out in 
Germany (in Hanover/Lower-Saxony) from 1973 to 1975 (with levometha-
done, L-Polamidon®), substitution treatment was introduced on a larger 
scale relatively late. The first methadone maintenance treatment (MMT) was 
started at the end of the 1980s (initially in North-Rhine Westphalia) as a 
response to the threat of HIV/AIDS. Since then, a number of other substitute 
substances have been authorised such as methadone (1994), buprenorphine 
(2000), dihydrocodeine, and codeine. The German Narcotics Act was revised 
in 1992, finally clarifying that drug substitution treatment is legal. A rando-
mized, controlled heroin trial started in 2002. According to the drug commis-
                                                          
1  The field visit, conducted by Heino Stöver. Thanks to Inge Schulten and Klaus Tieding, 
Prison of Lingen, who also provided information and support. 
2  Parts of this section are based on Gerlach 2002. 
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sioner, the number of participants in drug-substitution treatment has risen 
over the past 15 years, from 1 000 to an official figure of 56 000 by the end 
of 2003 (Die Drogenbeauftragte der Bundesregierung, 2004, p. 82). 
Until the early 1990s, methadone could only be administered to drug users 
when tight indication criteria were met (e.g. emergency cases, such as life-
threatening conditions of withdrawal or conditions of severe pain). In general 
medical practice, however, German doctors were prevented from using 
methadone to treat heroin addicts, since MMT was considered to be medical 
malpractice. Nevertheless, there were a few general practitioners (GPs) who 
ignored the legal regulations and prescribed methadone to opiate addicts, 
most of these doctors were persecuted and prosecuted as a result of ‘evi-
dence’ presented by medical ‘experts’. 
The final goal of the substitution treatment is abstinence. But, as essential 
steps to reach this goal, other goals are pursued: to secure survival, health 
and social stabilisation, social and professional rehabilitation. Moreover, 
substitution treatment is supposed to help prevent infectious diseases (Die 
Drogenbeauftragte der Bundesregierung, 2003, p. 76). 
Legislation on drug-substitution treatment 
The German Narcotics Act was passed in 1971 and modified in 1982. With 
regard to substitution treatment, it was only in 1992 that the amendment of 
the Regulation on the Prescription of Narcotics (BtMVV – Betäubungsmit-
telverschreibungs-Verordnung) was introduced which clarified the legal 
position of methadone prescribers. Doctors prescribing substitute substances 
have to keep to the “generally accepted state of the art of medical science”, 
as defined by the Federal Medical Board. In March 2002, this board released 
“Regulations for the Substitution Treatment of opiate addicts”, according to 
which substitution treatment is indicated as permissible: 
− When there is long-term opiate addiction and attempts to achieve absti-
nence have not been successful, 
− When a drug free therapy cannot be carried out  
− When substitution treatment offers the biggest chance for healing and 
recovery 
The main regulations, as documented in Section 5 of the Regulation on the 
Prescription of Narcotics (BtMVV), are summarised below: 
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In accordance with section 13 (1) of the Narcotics Act, substitute drugs may 
be prescribed for the following regulation purposes (treatment goals): 
1. Treatment of opiate addiction with the goal of step-by-step recovery to 
abstinence including the improvement and stabilisation in general health 
status;  
2. Treatment of patients addicted to opiates who have undergone medical 
treatment for severe medical illnesses; 
3. To reduce the risks of opiate addiction during pregnancy and after birth. 
Doctors are authorized to prescribe substitute substances if and as long as: 
1. The patient is eligible for substitution treatment; 
2. Substitution treatment is embedded in a comprehensive treatment incor-
porating psychiatric, psychotherapeutic or psychosocial care; 
3. Patients are registered at the Federal Narcotics Control Board (Bundes-
opiumstelle) (effective of 1 July, 2002); 
4. There is no evidence that the patient: 
a. receives substitution substances on prescription from another doctor, 
b. does not participate in accompanying treatment and care, 
c. uses substances that endanger the purpose of substitution treatment, 
d. does not use the substitute as directed by law; 
5.  The patient sees his/her doctor regularly (usually once a week); 
6.  They have qualified for addiction treatment according to the guidelines 
of the relevant state or regional medical boards (effective 1 July, 2002). 
Doctors are obliged to document all relevant patient and treatment data. Sub-
stitute substances must not be prescribed for intravenous use. The substitute 
may be dispensed and/or taken under supervision in GP's offices, hospitals, 
pharmacies or other facilities approved by the relevant state authorities. For 
substitution treatment funded by the Social Health Insurance (SHI) addi-
tional guidelines have been drawn up by the Federal Association of Physi-
cians and Social Health Insurance Organisations (Kassenärztliche Bundes-
vereinigung) which regulate the conditions for reimbursement of treatment 
costs (BUB-Richtlinien). These guidelines may be ignored with patients who 
have no public health insurance. 
Doctors are required to test patients’ urine and to monitor poly-drug use. 
There are no rules regulating the frequency of taking urine samples. In prac-
tice, during the first weeks of treatment, doctors usually test their patients’ 
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urine at least once a week. According to the BUB guidelines, continued col-
lateral use of addictive substances must result in the termination of treat-
ment. 
All doctors seeking to provide drug-substitution treatment must provide evi-
dence of having sufficient qualification in pharmacology and drug addiction 
by participating in special medical qualification programs. Training covers 
topics such as opioid dependence, the role of substitute substances, under-
standing and caring for the substitution patient, assessment and management 
and clinical practice dosing procedures (Poehlke et al., 2000). By December 
2003, approximately 8 000 doctors had completed this vocational training 
(but only 2 600 actually provided substitution treatment; see Die Drogen-
beauftragte der Bundesregierung 2004, p. 82). 
Depending on the number of substitution treatment providers in a given area, 
doctors can be authorised to treat up to 20 patients funded by Social Health 
Insurance (SHI). There is no such limitation given in the Regulations on the 
Prescription of Narcotics (BtMVV). Thus, doctors approved to treat 20 SHI 
patients may care, for example, for another 20 patients funded by social wel-
fare or paying for their treatment themselves. Despite the fact that the BUB 
guidelines are effective nationwide. there are considerable variations bet-
ween the federal states on the organisation and delivery of substitution 
treatment and accompanying psychosocial care. 
As documented above, legislation on drug substitution treatment remains 
oriented towards abstinence rather than maintenance, although research fin-
dings and experience gathered from medical practice indicate that limiting 
the duration of participation in treatment does not prove successful for the 
majority of the patients (Gerlach 2001). 
Treatment modalities and costs 
In Germany, treatment and prescription (medication) costs are generally 
covered by social health insurance schemes (SHI) which are mandatory for 
almost 90 percent of the population (in special cases, e.g. homelessness, 
doctors’ fees are met by social welfare services). There is also the freedom to 
choose one’s own general practitioner (GP) or hospital (Whitney 1993; Weil 
& Brenner, 1997). However, this praised German health care system has 
failed in respect of opiate addiction treatment since public health insurers are 
not under a legal obligation to meet drug-substitution treatment and pre-
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scription costs. Up to the present, they do not accept opiate addiction as a 
sufficient indication for treatment with substitute substances. 
Psycho-social care 
The legal guidelines (of both the BtMVV and the BUB) demand mandatory 
participation of patients in psychosocial care, although there is no empirical 
evidence of an obligation for all patients to attend psychosocial support 
(Ullmann, 1996). However, these regulations do not provide any instructions 
on the frequency, mode and scope of psychosocial care provisions and, to 
date, there are no nationwide standards of how to organise and structure 
accompanying support. Psychosocial care is a collective name for a number 
of different areas. These may include, for example, legal advice, managing 
financial problems (e.g. debts, rents), recreational activities, crisis interven-
tion, (psychotherapeutic) group sessions, assistance with finding accommo-
dation and jobs, and qualifying for school and vocational training. Psychoso-
cial care is not funded by the SHI. There are great variations in psychosocial 
provision between different states and communities, and variations in quality 
and funding. 
1.2.2 Substitution treatment in prison 
1.3 Prison population  
Table 9 Data on the prison situation in Germany (Source: King’s College London, Interna-
tional Centre for Prison Studies, Prison Brief for Germany) 
Country  GERMANY 
Ministry responsible  Ministry of Justice (Bundesministerium der Justiz) 
Prison administration  Prison and Probation Service (Das Referat Strafvollzug und Bewährungshilfe) 
Contact address  Mohrenstrasse 37, 10117 Berlin, Germany 
Telephone / fax / website  tel:   +49 30 20 25 92 22 fax:  +49 1888 10 580 92 22 
Head of prison administration  
(and title)  
Christian Lehmann  
Ministerial dirigent 
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Prison population total  
(including pre-trial detainees / 
remand prisoners)  
79 153 
at 30.11.2003 (Federal Ministry of Justice)  
Prison population rate  
(per 100,000 of national popula-
tion)  
96  
based on an estimated national population of 
82.62 million at November 2003 (from 
Council of Europe figures)   
Pre-trial detainees / remand pris-
oners (percentage of prison popula-
tion)  
21.2% 
(30.11.2003)  
Female prisoners (percentage of 
prison population)  
5.0% 
(30.11.2003)  
Juveniles / minors / young pris-
oners (incl. definition percentage of 
prison population)  
4.4% 
(of pre-trial prisoners only – under 18, 30.11.2003)  
Foreign prisoners (percentage of 
prison population)  
29.9% 
(31.3.2002 – Council of Europe Annual Penal Statistics)  
Number of establishments / 
institutions  
222 
(2002)  
Official capacity of prison system  78 753 (30.11.2003)  
Occupancy level (based on official 
capacity)  
100.5% 
(30.11.2003)  
Recent prison population trend 
(year, prison population total, 
prison population rate)  
1992      57 448      (71) 
1995      66 146      (81) 
1998      78 584      (96) 
2000      78 707      (96) 
Legal responsibility (Prison Act) for medical care of prisoners 
Whilst the German Prison Act (Strafvollzugsgesetz) is a federal law, its 
implementation is in the hands of the 16 individual states. The Prison Act is 
supplemented by many administrative regulations at state level as well with 
those of particular prisons (cf. Feest/Bammann, 2003). According to the 
Prison Act (§§56-66), the state (i.e. 16 Ministries of Justice) is responsible 
for providing adequate medical care to prisoners. Medical care must follow 
the guidelines of the National Health Insurance system and comply with the 
medical standards outside the prison. Therefore, substitution treatment 
within the prison system should follow the same regulations and standards 
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that apply to substitution treatment under the National Health Insurance sys-
tem outside of prison. 
This principle of equality is basically reflected in two paragraphs of the 
Prison Act (Art. 3, cf Feest/Bammann, 2004). It is based on: 
− The principle of normalisation: meaning life in corrections shall resemble 
general living conditions outside prison as much as possible, and 
− The principle of damage reduction: correctional authorities shall mitigate 
against the damaging consequences of imprisonment. 
However, with regard to substitution treatment, there are several important 
distinctions (see Keppler/Stöver, 1998): 
1 In German prisons, patients may not choose their doctors, i.e., the relati-
onship between patient and physician is somewhat coerced. In general, 
inmates have tendency to mistrust doctors and meet them with reserva-
tion and prejudice. 
2. Outside prison, methadone patients are often required to disassociate 
physically, socially, and mentally from the drug scene, which was the 
focal point of their lives and personal experience. Behind bars, this dis-
association is only possible to a limited extent. 
3. Effectiveness and attraction of substitution treatment depends on the 
positive attitude of the treatment staff as well as on the entry threshold 
level. The prison system often has problems with both of these condi-
tions. 
4. Where politicians and the public are concerned, methadone maintenance 
was linked to expectations which were partly unrealistic and which 
exceeded medical outcomes. These expectations were not fulfilled. The 
large-scale distribution of substitute drugs was supposed to have a wide-
spread effect which – in addition to medical and social stabilisation – 
should eliminate drug subcultures and drug scenes in and outside prison. 
The outcome, however, fell short of expectations. 
5. Maintenance is considered very time and labour intensive, particularly in 
the starting phase of treatment and medical staff have to acquire the nec-
essary ‘maintenance know-how’. This can sometimes be an arduous 
process. However, methadone maintenance remains costly throughout 
the programme, i.e., when the number of methadone patients increases. 
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6. Methadone maintenance is still approached in entirely different ways 
across the nation. It varies from state to state and even from prison to 
prison. 
7.  Drug testing for the additional use of psychotropic substances is manda-
tory for all methadone patients. This also applies within the prisons. Due 
to a variety of manipulation techniques in urine testing, usual testing 
procedures should be interpreted with great care. 
There is a consensus both outside and inside the prisons that, besides provi-
ding the substitute drug, supportive psychosocial measures are sensible and 
can contribute to achieving therapeutic objectives. 
The number of drug addicts in prison 
There are approximately 80 000 prisoners in Germany (including remand 
prisons). 25% of these are estimated to be intravenous drug users (IVDUs) 
(Stöver, 2002a). Detailed studies show that up to 50% of the prisoners have 
experienced illicit drugs (with even higher numbers in juvenile and women’s 
prisons). Despite rigid controls, about 50% of all imprisoned IVDUs conti-
nue to use drugs. It is estimated that the drug using population in prisons 
exceeds 10 000. These are only rough estimates since no specific data is 
available. Neither is any information available on the number of substitution 
patients in penal institutions. Only 6 out of 16 federal states in Germany pro-
vide substitution treatment in prisons (Hamburg, Bremen, Berlin, Hesse, 
Lower Saxony and North Rhine-Westphalia). Admission criteria varies bet-
ween states and substitution treatment is not available in each of the single 
state’s prisons (Keppler, 2000; Stöver, 2001). 
Goals of Substitution Treatment in prisons 
In German prisons, substitution treatment is often an integral component of a 
broader drug service concept (c.f. Ministry of Justice/North Rhine-Westpha-
lia/Germany 1998) and includes psycho-social support, provided by prison 
staff, alongside health or social workers. The goals of the treatment are 
diverse and can be grouped into the categories of medical, socio-rehabilita-
tive and prison-code requirements: 
Medical goals: 
− Reduced use of drugs through injection needle and medical drug sharing  
− Reduction in the spread of infectious diseases and drug-related health 
deterioration (HIV, Hepatitis B+C, abscesses, overdoses) 
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− Stabilisation of drug users who had been in substitution treatment before 
imprisonment 
− Preparation of inmates for a transfer to an open prison 
Socio-rehabilitative goals: 
− To improve the success of relapse prevention (with stabilisation through 
methadone as the basis for preparation for release) 
− To reduce recidivism 
− To promote personal potential and development 
Prison-code specific goals 
− Reduction in drug use and smuggling within in prison 
− Reduction in the development of prison specific and sub-cultural depend-
encies, meaning that prisoners no longer need to buy and sell drugs on the 
prison black market 
− To draw inmates out of the prison subculture, by giving them medical and 
psycho-social support in order to distance them from the drug scene 
Consistency of substitution treatment in prisons 
The practice of methadone use in prison is consistent with external practise 
in the community. Thus, in places where methadone is freely prescribed in 
the community, it is also prescribed in the prisons. Conversely, in those 
locations where it is offered rarely, it is seldom found within the prisons. 
Up until now, maintenance treatment has not been implemented on a regular 
basis or in all prisons. There is a distinct difference between Northern and 
Southern, Eastern and Western Germany. Only a few states continue metha-
done treatment in prison if it was initiated before detention. These opportu-
nities are usually restricted to short-term detainees in order to help them 
“bridge” the time spent in prison. Long-term methadone treatment has been 
rejected by most prison doctors in Germany (Stöver, 2002c). Some penal 
institutions offer a “gradual withdrawal” program for addicts. A few drug 
addicted inmates who are likely to relapse after imprisonment, and for whom 
post-incarceration treatment has been planned, are permitted to begin metha-
done shortly before their prison sentence ends in order to prepare them for 
release. 
States that have adopted methadone maintenance are the city-states of Ham-
burg, Bremen and Berlin, as well as the states of Lower Saxony, Hesse and 
North Rhine-Westphalia. All of the other ‘old’ federal states have a rather 
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negative attitude towards maintenance treatment. According to the low 
spread of opiate use in Eastern Germany, the provision of substitution treat-
ment in East German prisons is low as well. 
In August 1994, at a hearing of the Ministries of Health and Justice, metha-
done maintenance in prison was still proving controversial with positions on 
social indication differing markedly. Some of the participants favoured an 
expansion of maintenance programmes in order to achieve a reduction in the 
demand of drugs, reduce crime in prison, achieve psychological, physical 
and social stabilisation as well as reinforce the motivation for abstinence. 
The representatives of Bavaria and Baden-Württemberg agreed that in indi-
vidual cases the maintenance treatment could be continued if it existed prior 
to the person’s imprisonment. Both states laid emphasis on prison doctors 
being able to act at their own discretion, but immediately limited this medi-
cal licence by issuing guidelines. For Bavaria, consideration of large scale 
methadone programmes is out of the question and the so-called ‘cold-turkey’ 
method of detoxification is used instead of methadone-based withdrawal. In 
principle, Saarland and Schleswig-Holstein are inclined to implement main-
tenance treatment in order to prepare inmates for their release from prison, 
while Rheinland-Pfalz argues that drug dependents in prison are usually 
detoxified already rendering maintenance pointless. In Schleswig-Holstein, a 
decree providing for maintenance treatment was issued by the Ministry of 
Justice, giving methadone maintenance political backing. However, the rep-
resentative from Schleswig-Holstein indicates that maintenance treatment in 
prison is not implemented regularly enough. 
In terms numbers, the drug problem in Germany’s five new states is only 
small. Hence, the use of illegal drugs in prison is low and maintenance 
treatment is not administered often. 
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Table 10 Possibilities for substitution treatment in penal institutions in the Federal Republic 
of Germany 
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Table 11 Substitution treatment in penal institutions in the Federal Republic of Germany 
 
Number of prisoners in substitution treatment 
No precise figure is available for prisoners in substitution treatment in Ger-
man prisons. The current situation can be described as follows: it is estima-
ted that methadone patients number approximately 700 among the 20 000 in-
carcerated inmates who use hard drugs (25% of the total number of inmates, 
80 000). Given that half quit their drug use (Weilandt et al.) and only a third 
of the remaining group, 10 000 drug users, are eligible for substitution treat-
ment, there should be more than 3 333 prisoners in substitution treatment in 
German prisons. In reality, the prevalence o f treatment is much less com-
mon. 
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Reasons for the discontinuation of substitution therapy in prisons 
Keppler et al. (2004) found that the reasons for the discontinuation of treat-
ment and other basic problems in prisons are nearly identical to those found 
in similar programmes in the outside community. Other difficulties are pri-
son specific. The latter issues include the following: 
− Basic abstinence orientation: Doctors view the period of imprisonment as 
the most appropriate time to overcome drug addiction and to attain a drug-
free state. This philosophy rejects methadone treatment as counterproduc-
tive in that it prolongs the addiction. 
− According to a French survey, the criteria for receiving substitution treat-
ment are unclear: “In prison some people are regarded as patients and oth-
ers as drug abusers” (Trabut, 2000, p. 30). This distinction arises because 
some patients have been in a number of programmes. Given the variation 
in prison practices, prisoners perceive the prescription of substitutes to be 
allocated on an arbitrary basis. 
− The provision of methadone treatment is determined by the medical team 
located within each institution 
− Methadone is often seen by staff as a drug that provides pleasure, rather 
than as a medical treatment (Keppler/Stöver, 1997) Staff members are 
often critical of substitution treatment because many recipients supple-
ment that drug with others (often illegal and often through injection). 
− It is impossible to ensure that users distance themselves from the drug 
scene and the prison subculture fully. In some prisons in Germany and 
Austria, inmates who receive methadone treatment are housed in special 
units and provided other forms of support. 
− Anonymity and confidentiality are difficult to secure because inmates in 
methadone programmes are generally housed with other offenders and 
easily identified by them. 
− Some studies suggest that methadone treatment is non-disruptive and has 
a positive effect on prisoners’ drug using behaviour (for Scotland see 
Shewan et al., 1996), constitutes a basis for further medical contact and 
treatment, has a significant impact on the reduction of the transmission of 
communicable diseases (Hall/Ward/Mattick, 1993), prevents opioid-rela-
ted overdoses, along with other advantages. Despite these advantages, 
methadone is seen by many officials as undesirable because it undermines 
the prisons’ efforts and strategies aiming at abstinence: 
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− Detoxification doses and procedures are discussed often. In some coun-
tries, criticisms have suggested that there are no standard procedures and 
that doses are reduced too quickly (Italy, Germany). 
− Some countries lack personnel and financial support and are inconsistent 
in their use of methadone treatment. 
Finally, problems exist in relation to the continuation of substitution treat-
ment during home leave/holidays, following release or after transfer to 
another prison. 
Problem Areas of Substitution Treatment – Case studies 
As indicated above, the limits and extent of medical care for prisoners are 
defined by the Prison Act in the chapter on medical aid (§§ 56-66). The Pri-
son Act refers repeatedly, and sometimes adheres literally, to the restrictions 
laid down by the German Social Health Insurance system (SHI: comparable 
NHS in England). The gist of the law is quite clearly to make prison medical 
care conform to the treatment prescribed for SHI insures. Nevertheless, the 
guidelines for reimbursement of treatment costs (BUB-Richtlinien) on drug 
substitution laid down by the CHI are only valid in prisons via a sub-ruling. 
In some federal states, for example, drug substitution treatment is so closely 
circumscribed that in all cases the BUB guidelines are explicitly referred to. 
The transfer of patients on drug substitution treatment from the CHI system 
into the prison system, and vice versa after release, invariably meets with 
difficulties. 
This is demonstrated by the following case studies3: 
No continuation of treatment due to prison doctor’ s negative attitude 
Anton B. is currently receiving methadone maintenance under the CHI sys-
tem due to an existing HCV infection complicated by HCV-RNA. Even 
under the old, restrictive guidelines laid down by the BUB (see above), this 
treatment is clearly indicated, and permits unlimited methadone maintenance 
chargeable to the CHI. To date, treatment has gone off without a hitch. How-
ever, Anton B. is in Prison X in Baden-Württemberg (one of the 16 ‘Länder’ 
in the South of Germany) on account of a crime committed three years pre-
viously; the gap between offence and imprisonment being so long on account 
                                                          
3  All names and personal characteristics changed. 
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of various appeal procedures. Methadone maintenance is not available here 
because the doctor in charge considers it “capitulation in the face of addic-
tion”. Substitution is discontinued and Anton B. is switched to withdrawal on 
codeine compounds. Anton B.’s only option is a laborious appeal procedure. 
Court rulings have already been passed in such cases, – the District Court in 
Dortmund (LG Dortmund 1995) stated in a case summary that although the 
court could not force a doctor to provide drug substitution, it could rule that 
the prison system must enable a detainee to receive treatment. In practice, 
this might mean transfer to a different institution. Similar rulings have been 
handed down by District Courts in other cities (Frankfurt and Bochum). 
Substitution discontinued on account of failure to approve treatment by the 
Union of CHI approved Doctors (UCD) 
Christian D. is undergoing “private” drug substitution which means that, 
although his doctor works under the CHI system, the allotted number of pla-
ces in his UCD substitution scheme has been used up. Christian D. starts his 
sentence in Prison Y in North Rhine Westphalia where drug substitution is 
standard procedure. Although the substitution scheme is already full up here 
too, a legal ruling allows the prison doctor to use his judgement to continue 
treatment if the patient had been granted UCD treatment under his previous 
doctor. A call to his GP reveals that Christian D. is not registered for substi-
tution treatment with the UCD and his methadone is withdrawn. In many 
cases a prison doctor’s decision to discontinue drug substitution might be 
simplified if the patient is a recognisable “subsidiary user” on entry, or if he 
has been neglecting his substitution treatment on the outside. 
Substitution discontinued on grounds of limited capacity in  
drug substitution schemes 
Emil F. is a drug user and has received notice that his prison sentence will 
begin soon. He has heard that the prison in which he will be serving his sen-
tence provides a substitution programme and that he will have a much better 
chance of being accepted if he begins treatment beforehand. Therefore, he 
registers with Dr. Z. (a local doctor who administers drug substitutes in 
cooperation with a local drug advice centre), but Dr. Z. has no places free on 
his programme at that moment. Emil F. explains that he is due to start a pri-
son sentence in a few days time, and is hardly going to be a burden on 
Dr. Z’s limited resources. In view of this, Dr. Z. agrees to start treatment, 
and after a few days Emil F. reports at Prison Y to start his sentence. This 
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institution is known for its committed attitude and wide range of substitution 
programmes, but the burden of this is carried solely by the existing medical 
staff. Although they have been providing substitution for over 10 years and 
are currently treating more than 100 patients they have never officially recei-
ved any additional financial resources or extra staff. Their aim, therefore, is 
to keep the substitution programme down to roughly 100 patients, with 15 on 
the waiting list (some of whom have been waiting several months). From ex-
perience, the doctor in charge knows that far more patients on drug substitu-
tion arrive than can continue treatment during imprisonment. For this reason, 
criteria have been drawn up among the staff to decide which new patients 
should receive uninterrupted treatment, and which should go on a waiting 
list. Emil F’s is a typical case that the doctor has seen before; the patient 
starts drug substitution shortly before starting sentence to ensure continued 
treatment in prison. The doctor and his staff have decided to ignore patients 
with less than 4 weeks treatment prior to arrival. Emil F. is given withdrawal 
on methadone and an option to go on the waiting list. 
Substitution refused on grounds of insufficient experience with the new 
substitution drug Buprenorphin (Subutex®) 
Grete H. is a pregnant drug addict. Before starting sentence, she begins 
treatment under her home GP with the new substitution drug buprenorphine 
(Subutex®). Buprenorphine causes fewer neonatal withdrawal symptoms 
than conventional methadone treatment and, in some cases, none at all. 
Haven been taken into custody in a Women’s Prison in Bavaria, it turns out 
that the new drug has never been administered there. She receives no answer 
when she enquires whether she can switch from buprenorphine to metha-
done. The buprenorphine is discontinued and she is simply treated for with-
drawal symptoms. 
Continuation of substitution to prevent subsequent relapse meets with 
difficulties on release from prison 
In preparation for his release from prison, Ingo J. commences Methadone 
treatment. Ingo J. and the members of the prison drug counselling staff hope 
to reduce the danger of a relapse during the difficult adjustment phase after 
release. The counselling staff attempt to find a doctor in a large town in Thu-
ringia who would be prepared to continue treatment after Ingo J. is released. 
But not one doctor in the whole city is prepared to take him on as a substitu-
tion patient. In view of this, Ingo J. decides to move to a large town in Hesse 
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after his release. The counsellors contact the drugs advice centre there and 
ask for a list of doctors providing substitution treatment. But after ringing 
through the entire list, it turns out that all of them are full up and no one has 
a free space for him in a substitution scheme. After this set back, the coun-
selling staff ring the local drugs advice centre again. Strictly in confidence, 
they are advised to let Ingo J. wait until the end of his sentence and then 
simply go to a doctor and explain that he is a newly released prisoner on 
drug substitutes. At this point, he will be treated as an emergency and his 
substitution treatment continued. 
This unsatisfactory situation among the medical profession arises from their 
dislike of administering substitution treatment. They are afraid that having 
drug addicts as patients will frighten their regular clientele away (“I wouldn’t 
go to a drug doctor”). In addition, the rates paid by the UCD for substitution 
treatment are so low that they provide absolutely no incentive to work in this 
sector. 
No substitution possible in home town, resulting in rejection of transfer in 
spite of detainee being an AIDS sufferer 
Karl L. is getting substitution treatment in a prison in north Germany. He is 
HIV positive and suffers from several AIDS related diseases. He is on 
methadone maintenance following high level addiction. Five years ago, he 
robbed a north German petrol station to meet his addiction expenses. Origi-
nally, he comes from south Germany and still has contact with his family 
there. As he doesn’t know how long he has to live and he wants to be closer 
to them, he applies to be transferred to a prison nearer home. His drugs 
counsellor enquires about methadone maintenance in the south German pri-
son before the transfer and is told it wont be possible there. Staying on 
methadone is so important to Karl L. that he takes the decision to turn down 
the transfer and stay in the north German prison, managing without family 
contacts for the length of his extended sentence. If family members want to 
visit, they have to cope with a journey of 700 km each way. If Karl L. ever 
gets out on parole and wants to visit his family, he will have to travel the 
same distance. 
Substitution in a Mother and Child detention centre 
Maria N. lives in Bavaria. She is a drug addict with two children. Her oldest 
child died at the age of six as a result of physical abuse by the father. The 
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court ruled that the young, overburdened mother, herself a victim of her hus-
band’s abuse, should have realised the danger of potentially fatal injuries to 
her child. Therefore, she received a 4 year sentence for abetting and failure 
to assist an injured person. Now, Maria’s youngest child is 1 year old and 
she has come to terms with the fact that her addiction may have been part of 
the reason for her choice of husband, the state of their partnership, and the 
events leading up to her older child’s death. To avoid all potential harm to 
her youngest child, she takes the decision to keep her addiction under control 
by getting into a drug substitution scheme. She doesn’t want to be parted 
from her child and tries to gain admittance to a prison with a Mothers and 
Children ward. But none of the prisons in her home state of Bavaria allow 
either drug substitution treatment or the admittance of addicted mothers with 
children to their Mother and Child centres. Enquiries to Mother and Child 
centres in other federal states reveal a similar picture. Only one state has 
recently started admitting addicted mothers, and then, only if they demon-
strate willingness to end their addiction, for example, by entering a substitu-
tion scheme. 
Substitution refused despite assurance of continued treatment to a 
“voluntary surrendered” 4 
Klaus S. lives in freedom, has been on drug substitution treatment for some 
time, but still has an 8 week sentence to serve. A drugs advice counsellor is 
able to get a judge’s postponement of the sentence until provision has been 
made to continue administering substitutes in the prison in question. Klaus S. 
is sceptical, having had first hand experience of interrupted substitution 
treatment in prison. But the guarantee of continued treatment allays his fears 
sufficiently for him to report on time to finish his sentence. 
However, a routine admission urine test (conducted for administrative rea-
sons at a different prison) shows up traces of subsidiary drug use. The doctor 
responsible decides to ignore the existing agreement and transfers Klaus S. 
to yet another prison, one in which methadone maintenance is never permit-
ted, regardless of Ministry of Justice rulings, even for non-subsidiary users. 
Viable alternatives for a transfer still exist at this point but, at the doctor’s 
discretion, Klaus S’s dosage is immediately reduced from 140 mg to 0 mg. 
                                                          
4  Case study description has been delivered by Inge Hönekopp, Manheim, Baden-Württem-
berg. 
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Protests and attempts by other doctors to maintain substitution during the 
relatively short period that Klaus S has left meet with no success. The reason 
given being that the prisoner must have known that subsidiary drug use 
would cancel any entitlement to continued treatment. The community-based 
doctor is left to prescribe the substitution drug. 
Conclusion  
To summarise how substitution works in the various federal states and, with 
the help of case studies, to highlight the difficulties surrounding substitution 
on admission to prison, during sentence, transfer and release. In spite of the 
formal parameters of federal law, and specific administrative regulations laid 
down by the federal states, the practice of drug substitution in individual 
German prisons is inconsistent in relation to the following questions: 
− Whether to administer substitutes at all 
− Whether to administer substitutes as a withdrawal treatment only (tailored 
to meet individual patients’ needs)  
− Whether to use substitution as a long term treatment with controlled tran-
sition upon release 
− Whether to instigate treatment during imprisonment (directly after arrival 
or as a health stabiliser prior to release) 
There is similar variation in the choice of substitution drug and its average 
dosage within each prison, as well as the type and organisation of psychoso-
cial support. Coherent practice on a federal level is imperative, if only to 
avoid the pitfalls shown in the cases above, and certainly if any degree of 
consistency in conditions in and outside of prison walls is to be achieved. 
2 The field visits 
2.1 Women’s prison Vechta, Lower-Saxony5 
2.1.1 Short description 
The Women’s Prison in Vechta, 40 km south of Oldenburg in the North 
West of Germany holds approximately 170 inmates and is the only women’s 
prison in Lower-Saxony. Prisoners are on remand as well as sentenced. 
                                                          
5  The visits took place in May and August 2003. 
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2.1.2 Goals and practical procedures of the provision of substitution 
programmes 
The medical doctor explained that he started substitution treatment in 1992 
with five drug addicted inmates. The programme started without any official 
recognition from the chief medical supervising doctor in Hanover (Ministry 
of Justice), a formal ruling was only laid out in 1995/1996. At the time sub-
stitution treatment started, no support was forthcoming from the Ministry of 
Justice. On the contrary, they were advised to stay away from that form of 
treatment. The number of drug addicted women in substitution treatment 
rose to 35 and now there are approximately 50 patients.  
Substitution treatment is provided for those previously in treatment in the 
community and for those who are already imprisoned. 
− Nearly all of those who get substitution treatment in the community will 
be able to continue when entering prison. In these cases, the nurses con-
tact external doctors to confirm the dosage. 
− No prescription is given to those who commenced treatment during the 
last 4 weeks before admission to prison (on the suspicion that they were 
just trying to get into the prison methadone program). 
− No methadone is prescribed for those who are coming from the commu-
nity or from another prison and for whom the reduction of the methadone 
dosage has already been started (either because they were “topping up 
drugs” or the prisoner didn’t turn up for his/her methadone in prison dur-
ing the last days before transfer to the prison of Vechta). 
− Those who were already receiving substitution treatment in another prison 
(i.e. Hanover) will be able to continue their treatment. 
− Those who want to get substitution treatment whilst already in the prison 
are put on a waiting list. The limitation in numbers is due to a limitation in 
staff and other resources and /or limited places in accompanying psycho-
social care. 
Decisions regarding admission to methadone treatment 
Every 4-6 weeks, a group of professionals decides who to take from the wai-
ting list into the methadone programme. This co-operative group consists of: 
− medical doctor, 
− two internal drug counsellors, 
− lead nurse. 
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All relevant problems (preparation for release, waiting list, expulsions, new 
treatments) are discussed within this interdisciplinary group. No formal 
medical treatment plan is drawn up. But, within the psycho-social care set-
ting, certain targets are laid down together with the prisoner. This forms the 
general framework within which advances or relapses are discussed. 
Co-operation with other professionals and institutions 
The main co-operation partner is the psycho-social care manager of the pri-
son. Only in exceptional cases are external drug counsellors included and, 
when this occurs, they come from an NGO to provide counselling and prepa-
ration for release and transfer to a therapy institution. 
Contact with a doctor whilst on leave for more than 1 day, or on release, is 
made by the prisoner herself, supported by the psycho-social team. For a 
week-end leave, the prisoner can take methadone with her from the prison; 
the nurses will provide her with enough. 
Main goals of substitution treatment in Vechta: 
− Heroin abstinence, abstinence from all injected drugs 
− Preventing the intravenous use of drugs  
− Compliance towards other medical therapies: 
Healing of abscesses 
HIV/interferon therapy  
− Everyday activities should be stimulated (work, qualifications, school, 
going to relevant institutions) 
− Stabilisation in the area of family and social relations 
These goals are also valid for the psycho-social care (see interview below). 
Different patterns of methadone reduction in one state: In the penal institu-
tion in Hanover (capital of Lower Saxony with the biggest male prison in the 
state), methadone is reduced every week by 1ml (a decrease of 10 mg in 
7 days). In the Women’s prison in Vechta, a reduction of ½ ml (5 mg) is 
made every second day, so that, every 4 days, 1 ml (10 mg) less is given. 
This is a significantly faster decrease than in Hanover. Given a starting dose 
of 50 mg, the reduction rate applied in Hanover and Vechta means: 
JVA Hanover 50 mg 10 mg less per week down to zero in 35 days 
JVA Vechta 50 mg 10 mg less every 4 days down to zero in 20 days 
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The reason given by the doctor for not extending the length of the methadone 
reduction phase further is that, according to patients, they want a shorter 
period of reduction time. The doctor quotes his patients as often saying that 
they do not want a long period of reduction because then detoxification and 
the weekly dose reduction remain a dominating topic over a longer period. 
According to his experience over the last 10 years, most of the patients pre-
fer the faster reduction scheme. 
In cases of demonstrable withdrawal problems at the end of the reduction 
(sweat on the skin, widening of the pupils etc.), the period of reduction is 
prolonged according to individual needs. For instance, that might mean slo-
wing down the dosage reduction to a rate of 5 mg every three days. 
Although patients initially express fears that reduction steps may be taken 
too quickly (10 mg decrease every 4 days), the explanation given, together 
with the assurance that the dosage reduction steps will be adjusted according 
to individual needs, generally reassures them. 
Co-medication 
No other medication, especially benzodiacepines or barbiturates, is prescri-
bed by the doctor. This is only done by the psychiatrist and then only on the 
basis of a diagnosed psychiatric disease. For sleeping problems, Atosil® is 
given by the prison doctor. 
Although there is a “Quality supervision group” (meeting bi-annually) of 
prison doctors for Lower-Saxony and Bremen (two of the 16 states in Ger-
many), differences in standards for substitution treatment and reduction 
schemes persist. This is not seen as a problem and is not a topic of discussion 
and so different practices and standards remain. One example is the pres-
cription of Codein products as substitution means. This opioid is still pres-
cribed by some doctors, although state regulations require that substitution 
treatment should be done with methadone. 
Substitution Substance and average dosage 
Substitution treatment is mainly done with methadone. Buprenorphine 
(Subutex®) is only prescribed to pregnant women. According to the doctor, 
Subutex® is sometimes demanded by drug users who want to test a new sub-
stance. But even outside (see figures above) it is not very widespread. In 
Vechta only dl-methadone is prescribed, not the stronger version levometha-
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done (Polamidon®). To concentrate on one substance is easier in technical 
terms (i.e. the methadone suspension automate) than to prescribe two or 
three substances to the 50 patients receiving methadone. This is also the rea-
son for confining the prescription of buprenorphine to pregnant women. 
Patients who have been prescribed levomethadone externally will be swit-
ched to methadone without any problems. 
According to the nurses, the procedure of dispensing buprenorphine was just 
as complicated. The substance is given sublingually and, during the time the 
substance is dissolving, the inmate has to be observed. This is seen as too 
time consuming. 
Externally, the average dosage of methadone is approximately 8 ml (80 mg) 
whereas the average dosage in Vechta prison is 7.8 ml (78 mg) (August 
2003). The doctor stated that the dosages prescribed outside in the commu-
nity are relatively high and are not needed in the prison setting. For instance, 
they had the case of a patient getting 230 mg outside and only 130 while in 
prison, without any problems. Sometimes these patients are given the dosage 
on a “take-home” basis and are tempted to sell a part of the dosage. But in 
the majority of cases the same dosage is prescribed inside as outside the pri-
son. 
Detoxification of multiple addiction 
In the admission phase, a ‘fractionised detoxification’ is carried out: if alco-
hol is the dominant drug it will be reduced with “Distraneurin®” and metha-
done will be continued on a stable dosage as well as benzodiazepines (here 
Valium® is used). When the alcohol detoxification is concluded, methadone 
would be reduced and, after that is finished, benzodiazepines would play an 
important role. They are continued and reduced afterwards. In this process it 
is crucial to work with the patient. The doctor does not prescribe any other 
psychoactive drugs, if there is a psychiatric disease the psychiatrist will pre-
scribe the drugs. For anxiety and other psychiatric diseases “Atonil”® is 
given by the prison doctor only. 
Scheme for starting substitution treatment 
For those prisoners who are applying for the methadone programme the fol-
lowing scheme is foreseen: 
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Day ml/mg 
1 2/20 
2 3/30 
3 4/40 
4 5/50 – stop for one week, to see how the patient gets along with this dosage 
Qualification of the doctor prescribing substitution substances 
Since 1 July 2002, doctors who wish to prescribe substitution substances 
have to be qualified in addiction treatment in accordance with the guidelines 
of the appropriate state or regional medical boards. According to the doctor, 
this may be an obstacle for some prison doctors, who first have to undergo 
further training before they are allowed to prescribe. He also states that by 
asserting the lack of time needed to become qualified, doctors can use this as 
a reason not to provide substitution treatment. 
Practice of daily methadone provision 
According to nurses, organising the administration of methadone goes as 
follows: issuing starts at half past six at the main sluice-gate. Here prisoners 
from the nearby open prison arrive, those who are working outside (day re-
lease system), and those who are either coming into the prison or supposed 
to leave the prison and take their methadone. After that, prisoners from diffe-
rent wards come one after the other, ward by ward. The prisoners wait in the 
waiting room and will be called into the doctor’s room one after the other. 
Their visit finishes by swallowing some water to ensure that they drank the 
solution. Inmates do not complain about the practice which is supposed to be 
fair. In the doctor’s room there may also be time for a chat about problems. 
At weekends, the nurses report that methadone has to be dispensed by one 
nurse alone which might lead to difficulties in managing the volume of treat-
ment. 
Urine controls 
Under national law, randomised urine controls have to be carried out. Seve-
ral positive urine tests will lead to a loss of acquired privileges or even an 
exclusion from the treatment. The same is true for any other conspicuous 
misbehaviour. Both instances of controls (medical service and prison-code 
instigated urine controls) must remain separate in order to respect the confi-
dentiality of the medical services. The results of prison urine controls may be 
noted by the medical department, but not vice versa. The urine controls rele-
202 
 
vant for the substitution treatment can be ordered either by the doctor/medi-
cal department or by the psycho-social care manager on suspicion that other 
drugs are being used on top of the prescribed methadone. The urine controls 
are not announced in advance and are taken in the morning during metha-
done issue. 
Methadone is weighed and portioned by a methadone dispensing automat 
which is computer-based and measures every individual dosage. According 
to the nurses, inmates express distrust concerning the purity and quality of 
the methadone dispensed. Inmates’ comparisons with methadone received in 
other prisons show that the quality of the methadone dispensed in Vechta is 
much lower than elsewhere. 
Methadone for day leaves 
For day leave, confirmation of substitution treatment is given to the patient, 
and a call is made to the nearest external doctor. According to the nurses, the 
head guards of certain wards expect their prisoners to join the methadone 
programme. These prisoners can then increase their chances of getting a 
positive response to an application for home leave. 
Financial conditions 
The prison is taking part in a pilot project in which three out of over 20 pris-
ons in Lower-Saxony are given their own budget across all relevant areas of 
activity. It is notable that there are no financial constraints for admissions to 
or continuation of substitution treatment. 
Training in managing substitution treatment 
Training in the management of substitution treatment is done by the doctor 
and the nurses of the prison for other staff. 
Suitable prison setting for substitution treatment 
The prison doctor of the women’s prison in Vechta stated: “Even if mainte-
nance behind bars is frequently seen merely as a slight improvement of ‘mis-
ery management’, i.e., only as a harm reduction tool and not as a suitable 
measure suitable for solving the dilemma of a prohibitionist policy, it is still 
useful and necessary on practical grounds alone. Since methadone mainte-
nance is known and accepted in the community, drug-dependent people may 
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develop an interest in maintenance treatment during the phase of internment. 
Prison medicine should be responsive to such wishes. In principle, metha-
done maintenance is a form of treatment that is particularly suited to the cor-
rectional system. On the one hand, most of the resources needed for mainte-
nance treatment and psychosocial support are already available. On the other 
hand, prisons are filled with precisely the kind of clientele that comes under 
consideration for methadone maintenance, i.e., intravenous drug addicts with 
prolonged drug careers and various unsuccessful attempts to achieve absti-
nence. Maintenance treatment could be a stepping stone for further treat-
ment. It is extremely important with regard to the new treatment options for 
HIV/AIDS and hepatitis. Often, the phase of internment is also a phase of 
new health awareness in which methadone maintenance helps to achieve 
better compliance with the new treatment.” 
Substitution Treatment as bridge function 
The doctor assumes that inmates participating in methadone treatment will 
also become more receptive to other services provided in detention facilities. 
The treatment helps offenders to break away from the drug scene and elimi-
nates the risks encountered when using injection equipment. 
Methadone maintenance is a medically based method of treatment that 
should be pursued, regardless of the patient’s whereabouts. Interruptions in 
treatment should be determined by medical or psychosocial considerations 
and not as control or punitive measures. Thus, methadone should not be han-
dled as a “special treatment”, granted to those who have behaved well but 
rather as routine treatment for sick people. Given medical necessity, the 
offender is entitled to the treatment; the prison management may not refuse 
to grant it. 
Psycho-social care team  
According to German law, participation in the psycho-social care pro-
gramme is obligatory. The Ministry of Justice requires that a “contact talk” 
should be conducted every two weeks and that urine controls are to be taken 
once a month. 
Psycho-social services are offered on a weekly basis for individuals or 
groups. Prisoners may switch from individual counselling and support to the 
group sessions. Especially when starting substitution treatment, women often 
hesitate within a group context. They are offered the option of psycho-social 
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counselling to ascertain individual goals for 1-2 months and then enter the 
group. The group is good for training of certain skills which will not be 
achieved in an individual setting. 
There is a basic problem with group settings in prisons. Women fear to 
express themselves in a group because everybody knows each other and it is 
impossible to avoid one another. This has resulted in talks being rather 
superficial. Therefore the social worker aimed to concentrate on certain top-
ics that are relevant for the prisoners. Groups work on the basis of the con-
cept of “Psycho-Social Education”, designed especially for the heroin pres-
cription pilot project. This training lasts 3 months. It aims to provide some 
basic skills (increase of self control, self esteem etc.) which are supposed to 
be useful after release. But, because there is a high fluctuation in partici-
pants, it is not easy to continue any particular group for more than 3 months. 
At the moment, there are about 35 women in this programme. 
Special attention is attached to preparation for release. The programme aims 
to enable the women to contact and cope with external doctors, psycho-
social care and other services on their own in order to improve their inde-
pendence. The social workers provide the basic framework (for instance lists 
with doctors in the respective areas that the women will go to after release). 
The social workers emphasise the length of their experience with substitution 
treatment in prison (since 1992) which has led to fruitful cooperation in the 
state of Lower-Saxony and with many doctors outside who are willing who 
continue substitution treatment after release. 
Once a year, experiences and information are exchanged with colleagues 
from other prisons and all prison drug counsellors meet once a year as well. 
In this forum, new professional developments are discussed (needle ex-
change projects, new developments in addiction therapy). At the beginning 
of the 90s there was a controversial discussion of the pros and cons of sub-
stitution treatment. It became obvious that the existence of substitution pro-
grammes was largely the result of drug counsellors demanding such facilities 
in prisons. If someone working in the field was in favour of this treatment 
then it would be extended. If not, programmes may be reduced or abolished. 
It also depends on whether the doctor is convinced of the value of that treat-
ment or not. 
Another important factor for the existence of substitution treatment pro-
grammes is whether a medical doctor is based in the prison or comes in from 
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outside for limited hours. If a doctor comes in for 2 hours per day, the nurses 
may not feel they have the necessary backing, as it is primarily their respon-
sibility to supervise the daily dispensing of methadone. 
Cooperation is also important with the two external drug counsellors (NGO) 
whose basic task is to prepare prisoners for drug-free treatment instead of a 
prison stay (“Therapy instead of punishment” for prisoners with a sentence 
of less than 2 years). If they arrange a place in external therapy which has a 
waiting period (for instance one month), then it is appropriate to integrate 
those prisoners into the substitution programme until they can be moved to 
the therapeutic institution. In these cases, the prisoners are mostly but not 
necessarily in regular contact with the external drug counsellors (at the mo-
ment 3 out of 35). In these and other cases, internal and external drug coun-
sellors cooperate closely. 
Nemexin® is also offered but this constitutes a completely different appro-
ach towards addiction. This is offered to women who fail in the substitution 
programme due to topping up drugs. The women are told that the Nemexin® 
programme (which at the moment includes 6women) is based on a different 
approach towards addiction. It is a more passive and medication-oriented 
approach. Furthermore, Nemexin® is an opiate blocker but, as most of the 
women are multiple drug users, it only blocks one drug and not others  
(e.g. cocaine). 
Exclusion from the substitution programme 
The social worker states that “In the group including the doctor and nurse 
(mentioned above,) the success or failure of every single case is discussed.. 
Topping up drugs is not always the problem, sometimes it is resistance to 
work, dealing or other criminal offences. There are several factors which are 
criteria for a successful treatment. Sometimes this is not adequately commu-
nicated to the women. Often they do not understand why some inmates are 
allowed to stay in the programme while others are expelled. The prisoners 
often support having strict rules, for instance two positive urine tests will 
lead to exclusion from the programme”. 
Criteria of success in substitution programmes 
Obviously the criteria for successful substitution treatment vary between the 
services involved: “The medical staff would sometimes appreciate stricter 
rules and clear limits. Our assessment of individual cases, and the success of 
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their participation in the substitution programme, is sometimes completely 
opposite to the medical service’s view. Sometimes, we can utilise the differ-
ent viewpoints of the parties involved: for instance, we can tell the women 
‘Don’t wait until you will have a positive urine test, discuss this with us 
now’. Then we can work with them on the subject of relapse. Of course, to be 
honest about that, it’s not easy for somebody who’s been in the drug scene 
for 15 years, there is a lot of distrust towards officials. And you are being 
‘tested’ by the prisoners as well. In most cases, though, it is not an alterna-
tive to expel inmates from the programme, there is no other alternative for 
them in prison. Sometimes the warning to expel them is useful to get them to 
acknowledge the value of the substitution treatment. We don’t want to punish 
the prisoners but to work out viable solutions for them and with them. On the 
other hand, there are inmates in the substitution programme who decide to 
start a drug-free therapy. The transfer to drug-free therapy institutions has 
been facilitated in recent times. Now, we can send prisoners to certain ther-
apy institutions who are receiving as much as 60-70 mg. They are detoxified 
there within 5-6 weeks.” 
“If a prisoner is obliged to work in prison and she is resisting work, then 
obviously she has no interest in co-operating. This is seen as problematic for 
the success of substitution treatment because work simultaneously gives you 
a daily structure. And, when they’re topping up drugs too, it becomes rather 
difficult to keep someone in the programme.” 
Keeping the Balance between the varying interests 
The social workers do not regard themselves as lawyers of the imprisoned 
women. They define themselves as a clearing post, where solutions are 
sought, together with the women: “I am trying to keep a balance between the 
interests of the prison, the interests of the clientele, the interests of the medi-
cal department. But it’s not a classical lawyer’s role that we play. Being a 
lawyer means being paid by your clients. We deal in a different currency, 
which is confidentiality and trust. In the meetings with the medical service, 
we bring in the social aspects. Sometimes, the doctor forwards information 
and then reports to us to get our opinions on certain problems. In most 
cases, we discuss what has been passed on to us with the prisoner and then 
give a final assessment back to the doctor.” 
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The substitution treatment programme is not a low threshold offer. This is 
due to the limited places (40 at the moment). “The places should go to those 
women who really benefit from the treatment.” 
Urine testing 
According to judicial demands, regular urine tests have to be done on a 
monthly basis and are ordered by the social worker. Other urine controls can 
be ordered by the prison in order to check on whether somebody is eligible 
for home leave. Sometimes, the women even ask for these tests because then 
they can send the negative results to the court or use the results as evidence 
of being abstinent. 
Self help organisation 
A user-group (JES-Oldenburg) and the Oldenburger AIDS, Hilfe, visit the 
prison once a month. These group meetings are frequented by many prison-
ers in the substitution programme. 
Impact of participation in a substitution programme on the sentence  
and on release 
Being in the substitution treatment programme may lead to some positive 
effects when it comes to court decisions and prognoses for the future. Some-
times the participation in a substitution treatment is seen by the court as 
proof of therapeutic effort. The same is true for the system “therapy instead 
of punishment”. Within this model, the judge may consider participation to 
be an essential step forward towards therapy. Moreover the court may 
release a prisoner after two thirds of their sentence. This usually is not done 
for drug addicted prisoners because of the negative social prognosis. 
2.1.3 The view of prisoners 
All six inmates have been imprisoned previously in the Vechta women’s pri-
son; three had additional experiences in another prison. All are serving sen-
tences between 4 months and several years. All have a long history in taking 
illicit drugs. Basically all prisoners (P1-P6) agree with the methadone pro-
gramme and practice in prisons. There are no basic complaints. 
Prisoner 1 was lying in hospital for two days prior to imprisonment. She was 
on a dose of 100 mg and within 14 days her dosage was reduced to 30 mg 
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because the doctor found her dosage was too high. After she had been redu-
ced to zero, she was given methadone again after 4 weeks. 
P2 complains that during her previous sentence she wasn’t given methadone 
for the first two days, because she wasn’t in an official substitution treatment 
programme in the community, although she had been on methadone prior to 
admission to the prison. After severe, 2 day withdrawal symptoms, she was 
given methadone again. 
P3 reported that she was given the same dosage on transfer to Vechta from 
another prison and that the doctor increased the dosage from 80 to 90 mg. 
During a previous stay in Vechta she reported being without methadone. 
This ended up in a permanent search for drugs in the prison: “Without 
methadone you really go nuts about any kind of drug you can find here.” 
P4 told us of a case in prison where a woman went to the doctor and, quite 
by coincidence, discovered that her methadone had already been reduced 
(from 100 mg to 35 mg), she had ot been told. On the one hand, P4 thinks 
this was justifiable from a psychological viewpoint but worried that some-
thing might have happened (high or low blood pressure) that might have 
conflicted with the reduction of methadone. None of the others have had 
similar personal experiences but all have heard of such a case. 
P5 told us about her withdrawal from other drugs (benzodiazepines) upon 
entering prison. Her benzodiazepines have been reduced and she then asked 
for methadone reduction from 50 to 40 mg. 
P6 has a long history of methadone consumption. Before admission to 
Vechta prison she was in an official methadone programme for less than the 
required 4 weeks. But she got methadone because of the extent of her past 
experiences. She is wondering about the speed of reduction, which she expe-
riences differently inside prison: “I’ve realised that the reduction steps are 
taken very fast, which is ok in a normal reduction scheme because you are 
going into a detox centre of your own free will. But it is different here inside, 
it is rather rushed here.” She complains about the varying times of metha-
done dispensing. “While it is 7.15 in the morning on working days, it is 11 
o’clock at the weekends. At 11 o’clock you’re already starting to sweat, feel 
the cold and that’s not normal. Maybe that means the methadone you’re get-
ting is poor quality.” 
She suspects that the methadone is not of a good quality, because it is only 
effective for 8 hours and should be for at least 36 hours. She doesn’t under-
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stand the difference between d,l-methadone (racemic mixture) (d,l-metha-
done has only been available since 1 February 1994) and levomethadone  
(l-methadone, L-Polamidon®) both forms, containing different strengths of 
methadone, are registered as substitution substances (levomethadone is twice 
as strong as d,l-methadone). She has heard of the pharmacological term 
“racemic” and wonders whether the racemic mixture is a sort of waste prod-
uct of the levomethadone. So, she isn’t really informed about the differences. 
She insists that the methadone has side effects and that the patients are the 
experts who have the experience and competence to be able to compare 
treatments and substances. “The doctors, they only know about the effects 
and side effects from book, but we are the experts. For instance, the doctor 
says that everyone who gets methadone feels the same thing but that’s not 
true.” 
For P5, it is not clear who should be excluded from the methadone pro-
gramme. They all know the rules, but there are between one to three warn-
ings before someone is excluded. Sometimes she finds decision making 
arbitrary. And she has the impression that arguing with the doctor may lead 
him to take it personally, for instance, when she says she will look for infor-
mation elsewhere. 
P1 tells us that urine has not been tested for THC for the previous three years 
but is now. That is still no reason to exclude someone from substitution 
treatment, or to not let prisoners out on home leave etc. It leads to a loss of 
privileges as well, like the consumption of cocaine, alcohol, tablets or heroin. 
Unanimously, the women confirm that there are enough warnings before 
someone is expelled from the programme. But they regret that there is no 
deeper understanding of their drug history, as they are dismissed as drug 
users having been dependent for more than 5-10 years. “That’s the problem 
with the doctor, he thinks that being in the methadone programme means 
that there is no desire for other drugs. But that’s a mistake.” 
P3 says she hesitates to tell the prison social worker about her additional 
drug use, because it may get back to the doctor and she will suffer the conse-
quences. 
All of the women are using the psycho-social support on offer (weekly group 
sessions or fortnightly individual counselling). The participants are profiting 
from the sessions. 
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P2 has experience of other substitution substances, especially buprenorphine. 
She claims that detoxification with this substance is much easier than with 
methadone. She says she has been addicted for more than 12 years and that: 
“I’ve tried lots of detox methods which were no good, but buprenorphine 
really worked”. She says that if patients have to be detoxified, she would 
prefer to do it with Subutex®. She recommends it for those who are exclu-
ded from the methadone programme and who get into a drug reduction 
scheme. 
P1 says that in her experience Codeine is a good substitution substance. She 
too would prefer the use of Subutex®. But at least detox is better with 
codeine than with methadone. 
Unanimously, the women confirm the view that withdrawal from methadone 
is extremely hard. “I never had cold turkey like coming off methadone, it’s 
really shit.” 
So, the prisoners would prefer a variety of substitution substances for differ-
ent situations and purposes instead of only making use of one substance 
(here methadone). 
Regarding the value of methadone maintenance treatment, P4 states that she 
wouldn’t miss it. “It definitely stops you wanting other drugs and I’m not 
scared of coming down off methadone. I’ve been using methadone for 6 
years now and I don’t want to come off it here in a fortnight. People should 
be allowed to decide for themselves.” 
Regarding the daily practice of administering methadone, the women have 
no complaints to make about the procedure (described above). “I mean, you 
always get envy, like: ‘Why is she getting methadone and not me …, but you 
get envy for a lot of reasons round here.” 
Regarding the attitude of the staff towards prisoners who get methadone, the 
prisoners have varying views. Some say that the employees keep an eye on 
those receiving methadone. “They pay more attention to those on methadone 
… they watch out that you’re not just hanging around or getting up to some-
thing … well I’ve been on methadone over 4 years now, so I know how I’m 
going to react. I’ve got hep C as well and I always get these tired spells. But 
you get the impression the warders put it all down to the methadone, heada-
ches, whatever ... and that’s not true, but you can’t get anyone to listen.” 
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Others say that the patients in the methadone programme are treated the 
same way as others. One prisoner puts it this way: “It’s not like anyone gives 
us looks or anything, on our ward it’s not a big deal.” 
Methadone continuation transport from one prison to another 
Prisoners state that the continuation of methadone prescription from one pri-
son to another causes no problems: “… I was transferred from Hanover and 
it wasn’t a problem. I got my methadone in prison X, got it in the morning 
before we started off and the next day I got it here. Of course, when I’m 
released I´m going to try and get hold of my old doctor two weeks before I 
go and see if he’ll take me on again. If not, I’ll try another one. I’ve got two 
doctors and one of them’s bound to do something”. 
“… right up till you’re released, like about 6 o’clock, you still get some; … if 
you’ve got parole, they give you something in the morning and if you’ve got 
three days outside, you have to collect it at the nearest prison or go to a 
doctor …” 
2.2 Men’s prison Groß-Hesepe/Lingen/Lower-Saxony6 
2.2.1 Short description 
The closed men’s prison in Groß-Hesepe, between Lingen and Meppen in 
Lower-Saxony (near the Dutch border), is administratively part of the bigger 
institution in Lingen (some 25 km from Groß-Hesepe, with remand and 
sentenced inmates) and holds 350 men who are all sentenced. The proportion 
of drug users is considerably high: according to the doctor, approximately 
70-80% have a drug problem (with hard drugs). 
2.2.2 Goals and practical procedures 
The doctor, also an external GP, is employed part time. According to him, 
substitution treatment started in that prison in 1994. At present, they are offe-
ring 40 places for maintenance treatment, of which 10 are reserved for those 
going into treatment and those who want to decrease their dosage. At the 
time of the visit (March 2004), 25 patients received substitution treatment 
(during 3 months in 2004 they had 30 new patients which demonstrates the 
                                                          
6  The field visits took place in February and March 2004. 
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coming and going): “We started off with 10 on maintenance. But the whole 
thing escalated so fast, we had to come to an agreement with Admin and the 
Drugs Counsellors to draw the line at 40 to 50. And that’s about our capa-
city now. We’ve got 30 permanently on maintenance and there are always 10 
who are gradually coming down off it or getting methadone support in pre-
paration for therapy.” 
With regard to the need for substitution treatment, it is said that it would 
increase when restrictions were lifted. Substitution treatment is regarded as a 
sort of baseline intervention (with clear rules to follow for the patient) and 
not as an opioid treatment as such: “If we lifted the restriction, the demand 
would increase too. But the question is, what can you realistically hope to 
achieve? Are you going to treat all the addicts? Put them in therapy? Or on 
maintenance to keep them quiet? We’ve found that most don’t want therapy. 
They just want to continue on substitution treatment to offset the addiction.” 
Another reason for the restriction is the increase in the prisoner population 
from 160 prisoners in 1988 to 350 in 2003 without a corresponding increase 
in resources and, at the same time, new restrictions (e.g. the notification 
system introduced in 2002). The drug problem is regarded as the major 
health topic in the institution: “We don’t really get problems with illness as 
such, ... what we’ve got is problems with drugs. That much ought to be clear. 
The drug problem leads to escalating developments.” 
As the institution does not have an admission unit for new prisoners and has 
no remand prisoners, new inmates mostly come from the remand prison in 
Lingen. There, a substitution treatment is already provided and this is conti-
nued in Groß-Hesepe. According to the nurse, the policy with the drug coun-
selling personnel is that there is a space of 4 weeks in which to determine 
whether the patient is eligible for methadone substitution, according to the 
criteria of the institution: 
− Therapies already undertaken 
− Compliance 
− Urine tests 
− Additional drug use 
− Length of sentence (6-12 months) 
Another differentiation is done regarding (i) whether they are suited to ther-
apy, (ii) HIV positive or negative. This is the only disease when substitution 
treatment is always carried out. 
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Incidences of taking prisoners out of treatment reflects that guidelines have 
to be obeyed, which set some rules for adherence to the therapy (e.g. no ad-
ditional drug use). Here the difference to the outside situation becomes appa-
rent where prisoners have more choices to look for different options. 
“Between 30% to 40% just want their methadone with no questions asked 
but we can’t work like that. They’ve got to get social support, they’ve got to 
take urine tests, ... They probably got it with no questions asked on the out-
side, and people out there take massive amounts of stuff on the side, I’d say 
50% of them do. You can’t do things like that here, a lot of them are absolu-
tely speechless when I tell them there’s no extra Benzodiazepam to go with 
their methadone, because it causes depression. They wont listen. Diazepam 
is like eating a lump of sugar for them, that’s how they look at things.” 
These strict rules reflect both the limited places and the legal requirements of 
adequate substitution treatment. The latter is seen as the major obstacle 
whereas the proportioning and the documentation would absorb much time. 
In relation to whether the length of sentence limits substitution treatment dif-
fering statements have been given ranging from 6 months (doctor) up to one 
year (drug counsellor). 
“Generally speaking, maintenance is customary procedure for short senten-
ces under a year. If the sentence is longer, the Addiction Advice Service has 
to help determine what kind of role maintenance is going to play during 
imprisonment. Whether there’s an opening in therapy for them in the near 
future, and if not, then you just have to draw the line and say no.” 
This is a different practice to the connected prison of Lingen (remand and 
sentenced), where the general line is to maintain prisoners who are in sub-
stitution treatment. 
According to the nurse, urine tests are done twice a month and the sanctions 
are clear and understandable to prisoners (e.g. outlined in a leaflet): “Gener-
ally, the first time they test positive, we hold up the yellow card. And the sec-
ond time, we start phasing them out.” (A nurse) 
It is up to the prisoners to decide when to show up for a urine test. Despite 
this liberal practice, there are some prisoners who still have positive urine 
tests. “We’ve organised the regular urine checks on a voluntary basis, either 
every first and third week, or every second and fourth. They can choose for 
themselves. If someone comes to our attention, then we do spot checks. It’s a 
lot of work. It means about eighty a month.[The interviewer: But in this sys-
tem you shouldn’t really be getting any positive results?]We do though. One, 
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two, four – the last one was positive. He came in off his own bat. He was 
positive” (A drug counsellor) 
“…we always catch a few. They never know when there’ll be spot checks. 
The man who was here just now, he does one every week. As I said, we toler-
ate THC.” (A drug counsellor) 
Generally, interviewees say that prisoners in substitution treatment are easier 
to manage. 
“It depends on what you want. If you want to keep the patients quiet, you 
could increase the intake ... it just puts them out of action, it changes them, 
makes it easier for them to work ....” 
Benzodiazepines are not prescribed to patients in substitution treatment. The 
detoxification scheme is a reduction of 10 mg every two days. It is reduced 
until 30 mg, from then on 5mg every two days, so if somebody is on 50 mg it 
will take 14 days. The daily provision so that prisoners are led to the medical 
unit, ward by ward, and supervised by the nurse who ensures that the dose 
has been swallowed. 
Every single case is discussed with the drug counselling service in terms of 
the patient’s needs and perspectives regarding treatment (“therapy instead of 
punishment”) and sentence planning. The AIDS-help Group from Lingen is 
involved in the psycho-social support and is offering an open group every 
fortnight, which is attended by approximately 30 inmates. Apart from this 
activity, several other groups are accessible for drug and alcohol users (e.g. 
the self help group “Kreuzbund” with regard to alcohol, a therapy prepara-
tion group). 
Provisions for home leave are administered either by the institution or by the 
doctor nearest their home. Here, patients have to pay for the prescription 
themselves. Before release, a search is made for a doctor to continue the 
treatment. The medical service writes an accompanying letter for the GP in 
the community. There is a problem with finding external GPs who are will-
ing to prescribe because the interviewees identify a town-countryside gap, 
where it is easier to find a prescribing doctor in the city. 
The methadone will be weaned off if the prisoner cannot find a doctor who 
will continue treatment after release: “…we gradually withdraw their main-
tenance if they aren’t covered for further treatment after release. We always 
do it like that. If they can´t show us a letter from their doctor, then they’re 
always withdrawn.” (Drug counsellor) 
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The drug counsellors stress the point that the movement of the prisoners 
(coming in for only short periods sometimes without having a doctor conti-
nuing the treatment after release) is posing severe problems in time mana-
gement, in terms of having the time for gradual detoxification steps: “Of 
course we warn them: If you want to stay on maintenance, bring us a doc-
tor’s certificate. Otherwise you come off it. That usually works, but not 
always. We’ve got some who´ve only got another six or eight weeks. Some 
are over from Lingen. If nothing’s been sorted out, then we start reducing 
them right away, so as to stay inside the time line. You can’t reduce them 
from 10 ml [100 mg]) to nothing in a week.” (Drug counsellor) 
The prison-based drug counsellor assist prisoner in finding a doctor willing 
to continue the treatment by offering a doctor’s lists all over Lower-Saxony. 
Post, fax and telephone calls can be organised in the office of the counselling 
team. So prisoners have to look for a suitable doctor in their community right 
in advance. This process of organising thing for release is seen as part of 
enabling prisoners to attend to their affairs. In most of the cases the search 
ends up successful. 
According to the experiences of the doctor and nurses, they focus their pres-
cription on methadone as central agent in substitution treatment. It is said the 
degree of being familiar with a substance is an important point: 
The interviewer: ... You only prescribe methadone? Not Subutex? 
We don´t like to. I suppose it all depends on how familiar you are with a 
certain drug. Luckily we´ve had no problems with methadone since 1994. 
I´ve only had discussions about Subutex with maybe 5 to 10 patients, no 
more than that. And in all that time we´ve had maybe 4 Subutex patients. 
Subutex isn´t part of our normal range of maintenance treatment. We only 
ever fall back on it in individual cases, when someone´s had it prescribed 
outside. 
According to the experience of the drug counsellor, those prisoners who 
have been referred to an in-patient therapy outside (“Therapy instead of 
punishment”7), drop out there mostly return to the institution being in a 
substitution treatment in the community. These persons are generally weaned 
off. 
                                                          
7  This is possible for those drug dependent prisoners when their sentence is no longer than 
24 months they can apply for a place in an inpatient treatment. 
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“Our problem is: the people who we’ve referred to inpatient therapy, all 
land back here sooner or later. And the funny thing is, they all come back 
with prescription methadone. We call them our therapy drop outs. First thing 
we do is, we reduce their dosage right down to zero. We say: therapy drop 
outs have had their chance, and for whatever reason, they’ve messed up. 
I just don’t understand why they put them back on maintenance. Somebody 
in Lingen, or wherever, can’t read. I think the doctors take the easy way out 
– the same people keep on coming back and coming back until they get treat-
ment. But we always take them off it here. Sometimes we have our differen-
ces with the medical supervisor, but, in the long, run they all get taken off.” 
(Drug counsellor) 
The drug counsellors point out three reasons to expel patients from the 
treatment: 
“Three good reasons: dropping out of therapy, taking drugs on the side, and 
not bringing in urine samples. And I’ve got it all down on paper, starting 
from this year. I pass the information on to Admin, and wait for them to 
react. If they don’t, well that’s just too bad. Basically, the medical Admin 
team take the decisions. I just keep them up to date on substance abuse and 
missing urine tests. I do that every day.” (Drug counsellor) 
The whole process is well documented and there is a daily exchange of 
information with the medical unit. Exchange of information between differ-
ent wards regarding statements on prisoners is done via intranet, which can 
be accessed by the drug counsellor. 
“Yes, that’s on our local intranet now, so we’ve all got access to it, XY 
always keeps it right up to date. Of course, you could always ring up and ask 
something in person, but we’ve even got a web page for exchanging infor-
mation.” (Drug counsellor) 
2.2.3 The views of the prisoners 
Four prisoners attended the focus group who have had extensive experience 
in substitution treatment in the community as well as in other prisons. 
Prisoners made comparisons to substitution practice in other prisons and 
complained about the fact that their treatment is not continued in Gross-
Hesepe. Two points were criticised, a continuity of dosage, when compared 
to external practice has been given in the prison of Lingen (approximately 
25 km off of the site) and that, even in two prisons of one institution (admin-
istratively one system), the practice is varies considerably: 
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“In Lingen, you usually get what you’d be getting outside, but the doctor 
here always starts from scratch.” (Prisoner) 
“I’ts different in Lingen. When I was there, I always got my Benzo. When I 
was transferred, I was getting say 13 ml of methadone and 10 Diazepam and 
here they started me straight off on 8 ml and no Benzo at all. I’ts shit, they’re 
all part of the same prison really, so I never understood it. And there was 
them always telling us: don’t worry about transferring to Hesepe.”  
(Prisoner)  
Prisoners perceive that there is an unspoken assumption that they will get 
hold of the drugs in order to get hedonistic instead of therapeutic effects. The 
mistrust in the doctor-patient relationship was expressed repeatedly: 
“I think its rotten how they always act like you was just trying to get 
stoned.” 
“I’ve met that too – I wanted a couple of Paracetamol for toothache and the 
chap said I was trying to get a buzz. That’s crazy. They don’t seem to know 
how anything works.” 
With regard to psycho-social support, the prisoner stated that, although there 
is a drug counselling service, problems have to be solved by individuals 
themselves and that there is no formal structure, a place to go to once in a 
week, as there is outside of prison: 
“The only people we could go to in here are the Addiction Advice Service. 
Basically, you’ve got to sort it out on your own. If you’ve got a problem, I 
assume you could ask them, – it’s their job. But it’s not very well organised. 
Outside, you’d see someone once a week.” 
The prisoners are making proposals of how to deliver the methadone on a 
daily base, which offers advantages for the prisoner’s everyday organisation: 
“If you don’t work its OK but, for the ones with jobs, the system in Meppen 
is much better. We haven’t got so many people on methadone here, 30 to 35 
at the most. In Meppen, the medical assistant packs a case and goes round 
from block to block. He just gives it out in the front office, before everyone 
goes to work. Here, you get to your job at ten to seven, and then at five past 
you get sent over to the medic, so the whole lot of you get there at once.” 
(Prisoner) 
“And they’ve lumped it together with consulting hours in the sick bay, at five 
past seven, which used to be separate at ten o’clock. Usually, the warders let 
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us go later but, if you’re not careful, you might get one who can’t be bothe-
red and then you’re left waiting until the medics have finished up. Then 
you’ve missed breakfast, – or almost, – but anyway, they’ve got a nerve. 
There’s always one on duty and it wouldn’t hurt them to pack a case with the 
stuff and bring it round, say, at quarter past six. Only takes a second to 
drink. Wake up call is at six.” (Prisoner) 
Some critics focused on confidentiality which is not sufficiently secured. 
Although most of the guards know who is getting the substitute, prisoners 
feel that they should not be present when the dose is taken: 
“Being on maintenance isn´t such a big deal. Most people know anyway. 
There’s always a warder there anyway, that’s how it’s done here. In Wolfen-
büttel you each went into the medical room separately to take your metha-
done. But here they just open the door to the toilets, put a board across the 
opening like a counter, the medic stands behind it and we’re lined up on this 
side. It’s none of the warder´s business, he shouldn’t even be there. Mainte-
nance treatment is supposed to be confidential.” 
“There’s no privacy here. The warder sits in, but he shouldn’t normally be 
there. It’s no business of his what you’re seeing the doctor for. 
Even apart from the methadone, you can’t discuss anything about your 
medical treatment here. As often as not the warder listens in and he can read 
your file too. It’s not right. 
Anyone who wants can read the results of my urine tests here. I’ts all wrong. 
Prisoners don’t know if it is an advantage for the present sentence to be in a 
substitution treatment or not  
“I’m not really sure how they rate you when you’re on substitution; if it’s 
better or worse. Normally I’d say it ought to go in your favour, but there’s 
no accounting for prejudice. You might get one who says: well, if he’s still 
getting methadone, who knows what he’ll get up to when he’s released ... 
somehow you’re still an addict.” 
The practice to strictly prescribe methadone only is criticised by prisoners 
who are used to a diversity of substitution drugs outside: 
“You might get turned down because Polamidon® is a few pence dearer 
(than methadone). I’ve reached the stage where I’d pay the difference 
myself, just so I know I was getting something that was better for me.” 
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3 Summing up 
Substitution treatment in German prisons is heterogeneous in access and 
treatment modalities. The access is very patchy and the number of patients 
who might receive substitution treatment is limited by a lack of resources 
and budget constraints. This accounts for the number of staff, both in medi-
cal units and among drug counsellors, needed to provide more substitution 
treatment in prison. Moreover, resistance – linked to the widespread drug-
free orientation – can be found towards substitution treatment which views 
the provision of substitution drugs as means of detoxification etc. In total, 
the demand of prisoners for substitution treatment is far bigger than the 
actual number of places. 
Certain issues became apparent in the interviews in the two prisons: 
− Enormous differences in policy and practice of substitution treatment be-
tween prisons in the same state (Lower-Saxony) but even between prisons 
of the same administrative unit (e.g. duration of prescription ranging from 
expected 6-12 months sentence in one prison to indefinite durations in 
others, disparities in urine tests). 
− Practices and policies are not discussed and there seems to be no attempts 
to harmonise these different approaches. 
− Inflexibility of the system in introducing new substitution drugs (e.g. 
buprenorphine) due to practical obstacles and lack of experience. 
− Lack of adequate patients’ information (leading to a mistrust about the 
substance dispensed). 
− Assistance is given in both prisons with regard to finding a doctor after 
release, this is part of an education process to enable prisoners to attend to 
one’s affairs. 
  
Greece1 
1 General data:  
drug use, substitution treatment and prison population 
1.1 Number of drug users 
According to EMCDDA figures (2003), Greece reported the number of 
problematic drug users to be 25 512 in 2001. Looking solely at heroin users, 
the Greek focal point2 estimated that there are between 15 000 and 22 000 
heroin users between the ages of 15-64. The majority of these (between 10 to 
15 000) lived in Athens and predominantly smoked heroin (“chasing the dra-
gon”). According to experts, this is the main reason for the low HIV-preva-
lence in Greek prisons. 
The total number of drug users in prison on January 1st 2000 and 2001 was 
2 880 and 3 187 respectively (Sioti, 2001). A study from Koulierakis et al. 
(2000) showed that 33.7% of prisoners had injected drugs at least once in 
their lifetime, 60% of whom had injected while incarcerated. From those 
who had injected during incarceration, 83% had shared needles and other 
drug paraphernalia. The duration of imprisonment, previous convictions for 
drug offences, being convicted instead of being on probation and the number 
of sexual partners during the year before incarceration, were found to be the 
most significant factors leading to a risky behavior (Koulierakis et al., 2000). 
These trends have been confirmed by the study (N=80 randomly selected 
convicted and remanded prisoners in a prison in northern Greece) of self-
reported substance misuse in Greek male prisoners (Fotiadou et al., 2004), 
who found 27.5% of prisoners were dependent on opiates, 26.3% on alcohol, 
while 13.8% were misusing both alcohol and illicit drugs. Additionally, the 
authors found 26.5% of prisoners to be HepatitisB positive. 
There was no official estimate of the re-incarceration rate due to lack of data 
processing services in Greek prisons. Unofficially, the medical staff in 
                                                          
1  The field visit in Greece has been conducted by Heino Stöver and Birgitta Kolte (both 
“Bremer Institut für Drogenforschung”, Bremen/Germany), with help from Dr. Anna 
Tsiboukli, Educational Psychologist, Head of KETHEA, Department of Education. 
2  http://profiles.emcdda.eu.int. 
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Korydallos prison estimated that the percentage of drug users, who have 
been re-incarcerated in a 3-5 year period, might exceed 70%. Official state-
ments3 are based on an assessment of the prevalence of drug addicts senten-
ced for drug offences as one third of the prison population. This has been 
questioned by several criminologists (Spiro Stamatis personal communica-
tion, 8th March 2003 and Effi Lambropoulou) who identify 60-70% of priso-
ners as having been convicted due to drug-related offences. 
1.1 Substitution treatment 
1.1.1 Historical and legal background  
In 1996, Greece was one of the last countries of the European Union4 to 
introduce methadone5. Douzenis reports that one of the reasons for this delay 
was the belief that the available treatment options (mainly detoxification 
units and therapeutic communities) were sufficient to deal with the problem. 
This quickly changed with the AIDS epidemic as well as with a dramatic in-
crease in heroin induced deaths. Until 1990, there were 76 reported deaths 
but, by the end of 1995, this figure has risen to 179. It became clear that new 
treatment options had to be set up. When the methadone programme was 
launched, the response from intravenous was extremely encouraging. Within 
2 weeks, O.KA.NA. (The Greek Organisation against Narcotics) received 
approximately 500 applications for the 200 available places for the Athens 
unit. Currently, there are 1 500 applications from intravenous heroin users 
wishing to participate. There is no doubt the methadone programme needs to 
expand to cater for the demand for the methadone programme and alleviate 
the pressure that arose from the creation of a waiting list. The people who 
work in the programme are continuously confronted with requests for trans-
mission and the Greek TV runs programmes of varying quality on a daily 
basis highlighting the predicament of users and their attempts to gain admis-
sion. 
                                                          
3  For instance, that of the previous Greek Minister of Justice, Mr. Petsalnikos, on the High 
Level Conference Towards an Effective Policy on Drugs, Athens, 6-8 March, 2003. 
4  i.e. EU before enlargement. 
5  In Belgium, before 1994, substitution substances were only accepted in detox and, al-
though from a Consensus Conference in 1994, substitution therapy was largely accepted, 
the legal status of substitution therapy was only accepted by law in 2002 (see country 
report, Belgium). 
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According to Siouti (2001), OKANA is the only organization authorised to 
implement substitution programmes in Greece. There are five Methadone 
Substitution Programmes, (3 in Athens and 2 in Thessaloniki), a programme 
administering Naltrexone and a pilot buprenorphine substitution programme. 
According to Ms. Tsaklakidou, there are 1 000 places in substitution treat-
ment all over Greece and enormous waiting lists: In Athens and Thessaloniki 
drug users are waiting an average of up to 3 years, in Athens 900 people are 
on the waiting list and in Thessaloniki 350. Regarding the Therapeutic Pro-
grammes’ Network there were 2 474 people on the waiting lists for substi-
tution programmes in 2000. The total number of intravenous drug users  
in methadone/buprenorphine substitution programmes is 871. Substitution 
treatment is paid for by the Ministry of Health, but financial aspects do not 
seem to impact upon the implementation of substitution treatment in prisons 
(see below). 
1.2.2 Substitution treatment in prisons 
Health care in prisons is in the responsibility of the Ministry of Justice. Sev-
eral interviewees identified a lack of doctors and also an exchange of infor-
mation among professionals among the different prisons. 
Substitution treatment does not exist in Greek prisons. Those patients parti-
cipating in a substitution programme in the community will get a 15-day 
detoxification treatment when entering the prison system. Methadone will be 
sent in daily portions from the community to the medical units and then the 
intake will be supervised by the medical staff. 
Sioti (2001) points out that there is no established legislative procedure gui-
ding this detoxification. Therefore, for the detoxification of each of the 
methadone patients a number of bureaucratic obstacles need to be overcome. 
Many of the imprisoned drug users receive psychotropic drugs prescribed 
from the prison psychiatrist. 
According to the previous Minister of Justice6 the main goal is a drug free 
orientation in the prison setting, which leaves no space for harm reduction 
approaches. Consequently, drug free oriented work is supported in Greek 
prisons. Like KETHEA, an NGO, which has worked in prisons since 1985 
                                                          
6  Personal communication, Athens, 6-8 March 2003, High Level Conference Towards an 
effective Policy on Drugs. 
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and which provides counseling, motivation to access drug free therapies after 
release, education and information work. In 2001, 610 persons attended these 
programmes (KETHEA, 2002). A specialised prison for drug users, offering 
a drug free treatment program, was opened in Elaiona, Thiva (a place not far 
from Athens, see chapter field visit). 
Reasons for not implementing substitution programmes in Greek prisons 
According to Domna Tsaklakidou (OKANA) the public debate about sub-
stitution treatment in general is still at an early stage. It was only in 1996 that 
the first substitution programmes were integrated into medical care for opiate 
dependents in Athens and in Thessaloniki. Before that date, all offers have 
been abstinence oriented. The general public and the drug users themselves 
are familiar with drug free oriented services and, for a long period, accepted 
that substitution treatment was not offered. Thus, the majority involved in 
drug services remained sceptical towards substitution treatment. Only a few 
doctors are interested in this treatment form for opiate addicts and much 
resentment towards drug addicted patients persists. Finally, a lack of educa-
tion and training is seen by Ms. Tsaklakidou as a main barrier for the intro-
duction of such programmes. 
Although several initiatives are looking at the provision of substitution pro-
grammes, the reasons just cited are responsible for a very low spread of this 
treatment form in many places. Moreover, there is an enormous lack of 
information, guidelines, communication and cooperation necessary for the 
introduction of the medical and social elements of substitution treatment. 
Due to a paralysing bureaucracy and political institutions, no supporting 
structures and initiatives have been implemented in order to introduce sub-
stitution treatment programmes. 
Ms. Tsaklakidou emphasized the fact that the criminal stigma of drug addic-
tion has still to be overcome in favour of a medical perception and an appro-
ach of acceptance. Under the presidency of Greece the High Level Confe-
rence Towards an Effective Policy on Drugs (Athens, 6-8 March, 2003) was 
organised, indicated that the previous government was very interested in a 
new debate about drugs policy.7 Greek participants and contributors suppor-
ted the idea of a balanced approach, distinguishing between drug traffickers 
                                                          
7  The government changed in 2004 and until now the drug policy of the new government, 
the conservative Nea Democratia, is not known. 
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and drug addicts, who should be offered more treatment facilities. It was 
acknowledged that the number of places in methadone programmes should 
be enlarged. As a first step into a treatment oriented approach in penitentia-
ries, the opening of the prison-based therapy institution “Eleonas” (see be-
low) has been regarded as an essential step forward. 
1.3 Prison Population  
Table 12 Data on the prison situation in Greece (Source: King’s College London, Interna-
tional Centre for Prison Studies, Prison Brief for Greece) 
Country  GREECE 
Ministry responsible  Ministry of Justice 
Prison administration  Direction General de l'Administration Penitentiaire 
Contact address  96 Avenue Messogion, GR-11527 ATHENS, Greece 
Telephone / fax / website  tel:  +30 1 77 96 452 fax: +30 1 77 17 182 
Head of prison administration  
(and title)  
(Mme.) Sevasti Anastassakou - Papamitropoulou  
 Directrice des Affaires Pénitentiaires 
Prison population total  
(including pre-trial detainees / 
remand prisoners)  
8,841 
at 1.12.2003 (national prison administration)  
Prison population rate  
(per 100,000 of national popula-
tion)  
83  
based on an estimated national population 
of 10.6 million at December 2003 (from 
Council of Europe figures)  
 
Pre-trial detainees / remand pris-
oners (percentage of prison 
population)  
28.5%   (1.9.2003)  
Female prisoners (percentage of 
prison population)  4.9%     (1.9.2002)  
Juveniles / minors / young prison-
ers incl. definition (percentage of 
prison population)  
6.9%     (1.9.2001 – under 18)  
Foreign prisoners 
(percentage of prison population)  42.4%   (1.12.2003)  
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Number of establishments / insti-
tutions  
25 
  
Official capacity of prison system  5,584      (1.12.2003)  
Occupancy level (based on offi-
cial capacity)  158.3%  (1.12.2003)  
Recent prison population trend 
(year, prison population total, 
prison population rate)  
1992     6 252     (61) 
1995     5 887     (56) 
1998     7 129     (68) 
2001     8 343     (79) 
2 The field visit 
2.1 “Eleonas”/Thivas prison8 
2.1.1 Description of the prison 
The buildings of the drug treatment institution “Eleonas”, near Thiva some 
70 km out of Athens, have been built up and were utilised for agricultural 
purposes by Jehova witnesses until 2002. The Greek government then 
bought this estate in order to build up this treatment institution. 
2.1.2 Treatment procedure 
In 2002, the treatment institution was installed as the “Rehabilitation Centre 
for Prisoners” (Lambropoulou, 2003) as a pilot project for the Ministries of 
Justice and Health. The installation of such an innovative treatment facility 
offers treatment options for incarcerated drug users whose rehabilitation pro-
cess should be supported. The patients should recover physically and psy-
chologically and these patients should be taken out of the overcrowded 
situation which are not regarded as fruitful ground for treatment processes. 
The concept of the treatment institutions is similar to that of a therapeutic 
community. At the time of the field visit, 45 men were in treatment, this 
number should be increased to 60 and finally it is aimed to expand the capa-
city to 300 persons. The project is well equipped with security officers, 
social worker, a psychologist, 2 doctors and medical personnel. Medical as 
well as the dental medical provision is on a high level. The 2-year treatment 
                                                          
8  Visited on the 8 March, 2003. 
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programme is based on group and individual sessions, as well on facilities in 
various working areas (garage, joinery, kitchen, agriculture, assistance on the 
medical unit). On several thousand hectares of land, fruit and olive trees and 
vineyards are being cultivated. All these efforts are undertaken to increase 
the chances for the incarcerated men on the labour market. 
Requirement for an uptake to “Elenoas” is (i) that a large part of the sentence 
has already been served and (ii) the intention of an absolute drug free orien-
tation. Positive blood or urine tests immediately lead to exclusion from the 
programme. 
The five prisoners interviewed seemed contented and expected to overcome 
their addiction. According to official information, neither relapses nor flights 
have occurred. There is no scientific evaluation for this programme. One of 
the difficulties is that only drug addicted persons are selected for the treat-
ment programme and not drug traders. So, participants of the treatment pro-
grammed have been very well selected. On average, they are serving senten-
ces of 10 years. Another difficulty is the high number of migrants in society 
as a whole and among the prison population. This leads to language pro-
blems and migrants often face hostile attitudes. 
The director of “Elenoas” explained that this is a completely new approach 
towards drug treatment in Greek prisons and that additional institutions with 
similar concepts are being planed in northern Greece (Chalkidiki) and on 
Crete. 
3 Summing up 
Substitution treatment has only been introduced in the community since 
1996. Policy and practice regarding this form of treatment must be characte-
rised as high threshold with very centralised structures (only one organisa-
tion is offering substitution treatment) with limited places (there are conse-
quently long waiting lists) and very limited access in the two largest cities 
(Athens and Thessaloniki). There is a higher demand for treatment places 
than capacity can accommodate. In prisons, no substitution treatment is 
implemented. On the contrary, the drug free therapeutic approach is suppor-
ted and put into practice. This situation can be compared to other Western 
European countries in the 70s and 80s where, for a long time, the abstinence 
oriented approach remained dominant until the increase of substitution pla-
ces changed policy and practice in prisons as well. Externally, there is a big 
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debate and predominantly a sceptical position towards the usefulness of sub-
stitution treatment. This must be regarded as the primary barrier to introdu-
cing this option into the prison setting. But, looking at the spread of drug use 
and infectious diseases in prisons, things may change in the near future. 
  
Ireland1 
1 General data:  
drug use, substitution treatment and prison population 
1.1 Number of drug users 
According to the EMCDDA (2003) the number of problematic drug users in 
Ireland is 13 735. This is a middle range rate of 586 per 1 000 people aged 
15-64 in the general population. 80% of all intravenous drug users in Ireland 
are infected with HCV. Studies show a correlation between length of impris-
onment and HCV status: The more time spent in prison, the more likely the 
prisoner is to be HCV positive. Several studies in prisons have indicated a 
high level of risk behaviour in prisons. Long (2003) pointed out that injectors 
take risks that they would not take outside. Allwright et al. (1999) found that 
among 1205 prisoners, 21% reported having injected drugs in the medium 
risk prison and 58% in the high risk prison. 60% of the women prisoners 
reported injecting drug use and 21% of intravenous drug users first start 
injecting in prison. Another study states that the use of heroin is widespread 
among the prison population. According to that study, 30% of males and 
56% of females have used heroin at least 3 times, 8% resp. and 12% once or 
twice (Centre for health promotion Studies 2000, p. 38). 
1.2 Substitution treatment 
1.2.1 Historical and legal background  
Methadone is the only registered and authorised substitution drug in Ireland. 
According to interviewees, the first prescriptions of methadone date back to 
1969. From the early 70s, methadone was used mainly for gradual detoxifi-
                                                          
1  The field visit in Ireland (10-14 December 2003), conducted by Heino Stöver, was facili-
tated by Dr. Enda Dooley, Director of Prison Healthcare and Frances Nangle-Connor, 
Coordinator of Nursing, Health Care Directorate, Ministry of Justice of Ireland who also 
provided national information and support with the finalisation of this country report. Inter 
were conducted with Probation and Welfare Service officers, nurses, guards, doctors, 
social worker, prisoners, consultant psychiatrist in substance misuse, Director of Prison 
Health Care, coordinator of nursing, health care directorate, scientists, NGO members. 
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cation and, in rare cases, it was used over a prolonged period of time to 
maintain addicts and stabilise their condition (UISCE 2003, p. 7). As a re-
sponse to the HIV/AIDS crisis, substitution treatment was then introduced in 
the mid 80s. In 1992, there were 200 patients receiving substitution treat-
ment. From then on, this treatment rapidly expanded. According to Brion 
Sweeney, there were about 6 000 drug users in substitution treatment in Ire-
land at the time of the visit. Methadone is available, free of charge, to every-
one undergoing treatment for opioid dependence. 
In 1998, the Irish Government issued the ‘Methadone Protocol’ which regu-
lated access and the treatment modalities of substitution treatment. One of 
the major concerns was about the methadone black market. As a conse-
quence, GPs were no longer allowed to prescribe methadone unless they 
signed up to the protocol procedures. These included limits on patient num-
bers, centralised patient records, training for GPs who wish to prescribe etc. 
Physeptone2, which was thought to be less suitable in the pharmacotherapy 
of opioid dependence, has been replaced by methadone DTF3 (see Depart-
ment of Health and Children). Service users, UISCE (Union for Improved 
Services, Communication, and Education) found out that the vast majority of 
users (88%) preferred Physeptone, because they felt that Methadone DTF 
was less effective. Although difficult to generalise from, this study expresses 
high levels of dissatisfaction with substitution treatment (respondents’ had 
the impression of drug treatment service personnel as being impersonal and 
uncaring, too many sanctions used by health professionals, lack of confiden-
tiality of service providers and a lack of complaint procedures etc.). 
O’Connor (2002) reported service users’ dissatisfaction with several issues 
(amongst others having to comply with punitive contracts and having to con-
sume methadone in a public space in pharmacy retail outlets). Dillon and 
Mahon (2002), who studied users’ perspective on methadone maintenance 
(n=71), point out that participation on the methadone programme offered 
clients an alternative to the generally chaotic lifestyle they associated with 
heroin use. Respondents did not equate ‘success’ on methadone maintenance 
with becoming drug free. Success in this context was found to be relative 
and much more complex than a simple measure of abstinence. Instead, MMT 
service users felt that the programme had a positive impact on their quality 
                                                          
2  Referred to in the prisoner interviews as the “brown phy”, which was supposed to be 
damaging to teeth due to sugar ingredients (UISCE 203, p.11). 
3  Referred to in the prisoner interviews as the “green phy”. 
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of life in a number of areas: “In this context, clients valued the stability the 
programme offered and argued that it gave them an opportunity to get their 
lives ‘back on track’.” (Sinclair 2002, p. 7) 
1.2.2 Substitution treatment in prisons  
The Prison Service adopts a multifaceted approach to drug treatment, which 
includes provision of addiction counselling, education programmes, detoxifi-
cation, drug therapy programmes, information forum, drug free areas and 
methadone maintenance. This variety of responses to the challenge of drug 
addiction in prisons has been recommended by the First Report of the Steer-
ing Group on Prison Based Drug Treatment Services (Irish Prison Service, 
2000). This Steering Group proposed a coordinated and partly centralised 
approach to drug treatment services in the prison system with significant 
focus within the Mountjoy Prison Complex (see Department of Justice, 
2002). Evidence for this approach has been delivered by the report of Allw-
right and others (1999) who found a high prevalence of infectious diseases 
and drug related risk taking among prisoners. They recommended: “One 
third of drug users were on a methadone programme prior to their imprison-
ment. Prisoners rarely maintained on methadone in prison. If a greater pro-
portion of drug users were offered methadone maintenance in prison, this 
would have the effect of lessening risk of viral transmission. This is a matter 
of some urgency.” (p. 30) 
In 2000, methadone maintenance was introduced into the prison system for 
those already on approved treatment programmes in the community. “As a 
result, offenders who had been on methadone maintenance in the community 
no longer have to terminate their treatment on committal. By December 
2000, 184 prisoners were on methadone maintenance in 5 Dublin prisons.” 
(Irish Prison Service Report4 1999/2000, p. 17) “However, there are difficul-
ties in placing prisoners on methadone programmes in prison who have not 
been on such a programme in the community as there is no guarantee from 
the Health Authorities that prisoners could be continued on these pro-
grammes on their release. The Group noted that the First Report of the Stee-
ring Group on Prison Based Drug Treatment Services envisaged that priso-
ners with a drug dependency could apply for treatment within the prison to 
                                                          
4  See www.irishprisons.ie. 
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be commenced in a similar way as would apply in the community and with 
similar waiting times applying.” (Irish Prison Service, 46) 
In a general healthcare study of the Irish prisoner population (Centre for 
health promotion studies, 2000, p. 29), prisoners were asked to rate the pri-
son health service. 40% of male and 29% of female prisoners reported that 
the prison health service was poor, while 23% of male and 45% of female 
prisoners thought it was fair. 23% of male and 27% of female prisoners rated 
the prison health services as very good or good. Among prisoners’ suggesti-
ons on how to improve the service, more time was demanded for patients on 
the part of the prison doctors, better doctor-patient communication, retrai-
ning of health staff so that staff would identify and address the specific needs 
of prisoners, such as drug addiction and mental ill-health, as well as impro-
ved confidentiality in the health service. 
In the 90s, the gap between substitution treatment in community and in pris-
ons widened. Whereas the number undertaking substitution treatment in the 
community rapidly increased, there were only a few doctors to prescribe it in 
Irish prisons. Methadone was first introduced in Irish prisons in the early 
nineties. Until 1995, prisons offered a detoxification treatment to opioid 
dependent inmates including reduction schemes of 3-5 days. In 1996, sub-
stitution maintenance treatment in Irish prisons began in Mountjoy prison 
with a few HIV positive inmates and other persons in need (e.g. pregnant 
women). This developed and, in 1998, any HIV positive inmates received 
methadone. At the time of the visit, there are approximately 500 inmates 
receiving methadone with the intention to expand services. With a time lag 
of several years, substitution treatment expanded at the end of the nineties. In 
2000, a policy was applied to continue substitution treatment from the com-
munity to prisons and vice versa. One reason for the belated introduction was 
the initial doctor’s resistance to treatment due to a lack of resources in the 
prison health service. However, implementation of this policy has been de-
layed. 
It was seen as illogical to confine this treatment to HIV-positive inmates and 
pregnant women. Those patients who were already on methadone mainte-
nance treatment in the community, and who expected a short time in prison, 
were then provided with substitution treatment as part of a pragmatic appro-
ach. The time of maintenance therapy could be prolonged, predominantly in 
the Dublin area, but could not be ensured for other regions (e.g. Cork, Lime-
rick), meaning that inmates were not transferred to other institutions there. In 
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Dublin, there are also differences in access to substitution treatment, depen-
ding on the district (East, North and South-West) that drug users come from. 
The length of waiting lists varies a great deal, depending on the resources 
available to each health centre, and, in some areas, a wait of up to one year is 
not rare. Only those drug users who are in treatment outside and who will be 
taken into treatment again after release are guaranteed treatment in prison. 
The situation inside prison mirrors that on the outside; services are restricted 
by limited resources and waiting lists remain in operation. 
The expansion of methadone treatment happened under the guidance of and 
with advice from community experts and specialists. Apparently, several 
problems derive from the link between being on treatment in the community 
and securing a place for treatment in prison: 
− The number of prisoners receiving methadone maintenance treatment de-
pends completely on the resources and possibilities in the communities 
(either GPs or clinics). If there is no such infrastructure in villages and 
smaller cities then substitution treatment cannot be continued in prison. 
− There are not enough counsellors in prison to support prisoners on sub-
stitution treatment although some input is given by probation and welfare 
officers and very few psychologists. 
Furthermore, there are additional problems, which are quite common to 
regimes in other European prisons: 
− There is a shortage of nurses and the relevant training (supervision of 
urine tests, dispensing, contact to the community, awareness of topping up 
drugs etc.). There is a particular need for senior nurses to coordinate the 
services. 
− There are not enough specialised doctors (level 25) to prescribe metha-
done in prisons. 
− The staff saw substitution treatment as a harm reduction measure and the 
Officers Association is against this approach. 
All in all, the prisons do not have enough resources. Staff shortages, espe-
cially of nurses, contribute to substitution treatment problems. This stated 
frankly by the Irish Prison Service: “Unfortunately, the trained staff and 
                                                          
5  Level 1 – GPs need little training and can prescribe for up to 15 patients. Level 2 – GPs 
can treat up to 35 people and have more extensive training. 
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other resources which would be considered necessary in the external com-
munity context to adequately address the range of problems and issues asso-
ciated with a population of this size are not currently available in the prison 
context. This has presented on-going difficulties in ensuring the safety and 
stability of this treatment provision. In the context of inadequacy we must 
consider that we remain fortunate in avoiding any significant mishap in the 
provision of this treatment”. (Irish Prison Service 2001, p. 30) At present, 
the potential for improving services and substitution treatment relies too 
heavily on the individual motivation of doctors and nurses. Most of the doc-
tors are employed part time. It is difficult to recruit doctors, which accounts 
for problems of getting doctors of level 1 qualification in Limerick and level 
2 in the Dublin area. Many doctors are not motivated to treat drug addicts. 
As it was said by one interviewee “Drug users are a difficult group to deal 
with, if you can you would avoid it”. Experts say that “difficult prisoners” 
are sent to Dublin, where a better health care and expertise is expected. 
The decision of whether to continue treatment is taken by the doctor. Routine 
detoxification is undertaken by the primary care doctor. The national treat-
ment list6 can be accessed by the nurse to check whether a patient received 
substitution maintenance treatment in the community. The nurse will ring the 
respective clinic at the day of admission. Only a very small percentage of 
prisoners who have received treatment did so for the first time in prison. 
Psycho-social care for patients on substitution treatment is optional. Accor-
ding to several interviewees, women with multiple problems and a lot of 
drug associated problems (see Carmody and McEvoy, 1996) do not receive 
enough psychological support. But, as it is a high need group more invest-
ments need to be made. There are links in the Dublin area with ‘Merchants 
Quay Ireland’, an organisation which is providing harm reduction measures 
and housing in the community and which gives support for prisoners who 
have been on methadone maintenance. There is also the possibility to switch 
to a Therapeutic Community, when certain requirements are fulfilled (nega-
tive urine etc.). 
There is no specific legal regulation for substitution treatment in the prison 
setting. But, a treatment programme for the Irish Prison Service has been 
                                                          
6  A list to avoid duplicate prescribing. 
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elaborated and is serving as a basis for this treatment in custody. The follo-
wing steps in methadone treatment are7: 
− Individual committed to prison 
− Assessment by nurse on first day 
− Urinalysis (6 A. Morph) 
− Verification with the central treatment list 
− Doctors’ assessment 
− Treatment plan (maintenance, detoxification) 
Contract signed (copy to service user) in which service user is given detailed 
information on the treatment and on the risk of using other drugs as well as a 
list of medications not to be used: 
− Psycho-social follow up by Counsellor/Key Worker (where possible) 
− Stabilisation period to establish the right dose 
− Maintenance or detoxification regime 
− Regular review to set new goals (depending on type of treatment) 
1.3 Prison Population  
Table 13  Data on the prison situation in Ireland (Source: King’s College London, Interna-
tional Centre for Prison Studies, Prison Brief for Ireland) 
Country  IRELAND, REPUBLIC OF 
Ministry responsible  Department of Justice, Equality and Law Reform 
Prison administration  Irish Prison Service 
Contact address  Siac Building, Monastery Road, Clondalkin, Dublin 22, Ireland 
Telephone / fax / website  
tel:    +353 1 461 6002 
fax:   +353 1 461 6027 
url:    www.irishprisons.ie 
Head of prison administration  
(and title)  
Sean Aylward    
Director General 
Prison population total (including 
pre-trial detainees / remand 
prisoners)  
3 602 at 28.4.2004 (national prison administration – 
of which 309 were on temporary release)  
                                                          
7  Methadone Treatment Programme Guideline for the Irish Prison Service, p.17 
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Prison population rate (per 100,000 
of national population)  
90  
based on an estimated national 
population of 4.0 million at April 2004 
(from Irish Census 2002)   
Pre-trial detainees / remand 
prisoners  
(percentage of prison population)  
14.8%   (28.4.2004)  
Female prisoners  
(percentage of prison population)  3.8%     (28.4.2004)  
Juveniles / minors / young prisoners 
incl. definition (percentage of prison 
population)  
1.5%     (1.9.2002 – under 18)  
Foreign prisoners 
(percentage of prison population)  9.2%     (28.4.2004)  
Number of establishments / institu-
tions  16          (2003)  
Official capacity of prison system  3 313     (1.9.2003)  
Occupancy level (based on official 
capacity)  99%      (1.9.2002)  
Recent prison population trend 
(year, prison population total, prison 
population rate)  
1992       2 155       (61) 
1995       2 054       (57) 
1998       2 648       (71) 
2001       3 025       (78) 
2 The field visits 
The field visit in Ireland (10-14 December 2003) was conducted by Heino 
Stöver and facilitated by Dr. Enda Dooley, Director of Prison Healthcare, 
and Frances Nangle-Connor, Coordinator of Nursing, Health Care Director-
ate, Ministry of Justice, who also provided general information and support 
with the finalisation of this country report. Two prisons have been visited: 
the new women's prison attached to Mountjoy Prison in Dublin and Wheat-
field Prison for sentenced men (adjacent to Cloverhill ) in Dublin. 
In both prisons, interviews were conducted with nurses, social worker, focus 
groups of prisoners, probation officers and doctors. Additionally meetings 
were held with Dr. Brion Sweeney, Consultant Psychiatrist in Substance 
Misuse, and Rick Lines, Executive Director, Irish Penal Reform Trust 
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(IPRT). Finally, there was a meeting with Jean Long, Drug Health Research 
Board, Dublin. 
2.1 Dóchas Centre 
2.1.1 Description of the prison 
The Dóchas Centre is the new women's prison attached to Mountjoy Prison.  
This prison has a daily population of approximately 90, 30 of whom receive 
methadone substitution treatment at any one time.  The turn over is relatively 
high as 15-20 women enter the institution and/or leave it per week.The per-
centage of drug users among the inmates is considerably high and has 
increased in recent years. Almost 75% of all prisoners committed offences 
related to drug use. A considerable shift of patterns in drug use has been 
observed towards the spread of multiple drug usage. 
The reduction scheme, if somebody wishes to detoxify or is not on the 
National Treatment list, is a reduction of 5 mg in 7 days, 40 mg in total. 
Interviewees stated that psycho-social support is lacking. Apart from an 
anxiety and a drug awareness group, additional counselling is provided by 
probation service and welfare officers and is not regarded as sufficient. The 
probation and welfare service conducts committal interviews. Methadone is 
dispensed from 8-9 in the morning. Daily problems relating to supervision 
and control were reported. 
2.1.2 Goals and practical procedures of substitution treatment 
The doctor stated that their goal was to continue methadone maintenance 
treatment from the community. What makes their work difficult is the wide-
spread use of additional drugs, mainly benzodiazepines, which are often used 
in an addictive pattern. This co-addiction makes it hard to monitor. Recently, 
guidelines have been developed by Irish doctors that recommend not to pre-
scribe benzodiazepines for a long term course. The widespread addiction of 
benzos makes it necessary for the doctor to develop reduction schemes. First, 
sleeping pills are given and then these are reduced over a period of  
1-2  weeks. The prescription of sleeping pills will be adjusted to the individ-
ual’s situation and could go up to 3-4 weeks. It is regarded as necessary to 
apply a clear policy on sleeping pills in order to avoid constant arguments 
with inmates. 
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The average dose of prescribed methadone is around 40 mg. The reduction 
scheme is 10 mg less per day over14 days/ Individual approaches to treat-
ment are necessary and, in 90% of cases, the stabilisation of former chaotic 
behaviour is achieved. 
2.1.3 Views of prisoners – focus group in Dóchas Centre 
All of the participants at the focus groups were receiving methadone and had 
several years of experiences with methadone programmes, outside and inside 
prison. Five prisoners attended the focus group. 
One of the issues surrounding substitution treatment in prison is the conse-
quences of topping up with other drugs, e.g. cannabis: 
“… when you come into the prison, they give you so long to clean whatever 
you have in your urine, like if you have cannabis or…most prisoners come 
in, when they come in they have probably cocaine and heroin and all that in 
their urine, so when you come into the prison they give you a while…a month 
is it, or something? … Yes. … to clean it out and then, after that, if it’s still in 
your urine you get docked ten milligrams, so …” 
The consequences were not clear to all respondents and doubts are remained 
regarding the exact protocol for reduction if cannabis is found: 
“But, I think, I don’t know, I think probably ten milligrams would be a bit 
much, you know. Especially if it’s only for cannabis because it’s not really a 
big, you know, it’s not, it wouldn’t be a Class A drug or whatever, …” 
The doubts regarding consequences of cannabis use might come from having 
experienced a different testing policy in the community: 
“But, other than that now, in the community, I don’t think … I think you can 
sort of have it if you’re just on your maintenance, on your methadone and 
with no other drugs you can kind of just get on as normal as…as, as anyone 
else, you know.” 
Prisoners report that their cannabis use is becoming problematic as the con-
sequence of a positive test is a reduction in their methadone dosage. 
“You know, you’re cut every day and, em, at the moment, like, even speaking 
of ... I’m having a bit of hassle with my maintenance, like. Like X said, I un-
derstand that cannabis is a Class A drug and, you know, legally, by right, 
we’re not allowed have drugs in prison, d’you know what I mean? It’s black 
or white, you know. You don’t have … although that’s what I ... my argument 
was, ‘Ah, but it’s only cannabis’ and I was told coming into prison that you 
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don’t have, you know, drugs, it’s that straightforward, and all. But drugs do 
come in, you know. It … it’s a natural occurrence and it is going to happen. 
And sometimes you can even see where the tension is so high, and then when 
drugs come in, like, it mellows it for a while and then it goes up again, and, 
you know. You do need a bit of a release, you know, there’s not a lot of 
things that we have here for release. Now, I had a problem with … I had 
cannabis four weeks ago, say. Now cannabis takes a long time to get out of 
your system. So, because I took cannabis, I was cut, and then the next week, 
because it was in my urine still, they cut me again, you know. And then I was 
cut again – so I was cut three times for one, you know. So, that’s … that’s an 
issue, like, you know. They don’t give you enough time for it to actually leave 
your system, you know. Where, instead of keep cutting it, you know, they say 
‘Well it takes a while. If you were taking heroin, that comes out of you 
quicker. You’d be better off taking heroin.’  
As an important goal and an indication for stabilisation, the take-home 
regulation is named: 
“… if you’re clean, you know, you’re just on your methadone, the clinics on 
the outside will give you … your methadone to take home. So you can, like, 
you’d probably get, like, a week and you’d just go to the clinic, like, once a 
week. But you have… like, that’s when you’re kinda doing okay, you’re 
feeling okay.” 
“So, you know, I think, … if you’re getting your methadone to take home, 
that’s great because it’ll, you know, make you kinda stay stabilised that little 
bit longer, you know, and get a bit further.” 
Prisoners do see difficulties and temptations to use substances other than 
methadone, not only in prison but also on the outside in the methadone 
clinic: 
“… a lot of people would be doing okay, but when you go to the clinic some-
times it can be a downfall, you know, ‘cause you meet other people there and 
you end up, probably, like, some people think, you know, when you go there 
you’d be doing okay, and then you end up going off and probably getting 
whatever sort of drugs you’re into, you know … You’d be more inclined to 
use when you’re meeting people, wouldn’t you? … Sometimes, yeah. The 
clinics, I think the clinics on the outside would be a bit of a downfall, you 
know, in regarding that, meeting other people and, if you’re easily influen-
ced and easily led, you will go, you know … … you could get a bad day 
where you’d go and you’d meet other people and you’d end up going off, 
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probably getting cocaine or heroin or whatever you’re into, you know. … 
It’s different here, yeah. Because, like, you’re in the prison and you can’t get 
at it really, you know.” 
The transfer from the community methadone programme to the prison-based 
programme was described as smooth and void of problems: 
“… They ring up the clinic, you know, when you’re committed and check 
what dose you’re on, what other things you’re on.” 
Prisoners stated that this is a development in the substitution programmes 
and, compared to previous stays in prison, an improvement has been seen: 
“… it wasn’t always the case. We used to only get a detox, years ago. Even if 
you were on maintenance and you were clean. If you were clean, you got 
maintenance of seven days – not a maintenance, a detox – cut every seven 
days and that lasted seven weeks. You got forty milligrams. Forty, yeah, and 
you were cut every seven days. Forty milligrams. And you were cut, like 
what was it, five milligrams? If you were clean on the maintenance at seven 
days, and five milligrams. Yeah, five milligrams every seven days but if your 
urine was dirty it would start on 35, wouldn’t they, and cut you every five 
days, and five milligrams or three days, or whatever, and so on depending 
on if you used the smokes, wasn’t it? 
[Interviewer: So, it’s an advancement?] 
“Yeah. Big-time … Like, even if you were on a maintenance outside you 
were still, three years ago, you were just getting cut in here and that was it, 
you know.” 
Prisoners confirm that the prescriptions they get in the community-based 
methadone programme are continued smoothly inside prison: 
“So, it’s grand like that the maintenance is here now, so a lot of people, they 
… it would be easier coming into prison knowing that you’re getting your 
maintenance, you know, and your methadone and you’re not getting cut.” 
Prisoners report that the standard dosage suitable for all prisoners will not be 
sufficient for all needs 
“No. It wouldn’t be. Not if you were on maintenance for a long long time ...” 
“It wasn’t sufficient, you know, you’d be in prison and you’re still not get-
ting proper sleep and you’re not feeling, like … it takes a long long time …” 
(A prisoner) 
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The participants in the focus group also brought in their experiences from 
other prisons and the detoxification schemes there. 
“That was very different. They kinda like – excuse me – they cut every day 
there, you know. It’s like a crash course, you know, it’s just boom, boom, 
boom and they’re finished then, you know.” 
One of the key issues addressed in the focus group was the prescription, or 
rather non-prescription, of additional medication (e.g. sleeping pills). It be-
came clear that drug use patterns for women outside contained multiple drug 
use pattern including sleeping pills. The prison prescribing policy is against 
the continuous prescription of these drugs. The women are very well aware 
of this double standard. 
“You know, a lot of us are not really into cannabis anyway, you know. When 
you’re on the clinic, you’re getting your methadone and you’re getting your 
sleeping tablets, but when you come in here, like, they’d all be on sleeping 
tablets for years, you know, and when you come in here you get them for two 
weeks, fourteen days and that’s it after that. And because you can’t sleep, 
like … I’m not here … I don’t need … I don’t smoke cannabis, not … not 
very often, but when I came in here I did and, like, it’s years, probably about 
three years since I did, because I wasn’t sleeping when I came off my sleep-
ing tablets, I ended up I did smoke cannabis and because it’s in your urine 
for so long you’re getting cut and cut. But, I think if they just gave like kept 
you probably on your sleeping tablets as well.” (A prisoner) 
Furthermore the participants of the focus group regard the two weeks period 
for withdrawal of sleeping pills as too short. 
“Say, maybe you got a five-year sentence and they’d give them something to, 
you know, relax, not Valium, but sleeping tablets, you know what I mean, but 
after, like, that would have been a few years ago and you were getting them 
for, as I said, the duration of your sentence. But now, it’s changing, and you 
come in and you’re only just getting them for two weeks, no matter how long 
you were on them – it’s just stopped. Not detox, but the same amount for the 
week.” 
“And you’re coming in, like…when you come in at first you’d be probably 
strung out on heroin and strung out on cocaine and strung out on these tab-
lets, them drugs, yeah. So, when you’re getting them for only two weeks in 
here you still, you know, with withdrawing from everything else, you know, 
you will, you will, if there’s cannabis around, because it’s, it’s …” 
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The prisoners think that it is maybe a misunderstanding of the pharmacologi-
cal effectiveness of methadone that leads medical staff to think it is powerful 
enough to ease all withdrawal pain. Prisoners argued for the continuation of 
the prescription of sleeping pills. 
“I think they think the methadone is gonna, will overcome everything. Yeah, 
you know, withdrawal symptoms and everything, but it doesn’t.” 
“I think if you were kept on your sleeping tablets, and just get sleeping tab-
lets and your methadone, it would cut out all other drugs, you know like, it 
would cut out hash, cannabis anyway with a lot of people.” 
Prisoners complain about the detox scheme for sleeping pills but risks of 
dependency were not mentioned: 
“I’d say detox, you know, them drugs. See, they give you the same amount 
for two weeks and that’s it. They don’t even wean you down, like.” 
“They don’t reduce you slowly, like, whatever, like.” 
“They should be easier with your sleeper, like cut you gradually.” 
Prisoners regard a good detox treatment as essential for well-being: 
“If they’d give you a good detox, then you wouldn’t feel half as bad.” 
“They are very dangerous when you get strung out on tablets, and coming 
off them too quickly, you can go into fits or anything.” 
“When I came off them, when I was on them drugs and they just cut me and I 
was very, very sick for a long time.” 
“And they think when you are coming off them drugs you can take fits and 
they give you anti-fit tablets.” 
Cannabis consumption is seen differently in external clinics and within the 
prison-based methadone maintenance programme. Prisoners are very well 
aware of these different policies: 
“[Interviewer: Is it the same outside – when you smoke cannabis that you 
will be expelled?] 
No. No. No. They’re a bit more lenient. You know, as regards heroin and 
cocaine …” 
And different policies are perceived between the two with regard to the pre-
scription of sleeping pills: 
“I mean, they’re cutting you. It’s silly because they’re cutting you and then 
you go back out to the clinic and the clinic isn’t cutting you back there.” 
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“Yeah, … in the community you actually have them from your maintenance, 
and then they cut you and you go back out and then you just say it to your 
doctor and he’ll put you back on them drugs.” 
“There was a time, what your clinic gave you on the outside you got it when 
you came in. But now it’s only methadone you get the same as the clinic, you 
know. But anything else, they take you off, even Valium … Like, some people 
are on Valium since they’re, like, thirteen and fourteen, you know.” 
Different policies also exist in relation to urine tests: 
”… you’d probably just have the one, like, within six weeks and then you’d 
have one dirty urine and then you’d have another, like, come in for six weeks 
or whatever. You’d be more inclined to give dirties on the outside than you 
would in here, so ...” 
Urine testing does pose the problem that prisoners might switch from canna-
bis to heroin, which is to be detected only for a short period of time. Prison-
ers confirmed this view: 
“Yeah, ‘cause it goes after four days, yeah.” 
“You won’t be cut as much. … You know the way the heroin doesn’t stay in 
your urine as long as the cannabis does? And then you wouldn’t be cut as 
much, you know, on your methadone. Yes, you know, like when you’re giving 
a dirty urine, you know.” 
“Yeah. Various people that have said: ‘Well, I’m going back on heroin. If 
they’re going to be cutting me for hash, I’m going to go back on it. What’s 
the point in staying off heroin as well?’ Like, methadone substitutes heroin. 
If you’re feeling sick down to being cut, what do you take? You take heroin 
down, d’you know what I mean.” 
Urine testing does play a role in the management of additional drug use 
(either cannabis or others): 
“Some people don’t want to get clean, you know. If you’re getting, giving a 
urine on Monday and Saturday, people know, okay, I’ll have a turn-on on 
Monday night and it’ll be out of my urine for Saturday morning. You know, 
some people do want to get out of it, and then there are people that don’t, 
and they fuck it up for people who do want to, you know like, let’s be honest. 
You know, I’ve often said ‘Okay, I’ll give a urine on Monday and, okay, I’ll 
have a smoke Monday night, ‘cause it’ll be out of my system for Saturday. 
You know, people do do that, you know. That’s the way it operates. People 
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do give bogies, you know, you can … you know, we can all use bottles and … 
you know … everything. You know, it can be … there’s a ways and means to 
everything, d’you know. I’m just saying this is the way it goes on, you 
know.” 
Prisoners are aware of the consequences of manipulating urine tests as con-
trols may be increased for all prisoners and the situation may worsen: 
“But what I’m saying, what I mean … what I’m saying about people … 
I mean it’s hard at the same time because it messes it up for people who do 
genuinely want to get it together, you know what I mean. So, they’re putting 
more rules and more rules and it’s falling back on the people who want to 
get it together, because it’s for the benefit of people who don’t. Do you 
understand what I mean? Like, I’m trying to push people who don’t want to 
get clean, and they’re crawling back then.” 
“There’s a lot of people who want to do well on the methadone and there are 
others who don’t. For the group that don’t want to do well, em, they’re put-
ting all these regulations and rules in place that are having a negative effect 
on the ones that are trying to work hard. Of course, yeah, yeah. So every-
body pays for the small number that don’t want to do anything about it that 
don’t want to give up.” 
Prisoners reported difficulties in cooperating and communicating with coun-
sellors inside the prison. One reason was that they have someone they trust 
outside and do not want to report twice as they do not trust the counsellors. 
“A lot of people have counsellors in their clinics on the outside that they 
would have years and would know well, and would, you know like, don’t 
mind talking to them when you have them so long. And then, if you want a 
counsellor in here, it’s a different person and you have to go through the 
whole rigmarole, you know. And most people don’t want to open up the way 
they opened up with this certain person, you know, because you’re used to 
that person.” 
“It took me a long time to open up to the person on the outside, without 
having to start all over again with strangers in here, you know what I 
mean.” 
However, an inconsistency was evident. On the one hand, prisoners reject 
counsellors and, on the other hand, they express the need for more counsel-
lors in the prison. 
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“They’re not like proper counsellors, like … you’re supposed to go and get 
counselling off XY, you know at the station, but, like, you couldn’t sit there 
and talk to them about your problems.” 
“There’s definitely counsellors needed.” 
“In this system the Probation and Welfare Service provide a counselling ser-
vice. But the girls are saying they wouldn’t trust them.” (A nurse) 
“No. Because they work too close with the governor and the officers.” 
“… If you’re looking for accommodation if you’re getting out, or a hostel or 
whatever, but you wouldn’t be able to sit down and talk about your problems 
with them or anything, you know what I mean. You couldn’t really talk to 
them. There’s no one, like, really there to talk to.” 
Some prisoners raised the possibility of integrating counsellors from outside: 
“But, I don’t think … I wouldn’t trust a counsellor in here either, girls, you 
know. Unless, unless … your one, whoever you have in your clinic would 
come in – you wouldn’t mind that. But I personally wouldn’t …” 
Also self help groups are not easily accepted in the prison setting. One of the 
basic problems is the lack of confidentiality surrounding the information 
given. 
“NA (Narcotics Anonymous) meetings … Twice a week, they’ve started now. 
… I think … Well, I used to go to it, but when you go to it there are people in 
the group and then what you’re saying they carry it all round, you know, and 
the girls talk about it. It’s not the same as the meetings on the outside, either, 
do you know what I mean. Some of the girls wouldn’t really want to be there 
and they’d be just messing a little bit.” 
Privileges (12 and 24 hour house) are only available for those who are stable 
on a methadone maintenance programme. Prisoners expressed that they feel 
disadvantaged against non-drug using women: 
“Like, I was in a privilege house. I got into a privileged house because I was 
giving clean urine. And, you know, there was people in the house who 
wouldn’t be on phy, like, they’d be just in it, you know what I mean … they 
weren’t on drugs, like, and the things that they could get in … It’s only little 
things, do you know what I mean, but they’d be allowed more things into the 
prison than I’d be allowed in, you know, you know what I’m talking about. 
Things that the addicts weren’t really allowed, just in case we were getting 
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drugs into the prison, d’you know what I mean. You know, you know stuff 
that you wouldn’t be allowed.” 
The fact that they are ex-drug users was obvious to the staff and the way in 
which individuals cope with addiction leads to privileges being granted or 
taken away: 
“That’s the only ammunition they have, is ‘You take drugs’, you know, that’s 
all they say, like, you know.” 
“Or ‘Is your urine clear now?’ You know, they know. They know anyway.” 
Prisoners requested greater integration into therapy modalities: 
“… whatever the patient feels themselves, you know. When they come, if they 
feel, like, ‘Well I’m on them so many years, so … you know, they should have 
the choice, like, I think, you know.” 
“Because it means if someone comes along with a bit of gear or whatever, 
you’d be more inclined to say, ‘Well, fuck it, give us it. I’ll probably get a 
sleep tonight with it.’ You know what I mean, so … you know, for that reason 
you would be tempted – just to get a night’s sleep. Because you do … you 
know … it is … you know … it’s mad.” 
Prisoners miss direct communication with the doctor himself/herself : 
“So I have asked, even last week to see the doctor, and the week before last 
week, and I’m still waiting. You know, like, I think even on my last sentence I 
saw the doctor the day I was committed and that was it. I haven’t seen her 
again since. It’s so hard to get to see the doctor in here. It’s unbelievable.” 
“… You know cell doors were open and you’d say, ‘Will you put my name 
down for the doctor.’ Now you need to be dying on your two feet. You tell a 
medic and they say, ‘What’s wrong with you?’ They have to decide whether 
you’re to see a doctor. Do you know what I mean?” 
“The nurse decides whether you are sick enough to see the doctor.” 
“But, if you say to the medic, whoever is giving out the medication the night 
before, if you say ‘I want to see …’ But, if I want to see a doctor I say it to 
the nurse or the medic and they say to me ‘Why, what’s wrong with you’ 
they’ll say to me, and I might not want to tell them what’s wrong with me. 
But you have to tell.“ 
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2.2 Wheatfield Prison 
2.2.1 Description of the prison  
Wheatfield Prison is a large prison for sentenced men (adjacent to Cloverhill 
in Dublin). The building consists of 20 living units that open off main spinal 
corridors. Each unit has 16 rooms designed for single occupancy and has its 
own day room for indoor association. Every room has its own washbasin and 
lavatory. The prison holds approximately 380 sentenced men. There are 
2 drug free units, one on the “protected” unit, one “ordinary”, each unit holds 
16 places. The drug free environment unit is open to all offenders who vol-
unteer to abide by the rules and regulations (Irish Prison Service 2002, 33f). 
One of the requirements is a contract between prison and prisoner to keep 
abstain from drugs. The unit is mixed 50:50 between former drug users and 
prisoners who have never been in contact with drugs. Successful stays are 
rewarded with some extra visits etc. The atmosphere is supposed to be more 
relaxed. The prison gets most of their inmates from Mountjoy Prison, at the 
time of the visit there were 45 lifers, the average age was 23. 
2.2.2 Goals and practical procedures of substitution treatment (access, 
rules, urine testing, provision on day leave, exclusion from the pro-
gramme etc.) 
At the time of visit (12th December, 2003), 75 prisoners out of 374 were on 
substitution treatment. The prison has two dispensing sites, one in the segre-
gated area and one in the ordinary prison. One half time doctor is responsible 
for the methadone treatment and the prison has more nurses than medical 
prison officers. It is aimed at replacing all “medics” by registered nurses. In 
total, there are 11 nurses and 3 medics who guarantee a 24 hour supervision 
of the entire health care provision. 
As in the female prison, many male prisoners have had extensive experience 
with benzodiazepines. According to the nurses, the problem is that many pri-
soner don’t see benzos as a problem and need to be taught about their highly 
addictive potential. Several interviewees said that the structured substitution 
programme was responsible for the absence of a chaotic situation regarding 
drug use and misbehaviour. According to the enormous use of opiates and 
other drugs before admission, and the experiences of many inmates with 
drug culture, substitution treatment constitutes a major factor in making the 
situation in prison more manageable in terms minimising disruptive and dis-
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ciplinary problems and self harm. Overall stabilisation takes lot of the pres-
sure with less aggressive behaviour. 
The prison could cope with more than 77 prisoners on substitution treatment 
but a lack of resources (nurses addressing any defaults, vaccination) makes it 
difficult. At the time of the visit, 10-15 prisoners would like to be on the sub-
stitution programme but the prison had reached its limits, especially regard-
ing accompanying services such as education work. Nurses reported that 
they got the feeling that prisoners who take the detoxification option would 
be better off under the maintenance option for physical reasons. 
The regulations for release and home leave have been improved recently and 
cooperation and community links have been placed on a broader and more 
strategic level. 
2.2.3 Views of prisoners – focus group in Wheatfield 
Four prisoners with several years of experience with prisons and different 
forms of substitution treatment (detoxification, maintenance) in and outside 
of prisons attended the focus group. The average dosage of the prisoners was 
65 mg. 
Prisoners in the focus group express their fear about detoxification of metha-
done in general and in the prison setting in particular. For this they complain 
about the lack of additional help. 
“You know. I’m on it now seven years. Had a try with coming off it, and …. 
And, like, anyone that wants to come off methadone, I think there’s just fear 
and the whole lot around it. I think people are just afraid of being sick when 
they’re coming off it. And I think that’s why it is … like, people don’t want to 
come off methadone because of the sickness. Because there is no other thing 
to cure the sickness … Because there is no other thing that will cure the 
sickness, like, that you’re going to go through. You know, something that 
would stop the sickness, you know.” 
“[If you were outside, you would probably find it easier, wouldn’t you?] Ah 
yeah, a lot easier. Because you’d be able to go out and you could buy a few 
sleepers and you could go through the withdrawal. Yeah. But in here, that’s 
why people are afraid to come off it because they don’t … like, what, you get 
one sleeper and that’s it. Like, one sleeping tablet – it’s not even a sleeping 
tablet it’s a relaxing tablet – and they give it to you and that’s it. ‘That’s it’, 
you’re told, ‘that’s all you’re getting’ and you’ll have to do without. There’s 
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people in here now are coming in on large amounts of physeptone and 
they’re getting handed the relaxer – there, that’s all we can do for you – and 
you’re on your way for the next six weeks to eight weeks, you’re on your 
tod.” 
In the prisoners’ views the development of pharmacotherapy in Irish prisons 
can be seen over the last eleven years: From a 3-day detoxification in 1992 
to 7-days after 1995 to three week detoxification and then to maintenance 
treatment in the year 2003. From this, it is clear that restrictions to access to 
substitution treatment have fallen away over time: 
“I had to go through it all. When I first went into XY-prison you used to get a 
three-day detox…thirty, twenty, ten, that was it.” 
“Between mid ’92 and ’95, yeah. You’d get a three-day. Then they changed 
the detox to … You used to get – what? – a seven-day detox then. It was 
brown the methadone – it was a brown phy that time. That was a couple of 
years later, it was a seven-day. After that again, I think it was three-weeks, 
wasn’t it?” 
“Say, ’95, 1995, we used to get, em, 60 mg of brown phy over a three-week 
period, you see, and it would reduce, gradually reduce, you know. But, and 
then, em, there was no such thing as maintenance programmes in prisons at 
that time.” 
“From back then, like, when I look at back then, a three-day detox. There 
was no such thing as maintenance programmes. The only people that were 
getting maintenance programmes were HIV prisoners, they were the only 
ones that were getting methadone treatment programmes.” 
“At the same time, the consequences become clear, if substitution treatment 
is only restricted to certain groups like HIV-positive inmates, they feel as 
outcasts.” 
“I’ll tell you what way you were- big white boiler suits, gloves, masks … and 
you’d be like a leper. There’d be a big long corridor from here to the end of 
the room and you’d have to walk out in your dizzle dazzle, you know. They 
didn’t know what … HIV was at that time.” 
Prisoners are very well aware of the fact that maintenance was only introdu-
ced a few years ago as a result of prisoners’ struggles: 
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“Everything outside about the maintenance is better than it is in here. Be-
cause they’re only learning in here … Like, it’s only all new here with them, 
do you know what I mean. They’re only starting to learn. They’re only star-
ting. It’s only here, it’s only out a few years, isn’t it?” 
“… Eighteen months, two years. Like people fought and fought and fought 
for maintenance and eventually people got it. But like there’s after being so 
many people overdosing and dying. People had to go to the extremes.” 
Despite the changes and developments, a heterogeneous situation of metha-
done provision can be observed throughout Irish prisons. Some prisons still 
do not prescribe any methadone. This obviously has consequences for the 
provision of substitution treatment in other prisons, as the inmate is not 
known to be on maintenance treatment. Prisoners have to struggle to get into 
the maintenance treatment again: 
“… when I got arrested I went to XX. So, I wasn’t offered anything even 
though I looked for treatment. I got no treatment, you don’t get methadone in 
XX Prison. … nothing whatsoever, not even a pain-killer.” 
“… So when I came out of that, I was after losing my maintenance then, 
d’you understand me? So I came from there to ZZ and I was looking for the 
maintenance and the doctor was trying to tell me that he never heard of me, 
you know what I mean. So, from 2000 … I got the maintenance programme 
in 2002 – that’s how long I was looking for it. Up here I eventually got it in 
2002. While I’d been in prison since 2000, but I only got it in 2002.” 
At the same time, prisoners knew that they have to be in the clinic in the 
community in order to ensure continuity of care.  
“Like I was on maintenance outside and I was told I wasn’t getting a main-
tenance when I came in to prison. You know, I was only on it for a couple of 
weeks before I came in.” 
To get into a treatment programme takes effort on the part of the prisoner: 
“He gave me the detox programme. While I was on the detox programme, I 
saw the methadone doctor and she told me, she was after telling me that 
there was a lot of red tape around my case and that when … no one actually 
wanted to put me on … no one actually wanted to start me. But when I was 
on the … well, she said ‘You’re on a maintenance now,’ she says, ‘I’ll sort 
you with the contract. And that was it, I got it from then.”  
“Now, I was fighting tooth and nail for this, for the maintenance pro-
gramme, and I was getting nowhere. I brought the Governor to court three 
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times with an application, a mandamus [a directive from a higher Court to a 
lower] … and, I don’t think I’m going to go there, but it was all … just 
refused anyway ….” 
 “… they said, ‘Look, get a letter confirming that and it’ll be taken up imme-
diately upon his release and he’ll be started straight away.’ … I was given a 
detox while we were awaiting the decision. So while I was on the detox they 
decided, seeing as the doctor put me on the detox, ‘I’ll keep you on it then. 
You’ll be a maintenance programme now.’” 
Prisoners try to reduce their dosage before release, because they don’t want 
to go to the clinics anymore. Obviously they see the clinics as a symbol of 
being a drug addicted patient. Prisoners anticipate the situation and tempta-
tions related to the provision of methadone in the local clinics. So it is not 
the treatment in the clinic itself the associations which are disliked: 
“I’m only after getting over it, like, ... I had it, like, for about six or eight 
months before I eventually, you know, copped on to it. And, anyway – diffe-
rent story. So, I’m after coming from the 90, I’m down to 30 mg now. I’m 
after detoxing down gradually and I’m on 30 milligrams now. … I want it 
myself. I done it myself. Because I want to be off it. I need to be out. I’ve 
eleven weeks left out of five years, so, you know what I mean, I want to be, 
I don’t want to be going to clinics. I want to be away from all that.” 
“I don’t know. I’m fed up with it. Like, I’ve no desire for heroin any more. 
I’ve no desire for heroin whatsoever. And I don’t want to spend the rest of 
my life on methadone. I don’t want to go to clinics outside. When I leave 
here I want to go and get my life together.” 
The prisoners expressed their wish to choose a certain treatment (here sub-
stitution treatment): 
“… prisoners should be offered maintenance programmes if they want it. 
Like, they can tell … the prison authorities can tell by a prisoner’s … 
everyone has a file … so they should know by the file if it’s a case … I think I 
speak for here, the majority of the group, you should be offered the choice if 
you want a maintenance programme or not, you know.” 
One prisoner observes that the decision of the doctor determines who is 
given treatment and, according to the prisoner, their views are not comple-
tely independent and reflect the Governor’s policy: 
“Like, in jail, in jail everyone … like there’s drugs … everyone knows. I’m 
not going to bring it up, but it’s open, it’s everywhere … there should be a 
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maintenance programme, and in your own … when you’re ready to come off 
it yourself, you know. Like, I know, I warned them ‘cause I … I needed that 
maintenance programme at the time because I was using heroin at the time 
and I was putting in all my mandamuses that I was at risk of contracting HIV 
and AIDS. But still, like, the Judge was saying he’s not going to over-rule the 
executive arm of the government, in other words the Governor or the ….  
And the Governor was telling me he can’t over-rule the doctor and the doc-
tor was telling me if the Governor says ‘Yeah’ that he’ll give it to me. Sure, I 
mean I was getting the run-around from Billy to Jack and I was getting now-
here. So, em, I got it in the end. But I think people, prisoners, should be 
offered it.”  
Prisoners expressed good intentions to stop using drugs when released with 
alternative personal strategies used to fight against the desire to continue 
drug use: 
“… I know, like, there’s been heroin around me all the time and I just … like 
the lads will tell you there, I’ve been, I’ve been swapping it for hash. Do you 
know what I mean. I just kept away …. I just want hash, that’s the thing, you 
know. Like, I don’t bother with the gear we bought. I could have a bag of it, 
the gear, in my pocket and it wouldn’t even tempt me to take it. Do you know 
what I mean.” 
Prisoners express their reservation against prison officers with training in 
health subjects (they call them “medics”) and feel they are not adequately 
treated. One critique is that the medical officer decides who does and does 
not see the doctor: 
“He came in and he seen so many people strung out and they were coming 
up and ‘Look, we’re looking for a detox, we’re not looking for a mainte-
nance, we’re just looking for a bit of help here.’ And the medics were ‘Look, 
get away, he’s only here, it’s his first morning, like. Get away from the door. 
I told you already, none of you will be seeing him.’ He was just picking and 
choosing who he wanted to bring in.” 
The role of the “medics” in the everyday life of the health unit is seen as 
very important. Prisoners express their fear of being excluded from treat-
ment: 
“The medics have a big say in it. The medics have a big say in whether 
you’re seen, and what goes on. Now, the doctor was going to start me down 
there on a maintenance programme, only for a certain medic turned around 
and said, ‘No.’” 
252 
 
“If I was arguing with a medic, without the doctor being there. Say you’re a 
medic, I’m a prisoner, that’s the doctor – the doctor’s not here. I argue with 
you and fall out with you; so you have a word with the doctor and I don’t get 
a maintenance.” 
Participants reported the consequences of positive urine controls; topping up 
methadone with benzoziazepines will lead to a reduction whereas cannabis 
in the urine will not be sanctioned. 
“If benzos are in your urine you get reduced on your amount … Everyone 
smokes hash.” 
“Anyone that’s on phy smokes hash. Everyone that’s on phy.” 
The sanctions depend on the individual case: 
“Don’t take that the wrong way. See the way this is, there’s no sanctions. 
Like, if the doctor wants it, if you give a dirty urine and there’s cannabis in 
it, if the doctor feels, like, right, he’s after giving… but the only odd dirty 
urines and we haven’t done anything like, and we’re grand now. Bring him 
in and we’ll tell him ‘Look, no more dirty urines, any more cannabis urines, 
and you’ll be cut. But they don’t mind up here. The cannabis is the, like, the 
way they look at it is that cannabis is … it’s just cannabis. It’s recreational. 
You don’t have to go down and cook it up and stick it in a needle or any-
thing; you don’t have to stick it on tinfoil and smoke it, smoking a roll. And 
the officers don’t mind it.” 
“… if it’s coming from your urine, they don’t bother. It goes on, they know it 
goes on.  If it’s in your urine… you haven’t got it in your hand.” 
The outspoken sanctions vary considerably regarding the additional use of 
benzodiazepines. 
“You get a punishment. You’re cut.” 
“…If you’ve taken it on a visit, you’ll have no visits for two months.” 
The participants understood and supported the messages that prison staff 
send out regarding the dangerous effects of constant use of benzodiazepines: 
”… there are no strict sanctions on cannabis, but every other drug there is, 
you’re not allowed, you’re not allowed. Anything like a stimulant, say, any-
thing from cocaine, tablets, from speed to, like, any barbiturates, any benzos 
– they’re not allowed. You get severely punished. Which, which is right, like, 
you know what I mean. But, at the end of the day, it’s stops. It’s better here, 
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that’s why … I’m only realising it now, like. If I was here twelve months ago, 
I’d be saying ‘Fuck that, we should get, we should get both, we should get 
…’ you know what I mean. But now I know, like. Now, but don’t get … in 
here when you’re coming off the methadone, the only thing I’d suggest is 
that, like, I know they’re saying to you, ‘Them drugs are barbiturates, 
they’re highly addictive.’” 
“Now they’re afraid to give them out. They don’t like to give them out, 
Roach, when you’re on a maintenance programme for the simple reason 
being it’s very dangerous. You could be like, what, choke on your own vomit 
or anything, like. There are too many people dying on it.” 
Prisoners are frank about the dosage of methadone provision and discuss that 
high amounts of methadone are not needed. 
“When you’re on methadone here, you know when they put you up to a cer-
tain amount, right? Like, see all that – 90 and 110 mg, that’s bullshit, people 
don’t need that, you know what I mean. That’s greed, that’s the drug 
companies.” 
Respondents point out that, according to their fears or experiences, they have 
to behave well and avoid any insults or other misbehaviour, otherwise they 
feel they are sanctioned around their substitution treatment. 
“They have you over a barrel, you see. You can’t mess, you can’t give any 
trouble. You’re on your best behaviour because they’ll shift you down to 
Cork and you’ll get no phy and you’re just left in a cell …” 
“The way it works is, if you abuse a medic or a nurse up here, now. If I was 
to go out there and, say, they were calling me for my phy and I was sitting 
here and talking to you and I went, ‘Will you fucking wait for a minute.’ 
You’d be told, ‘Right, that’s it.’ Bang. ‘Close that door. Forget about him. 
Leave him there.’ And, like if you’re five minutes late and that, if that sur-
gery closes, you won’t get it that’s it with your phy, you know. You may do 
without it for a day.” 
Prisoners point out that the supervision of intake needs more attention so that 
other prisoners, who know about the provision of methadone, wont them 
under pressure to get the prescribed drug8. They make clear that different 
staff groups apply a different practice (e.g. nurses and “medics”). 
                                                          
8  see also Ó Loingsigh 2004, p. 14. 
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“They weren’t supervised because, like, because there was people like that 
were on meth or physeptone, … and there was people that were strung out 
and they were coming over and, like, saying, like, ‘Give me your phy.’ You 
know what I mean. And these were only kids, like, coming in, strung out to 
bits, like, strung out on heroin. That’s their first time in prison, and they’re 
getting their phy took off them. And the medics are standing there watching 
it.” 
“The nurses, like, now, they make sure you take your phy. With the medics, 
like, the medics …they don’t care. When the nurses give you your metha-
done, you drink your methadone, you don’t walk away. You’re asked your 
name, your date of birth, where you’re from and where you’re going. They 
try and have a conversation with you when you’ve finished drinking your phy 
– just like they know it’s gone.” 
Prisoners doubt the guarantee of confidentiality within the treatment process 
on an every day basis. 
“… see the medics that wear white, like these are prison officers, like they 
are prison officers. Like, at the end of the day they go off at the end of the 
day with the prison officers …and talk … They’re sitting down in the pub, 
‘Ah, wait till you hear about ((prisoner’s name)) today, Ah yeah, like.” 
3 Summing up 
In recent years, enormous improvements have been achieved around the 
broad introduction of methadone maintenance in prisons. In some instituti-
ons, the options (detox vs. maintenance) are offered to opioid dependent 
inmates. Although a lot has changed since 2000, the coverage of substitution 
treatment is (i) patchy throughout Ireland (there are several regions and pris-
ons who do not prescribe at all) and (ii) is completely dependent on the 
advancements of this services in the community. Although the latter cannot 
be changed in the near future, the Irish Prison Service acknowledges the 
need to expand substitution treatment to all prisons in Ireland. This is de-
manded by the patients and recommended by scientific experts and NGOs9. 
Prisoners express their wish to be allowed to decide whether to have detoxi-
fication or maintenance treatment. 
                                                          
9  See Irish Prison Reform Trust & Merchants Quay Ireland (2002): A Call for Action: HIV/ 
AIDS and Hepatitis C in Irish Prisons, p. 6; see also Ó Loingsigh 2004, p. 14. 
 255 
 
Furthermore, the Irish Prison Service identified the need for more resources 
in terms of doctor hours and registered nurses who could replace the medical 
prison officers. At least in the Dublin area, community links with all invol-
ved in drug treatment are institutionalised via a special group10, which is 
about to focus on substitution treatment. Staff training programmes, designed 
to enhance and further the professionalism of Prison Officers involved in 
interpersonal work with prisoners undergoing drug treatment, are delivered 
by a specially appointed ‘Assistant Training Officer’ (Irish Prison Service 
2002, p. 34). 
Different policies were applied regarding the toleration of cannabis and ben-
zodiazepines on several levels (i) between prisons (those two visited) and (ii) 
between the community and prison. This leads to different consequences in 
the two prisons visited. In the men’s prison educational work on the addic-
tion potential of benzodiazepines has begun and seems to be successful. 
For the Irish Prison Service a manual has been elaborated as a practical guide 
to all involved in substitution treatment (Methadone Treatment. Programme 
Guideline for the Irish Prison Service). 
                                                          
10  Special linkage group, the Prison Community Drugs Liaison Group, established in 2001 
(see Irish Prison Service 2002, p. 34). 
  
Italy1 
1 General data:  
Drug use, substitution treatment and prison population 
1.1 Number of drug users (and type of drugs used) 
It is estimated that there are 155,096 drug users in the country. (Year Report 
for 2002 to the Parliament on Drug Addiction in Italy by the Welfare Minis-
try). EMCDDA (2003) reported that in 2001/2002 there were 86,778 persons 
in substitution treatment in the country. About 40,000 to 50,000 drug using 
prisoners are supposed to pass through the prison system every year. On 
31 December 2001 there were 15,442 prisoners assessed as having a drug 
problem, representing 27.9% of the total adult prison population on that date. 
(Reitox Italy, 2001) On 31 December 2001 12,019 people (i.e., 22.8% of all 
prisoners for non-drug law offences: 17.9% Italian and 4.9% non-Italian) 
were assessed as drug users and held in prison for non-drug law offences. 
(Reitox Italy, 2001) 
It is estimated that there are 1860 prisoners are on substitution treatment in 
prison on a given day (31 December 2003, www.giustizia.it/statistiche dap 
2003) and approximately 5000 a year. 
Surveys show that alcohol, tobacco and cannabis consumption remain com-
mon. Although heroin is the most problematic drug used, evidence shows 
that the use of heroin as primary drug has decreased and that heroin is 
increasingly sniffed or smoked. Cocaine use has increased to become the 
second mostly used illegal drug after cannabis. It is estimated that in 2001 
there were 233,075 to 279,820 of heroin users. Regional variations are 
reported: cannabis and cocaine being available throughout the country, but 
amphetamine and ecstasy being predominantly offered in the northern and 
central regions. LSD use remains rare. (Reitox Italy, 2001) 
                                                          
1  The field visit, conducted by Laetitia Hennebel, was facilitated by Dario Foa for the Milan 
area, and Susanna Falchini for the Florence area; who provided support with the writing of 
the report. 
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1.2 Substitution Treatment 
Data comes from interviews and on-going review of research reports, web-
sites and laws/ regulations. 
1.2.1 Historical and legal background 
Within Italy treatment services are provided either by the National Health 
Service managed drug treatment programmes – the Servizi Tossicodipen-
denti (Ser.T) or Drug users Service – or by private, not for profit organisati-
ons. In 2000 there were 555 Ser.T throughout Italy and 1,335 socio-rehabi-
litative structures. Staff in Ser.T. are mainly doctors and nurses, with some 
psychologists and social workers. (Reitox Italy, 2001) 
Substitution treatment in Italy is almost exclusively provided by the Ser.T. 
(Reitox Italy, 2001). Substitution treatment was regulated with the D.M. of 
7 August 1980 (Health Ministry Decree) regulating the ‘Discipline of the use 
of preparations with analgesic-narcotic action in the treatment of drug-
addicts”2, followed by the article D.M. 10 October 1980 regulating the ‘Use 
of basic preparation of methadone and morphine for the treatment of drug-
addicts’3. 
Article D.M. 23 October 1985 revoked the authorization for the experimental 
use of morphine in the treatment of drug-addiction, resulting in having 
methadone as the main treatment for addiction to opium-based substances in 
Italy. 
The D.P.R. (Republic President Decree) 309/904 concerns the ‘collection of 
laws concerning the discipline of narcotics and psychotropic substances, 
prevention, care and rehabilitation of the corresponding conditions of drug-
addiction’ and states that: 
− The Department of Health is in charge of identifying individuals with a 
habitual use of narcotics (precondition needed for substitution treatment), 
                                                          
2  D.M. of 7 August 1980 Regolamento dell’impiego di farmaci ad azione analgesico-narco-
tica nel trattamento dei tossicodipendenti. 
3  D.M. 10 October 1980 Impiego di preparato di base di metadone e morfina per il tratta-
mento dei tossicodipendenti. 
4  The D.P.R. 309/90 Testo Unico delle leggi in materia di disciplina degli stupefacenti e 
delle sostanze psicotrope, prevenzione, cura e riabilitazione dei relativi stati di tossicodi-
pendenza. 
258 
 
and of giving instructions for diagnostic, care and medico-legal procedu-
res to these identified individuals. 
− The National Health Service managed public treatment services (Ser.T.) is 
in charge of defining the therapeutic treatment programme using substitu-
tion treatment, and of setting up the treatment modalities (mode, dosage, 
duration, check-up method). 
There has been an increase in the number of Ser.T.’s patients receiving a 
substitution treatment resulting in over 50% of Ser.T.’s patients (excluding 
prisoners) receiving a methadone treatment (in 2000). Although the empha-
sis has been on prevention and abstinence and thus a detoxification-basis 
treatment, there has been an increase in long-term methadone maintenance 
(longer than 6 months) and a decrease in short-term treatments. Prescription 
of substitution treatment varies largely from one region to the other. (Reitox 
Italy, 2001) 
There is no single model, set of guidelines, or good practice for substitution 
treatment in Italy. The Guidelines for Harm Reduction Interventions (Minis-
try of Health) state several different objectives of substitution treatment as 
(i) drawing and retaining patients in a treatment centre, (ii) harm reduction, 
and (iii) offering stability for interventions towards abstinence. Variances 
occur locally where different objectives are aimed. As with the objectives, 
there is little data about the criteria for admission into a substitution treat-
ment. Medium length treatment is defined as 3 to 6 months, whereas long 
term is defined as over 6 months. (Reitox Italy, 2001) 
A document was drawn further to the consensus conference held in Milan on 
1 February 2000, organized by the A.S.L. (local health centre) of the city of 
Milan and the prison San Vittore (in Milan), stating intervention guidelines 
for the provision and initiation of the methadone treatment in prison. 
The funding of treatment services for drug users comes from the general 
allocation to Regions for all health care provision, as well as from local 
taxation and from projects financed through the National Drugs Fund. Regi-
ons have autonomy in the provision of health care services, which are defi-
ned according to the local needs. (Reitox Italy, 2001) 
1.2.2 Substitution treatment in prison 
The development and provision of substitution treatment in prisons started 
with the D.P.R. 309/90, which was generally unapplied (for the treatment of 
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sentenced prisoners) until 2000, when the Legislative Act 230/99 became 
effective and all the duties, the responsibilities and the personnel of the drug 
services in prison were delegated to the National Public Health Service 
A.S.L. 
The treatment of drug and alcoholic addicts in prisons is regulated by Presi-
dential Law 309/90, which brings together the norms contained in Law 
No. 685/75, Law Decree No. 144/85, Law Decree No. 103/88, the Penal 
Procedure Code and Law No. 162/90 (Galetto et al, 1999). 
Article 29 of Law 162/90 provided for assistance in the prison and states 
that: ‘The Local Health Units, in agreement with the penal institutes and in 
collaboration with the Health Services within these institutes, should provide 
care and rehabilitation services for drug and alcohol addicted prisoners.’ 
Health care in prison is provided by the Penal Health Service (Prison admi-
nistration, Ministry of Justice), except for the care of drug users, which is 
provided by the Public Health Service (Ministry of Health) through the 
A.S.L. The Local Health Agencies, in collaboration with the Prison Health 
Service, are responsible for providing prevention programs and multidisci-
plinary rehabilitation and care services. They carry out awareness campaigns 
in the prison, prepare the individual treatment programs, and act as interme-
diaries between the operators in the Treatment Centers (auxiliary agencies – 
Art. 114) and the Ser.Ts, which have territorial jurisdiction for the prison in 
question. The Director of the Institute must act as “guarantor” for all the ac-
tivities Ser.T carries out in the prison and ‘do his best’ to implement these 
activities (informing new prisoners, etc.) (Galetto, 1999). 
The legal frame of substitution treatment in prison is provided in the D.M. 
445/90 ‘Discipline concerning the determination of the limits and the mode 
of usage of the substitution preparations on the treatment programmes of 
drug-addiction stages: first directives5. With the circular number 20, dated 
30 September 1994, the Health Department promulgated some guidelines for 
the substitution methadone therapies. Some Italian regions further defined 
the guidelines and the legal norms for the use of substitution treatment; for 
instance, the region Lombardy, which on 30 March 1995 produced the delib-
eration of the Regional Committee number 5/65411. This allows for substi-
                                                          
5  D.M. 445/90: ‘Regolamento concernente la determinazione dei limiti e delle modalità 
d’impiego dei farmaci sostitutivi sui programmi di trattamento degli stadi di tossicodipen-
denza – prime direttive’. 
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tution methadone therapies to be offered inside prison further to specific 
rules by the Ser.T and the prisoner’s informed consent. 
The main substance of substitution treatment is methadone. Buprenorphine 
has only been recently 2002 initiated in the country. The prescription of 
other psychopharmacological drugs such as benzodiazepines is not advisa-
ble. The national and regional guidelines provide two different schemes for 
urine analysis, which are however not applied. Methadone is provided daily 
and is carried out by a professional nurse on the basis of a doctor’s instruc-
tions. 
There are no evaluation studies available about methadone treatments in pri-
son. The protocol of Professor Icro Maremmani’s for substitution treatment 
is used in the Lombardy area: ‘Manual of the Ambulatory Treatment with 
Methadone’ (‘Manuale del trattamento ambulatoriale con metadone’). The 
procedure of the substitution treatment was certificated only by the A.S.L. of 
the city of Milan in 2000. 
The general aims of the substitution treatment in the Italian prisons mainly 
concern health stabilisation. Substitution treatment is limited to the biggest 
institutions and prisons, with differences from one region to another. Treat-
ment options essentially focus on detoxification, and in very few prisons 
focus on maintenance and initiation of substitution treatment starting in pri-
son. The Ser.T is the external centre involved with substitution treatment, 
which is part of the whole strategy of the drug services. 
The decision to initiate a substitution treatment in prison is made by a doctor. 
The most relevant clinical criterion is the evaluation of the withdrawal de-
gree through a medical check-up and the scale of Wang (BUR Lombardia, 
July 22, 1995, n. 29). Before the beginning of the treatment, the patient is 
asked to sign a contract ‘Informed consent to the methadone treatment’, 
which underlines the problematic side of substitution treatment in prison, 
such as anonymity, daily practical problems, topping up drugs, etc. 
To continue substitution treatment in prison (initiated prior to incarceration 
in the community) contact is established with the community doctor for offi-
cial confirmation of the prisoner’s programme (duration, dose). 
Prisoners transferred to another prison will continue their substitution treat-
ment if the treatment is available in the new prison. If so, the ‘File-card’ with 
details on the methadone treatment is transferred to the new prison and the 
treatment can be continued. The same procedure applies for prisoners trans-
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ferred from remand to sentenced prisons. In order to continue substitution 
treatment after release, contact must be established prior to release with a 
competent Ser.T.; the request and plan to continue the treatment after release 
is sent by fax to the relevant Ser.T. 
The general attitude of the prison staff is not particularly in favour of substi-
tution treatment because of the apprehension for overdose due to prescribed 
medicines being topped up by smuggled drugs and alcohol. 
The methadone treatment has always produced controversies. Even though it 
was widely employed in the community, a great number of organizations, in 
particular the therapeutic communities underlined that methadone can create 
new ‘addiction’ and not heal previous dependence. That attitude seems to be 
resumed at present thanks to the governmental political forces, which 
emphasize more drug free treatment. The main objection in prison concerns 
the initiation of methadone treatment rather than a long-term maintenance 
methadone treatment. The argument against the initiation of methadone 
treatment in prison lies within opposition to certain harm reduction policies 
from the Ministry of Justice without the promotion of alternative evidence 
based approaches. 
Substitution treatment in prison is paid for by the A.S.L., covering expenses 
related to staff, doctors, nurses, and laboratory analysis. 
Psychosocial care and training 
Prisoners in substitution treatment do not receive specific psychosocial care. 
If the treatment is inserted into a global therapeutic programme, then there is 
a systematic link between the doctor/ nurse and psychologist/ educator. 
However, the psychosocial support is offered on a voluntary basis and avail-
able to all (not just substitution treatment patients). (Reitox Italy, 2001) 
There is no specific training on substitution treatment offered to prison staff 
as training for professionals depends on individual regions and local health 
authorities (Reitox Italy, 2001). Professionals working in Ser.T tend to be 
specialised in drug issues and treatment of drug use. Although a few have 
acquired this specialisation through training as part of or after their vocatio-
nal training, the majority tends to learn while working with drug users. 
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1.3 Prison Population 
Table 14  Data on the prison situation in Italy (Source: King’s College London, International 
Centre for Prison Studies, Prison Brief for Italy) 
Country  ITALY 
Ministry responsible  Ministry of Justice 
Prison administration  Department of Prison Administration 
Contact address  Largo Luigi Daga 2, I-00164 ROME, Italy 
Telephone / fax / website  
tel:  +39 06 66 59 13 21 
fax: +39 06 66 16 51 39 
url:  www.polizia-penitenziaria.it 
Head of prison administration (and 
title)  
Giovanni Tinebra  
Head of the Department of Prison Administration 
Prison population total (including pre-
trial detainees / remand prisoners)  56,761 at 1.9.2003 (national prison administration)  
Prison population rate (per 100,000 of 
national population)  
99 based on an estimated national population of 
57.4 million at mid-2003 (United Nations)   
Pre-trial detainees / remand prisoners 
(percentage of prison population)  20.9%  (1.9.2003)  
Female prisoners (percentage of prison 
population)  
4.4%    (1.9.2002 – plus 40 females in juvenile institu-
tions)  
Juveniles / minors / young prisoners 
incl. definition (percentage of prison 
population)  
0%       (1.9.2002 – under 18, but 461 are held in juvenile 
institutions)  
Foreign prisoners (percentage of prison 
population)  30.1%  (1.9.2002 – plus 231 in juvenile institutions)  
Number of establishments / institutions 
205       (31.12.2001 – 163 remand prisons, 34 institutions 
for the execution of prison sentences, 8 institutions for the 
execution of security measures – plus some penal 
institutions for juveniles)  
Official capacity of prison system  41,798   (1.9.2002 – plus 622 places in juvenile institu-tions)  
Occupancy level (based on official 
capacity)  
134.5%  (1.9.2002 – 74.1% occupancy in juvenile 
institutions)  
Recent prison population trend (year, 
prison population total, prison 
population rate)  
1992      46,152      (81) 
1995      49,642      (87) 
1998      49,050      (85) 
2001      55,136      (95) 
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2 The field visits6 
Time frame. The field visit took place at the end of June 2003. 
Location. Visits were conducted in two prisons: San Vittore Prison (in 
Milan) and Soliciano Prison (in Florence). 
Map of Italy 
                                                          
6  Methodology. Interviews were conducted with the individuals in and out of prison in the 
Milan and Florence areas. Four focus groups with a total of 28 prisoners were also con-
ducted. The tape-recorder was used with 3 out of 4 focus groups. The researcher conducted 
all interviews/ focus groups on her own, accompanied by a freelance and neutral inter-
preter. All participants were briefed and told about ethical issues. 
Soliciano Prison 
(Florence) 
San Vittore 
Prison 
264 
 
2.1 San Vittore Prison7 
2.1.1 Description of the prison 
San Vittore Prison, built in 1878, is a remand prison located in the centre of 
Milan. Due to overcrowding, it also holds sentenced prisoners. At the time of 
the visit there were 1 321 prisoners, of which 126 female prisoners (held in a 
separate wing), for a total capacity of 800. The prison population counts 
around 50% foreigners, mainly illegal immigrants. 
The prison has 6 wings, of which one is for female prisoners (with only 
female guards) and one is for ‘El Nave’ (the ship) where specific rehabilita-
tion and reinsertion projects for drug using prisoners are offered. La Nave 
was created in January 2002 and has a capacity of 43 but at the time of the 
visit held 38 prisoners for sentenced and remand prisoners. It is a ‘special’ 
section of the prison where prisoners who have shown good behaviour and 
progress have access to psychosocial support, cultural, artistic, leisure and 
computer classes. Benzodiazepines prescriptions are not allowed in this sec-
tion, but prisoners can be on a substitution treatment. At the time of the visit, 
4 prisoners of La Nave were on methadone and 4 on buprenorphine. 
2.1.2 Goals and practical procedures 
It was reported that a consensus of treatment and guidelines of ASL are used 
by the prison and the ASL specifying the dose of substitution treatment and 
benzodiazepines. This clarifies the provision of health treatment and facili-
tates the collaboration with the prison staff.  
It was reported that substitution treatment (buprenorphine and methadone) is 
mainly provided as a detoxification treatment and is delivered by the medical 
team of the ASL. Doctors working in prison for the Ministry of Justice do 
                                                          
7  Data comes from interviews conducted with: 
– The prison governor 
– A GP and director of the Penitentiary Area Service for the ASL  
– A psychiatrist, ASL 
– A GP, ASL 
– A psychologist and criminologist, in charge of the clinical and treatment aspects at  
‘La Nave’ 
– A psychologist 
– A counsellor, ‘La Nave’ 
– A guard, head of section. 
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not provide the treatment. On the whole, drug users are under the care of the 
ASL and not the Ministry of Justice or consultant psychiatrists. 
At the time of the visit, there were 125 prisoners on substitution treatment of 
which 15 women and 40 foreigners (such as from North Africa). 
After medical examination, the treatment is provided on a continuation basis 
for prisoners who started the treatment prior to incarceration. The treatment 
may also be initiated in prison after medical examination. In general, substi-
tution treatment is provided towards detoxification. However, for some 
cases, it may be provided as a maintenance treatment when doctors estimate 
that such treatment is necessary; a link is created with external services in the 
community to ensure the prisoner can continue her treatment once released. 
Some prisoners on substitution treatment only stay in prison for a short 
period of time and are then transferred to a SerT centre in the community. 
When transferred, the prisoner’s medical file follows. 
Substitution treatment is often initiated in prison for illegal immigrants. 
However, such treatment cannot be continued once they are released since, 
having no papers, they are not entitled to health treatment in the community. 
Therefore, such prisoners are usually given a detoxification treatment. 
Methadone is provided on a daily basis in a liquid form. The intake is easy 
and easily controlled; and the doses can be reduced easily. The starting dose 
is usually 20 mg on the first day and is often increased the following day 
after medical examination to 40 mg. This dose is considered as sufficient to 
stop any withdrawal symptoms. However, if the prisoner needs more, his/her 
dose will be increased. An individual approach is provided to all prisoners. 
Buprenorphine is not well known in prison and in the community. The 
supervision of the intake is more difficult and sometimes not fully supervised 
by nurses who do not wait until the pill has dissolved in the prisoner’s 
mouth. It was reported by the doctor that buprenorphine is provided in a 
powder (sub-lingual) to avoid any type of traffic. Because its effects are slo-
wer than methadone, the doctor said that prisoners tend to favour methadone 
to buprenorphine. 
It was reported that nurses distribute substitution treatment first to those who 
work or who need it urgently (for instance, those with physical or psycholo-
gical specific problems); then, nurses distribute it to male and female priso-
ners in the morning. There is no specific time and depends on nurses’ avail-
ability. 
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In the COC area nurses set a table on 1st or 2nd floor. The guard opens the 
cell (one at a time) – guards therefore see which prisoners are on ST  
(NO medical secrecy). 
Guards are asked to cooperate and work with discretion with the medical 
team. Nurses distribute the substitution treatment; a GP is always nearby in 
case of health issues arising from the intake of the treatment. GPs and nurses 
therefore work together as a team. Guards are involved to ensure security 
and protection of nurses. Guards may be asked to interfere when prisoners 
put pressure on nurses for higher methadone doses. Guards take part in team 
meetings with the medical staff and tend to be informed on prisoners’ health 
situation. The medical staff believes that it is important to include guards in 
the substitution treatment process. Nurses who provide substitution treatment 
tend to be willing and sensitive to drug issues. A guard reported that a desig-
nated guard works with the nurse for the distribution of substitution treat-
ment and makes sure the dose is taken and no traffic occurs. He further said 
that guards are not reluctant to substitution treatment since methadone helps 
to manage, stabilise and calms them down. 
Prisoners are given clear information (verbal and leaflet) and a contract when 
getting on a substitution treatment in prison. 
The governor stated that he was in favour of substitution treatment because it 
helps to stop and reduce withdrawal crisis; it can also be provided as a deto-
xification or maintenance ‘therapy’, or as an alternative to benzodiazepines, 
which are subject to a lot of traffic in prison. 
Advantages and disadvantages of substitution treatment 
Medical staff reported that they were very pleased with the provision of sub-
stitution treatment, which is working well. The advantages reported for sub-
stitution treatment are that it helps to stabilise the individual. A doctor 
reported that the advantage of methadone treatment is that it facilitates deto-
xification. A psychologist stated that she was in favour of substitution treat-
ment because it stabilises prisoners’ mood and balance. However, specialists 
are needed to manage the follow-up and it may be difficult to know how to 
process the dosage, when the dose is too high, when to decrease, etc. 
A counsellor reported that she is not in favour or against substitution treat-
ment. She said that it depends on how and where the treatment is provided 
and distributed, whether the prisoner takes other drugs or not. She stated that 
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methadone is a very serious medicine and is often not taken seriously in pri-
son. Because San Vittore is a large prison, it is difficult to follow and 
respond to all individual differences and needs. Moreover, there are misun-
derstandings and illusions from prisoners as regards to substitution treat-
ment. 
The disadvantages of the methadone are linked to the possibilities of traffic, 
which occurs in prison as well as in the community. 
It was reported that various issues must be taken into account when deliver-
ing substitution treatment. 
(i) Nurses are often over-qualified for a job that is limited to the provision 
or distribution of methadone. Costs to employ these nurses are high 
when methadone could be delivered by an ‘assistant nurse’ (operatore 
santaria) who could be specifically trained for the delivery of the treat-
ment. A more motivated and human approach may be accepted from 
such staff. 
(ii) An evaluation and validation as well as scientific criteria and guidelines 
regarding the transfer from buprenorphine to methadone (or vice versa) 
is needed. 
(iii) Acupuncture as a complement to substitution treatment should be of-
fered as it reduces craving, the desire and need for benzodiazepines, 
smoking, drugs and treatment. 
(iv) The use of substitution treatment should be defined and not widely pro-
vided with no objectives in mind. Abstinence is the best end-goal but 
each case, individual needs and differences must be taken into account. 
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2.2 Soliciano Prison (Florence)8 
2.2.1 Description of the prison 
The Prison Soliciano, built in the 1980s, is a remand prison (with about 25% 
of sentenced prisoners), that holds about 850 prisoners of which about 70% 
are foreigners (the majority are illegal immigrants and mostly come from 
Morocco and Algeria). The prison is mainly for male prisoners, although it 
has a separate wing for female prisoners. 
The prison is located in the city of Florence. Next door is the prison Gozzini 
that acts as a reinsertion alternative sentence area for 50 detoxed prisoners 
who have had a problematic substance use. 
2.2.2 Goals and practical procedures 
Substitution treatment is provided by the SerT centre. The SerT is located in 
one wing of the prison and does not have access to the whole prison. The 
SerT counts 3 GPs, 2 nurses, 2 social workers and 4 psychologists. There is 
also collaboration with the guards and the prison health centre. Prisoners are 
escorted by guards to the SerT centre for health care. After the medical eva-
luation conducted at prison entrance with all new prisoners or upon self 
report, any prisoner said to be or to have been a drug user is sent to the SerT 
as drug users are taken care of by the SerT. A guard reported that sentences 
are shorter and less severe for drug users: prisoners always try to play on this 
and declare themselves as drug users. 
                                                          
8  Data comes from interviews conducted with: 
– The assessor of social policy for the Tuscany Region. 
– A judge of the application of the sentence, Youth Tribunal Florence. 
– The governor of the Gozzini prison, Ministry of Justice. 
– The medical doctor and expert on drugs and substitution treatment in prison, SerT, 
Ministry of Health. 
– A social worker, SerT, Ministry of Health. 
– A nurse, SerT, Ministry of Health. 
– The chief doctor, manager of the Health Care Team, Prison Service, Ministry of Justice. 
– The educator, manager of the Team for prisoners’ social activities, Prison Service, 
Ministry of Justice. 
– A Psychologist, Prison Service, Ministry Justice. 
– A prison officer, Ministry of Justice. 
– A pedagogue, NGO ‘CEIS Firenze’. 
– Officer of the Probation Service, Ministry of Justice. 
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A prison staff reported that one third of all new entrants are drug users, 
although the actual figure may be higher. Support and treatment can be offe-
red to prisoners who declare themselves as drug users on arrival or at a later 
stage. However, a prisoner who hides his drug use is likely to go through 
withdrawal without the SerT’s support and at best with the prison psycholo-
gist’s support. 
The two substances used for substitution treatment in prison are methadone 
and buprenorphine, although the latter was only introduced 2 years prior to 
the field visit and is only offered to prisoners on a buprenorphine treatment 
prior to incarceration and is thus not initiated in prison. The maximal dose of 
buprenorphine is 24-32 mg. 
At the time of the visit, out of the 40 prisoners consulting the SerT centre, 
one received buprenorphine on a continuation programme started outside 
prior to incarceration. The doctor reported that this prisoner was very young. 
He was incarcerated for the first time and is not content about ‘getting clean 
soon’. Approximately 45 prisoners received methadone at the time of the 
visit: 40 men and 5 women. 
It was reported that prisoners on a methadone treatment prior to incarceration 
continue their treatment while in prison but on a smaller dose than that offe-
red outside and usually on a detoxification basis. Outside, doses are higher 
(100-120 mg) and maintenance is provided, whereas in prison it is not as 
methadone is mainly used to reduce withdrawal symptoms and for detoxifi-
cation. New entrants may receive a maximum of 50 mg of methadone (and a 
maximum of 35 mg on the first day). A higher dose may be provided if they 
need more, although the focus is on managing withdrawal symptoms and 
craving. 
Each prisoner has his own treatment programme. Although a doctor reported 
that it can be a struggle to decrease the dose, some prisoners ask for a detoxi-
fication programme themselves. Some prisoners ask for a slower decrease  
(1 mg every 2-3 days). The decrease is a maximum of 2 mg every day. The 
rule of thumb the SerT uses is to decrease 1 mg every day and do a pause of 
3-5 days every 5 mg. 
The nurse reported that although substitution treatment is given mainly as 
detoxification – and not as maintenance – the GP decides when to decrease 
or stabilise the dose on individual cases. The methadone dose is not decrea-
sed for HIV prisoners. 
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Methadone comes directly from a pharmaceutical company located nearby. 
Methadone orders are managed by the ASL. Methadone is prepared in bott-
les. The nurse prepares the doses for each prisoner and writes the name of 
the patient on each bottle. Designated and trained guards bring prisoners in 
groups (around 8 at a time) to the SerT unit for substitution treatment. One 
prisoner at a time enters the nurse office where his treatment is given in the 
presence of the GP, the nurse and a guard. The latter controls the prisoner 
while the GP and nurse focus on providing health care. 
A prisoner on a substitution treatment is usually not transferred to another 
prison. If he is, the SerT will communicate his treatment details to the SerT 
of the new prison. 
There are no reported cases of overdoses of prisoners on substitution treat-
ment. 
During the night and over the weekend and holiday, the SerT is closed. The 
Prison health service takes over and covers for the SerT ensuring that new 
prisoners arriving at the prison when the SerT is closed are taken care of, 
although substitution treatment is only provided by the SerT. 
Advantages and disadvantages of substitution treatment 
A social worker reported that substitution treatment acts as a means to attract 
prisoners to the SerT centre and to discuss a rehabilitation project. It was 
reported that substitution treatment has a tranquillising effect and allows pri-
soners to gradually reach abstinence. A nurse stated that substitution treat-
ment allows a special contact and relation-dialogue to develop with prison-
ers, and allows for the treatment of infectious diseases. The nurse also said 
that substitution treatment helps prisoners to overcome the detoxification 
phase more easily and with less pain. The educator stated that methadone 
maintenance gives him some of his ‘dignity’ back and methadone allows 
ending the use or misuse of drugs. A doctor reported that the number of 
overdoses has been decreased with substitution treatment and prisoners’ 
quality of life has improved. 
Further advantages were reported by a GP. Foreign prisoners have no access 
to SerT outside the prison, but they do in prison. They can receive metha-
done for the first 10 days of incarceration to help with the detoxification pro-
cess. Moreover, substitution treatment is a link to bring prisoners to the SerT 
and create a contact with the SerT outside as it encourages them to consult. 
 271 
 
Once released, there is a higher chance that they will visit a SerT, which they 
have often never done. Finally, substitution treatment allows for clinical 
intervention and thus for the prevention of infectious diseases. Prisoners used 
to be reluctant to engage into health treatment, whereas now they are not and 
they tend to agree to have a health examination, even for HIV. 
SerT staff reported that the disadvantage of substitution treatment is that 
there is a strong link between the prisoner and the substance and a certain 
dependence towards the SerT centre and staff, which limits the autonomy of 
the choices. There is a kind of ‘maternity’ from the SerT and a habit (and 
dependence) from consulting. Once a prisoner has finished his substitution 
treatment, he no longer visits the SerT centre and may find this interruption 
disturbing. When a substitution treatment is finished, the SerT conducts a 
check up once a week for one month, and then once one month after the end 
of the treatment. The prisoner’s health care is then transferred to the prison 
GP as he no longer needs the specialised support from the SerT. 
It was reported that substitution treatment may work better in prison than 
outside because patients outside may top methadone up and there are more 
risks for traffic. In prison prisoners are more controlled and are ‘pushed’ to 
‘get clean’ using substitution treatment. 
A guard reported that the problem with substitution treatment outside was a 
lack of structure to help released prisoners. ‘After spending 3 years in prison, 
where do prisoners go? There is nothing out there’. 
Training and psychosocial support 
No training on substitution treatment is provided. However, the SerT medi-
cal doctor explains how methadone works. It was reported that this was suf-
ficient for the nurse to work properly. 
The guard involved in the SerT activities and substitution treatment distribu-
tion said he must follow some specific courses in prison (through work) and 
outside (on a voluntary basis, through courses, team activities, etc.). He 
reported that each guard is assigned to a specific role and tasks. Guards in 
the SerT develop a close collaboration with the GP. 
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3 Prisoners’ experiences 
Interviews were conducted with 4 groups of prisoners, aged between 28 and 
51, with a mean of 37 years old: 
− One focus group with 5 female prisoners – San Vittore (Milan) 
− One focus group with 8 male prisoners – San Vittore, La Nave (Milan) 
− One focus group with 7 male prisoners – San Vittore, El Coc9 (Milan) 
− One focus group with 8 male prisoners (4 of foreign origins) – Soliciano 
(Florence) 
There were no differences between what men and women reported. 
Most prisoners reported being on a detoxification methadone based treat-
ment. The decrease path varies from one person to the other but tends to be 1 
mg at a time, every 2 days or sometimes 5 days. Most of the prisoners have 
been in contact with a SerT outside and some have had a substitution treat-
ment through that service. Prisoners reported differences between treatment 
offered outside and inside. Methadone maintenance is frequent outside 
whereas it is not in prison. In prison, only a few prisoners said they were 
maintained on a low dose, although they had decreased on a detoxification 
type of treatment previously. Many prisoners reported wanting to decrease 
the dose while in prison as the prison environment facilitates being drugs 
free, contrarily to outside. Some refused to take a substitution treatment be-
cause they said they did not want to be ‘dependent’ on another substance. 
‘In prison I have stopped using drugs but the psychological dependence still 
exists. It’s ugly to be in prison but it’s in prison that I could really stop. Pri-
son helps, puts you in a detoxification system, but afterwards, once in the 
community, it is more difficult to stay clean.’ 
‘You can only stop here in prison [to use drugs]. Outside it’s not possible.’ 
‘Some can stop [drugs] in prisons, others can’t. It depends on each individ-
ual and it’s personal. It depends on your psychological state.’ 
‘Methadone is to help someone detox from drugs. If it is used appropriately, 
it helps. Methadone is not made for maintenance. The same goes for benzo-
diazepines.’ 
                                                          
9  The COC is the centre of observation for new entrants who are/were drug users. 
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Some prisoners agree with a ‘fast’ decrease of methadone, but it may be not 
be appropriate. 
‘I wanted to decrease immediately but the doctor disagreed with me and 
wanted me to decrease more slowly. I wanted to decrease and stop immedi-
ately because I have never really agreed with methadone, which is a depend-
ence on another substance. My treatment has been finished for 2 weeks now 
and I am not feeling well. I don’t sleep, I shake, I have muscular pains, I am 
very tired. I have decreased my methadone doses very fast actually.’ 
Some prisoners said that they did not get substitution treatment because they 
lacked information and were scared. ‘I didn’t know the service, I didn’t know 
anything. I trusted nobody. I was scared. I didn’t have the information.’ 
Prisoners stated that the equivalence of care and health care over the week-
end and throughcare (on release) were lacking. 
‘In here, they tell us what we need to do and they decrease the dose. But out-
side, we must follow treatment programmes and a lot of people are on a 
maintenance treatment programme. They can’t do things in and out [of pri-
son] differently because you are here, in prison, today, but maybe not tomor-
row, so it’s better to all agree, otherwise it doesn’t make sense.’ 
‘The only problem is that if you get arrested on a Friday, you are Friday, 
Saturday and Sunday without methadone. You suffer and you must wait until 
Monday to see a doctor at the SerT.’ 
‘I think that the psychological problem linked to drugs is very important. 
Drug dependence cannot be treated in prison – that is not possible I think. 
The sentence is not all that important but the treatment must matter for the 
person. I think that the only way to stop [drugs] is to have a psychological 
support on an individual basis in order to understand the problem we have, 
because each one of us has a different problem. And to be followed by some-
one in the field who know these things well.’ 
‘When we are released, we don’t get regular treatment, we get nothing. 
There are a lot of problems surrounding you. Even if you decrease in prison, 
when released, if you are clean, it helps, but if they put drugs under your 
nose, how can you refuse?’ 
‘I think that we should get support when we are released. Prison cuts you 
away from the world. When you get out, you must face life, work … It’s 
always more difficult to reintegrate.’ 
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They also claimed that too many differences exist from one prison to another 
within the country regarding substitution treatment. 
‘Why are there so many differences between all these prisons? I don’t under-
stand why they are so many disparities between prisons. We are still in Italy 
though. I have seen that in prison […] they don’t give methadone. They 
should actually have one penitentiary treatment.’ 
Prisoners reported that psychosocial support was insufficient and that sup-
port was provided in emergency cases.  
‘On my first day I was asked whether I wanted to receive psychological sup-
port. I said yes but then never got any. If you open your veins, then they call 
the psychologist and the whole team who give you support.’ 
Some prisoners said they felt stigmatised and perceived differently in the 
public eyes but also by other prisoners and prison staff, who name them the 
‘irrecoverable’. They stated they did not like being identified as a prisoner on 
a methadone treatment. 
‘I am married and my wife does not know I have used drugs. I get a psycho-
logical stress (…) you need to queue in front of everyone to get the metha-
done and everyone can see you. I don’t like if when others can see me getting 
methadone. Because I know that it is not great. They all take us for drug 
‘addicts’ anyway. We are stigmatised two times: drugs and methadone. And 
I know they lack of staff.’ 
3 Summing up 
The provision of substitution treatment in Italy, and in prisons, vary extre-
mely from one region to the other. However, there is a tendency to offer 
methadone treatment for detoxification. Maintenance (long term) treatment 
and buprenorphine are also offered but to a more limited number of prison-
ers. 
In prison, health care to drug users is provided by Public Health Service 
(Ministry of Health) through the A.S.L. Ser.Ts are specialised centres for the 
treatment of drug use. 
Prisoners reported that differences in the provision of treatment from one 
region and prison to another were striking and problematic. Although many 
prisoners wanted and were on a short term, detoxification substitution treat-
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ment, they also questioned whether it was appropriate and successful in the 
long run. 
Medical and prison staff valued substitution treatment. Although they recei-
ved very little training, they stated that they felt they managed the treatment. 
They reported that health care and support is provided through Ser.Ts, but 
little is provided once out of the Ser.T structure. The lack of through care 
(i.e. psychological care within the same prison after a detoxification substi-
tution treatment, health care on release or when transferred to another prison) 
is problematic for long-term rehabilitation. 
  
Luxembourg1 
1 General data:  
Drug use, substitution treatment and prison population 
Compared to the country reports for the other 17 countries that this research 
covers, data for Luxembourg only comes from a review of research reports, 
laws, regulations and websites. No interviews were conducted at all. 
Requests for authorisation to conduct the STEP research were made repeat-
edly through emails, letters and phone calls over a period of one year. 
Regrettably, the Ministry of Justice – and specifically the International Rela-
tions Office said to be in charge of approving research – did not respond. 
The Prison Administration stated that the research had not been approved by 
the International Relations Office, mainly because of a lack of time to facili-
tate the research. The Prison Administration explained that they played no 
role in this decision which was taken by the International Relations Office 
alone. 
1.1 Number of drug users (and type of drugs used) 
The estimated prevalence of problematic drug use is 1 900 to 2 200 people 
(EMCDDA, 2002, Briefing 1). The number of drug users on substitution 
treatment is 864 (164 in the official programme and approximately 700 who 
are prescribed methadone in pill form by GPs (EMCDDA, 2002). 
There are approximately 18% (n=191 in 2003) of drug users in prisons. 
(de Surveillance du Sida Luxembourg, 2003). All these drug users in prison 
were on a substitution treatment in 2003. (Comité de Surveillance du Sida 
Luxembourg, 2003) 
The most common, illicit psychoactive substances in Luxembourg are can-
nabis, hallucinogens (for the younger population), ecstasy, heroin and, to a 
lesser extent, cocaine. Poly-drug use is widespread (Relis, 2002). Among 
                                                          
1  As described in the methodology chapter, Laetitia Hennebel was in charge of Luxembourg. 
Special thanks are offered to Caroline Lieffrig, Prison Administration, who tried to help 
with the conduct of the research in Luxembourg. 
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problematic drug users, using mainly heroin, approximately 1000 receive 
substitution treatment: 75% of them get substitution treatment from a private 
GP whereas the others get it in specialised centres within the frame of a pub-
lic treatment programme. 
1.2 Substitution Treatment 
Because Luxembourg is a small country with a total of 2 prisons, a descrip-
tion of these prisons is provided towards the end of this chapter. 
1.2.1 Historical and legal background 
The law of 19 February 1973 (‘Loi concernant la vente de substances 
médicamenteuses et la lutte contre la toxicomanie)’ is the basic national drug 
law. It regulates the sales of prescribed medicine and the response to drug 
dependence (Reitox Luxembourg, 2001). 
The methadone substitution programme only delivers methadone in a liquid 
oral form. Buprenorphine has been delivered since 2000 (Origer, 2001).  
After the 1999 legislative elections, the Ministry of Health was made respon-
sible for the general coordination of actions in the drug use and dependence 
arena. In 1989, the Ministry of Health and the JDH Foundation (Jugend- an 
Drogenhëllef) set up a Methadone Substitution Programme. In 2001, 
158 patients received substitution treatment (Relis, 2002). This methadone 
substitution programme was replaced by the ‘Surveillance Commission on 
Substitution Treatment’ following the January 2002 decree (Reitox Luxem-
bourg, 2002). 
The 1973 law has been successively amended2, recently by the law of 
27 April 2001 which includes decriminalisation of cannabis use, alleviation 
of penalties for simple drug use, a differentiation of penalties according to 
the type of drug offence as well as foreseeing a legal framework for harm 
reduction measures, such as drug substitution treatment. No legal framework 
regulating substitution treatment existed prior to this law (Origer, 2001). 
Two decrees focus specifically on substitution treatment. First, the grand 
ducal decree of 7 December 2001 regulates the duration of validity for some 
                                                          
2  Law of 23 February 1977; law of 7 July 1989; law of 17 March 1992; law of 11 August 
1998. 
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prescribed drugs and sets the lifespan of the prescription to 3 months for 
methylphenidate, 21 days for oral morphine and transdermic fentanyl, and 14 
days for methadone (Reitox Luxembourg, 2001). 
Second, the grand ducal decree of 30 January 2002 (‘Règlement grand-
ducal du 30 janvier 2002 déterminant les modalités du programme de trai-
tement de la toxicomanie par substitution’) regulates the modalities of sub-
stitution treatment at the national level, such as the quality and control man-
agement of substitution treatment. This decree gives an official definition of 
substitution treatment, states the substances used for substitution treatment, 
as well as admission criteria and information on the national treatment pro-
viders (GPs, specialised agencies, pharmacies). Furthermore, the decree 
foresees that the Ministry of health will manage mandatory licenses for sub-
stitution treatment providers and training needs, as well as setting up a sur-
veillance commission on substitution treatment. This ‘Surveillance Commis-
sion on Substitution Treatment’ replaces the former ‘Methadone Commis-
sion’ (Reitox Luxembourg, 2001). 
The ‘Surveillance Commission on Substitution Treatment’ was established 
in 2002. The Commission is made up of delegates from the methadone pro-
gramme, the Directorate of Health, the AST, two pharmacists and two GPs 
affiliated to the methadone programme. Its objectives are to control and 
coordinate all aspects of substitution treatment at the national level: it over-
sees admissions, releases and the exclusion of patients from substitution 
treatment. One of its tasks has been to set up, within the Directorate of 
Health, a central database register for substitution treatment. Information is 
updated on a daily basis, avoiding duplication of prescriptions. Indeed, a new 
substance has been fuelling the black market due to multiple prescriptions of 
methadone in the form of a pill (Mephenon® prescribed by GPs) (Absil et al, 
2003).  
According to the 2002 Decree, substances used for substitution are mainly 
methadone and buprenorphine. Morphine-based (salt) medications can also 
be prescribed when the medical authority estimates that the other substances 
are inadequate. In addition, heroin prescription is allowed within the frame-
work of the implementation of a pilot project coordinated by the Directorate 
of Health (Ministry of Health). 
Substitution treatment is provided as a means to detoxification aimed at ab-
stinence (the trend until 2001), or maintenance aimed at harm reduction. As 
defined by the 30 January 2002 Decree, substitution treatment is a medically 
 279 
 
assisted treatment aimed primarily towards the psycho-social and medical 
stabilisation of the patient. Individual assessments are conducted to deter-
mine the development and outcome of substitution treatment on the basis of 
the patient’s condition and the reduction of public nuisance (Absil et al, 
2003). 
As well as specialised drug substitution centres, substitution treatment is 
provided by private GPs for patients on a waiting list for the national drug 
substitution programme or for those wishing to receive substitution treatment 
for detoxification or maintenance. In 2001, 147 GPs prescribed Mephenon®, 
Methadict® and Subutex® to 849 patients (Relis, 2002). 
Only GPs and authorised drug substitution centres to provide the treatment. 
In contrast to the mandate of GPs, centres must ask for authorisation for each 
new treatment. GPs were opposed to having to request authorisation for each 
new treatment as it questioned their prescription rights (their argument was 
granted). The most serious cases are seen in centres, justifying the need for 
more control. Annually, centres manage approximately 160 patients, whereas 
GPs manage 900 cases (Absil et al, 2003). 
Although the majority of drug-related deaths involve heroin (76% of the 
cases), since 2000 there has been an increase of overdoses with methadone 
or buprenorphine, mainly when topped up with other substances (Origer, 
2001). 
Psychosocial support and staff training 
The treatment provider is said to ensure a psycho-social follow up, including 
support to the patient, referral to a pharmacist, regular toxicological evalua-
tion and possibly a job and housing search. According to the 2002 Decree, 
doctors prescribing substitution treatment must engage in an ongoing specia-
lised training on the treatment and multi-disciplinary exchanges. 
1.2.2 Substitution treatment in prison 
There are no formal guidelines for substitution treatment in prison (Reitox 
Luxembourg, 2002). The substitution substances prescribed in prison are 
methadone (Mephenon®), buprenorphine (Subutex®) and, to a lesser extend, 
codeine. Benzodiazepines are widely prescribed (Reitox Luxembourg, 
2002). 
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Substitution treatment is offered in prison as (i) a detoxification treatment, 
(ii) a maintenance treatment, or (iii) a measure of harm reduction (Comité de 
Surveillance du Sida Luxembourg, 2003). 
Substitution treatment is provided to: 
(i) Prisoners who were on a substitution treatment prior to incarceration. 
The prescribing doctor or programme is contacted to verify the accuracy 
of the information that the prisoner has provided. If confirmed, the 
treatment is continued. Eventually, notwithstanding the type of treatment 
provided outside, it may be offered as detoxification or maintenance. 
(ii) Substitution treatment may be initiated in prison although this is less fre-
quent and mostly applies to those who started using opiates in prison. 
(iii) Prior to release (6 weeks) prisoners can apply to a substitution treatment 
programme in the community to continue their treatment (Reitox Lux-
embourg, 2002). 
The law of 27 July 1997 regulates the creation of specialised medical units 
for drug users and psychiatric patients in prison. Detoxification treatment is 
provided by these medical units or by the external detoxification units of 
general hospitals. Psychosocial and therapeutic care is provided by prison 
staff members and staff from external specialised drug centres. Such care is 
said to be insufficient. (Reitox Luxembourg, 2002) 
Since 1998, the number of prisoners of foreign origin has largely increased 
and now makes up 50% of the total prison population (Relis, 2002). Portu-
guese patients compose the majority of non-Luxembourg natives in substitu-
tion treatment in the community (Reitox Luxembourg, 2002). The largest 
immigrant population in Luxembourg is of Portuguese origin. Most Portu-
guese prisoners are residents in Luxembourg. 
At the Centre pénitentiaire de Luxembourg à Schrassig (CPL Prison) no 
urine tests for illicit drugs are conducted in order to mark the boundary be-
tween the health care and security issues. Indeed, the Prison Administration 
regularly requests such tests. The prisoner decides on the type of substitution 
treatment (and the dose) he wants, which is then revised with the GP. Nearly 
all opiate users decide to be on a substitution treatment. (Comité de Surveil-
lance du Sida Luxembourg, 2003) 
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In 2003, 191 patients received substitution treatment at CPL: 177 had 
methadone and 15 were on buprenorphine (compared to 30 in 2002 (Comité 
de Surveillance du Sida Luxembourg, 2002)). Three quarters of the patients 
on substitution treatment reduced the dose while at CPL, compared to half of 
the patients in 2002. (Comité de Surveillance du Sida Luxembourg, 2003) 
In 2002, the average dose of methadone was 50 mg per day although the 
dose varied from 5mg to 220 mg. In 2003, the average dose of methadone 
was 35 mg per day although the dose varied from 2.5 mg to 110 mg. The 
average length of treatment was 97 days in 2002 and 99 days in 2003 
although it varied from 3 to 365 days. (Comité de Surveillance du Sida 
Luxembourg, 2002 and 2003) 
The average dose of buprenorphine was 6.25 mg per day, varying from 
0.4 mg to 32 mg in 2002, and 3.25 mg per day, varying from 0.2 mg to 
16 mg in 2003. The average length of treatment was in 2002 115 days, vary-
ing from 4 to 365 days, compared to 176 days, varying from 4 to 365 days in 
2003. (Comité de Surveillance du Sida Luxembourg, 2002 and 2003) 
Compared to 2002, in 2003, the average dose of methadone or buprenor-
phine has decreased by half. In 2003, the number of patients on buprenor-
phine has also decreased by half. (Comité de Surveillance du Sida Luxem-
bourg, 2003) 
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1.3 Prison Population  
Table 15  Data on the prison situation in Luxembourg (Source: King’s College London, Inter-
national Centre for Prison Studies, Prison Brief for Luxembourg) 
 
Country  LUXEMBOURG 
Ministry responsible  Ministry of Justice 
Prison administration  Direction Générale des Etablissements Péniten-tiaires 
Contact address  B.P.35, L-5201 Sandweiler, Luxembourg 
Telephone / fax / website  tel:   +352 47 59 81 348 fax:  +352 47 59 81 395 
Head of prison administration 
(and title)  Vincent Theis, Directeur 
Prison population total (including 
pre-trial detainees / remand 
prisoners)  
498 at 1.9.2003 (national prison administration)  
Prison population rate (per 
100,000 of national population)  
111 – based on an estimated national population of 
450,000 at mid-2003 (from Council of Europe fig-
ures)   
Pre-trial detainees / remand pri-
soners (percentage of prison 
population)  
43.6%    (1.9.2003)  
Female prisoners (percentage of 
prison population)  6.1%      (1.9.2002)  
Juveniles / minors / young priso-
ners incl. definition (percentage 
of prison population)  
2.4%      (1.9.2002 – under 18)  
Foreign prisoners (percentage of 
prison population)  63.9%    (1.9.2002)  
Number of establishments / 
institutions  2             (2002)  
Official capacity of prison 
system  369         (1.4.2000)  
Occupancy level (based on offi-
cial capacity)  110.0%  (1.4.2000)  
Recent prison population trend 
(year, prison population total, 
prison population rate)  
1992      352        (89) 
1995      469      (114) 
1998      392        (92) 
2001      357        (80) 
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2 The field visit 
No field visit was conducted in Luxembourg. 
Map of Luxembourg 
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There is a total of 2 prisons in Luxembourg: Centre pénitentiaire de Luxem-
bourg à Schrassig (CPL Prison) and Centre pénitentiaire de Givenich (CPG 
Prison). On 31 December 2001, the total prison population was 341 (CPL 
285 and CPG 56) (Reitox Luxembourg, 2002) with a capacity of 270 and 90. 
(Ministry of Justice website http://www.mj.public.lu/) 
The CPL prison is a closed prison. The CPG Prison, located in the country-
side and opened in 1938, is a semi-open prison where prisoners work during 
the day (job or workshops) in or out of prison. At night they are locked in 
their cells. 
In fact there are agreements with the Hospital Centre of Luxembourg (CHL) 
who sends GP, specialists and nurses to the prison for somatic treatment. 
There is also an agreement with the Neuro-psychiatric Hospital Centre of 
Ettelbruck to provide psychiatric service (psychiatrists and nurses) in prison. 
Prisoners’ experiences 
No prisoners were interviewed. 
  
The Netherlands1 
Structure of country reports 
1 General data: 
drug use, substitution treatment and prison population 
1.1 Number of drug users 
According to figures of the “Nationale Drugmonitor (NDM, 2002) the num-
ber of opium users is between 26-30 000, of whom 17 500 are treated, giving 
a treatment coverage of 70%. At the moment only methadone is registered as 
a means of substitution2 
According to the National Health Council of Netherlands, one third to half of 
all detainees have some form of addiction problem, between 5 000 and 7 500 
prisoners on any one day. On an annual basis, this amounts to 15 000 to 
23 000 individuals (excluding Youth Custody Centres and placements under 
a hospital order). “In two thirds of those inmates of standard penal instituti-
ons who have addiction problems (10 000-15 000) these problems can be 
defined as ‘serious’. Such individuals have often been addicted for many 
years.” (Gezondheidsraad 2002, p. 20). Most of the addicted detainees are 
poly-drug users, injectors are in the minority. 
The average stay in prison for drug addicts is shorter than the period of de-
tention served by the general prison population: “Fifty percent of them serve 
as little as two months, while 75% re-enter society within four months. There 
are relatively few women among the group of detainees who are addicted to 
drugs. More than half of this group of drug-addicted detainees were born in 
the Netherlands”. 
                                                          
1  The field visit, conducted by Heino Stöver, was facilitated by Jan Flikkema, Ministry of 
Justice of The Netherlands, who also provided general information and support with the 
finalisation of this country report. 
2  Personal communication with Prof. Wim van den Brink. 
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1.2 Substitution treatment 
1.2.1 Historical and legal background 
Substitution treatment was introduced in the community in at the end of the 
60s/beginning of the 70s and first introduced into the prison setting in 1972. 
Since the beginning of the 70s methadone has been dispensed as the main 
substitute drug for outpatient opiate using clients in The Netherlands3. It is 
dispensed in special programmes of addiction treatment services (a total of 
about 50 teams; in Amsterdam half of the GPs dispense methadone). Since 
1994, the number of methadone clients increased by 29%. Out of 11,383 pa-
tients, 98% of the clients are on a maintenance programme, 50% of the cli-
ents are older than 40 years, most clients (70%) have a multiple use pattern, 
those clients using cocaine and opiates and alcohol and opiates both increa-
sed since 1994 and the mean methadone dose was 57 mg in 2002 (the mean 
dosage level increased from 37 in 1994). It is part of the national drug policy 
to make methadone widely available for those in need of it. 
1.2.2 Substitution treatment in prisons 
The responsibility for medical care is in the hands of the Ministry of Justice. 
Prison inmates do have the same right to health care as any other citizen in 
The Netherlands (principle of equivalence). “On the basis of the Custodial 
Institution Act, detainees have the right to adequate medical care from the 
physician associated with the institution in question” (Gezondheidsraad 
2002, p. 21). This includes psychological and psychiatric care and the treat-
ment of drug addiction. The “Medical Treatment Agreements Act (“Wet 
Geneeskunige Behandlingsovereenkomst”,WGBO”) is also applicable to the 
relationship between the penal institution’s physician and the detainee. 
There are early reports from 1972 concerning the start of substitution treat-
ment for opiate addicts in prisons in Haarlem (Roorda, 1989). Roorda, an 
advisor for drug addiction in the penitentiary system in the Ministry of Jus-
tice and former physician in Haarlem prison, states that methadone prescrip-
tion in prisons was a controversial issue in the 70s and 80s. During this 
period, methadone was used for detoxification purposes by the majority of 
doctors in the prison setting. A minority, however, rejected methadone and 
so the range of treatment for drug users in prisons went from ‘cold turkey’, 
                                                          
3  Data taken mostly from the LADIS bulletin, June 2004, see www.sivz.nl  
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i.e. detoxification without any supplementary therapeutics, to a free choice 
between detoxification or methadone maintenance treatment (1989). Roorda 
was of the opinion that “… the termination of an addiction can only be the 
result of a intra-psychological process. If someone is forced to a detoxifica-
tion, this internal process is terminated on the surface, but the enemy has 
been projected to outside (the doctor). The idea that a coercive detoxification 
has deterrent effects has been proven as false”. (p. 90) 
The substitution treatment is paid by the Ministry of Justice. 
In The Netherlands, drug services for addicted inmates are structured on 
three levels: 
− Drug Services in the general prison setting; 
− Addiction Support Sections (VBAs): These sections have been specially 
set up for addicts, who are motivated to give up their drug habit. Cur-
rently, the use of methadone is a contra-indication for placement in such a 
section. Every year, approximately 1 200 detainees are admitted to these 
sections. In 2002, the VBA’s were under-utilised by around 25% (availa-
ble places in drug.-free units are approximately 250); 
− In 2002, the penal care facility for addicts (SOV: Strafrechtelijke opvang 
Verslaafden) had a total capacity of 221 places in three sites: Utrecht, 
Amsterdam and Rotterdam). 
The latter two are more or less dominated by an abstinence oriented 
approach which does not include the use of methadone. 
The modalities for substitution treatment in prisons have changed over time. 
According to an interviewee at the Ministry of Justice, views on addiction 
and the impact of methadone prescription have undergone essential changes 
among health professionals in the last decade: 
“Some doctors said from the start say ‘you are now in prison so we stop the 
methadone’. After six months they go out and start again. So, the discussion 
about the methadone’ handreiking’ (guidelines) and the methadone ‘circu-
laire’ made a little movement in prison and with the doctors to get the 
methadone continued, that does benefit. Not only this circulaire but the cir-
culaire before; there is a new one, but the most of this circulaire already 
exists. But now we are making them better and try to get more doctors to 
make consent with this circulaire … it takes years and it is also the view of a 
kind of scientific movement in the addiction world. Most people in prison 
saw addiction as a bad custom and they are now changing: addiction is a 
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kind of disease and the patient, a kind of diabetic. A diabetic gets all his life 
insulin so addicted persons need lifetime methadone. A new kind of move-
ment ...” 
The elaboration of the most recent guideline (“Circulaire”, see below) re-
flects the nature and character of the phenomenon of addiction as a chronic 
disease. 
“… and when we think it’s a chronic disease you get another programme, 
other measures than for a bad habit to stop it. And I think the surrounding 
view around us about addiction is more a hyphothesis of a disease with life-
time methadone or lifetime heroin or lifetime other treatment. In prison, we 
get used to that idea and so we change a bit.” 
The development of substitution treatment has been subject to ministerial 
letters, circulaires and regulations. The Ministry of Justice issued letters and 
guidelines for methadone prescription to inmates already in the mid 80s. Dr. 
Roorda (see above) sent a letter to all institution’s practitioners recommend-
ing that they should distinguish between short and long-term prisoners. The 
short-term prisoners should be kept in a methadone programme, for those in 
long-term substitution, the goal should be detoxification and abstinence. This 
advice should have been contributed to a more homogenous practice at that 
time. 
In the mid 90s, another letter was sent to GPs in the institutions (brief van de 
Dienst Geneeskundige Inspectie van 13 December, 1996, dM/96268), and 
another version of guidelines dating from 2001 (“Methadonverstrekking aan 
gedetineerden” (17th of August 2001, No. 5113734/01/DJI). Here, the maxi-
mum length of sentence for which substitution treatment has been continued 
was three months. These guidelines currently have been reconsidered and 
have been changed as a response to the advice of the National Health 
Board’s report (“Treatment of drug addicted inmates”, see Gezondheidsraad) 
on substitution treatment in Dutch prisons. 
At time of the field visit to Holland (June and September 2003), the Ministry 
of Justice was in the process of drafting this version of the methadone pre-
scription guidelines which was finally released in April 2004. These guide-
lines, disseminated in the form of a ministerial “Circulaire” to the doctors 
and medical units in all Dutch prisons, do not have the status of formal 
regulations, but serve as guidelines for the physician prescribing methadone. 
One of the reasons for issuing these guidelines on methadone prescription in 
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prisons is the varying practice in Dutch prisons and the need to deliver a 
protocol of best practice. The physicians still have therapeutic freedom. 
“According to guidelines issued by the Ministry of Justice, methadone can 
be administered to short-term detainees provided that they have been pre-
scribed the drug prior to their detention. In practice, however, some institu-
tion’s physicians contravene these guidelines by cutting down the amounts 
of methadone provided or by suspending such provision altogether” (Ge-
zondheidsraad 2002, p. 22). The reason for this might be that the penal 
addiction policy aims at abstinence and promotes a drug-free environment. 
The guidelines recommend that maintenance treatment should be continued 
for those inmates in methadone programmes prior to their incarceration and 
if they plan to resume such a treatment after a short period of detention. A 
‘short period’ is defined as ‘less than 4 weeks’, for example, this point of the 
guidelines has led to some discussion in The Netherlands. In June 2002, the 
National Health Board, on request of the Minister of Health, Welfare and 
Sport and the Minister of Justice recommended to extend the four week 
period: “Scientific studies have shown, however, that abstinence pro-
grammes must be followed for a given period of time if they are to have any 
effect. The Committee therefore recommends that this four-week period be 
considerably extended. In this context, the Committee draws a distinction 
between those detained on remand and individuals who have been sentenced. 
Methadone maintenance should always be continued for those on remand, 
provided that addicts indicate to the physician that this it what they want. 
This is because the duration of detention for those on remand is, by defini-
tion, uncertain. The Committee feels that an abstinence programme (involv-
ing reductions in the dose of methadone) should only be considered if the 
period of detention is to exceed six months. The latter would apply to very 
few addicts in normal detention. The institution’s physician requires the 
addict’s informed consent in order to initiate an abstinence programme.” 
(Gezondheidsraad 2002, p. 24) 
Moreover the National Health Board is emphasises two issues: 
− Continuity of care in the methadone prescription (which is interrupted 
when it comes to detoxification and which my lead to an increased danger 
of overdose for those patients/detainees detoxified). 
− Risk of overdose, when the prisoner is continuing his opiate habit after 
release. 
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On the institutional level, the details of treatment are discussed by professio-
nals of the psychological and medical services in a special multidisciplinary 
meeting group (PMO: “Psycho-medisch overleg”). 
Detoxification 
One of the key issues in the debate on the appropriate prescription policies in 
Dutch prisons is the point of detoxification of those, mostly long-term sen-
tenced inmates who don’t wish to reduce their dosage themselves. According 
to the National Health Board, this can only be done on the basis of informed 
consent with the patients. Otherwise, it would be a compulsory treatment. 
The background is that the National Health Board defines methadone treat-
ment as a treatment of care for stabilisation and if it becomes a treatment or 
cure (with the focus on abstinence) it needs to be supported and requested by 
the patient himself/herself. 
These recommendations have been discussed by the Ministry of Health, 
Welfare and Sport (Ministerie van Volksgezondheid, Welzijn en Sport 
(5 December 2002) which led to a response of the National Health Council 
(23rd December 2002). Generally, the recommendations of the Health Coun-
cil are supported (especially the suggested six months period). However, the 
Ministry of Health, Welfare and Sport disagrees with the term “compulsory 
treatment” in case the methadone maintenance treatment is stopped (detoxi-
fication treatment) with the goal of abstinence without the informed consent 
of the patient. According to the Ministry it is up to the responsible doctor to 
decide whether to stop or continue in each individual case on the basis of an 
approved evidence-based protocol (guidelines for the methadone prescrip-
tion). 
The Health Council, in it’s response to the Ministry of Health, Welfare and 
Sport (23rd December, 2002) is still of the opinion that, according to the 
agreement between provider (medical doctor) and user of the provision of 
medical services “Wet Geneeskunige Behandlingsovereenkomst” (WGBO), 
stopping treatment is a form of medical treatment and therefore requires the 
informed consent of the patient/inmate – especially when a medical decision 
(from maintenance to detoxification treatment) marks a fundamental change 
of treatment from care to cure. 
Despite the guidelines set out by the Ministry of Justice, the therapeutic free-
dom of the doctors allows them to either follow the six months of sentence 
rule or to expand this time line. The doctor has to justify his/her decision on 
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paper to the headquarter of the Dutch NACI. As an interviewee at the Min-
istry of Justice stated, the start of methadone prescription is possible for 
those who are not already in the methadone programme in the community: 
“... When you are not in the programme you can debate with the prison to 
start a programme; but when your imprisonment is longer than six months 
then one doctor says “I Stop because it’s more than six months. Another 
doctor will say there’s medical interest to continue the programme or to 
start a programme and than he can continue the programme. There will be a 
discussion. Each doctor has his own opinion about this. And, at this moment, 
most of the doctors will stop the programme because it says that it gives 
them a possibility to stop.” 
The question of continuation of methadone treatment cannot be solved eas-
ily. An interviewee at the Ministry of Justice discussed the possibility of 
providing methadone to lifers: 
“Some doctors will accept the six months but it’s not their vision, they would 
stop immediately. ‘But alright, when the pressure is big enough I accept the 
six months.’ But after that there is a phase to introduce lifetime methadone.” 
The role of methadone within the SOV penal care was not fully discussed: 
“SOV is one experiment where you can start with a complete treatment for 
the addiction with or without methadone. That’s also an experiment when 
you can say ‘Alright when we try to continue the methadone on a lower level 
than you came in, as a maintenance dose.’” 
Conclusion and recommendations of how to improve the quality of 
methadone provision in The Netherlands 
The Committee set up by the Health Council to examine the treatment for 
drug addicted prisoners concludes that Dutch penal institutions vary mark-
edly in terms of the methadone treatment that they provide. “The Committee 
feels that this situation is far from ideal. The members of the Committee 
have explored the problem of how to promote consensus on this issue. They 
consider that the professionals involved should themselves develop a con-
sensus in order to draw up a guideline for methadone medication for these 
professionals to follow. Given the large numbers of professional associations 
and institutions that will be involved in drawing up a common guideline, the 
Committee believes it is vitally important to coordinate the relevant activi-
ties. This, the Committee feels, should be undertaken by the Steering Com-
mittee for the Development of Multidisciplinary Guidelines in the mental 
health care service.”  
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It should be noted that the six month regulation is only relevant for inmates 
who are already sentenced and not for remand prisoners. 80% of drug users 
whose sentence is less than 6 months could theoretically benefit from this 
regulation. But according to an interviewee in the Ministry of Justice: 
“… in practice there are still too many doctors who say, ‘We reduce metha-
done, despite the fact they have only a short sentence’. We our struggling 
against that, and times are changing – although slowly follow. More and 
more doctors start to prescribe according our advices. But still there are 
prisons in which methadone is not prescribed although there is the indica-
tion to do so. The Inspector, who is inspecting the health care in prisons and 
is based at the Ministry of Health, is also supporting us in this question of 
methadone treatment.” 
In the Netherlands, inmates can complain about a medical treatment which 
they think is inadequate. According a member of the Ministry of Justice, the 
proceeding in these cases is as follows:  
“If a prisoner complains with regard to the cessation of the methadone pre-
scription, we are the ones who try to mediate between doctors and prisoners. 
In these cases we try to motivate the doctors to follow our advice to continue 
methadone prescription. If the doctor refuses to follow this advice then the 
complaint will be dealt with by a judge and it happens that inmates receive a 
small compensation of about 50 Є because he didn’t receive methadone.” 
One of the reasons to fix the timeline at 6 months for the continuation of the 
methadone treatment is based on scientific evidence pointing towards the 
prevention of overdoses after release. “These six months are based on scien-
tific data saying that if methadone is coercively reduced within a sentence of 
less than 6 months, the consecutive period is dangerous and relatively many 
may die of overdoses. This hasn’t been known in former times when setting 
up regulations.” 
The guideline on methadone prescription is aimed at informed consent. 
When somebody has a sentence of more than six months and doesn’t agree 
with the reduction of methadone (see group B2 in the graphic above) then a 
second opinion (carried out by the Ministry of Justice) is integrated in the 
decision making process. 
“We do have very old opiate users, and when somebody has a career of 
already 30 years then it is most likely that it doesn’t make any sense, just the 
opposite, maybe it isn’t possible for him to produce endorphins so he should 
have methadone compared to insulin.” 
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One of the problems with the provision of health care, and especially the 
question of methadone in prisons, is that is that there are not enough doctors 
in the general community and especially those who are willing to work in 
prisons. So the choice is not that great. 
Regarding the prescription of benzodiazepines, The Ministry of Justice fol-
lows a strict policy and has communicated it to the prison doctors. If these 
substances have been used for more than 3 weeks they should be reduced to 
zero. Instead of benzodiazepine anti-depressants should be introduced. 
Aftercare 
Within interviews at the Ministry of Justice, aftercare is identified as a prob-
lematic area with respect to methadone treatment. Due to a lack of personnel 
the connection can not always be organised without gaps. 
“At the end of the prison time there has to be aftercare; but the aftercare is 
not very well organised so here at the end of the prison there is no continuity. 
You leave Friday, you can start Monday at the clinic. That’s two days, so 
they get lost. So we have to manage when they leave the prison at Friday that 
they are taken to the clinic at the same day. These are very small things but 
it’s the only way to ensure continuity. We don’t have the money or we don’t 
give the money to organize the care; the clinic says they have not the per-
sonal to get them, so he gets lost. With a small amount of energy you can get 
it connected.” 
1.3 Prison Population 
Table 17  Data on the prison situation in The Netherlands (Source: King’s College London, 
International Centre for Prison Studies, Prison Brief for The Netherlands) 
Country  NETHERLANDS 
Ministry responsible  Ministry of Justice 
Prison administration  National Agency of Correctional Institutions (NACI) 
Contact address  P.O. Box 30132, NL-2500 GC, THE HAGUE, Netherlands 
Telephone / fax / website  tel:  +31 70 370 2771 fax: +31 70 370 2910 
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Head of prison administration (and 
title)  
Peter Jägers General Director of NACI (Director 
of Prison Service: Peter van der Sande) 
Prison population total (including pre-
trial detainees / remand prisoners)  
16 239 at 1.9.2002 (Council of Europe Annual 
Penal Statistics - includes 2 009 in juvenile insti-
tutions and 1,230 in TBS psychriatric clinics)  
Prison population rate (per 100,000 of 
national population)  
100  
based on an estimated national popu-
lation of 16.16 million at September 
2002 (from Council of Europe fig-
ures)   
Pre-trial detainees / remand prisoners 
(percentage of prison population)  44.2%  (1.9.2002)  
Female prisoners (percentage of prison 
population)  6.8%    (1.9.2002)  
Juveniles / minors / young prisoners 
incl. definition (percentage of prison 
population)  
0.8%    (1.9.2000 – under 18)  
Foreign prisoners (percentage of prison 
population)  36.4%  (1.9.2002)  
Number of establishments / institutions  
79         (1.9.2001 – 50 adult prisons, 13 TBS 
psychiatric clinics, 16 juvenile institutions [places 
also in 6 other institutions / clinics])  
Official capacity of prison system  16 686   (1.9.2002)  
Occupancy level (based on official 
capacity)  97.3%  (1.9.2002)  
Recent prison population trend (year, 
prison population total, prison popula-
tion rate)  
1992        7 397      (49) 
1995      10 249      (66) 
1998      13 333      (85) 
2001      14 968      (93) 
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2 The field visits 
2.1 Penitentiaire Inrichting Over-Amstel (PIOA) – “Het Schouw” 
2.1.1 Description of the prison 
The Amsterdam prison Penitentiaire Inrichting Over-Amstel (PIOA, popular: 
Bijlmer Bajes), here “Het Schouw” was visited. Het Schouw is a remand 
prison for males with 144 cells over 6 floors, structured in 12 sections and 
each section has 12 cells (single cell occupancy). As it is a remand prison, 
substitution treatment is generally continued from the community. But, there 
were more controversial issues (prescribing policies etc.). It became evident 
that problematic drug use outside (mainly characterized by poly-drug use) is 
entering prison and that the prison has to find its response to that challenge. 
So, increasingly the prescription policy on benzodiazepines is of interest as 
well as the prescription of methadone. 
2.1.2 Goals and practical procedures of substitution treatment (access, 
rules, urine testing, provision on day leave, exclusion from the pro-
gramme etc.) 
History 
At time of the visit, 30-40% of prisoners were on methadone when admitted, 
with 8 out of 10 on one floor receiving methadone, a figure that differs from 
week to week. Since 1980, the substitution prescription policy in the prison 
“Het Schouw” has changed over time. In the first phase, methadone was just 
used for detoxification purposes. From approximately1993 onwards, mainte-
nance was the dominating strategy with dosages of 30-40 mg used and, more 
recently, the dosage has been increased to up to 100-120 mg. These changes 
are due to developments in the drug using patterns of users and changes in 
the methadone provision policy in the communities. The GG&GD recom-
mended higher dosages and there has been a corresponding increase in dos-
age in prison as well: 
− Pressure from outside has led to a shift from detoxification only to main-
tenance treatment in prisons, 
− Methadone prescription facilities in the community have prescribed 
higher dosages in the last decade. 
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− More and more psychiatric problems have led to co-morbidity, where 
methadone is used as a basic medication. Here methadone works as anti-
psychotic drug 
− Withdrawal of methadone may exacerbate the physical state of the priso-
ner. For users for 20-30 years, it is unrealistic to detoxify from metha-
done. 
Additionally, nearly every incoming patient from a methadone programme is 
using tranquilizers. So the drug using patterns and the prescription policies in 
the community have changed over time and the prison methadone prescrip-
tion policy is responding to that. 
The supplementary use of benzodiazepines has become a major problem in 
the substitution treatment, because of demands from prisoners to get ade-
quate doses like outside in the community. 
In interviews with provider and users it became clear that there are substan-
tial differences in the prescribing policy from prison doctor to prison doctor. 
The goal of methadone prescription is stabilise inmates and to adjust the 
dosage to the prison setting. It is said that the dosage should be lower for the 
prison setting than outside, where inmates have to face the whole range of 
the drug market. If the dosage is very high (80-100 mg) the reason for such a 
high dosage is questioned. Discussions are led with the inmate and, if neces-
sary, with outside clinics/physicians. 
The prescription of benzodiazepines has become a big issue, reflecting the 
situation of poly-drug use of methadone, heroin, benzodiazepines, alcohol, 
cocaine/crack outside prison. It has become an important debate between 
doctor and patient over the years. In former times, sleeping pills have not 
been prescribed at all. Now sleeping tablets are given when methadone has 
been stopped. The aim is to reduce the consumption of sleeping tablets so 
they are only prescribed for a few days as there is no medical indication for 
prescribing sleeping tablets on a long-term basis. Prescribing it for longer 
would mark a shift in purpose towards the psychoactive effects of the sleep-
ing tablets. The problem seems that not many of those taking benzodiacepi-
nes regularly accept that they are addicted to it. Sometimes inmates, bring a 
letter with them from the methadone post indicating that they are prescribed 
benzodiazepines outside. 
Methadone provision is not based on a formal contract or a fixed agreement. 
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Practical procedure 
If inmates are already in a methadone programme, this will have been con-
tinued in police arrest, they will bring a letter with them and the nurse will 
give them the same dosage they got in the treatment before. If the patient 
doesn’t bring the letter, the nurse will call the methadone post (GG&GD) in 
the community to confirm the treatment and dosage. The only problem is 
when prisoners come from other cities (like Utrecht), in the evening. For 
these cases special arrangements are foreseen. The day after admission, the 
patient is seen by the doctor. If he expects a longer sentence then detoxifica-
tion will be indicated, if he expects a short sentence then the dosage will be 
kept adjusted accordingly. 
The prescriptions are sent to the pharmacy by the nurse, and the guards get it 
and provide the methadone to the inmates at 8, 12 or 5 o’clock. The excep-
tion is on week-end when the warden brings the methadone to the cells 
directly. The guards hand out the methadone (in 5 mg tablets) and the patient 
has to swallow it under supervision of the guard. The average dosage is 
around 40-50 mg. 
The medical decision to continue or to stop substitution treatment, or to 
reduce the dosage, is the responsibility of the medical doctor. But there are 
weekly discussions about in inmates among an interdisciplinary team with 
psychologist and psychiatrist (PMO, see above). Sometimes prisoners ask for 
detoxification treatment themselves, because they can then abstain from 
drugs during their detention. 
The methadone reduction scheme is done in decreasing steps of 5mg every 
two days followed giving 5mg a week more, depending on the needs of the 
patient. Being on 10 tablets (50 mg) (“Symoron”) means detoxification over 
20 days (one tablet every two days). 
In some cases, the inmates can start methadone treatment while in prison in 
order to stabilise their behaviour. The building up process is done very care-
fully (for instance every week 5mg more), and it is individually adjusted and 
discussed between doctor and patient. 
If prisoners go out for home leave or a weekend (generally not more than 
3 days) they take methadone with them. The same applies for the release 
situation. If they are not known to a methadone post in the community, they 
are told to continue the methadone. 
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Urine controls don’t play any role in substitution treatment so as to facilitate 
the process of honesty between health care staff and prisoners. Urine con-
trols are only ordered by prison staff. 
According to some providers, the perception of substitution therapy has 
change from having negative connotations towards treatment being accepted 
as a medical, supervised and controlled therapy by the personnel. 
2.1.3 The views of prisoners 
The prisoners acknowledged the change in substitution treatment form 
merely detoxification towards maintenance. Other experiences of the prison-
ers indicate that the practice in different prisons varies significantly. 
In relation to the detoxification process, inmates wished to be more involved 
in the decision making process and to be asked about the steps of reduction. 
The plea is for leaving the decision to the inmates, whether or not and if, in 
which steps they want to reduce their methadone. The practice is perceived 
as inflexible and not adapted to the wishes of the inmate/patient. This applies 
particularly to those drug users who are addicted for twenty or more years 
and for whom methadone became a sort of basic therapeutic for many years. 
The detoxification procedure has been perceived as too rigid with not enough 
space to negotiate. This was considered to be an inferior characteristic com-
pared to the provision of methadone in the community. Interviews made 
clear that there is a struggle with the doctor about benzodiazepines and the 
right dosages. 
2.2 Stadsgevangenis Rotterdam 
2.2.1 Description of the prison 
The second prison visited is the Rotterdam town prison (Stadsgevangenis 
Rotterdam). It is a men’s prison with two units – a regular unit with 
120 places and a treatment unit “SOV” with 72 places. 70-80% of the 
120 inmates are drug users and only 60 inmates receive methadone in the 
regular unit. In the SOV unit, 6out of 72 get methadone. According to the 
staff, there is little drug use in prison (crack/cocaine) with almost no “intra-
venous drug use”. A scientific evaluation of drug policy is currently being 
carried out and will be finalised this year (2004). 
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2.2.2 Goals and practical procedures of substitution treatment 
The staff and the doctor were well aware of the new recommendations of the 
Dutch Health Council (Gezondheidsraad, see also the scheme above). The 
scheme to prescribe methadone to new detainees was as follows: Every day, 
5-10 new prisoners are admitted to the prison. They are asked if they are 
drug users and if they are on some kind of therapeutic regime already. Eve-
rybody who has been in substitution treatment before at the CAD (Consulta-
tiebureau voor Alcohol en Drugs, consultation office for alcohol and drugs) 
in the community and whose sentence will not exceed 6 months, will get 
have their dosage continued. If his sentence is longer than 6 months, he will 
be reduced so long as there is no contra-indication. Contra-indications in-
clude the fact that somebody is a chronic drug user and suffers from multiple 
diseases (co-morbidity). In these cases, the methadone treatment can be 
prolonged. 
If there is somebody who is only in the prison for 2 or 3 weeks, and they are 
not known in the methadone clinics outside, he will receive some 20 or 
30 mg of methadone in order to keep him stabilised. But,, in all cases the 
prison doctor decides on an individual basis. 
The staff appreciated the new scheme which was introduced by the Ministry 
of Justice in the form of a ‘handreiking’ (guideline, circulaire, see above). 
One reason for this new regulation is that if somebody is a short-term pris-
oner and will be reduced this will disturb the relationship between doctor and 
patient and will create some kind of tension and stress. Staff and nurses said 
that there had been some complaints about detoxification treatments and this 
new regulation will lead to a higher degree of transparency. So, in all cases, 
there is communication between the doctors/nurses inside and outside and 
prisons, a relationship which is characterised as very good. 
The goals of methadone prescription are: 
− not to disturb a balanced system, 
− viewing real drug addiction is an illness that has to be treated. 
Methadone is brought to the cells by a special guard at 12 o’clock, together 
with all other prescribed drugs, e.g. co-medication. The intake is supervised, 
patients have to drink some water afterwards in order to be sure they swal-
lowed the methadone and possible other drugs. 
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The average dosage of methadone is 50-70 mg. All other drugs are brought 
to the wards at 5 o’ clock. If the guard notices that someone is intoxicated in 
the cell he will call the nurse in charge. 
Benzodiazepines and sleeping pills are only prescribed by the psychiatrist. 
There is very little discussion with the prison doctor about the prescription of 
benzodiazepines, because the policy and practice is well known among the 
inmates. Benzodiazepines are prescribed only to ease insomnia – inmates 
who suffer from this disease will get benzodiazepines three times a month. If 
an inmate is known to a psychiatrist outside and gets medication from him, 
then this would be continued inside prison. This is not the case when he gets 
the drugs from a personal doctor. In all cases, there is communication with 
the doctor outside about indications for prescriptions. 
The reduction scheme for benzodiazepines is: reducing 1 tablet per week: 
Diazepam 3, 2, 1,0. 
At the time of visit 6 men in the SOV got methadone and 60% of the detain-
ees in the main unit. 
Special issue SOV 
The special treatment inside a SOV unit is drug free oriented. After a detoxi-
fication period of up to 3 months patients do not receive any methadone 
although, if there are medical reasons (counter-indication), the methadone 
prescription will be continued. To wean drug users off methadone is not a 
coercive treatment because SOV provides additional psycho-social care to 
support prisoners (psychological, psychiatric, medical health care). In the 
interview with staff of the SOV, the difficulties of reducing methadone be-
came clear: 
“It’s [methadone] the most important thing we have here because they are 
all addicted for a very long time, some of them haven’t been clean for almost 
20 years. So even in times they used heroin and cocaine they always have 
methadone. If you want to take that from them, they panic. So in the first 
stage it’s the most important thing you have to communicate about it then. 
And its the most difficult part to motivate to keep them ... because taking off 
the methadone is take off the security, their image, stability, its almost all 
they have. So it’s really very heavy. So we start reducing that they have their 
border. And then it starts getting difficult here. All the people who have 
methadone are there. Then they are clean and stabilised then they go further. 
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Because if you have methadone in that part of the treatment it becomes very 
difficult. So we try to reduce that.” 
According to the staff, most prisoners have experiences of weaning off 
methadone in a prison setting, because this is common practice in Dutch 
prisons when the sentence exceeds 6 months. But, in the very first period, 
this has some strong effects on the relationship with the staff: 
“When you are reducing methadone they really are scared, they are afraid 
they don’t feel good, sometimes they are a bit aggressive, they are sad, their 
body is aching. So they have lots of complaints there. But it’s clear that eve-
rybody has to reduce, that’s ok, they see it that way. They accept it. And it’s 
in all prisons in Holland. If you are in for longer than half a year they 
reduce your methadone. That’s not new for them. Most of them have had a 
prison time before ... and outside they experience clean periods too. It’s not 
the first time they are in reduction. It’s the first time they can nothing do 
about it. That’s what scares them. 
Those who are sentenced for 2 years, they always get three weeks for it. So 
they don’t love us when they come in. So their actions are part of their fight 
with us. They don’t like the SOV because it’s too long for a too small offence. 
The reduction scheme and the whole process is described in detail by a staff 
member of the SOV treatment unit: 
“They go to the medical service and they tell them how to reduce, how it’s 
going to happen. And it’s always the same: one tablet [5 mg] in four days. In 
the beginning that’s not to bad. They blow something and they have some-
thing in reserve, that’s not a problem. The problem starts below ten. When 
they come below ten tablets then they start- at least I think – they start suf-
fering. When they go to four tablets then they really go suffering. I guess that 
the last parts are the hardest … they hang to it, really cling to it and they 
really have pain. So we don’t try to ask too much. They have a little bit more 
privileges to go on their cell or cry a bit louder, they are given a bit more 
space to freak it out.” 
The length of the detoxification process is reported to be different according 
to the individual case. The starting point is the dosage they are come in with, 
it’s not a general scheme that fits all: 
“... one tablet in four days, that’s a fairly long time, – its about four weeks –, 
yes, it’s not too long, he has two years, he is not running out of time. We 
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don’t hang on to that scheme because if they have so much methadone, we 
try to make a pause in between. Halfway we stabilize on a dose for a week or 
two weeks if necessary. Then we go further. If you have to come from 
30 tablets it’s really a long way to go and they are really afraid, if they have 
so much ... we do one tablet in four days everybody unless someone is really 
suffering. And suffering is not only because the withdrawal but everything is 
lying beneath the methadone is going to wake: headaches, pain in the legs, 
in the teeth, all kinds of pains are coming back, memories, flashbacks, its all 
awaking. And they know it’s waiting there. You are driving them into a room 
where all their pain is waiting for them. You must be crazy if you like that. 
So they don’t. And they fight. And they get space. That’s why we don’t drive 
them up. We give them a bit space, they are allowed to do just a little more 
than in other times.” 
The staff see the withdrawal of methadone as an inevitable process which 
forms the basis for the individual (having achieved the first goal of treat-
ment) and the therapeutic intervention: 
“If you drive them mad then you cannot work the 2 years after together. So 
you have to try to be in contact, within the knowledge they have to reduce. So 
that’s clear, the first stage is 6 to 9 months. In the first 2 or 3 months we try 
to do the diagnosis and reduce the methadone. They have psychological 
search, … we try to recover them…sometimes they are really in a bad shape 
when they come in, physical ... this all we try to do ... it’s really going fast, 
the turkey, a kind of restlessness, it’s really easy going, you don’t have to 
fight you don’t have to score, you have your dinner at time, your breakfast at 
time, it helps a lot. Sometimes they double and then they look like nine 
months pregnant.” 
The inmates are very heavily involved in the process of reduction of metha-
done. The detoxification process is very much in their mind and is explained 
as part of the dynamics of addiction. 
I think there is not much other in their mind, life is situated around drugs, 
methadone and dope. That’s the point they are circulating around. And they 
still are here. So if you have methadone you have a lot of money over there 
and now it’s gold, one methadone tablet is really gold … So they know they 
can’t manage outside as they have the freedom to use, they have the freedom 
to choose, they wont manage.” 
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From the treatment point of view, and on the basis of experiences, staff 
members doubted whether inmates are able to control or if they can be given 
more control over their substances or even reduction schemes. 
“Be sober is just a nice idea. That’s the fight they have in their cell, their 
fight they have with us. And once that fight is over, I think 80% of the people 
are really glad. That doesn’t mean they stay clean … some of them say: it’s 
ok that you take the decision ‘cause I can’t.” 
Evaluation of the outcome and social prognosis of the treatment programme 
is needed: 
“When they are over in that department they all think: I don’t use drugs out-
side. When they are outside, it’s a different story. When they are here it’s 
safe, they have work, they go to school, training courses, they really feel 
good and strong and healthy. It changes dramatically when they have the 
possibility to get outside the ward. I think two years is too short. But how 
many years do you need? I don’t know, we have 5 people in here who asked: 
can I live here? Can I stay here for the rest of me life? People are so scared 
to go outside because they know they wont manage all that and they feel 
good without dope … I think those people are so damaged- it’s not the lack 
of skills, and society is complex, and we have people here around the age of 
40. So they don’t have the experience of how nice life can be. When they 
come outside it’s really difficult for them to find a place in social networks. 
It’s difficult for us, so it’s so much more difficult for them, lack of self-
esteem, the only way they know are the prison ways and the street life ways.” 
At the time of the field visit an interviewee at the Ministry of Justice stated 
that there is a discussion with doctors and the staff about whether it would be 
better for the patient to continue the programme because he is so much more 
stable during the measure. 
2.2.3 Views of prisoners  
The prisoners interviewed in the SOV were discussing the topic of weaning 
off methadone and how it is done. They reported that there should be more 
space for negotiation between doctors, nurses and inmates about methadone 
schedules. The prisoners demanded more participation in the steps of dos-
ages. They especially point out that for drug users with a drug career of more 
than 20 years, weaning off of methadone is a basic decision, because metha-
done has been served as a coping strategy in times of heroin scarcity. They 
said they were able to manage craving and adverse effects of their drugs with 
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methadone. Although it came out that there is a “love and hate” relationship 
to methadone: it is not the substance of first choice. The prisoners valued 
methadone in the double sense: on the one hand methadone is seen as a 
therapeutic medicine, on the other as a psychoactive drug and it depends on 
the situation in which it has either the one or the other quality. Furthermore, 
the structure of the SOV is criticised in that way that motivated inmates are 
together with non-motivated. Finally, they criticised the selection of the per-
sonnel which, in their view, consists of too many guards and only a few 
health care workers. 
3 Summing up 
Methadone maintenance has been a stable part of addiction care in The 
Netherlands for almost 30 years. For those in a community-based pro-
gramme before admission, it is possible to continue the treatment. But obvi-
ously this is not true for all Dutch prisons as there were several complaints 
from prisoners to continue treatment. The National health board then set up 
an expert committee with the aim of increasing access for prison-based sub-
stitution programmes. This resulted in changes of the prescription policy in 
prisons (e.g. increase of time to be served as eligible for maintenance treat-
ment from 3 to 6 months) and the situation is likely to improve over time. 
Both show flexibility within the system (i) prisoners ability to complain 
which constitutes a major improvement and (ii) the way in which the health 
council is identifying a problem and is demanding changes accordingly. 
The one exception was the Penal Care Facility for Addicts (SOV: Strafrech-
telijke opvang Verslaafden) where methadone was detoxified at the begin-
ning of the treatment. Interviewed prisoners reacted with dissatisfaction to 
this decision because they were used to methadone for many years, which 
enabled them to cope with opiate addiction themselves. Coercive treatment 
and detoxification here has to prove its effectiveness (a study is currently 
being carried out). But, again, treatment modalities are changing and a turn 
towards the provision of methadone in these treatment units is discussed and 
in some facilities has already been realised. 
  
Poland1 
1 General data: 
drug use, substitution treatment and prison population2 
1.1 Number of drug users 
According to the EMCDDA Poland Report (2001), the number of ‘problem-
atic drug users’ (those with regular and problematic use) varies from be-
tween 32 000 and 60 000 users. According to the National Bureau for Drug 
Prevention, Cocaine use is rare. There has been an increase in the use of 
amphetamines and cannabis. Amphetamines are available in tablets and 
powder that can be inhaled or drunk. Injecting has a bad image and this has 
led to a decrease in injecting and an increase in multi-drug-use patterns. In 
Poland, opiates remain the main drugs associated with problematic use. 
‘Brown sugar’ heroin is increasingly available whereas the Polish ‘compot’ 
(home made from opium straw) is becoming rare on the streets. It is possible 
that the poor image of this drug, because of its connection with death and 
social deprivation, is responsible for this trend. According to Mr Janusz 
Sieroslawski of the National Bureau for Drug Prevention, drug using patterns 
have changed over time. Whereas, in 1987, injecting compot users consti-
tuted the majority of drug dependents in the community but, by 2003, only 
20% are injecting. 
For 1995-2001, data on the prevalence of HIV among reported injecting drug 
users (IDUs) suggests some stabilisation. In 2001, 0.68 % per 100 000 
population were HIV positive. Trends for the number of new HIV cases 
among IDUs show a slight downward trend during the period from 1997 to 
2001. In absolute terms, there were approximately 300 new HIV infections 
per year and this trend has been stable since 1990 (see EMCDDA figures). 
                                                          
1  The field visit, conducted by Heino Stöver, took place from 17th to 23rd November, 2003 
and was facilitated by Marek Bujak / Marzena Ksel, Healthcare Department, Polish Prison 
Service and Maria Salivonenko, International Projects' Co-ordinator, MONAR, NGO, who 
also provided national-general information and support with the finalisation of this country 
report. 
2  For further information see also MacDonald (2004). 
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The incidences of Hepatitis C vary significantly. As of 1999, Hepatitis C 
rates reached 1.4 per 100 000 people, as indicated by the World Health 
Organization (2001). Since 1993, the incidence of Hepatitis C decreased by 
80% and maintains a lower average of incidence than in the European Union 
(pre-expansion). 
Drugs are considered to be more easily available in Polish prisons than alco-
hol. The prison service acknowledges that there are drugs in prison. Accord-
ing to the President of the Polish Association of Probation Officers, the 
reason for this is that, on the one hand Poland has become a country for drug 
trafficking and, on the other hand, the demand for drugs is high, especially 
among young people, because they are living in an extreme transition proc-
ess. At the time of the visit, the proportion of drug users in prison was esti-
mated to be 30%. Another 30% of prisoners were estimated to have alcohol 
problems. 
According to Sierosawski3 (2003), the drug problem in the Polish peniten-
tiary system was of marginal importance until the late 80s because of limited 
drug use in general and liberal drug legislation. It was only at the beginning 
of 2000 that a research project, carried out by the Institute of Psychiatry and 
Neurology in Warsaw, provided evidence about the scope of the drug prob-
lem in Polish prisons. A representative sample of 1 186 men held in peniten-
tiary institutions all over Poland demonstrated that almost every fifth inmate 
had been an occasional user of drugs such as cannabis, amphetamines, 
ecstasy or cocaine, prior to imprisonment. This figure increased to 30% for 
those between 17-24 years. The results of this study showed that, within the 
prisons, 22.5% of all prisoners interviewed (33% of those being between 20 
and 24 years old) used drugs, predominantly sedative drugs such as tran-
quilizers, cannabis-based products and amphetamines. 3.3% of prisoners 
confirmed intravenous drug use, while 1% reported sharing of syringes. 
According to those being interviewed, it is easier to access illicit drugs than 
alcoholic beverages. 
Sieroslawski (2003, p. 21) states that it is necessary to undertake activities to 
both limit the demand for drugs and to reduce the harm; supply reduction 
measures alone are not sufficient because drug users in prison are predomi-
nantly young people, under 25 years, who engage in high risk behaviour. 
Sieroslawski (2003, p. 21) concludes: 
                                                          
3  Institute of Psychiatry and Neurology in Warsaw. 
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“Although intravenous use of drugs does not happen very often in peniten-
tiary institutions, the lack of access to sterile needles and syringes poses the 
serious threat of infectious diseases, including HIV/AIDS. Programmes that 
involve administration of methadone as a drug substitute seem to provide the 
best response to the increasing threat.” (p. 21) 
1.2 Substitution treatment 
1.2.1 Historical and legal background 
The Polish National Programme for Counteracting Drug Addiction, 1999-
2001, prioritises increased treatment, rehabilitation, prevention and harm 
reduction (both availability and quality of provision), strengthening law-
enforcement activities to combat illicit drug trafficking as well as develop-
ment of drug problem monitoring and international cooperation. The new 
Programme for 2002-2005 is currently being developed (EMCDDA, 2003). 
In 1993, substitution treatment was introduced in Poland by the Department 
of Psychiatry and Neurology in Warsaw. The dominating concept behind 
drug services in Poland was drug free orientation (Sieroslawski, Focal Point 
Poland 2003). As a result, substitution treatment was conceptualised as a 
high threshold programme with strong controls and limitations. In November 
2003, at the time of the visit, attempts were being made to change the regu-
lation of substitution treatment in order to open it up to a higher number of 
opiate addicts. There has been a marked drop in the number of opiate users 
in Poland; from 900 to 700 over the course of 2003. (Rudalski, Regional 
Director of Prison Health Service, November 2003). 
Drug treatment is offered through drug-free programmes conducted in resi-
dential centres and usually managed by NGOs. Methadone substitution pro-
grammes are offered by ten public health care facilities and reached 
approximately 4 per cent of opiate addicts in 2001. Amongst the acceding 
and candidate countries to the European Union, Poland has the longest tradi-
tion of therapeutic groups working towards rehabilitation and prolonged 
abstinence. The role of these communities has superseded the position of 
psychiatric institutions, which are dominant in most other CEECs. 
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1.2.2 Substitution treatment in prisons  
Since Sierosawski’s study in 2003, which recorded drug and opiate use in 
Polish prisons, prison staff have been trained in dealing with drug users and 
raising their awareness of drugs and related issues. However, the main focus 
of the Prison Service drug strategy has concentrated on supply reduction and 
control measures (i.e. urine testing). Neither of the sample prisons had a 
written prison drug strategy. 
Substitution treatment is not available across the whole of Poland. This has 
caused problems for the introduction of this treatment in prison as it cannot 
be guaranteed that prisoners will be able to continue their treatment in the 
community once released. This is the key argument of experts and practitio-
ners from the outside who argue that it is only justified to provide substitu-
tion treatment if it is possible to continue it in the community. 
Despite these arguments, substitution treatment programmes have been es-
tablished in some prisons. Montelupich prison is one example, where, prior 
to the methadone programme being established, there was extensive nego-
tiation with the community providers of the methadone programme and 
thorough training of prison staff. The main problem with the implementation 
of the methadone programme in prison is the lack of a national strategy. For 
example, when participants in the pre-trial prison are sent to other prisons in 
Poland, the continuation of the treatment is unlikely or impossible but they 
will be definitely detoxified. 
1.3 Recent developments – an update of the introduction of 
substitution treatment 
Since January 2003, when the first pilot on substitution treatment was intro-
duced in the Kraków Remand Prison (see chapter 2.2.2 below), three more 
programmes have been started in pre-trial institutions in Warsaw (April 
2004). Wojciech Rudalski, M.D., Regional director of Prison Healthcare 
Service, Polish Prison Service, is reporting recent developments4: 
The NOVA-Methadone Substitution Programme is aimed at opiate depend-
ents, imprisoned in Warsaw penitentiary institutions – Remand Prison War-
                                                          
4  For full article see: Wojciech Rudalski (2004): Methadone behind bars – the implementa-
tion of the first methadone program in Warsaw penitentiary institutions, ‘Connections’ 
May 2004. 
310 
 
saw-Mokotów, Remand Prison Warsaw-Białołęka and Remand Prison War-
saw – Służewiec. The number of participants was set at a maximum of 
15 people per year. It is intended to be an extension of the available health 
services for imprisoned dependent drug users and is planned to continue for 
many years. The duration of individual cases will depend on the level of the 
patient’s rehabilitation. The programme will be implemented in close coop-
eration with existing external methadone programmes (including The Insti-
tute of Psychiatry and Neurology in Warsaw, the Judicial Psychiatry Ward of 
the Prison Hospital in Remand Prison Warsaw-Mokotów, the National AIDS 
Centre and the Drug Prevention Office). The programme offers an alterna-
tive to imprisoned drug users where other methods of treatment have failed. 
The programme is targeted towards individual gains for each participant. It 
will allow them easy access to reliable medical, psychological and therapeu-
tic information and thereby influence social attitudes and education regard-
ing moral, social and health issues. It will allow the participants to realise the 
mechanism of dependence, “look into themselves”, find out means of react-
ing and behaving in different situations and conditions. This will also 
improve the health and social functions of the imprisoned patients taking part 
in the programme. 
In the NOVA programme, Methadone is used as a medium for improving the 
contact with a drug dependent prisoner, which in turn offers the possibility 
for psychological stabilisation, the treatment of HIV infections and other 
serious diseases, improving the somatic state and achieving desirable sociali-
sation and psychological goals. 
In the first 24 hours of his stay, a doctor will examine every opiate-depend-
ent patient brought to the remand prison in order to evaluate his psychologi-
cal and somatic state. If the patient meets the qualification requirements, set 
by the Polish Ministry of Health and Social Care in a separate decree, the 
programme director will accept the individual into the programme and 
inform the proxy of the prison service regional director. Additionally, the 
participant must have prisoner status. For a new patient, the possibility of 
continued methadone substitution treatment, after leaving the penitentiary 
institution, must be secured before they can start the programme. However, 
in special cases, the doctor can waive this requirement for health reasons. 
The fundamental principle of the NOVA programme, is the complete free-
dom to take part in it. Two forms of the programme are planned: 
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− Form A – continuing methadone treatment to patients in substitution pro-
grammes outside prison who, due to breaking the law, have entered peni-
tentiary institutions. 
− Form B – including into the program new opiate dependents, who, due to 
breaking the law, have entered penitentiary institutions and fulfil the pro-
gramme criteria. 
In Form A, participants of substitution programmes outside prison will 
receive methadone according to the rules of their original programme. The 
therapeutic team will contact the director of such a programme in order to 
gain the necessary data and a guarantee of returning to the programme on 
release from prison. During imprisonment, the patient will receive metha-
done from the prison medical supplies. 
The first part of Form B qualifies the new patient to take part in the substitu-
tion programme. Those patients who meet the criteria of acceptance are 
given a preliminary examination – which takes place during the first 
48 hours and is based on the evaluations of the psychiatrist, the internist, the 
psychologist and the therapist – before the programme director accepts them 
onto the treatment. 
The second part of Form B concerns the implementation of the programme, 
namely, the everyday administration of a certain dosage of methadone, par-
ticipation in the therapeutic group, counselling, examinations, medical pro-
cedures and, possibly, detoxification. The patient will also be given the 
opportunity to work on prison grounds and receive education. During the 
meetings and therapy groups, the participant will take part in group psycho-
therapy and individual consultations with a therapist, a psychologist and an 
educator. Participation in these meetings is mandatory and is an integral part 
of dependence therapy. Psychological and therapeutic care will be provided 
to NOVA participants by teams of specialists employed by the penitentiary 
institutions. Participants’ duties include taking part in random urine testing, 
which is intended to detect the presence of drugs other than methadone. 
Should the use of other psychoactive substances be detected, the participant 
will be subject to individual and specific therapeutic influences. Should the 
abstinence test be positive three times, the patient will cease to undergo 
methadone therapy. The decision to exclude a patient from a programme will 
be made by the programme director, after consultation with other staff. If a 
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patient is excluded, they receive medical and therapeutic care throughout 
their stay in the remand prison. 
The patient may voluntarily opt out of methadone substitution treatment. In 
such a situation, in outreach conditions or in the prison hospital, a gradual 
detoxification is administered, with the use of methadone, until complete ab-
stinence is reached. Should complications appear, it is possible to hospitalise 
the patient in the following Wards: Internal Diseases, Intensive Care and 
Psychiatric, as well as other wards of the Prison Hospital of the Remand 
Prison Warsaw-Mokotów. 
Participants in the programme will be provided medical care, centred on the 
diagnosis and treatment of infections and illnesses connected with intrave-
nous drug use (HIV, HBV, HCV, bacterial infections, thrombotic vein 
inflammation), as well as others including tuberculosis, venereal diseases 
and mental disorders. If required, prisoners may ask for consultation and care 
from the HIV/AIDS consultant, the contagious diseases consultant and other 
specialists employed by the ambulance and the hospital in the Warsaw- 
Mokotów prison and in the ambulance of other prison institutions where the 
programme will take place. Those people who do not agree to protracted 
methadone therapy after leaving prison will undergo gradual detoxification 
during their stay in the prison and, when they leave, they will be directed to 
institutions offering rehabilitation for addicts. 
The NOVA programme is a form of protracted methadone substitution ther-
apy. However, after the patient leaves the penitentiary unit they continue 
substitution therapy in their area of residence on a voluntary basis. For that 
reason, only those patients who, due to where they live, gain a guarantee of 
continued substitution treatment (in both existing and newly created metha-
done programmes country wide), will qualify under the first part. Finding 
such a places for patients in external programmes will be among the duties of 
NOVA staff. 
As mentioned previously, it is critical to consider methadone substitution as 
an extension of prison service healthcare for opiate-dependent prisoners. 
They provide continued treatment for some and offer a chance for those who 
have not met the requirements of other methods. We cannot forget that drug 
users are an inseparable part of the community, even if they are, at present, 
isolated from it. 
 313 
 
1.4 Prison Population  
Table 18  Data on the prison situation in Poland (Source: King’s College London, Interna-
tional Centre for Prison Studies, Prison Brief for Poland) 
Country  POLAND 
Ministry responsible  Ministry of Justice 
Prison administration  Central Board of Prison Service 
Contact address  Ul. Rakowiecka 37A, PL-00975 WARSAW, Poland 
Telephone / fax / website  tel:   +48 22 640 8311 or 8355 fax:  +48 22 640 8312 or 8332 
Head of prison administration  
(and title)  Jan Pyrcak Director General 
Prison population total (including 
pre-trial detainees / remand prison-
ers)  
80,093 at 31.12.2003 (national prison administration) 
Prison population rate (per 100,000 
of national population)  
210 based on an estimated national 
population of 38.20 million at end of 
2003 (from Council of Europe figures)   
Pre-trial detainees / remand prison-
ers (percentage of prison popula-
tion)  
25.6%   (31.12.2003)  
Female prisoners (percentage of 
prison population)  2.7%     (31.12.2003)  
Juveniles / minors / young prisoners 
incl. definition (percentage of prison 
population)  
0.7%     (8.5.2003 – under 19)  
Foreign prisoners (percentage of 
prison population)  1.5%     (31.12.2003)  
Number of establishments / institu-
tions  
156 (2004 – comprising 70 remand prisons and 86 
prisons. There are also 32 external 
departments(minimum security units), 14 hospitals 
and 2 facilities for mothers with small children)  
Official capacity of prison system  69,330    (1.9.2003)  
Occupancy level (based on official 
capacity)  116.4%  (1.9.2003)  
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Recent prison population trend 
(year, prison population total, prison 
population rate)  
1992      58,619      (153) 
1995      62,719      (163) 
1998      57,382      (148) 
2001      70,544      (183) 
2 The field visits  
2.1 Sluzewiec prison 
2.1.1 Description of the prison 
Sluzewiec prison has a capacity for 680 prisoners but, as of September 2003, 
held 858; an occupancy level of 126%. Prison cells are a maximum size of 
2.53 square meters5 and sometimes groups of between six to eight prisoners 
are housed in one cell. According to the prison director, the custodial condi-
tions in his prison do not yet meet European standards. 
2.1.2 Goals and practical procedures of substitution treatment 
In the prison visited Sluzewiec, Warsawa, the prison director Mr. Rost-
kowski, reported that prisoners are assessed upon admission. The doctor 
describes dependency symptoms. If there is a person with withdrawal 
symptoms, he will be referred to community services or the prison hospital 
(Rakowiecka Str.) for detoxification. During their first three days in prison, 
they are supported by an educator who provides basic support. The educator 
plays a key role in working with inmates: 20% have a higher education 
qualification and have run special programmes with addicted inmates. Their 
work covers legal aspects, helping to re-build or support family contacts and 
offer individual counselling to inmates. 
At Sluzewiec prison, drug dependents are treated in one of the ten specific 
therapeutic units in Polish prisons. These units are connected in that they are 
all abstinence-oriented. The structure of these units is underpinned by the 
Executive Penal Code (1997, §117). However, the working of the units can 
be flexible to meet local circumstances and needs. Representatives from the 
ten units meet twice a year to exchange information and experience. 
                                                          
5  The official minimum space specification per prisoner is 3 square metres (Penal Executive 
Code 1997, Article 110). 
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The Therapeutic Unit at Sluzewiec prison is the only one in Warsaw and 
house 34 prisoners at the time of the visit. The unit sees approximately 
70 prisoners over the course of a year. The unit is for opiate and ampheta-
mine users who have no psychiatric illnesses. The average age of the prison-
ers is 24 years. The unit is run by a therapeutic team consisting of a director 
(who is a psychologist), a nurse and another psychologist. 
The prisoners on the unit must be diagnosed as drug dependent and they 
must have been sentenced to compulsory treatment as part of their sentence. 
The treatment provided by the unit is underpinned by the Executive Penal 
Code (1997 §117). According to the treatment team, it doesn’t make any dif-
ference whether the prisoners come to the unit on a voluntary basis. Prison-
ers from other prisons can also attend the unit. 
Within the programme, withdrawal is seen as a good starting point to in-
crease the prisoner’s motivation to change their behaviour. The treatment is 
in three phases: 
1. Introductory phase (approx. 1 month): The goal of this introductory 
phase is to identify and raise awareness of the symptoms of dependency. 
Basic education is provided on issues relevant to drug users: HIV/AIDS, 
Hepatitis, how to deal with withdrawal symptoms and so on. HIV testing 
is offered to the prisoners. 
2. Phase two: Group meetings where the social and individual costs of drug 
use are discussed with particular emphasis on the impact on individual 
prisoners. 
3. Phase three: A mixture of individual and advanced group work that con-
centrates on topics like emotions, feelings of shame, anger, dealing with 
the nature of the illness, perspectives after release. In this phase, individ-
ual treatment plans are elaborated and meetings and therapy groups with 
drug dependents from outside are organised in the form of peer-groups 
with patients and ex-prisoners. 
The unit is linked with community service staff who come into the prison 
once a week to provide individual counselling. The prison co-operates with 
the NGO MONAR who care for prisoners on a conditional release (see be-
low). 
After completing six months in the therapeutic unit, prisoners return to other 
sections in the prison. On average, the prisoners stay six months in the unit. 
The work of the unit has not as yet been evaluated. The unit has a waiting list 
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of 100 people until May 2005 (from November 2003). Originally, the pro-
gramme lasted 1 year but, as more and more prisoners wanted to take 
advantage of the programme, it was reduced to six months. 
At Montelupich prison, in Kraków, the peer group for drug users is led by a 
psychologist who works both in the prison and with an outside organisation 
called ‘Formaticja’. The peer group is an open group that meets for one and a 
half hours each week. In the group the prisoners receive information about 
alcohol and drug use, after this the prisoners can attend an outside group 
organised by ‘Formaticja’ which focuses on motivation building. 
Individual counselling is also provided for drug users by a psychologist at 
Montelupich prison. According to a new law every prisoner who is younger 
than 21 and has a sentence longer than six months will have an obligatory 
diagnosis of drug use. From 2001, it is mandatory to have diagnostic units in 
every regional directorate. In Montelupich prison, the psychologist involved 
with the diagnostic unit stated that he found that approximately 70% of the 
juveniles had had contact with illegal drugs. 
MONAR Association 
The main goal of MONAR Association activities in prisons is to build an 
integrated assistance system for counteracting drug abuse, marginalisation 
and social disintegration within prison system. They also work to build a 
bridge between this system and the services available in the community. 
According to the President, Jolanta Lazuga-Koczurowska, and her colleague, 
Masha Salivonenko, MONAR has been active in the prison field for more 
that 15 years; long before anyone else was working with prisoners and drug 
use. In the beginning, they worked in 15 prisons conducting educational 
activities. One key element to their programmes is the self help perspective 
and the use of ex-addicts and ex-prisoners to talk to prisoners. 
At the beginning of the nineties, as prisons started to think about treatment 
after release, the process of therapy instead of punishment was started, that 
meant the rest of the sentence was suspended (after 1 year). Starting in 
Gdansk prison, peer groups and self help groups were established. In the 
course of the nineties, in response to HIV/AIDS, cooperation between 
MONAR and the prison system intensified. Externally, there was a parallel 
development as social work targeted those with HIV/AIDS as well and 
prison staff started to visit these facilities in the community. 
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Now, MONAR is looking for better funding from the Polish Prison admini-
stration in order to support prisoners needs more systematically. An agree-
ment between MONAR and the Polish prison service will be signed in 
December 2003. This will provide solid grounds for more centralised and 
structured prevention work and the awareness training that MONAR will 
carry out in prisons. It would also provide MONAR with official permission 
to go into all prisons. The work plan includes: 
− Therapy motivational work. 
− “Half and Half” – after half a sentence is served, a transfer to a therapeutic 
community becomes possible. 
− Treatment in therapeutic communities. 
MONAR proposed a special therapeutic community (Lipianka, 150km north 
of Warzawa) as a place for all ex-prisoners. In addition, MONAR is provid-
ing training for prison staff in order to better their understanding of the needs 
of prisoners and to improve connections between services inside prison and 
those outside. However, due to budget cuts, MONAR will not be able to 
continue this work. 
In Warsaw, Adam Nyk, sociologist, volunteers to provide individual coun-
selling and group meetings with all addicted inmates. One of the aims is to 
motivate prisoners to continue their therapy after release. A substantial num-
ber of prisoners have continued therapy in the MONAR centre after release 
(20 in 2002). 
2.1.3 Views of prisoners  
The focus group consisted of five male inmates, who all reported previous 
stays in prison. First of all, the inmates reported that, in AS Sluzewiec, there 
are 3-6 inmates per cell. Some hygienic problems were related to cold and 
hot water from the tap. Each cell has a toilet room of its own but basic hygi-
enic equipment (toothbrush, soap, toilet paper) is of a bad quality. Access to 
a shower is granted twice a week, better than the normal rule of once a week. 
Access to a fitness club is permitted every day (table tennis etc.) for 
1¼ hours. Access to education is confined to education on drugs, HIV/AIDS 
and infectious diseases. Access to medical care is via the nurse, who can be 
contacted daily and in emergencies. The doctor is open to visits twice a 
week, for a few hours. Medical records are kept. Because of the nature of the 
therapeutic unit, psychologists can be contacted daily. 
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Prisoners stated that there is no drug use in the therapeutic ward but that it 
does exist on the other wards where marijuana is smoked if available. 
According to inmates, they were not offered a professional detoxification 
treatment before entering prison. Some told about long waiting lists to get 
into a qualified programme. Others said that they paid the doctor for pre-
scribing them pills at home prior to their incarceration (approximately 
500 Zloty for 10 days). None of the respondents underwent a qualified de-
toxification programme in the prison hospital. 3 out of the 5 prisoners are in 
the unit on a voluntary basis and 2 are obligatory cases who tried to make the 
best out of it and have become more self motivated. Everybody said that 
living conditions in this unit are much better than normal. 
In the therapeutic unit, prisoners receive information on HIV/AIDS and other 
infectious diseases from the nurse. Regarding condoms, prisoners stated that 
there is no need to provide them in prisons. 
One of the key issues raised in the prisoner focus group was the question of 
whether patients felt prepared, having run through the therapeutic unit, to go 
back to the normal ward and whether they would be able to resist the temp-
tation to use drugs again. Most of them were unsure about this. Other issues 
included the need for: 
− Better food, bigger rations. 
− Bigger cells, overcrowding. 
− Temporary/conditional releases. 
− Better attitudes of prison staff towards prisoners. 
− More activities for prisoners. 
− Hot water. 
In 1998, social rooms in the prison had been rebuilt as cells due to over-
crowding. 
2.2 Montelupich prison 
2.2.1 Description of the prison 
Montelupich prison, according to its director, has a capacity of 702 prisoners 
but currently holds 815, of which 329 are sentenced and 486 prisoners are 
pre-trial. The rooms in the prison hold from between 1 to 15 prisoners with 
an average space per prisoner of 2.53 square metres and, in the hospital, an 
average of 4 square metres. 
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2.2.2 Goals and practical procedures of substitution treatment 
According to Mr. Potoczny, Director of the Kraków prison, Montelupich, the 
following procedure is applied when new drug users come into prison: the 
person talks to the educator which includes previous drug history. There is 
no tendency to hide; if they are drug users, prisoners will admit it. In the first 
phase, they will also go to the medical department – as a rule within the first 
3 days but most go on the same day as admission. If present, the doctor will 
notice withdrawal symptoms. If there are symptoms of severe addiction, the 
person will either be treated in prison or in the prison hospital. They are 
working closely with Kielza, a big prison hospital with a therapeutic unit (the 
waiting list for this unit is about 4 months). After the detoxification phase, 
prisoners can enter a peer group. A social worker (Marek Hanusz) leads this 
group. Some prisoners are allowed to meet in this, and other, groups but 
some remand prisoners are not permitted due to juridical constraints. For 
them, individual counselling is organised. 
The peer group is a mixed one, with alcohol and drug addicts, and consists of 
approximately 20 participants. The psychologists think that meeting only 
once a week with a group is too seldom. The prison is also cooperating with 
MONAR, who also take care of drug addicts in the prison. 
At the time of the visit, the only substitution treatment programme in a Pol-
ish Prison was in Montelupich prison in Kraków. Montelupich prison pro-
vides substitution treatment for 10-15 prisoners but, at the time of the visit, 
there were 6 prisoners on the programme. According to the doctor in charge, 
Dr. Katarzyna Leśniak6, interested inmates have to fulfil three conditions to 
be accepted onto the methadone programme: 
1. They must be at least 21 years old. 
2. They must have a 3 year history of injecting drug use. 
3. They must have undergone 3 unsuccessful treatment attempts and give 
assurances that they will take the methadone. 
                                                          
6  Head of Internal Diseases Department, prison hospital, Montelupich, Kraków. The follow-
ing description of the methadone programme is based on her presentation to the CEN-
TRAL AND EASTERN EUROPEAN CONFERENCE ON DRUG & INFECTIONS SER-
VICES IN PRISON: “Dealing with Drug Use in Prison: Reviewing the European Experi-
ence and Sharing Good Practice” (18-20 September 2003, Popowo, Poland). 
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These conditions are based on a Ministry of Health regulation (6/9/1999)7 
about substitution treatment. Additionally, the person attending the substitu-
tion treatment has to sign a contract with the doctor. The methadone pro-
gramme is not available for prisoners without medical insurance because 
they cannot be transferred to programmes outside. The high threshold is a 
tribute to the drug free orientation in Polish drug treatment. The substance 
used in the substitution treatment is methadone. 
Currently, there are 6 inmates in the first methadone maintenance therapy 
which has 10-15 places for drug users. The prison hospital in Montelupich is 
able to test the presence of opiates in urine within its analytical laboratory 
(urine controls are taken once a month). The presence of opiates have to be 
confirmed before the start. The tests are also used to control abstinence from 
other drugs during methadone therapy. 
“I think I’ve been in good contact with drug users from the treatment group. 
Other members of my team feel the same about themselves. I determine an 
optimum dose and decrease in dose in concert with the drug user. We’ve ob-
served satisfactory change which takes place in our patients after weeks or 
months of treatment. Some of the prison staff, outside our team, confirm our 
observation.” (K. Leśniak) 
Methadone is given, under supervision of a nurse, before 12 o’clock. There 
is a central register of all methadone users. Views among the staff vary; 
some staff members think that prisoners are calmer when prescribed metha-
done. 
Substitution treatment was first initiated in Kraków because they fulfilled all 
the requirements mentioned above and, in May 2002, their set up was 
accepted by local authorities, this included: 
− Team (psychologist, a psychiatrist, a sociologist and a nurse) 
− Infrastructure 
− Methadone supply 
− Proper facilities 
After the one year pilot programme (from January 2003 to Jan. 2004) an 
evaluation must be made. This assessment has to be done within a very short 
                                                          
7  According to Marek Zygadlo, MONAR, Kraków, these regulations will be discussed in a 
meeting in December 2003. 
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period of time. It will contain a statement that the programme should con-
tinue. Since the beginning of the programme, the treatment team has cooper-
ated and has been in permanent contact with the Public Health Center for 
Drug Addicts in Kraków which runs methadone therapy in the city and the 
region. The team members are also in close contact with social institutions 
like MONAR. They have the telephone numbers of all medical institutions in 
Poland so that prisoners on the methadone programme can be referred to 
other prescribing institutions. At present, there are nine such institutions in 
Poland. The doctor has access to patients’ data within these programmes 
when they are sent to prison. 
The following reasons were given for disqualification from the programme: 
− The person didn’t fulfil the condition of three unsuccessful attempts at 
other treatment. 
− He or she didn’t have the medical insurance. 
− Before coming to prison, the person had been disqualified from the 
methadone therapy by the medical institution conducting methadone ther-
apy externally. 
As most of the prisoners are on remand, the medical center closest to the 
drug user’s residence is informed that he or she should be included in the 
substitution programme, as well as the date of release if known. One central 
problem for remand prisoners is the possible transfer to other prisons as, at 
the time of visit, there were no other prisons providing substitution treat-
ment. 
The doctor in charge, Dr. Katarzyna Leśniak, concluded from the pilot pro-
ject: 
“My modest experience induces me to present the following conclusions:  
− methadone therapy in prison is really needed, 
− its realisation is not too difficult for prison medical staff. 
I’m strongly convinced that clear conditions for participation in the pro-
gramme are indispensable. I’m sure that some requirements for drug users 
such as abstinence and submitting to the other methods of therapy (e.g. 
workshops, psychotherapy) are necessary. I think that, in Polish conditions, 
participation in methadone programmes inside and outside prison should be 
regulated so that there wouldn’t be obstacles for drug users to cross between 
centers. On the other hand, prison authorities should consider possibilities 
to form more centers of methadone therapy and to determine therapeutic 
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units which would also run methadone therapy. In conclusion, I’d like to say 
that, if proper regulations are introduced, prison may be a place where a 
drug user could stay not in a passive way but in an active way. It means to 
listen what’s going on in himself or herself, to feel and to understand what 
had happened in his or her life and how to fight with addiction.” 
According to Marzena Ksel, Director of Medical Service, Central Board of 
Prison Service, prison doctors need to be more qualified and Governors’ 
knowledge of and views about drug problems should be developed. Accord-
ing to Dr. Ksel, one of the key problems is the continuation of the methadone 
programme after release. One of the preparations for a better understanding 
of substitution treatment is a meeting with prison doctors in Torun, June 
2004. 
The role of the prison hospital in the enlargement of substitution pro-
grammes is crucial: It is well equipped, has lots of specialists and experience 
in detoxification at least. Difficulties are still experienced regarding the high 
thresholds for methadone maintenance treatment in the current regulation. 
When introducing substitution treatment in prisons, giving prison doctors 
experience through visits to other prisons is also important.. This has been 
done in Canada with two doctors. There they could direct their questions and 
insecurities to the staff and prescribing doctors; they returned convinced of 
the benefits of substitution treatment. 
According to Wojciech Rudalski, the following requirements have to be met 
by every prisoner: 
− They should receive information that methadone is a drug. 
− They should participate on a voluntary basis. 
− They should abstain, absolutely, from all other drugs. 
− They should have participated actively in a scientific examination. 
− They should agree to be tested for other drug use. 
− They should have received temporary counselling from a psychologist. 
Meetings will be held with all relevant institutions (Institute for Neurology 
and Psychiatry, National Office for Drug Prevention) to get the approval for 
more prison-based programmes. 
The Polish Prison Health Education Society is involved in training doctors 
(40) and envisages training for nurses in matters related to substitution 
treatment. NGO representatives will be involved in this training.  
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As the Director of the Kraków Montelupich fears a pull towards the pro-
gramme – of large numbers of prisoners – the pilot is running without 
publicity or active recruitment. 
The central medical department of the Polish Prison Service has given finan-
cial support for training conferences. NGO representatives will be involved 
in this training. With this first pilot, the specific problem with methadone 
maintenance is that the prisoners cannot be sent to other prisons or drug 
treatment institutions. 
A close cooperation has been established with the Public Health Center for 
Drug Addicts in Kraków. The institution gave the green light to treat the 
prison programme’s patients after their release. But, this is not an easy task, 
as the number of places in external programmes is limited, it is likely that 
there will be cases where a place for the continuation of a patient’s treatment 
cannot be found externally. 
At Rydygier hospital, in Kraków, 80 drug users are in a substitution pro-
gramme It is estimated that there are 4 000 drug injectors living in the region 
of Kraków. Most of these are in contact with MONAR (Chrostek-Maj and 
Kosecka, Rydygier Hospital, November 2003). The methadone maintenance 
programme in the community has been running for three years. It is a high 
threshold programme according to the regulations set by Polish law. When 
the programme was first set up it was not anticipated that some clients re-
ceiving methadone would end up in prison and so no links were made with 
prisons at this time. This changed after the programme had been running for 
a year when both doctors from Rydygier Hospital saw the need for a substi-
tution programme in prison. 
2.2.3 The views of prisoners 
The focus group consisted of 4 male persons (one sentenced and three 
remand prisoners). 
One of the key issues addressed was the fear that the substitution treatment 
pilot could be ended and that they would be brought down to zero in the 
prison setting. Though there are no plans to end the substitution treatment in 
prison (on the contrary, much energy is directed towards qualification and 
training to support the pilot in Montelupich), this is anticipated by prisoners 
with long sentences. The prisoners understood that substitution treatment is 
continued in prison when the sentence is not longer than 6 months. So, espe-
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cially for those prisoners who are not yet sentenced, – and may get a sen-
tence for more that 6 months – and are receiving methadone, this is a signifi-
cant fear. This lack of information is contributing to the uncertainty of 
patients. 
Detoxification from methadone is described as a big problem. The prisoners 
describe it as a central fear, for which they do not find any understanding 
from the other inmates. The prisoners want to maintain the same dosage as 
they received outside. It becomes obvious that the dosage, and feared 
attempts to reduce the dosage by the medical unit, is a key issue for the 
inmates. Unanimously, if they underwent detoxification in prison, they 
wanted to get into the methadone programme after release. 
Offers of psycho-social care (group meeting mentioned above) are not 
known about by all inmates. The inmates express their feelings that, in the 
group meeting, there is a lack of understanding of methadone treatment and 
the goal that is pursued there is abstinence. When asked about their previous 
detoxification experiences, they all stated that detoxification happens in the 
cell. 
3 Summing up 
The combination of overcrowding and that the need for refurbishment im-
pacts on the possibility of addressing the health needs of prisoners and the 
possibility of providing equivalent services to those found in the community. 
In November 2003, at the time of the visit, the Polish prison system offered 
substitution treatment in one prison. This initiative is very rare due to the ab-
stinence oriented approach towards drug treatment in Polish prisons, which 
is in line with most of European prisons. The main problem identified with 
the implementation of the substitution programme is the lack of a national 
strategy on the implementation of substitution programmes. If participants in 
these programmes are sent to other prisons in Poland, the continuation of the 
treatment is unlikely or impossible. This results in the fears and uncertainties 
of the patients interviewed in this programme, and perhaps the pilot itself. 
But, the substitution programme is a good example for introducing, and de-
veloping, treatment in a setting which is not in favour of this form of treat-
ment as it is well prepared with exchanges of information and expertise with 
other experts and community links. 
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The drug treatment programmes in both sample prisons were cooperating 
closely with community based treatment agencies where professionals from 
the community were involved in the counselling and support of the prison-
ers. 
  
Portugal1 
1 General data:  
drug use, substitution treatment and prison population 
1.1 Drug use 
The most commonly used psychoactive substances are cannabis, heroin, 
cocaine, prescribed drugs, amphetamines, ecstasy and hallucinogens. (Reitox 
Portugal, 2002) Poly-drug use of heroin and cocaine, the use of cocaine is 
increasing and is reported to be the preferred substance, and also cannabis 
and amphetamines has risen in the past few years. Primary heroin users make 
up the majority of those searching for treatment. (Reitox Portugal, 2002) 
Amongst the prison population, communicable diseases (particularly HIV/ 
AIDS and hepatitis) are problematic. According to Fernandes (2003), 14% of 
Portuguese prisoners are infected with the HIV virus and 396 have AIDS. 
It is estimated that there are 100 0002 drug users in the country (all drugs in-
cluded). In 2000/2002, 12 863 patients were receiving substitution treatment 
(EMCDDA, 2003, p. 50). On 31 December 2002, 15 768 patients were in 
substitution treatment, of which 10 157 were on methadone and 1 987 were 
on buprenorphine. The remaining patients received naltrexone. (IDT, 2004) 
IDT estimates that between 25 and 42% of the total prison population in 
2002 were drug users. 607 prisoners were on substitution treatment in 2002. 
In four prisons where treatment is managed by the Prison Service directly 
and not the CAT centre, 293 prisoners were on substitution treatment 
253 prisoners, from 40 prisons, were treated with methadone in CAT’s cen-
tres and 31 prisoners were treated with antagonists through a CAT’s centre. 
(IDT, 2004) 
                                                          
1  The field visit, conducted by Laetitia Hennebel, was facilitated by Dr. Maria Estrela da 
Graça de Pinho Campinos Poças, Director Health Care Office, Prison Service Administra-
tion, Ministry of Justice. A special thanks to Manuela dos Santos Pardal for her support 
and feedback. 
2  Figure given in interview with IDT. 
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The treatment section (health care in prisons) falls under the jurisdiction of 
the National Prison Administration, Ministry of Justice, and the CAT cen-
tres, Ministry of Health. 
1.2 Substitution treatment 
Data comes from interviews3 and on-going review of research reports, web-
sites and laws/ regulations. 
1.2.1 Historical and legal background 
Between 1975 and 1980, the phenomenon of drug dependency emerged. Ini-
tially, it was seen as an issue related to justice, the Ministry of Justice 
responded by creating some community centres, and then became a health 
issue with the Ministry of Health developing additional centres. 
In 1990, these centres (belonging to the Ministry of Justice and the Ministry 
of Health) were integrated into a common service centre: the Service for the 
Prevention and Treatment of Drug dependence (SPTT) managed by the 
Ministry of Health. By 2002, across the whole country, there were 53 centres 
for drug users in the community. SPTT was responsible for the licence and 
management of these centres as well as for providing standard procedures to 
private centres. 
The SPTT is the national authority on specialised treatments for drug use. Its 
organisational structure is broken down into Central Services, Regional 
Offices and Local Centres. The services provided are entirely free and acces-
sible to all drug users who seek treatment. In 2001, as in previous years, the 
number of treatment units in the SPTT network increased. The treatment 
programme is tailored to each client’s specific problem and the facilities/ 
services include: Specialised Treatment Centres (45); Consultation Units 
(16); Detoxification Units (5); Therapeutic Communities (2); Decentralised 
Consultation Units (3); Day Centres (4). (Reitox Portugal, 2002) 
                                                          
3  Interviews were conducted at the national level with: 
– Health Service Director, General Directorate of Prison Services, Ministry of Justice. 
– Deputy General Director, General Directorate of Prison Services, Ministry of Justice. 
– Vice Director, IDT (Instituto da Droga e da Toxicodependĕncia), Ministry of Health. 
– Doctor, AIDS Commission Portugal for the area of ‘Prevention of AIDS and Hepatitis 
in Prisons’. 
– Doctor, CAT. 
– Staff, CAT Taipas Centre. 
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After the 2002 general elections, the government stated that drug abuse was 
seen to be a health problem and so the focus should be on ‘minimising the 
social problem’. The National Strategy and National Action Plan, Horizonte 
2004, will continue. (Reitox Portugal, 2002) 
Decree 120/2002 (3rd May 2002) ruled that issues surrounding drug demand 
and the National Institute for Drugs and Drug Addiction (IPDT) should be 
coordinated by the Ministry of Health. (The IPDT was previously located in 
the Council of Ministers). Decree 16-A/2002 (31st of May 2002) stated that 
the IPDT and SPTT should merge into a new agency: The Instituto da Droga 
e da Toxicodependĕncia (IDT). The IDT was then created through the Gov-
ernment Decree nº 269-A/2002 (29 November 2002). 
The IDT, created in 2002, manages the 45 CAT centres which are located in 
every province of the country. A CAT centre team is made up of a minimum 
of one GP or psychiatrist, a social worker, a social psychologist, an occupa-
tional therapist, and nurses. The largest of the CATs provide methadone 
treatment (Vice Director, IDT). 
IDT is about treatment, prevention, harm reduction and reinsertion. It was 
reported that the number of CAT centres is adequate. However, better liaison 
with all health services is needed, especially due to infectious due to drug 
use. (Vice Director, IDT) 
The Action Plan, Horizonte 2004, underlines the need for harm reduction 
programmes to be available for all drug users in prison. These programmes 
are managed by the General Directorate of Prisons (Ministry of Justice) in 
close co-operation with the IDT and the Institute for Social Rehabilitation. 
(Reitox Portugal, 2002) 
The IDT’s mission is to ‘guarantee the intrinsic unity of the planning, con-
ception, management, control and evaluation of the diverse phases of pre-
vention, treatment and reinsertion in the domain of drugs and drug addic-
tion, in the perspective of the best efficiency on the co-ordination and execu-
tion of the politics and strategies already defined’. (Government Decree, 
nº269-A/2002, 29 November) 
IDT’s services are located: 
− At central level: Department of Prevention; Department of Treatment, 
Harm Reduction and Reinsertion, Department of Planning and General 
Administration. 
− At regional level: regional delegations. 
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− At local level: the specialised unities.  
The IDT’s tasks: 
− To co-ordinate and conduct the national strategy for the fight against drug 
addiction; 
− To promote, to plan, to coordinate, to manage and to evaluate program-
mes of prevention, treatment, harm reduction and social reinsertion, 
through community work, alone and in collaboration with public and pri-
vate entities that work in this area; 
− To promote, coordinate, support and evaluate public and private initia-
tives in the domain of drug prevention; 
− To support The Commission for Drug Dissuasion, created by law 
30/2000, 29 November 2000; 
− To create, treat and spread information about drugs; 
− To support the EMCDDA; 
− To evaluate political policy and strategy on drugs and drug addiction; 
− To support research; 
− To support the training of personnel; 
− To study legal measures; 
− To give permission to private units of treatment; 
− To collaborate with the general Directorate of Health to guarantee the 
continuity of care to users of IDT services. 
(Government Decree nº269-A/2002, 29 November 2000) 
In order to pursue these tasks the IDT is mandated to create liaisons with 
labour associations, universities, services of the Ministry of Health, Ministry 
of Social Security and Labour and also with public and private units that 
work on prevention and treatment. (Government Decree nº269-A/2002, 
29 November 2000) 
Because of the large number of individuals convicted for a drug-related 
crime, (approximately 3 930, 42%, of the total prison population by the end 
of 2001), the Drug Use Decriminalisation Law (nº 30/2000 of 29 Novem-
ber)4 was implemented and Commissions for the Dissuasion of Drug Use 
(CDTs) were created. Many drug users are referred to and assessed by these 
                                                          
4  On the definition of the penal regime applicable to the consumption of drugs and psycho-
tropic substances, and on the social and health protection of people that use those sub-
stances without medical prescription. 
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Commissions (Reitox Portugal, 2002), with the result that some of them are 
sent for treatment or to therapeutic communities. 
The national strategy5 states that substitution treatment should only be used 
as a last resource, when other treatments have not been successful or for the 
prevention of infectious diseases. It also states that substitution is not seen as 
a life-long treatment but rather as a means to find physical, psychological, 
social and family equilibrium and allow for further attempts to join drug free 
programmes. 
In 2002, 91% of the 4 835 decisions made by the 18 CDTs were suspensions, 
as the consumers were not considered drug dependents, 25% were accep-
tances for treatment; 6% involved punishments, 5% were repeated inci-
dences. The majority of them involved males aged 16-34 (IDT, 2004). 
A protocol (Protocolo entre os Ministérios da Justiça e da Saúde, signed on 
21 of March 1997) implements the liaison between the health system and the 
prison system in relation to substitution treatment. Doctors or psychologists 
of CAT go to the prison to deliver methadone or prisoners are taken to the 
CAT where they receive methadone and psychotherapy. 
At the time of the field visit, prison reform was underway, resulting in a new 
‘Framework Law’ establishing action to be taken for the next 10 years. 
Moreover, a new ‘Law of Sentence Execution’ was to be produced, drawing 
up a new model of health care in prison, including the Ministry of Justice’s 
request for health care in prison to be provided by the Ministry of Health. 
Substitution treatment in prison formed part of the political agenda; there 
were discussions on whether the number of prisoners on substitution treat-
ment was appropriate or excessive, the type of treatment (pharmaceutical 
versus non-pharmaceutical treatment) to be provided and the need for stricter 
criteria governing access to substitution treatment (Director Health Care 
Office and Deputy General Director, Directorate General of Prison Services, 
Ministry of Justice). 
                                                          
5  A resolution of the Council of Ministers of the National Assembly, approved in May 1999, 
and published in the Official Journal of 26 of May 1999: Resolução do Conselho de Min-
istros nº 46/99. 
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In the community 
Methadone has been offered in Portugal since the late 1970s. It was first de-
livered in a CAT centre in Porto, where it was offered in a powder solution 
which is drinkable once it is mixed with water. (GP, CAT centre and vice 
director, IDT) At the time, methadone was the only therapeutic response 
offered to drug users and was highly criticised by all clinicians. (GP, CAT 
centre) 
In other locations, CAT centres started to offer methadone to tourists on 
methadone treatment and those on holiday in Portugal. The centres then 
started to offer methadone to problematic Portuguese patients and, eventu-
ally, it was provided to a larger sample of patients, numbering around 1000 
patients on methadone in 1995. (GP, CAT centre) 
Since the outset of methadone provision, the Ministry of Health has retained 
total control; any hospital or prison wishing to provide methadone treatment 
must make a request to the Ministry of Health. The Ministry of Health 
developed a protocol with the ‘Association of Pharmacies’ where (i) metha-
done is to be administered in pharmacy under a CAT prescription (the pa-
tient goes directly to the pharmacy to get methadone, instead of going every 
day to the CAT centre), and (ii) the Association of Pharmacies has developed 
a syrup to mix, stabilise and guarantee the quality of the medicine. (GP, CAT 
centre) 
At the outset, methadone was industrially produced by military laboratories 
whereas, today, it is bought through international tenders. The powder is 
then sent to the military laboratory where it is prepared. The military distrib-
utes the methadone throughout the country and in all the CAT centres. This 
has increased the availability of methadone in the country. In 2002 around 
13 000 patients in the Portuguese community were on methadone. The aver-
age dose is 60 mg; there is no maximal dose. The dose tends to be higher for 
patients on HIV/AIDS and/or tuberculosis treatments. (GP, CAT centre) 
Today, methadone and buprenorphine are used for substitution treatment. 
Only CATs can prescribe methadone whereas buprenorphine can be pre-
scribed by private doctors and CATs. Usually, the patient’s family or friend 
is involved in the treatment to ‘ensure’ the uptake. LAAM was prescribed in 
CATs previously but this stopped in 2002 further to the National Medical 
Agency’s decision. (Reitox Portugal, 2002) 
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Each patient on methadone is tested weekly for heroin, cocaine and metha-
done. If tested positive 3 times for illegal drugs, he is expelled from the 
methadone programme. (Social worker, CAT centre) 
The Ministry of Health does not control buprenorphine which results in the 
situation where any GP has the right to prescribe it. Methadone is provided 
totally free for all patients, buprenorphine is not. Patients must buy bupre-
norphine at the pharmacy. Even if the treatment is partly reimbursed, it 
remains expensive. ‘Buprenorphine is used more often in the CAT centres in 
the North part of Portugal. It all depends on the doctor’s approach.’ (Health 
Service Director, General Directorate of Prison Services) The costs of 
methadone treatment are comprised of the number of staff and specialised 
centres involved .(GP, CAT centre) 
In 2001, 12 863 patients of the SPTT were in substitution treatment (this 
does not include patients who take the substance at home): 3 576 were new 
admissions. The majority of clients on methadone received their treatment in 
a CAT. Health centres, pharmacies, NGOs and others also dispense metha-
done. Of those in treatment, 9 664 took methadone, 42 LAAM and 527 bu-
prenorphine. (Reitox Portugal, 2002) 
Substitution treatment is provided either according to a high or low thresh-
old.. The first aims at minimizing health risks and harm related to drug use 
by offering a broad treatment, including psycho-social therapy, and by trying 
to attain progressive detoxification and abstinence. The low threshold aims at 
street users not involved in treatment and tries to reduce harm due to drug 
use, as well as ‘attracting’ the user into a health care approach. (Reitox Por-
tugal, 2002) 
Methadone was detected in 5% of drug-related deaths in the community, 
mostly associated with alcohol and/or opiates, with a greater incidence 
among women. (Reitox Portugal, 2002) 
Buprenorphine may be more appropriate for stable and balanced individuals 
(e.g. those who have a job), as the provision allows for greater autonomy 
from institutions. Whereas, methadone may be appropriate for more prob-
lematic, disorganised drug users and may be a means to bring them in to seek 
medical support as it provides stability. Patients who have the will and 
strength to stop the treatment may do so. As substitution treatment perpetu-
ates a certain kind of ‘dependency’, to a substance and institution, alterna-
tives to substitution treatment may be offered. Hence, substitution treatment 
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may be viewed as a first step, although other options and treatments with no 
opiates – such as therapeutic units – are needed. (GP, CAT centre) ‘Substitu-
tion treatment is seen as a ‘transitory’ moment, but then other options must 
be offered.’ (Health Service Director, General Directorate of Prison Services) 
1.2.2 Substitution treatment in prison 
It was reported that substitution treatment first became available in prison 
around 1999. 
Because substitution treatment is provided in prison with the support of a 
CAT centre (either directly, the CAT provides the treatment, or indirectly 
through liaison and continuation of care), the provision of substitution treat-
ment in prisons follows the guidelines and system of substitution treatment 
in the community. 
Substitution treatment in prison is available either in co-operation with a 
CAT centre or through the prison, the situation in 3 prisons in 2001 (Reitox 
Portugal, 2002). Usually, prisoners go to the CAT centre for the provision of 
methadone and to receive psychological support. 
A GP reported that the prisons of Tires, Lisbon, and Oporto are the best 
examples of practice in Portugal, mainly because trained nurses (Ministry of 
Health) and experienced doctors are in charge of providing treatment to drug 
users. In the other prisons, protocols define the possible types of collabora-
tion: drug users either go out to a CAT centre to get treatment, which gives 
them access to the whole range of services (psycho-social care) or a doctor 
from the CAT visits the prison to treat the prisoner. 
Prisoners who receive substitution treatment are (i) drug users who continue 
methadone treatment started before incarceration in a CAT centre; (ii) drug 
users going through withdrawal: the prisoner is sent to a CAT centre for 
evaluation; if appropriate, the prisoner will start treatment; or (iii) drug users 
who started using while in prison and are motivated to stop using and have 
asked for support and substitution therapy. If accepted, the prisoner is sent to 
a CAT centre for evaluation (Vice Director, IDT). 
At the time of the visit, all prisons had to collect methadone from a CAT 
centre, where they are given the appropriate doses for the number of patients, 
except for the three prisons, Tirce, Porto and Lisbon, who manage the quan-
tity and distribution of methadone themselves (Vice Director, IDT). 
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Upon request, the CAT centre confirms whether a given prisoner has under-
taken methadone treatment and what dose they were prescribed. It was 
reported that the prisons are not reluctant to continue methadone treatment 
started in CAT centres. However, it may be more difficult for prisoners who 
wish to initiate the treatment in prison (Social worker, CAT Taipas centre). 
The prison and the Ministry of Justice respect the CAT centre’s decision. In 
most prisons, prisoners are sent to a CAT centre for medical consultation; the 
substitution treatment is then brought to the prison. If the prison doctor dis-
agrees with the treatment provided by the CAT centre, but the prisoner has 
the right to have it, then a nurse will supervise that prisoner’s treatment 
(Health Service Director, General Directorate of Prison Services). In prison, 
nurses deliver methadone to prisoners. This is not always the case, when 
there is a lack of staff, methadone may be delivered by guards (Vice director, 
IDT). 
It was reported that the Prison Administration (and the prison) receives little 
or no feedback from CAT centres. ‘The prison only helps to deliver the 
methadone but a better links, and cooperation should exist.’ (Health Service 
Director, General Directorate of Prison Services). 
Although methadone and buprenorphine are both available in prison, only 
methadone is free. Prisoners who wish to receive buprenorphine need to pay 
for the treatment themselves. Often, it is the prisoner’s family who pays for it 
(interviews with prisoners and professionals). 
Substitution treatment takes place on a detoxification or maintenance basis. 
It can be initiated in prison but, largely, is a continuation of community 
treatment initiated prior to incarceration. Substitution treatment in prison 
varies widely from one prison to the other, depending on the CAT centre 
and/or prison doctors in charge of the treatment. It also varies for one pris-
oner to the other, as their personal path and individual needs are taken into 
consideration (interviews conducted with professionals). 
A GP reported that, although substitution treatment is allowed in all prisons, 
in practice it is not offered everywhere. Out of 59 prisons, approximately 
33 prisons offer treatment. Another GP at a CAT centre stated: ‘At the level 
of ideas and principles, discussions are progressive and positive towards 
health treatment in prisons. However, practically nothing happens or very 
little development has taken place. It was possible to offer treatments similar 
to those offered out of prison, but practically it never took place … Prisons 
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could be used as a therapeutic centre, but for this more psychologists and 
doctors, staff who are properly trained, are needed’. 
Psychosocial support and staff training 
Ideally, psychosocial support should be provided to patients in substitution 
treatment. However, there is an obvious shortage of psycho-social staff in 
prison, as is illustrated in the two examples that follow. 
Staff working in CAT centres are specialised in drug issues. Training is on-
going. Several courses for CAT health staff (and other services like private 
Therapeutic Communities) have been organised. ‘CAT centre staff are all 
specialised on drug issues. It is their personal choice to work in this field. 
They have no specific university training but they get trained on the job; 
some do a specialisation in drugs after medical school.’ (Vice Director, IDT) 
All guards receive 4 months training and are tested on health, infectious dis-
eases and drugs issues. It is important that they have enough knowledge to 
be able to identify symptoms (Health Service Director, General Directorate 
of Prison Services). 
1.3 Prison Population 
As illustrated in Table 1, there is a high percentage of female detainees in 
Portugal (8.1%) and a general problem of overcrowding with the capacity of 
prisons being used at 121.8%. 
Table 19  Data on the prison situation in Portugal (Source: King’s College London, Interna-
tional Centre for Prison Studies, Prison Brief for Portugal) 
 
Country  PORTUGAL 
Ministry responsible  Ministry of Justice 
Prison administration  General Directorate of Prisons (Direcção-Geral dos Serviços Prisionais) 
Contact address  Travessa da Cruz do Torel, No. 1, 1150-122 LISBON Codex, Portugal 
Telephone / fax / website  
tel:  +351 21 881 2200 
fax: +351 21 885 3653 
url: www.dgsp.mj.pt 
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Head of prison administration (and 
title)  Luis Miranda Pereira, Director General 
Prison population total (including 
pre-trial detainees / remand prison-
ers) 
14,060 at 1.9.2003 (national prison administration) 
Prison population rate (per 100,000 
of national population) 
134 based on an estimated national population of 
10.46 million at September 2003 (from Council of 
Europe figures)   
Pre-trial detainees / remand prison-
ers (percentage of prison popula-
tion)  
29.2%  (1.9.2003)  
Female prisoners (percentage of 
prison population) 8.1%    (1.5.2003) 
Juveniles / minors / young prisoners 
incl. definition (percentage of prison 
population)  
2.1%    (1.9.2002 – under 18, Council of Europe 
Annual Penal Statistics)  
Foreign prisoners (percentage of 
prison population)  12.0%  (1.9.2002)  
Number of establishments / institu-
tions  
59         (2003 – 20 central prisons, 35 regional prisons, 
4 special prisons)  
Official capacity of prison system  11,603  (1.5.2003)  
Occupancy level (based on official 
capacity)  121.8% (1.5.2003)  
Recent prison population trend 
(year, prison population total, prison 
population rate)  
1992       9,183       (93) 
1995     12,343     (124) 
1998     14,598     (146) 
2001     13,500     (131) 
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2 The Field visits6 
Time frame. The field visit took place from 28 of January to 2 February 
2004 included. 
Location. Visits were conducted in two prisons: Lisbon Prison and Tires 
Prison. 
2.1 Lisbon Prison7 
2.1.1 Description of the prison 
Lisbon Prison is located in the centre of Lisbon. It is a male, remand and 
sentenced prison, holding approximately 1 100 prisoners with a capacity for 
840. It was reported that 70% of these prisoners have committed a drug-
related crime. 
The main building is made up of several wings: wing A is the Drugs Free 
Unit; cells in wings B and C are open all day; wing D holds more difficult 
cases; wing E only holds remand prisoners (approximately 300 prisoners); 
wing F holds remand prisoners with more serious cases, such as paedophiles 
and network criminals (a camera constantly examines each cell) and, finally, 
there is wing H, where prisoners are allowed to work in and outside of 
prison, but must sleep in the prison. 
The prison has a therapeutic unit, located in a separate building. This unit has 
a capacity of 45 and houses prisoners between 17 and 32 years old who have 
applied for admission. No substitution treatment is offered in this unit which 
                                                          
6  Methodology. Interviews were conducted with the individuals listed below. An interview 
with one prisoner from the Drugs Free Unit and a focus group with 5 prisoners were also 
conducted. The tape-recorder was not used. The researcher conducted all interviews/focus 
groups on her own, accompanied by a freelance and neutral interpreter. All participants 
were briefed and told about ethical issues. 
7  Data from interviews were those conducted with: 
– Director Assistant and Director of the therapeutic unit. 
– A guard at the therapeutic unit. 
– The Director Assistant of the prison. 
– A psychiatrist who also works with methadone patients. 
– A psychologist. 
– A male nurse. 
– A psychiatrist who also works in the Drugs Free Unit. 
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focuses on discipline, psycho-social and rehabilitation activities, daily edu-
cation, work and sports. 
2.1.2 Goals and practical procedures 
At the time of the visit, there were approximately 70 prisoners on methadone 
(and there is a waiting list) and 10 on buprenorphine (paid for by the pris-
oner’s family). 
It was reported that methadone is the main substitution substance provided 
and can be initiated in prison. This rarely happens with buprenorphine due to 
the costs incurred. Each prisoner embarking on substitution treatment 
(methadone and buprenorphine) must sign a contract. This includes a clear 
statement of the risks of topping up. Urine tests are taken and, if positive, the 
prisoner is expelled from the treatment (The psychiatrist). 
The dosage of methadone varies on individual cases, with on average a dose 
smaller than 100 mg. The prisoner is not automatically told about the dose of 
his treatment, but he is informed if he asks. The doctor and prisoner will 
meet and talk about decreasing the dose, prior to the actual reduction taking 
place (The psychiatrist). 
Many prisoners on a substitution treatment tend to have a dual-diagnosis, 
such as drug dependence and HIV/Aids, hepatitis or have had tuberculosis. 
The highest dose of methadone ever provided in this prison was 180mg for a 
difficult dual-diagnosis case (The psychiatrist). 
The psychiatrist did not see discrimination against prisoners on methadone 
as, she said, they are seen as being cured and not using drugs anymore. 
Although there is an estimated relapse rate of 50% with methadone (psy-
chiatrist reported), the medical team reported that substitution treatment 
offers various key advantages: 
− Continuation of treatment initiated outside. 
− The reduction of the search, the obsession for drugs and thus a better men-
tal focus of prisoners: drugs no longer are their main mental focus. 
− Prisoners’ stabilisation in prison. 
− Change of attitude in prison. 
− Reduction of conflicts, aggression (and thefts) between prisoners and bet-
ter relation and sociability. 
− Reduction of prisoners’ debts. 
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Although the nurse saw no disadvantages of providing substitution treatment 
in prison, the psychiatrist reported side-effects such as decreased appetite, 
decreased general health status especially for prisoners with other diseases, 
such as HIV, hepatitis, etc., the possibility of topping up, the risk of over-
dose, physical dependence (and thus need for other medicine) and anxiety 
and insomnia when reducing methadone. 
The psychiatrist stated that the best antagonist was naltrexone, as it prevents 
prisoners from using heroin and guarantees abstinence. But, this substance is 
expensive and, unless it is paid for by the prisoner’s family, it is not offered. 
Although the nurse said he saw no differences between methadone and 
buprenorphine, the psychiatrist stated that there were differences; buprenor-
phine did not have the side effects of methadone. It was reported that a psy-
chiatrist chose to crush and dissolve the buprenorphine pill in water before 
giving it to the prisoner, to decease any risks of misuse and trafficking. 
In the morning, a nurse prepares the methadone in individual bottles, tagged 
with the cell number and each prisoner’s name. Accompanied by a guard, the 
nurse goes to the different wings where prisoners on methadone are asked to 
queue in the main hall to receive their treatment. The prisoner must drink the 
methadone in front of the nurse. Previously, all prisoners on methadone were 
incarcerated in the same wing, which facilitated provision of the treatment. 
This situation has changed and a prisoner may be incarcerated in any wing 
(A nurse). 
It was reported that, with the current system for the provision of methadone, 
medical confidentiality is not respected. ‘There should be more confidential-
ity and respect of medical secret but it is almost impossible practically. It is 
difficult for security reasons to bring all prisoners on methadone outside of 
the wing.’ (A nurse) 
The nurse reported an increased desire among prisoners to reduce methadone 
intake. However, he thinks that prisoners are often unaware of the risks 
related to ending methadone treatment too quickly and the risks of relapsing. 
Psycho-social support and services offered in prison are limited due to lack 
of funds. The prison has only one psychologist working 4 days a week. The 
psychologist reported that substitution treatment offers prisoners stabilisation 
and the possibility to go to the Drugs Free Unit. However, the patient may 
develop physical dependence and go through withdrawal. The nurse and the 
psychologist reported that ‘Methadone is not sufficient on its own. It is essen-
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tial to provide psychological support, as well as support from CAT centre 
when released.’ 
2.2 Tires Prison8 
2.2.1 Description of the prison 
Tires Prison is located approximately 40 minutes from Lisbon. Various 
buildings are set next to each other in a green and ‘open’ environment: the 
administrative area, wings, the drugs free units and the medical area. 
This is a female prison, holding approximately 600 prisoners. By 31 Decem-
ber 2003, there were a total of 153 foreign prisoners (i.e. 21.8%), coming 
mainly from Latin America (mainly Brazil), Eastern Europe, Palop’s coun-
tries, and Europe (31). The average age of prisoners is between 30-39 years 
old, the youngest being 16 and the eldest older than 60 years old (20 prison-
ers). 
There is one remand wing (206 prisoners), 1 sentenced wing (214 prisoners), 
1 wing for mothers (35 prisoners) with 3 babies who do not go to crèche, 
1 Drugs Free Unit (20 prisoners), 1 creche with about 29 babies located just 
outside of the prison, 1 kitchen, 1 Administrative Department and 1 open 
wing (82 prisoners on an open regime). At the time of the visit, 1 wing was 
used by 80 male prisoners (part of their prison being in construction) (RAV: 
Regimo Aberto Virado o Interior). 
The Deputy Governor provided statistics from the prisons’ registered cases. 
By 31 December 2003, there were: 
− 56 prisoners with HIV+ 
− 2 prisoners with Hepatitis B (vaccination has helped to reduce the inci-
dence) 
− 243 prisoners with Hepatitis C 
− 128 prisoners with syphilis 
                                                          
8  Data from interviews were those conducted with: 
– Deputy Governor 
– Psychiatrist 
– The nurse who delivers methadone 
– A guard 
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At the time of the visit, there were 67 administrative staff (civil function, 
such as director, deputy director, psychologist, doctors, educators, admin, 
etc.), 123 female guards and 100 male guards. There are 2 psychiatrists 
(1 for general and 1 for drug users), 1 psychologist, 1 psychotherapist, 2 vol-
unteer psychologists (only working in the Drugs Free Unit), nurses and GPs 
on contracts as well as 3 social workers working only on social reinsertion 
issues and belonging to a social workers’ institution. 
2.2.2 Goals and practical procedures 
It was reported that 45% of female prisoners are drug users upon arrest and 
64% have committed a drug-related crime (The Deputy Governor, internal 
prison statistics). 
At the time of the visit, 16 prisoners were on methadone and 2 on naltrexone. 
Buprenorphine is rarely provided. The psychiatrist reported that the provi-
sion of buprenorphine is more difficult and requires extra staff to supervise 
the intake as the pill, which is of high value to prisoners as it can be sold, 
must be taken sub-lingually and takes approximately 10 minutes to melt. 
Methadone was first offered in this prison 6 years ago (1998). Previously, 
prisoners received antagonists such as naltrexone. 
The psychiatrist from the CAT Taipas centre works with the Drugs Free unit 
and substitution treatment prisoners. He stated that, although the methadone 
dose tends to be higher outside, the lowest and safe threshold in prison is  
30-40 mg. But the dose varies from one individual to the other. Prisoners are 
told about their dose unless they do not want to know. The Deputy Governor 
reported that the disadvantage of methadone is that the dose is low or insuf-
ficient, resulting in many prisoners topping up. The Deputy Governor stated 
that there have been occurrences of overdoses for this reason. 
The reported advantages of methadone were improvement in health and 
well-being, stability and the guarantee of the quality of the drug (‘It is a pure 
drug, not mixed’ Deputy Governor). The psychiatrist added that substitution 
treatment works for some individuals and improves the individual’s social 
life and psychological stability. However, the treatment may not work for 
others. 
Methadone is distributed in the medical centre by the nurse. In order to 
respect confidentiality no guards are present. Prisoners drink their metha-
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done with water and they often like to drink a glass of water afterwards to 
alleviate the taste of bitterness. 
The psychiatrist explained that those on substitution treatment are tested for 
heroin, cocaine and methadone. Benzodiazepines and other drugs are not 
tested; this would require different and more expensive testing materials. 
Results from the tests are provided within the minute. If tested positive three 
times, the doctor will meet with the prisoner and, after discussing the reasons 
behind the topping up, he will evaluate whether the prisoner is motivated to 
continue the treatment or not. Accordingly, she is removed or kept on the 
treatment. 
The deputy governor reported that, although there is good collaboration with 
the CAT Taipas centre (where prisoners are sent upon release), there is a 
lack of staff, especially psychologists, psychiatrists and social workers to 
develop socialisation, contact work and professional training. The prison 
only had one psychologist. No medical staff are present over the weekend, 
nor during the night on weekdays. However, medical support will be pro-
vided when needed: doctors are on call to come to the prison (The Deputy 
Governor). 
2.3 The views of prisoners 
Interviews were conducted with several prisoners, aged between 28 and 45, 
with a mean age of 37 years old: 
− One male prisoner from the Drugs Free Unit who had finished methadone 
treatment 
− Focus group with 5 male prisoners from different wings: all were on 
methadone 
− Focus group with 9 female prisoners: 6 were on methadone, 2 were on 
naltrexone (1 had just finished the treatment), and 1 had finished bupre-
norphine (paid by her family) and was in the Drugs Free Unit. 
There were no striking differences between male and female prisoners or 
among the prisoners in general. All prisoners reported that substitution treat-
ment had helped them to stabilise and improve their health and mental status 
as well as to reduce or stop illicit drug use. The majority aimed towards 
stopping their treatment, as they wished to be ‘drug free’, free from the 
medical institution and care. 
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The methadone dose raised various issues: prisoners disagreed with the dose 
being unknown; whether they knew the dose or not, several prisoners felt 
they did not have the appropriate dose. 
Prisoners reported that contracts were viewed positively: they reflected 
authority and made prisoners aware of what is and is not allowed; what is 
right and what is wrong. They also stated that they agreed with urine tests, 
which provides transparency and a minimum of control. 
All prisoners claimed that psychological support is lacking, although the 
psychologist was seen as doing excellent work. Prisoners felt that they were 
provided with very little or no support, except from the medical consultation 
and treatment (and rare meetings with the psychologist). Although they 
acknowledged the lack of psycho-social staff in prison, they stated that the 
methadone treatment was insufficient on its own. Prisoners in the Drugs Free 
Unit reported receiving excellent support, including psycho-social support. 
They stated that the Drugs Free Unit is seen as ‘the’ privilege section in 
prison. 
The only prisoner on buprenorphine chose that treatment rather than metha-
done because of the waiting list to get on methadone and because she had 
support from her family. She reported no side effects with the decrease and 
treatment. She said that because she (or her family) was paying for the treat-
ment, she was determined to take it properly. 
Although female prisoners did not report difficulties with prison guards, 
male prisoners felt that guards were discriminating against them, seeing 
methadone as ‘just another drug’ or using methadone as a means of control 
or pressure. Male prisoners also complained about the lack of confidentiality. 
3 Summing up 
Methadone is the main substance provided in prison in Portugal. The CAT 
centres are external centres, specialising in drug treatment, that play a key 
role in the provision of substitution treatment in and out of prisons, all over 
the country. 
The prison administration, the medical staff and prisoners stated that metha-
done has a lot of advantages such as improving the health and psychological 
state of prisoners as well as the prison environment. However, psychological 
344 
 
support was reported as being largely insufficient, although the existing sup-
port was seen as excellent. 
Only a few prisoners take buprenorphine; the treatment is expensive and 
must be personally paid for. Naltrexone was perceived as a ‘substitution 
treatment’ and seen as beneficial to those motivated to become drug free. 
Prisoners requested more transparency and a clear structure in the provision 
of substitution treatment with less interference from the prison guards. 
The general perception of substitution treatment is that it is a tool to reach 
better physical and mental health but that it is not an end in itself. On its 
own, substitution treatment is insufficient to achieve long-term rehabilitation 
and well-being. 
 United Kingdom: Scotland1 
The United Kingdom comprises two main Criminal Justice Systems: one is 
proper to Scotland, and the other covers England/Wales. The management of 
prisons and health in prison falls under the (Scottish) Home Office for Scot-
land, and under the (English/Welsh) Home Office for England and Wales. 
England/Wales has been going through a restructuring of the provision of 
health care in prison, transferring its management from the Home Office to 
the Department of Health (Ministry of Health). This transfer is expected to 
last for several years. 
This country report of the United Kingdom focuses on Scotland. No in-depth 
study or field visit were conducted in England/Wales, contrarily to Scotland. 
1 General data:  
drug use, substitution treatment and prison population 
1.1 Drug use 
The most commonly used psychoactive substances are cannabis, followed by 
amphetamines, LSD, magic mushrooms, ecstasy, temazepan (and other pre-
scribed drugs) and heroin (Reitox U.K., 2002). Cocaine use has recently 
increased (interviews with staff and prisoners). There was an estimate of  
55,800 people misusing opiates or benzodiazepines in Scotland in 2000 (Hay 
et al, 2001). During the field visit, it was reported that heroin is the most 
problematic drug used in Scotland, and cocaine use is increasing, with some 
geographical differences. For instance, in the North part of Scotland (i.e. 
Aberdeen, Inverness, etc.) crack-cocaine tends to be the main problematic 
drug. 
It is estimated that there are about 56,000 problem drug users in Scotland, 
almost 23,000 of whom are injecting (in 20022) It is estimated that approxi-
                                                          
1  The field visit, conducted by Laetitia Hennebel, was facilitated by Karen Norrie, Addiction 
Advisor at the Scottish Prison Service, who also provided national, general information. 
2  SPS: ‘A comparative overview of the use of Narcotics and Drug Treatment Strategies in 
the Scottish Prison Service’. 
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mately 77% of the prison population tests positive for illegal substance on 
admission.3 (Scottish Prison Service, (SPS)4. 
Approximately 700 prisoners are on a substitution treatment in prison.5 
The treatment section (health care in prisons) falls under the jurisdiction of 
the Scottish Prison System, Home Office (equivalent to the Ministry of Jus-
tice). 
1.2 Substitution treatment 
Data comes from interviews6 and on-going review of research reports, web-
sites and laws/ regulations. 
1.2.1 Historical and legal background  
The government policy document ‘Tackling Drugs in Scotland: Action in 
Partnership’ (2000) is the policy framework used to tackle drug misuse at 
both national and local levels (SPS). 
In the community, methadone is used on a maintenance or detoxification ba-
sis. Buprenorphine has recently been licensed in Scotland for substitution 
                                                          
3  The Mandatory Drug Test upon entrance at the prison usually examines the presence of 
cannabis, benzodiazepines, methamphetamines, LSD, amphetamines, barbiturades, co-
caine, temgesic. 
4  The term ‘addiction’ is regularly used in Scotland to designate professionals specialised 
and working on dependence issues, such as ‘addiction worker/ officer’. By addiction, it is 
understood problems related to alcohol, drugs, all volatile substances and tobacco. 
5 The Department of Health for England/Wales reported that in 2004 (a given day) in Eng-
land/Wales there were approximately 140,000 patients on substitution treatment in the 
community, and about 57,893 of prisoners on substitution treatment in prison. A new clini-
cal model for substitution treatment has recently been created for England/Wales and the 
two substances to be used are buprenorphine and methadone. 
6  Interviews were conducted at the national level with: 
– Addictions Advisor, SPS 
– Mental Health Co-ordinator, SPS 
– Principal of Psychologists, Psychological Services, SPS 
– Addiction Co-ordinators, SPS 
– Inclusion Manager, SPS 
– Nursing Services Manager, SPS 
– Acting Head of Health Care, SPS 
– Manager of NEDAC, community centre 
– Social worker, LINKS, residential house (focusing on detoxification). 
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treatment. Diamorphine may be prescribed as a maintenance treatment as an 
alternative to methadone (although this is rare) (Reitox U.K., 2002). Lofexi-
dine, codeine-based substances and benzodiazepines are used for detoxifica-
tion. Naltrexone is also offered for patients needing a treatment to remain 
drug free. (Reitox U.K., 2002) 
During the field visit, it was reported that substitution treatment is under-
stood as ‘maintenance treatment’, which is offered with methadone. Detoxi-
fication treatment is provided with methadone on a reduction basis or with 
other prescribed drugs. Buprenorphine (Subutex®) is allowed in prisons; 
however, it is practically only offered in the privately run prisons of Scot-
land. 
The Nursing Service Manager of SPS stated that substitution treatment is 
seen as a medical treatment used to stabilise the individual but not as an end-
goal. The stabilisation allows tackling the problem at its roots. SPS staff 
reported that substitution treatment is positive if it can be administered with 
all the support the patient requires and needs. 
The Acting Head of Health Care of SPS reported that there is a disillusion 
about substitution treatment due to the lack of staff. Financial means have 
been deployed for assessment to the expense of staff. This results in commu-
nity based centres being overwhelmed by needs and requests, and the conti-
nuity of care between prison and community being difficult. 
1.2.2 Substitution treatment in prison 
It was reported that substitution treatment is available in prison since 2003. 
During the field visit, the Mental Health Co-ordinator of SPS stated that the 
major outbreak in 1992-93 of HIV/Aids and hepatitis in prisons played an 
important role in developing substitution treatment in prison. There was a lot 
of resistance in and out of prisons regarding the use of methadone as people 
did not feel comfortable about using it. At first, methadone was about the 
prison environment (being calmer and more stable) and not about the pris-
oner’s health. Since 1995, health care matters much more than ever before in 
prisons. Since 1997 SPS puts the individual at the heart. 
At the time of the field visit, it was stated that there were 700 prisoners on 
methadone. It was reported that the number increased from 100 to 700 with 
no added resources (only 1 addiction nurse in each prison). Buprenorphine is 
not provided in prisons except for those which are privately run in Scotland. 
348 
 
This is due to a generated misuse of the substance in 1995: the substance was 
crushed and injected. Currently, resistances focus on the price and time 
needed for the supervision of the sub-lingual intake. 
The basis for the provision of substitution treatment in prison is underlined 
in the SPS Health Care Standard 10. Substitution treatment is offered in 
prison as (i) detoxification, (ii) stabilisation, and (iii) maintenance with 
methadone. Retoxification, lofexedine and naltrexone are also provided on 
individual basis. 
Standard 10 of the SPS Standards for the Healthcare of Prisoners (Substitute 
and Detoxification Prescribing Guidelines) are applied in all prisons and are 
complemented – as far as possible - by therapeutic support (individual and 
group basis). 
According to the SPS Health Care Standard 10: 
− ‘If a prisoner has been on a treatment programme in the community, then 
they should be offered the opportunity of continuing this in prison. 
− The prisoner should enter into an agreed contract prior to the initiation of 
a substitute/detoxification prescribing programme, a copy of which should 
be shared with the prisoner. An example of such a contract is given at 
Appendix 1. 
− A detoxification programme will be made available to prisoners only 
following appropriate assessment. 
− All drugs prescribed as part of a substitute/detoxification programme must 
be issued on a supervised, individual dose basis, within a safe and secure 
environment. 
− Initiation of a Methadone prescription in prison should only occur when a 
full and comprehensive assessment identifies clear risk factors appropriate 
to the initiation of a Methadone script, where Methadone prescribing is 
part of a full and comprehensive treatment programme involving support 
and counselling. Example of such high risk situations would be preg-
nancy, or high risk of transmission of a blood borne viral infection (e.g. an 
individual who is known to be HIV or Hepatitis C positive). Initiation of 
Methadone must only be done in collaboration with the prison's addiction 
team, together with the prisoner's General Practitioner or relevant Com-
munity Drug Problem Service, as appropriate. 
− Appropriate urine testing should accompany substitute/detoxification pre-
scribing. 
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− While substitute/detoxification prescribing has an important part in help-
ing prisoners deal with the problems of drug abuse they may have, it 
should in all cases be accompanied by the appropriate support, as outlined 
in SPS' Drug Strategy.’ 
(Source: the SPS Health Care Standard 10, SPS) 
The SPS Health Care Standard 10 recommends the continuation of metha-
done (when the treatment was initiated in the community) taking into consi-
deration the following: 
− ‘Urine should be tested prior to the prescribing of Methadone. Urinalysis 
should reveal the presence of Methadone. 
− If urinalysis reveals the presence of any illegal or illicit drugs, or any 
medicines which have not been previously prescribed, appropriate assess-
ment must take place prior to Methadone being continued. The decision to 
prescribe Methadone, however, remains with the Medical Officer. 
− Clinical examination will include noting signs of recent injection sites. 
A body chart should be completed for future reference so that new sites 
may be positively identified. This information will inform the on-going 
assessment process. 
− Written, usually facsimile, communication will be made with the commu-
nity prescriber to confirm the dosage, compliance and, if necessary, will-
ingness to continue prescription on liberation. 
− The community prescriber's plans will be taken into account in planning a 
substitute prescribing programme in prison, e.g. the intention that Metha-
done be prescribed on a maintenance or reduction basis.  
− If the appropriate assessment, examination, communication with commu-
nity agencies and urinalysis are satisfactory, then Methadone may be pre-
scribed. 
− Methadone should be administered on a supervised daily dose basis. 
− Urinalysis should be undertaken weekly, as a minimum, throughout the 
period of Methadone prescription, and the result recorded in the Health 
Care Record. 
− If subsequent urinalysis is found to contain illicit substances, assessment 
must take place involving the Medical and Nursing staff, together with the 
addictions team, to determine whether Methadone should be continued or 
not, subject to the contract that the prisoner has signed. 
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− Prior to liberation, contact must be resumed with the community prescri-
ber to confirm throughcare arrangements and the continuation of the 
Methadone prescription.’ 
The SPS Health Care Standard 10 recommends for pregnant women: ‘… in 
order to avoid foetal harm, serious consideration is given to the continuance 
of Methadone prescribing in those women committed to prison who are 
being prescribed Methadone in the community.’ 
(Source: the SPS Health Care Standard 10, SPS) 
There is a contract to be signed by the prisoner engaging in a substitution 
and detoxification treatment.  
Copy of a contract (Scottish Prison Service) (Source: SPS) 
 
SUBSTITUTE/DETOXIFICATION PRESCRIBING CONTRACT (to be 
filed in the Health Care Record) 
HM: …………………………………………………………………………
Prisoner's Name: ………………………………….. SPIN No: ………. 
I agree to take my medicines in a supervised fashion, as prescribed. 
I agree not to misuse illicit or prescribed drugs while on a substitute/detoxification 
prescription. 
I agree to provide supervised urine samples, as requested. 
I understand that failure to adhere to any of the above will lead to my substi-
tute/detoxification script being withdrawn. 
I understand that inappropriate behaviour towards health care and addictions staff 
involved in my treatment may result in my treatment being stopped. 
I understand that clinical prescribing may be reviewed and stopped if I do not par-
ticipate in non-clinical support programmes. 
Signed: …………………………………………. Date: …………………. 
Witnessed by: ………………………………...    Date: …………………. 
Detoxification prescribing is offered to problematic drug users and to indi-
viduals with (or likely to have) withdrawal symptoms during their first night 
in custody. The SPS Health Care Standard 10 recommends continuing 
assessment and multi-disciplinary support while on a detoxification pro-
gramme. 
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Although methadone is used for detoxification, it is common to use other 
prescribed drugs such as lofexidine, dihydrocodeine continus, diazepam and 
zolpidem. The recommended prescription regime is the following: 
a) Lofexidine and diazepam together 
Lofexidine should be prescribed as follows: 
3 tabs twice daily for 1 day; 
6 tabs twice daily for 8 days; 
4 tabs twice daily for 1 day; 
3 tabs twice daily for 1 day; 
2 tabs twice daily for 1 day; and 
then stop. 
Diazepam should be prescribed as follows: 
30 mgs once daily for 3 days; 
20 mgs once daily for 6 days; 
10 mgs once daily for 3 days; and 
then stop. 
b) Dihydrocodeine continues, diazepam and zolpidem together 
Dihydrocodeine Continus should be prescribed as follows: 
120 mgs twice daily for 3 days (Days 1-3); 
90 mgs twice daily for 3 days (Days 4-6); 
60 mgs twice daily for 3 days (Days 7-9); 
60 mgs once daily for 3 days (Days 10-12); and 
then stop. 
Diazepam should be prescribed as follows: 
30 mgs twice daily for 3 days (Days 1-3); 
20 mgs twice daily for 3 days (Days 4-6); 
15 mgs twice daily for 3 days (Days 7-9); 
10 mgs twice daily for 3 days (Days 10-12); 
5 mgs twice daily for 3 days (Days 13-15); 
5 mgs once daily for 3 days (Days 16-18); and 
then stop. 
Zolpidem should be prescribed as follows: 
10 mgs at night for 6 days only (Days 13-18). 
(Source: SPS) 
The SPS recommends a treatment pattern as part of its drug strategy. 
Table 20 Treatment Algorithm of the SPS Drug Strategy: (Source: SPS) (next page) 
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RECEPTION NURSING ASSESSMENT 
 Is there evidence of cur-
rent opiate or benzodi-
azepine use? 
 No 
Complete 
health assess-
ment 
    
  Yes   
    
 Contact Medical Officer to 
decide if treatment is 
required. 
No treatment required 
Health assess-
ment com-
pleted 
    
  Yes - treatment 
required 
  
    
 Dihydrocodeine Continus, 
60 mgs and/or Diazepam, 
30 mgs prescribed, as 
appropriate, and adminis-
tered. 
  
INITIAL MEDICAL ASSESSMENT 
 Is there evidence of cur-
rent opiate or benzodi-
azepine use? 
 No Complete 
assessment 
    
  Yes   
    
Yes (seek specialist’s advice) Is the prisoner pregnant?   
    
  No   
    
 Is the prisoner on a metha-
done programme? 
  
    
 Yes  No   
    
Test urine, note recent injec-
tion sites and contact commu-
nity prescriber. 
 Select appropriate detoxification regimen and 
offer to prisoner. Ask patient to sign contract. 
Prescribe detoxification regimen and record in 
Health Care Record. 
     
   No   
Is methadone treatment to be 
continued? 
   
    
 Yes    
    
Agree plan for maintenance or 
reducing dose with patient. 
Complete Health Care Record. 
Ask patient to sign contract 
before prescribing methadone. 
Arrange appointment for re-
assessment. 
 
 353 
 
The Acting Head of Health Care stated that there are no restrictions on the 
doses of methadone. There used to be a limit of 60 mg as maximal dose with 
the original Health Care Standard 10 (1998). The new Health Care Standard 
10 (2001) has no dose limit. Upon arrival at the prison the dose of metha-
done is reassessed. Many GPs are reluctant to continue to prescribe a dose 
over 100 mg. Usually prisoners receive higher doses in the community and 
get their dose decreased once in prison. 
He further reported that bottles of 500 mg are delivered to prisons. Nurses 
pour directly from the bottle to the patient’s cup and add syrup. The prisoner 
takes the methadone in front of the nurse and must then immediately drink a 
cup of water. Guards are involved when methadone is administered, result-
ing in some confidentiality problems since guards bring prisoners to the 
nurse area. Medically (and ideally) guards should not know about what treat-
ment prisoners get. Confidentiality is an issue but not a problem as such. 
Prison officers should be regarded as part of the medical team since these of-
ficers stay on and look after prisoners in the evening and tend to be those on 
the spot when something happens. 
Within the Prison Service methadone treatment is prescribed by a GP. Psy-
chiatrists who work in prisons deal with severe mental health issues, not with 
substitution treatment or addictions. Addictions nurses have been specifically 
trained on drugs issues to offer service and support in prisons. 
Addiction team and psychosocial support 
The Principal of Psychologists at SPS reported that 45 psychologists from 
SPS cover the 15 public prisons in Scotland, which means there is a lack of 
staff. Psychologists focus on offending behaviour and the reduction of re-
offending and risk reports. Every prison has one psychologist trained in CBT 
(Cognitive Behavioural Therapy), which is not specific for addiction but for 
all types of prisoners. Although psychologists have a role to play with addic-
tions, they do not get involved in substitution treatment and rather deal with 
psychological impact of drug use, anger management, etc. ‘Addiction’ is not 
psychologists’ main focus as many other people work in this area. 
‘Addiction services’ are provided, increasing the number of people in prison 
accessing such services (to over 6,500 in 2003). The implementation of new 
contracted ‘addiction services’, who provide casework and transitional care 
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post- release support, as well as SPS staff7 and other partners carrying work 
on dependence, have been recently introduced in the Scottish prisons and 
have played a major role in increasing the number of prisoners consulting 
‘addiction services’.8 (SPS) 
1.3 Prison Population 
Table 21  Data on the prison situation in Scotland (Source: King’s College London, Interna-
tional Centre for Prison Studies, Prison Brief for Scotland). 
Country  United Kingdom: SCOTLAND 
Ministry responsible  Scottish Executive 
Prison administration  Scottish Prison Service 
Contact address  Calton House, 5 Redheughs Rigg, GB-Edinburgh EH12 9HW 
Telephone / fax / website  
tel:   +44 131 244 8522 
fax:  +44 131 244 8738 
url:   www.sps.gov.uk 
Head of prison administration (and 
title)  Tony Cameron, Chief Executive 
Prison population total (including pre-
trial detainees / remand prisoners)  6,803 at 20.2.2004 (national prison administration)  
Prison population rate (per 100,000 of 
national population)  
133 based on an estimated national population of 
5.1 million at February 2004 (from Office for 
National Statistics figures)   
Pre-trial detainees / remand prisoners 
(percentage of prison population)  16.2%  (20.2.2004)  
                                                          
7  SPS staff such as the inclusion manager and workers, inclusion being about addictions, 
social care, learning skills and employment. 
8  During the field visit, it was reported by the Addiction Advisor that all prisoners are 
offered an addiction assessment upon arrival at the prison and are then referred to Cran-
stoun Drug Services (CDS) workers who conduct a CAT (care and throughcare). The 
assessment focuses on 5 domains: health, work, financial issues, housing and education. 
CDS provides one-to-one motivation work, shares information on social, health and psy-
chological issues of prisoners, and works with centres located in the community. Before 
release, CDS liaises with transitional care team. 
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Female prisoners (percentage of 
prison population)  4.6%    (20.2.2004)  
Juveniles / minors / young prisoners 
incl. definition (percentage of prison 
population)  
2.8%    (1.9.2002 – under 18, Council of Europe 
Annual Penal Statistics)  
Foreign prisoners (percentage of 
prison population)  1.2%    (1.9.2002)  
Number of establishments / institu-
tions  16         (2004)  
Official capacity of prison system  6,135    (20.2.2004)  
Occupancy level (based on official 
capacity)  110.9% (20.2.2004)  
Recent prison population trend (year, 
prison population total, prison popu-
lation rate)  
1992      5,357      (104) 
1995      5,657      (110) 
1998      6,082      (119) 
2001      6,172      (122) 
In 2003, there were 62,000 to 67,000 prisoners for a capacity of 6,500. 
(Scottish Prison Service) 
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2 The Field visits9 
Time frame. The field visit took place from 9 to 12 December 2003 in-
cluded. 
Location. Visits were conducted in two prisons: HMP Shotts and HMP 
Cornton Vale. 
 
Map of Scotland 
 
                                                          
9  Methodology. Interviews were conducted with the individuals listed below. Three focus 
groups were also conducted with prisoners. The tape-recorder was used with two focus 
groups. The researcher conducted all interviews/focus groups on her own. All participants 
were briefed and told about ethical issues. 
HMP Shotts
HMP 
Cornton 
Vale 
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2.1 HMP Shotts10 
2.1.1 Description of the prison 
HMP Shotts is located approximately 30 minutes drive southwest of Edin-
burgh. It is a maximum-security prison for male adults who have a sentence 
of over 4 years. 
At the time of the field visit, there were 516 prisoners (the actual prison 
capacity, the deputy governor stated). 160 out of the 516 prisoners are lifers 
(i.e. on a life sentence). 
It was reported that usually, prisoners first go to a local prison and are then 
transferred according to their sentence. Prisoners are transferred to a less 
secure prison before being released, unless they fail to meet the criteria for 
transfer and are kept at HMP Shotts until the end of their sentence when they 
are released straight into the community. 
2.1.2 Goals and practical procedures 
At the time of the field visit, the prison counted 60 prisoners on methadone, 
of which 4 were doing a one month detoxification programme on methadone 
(the Health Centre Manager stated). The Clinical Manager stated that there is 
a lack of follow-up for methadone detoxification programme once the pro-
gramme is finished, which limits its success. 
The medical team follows protocols for the provision of substitution treat-
ment. It was stated that in the prison: 
(i) methadone is offered as long-term detoxification (over 1 year) with the 
goal of reducing, or as a short-term detoxification over 33 days,11 
                                                          
10  Data from interviews come from those conducted with: 
– Deputy Governor 
– Health Centre Manager 
– Clinical Manager 
– Head of Activities 
– Inclusions Manager 
– Senior Addiction Worker 
– Addiction Co-ordinator 
– Addiction Officers 
– Addiction Administrator 
– A guard 
Service Manager Cranstoun Drug Services. 
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(ii) prescribed medication, such as lofexidine, dihydrocodeine12 continus, 
diazepam, zolpidem, are provided for short detoxification13, 
(iii) naltrexone is provided for short to long term detoxification and absti-
nence, 
(iv) methadone is offered within a retoxification programme for ‘to be re-
leased’ prisoners, approximately 12 weeks prior to release, who present 
health risks (such as relapsing or overdoses), on the condition that the 
treatment can be continued in the community. The Clinical Manager 
stated that with retoxification prisoners feel they have better changes to 
get over their drug habits. Retoxification is used to reduce death rate 
upon release as well as prisoners’ anxiety, which tends to be high on 
release. Addiction officers opposed to retoxification believe providing 
only a medical treatment is not the solution and other aspects must also 
be treated. 
The Health Centre Manager stated that it is important to be able to offer a 
range of different approaches to meet individual needs. 
It was reported that the methadone programme is successful and is individu-
ally based. Among other things, methadone has permitted drug-using pris-
oner to re-establish communication and a relationship with their families, 
and has boosted their self-esteem. 
The Health Centre Manager stated that the methadone is ‘risky’ if the pris-
oner tops up, although topping up may be due to insufficient doses. Profes-
sionals may question the purpose of providing methadone: does methadone 
maintain the dependence or is it really treating it? Whatever the answer, if 
any, the advantages with methadone is that prisoners feel they receive proper 
treatment as ‘equivalent’ to that offered in the community. The contract 
                                                                                                                            
11  The Clinical Manager said that ‘if the prisoner used drugs for a long time, methadone is 
better taken over a long time. If some prisoners are always going to be using drugs, espe-
cially those who are dual-diagnosis, it is probably better to have them on methadone 
rather than on IV heroin’. 
12  Dehydrocodeine is an opiate based pain killer and is usually given for pain. It does not 
tackle the addiction itself and is not licensed for detoxification, as stated by the Health 
Centre Manager. 
13  The Clinical Manager stated that DF (dehydrocodeine and valium) is not often used but is 
with prisoners coming off methadone quickly or to prevent withdrawals. Lofexedine is of-
fered as a detoxification over 12 days. Sleeping tablets are also provided when prisoner is 
off lofexedine. 
 359 
 
underlines the risks methadone presents and is about prisoners and practitio-
ners’ safety. 
The Clinical Manager stated that the prison counts two GPs: one for drug 
issues and the other for somatic health issues. At the time of the field visit, 
the former had been working at the prison for 3 months, occupying a post in 
prison for the first time. Although he prescribes the medical treatment, he 
works with the whole team and after discussion/ meeting, decides on the 
treatment. 
The doctor decides on the dose – which is on average 50 to 60 mg and less 
than that offered in the community – and programme and discusses his/her 
decision with the addiction and medical team and the addiction team. The 
latter has access to the assessment file (conducted by the caseworkers) but 
not to the medical file. The number of new entrant prisoners who started 
methadone in the community has increased. The prison staff reported that 
waiting lists for methadone treatment within the prison are long and frus-
trating for them. They are a consequence of a lack of staff resources and a 
success of methadone programme in the community. 
The prison must respect quotas for the number of prisoners on a methadone 
programme in order to assure deliverance of proper support and supervision. 
The prison staff stated that at present there is nothing they can do to alter this 
situation. 
The clinical manager stated that the provision of methadone takes place un-
der the supervision of one competent member of staff (an Addiction worker) 
and a nurse. 7 to 8 prisoners can be brought at once to the medical centre for 
methadone treatment. Providing there are 60 prisoners on such treatment, 
this provision requires time every day. 
Prisoners on methadone who test positive on MDT, will get a yellow ‘warn-
ing’ card on the first occurrence. On the second positive MDT, the prisoner 
is expulsed from the methadone programme, even though the medical team 
tries to discuss and understand the triggers to this drug use. 
Other medication, such as lofexidine (as mentioned here above), is pre-
scribed for detoxification, although prisoners’ preferred medication is metha-
done. Naltrexone, offered indefinitely after 2 weeks of being drugs free (sup-
ported by 2 drugs tests), is abstinence-oriented. It is not very popular 
amongst prisoners, but at the time of the field visit, 4 prisoners were on a 
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naltrexone treatment. The Health Centre Manager said that ‘naltrexone is a 
real test to see whether prisoners are really motivated to stop using drugs’. 
Psychosocial support and staff training 
The Addiction team offers a therapeutic approach and provide motivational 
skills, explaining how to reach progress and better-well being, building pris-
oners’ self-esteem, trying to change labels of ‘drug users’, etc. They have 
received training on drugs: (i) STRADA certificate, (ii) training on counsel-
ling, (iii) training on HIV-AIDS, harm reduction, tolerance, motivational 
interview, training trainers, bereavement, etc. These officers have also 
learned from prisoners themselves. 
Addiction officers reported that it was difficult to see prisoners on a one-to-
one basis because of the lack of free spaces, sometimes having to see a pris-
oner in the hall (which is prevents confidentiality) or in his cell (which is 
unsafe) with one foot holding the door open. 
Prison staff reported that support for one another is lacking. They stated that 
relying on peer-support was insufficient, contrarily to the counselling super-
vision they previously received. Nurses were satisfied with the support and 
training they receive as they are entitled to clinical governance, i.e. support 
and supervision from nurses, psychologists and doctors. 
Prison staff claimed that training on substitution treatment, methadone and 
detoxification has been minimal. Further training has not been provided 
although officers have asked for it. 
The Clinical Manager reported that there is no support or supervision offered 
to Addiction officers, even though it is needed and this must be acknowl-
edged at the managerial level. 
The physical and mental health team and the Addiction officers are meant to 
work together. The former treats anxiety, depression, chronic and dual-diag-
nosis; whereas, the latter works specifically on addictions (drugs and alco-
hol). Both teams occupy the same area in the prison, which – it was reported 
– strengthens the links and teamwork and facilitates exchange of information 
as both teams work towards reaching the same goal. 
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2.2 HMP Cornton Vale14 
2.2.1 Description of the prison 
HMP Cornton Vale is located nearby Stirling (approximately one hour drive 
northwest of Edinburgh). This is a female prison, holding at the time of the 
field visit approximately 240 prisoners, on remand and sentenced, aged 16 to 
70. This is the only prison in Scotland only for female prisoners. Three male 
prisons have wings or accommodation lots for female prisoners. 
The Deputy Governor reported that on MDT most of these women (95%) are 
tested positive. 75% of them inject. The first drug used tends to be heroin, 
followed by cannabis; crack-cocaine is used but to a lesser extent and benzo-
diazepines, especially Valium®. She further stated that 80% of these female 
prisoners had been sexually abused. Most of them have experienced very lit-
tle or no recognition and awards, and very basic education and lack basic 
skills, such as cooking, parental skills, etc. 
2.2.2 Goals and practical procedures 
At the time of the field visit, there were 40 prisoners on methadone on an 
average dose of 50-60 mg, usually initiated at 10mg, with a maximum dose 
of 120 mg. Generally, a lower ‘initial’ dose is provided in prison than outside 
with a gradual increase. The GP in charge of substitution treatment stated 
that there was no medical evidence to go beyond this limit. 
Methadone is provided in a liquid lotion and arrives at the prison already 
prepared. 
                                                          
14  Data come from interviews conducted with: 
– Deputy Governor and Head of Opportunity & Social Inclusion 
– Head of Health Care Unit 
– Supervisor and head of nurses (Clinical Manager) 
– Doctor (GP)  
– Addiction Nurse 
– Social worker and senior practitioner 
– Team Leader, Cranstoun Drug Services 
– Case workers, Cranstoun Drug Services. 
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The GP stated that methadone is provided: 
(i) As a continuity of a treatment offered in the community. 
(ii) As initiated in prison if there is a follow-up in the community upon re-
lease (the doctor must contact various services in the community to as-
sure continuation once released). 
(iii) As detoxification especially if the prisoner keeps on using drugs (detoxi-
fication with methadone is avoided for those injecting heroin). 
(iv) As retoxification prior to release, although prisoners tend to stay in the 
community for a short time coming back to prison quickly. 
Other types of medicine are also provided, such as DHC and valium for 
heroin users for 12 days, diazepam for cocaine users (18 days programme), 
naltrexone. Although buprenorphine is available, the GP said that there were 
no ‘candidates’ for it. Buprenorphine is safer than methadone as fatal over-
dose is rare. However, the prediction, he stated, is that an increase demand in 
the community will generate a higher demand in prison. 
The Addiction nurse is in charge of any new prisoner with drug issues and 
who wants to address them, as well as to assess the prisoner’s needs, to look 
at how she wants to approach and tackle the issue. He works closely with the 
Addiction Team and they share information. 
Even though the GP prescribes the methadone, the Addiction Nurse reports 
to the doctor on whether methadone is a suitable treatment for the individual 
according to the assessment. The assessment and case of the prisoner is dis-
cussed between the GP and the nurse. The Addiction nurse reported that 
HMP Cornton Vale was based on an individual approach compared to other 
prisons. Medical is seen as a medical treatment but the prisoner’s under-
standing of methadone needs to be evaluated, as well as her willingness to 
look at psychological issues and engage with the Addiction team. He further 
stated that the challenge of methadone treatment is not about the lack of 
resources but rather is situated on an operational issue. The high increase of 
drug users on methadone in the community means there is an increase of 
prisoners on methadone in prison. 
The Addiction nurse stated that retoxification has decreased the number of 
deaths and recidivism on release. He says that ‘it is difficult to change the 
behaviour. It is more realistic to change the risks’. 
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It was reported that at night, there no longer is a night nurse. Although the 
nurse stays at the prison until midnight, there are first-aid trained staff and a 
night duty manager in charge during the night. The doctor can also be called 
if necessary. Prisoners tend to arrive at the prison in the evening. The nurse 
conducts the MDT and medical assessment, also covering drug issues. Medi-
cine is provided, if needed, according to the doctor’s general advice. If no 
medicine is provided to the prisoner, she is more likely to commit suicide. 
Therefore, the medical team prefers to give some medicine, even in the GP’s 
absence. On the first morning at the prison, the prisoner visits the GP. The 
GP stated that he feels he can cover (and do a good job) with the whole 
250 prisoners. 
The Head of Health Care Unit stated that methadone offers a means to ‘put 
the prisoner back together’ as she arrives at the prison in a ‘shocking state’. 
Very little can be done for a prisoner who is in prison for less than 6 months. 
However, access to health service in prison is available to all drug-using 
prisoners, often contrarily to outside. The disadvantage of methadone is 
increased pressure from some prisoners asking those on methadone to do 
drug dealing with the medicine they receive. This is especially the case with 
methadone where a tampon is placed in their mouth (i.e. called ‘spitting 
methadone’). Some of these prisoners are vulnerable people, whereas others 
are drug dealers. 
A social worker stated that substitution treatment is seen as fulfilling indi-
vidual needs. Most prisoners have a problematic drug-use and have commit-
ted a drug-related crime. Upon arrival at the prison prisoners ask for medi-
cine to help with withdrawal symptoms. Methadone has a bad press and 
many prisoners have heard about difficult withdrawal effects from it. How-
ever, if they tend to ask for methadone to continue the programme started in 
the community or to start a new treatment in prison. Prisoners often want to 
stay clean even though it is difficult and often unrealistic. Prisoners tend to 
ask for retoxification with methadone. Some also ask for naltrexone but it is 
uncertain whether they are really ready to use it safely, as, the social worker 
stated, it is usually very difficult for women to abstain from drugs. 
A social worker claimed that  
− Substitution treatment is too focused on medical protocols, and thus tends 
to put all prisoners in the ‘same basket’. It does not cover social and indi-
vidual needs. 
364 
 
− Concerns have been expressed regarding some prisoners being ‘encoura-
ged’ to have positive drug tests to be able to receive methadone treatment. 
− The Health Care Centre (1 Addiction Nurse and 1 Addiction doctor) is 
well under-resourced. 
− There is a need for more work on a one-to-one basis. 
− Although prisoners are encouraged to engage in different programmes, 
resources (availability and time) are lacking. 
The Deputy Governor stated that although substitution (medical) treatment 
helps, it is important and needed to tackle the root, the source of drug use. 
Social issues, such as parental, education, self-esteem, environment these 
female prisoners were brought up in need to be tackled. 
Psychosocial support and staff training 
Psychosocial support to prisoners are provided like at HMP Shotts, through 
the Addiction teams and caseworkers (Cranstoun Drug Services). 
The staff did not express any complaints about a lack of support or training. 
They felt well trained on substitution treatment and ‘addiction’ issues. 
2.3 The views of prisoners 
Interviews were conducted with several prisoners: 
− One focus group with 5 female prisoners (age 29 to 32, mean: 32) – HMP 
Cornton Vale 
− One focus group with 5 male prisoners – HMP Shotts 
− One focus group with 4 male prisoners (age 25 to 32, mean: 29) – HMP 
Shotts 
There were no striking differences between male and female prisoners or 
among the prisoners in general. Most prisoners mentioned methadone when 
talking about substitution treatment; buprenorphine was said not to be 
offered much in prison. 
All prisoners said that the situation in prison (health care and other support) 
is a lot better today than it was 4-5 years ago. All feel proper medical treat-
ment was provided at the prison. However, prisoners reported there were 
long waiting lists to get on a substitution treatment and to see a doctor. 
Equivalence of care between the community and prison was said to be lack-
ing in the type of and access to substitution treatment. 
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Access to substitution treatment 
‘I have been waiting for methadone for the past 11 months. I’ve been on a 
waiting list.’ 
‘You have to be off it. You got to want to be rid of it yourself. They have to let 
me detox when I want to, not f… 10 months later when they decide I can.’ 
‘We tell them we need help, and they put us on a waiting list for several 
months, which means that our problems are getting worse. We should be 
getting the help, not the waiting.’ 
‘There are 500 in this jail, and there are 300 prisoners who have a drug 
habit, who should get the help they need. Instead, they are on a waiting list.’ 
‘I think it’s just a numbers game. It’s just my opinion, if there’s 50 guys on it, 
it doesn’t matter if somebody next door to you is dying because he’s using 
too much drugs, someone else has to come off it before he can get on it.’ 
‘One needs to keep on pushing and asking for medical treatment. Asking just 
once is not enough in prison.’ 
‘It’s hard to see the doctor, but it is easy to see the nurses. It is also difficult 
to see specialists (such as dentists …).’ 
‘I went to a doctor outside, and said to this doctor, ‘I’ve got a heroin prob-
lem. I need help. I need methadone.’ He’d say ‘Give me a urine sample’. If 
the urine sample is positive, I’d start me on methadone. In here [prison], I 
wait a lot of months, and I don’t get help. There’s the waiting list for metha-
done. I mean, methadone isn’t everybody’s thing, maybe some guys want 
Subutex®, that was an offer in a private prison, but it’s not offered in many 
other prisons.’ 
Prisoners felt there was a lack of resources to provide methadone treatment. 
‘Only 25% of the guys are on methadone, and they’re so reluctant to go over 
25%. I don’t know why, maybe they can’t afford it. (…) They are short staf-
fed. We have to get it [methadone] at half 8 in the morning because they’ve 
not go the staff. They take us to the hall to get it.’ 
‘See, the drug workers, the addiction team, every one of them says the same 
thing: ‘Oh, if I could get you on methadone, I’d put you on methadone. If I 
had the resources, I’d have put you on it months ago.’ But they just don’t get 
the resources. Their hands are tied.’ 
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Although methadone if feared by some prisoners and doctors, prisoners also 
stated that methadone stabilises the person and allows him/her to get his/her 
life sorted and to go on with life. 
‘I am actually scared of methadone because I did an overdose with metha-
done once. I will not top up anymore because of my previous experience. 
Apart from this fear, I feel that I am fine with methadone and that the treat-
ment suits my needs.’ 
‘Some doctors prefer to stop methadone in order to save lives and avoid 
overdose and to give more stability.’ 
Methadone is mainly provided as a detoxification treatment, short term, or as 
a retoxification treatment (prior to release) on a long-term maintenance 
treatment. Some prisoners felt that methadone should also be provided on a 
long-term basis. 
‘They avoid the long term, because some guys don’t want to be on it long 
term. That’s good. (…) They’ll retox you, that’s the only way you can main-
tain, they’ll put you on it and reduce you.’ 
‘They give you retoxification a month before you get out. That stabilises you 
if you’re using drugs, so you don’t over do it.’ 
‘I’ve got to go to retox for three months before I get out. They’ll hold me up 
with methadone for the last three months so as I got a habit when I get out. I 
don’t agree with it because I’ll never kick smack without it, but I’m going to 
do it.’ 
‘Methadone is not for short term. Methadone’s long term.’ 
Prisoners stated they felt unease with the lack of confidentiality regarding 
treatment, although they said it did not cause a big problem to them. 
‘I overheard nurses talking about the case of such and such person in front 
of prisoners. There is no private or confidentiality in prison.’ 
‘It shouldn’t be broadcasted. It happens that they yell ‘it’s time for your 
methadone’ in front of 140 people. It should be the same as in the health 
centre. (…) It doesn’t help, but it’s not a problem here, really.’ 
It was clear to prisoners that if they fail the mandatory drug test (MDT), they 
are removed from methadone treatment. 
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‘I’ve been on a detox before and got kicked off it, for failing my drug test. 
(…) That’s an agreement, you sign a piece of paper saying that if you fail a 
drug test while you’re on it, you’ll be taken off it. So I failed that drug test.’ 
‘Previously I was tested positive on MDT. I was removed of any treatment 
and did not sleep for 36 nights. This time I have been in prison for 4 weeks. I 
received methadone on my first day. I was tested positive for heroin and 
methadone on MDT upon arrival at the prison because I had just started 
methadone treatment when I was arrested. Once in prison I was immediately 
put on methadone treatment.’ 
3 Summing up 
Methadone is the main substance of substitution treatment provided in prison 
in Scotland. Although under SPS Health Care Standard 10 (1998), metha-
done was mainly offered on a detoxification basis or maintenance basis for 
those who started the treatment prior to incarceration, this trend has changed 
since SPS Health Care Standard 10 (2001) with an increase in the provision 
of methadone maintenance treatment. 
Other medication, such as lofexidine, dihydrocodeine continus, diazepam, 
zolpidem, and naltrexone, is used in prison for detoxification. Retoxification 
is also offered to prisoners approximately 12 weeks prior to release as a harm 
reduction measure and to decrease the number of overdoses and relapses on 
release. Prisoners’ feelings on ‘retoxification’ were mixed, not clearly satis-
fied about this option. 
Upon entry to prison, drug testing is compulsory for all new entrants and 
various assessments (medical, social, psychological and specifically on drug 
use) are conducted. Specialised staff (addiction workers and caseworkers) 
provide rehabilitation programmes, care and throughcare to drug-using pris-
oners. Addiction workers and nurses are key actors in the treatment of drug-
using officers and as assistant to the GP, who often has very little time for 
each prisoner and has a more limited knowledge of each prisoner (compared 
to Addiction Officers or caseworkers). 
Even though there is structure and staff (from the SPS and from external or-
ganisations) in prison for drug-using prisoners, staff reported that too much 
time is spent on administrative activities and on assessments (often dupli-
cated), and that there is a lack of resources, especially facing prisoners’ high 
demand for substitution treatment due to the ‘success’ of the treatment in the 
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community. This results in prisoners being put on a waiting list for substitu-
tion treatment. 
Prisoners on a waiting list stated they were not satisfied with the whole 
health service offered in prison. They expressed a certain ‘disliking’ of the 
Addiction staff, as they do not accept the long waiting list and procedure. 
However, when global therapeutic structure was offered, prisoners expressed 
satisfaction towards the functioning of the prison system and substitution 
treatment. Female prisoners tended to be satisfied, whereas men tended to be 
unpleased as most of them said they had been on a waiting list for substitu-
tion treatment for months. 
 Slovenia1 
1 General data:  
drug use, substitution treatment and prison population 
1.1 Drug use 
Although, according to doctors’ reports, alcohol is a bigger problem than any 
other drug, the most commonly used psychoactive substances are cannabis, 
sedatives, ecstasy, alcohol, benzos, LSD, cocaine, heroin and amphetamines. 
(Lovrecic, 2004) 
The number of drug users in Slovenia is estimated to be 15-18 500 people, of 
which approximately 6000 are intravenous drug users. (Reitox Slovenia, 
2002) 
In 2003, the number of drug users on methadone substitution treatment was 
approximately 1800 (The Newsletter of the International Harm Reduction 
Development Program of the Open Society Institute, 2003, p. 15). On 31 Ja-
nuary 2004, there were 1927 patients. (Head of the Centre for Treatment of 
Drug Addiction, Slovenia) 
In 2002, the number of drug users in prisons was estimated at 13% of the 
total prison population (N=703 out of 5219 prisoners)2 (Government Ad-
viser, Head of the Treatment Department at the Prison Administration) The 
majority were connected with heroin3 (Hren et al, 2004 ) At the time of the 
visit, the number of drug users on substitution treatment was 222. (Govern-
ment adviser, head of the treatment department at the Prison Administration) 
                                                          
1  The field visit, conducted by Laetitia Hennebel, was facilitated by Joze Hren, from The 
Government Office for Drugs, who, with Borut Bah (Stigma Association), also provided 
national, general information and support with the finalisation of this country report. 
2  Statistics provided by the National Prison Administration. 
3  A study reported that the majority of prisoners who had committed a drug-related offence 
were mainly connected to heroin. Other drugs (cocaine, stimulants, hallucinogens, canna-
bis) were less connected or were topped up with heroin. (Hren et al, 2004) 
370 
 
According to Lovrecic (2004), the national prevalence of: 
− HIV/AIDS is less than 5% in the general population and, among drug 
users, less than 1 per million with HIV and 0.5 per million with AIDS. 
− TB is 21.3 per 100,000 population (N=423). 
− 23.5% of injecting drug users are being treated for Hepatitis C. 
The treatment section (health care in prisons) is part of the responsibilities of 
the National Prison Administration (Ministry of Justice). 
1.2  Substitution treatment 
Data comes from an on-going review of research reports, websites and laws/ 
regulations, as well as from interviews conducted during the field visit4. 
1.2.1 Historical and legal background 
The Ministry of Health is responsible for the planning and implementation of 
health care and substitution treatment. In 1994, national guidelines for 
methadone treatment were adopted by the Health Council. These guidelines, 
updated in 2000, provide recommendations for the identification of drug use, 
diagnostic methods, harm reduction strategy, methadone maintenance pro-
grammes5, and therapy offered in centres and hospitals. First established in 
                                                          
4  Interviews conducted at the national level with: 
– The Director General of the Prison Service. 
– National Prison Administration, Ministry of Justice. 
– Communication and International Affairs, National Prison Administration, Ministry of 
Justice. 
– Advisor to the Government, in charge of the health-treatment group working in prisons, 
National Prison Administration, Ministry of Justice. 
– The Head of Psychologists, National Prison Administration, Ministry of Justice. 
– The Head of Pedagogues, National Prison Administration, Ministry of Justice. 
– A psychiatrist, The National Centre for Treatment of Drug Addiction. 
– The psychiatrist and M.D. Head, The National Centre for Treatment of Drug Addiction. 
– Advisor to the Minister, Ministry of Social and Labour Affairs. 
– The Counsellor to the Director, Government of the Office for Drugs. 
– Social workers at the Centre for Social work, Ljubljana. 
– Social worker, Skala (NGO), Youth Street Education. 
– Social worker, Areal (NGO). 
– Social workers, Association for Harm Reduction Stigma. 
– A priest. 
5  The National Drug Policy includes methadone maintenance programme as a fundamental 
drug treatment and harm reduction programme. 
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1995, there are now 18 regional Centres for the Prevention and Treatment of 
Drug Addictions and 2 out-patient clinics that offer substitution treatment 
among their services. These centres are closely connected to prisons. The 
number of people seeking assistance has increased since the creation of these 
centres (Kastelic and Kostnapfel Rihtar, 2003). 
In May 2004, buprenorphine was registered as Subutex® tablets 0,4mg, 2mg 
and 8 mg. The launch was planned for the 2nd National conference on Addic-
tion, organised by the Sound of Reflection Foundation, in Slovenia, June 
2004. 
Methadone treatment is offered as: 
− short-term detoxification (decrease of the dose within one month), 
− long-term detoxification (decrease of the dose over more than one month), 
− short-term maintenance (same dose prescribed for up to 6 months), 
− long-term maintenance (same dose prescribed for over 6 months). 
(Kastelic and Kostnapfel Rihtar, 2003) 
‘Methadone maintenance programme is successful, when it includes the 
whole treatment and is supported by medicine, counselling and administra-
tion, when it takes into consideration the patient’s individual needs, assure 
enough stable and trained staff and considers appropriate methadone dos-
ages.’ (Kastelic and Kostnapfel Rihtar, 2003, p. 13-14) 
Specialised professionals reported that substitution treatment in Slovenia is 
not a controversial issue and is seen as a medical treatment. Generally, it is 
well accepted, although some professionals favour abstinence to substitution 
treatment. 
It was reported that public opinion on methadone is divided; 50% see metha-
done as supporting the drugs users’ use, allowing them not to tackle their 
habit and personal issues. The other 50% see it as a medical treatment, 
although ‘detoxification’ from methadone may be problematic. Finally, an 
NGO reported that distribution of methadone doses for the weekend on Fri-
days is likely to generate a black market. 
It is believed that buprenorphine is less addictive than methadone and is thus 
easier to detox from; it has a lower risk of overdose and is easier to pre-
scribe. However, buprenorphine is expensive and may be less effective 
among long-term drug users. As for methadone, a psychiatrist observed that, 
although there is theoretically no maximum dose, doses tend to be inade-
quately low. 
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1.2.2 Substitution treatment in prison 
‘Hospitalisation and imprisonment are not reasons for dropping out of the 
methadone program.’ (Kastelic and Kostnapfel Rihtar, 2003, p. 13) 
Methadone is the substitution treatment offered in all the prisons. It has been 
available since 1995 and is prescribed by specialist doctors from the Net-
work of Centres for the Prevention and Treatment of Drug Addiction. 
Buprenorphine has been integrated in Slovenian programmes very recently 
(2004) and is not yet offered in prison, although the National Prison Admini-
stration and the National Treatment Centre reported that it was only a ques-
tion of time before prisoners are prescribed buprenorphine. 
Substitution treatment is provided according to “Euromethwork” Methadone 
guidelines and Slovene Methadone guidelines. Nurses collect the treatment, 
prescribed by doctors, at pharmacists. 
It was reported that the philosophy of methadone treatment in prison is 
detoxification (gradual reduction) as prison is seen as an appropriate place to 
abstain from drugs. Maintenance treatment is also offered but with excep-
tions. Prisoners either continue the treatment they received prior to incar-
ceration or, in a recent development, may have treatment initiated in prison. 
Patients on this treatment have regular urine tests. (Government Adviser, 
Head of the Treatment Department at the Prison Administration) When 
transferred to another prison or released, prisoners on substitution treatment 
can continue their treatment according to the doctor’s advice. 
A patient must fulfil conditions6 to be included in a methadone program. The 
whole team of experts (such a team exists within each prison), which in-
cludes a psychiatrist, nurse, social worker, psychologist and therapist from 
                                                          
6  Conditions are: having a repetitive use of opiates, physical dependence to opiates, previous 
detoxification attempts, the willingness for methadone treatment, agreed and signed con-
sent for methadone treatment, minimum age of 16, health insurance (the Government pays 
for all Slovene citizens and all prisoners have the right to health insurance like any citizen), 
a family doctor and residence in the same region as where the Centre is located. 
 Although prisoners used to be insured, due to a contract between the Ministry of Justice 
and the National Health Insurance Company, currently the Ministry of Justice covers all 
health services costs for prisoners directly. A negotiation is currently taking place to have 
all health services for prisoners covered by the National Health Insurance, as applies to all 
citizens. 
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the prison, must agree to the treatment (Kastelic and Kostnapfel Rihtar, 
2003). 
Substitution treatment in prison is financed by The Prison Administration. In 
2002, the costs for methadone treatment (only for the medication methadone) 
in prison amounted to 15,000€ approximately (Government Office for 
Drugs). 
Psychosocial support and staff training 
A range of psycho-social treatments should be offered to patients on substi-
tution treatment (Kastelic and Kostnapfel Rihtar, 2003). 
Although medical staff are trained on substitution treatment through the 
Centres for the Prevention and Treatment of Drug Addiction, prison staff do 
not receive specific training. Nevertheless, several workshops and informa-
tion training were organised with the prisoners and staff, such as workshops 
with prisoners on harm reduction, training for prison staff on addiction 
treatment in prison and workshops on methadone maintenance programme 
with staff. Moreover, international conferences in Slovenia, including work 
with prisoners, were organised by the Sound of Reflection Foundation: Her-
oin Addiction in Europe (1997), International Society of Addiction Medicine 
and WHO Symposium on Substitution Treatment (2000), Harm Reduction 
Conference (2002), Adriatic Conference (2003), and two national confer-
ences on addiction (1999 and 2004). 
As part of the public health network, all prisons are closely connected to the 
Centres for Prevention and Treatment of Drug Addiction. Continuous coor-
dination and cooperation take place between prison staff and community 
health professionals. 
During imprisonment, prisoners are offered treatment within the public 
health network facilities. Drug free units have been opened in most prisons. 
Detoxification is offered along with individual counselling and group work. 
It was reported that, once a prisoner shows psychosomatic stability, s/he is 
prepared for integration into psychosocial programmes dependent on his/her 
willingness to engage in such programmes, which are provided by peda-
gogues, psychologists and social workers (Government Adviser, Head of the 
Treatment Department at the Prison Administration). 
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1.2 Prison Population 
Table 22  Data on the prison situation in Slovenia (Source: King’s College London, Interna-
tional Centre for Prison Studies, Prison Brief for Slovenia) 
Country  SLOVENIA 
Ministry responsible  Ministry of Justice 
Prison administration  National Prison Administration 
Contact address  1000 LJUBLJANA, Tivolska 50, Slovenia 
Telephone / fax / website  Tel: +386 1 478 5270 Fax: +386 1 478 5470 
Head of prison administration (and title)  Dusan Valentincic, Director General 
Prison population total (including pre-trial 
detainees / remand prisoners)  1,099 at 1.9.2003 (national prison administration)  
Prison population rate (per 100,000 of 
national population)  
55 Based on an estimated national population of 
2.0 million, September 2003 (from Council of 
Europe figures)   
Pre-trial detainees / remand prisoners (per-
centage of prison population)  23.8%   (1.9.2003)  
Female prisoners (percentage of prison 
population)  3.6%     (1.9.2003)  
Juveniles / minors / young prisoners incl. 
definition (percentage of prison population)  1.0%     (1.9.2002 - under 18)  
Foreign prisoners (percentage of prison 
population)  15.3%   (1.9.2002)  
Number of establishments / institutions  
7 (2002 - 6 prisons, 1 correctional home for 
juveniles. The 6 prisons have facilities in 13 dif-
ferent locations.)  
Official capacity of prison system  1,067     (1.9.2003)  
Occupancy level (based on official capacity)  103.0% (1.9.2003)  
Recent prison population trend (year, prison 
population total, prison population rate)  
1992:         836      (42) 
1995:         825      (41) 
1998:         756      (38) 
2001:      1,148      (58) 
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Slovenia has approximately 1000 prisoners in a total population of less than 
2 million. Although Slovenia only has 6 prisons, they are located in 13 dif-
ferent locations. It was reported that the prisons are overcrowded; not in the 
sense of a lack of physical space for prisoners (Slovenia usually adheres suc-
cessfully to the Council of Europe, CPT measures about detention) but 
regarding the number of staff per number of prisoners. 
2 The field visits7 
Time frame: The field visit took place from 22 to 30 September 2003. 
Location: Visits were conducted in two prisons: Ljubljana Prison and Dob 
Prison. 
Map of Slovenia 
 
                                                          
7  Methodology: Interviews were conducted with the individuals listed below as well as focus 
groups (tape-recorded with consent) with the prisoners. The researcher conducted all 
interviews/ focus groups accompanied by a freelance and neutral interpreter in both pris-
ons. All participants were briefed and told about ethical issues. 
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2.1  Ljubljana Prison8 
2.1.1 Description of the prison 
Ljubljana Prison has 4 departments located in different areas of the country. 
The department visited is located in the capital Ljubljana. Initially, it was 
built to be a hospital but has been used as a prison since 1964. It has a 
capacity of 128 but held 223 prisoners at the time of the visit. Prisoners are 
either on remand (95) or have a sentence shorter than 18 months (118). 
The prison has 105 staff, of which 70 are security guards and 12 are treat-
ment staff (doctor, psychologists, social workers, pedagogue, psychiatrists).  
At the time of the visit, the medical department reported having no registered 
cases of HIV, hepatitis A, B, C or tuberculosis but had reported 44 cases of 
self-harm and 2 suicides (one hanging and one overdose). 
2.1.2 Goals and practical procedures 
At the time of the visit 22 prisoners, aged 21 to 40 (average age 28), were 
receiving methadone. On average, the starting dose was 50 mg (the lowest 
being 25 and the highest 205). 12 prisoners were maintained on the same 
dose (for 1 year to 15 days) but it is unknown whether or not these prisoners 
had been on a detox programme at some point. The others’ doses were de-
creased. The length of treatment varied from several years to several months. 
At the time of the research visit, data was only available for prisoners on a 
methadone treatment. 
It was reported that, in this prison, substitution treatment is provided as a 
continued treatment, offered to the individual prior to incarceration; the ini-
tiation of substitution treatment is very exceptional. The team (a nurse, 
medical doctor, psychiatrist, pedagogue and possibly others, such as a psy-
chologist and social worker) reviews each case individually and collectively 
decides whether the treatment is appropriate. 
                                                          
8  Data from interviews were those conducted with: 
– The governor of the prison. 
– The nurse. 
– The doctor. 
– The expert group (9 people: the head of guards, 2 social workers, 2 pedagogues, a psy-
chologist, the chief of the group, 1 social pedagogue, a professor). 
– The Head of Guards. 
– Two police agents at the Police Detention, located at the base floor of the prison. 
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It was reported that nurses prepare the methadone treatment and label each 
bottle with the prisoner’s name. The bottle is delivered by a guard, at the 
same time as other medication, but the prisoner drinks it in front of a guard 
and a nurse or prisoners can take the treatment in the medical area in front of 
a nurse. A nurse stated that she thought it was appropriate for a guard to 
know who gets methadone. ‘There is a difference between alcoholics who try 
to hide their dependence and drug users who don’t hide their dependence 
and tell everyone they take methadone. If any prisoner wants confidentiality, 
then he can get it by going to the medical area to get the methadone – 
guards would not know about the treatment he gets.’ 
Guards reported that methadone provision is routine and is provided along 
with other medical treatment. Although it gives them an extra task, it does 
not bring any extra new stress. 
It was reported that methadone brings stability, less difficulties and less 
abuse of other substances. Staff training and good control of methadone have 
diminished any fear of overdoses. However, according to prisoners’ reports, 
it may be difficult to get off methadone completely. Moreover, the medical 
team observed that methadone may allow prisoners not to face or fight their 
dependence and that improvement of medical care in this prison would be 
limited as long as there is a staff shortage. 
The expert team reported fear of overdoses with methadone. They stated 
that, although methadone reduces drugs traffic, a new black market traffic is 
created and may also put pressure on prisoners having treatment to smuggle 
methadone. ‘You can’t expect prisoners not to know about who takes metha-
done, as several prisoners share the same room.’ However, prisoners are 
more stable, can work and do not anymore think obsessively about getting 
drugs. The expert team is in charge of prisoners’ programme (work, free 
activities, education, psycho-therapy and links with outside) but reported 
finding it difficult to keep up with the workload for the number of staff 
available. 
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2.2 Dob Prison9 
2.2.1 Description of the prison 
Dob Prison was built in the late 1950s and opened in 1963. It has 2 depart-
ments (located nearby in Dob) and is the largest prison in Slovenia with a 
capacity of 289 prisoners. At the time of the visit it held 364 prisoners. The 
department visited, located in the countryside, has a capacity of 233 and 
holds only prisoners with a sentence longer than 18 months. 
The prison has 6 sections (4 closed sections, 1 open-dislocated and 1 semi-
open), an intimate visits room and a Drugs Free Unit. Although, in Slovenia, 
7 m square is allocated per prisoner in one cell or 9 m square per prisoner in 
cells that have more beds, overcrowding and staff shortage (especially ex-
pert, specialised staff) were reported as being problematic. 
The prison has 222 staff, of which 110 are security guards. Dob Prison is the 
only prison in Slovenia that has a doctor paid by the Ministry of Justice (not 
contracted out). 
At the time of the visit, the medical department reported having no registered 
cases of HIV, hepatitis A or tuberculosis but had 57 cases of hepatitis B, 
17 cases of hepatitis C, 20 cases of self-harm and 1 case of suicide. 
2.2.2 Goals and practical procedures  
At the time of the visit, 12 prisoners, aged 25 to 46 (average age 29), were 
receiving methadone treatment. The starting doses varied from 30 to 80 mg 
(the highest being for prisoners on a treatment before incarceration). 9 out of 
12 were on a decreasing dose. A maintenance dose was offered to 3 prison-
ers who had been on a detox programme first, the dose was then increased 
again and, at the time of the visit, was maintained at the same level. Data 
was only available for prisoners on a methadone treatment. 
Every weekday morning, Methadone is provided in the medical centre where 
labelled bottles have been prepared. Guards deliver it over the weekend. It 
was reported that this is not problematic – there is no unnecessary spread of 
                                                          
9  Data that comes from interviews were those conducted with: 
– The governor. 
– The doctor (GP) and nurse. 
– The expert team (5 people: addiction therapist, psychotherapist, pedagogues). 
– The Head of Guards. 
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information – but links with other services (guards) are needed especially as 
there is a shortage of staff (Medical team). 
In order to minimise the risks of methadone traffic and misuse (and thus 
risks of overdose), a guard reported the importance of ensuring that prisoners 
swallow methadone. Guards are entitled to ask for urine test for suspicious 
prisoners. 
The medical team reported that methadone can be a good prevention against 
infections as prisoners’ drug use is identified, although prisoners tend to 
conceal their use for too long and are already infected when they go for a 
consultation. However, it was reported that methadone is seen by some pris-
oners who have ran out of money as a free drug to replace illicit drug use and 
not as a means to reduce or abstain from using. It was stated that not all pris-
oners are willing to consent to the urine test. 
If tested positive (on opiates, cocaine and/or THC), methadone may be re-
moved (usually, it is only removed after the third positive test). In such 
cases, prisoners have threatened to harm themselves. However, a doctor from 
the Centre for Treatment of Drug Addiction reported that this only occurs 
when doctors do not work according to the national methadone guidelines. 
The main purpose of urine tests is to examine whether or not prisoners top 
up methadone. The majority of doctors in prisons are not employed by the 
Prison Services and are not responsible for prisoners’ privileges scale. Prison 
governors and administration regard any drug use in prison as leading to the 
prisoner’s reduction or discharge of privileges. In Dob prison, it was reported 
that prisoners on methadone who tested positive for the third time may lose 
some of their privileges and/or be removed from the methadone programme. 
Prisoners doing well on the methadone programme and/or finishing the pro-
gramme are likely to be entitled to stay in the Drugs Free Unit, which priso-
ners reported as a privileged area, as it was more spacious and calm. 
However, prisoners take the treatment more seriously when signing the sta-
tement and the medical staff perceive urine tests to be useful and necessary. 
The medical team believe that too many tests are done on prisoners in treat-
ment at present and not enough random tests are conducted throughout the 
whole prison. The expert team agreed with the current policy. The medical 
staff also reported that the shortage of staff impedes the ability of a nurse and 
psychiatrist to concentrate on ‘addiction’ issues. 
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One nurse reported receiving training once a year as she belongs to the 
‘Association of nurses’ who provide seminars and lists of courses. The nurse 
stated that there could be more training, but there is a lack of staff. 
There are not many cases of overdoses. In the last 10 years they have had 
one case, 2 years ago. 
The expert team reported that, when discussing a prisoner’s methadone 
treatment, the expert team is consulted by the psychiatrist as the doctor needs 
to be informed of the individual’s behaviour and attitude. If methadone 
maintenance is suggested, agreement from the whole expert team is needed. 
If methadone is provided too quickly then prisoners want to keep the same 
dose (maintenance) ‘which is no life’ – these prisoners are rather passive and 
cannot take an active part in the prison, especially if they have received a 
high dose for a long time. 
Although medical staff feel well trained on substitution treatment, prison 
staff would welcome more training and information on drugs. 
2.3 Views of prisoners 
Two focus groups were conducted with: 
− 5 male prisoners aged 24 to 31 
− 7 male prisoners in their thirties 
Prisoners who took part in the research started using drugs at the age of  
14-16 and reported having used heroin (smoked and by injection), cocaine, 
marijuana, LSD, ecstasy, speed, party drugs, benzos and alcohol. 
Prisoners reported methadone being offered in prison but only on the basis of 
a team decision. They underlined individual differences in relation to the 
success of the treatment: 
‘I went into detox in December last year and the doctor prescribed some 
pills, like a sedative and some other stuff. Methadone was not approved for 
me. The psychiatrist said, yes to methadone for me, the GP, the medical 
doctor said yes, but the team of experts said no.’ 
‘After a long period of methadone, it’s harder to get off, but if you have it for 
six months, it’s easier. But some prefer to keep the doses, and take it long 
term.’ 
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Illicit drugs and methadone circulate on the black market in prison: 
‘I tried heroin when I came in here [prison]. Outside, I did mostly party 
drugs and speed. Speed became a very important part of my life. Gradually, 
I took it regularly, every day. It gave me a feeling of being more confident in 
the business of trafficking, I felt more confident on speed. I came here, to this 
prison. That was then, such a shock, a big change from the life outside, and I 
felt emptiness, suddenly. I felt this psychological pressure, and that’s why I 
started heroin when it was offered.’ 
‘I took methadone on the black market in here but fell asleep, standing up in 
the toilet. I don’t want to do methadone again.’ 
‘When I came, I was having cramps and withdraw. I was forced to get myself 
methadone from the black market. The psychiatrist said I looked ok and I 
was all right. The psychiatrist had me waiting two weeks. Normally you wait 
for one month.’ 
Prisoners reported valuing the Drug Free Unit and wanting to be there, with 
or without a substitution treatment. However, they stated that places are lim-
ited and sometimes given‘wrongly’ to child molesters and not drug users: 
‘I was clean for a month, failed the urine test, was clean for another month, 
failed the urine test. Over and over again, I tried to explain that I couldn’t 
remain clean in that section and asked to be transferred to the drug free sec-
tion, but no, no. They just let me stay there in that non-drug free section, 
until the time when I started to inject. Up to this time I had never injected, 
but then I started. Because they had nothing else to offer to me. Then they 
offered me detox. I had a month of detox, and after a month, they transferred 
me to the drug free unit.’ 
‘Sometimes people who’d like to come on the Drug Free Unit, can’t because 
there are no vacancies because other prisoners are transferred there for 
their protection, like child abusers/sex abusers. The staff knows that those 
criminals are safe there, and they’re not there because of drugs. The only 
violence is against them. No one likes them. In the drug free unit, it should 
be a little more rearranged.’ 
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3 Summing up 
The tendency in prison is to offer methadone treatment on a detoxification 
basis (with gradual dose decrease). Although prison staff show reluctance 
and resistance to offer methadone maintenance treatment, it is allowed and, 
increasingly as doctors try to work out an individual approach, it is offered. 
Buprenorphine was integrated in May 2004 and is expected to be offered in 
prison in autumn 2004. 
The decision to offer substitution treatment is taken within a team: the doc-
tor, the prisoner and the expert team (present in each prison). Prisoners 
wished for an individual approach and treatment, welcomed substitution 
treatment contact, but wished to stop associating the treatment with punitive 
measures. 
So far, substitution treatment has been a successful harm reduction and pub-
lic health intervention, offered with the cooperation and supervision of the 
Centre for Treatment of Drug Addiction. 
 Spain1 
1 General data:  
drug use, substitution treatment and prison population 
1.1 Drug use 
Cannabis is the most frequently used psychoactive substance in Spain. 
Heroine use and opiate use by intravenous have decreased. Significant in-
creases in cocaine-related problems have occurred in the last ten years. There 
has been an increase of the use of ecstasy and amphetamines for recreational 
use, but some users have needed health treatment. Drug users are mainly 
poly-drug users, with a general tendency to mix alcohol, tobacco and canna-
bis with other substances. (Reitox Spain, 2002) 
44,255 admissions for opiate (around 68%) or cocaine (around 19%) treat-
ment for a total of 44,255 admissions were recorded for 2001 (Reitox Spain, 
2002). ‘Those reported in 2001 for consuming or holding drugs in accor-
dance with the Organic Law 1/1992, of February 21, for the protection of the 
civic security were 112,270.’ (Reitox Spain, 2002, p. 31) 
In the community, 78,806 people were on a substitution treatment in 2001/ 
2002. (EMCDDA, 2003) 
In prison, during 2001, on a given day, 21,642 prisoners (19,474 men) of 
69 prisons (with a prisoner population of 57,365) were on a methadone treat-
ment (prevalence-day of approximately 22%) (Reitox Spain, 2002). 
                                                          
1  The field visit, conducted by Laetitia Hennebel, was facilitated by Graciela Silvosa Rodri-
guez, Head of the Prison Programme Services, the National Drugs Plan on Drugs (Delega-
cion del Gobierno para el Plan Nacional sobre Drogas). Special thanks to her and Julian 
Sanz Sanz, Head of Drug Treatment Services, Ministry of Interior, for their support. 
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1.2 Substitution treatment 
Data comes from an on-going review of research reports, websites and laws/ 
regulations, as well as from interviews conducted during the field visit2. 
1.2.1 Historical and legal background 
The Spanish Constitution of 6 December 1978 and the General Health law of 
14/86, of 25 April, were the first important documents establishing measures 
to take regarding health issues. 
The implementation of substitution treatment in Spain has been rather 
smooth. Substitution treatments are regulated in the Royal Decree 75/1990, 
of January 19, amended by the Royal Decree of 5/1996, of January 15. 
Substitution treatment has been offered, among other things, as a reaction to 
the HIV/Aids epidemic. Since the second half of the eighties, HIV/Aids 
infections are one of the major health problems associated with the use of 
drugs in Spain. The National Drug Strategy (2000-2008) sets forward the 
‘new’ National Plan on Drugs, and preventive measures. 
Methadone is the main substance used in substitution treatment. Buprenor-
phine was introduced in Spain in 2002 – first to be tested in Madrid – for 
‘drug users who cannot take methadone’. (Reitox Spain, 2002) 
1.2.2 Substitution treatment in prison 
All prisons in Spain offer initiation of methadone, methadone maintenance 
treatment, and detoxification with methadone. Brief and progressive detoxi-
fication may also be offered with opiates and benzodiazepines. 
Substitution treatment in prison has been developed as part of the harm 
reduction strategy since 1992, and was extended to all prisons in 1998. Sub-
stitution treatment has proven highly efficient and effective in preventing 
HIV infections. (Reitox Spain, 2002) It is reported that approximately 16% 
of prisoners are infected by AIDS and 46% by hepatitis C (Reitox Spain, 
2002). 
                                                          
2  Interviews were conducted at the national level with: 
– The Head of the Prison Programme Services, the National Drugs Plan on Drugs. 
– The Head of Drug Treatment Services, Ministry of Interior. 
– Social workers, NGO-based in the community. 
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Articles of the Spanish Constitution of 6 December 1978 underline the equi-
valence of health care between the community and the prison. The General 
Health law of 14/86, of 25 April, further states prisoners’ rights to access 
health services similar to those offered in the community. 
The circular 5/95 from the directorate general of prison services on the glo-
bal drugs policy 5/95 establishes that within the framework established by 
the National Drugs Plan (Plan Nacional sobre Drogas), in coordination with 
other sectors of public administration or other organisations and institutions, 
such as the Municipal and Regional Drugs Plans (Planes Autonómicos y 
Municipales sobre Drogas) and Non-Governmental Organisations and Enti-
ties, prisons will run specialised drug dependency programmes for prisoners 
who voluntarily request them, consisting of prevention, harm and risk reduc-
tion, methadone treatment, breaking the cycle of drug dependency and social 
reintegration. 
Health care in prison is under the management of the Ministry of Interior 
(Directorate General of Prison Services). 
Substitution treatment is offered in prison as part of ‘interventions’ for drug-
using prisoners. The objectives are: 
− To reduce of deaths due to overdose. 
− To control and reduction of physical health harm. 
− To control or reduction of infections like HIV. 
− To reduce of delinquent activity and recidivism. 
− To improve social and labour adaptability. 
− To modify drug use. 
− To provide a mean to remain abstinent for several periods. 
− To improve and facilitate rehabilitation and reintegration into social life. 
(Ministerio del Interior, 2001) 
Methadone is offered as: 
− a treatment with methadone (methadone treatment), or 
− a treatment of detoxification with methadone. 
These two types of treatment are not exclusive. A prisoner may go from one 
to the other, according to the biopsychosocial situation of the drug user. To 
reach efficacy, the biopsychosocial focus needs to be part of a drug user’s 
treatment. Methadone programmes must include health interventions, psy-
chosocial interventions (with group and individual therapeutic sessions) and 
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throughcare (or preparation for release and rehabilitation). (Ministerio del 
Interior, 2001) 
The Ministerio del Interior (2001) reported that methadone treatment is the 
most effective intervention for the number of drug using prisoners it attracts, 
and for individual and group benefits it brings. Moreover, it facilitates the 
reduction of drug use, reduces the intravenous use of drugs, improves physi-
cal and mental health, as well as hygiene and health habits. It reduces antiso-
cial activities, delinquent activity and recidivism (and return to prison). 
Quality of life, socio-labour situation (the social integration) is generally 
improved. 
The Ministerio del Interior (2001) stated that in order to reach all these 
advantages and benefits, methadone treatment cannot be limited to the sole 
prescription and distribution of the substance. Methadone must be delivered 
within a global therapeutic approach, taking into account individual differ-
ences and needs, and including psychological and social interventions. A 
sole distribution of methadone is a harm reduction measure, contrary to a 
methadone treatment that includes psychosocial activities and preparation for 
release (and, if needed, continuation of the treatment on release in a commu-
nity centre) and is thus a rehabilitation treatment. 
Detoxification treatment with methadone is offered to drug-using prisoners 
who wish to abstain from drugs and according to their health, personal, so-
cial, penal and penitentiary conditions. (The Ministerio del Interior, 2001) 
In 2001, (31 December), 7,531 prisoners (around 7% of total prison popula-
tion) went through detoxification programme. 21,642 (around 21%) went 
through methadone treatment (maintenance). (The Ministerio del Interior, 
2001) 
The Minister of Interior (2001) stated that the variety of treatment options 
and the plurality of therapeutic strategies are determining criteria for the suc-
cessful treatment of drug users. This diversity also increases the number of 
drug-using prisoners consulting and engaging in treatment in prison. 
It was reported that methadone treatment is delivered differently from one 
prison to another. (Sanz Sanz, 2000) 
In 1999, on 31 December, out of the 6,589 prisoners on methadone treat-
ment, 19% were on a dose less than 40 mg per day, 47% on a dose between 
40 and 80 mg, and 34% on a dose higher than 80 mg per day. (Sanz Sanz, 
2000) 
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1.3 Prison Population 
Table 23  Data on the prison situation in Spain (Source: King’s College London, Interna-
tional Centre for Prison Studies, Prison Brief for Spain) 
Country  SPAIN 
Ministry responsible  Ministry of the Interior 
Prison administration  General Directorate of Prison Administration 
Contact address  Calle Alcala 38-40, E-28014 MADRID, Spain 
Telephone / fax / website  
tel:    +34 91 335 48 81 
fax:   +34 91 335 40 64 
url:    www.mir.es/instpeni 
Head of prison administration (and title)  Angel Yuste Castillejos, Director General 
Prison population total (including pre-
trial detainees / remand prisoners)  
57,365 at 20.2.2004 (national prison administration 
website)  
Prison population rate (per 100,000 of 
national population)  
140 based on an estimated national population of 40.98 
million at February 2004 (from Council of Europe 
figures)   
Pre-trial detainees / remand prisoners 
(percentage of prison population)  22.4%   (20.2.2004)  
Female prisoners (percentage of prison 
population)  7.8%     (20.2.2004)  
Juveniles / minors / young prisoners 
incl. definition (percentage of prison 
population)  
0.3%     (31.12.2000 – under 18, Council of Europe 
Annual Penal Statistics)  
Foreign prisoners (percentage of prison 
population)  25.4%   (1.9.2002)  
Number of establishments / institutions  85          (2001)  
Official capacity of prison system  45,320   (1.9.2002)  
Occupancy level (based on official 
capacity)  112.5% (1.9.2002)  
Recent prison population trend (year, 
prison population total, prison popu-
lation rate)  
1992      35,246        (90) 
1995      40,157      (102) 
1998      44,763      (114) 
2001      46,962      (117) 
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The Ministry of Interior reported that there were approximately 45,000 pris-
oners in a total of 66 prisons in 2002 (this excludes the Catalonia region). It 
is estimated that 77% of prisoners have used drugs prior to incarceration. 
(Ministry of Interior) 46% of them have used heroine and/or cocaine, 
although they often have also used other substances (Ministerio del Interior, 
2001) 
Although the Penal and Penitentiary Law is the same for the whole country, 
Catalonia is the only autonomous community in the country that has compe-
tence for the management of prisons in the Catalonia region, i.e. the Gov-
ernment of Catalonia can regulate and make decisions about the management 
of its prisons. There are, in 2004, approximately 7,800 prisoners in a total of 
11 prisons in the Catalonia region. Around 50 to 70% of them have used 
drugs prior to incarceration. (Treatment Section and Rehabilitation Services) 
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2 The field visits3 
Time frame: The field visit took place from 14 to 16 July 2003. 
Location: Visits were conducted in two prisons: Madrid I and Madrid IV 
Navalcarnero. 
 
Map of Spain 
                                                          
3  Methodology: Interviews were conducted with the individuals listed below as well as focus 
groups with prisoners. One focus group was tape-recorded. The researcher conducted all 
interviews/ focus groups on her own. All participants were briefed and told about ethical 
issues. 
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2.1 The Prison Madrid I4 
2.1.1 Description of the prison 
The Prison Madrid I is located in the surroundings of Madrid. It is a female 
prison. Madrid II (male prison) is located opposite the female prison in a 
deserted area in the middle of the countryside. 
At the time of the visit, there were approximately 350 prisoners for 102 cells. 
Around 75% of the prisoners have used drugs. 
2.1.2 Goals and practical procedures 
At the time of the visit, there were 92 female prisoners on a methadone 
treatment. The treatment was initiated in prison for 26 of them, continued 
from another prison for 62 of them, and continued from a community centre 
for 4 of them. 
At prison entrance, prisoners get a medical evaluation. Blood tests are 
offered upon entry to the prison, and most prisoners comply with it. Most of 
the prisoners come from another prison. The demand for psychotropics is 
high. If they are drug users, methadone is offered. If the prisoner says she 
has been on a methadone treatment, after verification of the information, the 
treatment is continued. Over weekends, the medical staff may give a small 
methadone dose if they estimate that the prisoner is going through with-
drawal due to a lack of methadone. 
Methadone is offered as maintenance treatment or detoxification treatment. 
The treatment team comprises 3 social workers, 4 psychologists, 5 educators 
and 2 lawyers, and the team meets once a week to discuss individual cases. 
Psychosocial support is provided to prisoners as part of the treatment. 
Prisoners are called and brought to the medical centre where they drink the 
methadone syrup in front of the nurse; afterwards, they are asked to say 
something, proving they have swallowed the substance. 
Methadone doses varied from 5 to 205 mg. 10 were on a dose less than 
40 mg, 39 on a dose of 40-80 mg, and 43 on a dose higher than 80 mg. The 
                                                          
4  Data from interviews were those conducted with: 
– Guard 
– Doctor 
– Psychologist 
– Social worker 
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medical staff reported no difficulties or pressure from prisoners regarding the 
doses. 
Most of the women, even if on high doses, said they were stabilised thanks 
to methadone. Several women had a methadone treatment prior to pregnancy 
and continued successfully during the pregnancy. The dose was often 
reduced during pregnancy, but increased again after the birth. 
Buprenorphine can be prescribed, not as a programme but as a treatment like 
a benzodiapine or other prescribed drugs. However, the medical team said 
that it was rarely prescribed. 
Overall, the provision of methadone treatment was said to go smoothly and 
to satisfy prisoners’ needs. Medical staff and prison staff were all content 
with the treatment and benefits it brings to the prisoners and the prison set-
ting. 
Psychosocial support and training 
It was reported that psychosocial support and therapeutical approach is 
offered to prisoners on methadone. The psychologist’s office is always open 
and prisoners are encouraged to ‘walk in’ whenever they need to. Access to 
professionals is easy and available on an ongoing basis. The structure of the 
prison is friendly, located in the countryside, and prisoners are free to circu-
late in the setting. This increases a ‘friendly’ environment that promotes 
rehabilitation. 
Medical team reported that training on drug issues and substitution treatment 
are quite complete and sufficient. 
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2.2 Madrid IV Navalcarnero Prison 
2.2.1 Description of the prison5 
The prison of Madrid IV Navalcarnero is located in the surroundings of 
Madrid. The prison was built in 1993. The structure allows for all sorts of 
activities, such as education, work, training, sports (including a swimming 
pool), to be offered to prisoners. Cells are on a single or double occupancy. 
The prison is a remand prison for male prisoners. 
At the time of the visit, the governor reported that the prison has approxi-
mately 1 000 prisoners, for a capacity of 1 200. The staff are ‘funcionarios’ 
from the Ministry of Interior. The prison counts approximately 460 staff. The 
medical team comprises 8 doctors, 10 nurses and 18 clinical assistants. 
2.2.2 Goals and practical procedures 
It was reported that there was reluctance to start methadone treatment, espe-
cially due to a fear of high workload. Guards perceived the treatment as ‘just 
another drug’ and thus associated medical staff to the image of drug traffic. 
Training and information facilitated development of the treatment. Further-
more, substitution treatment was introduced in prison as ‘an order’ to imple-
ment the practise in prison from the Ministry in charge at the time. 
Methadone started in the prison in 1999. At first only one designated doctor 
with the support of one nurse provided methadone treatment. This was later 
opened to all doctors of the prison. 
Methadone is offered as a maintenance treatment or detoxification treatment. 
In general, the methadone programme was started in the community or in 
another prison and is continued at this prison. The majority of prisoners are 
on a maintenance treatment. Detoxification is less frequent and not encour-
aged as prison life is difficult, a nurse reported. 
                                                          
5  Data from interviews were those conducted with: 
– The governor of the prison  
– A doctor 
– Nurses 
– Psychologist 
– Guards 
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Methadone is provided in a syrup form. Buprenorphine is not offered in 
prison. A nurse stated the pill form is problematic and not ideal in prison as 
the supervision of the intake is difficult. 
Methadone is prepared outside of the prison by a Pharmaceutical Centre. 
Methadone is distributed to prisoners on a daily basis, and at the same time. 
Prisoners are called to visit the medical centre for the treatment. 
It was reported that confidentiality about methadone treatment cannot be 
entirely respected in prison. Guards are involved in the treatment indirectly 
(by bringing prisoners to the health centre, etc.). The medical team stated 
that the cooperation and relations with the guards were positive. 
Nurses reported that sometimes prisoners put pressure on the doctor (not the 
nurse) to get higher doses. 
Prisoners are aware of the doses they receive, which are individually based. 
There is no maximal dose. The dose provided at entrance of prison is care-
fully examined in order to decrease risks of fatal overdose; usually the start-
ing dose is 15-20 mg. Overdoses usually occur due to methadone being 
topped up, and is rare for prisoners included in a methadone programme. The 
nurse reported that in general, prisoners on a dose that is higher than 80 mg 
remain in treatment, whereas those on a dose less than 80 mg, if they remain 
in treatment, they tend to top up. She further stated that some prisoners take 
20-30 mg of methadone to continue using drugs but avoid any withdrawal 
symptoms. 
It was reported that some families put pressure on drug-using prisoners to 
abstain completely from drugs, including methadone. However, only a 
minority of prisoners on methadone decrease the dose towards a ‘drug free’ 
status. Decrease of the dose goes by 1 or 5 mg, depending on the individual. 
It was reported that methadone has reduced the number of overdoses and in-
fections. Prisoners’ quality of life has improved. Conflicts within the prison 
(especially, between prisoners) and aggressive behaviour have decreased. 
Methadone allows prisoners to think about something other than ‘getting 
drugs’. 
Psychosocial support and staff training 
It was reported that psychosocial support is lacking in the prison, mainly due 
to the number of prisoners and lack of staff. Some professionals said that 
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prisoners often lack motivation to engage in therapeutic work. Social work-
ers from external NGOs do provide work and support in prison but the needs 
are still higher than the offer. 
2.3 Views of prisoners 
Interviews were conducted with several prisoners: 
− One focus group with 8 female prisoners – Prison Madrid I 
− One focus group with 6 male prisoners – Prison Madrid IV Navalcarnero 
Female prisoners tended to talk all at once, resulting in the loss of a lot of 
information. The male focus group was dominated by one talkative prisoner. 
There were some differences between male and female prisoners, mainly due 
to the whole prison environment. Women were satisfied with the treatment 
and psychosocial support, whereas men complained about not receiving 
enough or any psychosocial support and ‘being put on methadone’ to gener-
ate peace and tranquillity within the prison. 
Methadone was seen as a positive measure. 
‘I’ve gone back to work thanks to methadone. My life is much better now.’ 
Providing methadone at the same time was also requested. 
‘I come from a prison where they gave me methadone at 9.00 am every day – 
and that for 1 year. In here, they don’t respect it and give it to you at differ-
ent times.’ 
The main complaints were from male prisoners who wanted higher doses, 
but at the same time some wanted to reduce and wanted a closer relation 
with the medical staff. They felt methadone was used to keep them quiet and 
their individual needs were not respected. 
‘I wanted to reduce my methadone but the doctor refused because she said 
that the risks that I topped up or use illicit drugs were too important. I want 
the medical staff to take individual needs more into account. I am not eve-
ryone, I have my needs, and I want to reduce, but with time.’ 
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3 Summing up 
Methadone is provided in all the prisons of Spain, and is the only substance 
offered as maintenance treatment for drug-using prisoners, or ‘long-term’ 
detoxification. Like in most countries, there was reluctance at first to provide 
methadone treatment in prison, although it was implemented as a ministerial 
health measure. The reluctance was due to the status of the medicine and the 
implication of providing the treatment in prison. 
Psychosocial support is seen as an important factor for the success of the 
treatment. However, during the visit, it was reported that psychosocial sup-
port was insufficient. Male prisoners also wanted more psychosocial and 
individual support. Female prisoners were generally satisfied about their 
treatment and support provided. 
Methadone was not talked about as a problematic or difficult to manage 
treatment. It was well integrated in the whole drug-using treatment approach. 
 Sweden1 
1 General data:  
drug use, substitution treatment and prison population 
1.1 Number of drug users (EMCDDA data) 
According to MOB (Mobilisering Mot Narkotika2) figures (2004) the num-
ber of problematic drug users is about 28-30,000 of which approximately 
half of them (12 200) are supposed to be opiate users. Amphetamine use is 
the predominant pattern for problematic drug use in Sweden. According to 
the respondents, the number of drug users in prisons amounts to 60%, which 
is an increase of 10% compared to the situation 6-7 years ago. Different 
views have been given as to the amount of illegal drugs in prisons. Prison 
doctors and ex-inmates from a NGO stated that there were drugs in prison 
(cannabis, benzodiazepine, Subutex®, anabolsteroids, cocaine) but that her-
oin was not widespread. The most frequently abused drugs were ampheta-
mine, benzodiazepine and dexepopozephin3. According to other views, the 
amount of drugs used in prison is not that widespread, at least not as much as 
is conveyed in the media. 
After more or less neglecting the drug problem during the 90´s the govern-
ment initiated a survey and a report was published about the extent of the 
drug problem in 2001. A parallel report was published within the criminal 
justice system. After that MOB was installed with funding of about 350 mil-
lion SEK of which 100 million was directed to the prison system4. The 
whole launch (2002-2004) is scientifically evaluated. 
                                                          
1  The field visit, conducted by Heino Stöver, was facilitated by Åke Farbring, Swedish 
Prison and Probation Administration, Programme Inspector, who also provided general 
information and support with the finalisation of this country report. 
2  The bureau that was installed to handle the government funding to reduce drug use. 
3  Dating back to a Stockholm based examination of used drugs in the criminal justice sys-
tem. 
4  used for ASI-reports, finding drug users in remand prisons and elsewhere, Motivational 
Interviewing (a semi structured programme), and cognitive based programmes aiming at 
reducing drug use. 
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1.2 Substitution treatment 
1.2.1 Historical and legal background 
Since 1999, methadone and buprenorphine have been registered and author-
ised agents in substitution treatment. According to an interviewee, there are 
about 800 patients receiving methadone in Sweden (more or less distributed 
over the cities of Stockholm, Uppsala and Lund). Subutex® is prescribed to 
approximately 1,000 drug users. There are different policies and practices 
applied, with gaps from South to North and from West to East, with ambi-
valent responses on the part of doctors. On the one hand an increasing resi-
stance can be noticed to prescribe substitution drugs, and on the other hand 
doctors are interested to give this patient group evidence based treatment  
(i.e. substitution medication). In 1967, methadone was launched in Sweden 
(Uppsala) (see Farrell et al., 2000, p. 13) but only in the first structured and 
scientifically evaluated programmes did not appear until the 80s. The metha-
done services have been restricted in terms of high-threshold programmes 
which are only provided in four specialist centres throughout Sweden, GPs 
are not allowed to prescribe methadone5, only buprenorphine (“Subutex®”). 
New regulations are coming up in August 2004 (they will begin to work at 
the 1st of January 2005), stating that heroin users who want substitution 
treatment should be offered that, and this is regarded a major change in pol-
icy, probably leading to a big increase in the number of patients receiving 
treatment! 
A specific “treatment philosophy”, corresponding to deviant behaviour, is 
deeply rooted as a cultural concept in the Swedish society. Subsequently, 
both drug policy and practice are basically treatment-oriented which means 
that the efforts of drug services and politicians focus on supporting drug 
users to abstain from drugs. Thus, substitution treatment is seen as an inter-
vention which is only indirectly trying to achieve this goal. This is despite 
encouraging research results on methadone maintenance programmes from 
Swedish scientists into the preventive effects of methadone on HIV infection 
(Gunne, 1987), treatment characteristics and retention rates of methadone 
programmes (Gunne & Gronbladh, 1981; Gunne, Gronbladh & Ohlund, 
2002) and the impact of methadone treatment for heroin mortality (Gron-
bladh, Ohlund & Gunne, 1990). 
                                                          
5  Although methadone is supposed to be used as a painkiller. 
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Encouraging results from a recent Swedish study on buprenorphine may lead 
to an intensified discussion about substitution treatment. In a double-blind, 
randomised controlled trial, Kakko et al. (2003) found a high retention rate 
(75%) of the buprenorphine-treated group6 after one year compared to a pla-
cebo group who only received psychosocial treatment (0%). Kakko et al. 
come to the conclusion that buprenorphine and psychosocial care “is safe 
and highly efficacious, and should be added to the treatment options availa-
ble for individuals who are dependent on heroin” (p. 662). The term substi-
tution drug is not used, medication assisted treatment is preferred which 
clearly indicates that any substitution drug is used as a medication: 
“So I think the kind of treatment, Subutex® or methadone, is very, very im-
portant for the patients if you do it the right way. And in Sweden we don’t 
like to say ‘substitution treatment’ because we don’t think it’s a substitute for 
the drugs. But we say, it’s a medication assisted treatment because we use 
those medicines like a medication, not like drugs. The way they can use for 
example Subutex® as a drug is not the way we take it.” (Doctor) 
1.2.1 Substitution treatment in prisons 
Substitution maintenance treatment in prisons is not available in Swedish 
prisons. In a few cases, a short-term detoxification treatment is carried out 
(see prison visit). The Swedish Criminal Justice system is mainly focuses on 
rehabilitation of inmates by means of different programmes for education 
and behaviour change. Käll reported that, in 2000, about 35% of all identi-
fied incarcerated drug users received drug treatment. Random mandatory 
drugs testing of urine is performed in all Swedish prisons. A refusal or posi-
tive test gives a 5-day extension of the stay in prison, up to a maximum of 
45 days. Neither methadone or buprenorphine maintenance programmes are 
provided in prison. Heroin detoxification is usually done by prescribing clo-
nidin, in severe cases supplemented with dextropropoxiphen. Consequently, 
no initiation of substitution treatment in prisons is offered. 
Interviews with inmates supported the view of Käll (2001), that changes in 
these policies and practices are currently being discussed and that ongoing 
maintenance treatment may be continued during a short sentence and prison-
ers may be permitted to apply for and start maintenance treatment shortly be-
                                                          
6  16 mg buprenorphine daily, which blocks 80-90% of opioid receptors. 
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fore release. Whereas methadone can only prescribed by doctors in specialist 
centres, buprenorphine can be suspended by GPs. 
The policy of substitution treatment is to provide a drug free prison atmos-
phere and environment that makes substitution treatment dispensable: 
“In prisons it has been still more controversial and the reason for substitu-
tion treatment is the craving for the drugs so that you shall not continue to 
take it. And our aim with the drug policies in prisons is, that there should be 
no drugs in prisons, so it will be not necessary to do anything for the craving 
because the supply of drugs should be zero … Supply and request gives the 
abuse. Of course, every one knows that the prisons, not even in Sweden, are 
not completely free of drugs, but the situation is not as bad as it is told in the 
papers. Examinations show that there are about ten prisons, I think, where 
they have daily problems with drugs. But the majority of prisons, they have 
problems with drugs now and then. So it isn’t as bad as it says in the 
media.” (Senior medical advisor) 
The Swedish approach towards the provision of substitution treatment in 
prisons is outlined by the senior medical advisor. The key aspects are that 
buprenorphine is judged as being superior to other agents and that doctors 
are allowed to use it in the process of initiation of a substitution treatment 
before release, to avoid overdoses, and it is assumed that there is contact 
with a prescribing clinic outside. 
“… so it is much more difficult to get drugs in prison than outside. Outside 
there is a completely free market in spite of the polices and the customs work 
… But we are now in the beginning of a discussion in the Swedish prison 
system whether we shall or not shall have programmatic substitution. That 
would be with buprenorphine, not with methadone. And we are having a 
continuing discussion about an experiment in some wards to see how it 
works out. But that is a programmatic thing of work. But in the health ser-
vice in prisons doctors are operating on their own responsibility. And I know 
of cases, where buprenorphine is used as a detoxifying agent, where we as a 
matter of fact recommend it in our pharmacological recommendations to our 
prison doctors. That, if abstinence troubles or they repeat, they should prefer 
buprenorphine to dextropropoxiphin-programmes. Dextropropoxiphin, that 
is an artificial opioid which is used as an analgetic which is prescribed in 
quite large amounts in the society. But because of it’s similarity to morphine 
it is acting in the same way in the receptors, in the brain. So, therefore it is 
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used. But it is very hazardous to your liver and your health, especially if you 
are a heavy user of alcohol or your liver is stressed anyway. So buprenor-
phine is less risky. If they are in a situation where they consider dextropro-
poxiphin we recommend them to use buprenorphine only in the detoxifying 
situation. In the substitution situation, our recommendation is that our doc-
tors should not introduce substitution treatment. If the patient is well known 
in officially legitimated policlinic and they want to take the responsibility of 
introducing substitution therapy before release so as to avoid relapses. The 
first hour of the release is the most dangerous hour in an addict’s life, 
because he is detoxified. And the first hour is when it is decided whether he 
will fall back or not, I think. So if they are willing to take the responsibility of 
their own patient and continue responsibility after the release we can accept 
that they introduce such a substitution-treatment sometime before releasing 
the prisoners ... And we also recommend that they have a small discussion 
with me before they do so. So we can have some control over the situation 
and also reach this certified policlinic.” 
In single cases, a continued prescription can be organised as well as the 
uptake of substitution treatment shortly before release (two weeks), which is 
illustrated in two examples by the senior medical advisor. 
“… I have two good examples: that’s from the XY prison in the southern east 
cost, a nurse who is interested in drug abuse. And he first contacted me. That 
was one patient who should do time in XX prison. And he already had a very 
good contact with a very highly respected addiction centre in ZZ. And so 
they called me and asked if it should be allowed to continue the substitution 
therapy while in jail and this was only two months. So I told them that clinic 
has a good reputation and if you can manage the prison social system, so 
that there will be no leak for the Subutex® for abuse, cause you can use one 
pill, you can divide it into ten to make misuse of it, because dose response. 
And he described exactly how he would do it. The patient would come to the 
nurse and sit there, the pill should be trashed and melted in mouth. The 
patient staying there for at lest ten minutes and then show his mouth again 
and then go back and take care of no pills himself … they managed that very 
well and before release they went to the addiction-centre in ZZ, the contact 
freshened up, he was released and I heard some days ago that it was still 
going very well for that patient.” 
“And another case had contact with ZY in Stockholm. So, about two weeks 
before release the nurse and this Patient went from ZW to ZY policlinic. And 
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he had a consultation with the doctor in the ZY, he decides about the dose 
and so on, he went back to jail with this ordination, it was carried out in the 
jail and the patient was released some weeks ago and we had time at the ZY 
clinic the day after release. It ought to be the same day but sometimes that 
can’t be.” 
As substitution agent buprenorphine is preferred by the senior medical advi-
sor: 
“But I think buprenorphine is ok. I don’t think it’s necessary to work with 
different treatments that are acting in the same way for the cellular mem-
brane. At leas, similar enough to make the purpose available of the treat-
ment. Methadone was introduced in ‘68, and was so controversial that it 
wasn’t a thing even to discuss in prison. I have been involved in some dis-
cussion concerning this exclusion criterion. Now, I don’t think it’s necessary 
anymore because buprenorphine exists. There are not such regulations 
around the buprenorphine. Our doctors could prescribe it as they want to, as 
an abstinence pill and they can take it as substitution in those few cases 
where it can happen. And its easy to handle – a pill that melts under your 
tongue as compared to liquids or methadone pills which are easy to hand out 
and so on. So there are reasons to prefer the buprenorphine. One thing that 
is not so good is that it’s very expensive. Methadone is very cheap” 
1.3 Prison Population 
Table 24  Data on the prison situation in Sweden. Source: King’s College London, Interna-
tional Centre for Prison Studies, Prison Brief for Sweden) 
Country  SWEDEN 
Ministry responsible  Ministry of Justice 
Prison administration  Swedish Prison and Probation Administration (Kriminalvårdsstyrelsen) 
Contact address  Slottsgatan 78, S-60180 Norrköping, Sweden 
Telephone / fax / website  
tel:   +46 11 496 3000 
fax:  +46 11 496 3420 or 3802 
url:   www.kvv.se 
Head of prison administration  
(and title)
(Mrs.) Lena Häll Eriksson  
Director General 
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Prison population total  
(including pre-trial detainees / 
remand prisoners)  
6 755 
at 1.10.2003 (national prison administration)  
Prison population rate  
(per 100,000 of national population) 
75  
based on an estimated national popula-
tion of 8.96 million at September 2003 
(from Council of Europe figures)  
 
Pre-trial detainees / remand prisoners  
(percentage of prison population)  20.7%   (1.10.2003)  
Female prisoners  
(percentage of prison population)  5.4%     (1.10.2003)  
Juveniles / minors / young prisoners 
incl. definition (percentage of prison 
population)  
0.2%     (1.10.2003 – under 18)  
Foreign prisoners 
(percentage of prison population)  27.2%   (1.10.2002, of sentenced prisoners only)  
Number of establishments / institu-
tions  84          (April 2004 – including 30 remand prisons)  
Official capacity of prison system  6 317     (1.10.2003)  
Occupancy level (based on official 
capacity)  106.9% (1.10.2003)  
Recent prison population trend 
(year, prison population total, prison 
population rate)  
1992     5 431     (63) 
1995     5 767     (65) 
1998     5 290     (60) 
2001     6 089     (68) 
2 The field visits  
2.1 Prison Österåker 
2.1.1 Description of the prison 
The Österåker prison is situated about 30 kilometres north of Stockholm and 
was originally built, in 1969, for 200 prisoners – a figure that has now redu-
ced to 146. In 1976, a therapeutic unit was installed on one of the wards for 
drug users, it was outlined as a therapeutic community within the prison 
system and the theoretical concept was largely based on cognitive behaviour 
therapy. The ward could host up to 15 prisoners. Despite the success of the 
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evaluated programmes in terms of reduced recidivism (see Farbring, 2000), 
the programmes have been reduced due to budget constraints (which also 
includes a reduction of time that NGOs come into prison supporting prison-
ers). The prison still has a treatment ward, where motivational interviewing, 
discussion and contact with other drug treatment services and family is pro-
vided. According to the people in charge, this approach is successful in sup-
porting prisoners to abstain from drugs. 
2.1.2 Goals and practical procedures of detoxification treatment 
As in all Swedish prisons, substitution maintenance treatment is not availa-
ble. The prison doctor only prescribes Subutex® (4 mg, 2 times a day) from 
time to time to drug dependent prisoners on admission. One of the reasons 
for the discontinuation of community-based substitution treatment is that 
committing criminal offences is one reason to be expelled from the pro-
gramme. And, if a drug user comes to prison this proves his/her inability to 
abstain from drugs and criminal behaviour. Another reason is that the ex-
change of medication among inmates should be avoided, and finally inmates 
are often moved from one prison to another, and it is difficult to followed up 
treatment everywhere. This would require the same prescription policy from 
doctors all over Sweden: 
“For the Subutex it’s quite good within the dependency ward but we have 
some private doctors, who don’t follow this and don’t care about the patients 
either, they just abuse the drug and it doesn’t help.” (Doctor) 
The detoxification process is described by a doctor: 
“… We give 4 mg twice a day and then we decrease the dosage after the 
third day; they get it in six or seven days.” 
One debate with drug using inmates is the issue of benzodiazepines, as a 
nurse states: 
“… but when they come, these people that want Benzos, there is a struggle, 
but there are not very many.” 
Everyday life in prison is perceived to be less complicated for drug using 
prisoners when compared to life outside, and reduces problems and tempta-
tions of continuous drug use. Coercive treatment 6 six months7 is legally 
                                                          
7  A study published on the effects of 6 month coercive treatment was not very positive . 
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possible and is seen as an valuable contribution to the experience for being 
off of drugs for a while: 
“I think the problem is that most of the people here have a problem to keep 
limit. And if you are in prison, life is much easier, not so complicated. So it’s 
easier to keep those limits, it’s not so complex as outside … They are usually 
functioning better in prison. And you have no money to buy drugs. We have 
this law for drug-addicts that we can force them into treatment for 6 months. 
Then they are in the treatment houses, they are forced to be there. They can 
keep free from drugs during this period.” (Doctor) 
Much effort is spent in the prison on the support of abstaining from drug use 
and on assistance on the process of release. The work of the medical service 
is explained by the doctor: 
“… we have limited possibilities. What we do: just a motivational interview 
and we try to arrange that they can manage to get away from the drugs. 
Sometimes it’s enough that we just discuss and they come back and we fol-
low up it. Sometimes we have to contact the staff to maybe arrange some 
other placement. Or something like that. But we mostly do just arrange the 
connection between the prison and the dependency ward when they are 
released. Most of the inmates use drugs less in the prison than outside. And a 
lot of abusers manage to get away from the drugs when they are in prison. 
But they don’t manage afterwards. So we try to motivate them to try to conti-
nue the treatment afterwards. And we use a lot of antidepressants because 
we see a lot of depression and anxiety when they get drug-free. And the 
treatment results are very good. But the problem is just to follow up after the 
release.” 
One big issue is the prescription of benzodiazepines and the gap between 
western and eastern Sweden which improved after discussions and lectures 
on the dangerousness of constant prescribing8: 
“... big difference. You will hear it from XX, we have a unique follow up for 
the medications within the prison system. So every doctor can see his own 
prescriptions over six month periods. They check it for all the prisons, all the 
remand prisons, and then they calculate the statistics for the remand prisons 
separate because its another need, and for the maximum security prisons 
and for the open prisons. So you can see while your prescription is above the 
                                                          
8  See Kriminalvardsstyrelsen. Planeringsenheten (2003): Läkemedelsstatistik 2003 Första 
Halvaret, Stockholm (www.kvv.se). 
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medium or below and we can see it for Benzodiazepines or opiate tranquili-
zer, for the neuroleptics, the psychiatric medication, so you can see all the 
groups. Its very good, because we had an enormous difference on the east 
coast in benzodiazepine prescription. And it’s getting better now, just as a 
result that you can see what you do…. 40 times more9. And now its about 
20 times ...“ (Prison doctor) 
When it comes to the criteria of introducing substitution treatment in the 
prison setting, the following prerequisites are needed: 
“You need those special wards, where the staff must be educated for this 
treatment, they have to manage to give the medication the right way, all this 
you need to manage the Subutex®. 
And then we need to choose the right persons as patients. If you get a wrong 
person, they can disturb the whole group. So how you choose them must go 
on very well, too ...” 
Discussions about the introduction of substitution treatment with Subutex® 
centre around release preparation: 
“… So I think from the beginning we can do it so they maybe get Subutex® 
during the last 3 months or 6 months or something like that before they are 
released. And then they can continue.” (Doctor) 
One of the practical problems would be to supervise the intake: 
“It takes a little bit of time to give it and supervise the medication.” 
The need for a infrastructure in the community, to allow the continuity of 
substitution treatment, is another prerequisite for introducing it in the prison 
setting: 
“… it must be discussed before. We can’t give treatment … which can’t be 
continued. We have to discuss it with the dependency ward in the community 
… The patients just move, when they are back in the community. When they 
get it for example in ZZ and then decide to move to Stockholm.” (Nurse) 
There are practical constraints in terms of personnel needed to supervise the 
intake. Although the staff do not oppose the provision, the intake has to be 
ensured by nurses: 
“In daytime the nurses are not distributing, it’s the staff. It doesn’t work very 
well, because you have to supervise all the medication here. And the staff 
                                                          
9  West coast. 
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don’t do it really. So its impossible to leave the Subutex® for the staff.  
It must be the nurse.” (Doctor) 
2.1.3 The view of prisoners 
The focus group was attended by two prisoners who had several years of 
experience in substitution treatment programmes in the community. 
Prisoners are very experienced and are also aware of the different effects of 
substitution agents 
“… with Subutex® you can’t sleep, I have been on Subutex® a couple of 
times, Methadone is the best for me, because I have been on heroin for so 
many years, Subutex® doesn’t make it feel like what I am looking for, its like 
you are drinking whiskey when you are supposed to have ordered wine …” 
The access to substitution treatment is only indirectly possible by staying in 
an open house and then organising Subutex® treatment: 
“Well, as we noticed, it’s impossible to get it inside the prison. The only way 
is, now we have a little opportunity to get 3:30:4 (an open house where you 
can get a treatment with Subutex® and any kind of treatment) the last couple 
of months before you get free from prison.” 
“… and its not just Subutex® but any kind of treatment ... You can’t stay at 
the service centre but you are allowed treatment while you’re sentenced …” 
Prisoners are very well aware of the structures and rules regulating substitu-
tion treatment: 
“To get this programme is like freedom and if you relapse once you are 
kicked out. So it’s a little bit a mess: you get one opportunity to get in this 
programme and if you fuck it up, you’re fucked up at least for 1/2 a year to a 
year then you can go back to the methadone again in the community. I am 
speaking of the methadone-programme. The Subutex® you can make a little 
bit faster with, that’s a little easier to get these days in Sweden.” 
One reason given was the different atmosphere and the exclusion of the 
drugs topic: 
“So I can say, in this prison I was quite good to be free, everybody is quiet, 
nobody is speaking so much for drugs. That’s a big help.” 
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3 Summing up 
At present, substitution maintenance treatment is not available in Swedish 
prisons. Substitution drugs are only used in the detoxification process and in 
single cases before release. The dominant agent of prescription is buprenor-
phine, which is easier to access because it can be prescribed by every GP in 
the community and in the prison as well. The value of it is seen ambiva-
lently. On the one hand, it is viewed as an effective treatment option (for 
detoxification purposes) with a high and acceptable safety profile. On the 
other hand, the supervision of intake is seen as very time consuming which is 
binding time of qualified nurses. 
Given encouraging results from Swedish studies into buprenorphine, it 
seems likely that, in the future, the prescription will be more regulated with 
regard to indication, monitoring etc. At the moment, there is a heterogeneous 
prescription policy. On the other hand, the introduction of buprenorphine is 
being considered as a substitution drug. First, discussions focus around two 
perspectives (i) the continued prescription of short sentences and (ii) a pres-
cription before release (3 to 6 months). In both cases, close cooperation with 
community based drug services and clinics/doctors is a prerequisite. As there 
were only two prisoners in the focus group, they were both in favour of a 
substitution treatment in prison but also pointed out that they were success-
fully managing to live without drugs. This new strategy needs staff training, 
i.e. nurses and establishing sustainable networks with the community ser-
vices. Homogeneous practice was also noticed regarding the prescription and 
use of benzodiazepines. 
 
 B. Emerging Issues 
In the following chapter, findings of the two prisons visited in the 18 coun-
tries1 with additional information on the situation in that respective country 
are presented. When examples are introduced with the country name follow-
ing the examples, only the two prisons visited in that country are indicated. 
The practice and policy is much too heterogenous, even in one country, to 
claim to have covered the situation completely. 
Data also comes from workshops at conferences with experts, such as the 
“7th European conference on Drug and HIV/Aids services in prison. Prison, 
drugs and society in the enlarged Europe: looking for the right direction”, 
where nine experts took part in a workshop on substitution treatment in 
prison. 
1 History and coverage of substitution treatment in prisons 
Introduction of substitution treatment in the prison setting 
Substitution treatment in prisons can only be understood in the context of the 
development of this form of therapy in the community. Looking back to the 
experiences in all countries, substitution treatment was first introduced in the 
community setting and then transferred to the prison setting. This was a long 
process. The more this treatment is acknowledged and put into practice on 
the outside, the shorter the time of import into the prison setting. As table 
25 shows, substitution treatment has mostly been introduced in prisons in the 
nineties, whereas in many countries, methadone has been prescribed in the 
community already since the end of the seventies/beginning of the eighties. 
The catalyst dynamics of the spread of HIV/AIDS which counts for an 
enlargement of substitution treatment in the community cannot be observed 
in the prison setting, but only indirectly via the increase of prisoners in sub-
stitution treatment outside who come in prison. Nevertheless, HIV-positive 
prisoners in several prisons were the first ones to benefit from the continuity 
of substitution treatment. As an initialising first indication: “My experience 
is that a GP simply does not welcome substitution treatment until the 
                                                          
1  Except for Sweden and Greece where only one prison was visited, and Austria where three 
prisons were visited, Luxembourg where no prisons were visited. 
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moment he gets the first HIV positive patient that is a drug user, and at the 
moment, the GP changes his generally negative approach to substitution 
treatment. Then he’s very much in favour, ready to study or learn more 
about addictions or dependences, and at that instant, he/she is ready to 
prescribe substitution treatment. Information or awareness has to be 
enhanced.” (A contribution from the Prague Conference 2004). 
The epidemic of hepatitis has obviously not developed such a shearing load 
as HIV/AIDS had. 
With Eastern European countries included in our study this process was 
shorter, because many good practice models in Western Europe already 
exist, which could be used as an example. Good cooperation with agencies in 
the community before the start of prison-based substitution treatment facili-
tated this process, as was the case for Poland and Slovenia. 
Historically seen and parallel to the situation in the community substitution 
treatment was first confined to certain vulnerable groups in prisons with the 
characteristics: HIV-infection, pregnancy, infectious diseases. Eventually, 
these constraints vanished and this treatment form is now more available to 
others. 
It has been that, generally, the integration of substitution treatment in prison 
follows the initiative and perseverance of one or two individuals (who often 
are GPs or psychiatrists). 
Table 25  Year of introduction of substitution treatment in the community and in prison2  
Country Availability of 
methadone in the 
community since 
Introduction of 
other substitute 
medications 
Substitution 
treatment intro-
duced in prison 
Austria 1987 Buprenorphine 
(1997) 
Slow release mor-
phine (1997) 
1987 
Belgium 1994 Dihydrocodeine 
Buprenorphine 
2000 
Czech Republic 1992 Buprenorphine 
(2001) 
2003 (experimental) 
                                                          
2  Elaborated version of Euromethwork – Training Manual, 2002. 
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Denmark 1970 Buprenorphine 
(1998) 
1983 
Finland 1974 Buprenorphine 
(1997) 
1997 
France  1973 (experimental) 
1996 
Buprenorphine 
(1996) 
2001 
Germany 1987 (controlled 
trial) 
Dihydrocodeine 
(1994), Buprenor-
phine (2000) 
Heroin (2002, 
experimental) 
1990 
Greece 1996  Not introduced  
Ireland 1992  1996 
Italy 1980 Buprenorphine 
(1999) 
1990 
Luxembourg 1989 Dihydrocodeine 
(1994) 
Mephenon (1989) 
Dihydrocodeine 
(1994) 
Buprenorphine 
(2000) 
1997 
The Netherlands 1970  1972 
Poland 1993  2003 
Portugal 1979 Buprenorphine  1999 
Scotland 2000 Buprenorphine 
(2000) 
2003 
Slovenia 1994 Buprenorphine 
(20004) 
1995 
Spain 1983 Heroin (2002, 
experimental) 
1992 
Sweden 1967 Buprenorphine  Not introduced 
The introduction of buprenorphine into the range of substitution drugs was 
welcomed as a valuable contribution to the diversification of substitution 
treatment and enlarged the treatment options of substitution treatment. It was 
now possible to use other drugs apart from methadone to meet the needs and 
eligibility of patients. 
412 
 
Parallel to its authorization and its introduction in the community, buprenor-
phine (and other substances) as a substitution drug had also been introduced 
to the prison medical health care with a time lag of several years in most 
countries (with the exception of France, where it was used predominantly in 
the community as well). The reasons for this development are manifold: cost 
aspects, the different every day practice, lack of regulations of (supervision) 
of intake etc. But it shows that only with a time lag of several years, patients 
in prisons benefit from new treatment options in the field of substitution 
treatment in the community. If the patients could benefit more quickly from 
new developments outside such as new substitution drugs, and if the health 
care in prisons were under the Ministry of Health cannot be said with the 
results of this study, but it seems likely in the field of substitution treatment. 
Scope 
Substitution treatment in Europe is widespread. Almost 400,000 patients in 
16 countries receive substitution treatment. 60% solely in Spain, France and 
Italy (around 250,000). There are approximately 100 000 patients in France. 
Looking at the scope of this treatment in prisons, we see a similar allocation 
in terms of concentration of this treatment in the prison setting in these 
countries. 
In several other countries the coverage rate of this treatment in prisons 
(according to the number of problematic drug users in prison) is considerably 
lower (see Table 26: Substitution treatment outside/inside), in others it is 
poor (see also Michel & Maguet 2003, 34). 
In most of the countries studied, the coverage is very patchy. There is not 
only a high heterogeneity throughout Europe, sometimes in one country, 
provision differs from region to region (e.g. French and Dutch speaking part 
in Belgium), from state to state (e.g. Germany), or even from prison to 
prison, or from doctor to doctor.  
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Nevertheless, the scope has been enlarged when comparing our work to that 
of others. For instance, Turnbull and McSweeney (1998) who conducted a 
research on 15 EU-Member States and found that prescribing methadone on 
a maintenance basis was commonly available only in Austrian, Danish, 
French, Luxembourg and Spanish prisons and occasionally in German insti-
tutions, whereas the prescription of other substitute drugs was available in 
five countries. 
In Greece and Sweden, substitution treatment is not provided in prisons, 
while there are at least some approaches in the Czech Republic. This is due 
to different reasons: late introduction of substitution treatment in the com-
munity (e.g. Greece 1996), and/or high threshold – substitution programmes 
in the community (Greece and Sweden), an abstinence-based overall drug 
policy, limited number of substitution places, limited drug problems or not 
opiate-related spread of problematic use of drugs in prisons, e.g. amphetami-
nes. 
In several countries the coverage of substitution treatment is seen as insuffi-
cient and far from ideal by experts, professionals in the field, government 
and non-government organisations. For instance, although The Netherlands 
do have a long tradition in substitution treatment, the number of prisoners 
receiving methadone drops significantly when entering prisons. This has also 
been criticised by the national health council who elaborated recommenda-
tions which were then set into practice by the Ministry of Justice. 
A lot of movement has been made in improving substitution treatment in 
prisons. Much work is spent on regulations, guidelines and improvement of 
particular treatment modalities. 
2 Treatment aspects 
Abstinence and/or harm reduction 
Although in several countries substitution treatment in prisons has been in-
troduced to a wide and obviously sufficient extent, covering treatment needs 
of patients. This process is not satisfactory in many other countries. Substi-
tution treatment in the community is most likely to result in a discontinuity 
of treatment when entering prison. The reasons for this at the prison level 
and service providers are manifold: 
− Basic drug free orientation in prison, which is identical with the purpose 
of the sentence to support prisoners not to commit any crimes any more 
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(and drug users are most likely to commit crimes, simply by purchasing 
their drugs). The culture of abstinence orientation is widespread among 
staff in many prisons. 
− Methadone (or any other substitution drug) is viewed more as a psychoac-
tive than as a therapeutic drug by doctors, health care staff, prison admini-
stration, etc. 
− Lack of understanding of the phenomenon of dependence as a chronic 
recidivist disease and the belief that the prison is a drug free setting. 
− Limited places (e.g. Germany) for substitution treatment due to adjunction 
to psycho-social care for the same amount. 
− Limited resources for carrying out substitution treatment properly and 
sufficiently (doctor hours, nurses etc. for instance in Ireland, Scotland, 
Italy). 
− Confinement only to those who are in a community-based substitution 
programme and a lack of substitution placers after release in the commu-
nity (Germany, Ireland, Belgium) is responsible for not taking new 
patients into the treatment.. 
− Access limited to HIV-positive, pregnant women and suffering from 
Hepatitis (similar when respective confinements do exist in the commu-
nity. 
− Lack of personnel to supervise (especially buprenorphine, e.g. Sweden, 
France) the intake and other organisational tasks. 
− Lack of knowledge and experience by doctors and nurses to either pres-
cribe at all or limit the substitution to certain drugs (methadone) because it 
is easier to handle and the risks are lower (overdose). 
− Misunderstanding of the potential and quality of methadone, buprenor-
phine (and other substitution drugs) as means to be used as short-term 
agents to achieve sustainable abstinence. This accounts also for the situa-
tion in the community (see studies of Caplehorn et al.) but allows patients 
to seek a doctor who acknowledges the value of maintenance treatment. 
Also, the prisoners’ reasons against a continuation of treatment are formu-
lated that partly cover the arguments above: 
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− Basic drug free orientation. The wish to be abstinent during the prison 
sentence. Substitution drugs are seen in this context also as hedonistic, 
psychoactive drugs (because it is also purchased on the black market from 
dealers who sell other illegal drugs) and not as drugs as part of a medical 
treatment for drug dependence. 
− Lack of understanding of the nature of substitution treatment. Although 
many prisoners interviewed admitted relapses immediately after release, 
resistance against a continuity of prescription was expressed by several 
inmates, who regarded their prison sentence as their only drug free time. 
These yo-yo effects were perceived as normal and not as explicitly health 
damaging. 
− Lack of understanding of the nature of drug use and drug dependence. 
Although in substitution treatment several prisoners wanted to reduce 
their dosage to zero shortly before release because they wanted to leave 
the prison ‘drug free’ either to avoid getting into the dependency of the 
methadone prescribing clinics outside again or wanting to avoid the drug 
scene around dispensing clinics. Not knowing, they exposed themselves 
to enormous risks when relapsing. 
− Prisoners want to hide their drug use for several reasons (one is that they 
fear prejudices and disadvantages for their current sentences as being 
viewed and treated as a ‘drug user’ when being in a substitution pro-
gramme), which would become apparent immediately when entering the 
medical units on a daily basis1. 
Substitution substances in European Prisons 
Methadone is still the predominant substitution drug used in prisons in the 18 
countries studied. The diversity of different substitution agents is mirrored in 
the medical services of the prisons only with a time lag of several years (with 
regard to buprenorphine). Protocols and practices are oriented more to the 
institution’s needs and requirements rather than each patient’s needs and 
wishes. For instance, the approximately 5 minutes for the supervision of 
intake of buprenorphine (sublingual) is seen as very time consuming and 
taking up too much staff time. Instead, methadone is prescribed: methadone 
                                                          
1  Some of these results may also be important for changes in the organization of substitution 
treatment in the community. 
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is a cheap substance; it is easy to deliver to the prisoner and the intake can 
easily be supervised; whereas buprenorphine is expensive and the intake 
must be supervised, which requires time and staff. The costs associated with 
the methadone provision are those due to staff and training of staff. This also 
accounts for retarded morphine where some different views can be noticed 
between prisons (remand vs. sentenced). In Austria, for instance, there is a 
policy to substitute these morphines prescribed in the community because it 
is perceived to have effects too near to the original substance of dependence, 
and subsequently changed to methadone. In the prison for sentenced prison-
ers, retarded morphine is seen as a valuable contribution to substitution 
treatment. Patients are complaining about these changes in their substitution 
drug and see double standards with regard to what happens in the commu-
nity. One of the reasons for their complaints is that unlike the situation in the 
community, they do not have the choice of visiting another doctor other than 
the one prescribing their preferred means of substitution. Prisoners express 
their wish to get the choice of what will be prescribed, which in their experi-
ence is the most suitable substitution drug for them. 
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Replacing one substitution drug with another (e.g. Ireland, Austria, France, 
see country report) obviously needs to be communicated to the prisoners, 
who feel that, for instance methadone (or methadone in a different composi-
tion) is less effective. Prisoners did not understand the obviously damaging 
effects of the replaced drug. 
In Germany, information on another form of methadone introduced as a cost 
effective measure, wasn’t understood by the prisoners (who have choices 
outside to either get the pure or the mixed form of methadone). In France, 
prisoners who were on buprenorphine and were offered to change to metha-
done because of their misuse of buprenorphine said they were satisfied. This 
satisfaction is related to the fact that methadone is provided in a highly 
supervised environment. The prisoner receives support and medical care 
daily, which is not the case with buprenorphine, which is delivered for up to 
several days, tapering off to once a week, and lacking contact with the medi-
cal team and centre. 
Both examples led to dissatisfaction (the psychological component is very 
important for patients on substitution treatment, especially in a setting with 
limited choices) and showed that there was only a little information given for 
patients on the substitution drug. This may have occurred because providers 
think everything is already known by experienced users, but is not always 
the case. 
Access to substitution treatment 
Access to substitution treatment for all prisoners who are in need of it is only 
given in a few countries (e.g. Spain, Austria). In other countries, access is 
limited either in general (limited places and resources), to specific vulnerable 
groups or dependent on various other reasons (as shown above). The other 
extreme is that there are several states, regions, prisons or prison doctors not 
offering maintenance at all. Here it is most likely that existing substitution 
treatments in the community result in a detoxification. 
Between several prisons, one consensus is applied that there will be a conti-
nuity for those patients being on substitution treatment in the community. 
But again, this is limited to the time being on substitution treatment before 
imprisonment (at least four weeks before admission to prison to avoid those 
patients who, in face of the imprisonment, started a treatment, e.g. prison 
visited in Germany), or depends on the expected length of imprisonment. 
Prisoners interviewed complain about the fact that not all who want to get 
substitution treatment get it. Although the access is limited to them, and be-
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cause of experiences of immediate relapse after release, they want to have 
the choice of either detoxification or maintenance. This increased demand is 
due to a broader access and availability of methadone in the community. Pri-
sons often do not have enough staff to deliver the treatment properly and put 
prisoners on a waiting list. The example in Scotland shows that the change of 
a different health care strategy in the community (substitution treatment) has 
not to adequate structures in the prison health care. This gap is more drama-
tic in face of the severe overcrowding in the prison system, so it demonstra-
ted that these two types of health care, service delivery and often financial 
structures, clearly fall apart. 
Although access may be guaranteed to all prisoners who need a continuous 
substitution treatment in guidelines and regulations, in practice this looks 
very different and depends on the factors outlined above, but basically on the 
doctor’s free choice of therapy. 
Assessment and the role of the doctor 
In most of the prisons visited, the decision about continuation or start of sub-
stitution treatment is made by the doctor. In some institutions, it is made 
within a multi-professional team, which guarantees different views (e.g. 
Austria, Slovenia). Classical diagnostic instruments (e.g. DSM IV or ICD 
10) do play a minor role in diagnosing patient’s status of dependence. How-
ever, the key element for assessment is the doctor or nurse’s expertise and 
experience with substitution treatment. Networking competencies and spe-
cialisation (e.g. in Scotland: ‘addiction nurse’, who works in close coopera-
tion with the GP/psychiatrist, received additional training and has become an 
expert on substitution treatment). Although the GP/psychiatrists prescribe, 
the nurses generally spend more time with the prisoner and are more apt to 
evaluate whether the prisoner’s treatment is adequate. Many other aspects 
include contributing to the assessment of the patient’s need for a substitution 
treatment (e.g. medical examination, drug history, previous treatments in the 
community or in remand prison, patient’s expressed needs). Nevertheless, 
the central and responsible role in substitution treatment is in the hands of 
the prescribing doctor, who is given the leeway within the therapeutic free-
dom to more or less engage in substitution treatment. 
The engagement of the doctor depends on his or her workload, the hours 
paid by the Ministry of Justice or health to start or continue substitution the-
rapy. In some sites, there has not been given additional personnel (nurses) or 
resources by claiming an increase of pharmaco-therapy, so that the engage-
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ment as such or the number of patients in substitution treatment remained 
restricted. 
We found some good examples of team structures as basis for the substitu-
tion treatment, for instance in Austria, The Netherlands (e.g. “PMO: Psycho-
medisch overleg”, psychological-medical consultation), Slovenia, Scotland, 
such a team structure including social worker, nurses, doctor and psycholo-
gist meeting on a regular basis has been very well established. 
Also, certain job-profiles with specialisation in certain health care areas (like 
‘addiction nurse’ in Scotland) has to be seen as valuable step towards more 
professionalism. 
While in the beginning of substitution treatment the role of the doctor is 
central, the ongoing everyday provision is done by the nurses or medical 
officers. So the nurse becomes crucial, because he or she is seeing the patient 
more often than any other person involved and can see the patient in differ-
ent situations. Regarding the crucial role of the nurses, it was said in several 
interviews that they should be offered more vocational training to be able to 
cope with new challenges and to be connected with prison services and expe-
riences of outside institutions. There is also often a lack of nurses, like there 
is of doctors and other psycho-social staff. 
In some countries prison officers with a special course in health care or drug 
issues are employed in the health unit (called ‘medics’, e.g. Ireland, who are 
currently replaced by registered nurses, ‘addiction worker’ in Scotland). 
Although in many respects these officers fulfil an important task, which is 
also very cost-effective, it is problematic from the viewpoint of patients. Pri-
soners interviewed trusted (registered) nurses more, who are seen as not 
having more distance to the prison system. This was not so much the case in 
Scotland, where prison officers received a job promotion and, because of 
personal interest, got training to do a different type of work. 
Continuity of Care 
Success of opioid substitution maintenance therapy depends to a large extent 
on a timely entry into treatment, longer duration and continuity of treatment, 
and adequate dosages (see part I). Several countries (for instance, Spain, 
Austria, Denmark, France, Portugal) continue substitution treatment started 
in the community more or less as a routine. Proof and diagnosis of the pris-
oner’s dependence status, apart from a quick check with treatment agencies 
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in the community, are done on a routine basis, so prisoners do not have to 
struggle for a continuation. In other countries structures do exist, such as 
official guidelines (e.g. Germany), agreements (Ireland) that recommend a 
continuity of therapy which is either not realized in all regions/prisons, or in 
all cases where it is needed. The coverage remains patchy and unsatisfying in 
terms of limited access for the patients. 
In several prisons studied, good cooperation links have been established with 
other institutions outside as part of an intended throughcare after release (e.g. 
to prescribing clinics in Denmark, or with individual doctors in Germany 
providing assistance for patients in finding doctors before release). 
Duration and Limitation of substitution maintenance treatment 
In some countries substitution treatment is explicitly limited formally within 
written guidelines (e.g. The Netherlands, Belgium). The time limits are fore-
seen for a period of time of 6 (e.g. Italy, The Netherlands, without counting 
the remand prison time) to 12 months. In other countries such time limits are 
informally applied but not subject of official guidelines or regulations, rather 
but everyday practice (e.g. Germany). Some countries, like Spain and Aus-
tria do not hold any time limit and rather offer the substitution treatment on 
an individual basis. In Spain, maintenance is common practise. 
Although these time limits do not affect the majority of (ex) drug using-pris-
oners because they mostly serve shorter sentences, it may become problem-
atic for some patients. The reasons for the limitation are seen in the drug free 
setting prison which is aiming at and which does not require such a drug – 
oriented treatment when a prisoner is serving longer sentence. In the first 
place it is assumed that prison drug treatment facilities should be successful 
in supporting individual prisoners into abstinence. But moreover, substitu-
tion treatment is also seen as a cost factor and an additional organisational 
task (to bring the prisoner to the medical unit or hand out the substance in the 
cell(on the ward). In a pragmatic way substitution treatment is also often 
seen as a way to bear the prison environment, as prisoners are more stable 
and detoxification does not occur through the cold turkey method anymore, 
which is a painful experience for prisoners but (although differently) also for 
staff. Another reason is, like in France, to use substitution treatment as a way 
to attract the prisoner to the health unit and to stabilise him/her, and then to 
provide care and support through therapies (group and individual) and 
eventually reach well-being, stability, no substitution treatment and absti-
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nence. Some doctors feel they are ‘drug providers’ or ‘drug dealers’ curing 
nothing, only prescribing. 
In The Netherlands for example substitution treatment is not automatically 
cut, when the length of the sentence exceeds 6 months. If the patient opposes 
this restriction, then a second opinion is integrated in the decision making 
process. 
But these prescribing restrictions are in process and are subject of reviewing 
the substitution treatment modalities (recently the Dutch Ministry of Justice, 
lifted the time span from 3 to 6 months). 
Reduction schemes 
When it comes to a detoxification treatment the heterogeneity found for the 
distribution and quality of substitution treatment as such can also be found 
regarding reduction schemes throughout Europe. The reductions steps vary 
considerably not only between countries and states but from prison to prison 
in one state (e.g. Germany, see country report). 
Being on a dosage of 50 mg means a detoxification period of 35 days (10 mg 
less per week) in Men’s prison Hanover or in 20 days (5 mg less every sec-
ond day, the same scheme found in the Amsterdam prison visited) in another 
prison (Women’s prison Vechta) in the same state of Germany. Apart from 
this example we found reduction schemes between 7 days and four weeks 
(for a 40-50 mg dosage). 
Although these schemes are not seen as completely static (periods may be 
prolonged according to individual needs in some countries) they give basic 
orientation and is a result of the experiences of patients (may be different 
women and men who may prefer either the faster or slower reduction 
scheme). The most important element of the reduction scheme is that it 
responds to the patient’s needs. Reduction schemes that are provided to all 
patients equally are likely to fail and/or to result in relapse as individual 
needs are not taken into consideration. 
There have been many criticisms of t reduction schemes by prisoners in the 
interviews, which point at the static scheme as such and the speed of reduc-
tion steps. According to them the reduction schemes are not sufficiently 
reflecting individual needs and abilities. The practice is often perceived as 
inflexible and not adopted to the wish of the inmate/patient. This applies 
especially to those drug users who are dependent for twenty or more years 
and for whom methadone became a sort of basic therapy for many years. 
Inmates express their wish to be more involved in the decision making proc-
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ess and to be asked about the steps of reduction. The plea is for leaving the 
decision to the inmates, whether or not and if, in which steps they want to 
reduce their methadone. Clear explanations provided by the doctor and dia-
logue with the prisoner are key elements in the success of the treatment. 
Apart from perceiving the detoxification procedure as too rigid, it has been 
criticized that medical time was not offering enough space to negotiate. This 
has been analysed as a lack and difference to the provision of methadone in 
the community. 
Detoxification and/or maintenance treatment? 
As said above the decisions either to detoxification a patient or to continue 
(or even start the substitution treatment) in prisons depend on several factors: 
lack of resources, personnel, which results in a limitation of the places  
(e.g. Germany), poor knowledge, depending on the development of substitu-
tion treatment in the community (e.g. Ireland) no supporting regulations/ 
guidelines, opposing substitution policy for the prison setting (Greece) or 
restrictive substitution policy outside in the communities (e.g. Sweden). 
Apart from these institution-related reasons, a constant factor seems to be 
that the wishes of drug using prisoners/patients have been expressed to have 
free choice for either of these options (see country reports in Ireland, Ger-
many, The Netherlands). This is what they experience mostly on the outside, 
especially with the growing facilities in the communities, and are facing in 
prison apart from other restrictions also the complete dependency from the 
decision of the doctor in charge of the team. This leads to disagreement and 
dissatisfaction. 
A lot of interviewed prisoners (Belgium, Spain, France) said they wanted to 
detoxification but the doctor did not want them to. Actually, often, once sta-
bilised, the prisoner wishes to detoxification quickly and be completely drug 
free, wishing to have no more contact with drugs, doctors, to hear or talk 
about dependence and problems related to drugs, wishing to start a new life 
and be ready and ‘clean’ for release. The doctor and nurses sometimes are 
opposed when s/he feels the prisoner is going too fast. Relapse and/or over-
dose are likely to happen, especially when detoxification occurs too fast. 
Here, the satisfaction is from prisoners who wish to detoxification and the 
doctor who is opposed to a quick (too fast) detoxification. Again this leads to 
disagreement, dissatisfaction and misunderstanding. One key element is that 
the doctor explains clearly to the patient the advantages and disadvantages of 
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a quick and long detoxification, if an individualized approach is taken (this is 
not possible in standardized forms of detoxification treatments of 15 days for 
all prisoners). 
Initiation of substitution treatment in prisons 
Initiation of substitution treatment remains a marginal offer. It is either done 
immediately on admission (despite having no registered previous treatment 
in clinics or individual GPs, e.g. Germany) or in a period of time before 
release (e.g. Scotland). The pragmatic reason for the rare initiation on admis-
sion lies in the fact that usually the demand already for those being in regis-
tered substitution treatment before imprisonment is higher than the places 
available in prison. 
To start substitution treatment before release is meant to be a sort of “immu-
nisation”, to avoid immediate relapse and overdose after release, which con-
stitutes a major problem in several countries. There are still remaining prob-
lems in several countries with respect to the continuation of treatment for 
prisoners to be released. In many prisons the goal of ST is detoxification in 
order to make sure that the prisoner is detoxed when released, because the 
continuity of substitution treatment is difficult or problematic to continue on 
release. Overdoses on release in most of the countries are problematic and 
have resulted in a change of attitude: it is advised to maintain the prisoner on 
a small, stable dose until released, to avoid (or decrease the risks of) over-
dose on release (e.g. Belgium). Overdoses on release and suicides in prison 
have been key elements in England/Wales to integrate substitution treatment 
in prison and propose a proper structure for such treatment (still being ‘con-
structed’ in England/Wales via the Department of Health). Scotland offers 
‘retoxification’ to vulnerable prisoners prior (approximately 3 months) to 
release in order to avoid overdose or relapse. England/Wales also wish to 
offer retoxification. 
Good cooperation with community services is necessary in order to provide 
retoxification or maintenance beyond release. 
No substitution treatment in prison 
The role of psycho-social care 
Psycho-social care is seen as an additional and necessary part of treatment to 
support the medical part of the substitution treatment in prison. The benefits 
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of substitution treatments depend on the dose but also on the medico-psycho-
social-educative measures provided to the patient. The aspect of psycho-
social support associated to substitution treatment is constantly underlined 
for the success of the treatment. However, such a support is rarely provided. 
Only a few consistent psycho-social programmes could be identified that are 
accompanying the provision of substitution drugs (e.g. women’s prison in 
Vechta, Germany). But apart from that, there are several structures within 
the prison that try to combine all efforts (counselling as well additional 
treatment services) made to support prisoners. Furthermore, prisoners wel-
come outside community-based agencies offering assistance. 
In some countries the professional psycho-social care is a mandatory require-
ment of substitution treatment (e.g. Germany) in others it is facultative 
(Austria, France) in many other countries such a formal intervention offer is 
not known or applied (e.g. Ireland, The Netherlands). Although psycho-
social support or any other personal assistance is acknowledged in many 
prisons visited, it is also lacking in many institutions. Many prisoners inter-
viewed have been demanding more time to speak to social workers, psycho-
logists (e.g. Austria). Community-based offers in prison are lacking in many 
of the institutions visited. 
In the interviews with prisoners, it turned out to be that self help groups are 
often perceived as ambivalent. On the one hand, they guarantee an exchange 
of experience and valuable information. On the other hand, the confidential-
ity of the personal input given is doubted, so that it may occur that some of 
the information is taken out of the group and misused. 
When looking at all the countries that were visited, dissatisfaction and com-
plaints (mainly from prisoners, but also from staff) about substitution treat-
ment were NOT on the substance itself, but focused on the support or lack of 
support associated with the provision of the substance. Some prisoners com-
plained about only receiving the substance, and seeing no psychologist or 
social worker to talk to (Belgium, Spain). Some prisoners felt they were not 
receiving any care or support, but rather a drug that they could misuse  
(e.g. France). Some of these prisoners were much more content on a metha-
done treatment as they could not misuse it because they had to go to the 
medical centre every day, and thus integrated a medical framework. Staff 
questioned the success or purpose of substitution treatment if psycho-social 
support was not provided (e.g. Portugal and France). 
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Dosage 
The average dosage we asked for in the prisons visited varied considerably 
(from 30-70 with individual doses far more than 70 and less than 30). Apart 
from the individual case-oriented prescriptions certain policies and philoso-
phies regarding dosage become obvious. On the one hand, there is the opin-
ion that relatively low dosages are sufficient (in contrast to the outside, see 
Interview with Jan Palmer) in the prison setting for two reasons (i) the in pri-
son mostly thoroughly applied supervision of intake guarantees a 100% of 
intake and (ii) the amount of other drugs taken is substantially reduced com-
pared to the situation outside. On the other hand,we found average dosages 
in prisons of 60 mg (Germany) and much more (up to 120 mg Denmark, 
Spain – this also reflects different cultures in the community). This has been 
criticized also by prisoners and NGO workers as ‘cosmetics’ or unnecessary 
to stop the craving. As there is no such a thing as average dosage, dosage 
questions should be left up to the doctor-patient-relationship and should be 
adjusted to individual needs. Though there should be space and time to 
negotiate the needs of the patients to either reduce or increase dosage (e.g. 
Austria). 
In most places the prisoner knows the dosage. In others, he is not told unless 
he asks (e.g. Portugal). In France, the maximal dose of buprenorphine is 
controlled by the pharmacist, and can overrule the doctor’s prescription if it 
is over the pharmacist’s limit. In many countries, it is advised not to go 
above a set maximal dose, although the doctor is allowed to go over it. Some 
doctors prefer to stick to the advise (e.g. Scotland). 
It is also reported that prisoners try to achieve an amount as high as possible 
in the beginning of their sentence to calm their fears, being cut off from the 
possibility to increase dosages the same as outside and the fear of going 
through pain and withdrawal) but are attempting themselves after a while to 
reduce these amounts, of down to zero. Sometimes these processes are vie-
wed by the doctors themselves as too quick and probably associated with 
additional risks (e.g. overdose after release or during home leave). 
Several experts said that one should not talk about and aim at low or high 
dose but rather about adequate dose. The most adequate dose is the one that 
is amicably negotiated between the doctor and the patient. 
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Supervision of intake 
The supervision of intake (of methadone either in liquid or tablets) is organ-
ised in different ways, done either by nurses or guards, depending on how 
and where the substitution drug is dispensed: either within the medical unit 
or on the cells/wards. This is to ensure that the substance is swallowed. In 
most cases, control is carried out by letting patients talk afterwards. 
Although methadone is the main substance provided in prisons, buprenor-
phine is also increasingly provided . Two examples indicate the differences 
in supervision and control policy and practice: 
In the Czech Republic, each prisoner on buprenorphine is on a short-term 
detoxification treatment. Each prisoner is called to the medical centre where 
the doctor, assisted by a nurse, provides the pill. The prisoner must stay in 
the medical centre for approximately 10 minutes, or as long as it takes to dis-
solve the pill sub-lingual. The provision is controlled and the intake is done 
as recommended. 
In France, the provision of buprenorphine is a lot different. Usually, the pris-
oner is asked to go to the medical centre every day for one week, where he 
receives the pill, is told about substitution treatment and gets in contact with 
the psycho-social team. Sometimes, this supervision only lasts a few days, 
and buprenorphine is prescribed and provided like any other substance (like 
for instance a sleeping pill), that is provided by the nurse who visits the dif-
ferent cells. The prisoner is normally allowed to make the request to go to 
the medical centre to get his medicine and have none delivered to his cell by 
a nurse. 
After the first week of buprenorphine provision, usually the pill is delivered 
by the nurse to the prisoner in his cell as described here above.  
The medical staff often states that this method of delivery takes place (i) to 
increase the prisoner’s responsibility in himself, (ii) for practical reasons: 
delivering every day to each prisoner under substitution treatment would 
require time and resources that are lacking, and (iii) to free the prisoner from 
the dependence and obligation to visit the medical centre every day. 
Unfortunately, this delivery has resulted in misuse and traffic of buprenor-
phine pills in the French prisons, echoing the situation outside. Prisoners 
tend to stock the pills, sell them and/ or misuse them. Usually, when misus-
ing, the prisoner crashes the pill until it becomes powder and then sniffs it or 
injects it, resulting in getting a kick. This results in buprenorphine being 
associated to the ‘white powder’ and to drugs to get high. The delivery of 
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methadone in the French prisons, however, is very different and is extremely 
controlled and supervised. Prisoners must go to the medical centre every sin-
gle day to receive their treatment. Traffic and misuse is thus highly minimi-
sed and inexistent. 
One particularity must be noticed to the supervision of intake of buprenor-
phine. For instance, in several prisons the buprenorphine tablets have been 
crushed by the doctors themselves in order to make sure that all the amount 
has been taken (this form of intake is not adequate and may lead to not ful-
filling it’s purpose), to reduce the risks of traffic and misuse, and to reduce 
the time of supervision (e.g. Sweden and Portugal). 
Prisoners have said that a supervision of intake protects those being in sub-
stitution treatment from other prisoners who wish to participate from the 
substitution drug. This pressure put on inmates can be avoided by a well 
organised supervision of intake. 
Urine controls 
The value and consequences of medically ordered urine controls varied sub-
stantially between the sites visited. In some countries, very few urine con-
trols are taken (e.g. Denmark1, comparably to the practice in the commu-
nity). It is thought that the use of (additional) intoxicants will be noticed by 
the medical staff and the guards. In other countries (e.g. in one prison Ire-
land) a positive urine test (e.g. cannabis) may lead to consequences for the 
substitution treatment itself (reduction of dosage). Also it has to be noticed 
that different standards are applied (i) from prison to prison in one city  
(e.g. Dublin, Ireland) regarding for instance the toleration of cannabis and 
(ii) from community services in comparison with prison-based substitution 
treatment. In Scotland cannabis is not tested for, as there is no treatment for 
cannabis use. Whereas in one prison the doctor is reducing the methadone 
dosage for some time, it is completely tolerated within the medical context in 
another. This is different when it comes to prison-control related urine tests, 
which may lead in both cases to consequences in terms of loss of home-leave 
for some time or other privileges. 
                                                          
1  At the time of the country visit in June 2003, meanwhile another policy seems to be 
applied (personal communication with Alette Reventlow). 
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Whereas the sanctions regarding urine tests in general, and cannabis use 
varies considerably throughout Europe, and depends on an individual doc-
tor’s view, there is a growing consensus about the negative effects of benzo-
diazepines within substitution treatment. The permanent consumption of 
benzodiazepines leads in several cases to an exclusion from the substitution 
treatment. So the range of sanctions regarding positive urine tests varies 
from toleration to exclusion from substitution treatment. 
Co-prescription of benzodiazepines and other drugs 
In those countries with a longer history of opioid use dating back to the late 
60’s (e.g. The Netherlands, Austria, Germany) the use particularly of benzo-
diazepines is widespread among drug users, mostly to bridge the gap be-
tween the lack of availability of the preferred opiate (merely heroin) use. The 
using patterns often constitute an additional dependence with severe syn-
dromes and problems in detoxification. 
With a time lag of several years the use of benzodiazepines is entering the 
prison system and constitutes a major health problem. Whereas there is a 
growing consensus about the dangerousness of these drugs taken chronically 
among doctors and health workers, this hasn’t lead to a complete ban of pre-
scribing them on a steady basis. In many prisons, interviewed prisoners were 
dependent on benzodiazepines before admission to prison (e.g. The Nether-
lands, Germany, Austria, Denmark). One of the debates with doctors and 
nurses is the continuity of prescription of these drugs in prison, which is not 
done in the prisons visited. In some countries more arguing is going on about 
benzodiazepines than about substitution drugs. In others we saw evidence 
that the lessons about benzodiazepines were understood by prisoners and led 
to an awareness of the harmful consequences of chronic use of benzodiazepi-
nes (e.g. Ireland). Although there is a growing demand from prisoners, only 
very little mostly in remand prisons is prescribed. When it comes to sen-
tenced prisons, a detoxification of these substances is organised in different 
steps, depending on how long the use has taken place. 
Information to patients 
The information to the patient about substitution treatment and drugs in gen-
eral and on particular rules, agreements, expectations is lacking in many 
studied prisons. It could be observed that prisoners didn’t understand the 
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goals pursued with the substitution treatment, nor the specific drug nor the 
specific treatment setting applied (rules, exclusion criteria etc.). 
The informed consent often has not been undersigned when it comes to 
additional information that has to be acquired from other persons and insti-
tutions. 
This leads to the fact that treatment modalities are either not completely 
understood, and/or are not transparent and seem arbitrary (buprenorphine 
intake is ‘sub-lingual’ which requires education/ information). The lack of 
adequate information is not contributing to a motivation to play an adequate 
role in the treatment process. 
Prisoners acknowledge positive developments (Ireland, Germany) as many 
of them have experienced insufficient regimes of substitution treatment in 
previous sentences. 
Guidelines, recommendations, regulations 
As listed below, several countries developed guidelines and regulations, 
protocols of how best to proceed with new inmates with regard to either 
detoxification or maintenance treatment. These documents provide every 
practitioner with either the legal basis of substitution treatment and/or with 
clear guidance and detailed protocols of how to cope with individual cases 
and problems. 
Confidentiality of treatment provision 
Confidentiality is an important part of the substitution treatment as it assures 
the prisoner that other inmates and staff are not aware of his or her treatment. 
The fear is that if somebody knows about the drug dependence, it will lead to 
consequences for the actual sentence in terms of disadvantages (e.g. access 
to work, qualification, jobs), prejudices, loss of privileges or simply by the 
negative attitude of staff and other prisoners. The patients moreover fear 
pressure from other inmates, who wish to participate from the substitution 
treatment in terms of smuggling substitution drugs out. 
Although it is hard to reach anonymity and confidentiality within the prison 
context, attempts have been made in many sites to organise the suspension of 
substitution drugs in a way that protects prisoner. Either the prisoners on 
substitution treatment are all put together in a wing (Portugal), or substitu-
tion drugs are delivered with other medicines. But also, we found examples 
where prisoner were complaining about the way substitution drugs are given 
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out (e.g. by shouting over the ward or by indicating substitution treatment on 
the nameplate at the door (e.g. prison in Vienna, Austria; Portugal). 
It must be taken into consideration that good results and success of treatment 
and supervision of prisoners have taken place in prisons where the different 
staff (psychologist, doctor, social worker, nurse, guard) take part in meetings 
and know about the treatment. Follow-up of prisoners is easier. Guards are 
often the only one present in the prison over night and weekend and it was 
reported that being informed (sometimes largely, just being informed that 
prisoner x takes various medication) has been useful. It also seems that when 
guards are completely shut out of the psycho-socio-medical support, barriers 
are built between the different professionals and sometimes prejudices and 
misunderstandings about the prisoner and drug use are stronger. Hence, it 
seems that basic cooperation and information and training of prison staff, 
including guards, is needed to ensure positive or better attitudes of staff 
towards drug users. 
Substitution treatment as a reward for a good behaviour? 
Prisoners interviewed often regarded substitution treatment as a kind of 
reward for good behaviour and not as part of a ‘normal’ treatment within a 
variety of medical and psycho-social treatment options of drug treatment. 
This understanding may of course have consequences for criticism within the 
doctor-patient-relationship or in the formulation of critics concerning the 
substitution treatment with the nurse. 
And in this sense misbehaviour within serving the sentence clearly leads to 
an exclusion from a medical treatment. It is this combination in practice that 
may reveal a close co-operation between the control and the care part of the 
sentence. 
Prescription before home leave/release 
This depends on the organization of substitution treatment in the community 
and either results in giving the amount needed for the respective day(s) to the 
prisoner (e.g. Denmark) or to co-operate with other doctors/pharmacies on 
the basis of a particular letter (e.g. Germany). When it is given to the pris-
oner, it also reflects trust and stabilization already achieved not to sell it etc. 
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Training 
Whereas in countries where a particular vocational training is needed to 
engage in substitution treatment (in ‘addiction medicine’ e.g. Germany), this 
necessary for prison doctors as well. Where this is applied or planned (e.g. 
The Netherlands), at least a baseline information is given to the GPs working 
in prison and the prison doctors. In several countries specific training for 
prescribing doctors is not specifically required. Additional training makes 
sense because the need for the changing treatment demands is expressed by 
many of those interviewed. 
Specific training on drugs and substitution treatment is clearly missing. Most 
professionals said they were learning on the field. Although this along with 
support from colleagues seemed to work fine and allowed them to do their 
job well, they still welcomed further specialisation and/or information. Some 
professionals have reported that some trainings and/or seminars focus on 
drugs and drug treatment as applied to the community environment, and lack 
information and advise for those working in prison. 
In some prisons officers are trained to become specialised on drugs, such as 
Scotland, or like in Italy where the staff of the Ministry of health is special-
ised in drug issues and works in prisons.  
Also for health care staff, refresher courses are needed as new developments 
are coming up (e.g. ‘new’ substitution drugs like buprenorphine). For in-
stance in some prisons buprenorphine has not been introduced, although 
authorized, simply because the knowledge on how to measure the switch 
from methadone to buprenorphine (if needed), or of how to supervise the 
intake is lacking. 
Finally, guards need to be trained in the nature of dependence and drug use 
and health care interventions, particular substitution treatment. 
A structural question is whether to employ nurses instead of officers with a 
short vocational training of several weeks, or to employ officers instead of 
nurses for the delivery of substitution treatment. 
Lack of evaluations 
Almost in all countries visited, we identified a lack of evaluation of the sub-
stitution treatment, taking the needs of the patients into consideration and 
also the views of the service providers. Also, it seems as if the consciousness 
of looking at the topic often stops at the gate(that means the point of release 
is taken at a sort of ‘natural barrier’ – more holistic perspectives need to be 
taken). 
  
C. The need to treat women separately in substitution 
treatment 
The issue of gender specific treatment needs has yet to be raised within the 
context of substitution treatment. Imprisoned female drug users often show 
severe and risky patterns of use within the context of multiple major health 
issues (physical and psychological) which require special attention within the 
delivery of health care (Zurhold and Rebernig 2004). Jan Palmer (Nurse and 
consultant on Substance Misuse HMPS Women's Team, England) was one 
of the first to raise this issue in “Clinical Management and Treatment of 
Substance Misuse for Women in Prison” (see References). 
HS: You gained your experience of clinical management of opioid addiction 
in the prison centre here? 
P: I began on secondment from the NHS to the prison service in January 
1997 and then I led the development of the first detoxification unit in the 
prison service in England. 
HS: What was the name of it? 
P: Holloway in London, the women’s prison. 
HS: This was the first detox unit in England and Wales? 
P: Yes. I didn’t know that at the time. When I was doing it I didn’t know it 
was the only one. That’s how I began working with substitution treatment for 
women in prison. 
HS: How did you analyse the need for this treatment and what were the main 
obstacles to introducing it? 
P: I didn’t identify the need. The prison service directorate of health care, as 
it was then, funded the setting up of the unit. So the prison service must have 
seen the need. I purely came along and lead that development. I wasn’t 
involved in the original planning, the prison service identified the need.  
HS: …the design? 
P: No, not the design. In fact it was very difficult. The prison service and my 
NHS trust got together to plan what the provision might be like. But neither 
of them had any experience of delivering that care in prison. So when I came 
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along and began to do the work it began to look very different to the way 
that they had planned it. So that was quite an interesting experience, because 
I had then to convince senior people in both the prison service and my own 
trust, that it was right to move things in a different direction, to the original 
plans. I had no previous experience in prison work. I was just working with 
what I was finding. So that was a very interesting time to begin to try and 
change the culture in a prison. 
HS: Why was it only in 1997 that the first detox came up in the prison while 
in the community maintenance must have been present for many years? 
P: That’s right. I have no idea because I wasn’t around in the prison system 
before that. But even in 1997 it was a detox unit. In the early stages, we were 
not allowed to do any maintenance. Everyone was detoxed. It didn’t matter 
how much they have been using, or for how long, apart from pregnant 
women and we didn’t pick them up to start with. So it was only a detox unit 
in the beginning. 
HS: The detox steps, the reduction scheme, was it initially set up as it is 
described in your handbook1? 
P: No, it was much less than is in the handbook. In dosage and duration. 
Much shorter. The level was probably similar, I can’t remember how much 
shorter. What we have got in the handbook is a very basic 10 day opiate 
reduction regime. But our minimum now is 14 days. And we will detox any-
body who is coming off methadone over a minimum of 21 days or more. 
When they come in, if they are on methadone, there is a 21 day withdrawal 
regime. We have a minimum of 14 days for everybody coming off street 
drugs, but a minimum of 21 days if they are coming off methadone. If they 
are positive to methadone, they need a slower withdrawal regime, because 
methadone is a much longer acting drug. We have basic fixed regimes, but 
there is also a blank sheet so that you can do anything else as well. So the 
baseline is really to make you act to ensure that everybody gets the safe 
minimum, and then we would do anything else on top of that, increased 
reduction or maintenance or whatever is needed. We would expand the 
                                                          
1  Jan Palmer (2003): Clinical Management and Treatment of Substance Misuse for Women 
in Prison. Central and North West London NHS, Mental Health NHS Trust, Substance 
Misuse Service, London, England. 
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regime upwards, so that you could have somebody detox over six weeks, or 
longer, and, of course, we now do maintenance. 
HS: The minimum is 21days when having been on methadone prior to 
arrest? 
P: It should be, and fourteen if it’s just heroin. But they are only minimums, 
we would encourage people to offer longer if it is needed. We have lots of 
locum doctors and inexperienced staff in prison at the present time and at 
least by having these minimum set standards, you can be sure that everybody 
is safe. When you have more experienced staff you can offer more individu-
alised care and try to have care plans for each person. We do that to a vary-
ing degree, not as much as we would like, we don’t have the resources yet. 
But we do now have maintenance as well. 
HS: So, is there any strategy to inform prisoners of the risks of reduced or 
zero tolerance in their body with occasional drug use in prison and after 
release? 
P: I mean, all the harm minimisation information is given out, very much in 
the CARAT’s team, and we give information on the clinical side as well to 
all people at risk of overdose. But my personal view is that it is of little 
value, because addiction is so powerful, and in prison they may be com-
pletely abstemious as there are no drugs that they are allowed to use, so 
when they leave it’s like Christmas. It’s very unrealistic to expect them to go 
out and to take nothing, and I think that overwhelms them when they leave 
prison. They are blind to the risks, even though they know what they are. We 
know with addiction that, cognitively, people don’t see the harm. The alco-
holic continues drinking, even when they know its killing them, they don’t 
seem to register the risks. And I think the same thing happens with opiate 
overdose, they know it as well as we do. When they are offered injectable 
heroin, the desire is too great. 
HS: So wouldn’t it be the best strategy to propose and promote maintenance, 
for short term prisoners? 
P: Yes, we do promote that. The problem we have is that most of our com-
munity services haven’t got the ability to pick people up when they leave 
prison. They might be on maintenance in prison, and we could keep them on 
that to preserve their opiate tolerance, but there is often nobody in the com-
munity to continue the prescription. So we have a big gap at the moment. 
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HS: It’s a very important point. What do you do with them, having them on 
the maintenance knowing that there is no continued prescription afterwards? 
P: At the moment our criteria for maintenance is that if you are in treatment 
before you come in, and you can go back to your previous prescriber, or if 
you are pregnant then we offer treatment. When they come in we check with 
the prescriber that they are on prescription and we ask the prescriber: will 
you take her back? If they say yes then we give them maintenance. If they 
say no, we might still maintain them for a while, and see if we could find 
another prescriber. If we can’t, then the patient has to choose: do they want 
to come off, maybe slowly, or do they want to continue maintenance to pro-
tect their opiate tolerance, and upon release return to using as they did 
before. 
HS: Is it up to the doctor and the teams discuss the pro’s and con’s of the 
maintenance programme with the inmates? 
P: Yes. I’d be lying if I said that we were that sophisticated in all our prisons. 
We are not; we are in some, not in others. Although we have a network of 
provision all over England’s prisons, it’s still in varying stages of develop-
ment. So one prison would be very good at one thing and one would be very 
good at another. We have the same standards and assessments and the same 
approaches to treatment in all the women’s prisons. But those who have had 
better investment, who have had more money, are better established. Though 
everybody understands that we are moving in the same direction, we are all 
at different levels at the moment. 
HS: How many women’s prisons are there in England and Wales? 
P: There aren’t any in Wales. They go to Gloucester. There are 17 now. 
HS: What do you think of the coverage and the scope of this design you have 
developed, the different options people can take, either to detox or not, and 
the communication with the outside agencies? In how many of the 17 prisons 
this is done satisfactorily? 
P: The bulk of all our work is done in our local prisons, the remand prison, 
and there are only seven of them. The other ten are training prisons. So the 
work I just described started off at the remand prisons, then, when people are 
sentenced, and if they are on maintenance, they can be transferred to the 
other ten. The other ten prisons will just continue the treatment and they 
manage the maintenance or very slow reduction, if people want to do that. 
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Our remand prisons are local prisons because they take everyone from the 
local courts. Our training prisons are where people are training and working, 
whilst they serve their sentence. They are either getting an education or 
working. 
HS: But the scheme you just worked out is for individualised care, at least 
for the pharmacotherapy? 
P: Not at the moment. It will be, and the principles are there and the idea is 
there and some of it is done. But it depends on the number of staff and how 
long the service has existed. Some of them are very new. One only opened in 
September last year, and one in December, so they are still in their infancy. 
They are very limited in what they can do, they haven’t got the staff, they 
haven’t got experience; they are just getting used to treating huge numbers of 
admissions every day. They might get 20 admissions into the detox unit per 
night, and you have got to stabilise and treat all of them. And tomorrow you 
get another ten, and the day after another fifteen and so on. Over the space of 
3 days you have got 50 new patients to process. So, to some extent, prisons 
will always have some tendency towards a standardised regime, at least to 
begin with, because otherwise how do you safely process huge numbers of 
people. Once you get a bit further on you can individualise the care a bit 
more. That is the way we are planning and progressing with the services. 
HS: So the continuity of the care depends very much on the capacity and the 
resources and the willingness of the community services, it’s closely linked 
together? 
P: Yes. 
HS: Are you involved in discussions about expanding places and capacities 
outside for methadone treatment?  
P: Not really. I mean, I did a presentation at a UK national drug treatment 
conference recently, and one of the things that I talked about was the diffi-
culty in getting prescribers to continue treatment for people who are leaving 
prison. So I had a wide audience of GPs and specialist drug services.  
HS: It takes time? 
P: Yes. Well I have always been saying the same thing, so they knew it 
already, but they haven’t got the money to provide the necessary additional 
services. 
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HS: Can you give a little bit of detail on the procedures, with regard to 
Buprenorphine. You mentioned that it’s taken sublingually under super-
vision, how long does it take, what is your scheme with it, you got ten min-
utes, or so? 
P: Well we are only using a very small amount of buprenorphine at the 
moment, as we have just launched it a month ago as our second line of pre-
scribing. Our main substitution in the women’s prisons has always been 
methadone. We have extensive use of methadone. We are now beginning to 
give buprenorphine as well, it will be given under supervised conditions,(as 
is methadone) its given sublingually and the patient will be observed until its 
gone. There is a whole procedure, I’ll send you the buprenorphine protocol. I 
think the need to supervise it and the length of the dissolving process will 
limit it’s use, it’s so time consuming and it is much more expensive than 
methadone and it isn’t superior clinically. 
HS: It is not? 
P: No, but it will be very useful for women who are reluctant to take metha-
done. 
HS: Only for some target groups like pregnant women? 
P: No, we wouldn’t use it for pregnant women, no. 
HS: Because I was told that the withdrawal process should be safer for the 
baby? 
P: Well, that’s debatable, if you mean the literature. Buprenorphine given in 
a low dosage doesn’t give you 24-hour-cover, whereas methadone does, so 
there must be a risk of the baby going into withdrawal. It is not licensed for 
use in pregnancy. We wouldn’t recommend it at the moment. If you use low 
dose methadone as we do in the prison, the neonatal abstinence syndrome in 
babies is very minimal, if at all. If we only give 30 mg of methadone, we get 
very, very minimal withdrawal and by the time women deliver we hope they 
are on less. You can also breast feed on methadone, but not with Buprenor-
phine. 
HS: That’s an important issue? 
P: Well it is, because babies are delivered in custody and they go to a 
mother-baby-unit, the mothers can stay on their methadone and breast-feed, 
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which protects her from relapse when she is released. She can have indefinite 
methadone maintenance if she has a baby in custody. 
HS: This is an important thing about buprenorphine in relation to metha-
done? 
P: At the moment, yes. This research I am doing for my masters is around 
the outcomes of pregnancy on doses of methadone at levels of less than 
50mg in prison. From observation we know that the obstetric outcomes are 
very good. But there’s nothing published to demonstrate that. So I am doing 
this research to evaluate the efficacy of the care that these women receive in 
prison. 
HS: Regarding the dosage of methadone, do you think there is a certain dos-
age, 50 or 60 mg has been set by Australian researchers, that is more likely 
to be successful in certain outcomes than low-dose-methadone programmes. 
P: Our experience of – I mean we must have detoxed in excess of 15-20 
thousand women, that’s a large amount of women. Our experience almost 
exclusively is, that because people’s supply of drugs is interrupted – when 
they get arrested, (they usually spend time in police custody) therefore their 
last use was often three days ago, they already have a drop in their level of 
use. When they get to us, the important thing appears to be the length of time 
you are prepared to prescribe for, rather than the dose you go up to. And 
without exception, once they are stable, they will always want to come down 
and we find 30mg averagely in prison is fine. We’ll go up to forty for those 
using street drugs who need it. 
It gets very complicated if you talk about someone who has been in treat-
ment with a high dose, supervised consumption of. 30/40mgs is unlikely to 
be sufficient, but it is still unsafe to give the whole amount that their com-
munity prescriber confirms is their once daily dose. This is a particular 
problem in pregnancy. And we are currently trying a combination of giving 
half the previous prescription, topped up with dose titration until a comfort-
able level is reached. In prison that appears to be fine because people aren’t 
exposed to the same level of drug-use as they were in the community. 
Most women using street drugs are stabilised and quite comfortable at 
30 mgs or, occasionally, up to 40 mgs. But 30 mgs is our average. They are 
generally stabilised on 30 mg. 
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HS: Is it that, in prison, vulnerability is reduced, the tempo is lower, the cir-
cumstances are much safer and the day-night rhythms regular? 
P: Well, they say they are fine on that sort of amount in prison. They then 
say they can’t manage on that in the community: “I am on 30 mg here but I 
need 90 mg when I am out” is a typical report. But that’s fine because we 
send them back to their prescribing agency, and that agency knows they are 
stable on 30 mg so they can start to increase again gradually to a level that 
meets their need in the community. So I would not say for one minute that 
lower doses would work in the community, but it works in prison, therefore 
we don’t (usually) need to give more. The other difference in prison is that 
there is 100% supervised consumption. We know that they take it all. When 
they get a script of 80 mgs in the community, they may sell 30 mg, so they 
take only 50 mgs. Which is probably another reason that they stabilise out on 
the level of Methadone that I have described. So it is low dose in prison, but 
it is 100% supervised consumption. Most of them are simultaneously with-
drawing from Benzodiazepines, so we are also prescribing diazepam at the 
same time. Again we have to be cautious with these reduction regimes, 
which are usually over a period of seven to ten weeks. 
HS: How did you organise the way patients are informed about the way you 
are treating them with pharmaceuticals? 
P: There is an information sheet that we give them. We give them an infor-
mation sheet about the opiate detox, the maintenance regimes, and the alco-
hol detox, there are several. 
HS: What is the interaction between methadone maintenance treatment and 
the HAART – or even Interferon treatment? 
P: Very few of our women are on interferon because they are not abstinent 
from drugs and the policy in many areas is that they won’t treat them when 
they are still actively using drugs or alcohol. They usually require them to be 
abstinent for six months. So very few get this treatment.  
For antiretroviral treatment they get the same. What we have had to do in the 
past – when we were reducing a lady’s methadone (at her own request) and 
her consultant wrote and asked if we could put her methadone dose back up 
because he thought her antiretrovirals would make the methadone less effec-
tive – is that we did, we got her level of Methadone up again. But it’s no 
problem to have the antiretrovirals and methadone together. 
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HS: Is the dosage increased slightly? 
P: Well, that’s the only time we had to do that, but we would be willing to do 
so if a consultant says that the effect of the antiretroviral treatment is less 
effective, we would put the dosage up as needed. 
HS: Yesterday we spoke of using urine control as drug tests, could you just 
repeat your experience in the way of handling it? 
P: We have several different systems in England, one of them is mandatory 
drug testing which is a prison service provision aimed at detecting illicit drug 
use. We then have voluntary drug testing which, again, is a prison service 
initiative, but it’s voluntary, and a therapeutic type of support to help people 
remain off drugs whilst in prison. Then for us, in healthcare, we have clinical 
urine testing. We test people on arrival and during their maintenance pro-
grammes, that’s clinical, it is medically confidential. We don’t disclose that 
to the prison for disciplinary purposes. 
HS: Do you have information from the test results of the prison service? 
P: Yes, we could have. We don’t use it often. But ours is medically confi-
dential. We have to have a positive urine test for opiates/methadone before 
prescribing takes place. I mean, occasionally somebody might have a nega-
tive result, as they have been in police custody for a while, but if you can see 
evidence of withdrawal, we would still prescribe. The urine testing is very 
much part of our assessment and in the “blue handbook” you will find a lot 
of information about semi-quantitative urine testing. We had a machine on 
site which was capable of doing this, it gives you levels of drugs present at 
admission. Temporarily, we are without that, but we are trying to get those 
machines into all the big local prisons so that we have an idea of the level 
that they have in their urine when they come in. It gives a better idea of 
expected tolerance to opiates, and the level of benzodiazepine needed. 
HS: What are the consequences of additional topping up, let’s say benzos or 
Cannabis? 
P: We don’t retest the Cannabis clinically (except for pregnant women) as 
we don’t prescribe against a cannabis positive result. The prison service 
wants to know about the cannabis in terms of Mandatory Drug Testing 
(MDT) and Voluntary Drug Testing (VDT). We would re-test for cannabis 
in pregnant women because we want to know about their ability to be drug-
free when caring for their baby. But otherwise we do a base-line of six 
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substances upon admission. At present the dip ‘n read tests are in common 
use but they don’t give levels. 
We are not yet that advanced in managing relapse, because most women on 
maintenance are very appreciative of receiving this treatment, so they don’t 
use on top. As we do more maintenance it may well become a problem. We 
recently had a situation where someone was using on top and, from a policy 
point of view, we are bit uncertain how to proceed with these situations. 
I think our approach (at the moment) is, if they use on top we are likely to 
suggest that they reduce the methadone, at least temporarily, and maybe put 
it back up if they are otherwise abstinent. We certainly won’t push the level 
of methadone up and up. I think the difficulty that we will have in the prison 
system is that if we increase people’s doses, due to their using on top, this 
will be an invitation for a lot of illicit use – we would lose credibility within 
the prisons. So our main approach at the moment is to say that if you do use 
on top, we have to reduce your methadone. We might reduce it by ten milli-
grams and review it in a week. If somebody really needs a high dose we 
might consider changing them across, to Subutex®, but we are not very clear 
about this the moment. That’s something we are currently feeling our way 
with. 
HS: Is heroin also prescribed? 
P: No, only methadone and subutex. 
HS: And not retarded morphine? 
P: I’ve never even heard of them. 
HS: In Austria, I have been in the prisons, they prescribe it on a wide scale. 
P: There is a lot of use of the DF118 (Dihydrocodeine) in the male prisons. It 
is now almost withdrawn in women’s prisons. We now have subutex as a 
second line, as we should always have a choice. DF118 is not effective, it is 
very highly misused, it’s short-acting, it’s not an appropriate opiate substi-
tute and not licensed for that treatment. The other drug that’s used in the 
male estate is Lofexidine. 
HS: Please describe that, this is something new. 
P: It’s not as effective as methadone or Subutex®, and is really considered 
more in the symptomatic treatment range. It was designed, for the commu-
nity, for less severely dependent users. It’s not really terribly effective for 
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severely dependent individuals. And we almost never use it for women, we 
have a problem with hypotension in our client group of young, underweight 
women, as it has a tendency to reduce their low blood pressure further. We 
don’t use it often because most of our women have very low (dystolic) blood 
pressures when they come in anyway. When you give them the Lofexidine, 
you have to monitor the blood pressure four times a day and, if the blood 
pressure drops, you can’t give them enough to control their withdrawal 
symptoms, so we don’t use it often. There is a protocol in the handbook but 
it’s not in common use, although it is useful for low or uncertain use, par-
ticularly if the admission urine test result is negative. 
HS: Can you just say some more words on the assessment you do. You said 
that your urine controls play a big role? 
P: We assess everybody in reception upon arrival in the prison. That’s the 
reception health screening. And according to what they tell us, they get urine 
tested for drugs and will then be admitted to the detox unit on the first night 
they come in. They will then get 10 mg of methadone on that first night and 
they will probably get some Diazepam if they are benzo dependent. If they 
are alcohol dependant then we start them on Chlordiazepoxide as well. So, 
they are always treated as far as we can on the first night. They get some-
thing. Then they are cared for in an inpatient detox unit where we have unre-
stricted observation. We have hatches in the doors, which are permanently 
open over 24 hours so the nurses can observe the women. So, as well as the 
initial assessment, we then monitor them for at least the first 72 hours and 
then we can see whether what we are doing is sufficient or whether they 
need additional medication.. The doctors/nurses interview is brief and there-
fore is not the same as in the community as we don’t have enough time. 
It isn’t practical, we can’t sit down and have a lengthy interview with every-
body as we would if they were in the community. So we use a self-assess-
ment questionnaire and we ask them to give that back to us in the first  
24-48 hours. 
We then check that with other information that we have picked up during the 
various stages of assessment, and put all of them together and this gives us a 
better picture. So it’s a mixture of all those things really. 
HS: One of the reasons why we talk about substitution treatment in depth is 
that there are enormous organisational problems. We see people under police 
arrest, then go to remand and sometimes different juridical, professional and 
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financial circumstances are having influence on the assessment and treat-
ment. How far are you cooperating with the doctor or the nurses or the whole 
team in the police arrest? 
P: Increasingly, we are trying to get the police doctors to send the informa-
tion to prison as the prisoner arrives. It’s very patchy. We get the information 
sometimes and we don’t get it at other times. That’s quite a gap really. There 
is something called the criminal justice intervention programme (CJIP) 
which has just started this year and they are supposed to be the link through 
which information can be passed as people come into prison. An arrest refer-
ral worker can also do that. There are quite a lot of opportunities for infor-
mation to be forwarded to prison but it is still very patchy at present. 
So, it’s very much around what we see; objective signs of withdrawal, what 
the patient says, what the urine test shows and then the confirmation we can 
get the next day about prescribed regimes. So there is quite a gap there and, 
equally, the other end. We are trying to make sure that, if there is a prescrip-
tion in place upon release, our health care staff always inform the community 
prescriber so that they pick them up as soon as they leave prison. 
HS. So can you – just for the maintenance situation and for the detox as well 
– say some words about the circumstances of the intake, how it is done? On 
the one hand, protecting privacy as probably not all of the other inmates 
should know that they are getting methadone? 
P: Women’s prisons have detox units to start with. Everybody in that unit is 
getting methadone so it’s not an issue, not at all. When they leave the detox 
unit, they either come back there each day or they go to some other central 
point in the prison. But other medications are supervised as well in the 
prison. So people will go and queue to get the medication every day any 
way. Other prisoners are not so interested whether that person is getting 
methadone or whatever. We are certainly developing methadone clinics, as 
in the community. That has to be built into the prison regime. So people are 
aware of women going to get their methadone, they doesn’t seem to bother 
them, it’s not becoming an issue at all. Earlier on, the only people that we 
maintained were AIDS/HIV positive patients. That was a problem. Immedi-
ately you could see that if this person was being maintained and they were 
not pregnant, they must be HIV positive. But because now we maintain lots 
of people who are on treatment for some other reason, that issue has gone. 
So that was an issue, but that’s now past. And if you go to a community 
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pharmacy or a community drug service for supervised consumption, people 
queue there, so it’s not a big deal. Certainly it’s not a big deal to women. 
They should have the opportunity to come to the dispensary one at a time 
and we do our best to do that. We can only work with the buildings and pro-
visions that we have, and none of those were ever designed with substitution 
treatment in mind. When we rebuild or develop new units, we plan dispensa-
ries of a more suitable design. We are very often working with the inherited 
clinics that we have no control over, so we just have to use what we have 
got. But we don’t often find women complaining about this at all. 
HS: Yesterday you raised the point that you should be gender-sensitive, that 
you should take a gender-sensitive view. Can you explain how it’s expressed 
in the division of labour you have? You are responsible for the women and 
your colleague for men I suppose. So what are the key issues in a gender-
sensitive aspect of the work? 
P: We have far less women in prison, we’ve got 4 700 women in prison in 
England and about 72 000 men. Because there are so many more men in 
prison, there is a full range of drug-use – from those with recreational drug 
use to dependency, occasional use and upwards. Because there are fewer 
women in prison, their drug-use is of the severely dependent type. The 
severity of drug-use of women coming into prison is out of proportion to the 
men. So, all women go straight to the in-patient detox unit. While in the male 
prison, they have levels of assessment and, by comparison, only a few need 
in-patient care. You begin from a different starting point, because their drug-
use is so sever and complex. You also get health related issues from their 
drug using life style, the percentage of injectors amongst women is high, it is 
about 85%. Undetected pregnancies are not uncommon, some don’t know 
they are pregnant until we detect it. And domestic violence, working as 
prostitutes, all of those additional problems, you don’t see in the male estate. 
Very often, the problem is that you have to deal with the fact that they have 
lost their children. And many of the women have been abused in the past or 
traumatized and use drugs to dull that. And when they stop using drugs they 
become hugely destructive and self harm is a big, big problem for women in 
prison. In all cases where we have developed a good detox unit and service, 
the self harm during the detox is much reduced, and the prisons are 
impressed by this. It then sells itself because people stop trying to harm 
themselves during detox. Unfortunately what happens is, that because the 
detox is quite short (by community standards), they still tend to self harm 
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once they are abstinent which is another reason we try to promote longer 
regimes in order to reduce the risk of self harm. If women can control the 
rate at which they reduce, they don’t self harm as the dose lowers, as they are 
in control. So self-harm in women’s prisons is a major consideration. 
HS: What else besides attempted suicide do you put under ‘self harm’? 
P: The most common attempts are ligatures. And these can by very success-
ful, unfortunately. They are very good at it, don’t ask me how. First night in 
prison, they have never tried to hang themselves in their life before, and they 
successfully tie a ligature which kills them. So the biggest problem of this 
sort is ligatures, followed by cutting, in women’s prisons. Outside in the 
community they might swallow pills or overdose. One of the biggest things 
which tips them over the edge is lack of nicotine. So, we try to give a little 
tobacco during the detox phase to the staff, so they can rescue people. You 
can clinically manage all the other things, but during withdrawal they are 
very impulsive; one minute they are cheerful and the next they are desperate 
and when in that state they attempt to hang themselves. This impulsivity, in 
this poly-drug withdrawal, is a major problem of both self harm and behav-
ioural management. They are often very disturbed, very agitated and impul-
sive. You sit with them, and one minute they’re fine, and you walk away and 
you come back and they have attempted to hang themselves. So tobacco is a 
big issue. 
HS: It’s a tragedy. What could you do to appease them? 
P: Give them nicotine, it’s nicotine withdrawal, they are heavy cigarette 
smokers and when they come in they get very little in the way of tobacco 
because they only get one pack for a week, so we are just trying to encourage 
prisons to give extra tobacco at that stage. 
HS: Do they have to pay themselves or who pays? 
P: Well, a little bit of extra tobacco for the unit can be purchased via the gen-
eral purpose fund. We don’t give them packages, just an occasional extra 
cigarette. We don’t encourage smoking cessation in the first six months (or a 
year) after detox. We say: no, it’s too much, just carry on. The other thing we 
do is, we try to make the withdrawal less uncomfortable by doing things like 
giving them hot chocolate drinks at night, extra food at night, give them in-
cell TVs which they don’t pay for during the detox phase. All of these com-
fort things help, as does having open hatches in all detox unit doors, which 
are then staffed 24 hours a day by nurses. So the way we care for them is 
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arranged to reduce the stress of isolation and that has an effect as well as all 
the clinical regimes. 
HS. What about the women coming from foreign countries? Does it make 
any difference? 
P: No, most of the women from foreign countries are the importers, the 
mules, so, mostly, they aren’t users. If they are, they are treated the same as 
anybody else. Not long ago, we had a lady from abroad who had been on 
maintenance for many years before coming in. She was expecting a short 
sentence and so we maintained her. She then got a 5 year sentence. So, once 
she settled down after the sentence we helped her to withdraw, at her own 
speed. Being from another country wouldn’t make any difference. We some-
times get women in from Europe, on very high, unfamiliar Benzodiazepines 
that we don’t have any experience of. We still treat them according to their 
clinical need, the same as if they were from the UK. We wouldn’t even think 
about it.  
Well, I do need to say, these services are very basic, this is just a baseline. 
We have done more in some places than others. I think the biggest thing we 
are trying to achieve, is the same level of care in all of our prisons. If you get 
admitted to a prison in Durham, and then get moved to London or Glouces-
ter, it shouldn’t make a difference to the care you receive. This is not abso-
lutely the case at the moment but it will be, hopefully, within the next twelve 
months – everyone will be using the same assessment, the same prescribing 
regimes, and the same criteria of flexibility. So, she should get the same 
level of care in Durham, Gloucester, Birmingham, London or wherever and 
that will then be continued in whatever women’s prison she is in until 
release. 
There is increasing support from high up in the prison service now for 
maintenance. 
… 
You have to go with what you can develop and get it consolidated. If you 
rush too far ahead and are too controversial, you might lose the support. We 
should at the moment really try to promote maintenance and, indeed, relapse 
prevention prescribing such as naltrexone. But very much a focus on main-
tenance. I think we’ve got a culture change and quite a lot of work to do to 
get that widely accepted. It takes a long time to change anything in prisons. 
It is so time consuming and you have to put so much energy and persistence 
into getting things changed. We have to focus on the big things at the 
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moment, and that is as an alternative to detoxification, promoting mainte-
nance. 
HS: Yesterday we discussed that it is one thing to give out regulations or 
publish something and another thing to implement it. Do you have an over-
view of all of the 17 institutions? Do you know everybody, and everybody 
knows this is our philosophy, this is the benchmark, this is the basic level of 
care that is expected – and more is better? 
P: Yes. I know everybody in all 17 institutions. I personally supervise all 
17 prisons. They all know me, and I know them. I spent much of my time on 
the motorways, visiting all the prisons. I spend all my time assisting the de-
velopment of services in those 17 prisons in order to achieve this standard, 
minimum level of care. It is my fulltime job. 
  
PART IV : 
Conclusions & Recommendations 
  
  
A. Conclusions  
This chapter discusses the findings from our field visits (see country reports) 
with the literature study, additional scientific results and the statements from 
our workshop on “Substitution Treatment in European Prisons” which was 
organised during the “7th European Conference on Drug and HIV/AIDS Ser-
vices in Prison1”. During a workshop several international experts contrib-
uted to a draft of the WHO on substitution treatment and harm reduction in 
prisons2. 
High prevalence of opiate use and drug-related infections in prisoners 
The prevalence of drug use in prisons with according drug-related problems 
for the institution and the whole system has been convincingly demonstrated 
(Thomas & Moerings, 1994; Shewan & Davies 2000; EMCDDA 2003, 
2001). A disproportionate number of prisoners have a history of drug use, 
drug problems and/or injection. There is indication that prison reception 
health screening is consistently even in underestimating drug use (Mason, 
Birmingham & Grubin, 1997). There is overwhelming evidence of severe 
problems for the individual’s health, that of partners, families and severe 
problems for the security, hygiene the cohabitation of inmates in prisons and 
health of staff. It is estimated that approximately one third of the inmates are 
supposed to be opiate dependent, and many more are experienced in drug 
use. In several prisons, this includes up to three quarters of the inmate popu-
lation. Although there is less frequent evidence of continued drug use and an 
uptake of drug use while in prison (Stöver, 2001). This is associated with 
high risk of HIV/Hepatitis transmission due to sharing/reusing injecting 
equipment and drug solution (Lines et al. 2004; Davies 2004). Also there is 
an extremely high risk for drug using prisoners to relapse and overdose 
                                                          
1  “Prison, Drugs and Society in the Enlarged Europe: Looking for the right direction” 
(organised by the European Network of Drug Services in Prison – ENDSP, and the Central 
& Eastern European Network of Drug Services in Prison – CEENDSP in Prague/Czech 
Republic from 25-27 March 2004). 
2  Draft “Prisons, Drugs and Public Health – The vital role of harm reduction in prisons in 
reducing the harmful effects of drugs in society” (prepared by the WHO Regional Office 
for Europe, Health in Prisons Project). Thanks to Alex Gatherer, health in prison project 
(WHO Regional Office Europe) for chairing the workshop. 
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shortly after release (Seaman, Brettle & Gore, 1998; Heinemann, Kappos-
Baxman & Püschel, 2002). 
Substitution treatment well indicated and effective 
Although prisons systems, for a variety of reasons, are slow in responding to 
the epidemics of viral infectious diseases (such as HIV and Hepatitis) and 
injection drug use threatens the health and wellbeing of inmates and chal-
lenges the institutions. This was the background for introducing substitution 
therapy as one of the most effective treatment options for opiate dependent 
inmates. As shown in the literature review, several studies indicated that 
methadone maintenance (MMT) treatment could reduce heroin use, drug 
injection and injecting risk behaviour (e.g. needle sharing), participation in 
the prison-based drug trade, and increased participation in drug treatment 
following release from prison (Kerr & Jürgens, without year). Substitution 
treatment is contributing to a reduction of opiate related mortality soon after 
release from prison. Moreover, the initiation of MMT also contributes to a 
significant reduction in serious drug charges and in behaviours related to 
activities in the drug subculture. Offenders participating in MMT had lower 
readmission rates and were readmitted at a slower rate than Non-MMT 
patients. There is evidence that continued MMT in prison has a beneficial 
impact on transferring prisoners into drug treatment after release. Finally, as 
expressed in many interviews during the field visits, the prison system bene-
fits from substitution maintenance therapy through reductions of withdrawal 
symptoms on admission, drug trade, increased productivity and may help to 
minimize the contradiction between control and care. 
The background of this body of evidence indicating the eligibility and suc-
cess of substitution treatment has been implemented in several countries as a 
regular service accessible for every inmate. 
Diversification of drug-treatment approaches including substitution 
treatment 
Many studies have shown that criminal justice interventions alone, without 
associated opioid dependence treatment, have very limited impact on drug-
using behaviour and re-offending among individuals with drug use. Por-
porino et al. (2002) pointed out that continuity of treatment provision is one 
of the key concepts, particularly following release, and that it is linked to re-
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offending rates. There is a consensus among professionals that drug treat-
ment can be effective if it is based on the needs of prisoners, is of sufficient 
length and quality and there is continuity of aftercare in prison and in the 
community (Ramsay, 2003). It is the combination of treatment in prison and 
follow-up treatment afterwards that provides the best impact. “That’s with 
drug free treatment, but logically there is no reason why the same thing 
shouldn’t be applied to substitution treatment” (Farrell, 2004). These are 
important baselines for a through-prescription that means a continuity of 
substitution treatment from the community to the prison setting and back to 
the community. 
As pointed out by the joint position paper of WHO/UNODC/UNAIDS 
(2004) on Substitution maintenance therapy in the management of opioid 
dependence and HIV/AIDS prevention “no single treatment is effective for 
all individuals, therefore services should be sufficiently varied and flexible to 
respond to the needs of clients, their severity of dependence, personal cir-
cumstances, motivation and response to interventions. The rational manage-
ment of opioid dependence calls for the balanced combination of pharmaco-
therapy, psychotherapy, psychosocial rehabilitation and risk reduction inter-
ventions.” Seeking an equivalence of health care in the community and in 
prison this outlined diversity of treatment approaches needs to be transferred 
into the prison setting. 
Enlargement of the scope of substitution treatment 
The substantial increase in the number of opiate users in substitution treat-
ment in Europe in recent years (almost 400,000 patients in 16 countries 
receive substitution treatment. 60% solely in Spain, France and Italy) has had 
and will have an impact on the number of substitution treatment in prisons as 
well. Compared to similar studies conducted in the nineties (Turnbull & 
Webster 1998; Bollini, 1997) we found the number of countries providing 
substitution treatment increasing (only Greece and Sweden were the only 
countries providing no substitution treatment, Czech Republic delivered 
detoxification with buprenorphine in a prison hospital). Consequently, the 
number of patients receiving substitution treatment in prisons increased con-
siderably (e.g. France where the percentage of prisoners receiving substitu-
tion treatment increased from 3.3% in 1999 to 5,4% in 2001; Morfini & 
Feuillerat, 2001). Much movement could be observed in recent years in the 
prison policy (protocols, regulations) and health care to follow the develop-
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ments outside in the community and to introduce substitution treatment. In 
several countries the continuation of substitution treatment begun in the 
community has been done routinely, close co-operations and communica-
tions with community-based addiction centres are guaranteeing a high stan-
dard of professionalism (exchange of new developments, harmonisation in 
terms of organisation of subsequent substitution treatment after release etc.). 
Although the scope has been enlarged, the solely quantitative view on the 
concrete treatment modalities shows insufficiencies, a process of quality 
assurance has to be initiated in many prisons regarding procedures and rou-
tines of administration, keeping confidentiality and many other treatment 
modalities discussed hereunder. 
Limited access, limited equivalence of care  
Despite The WHO recommends: “Prisoners on methadone maintenance prior 
to imprisonment should be able to continue this treatment while in prison. In 
countries where methadone maintenance is available to opiate-dependent 
individuals in the community, this treatment should also be available in pris-
ons ...”. In several countries, community-based treatments most likely result 
in discontinuation once entering the prison setting, for various reasons, or in 
restricted access to few substitution maintenance treatment places. Still, in 
many prisons visited the demand expressed by prisoners for substitution 
treatment is much higher than the actual provision. Long waiting lists, lim-
ited space and lack of resources and personnel in many prisons are demon-
strating that the increase of substitution treatment outside in the community 
has often not been followed by an adequately organized and financed sub-
stitution treatment in the prison setting. Especially the allocated budgets on 
the background of an overall overcrowding of the penitentiary institutions in 
Europe often leads to restrictions in the capacity for an adequate and qualita-
tively proper substitution treatment. It seems as if the prison services are 
swamped with the expectations of prisoners, professionals from the commu-
nity and politicians regarding the implementation of adequate structures of 
health care. Substitution treatment often reveals the missing interlinks of 
health care in the community and in prison as this medical treatment effects 
both systems. 
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Abstinence orientation 
What are the reasons for the disproportion in several countries that only a 
small part of those prisoners receiving substitution treatment in the commu-
nity will do so in prisons (e.g. France: 56% in the community whereas only 
20% in prisons, see Michel 2004)? Apart from insufficient resources to pro-
vide adequate substitution treatment programmes in prisons and limited 
places in the community, several other reasons for a resistance towards this 
form of treatment and barriers to service access can be identified. The pre-
dominant obstacle for the introduction is the basic abstinence-orientation of 
doctors, nurses, responsible persons in the prison service, and finally pris-
oners themselves. The goal of the sentence (to enable prisoners to live a life 
without committing criminal offences) is identical with abstinence from ille-
gal drugs (which have to be purchased on the illegal market). 
This abstinence orientation can also be pursued when substitution drugs are 
solely used as means of detoxification after admission to prison. Then it ful-
fils the function of a means to wean off opiate dependent persons, and it is 
more a technical understanding of this therapy potentials. 
According to Auke van der Heide (2004) one of the underlying problems is 
that many doctors regard addiction not as a disease, but as a moral behav-
iour. Because of this congruency the pedagogic approach of counselling, 
treatment and support was undoubtedly drug-free oriented for many years, 
despite harm reduction developments and the availability of substitution pro-
grammes on the outside. 
An exclusive focus on achieving a drug free state for all patients in the long 
run jeopardizes the achievement of other important objectives which may be 
of higher priority at the moment, because of life-threatening impact etc. Sub-
stitution treatment’s success’ is more than abstinence orientation. It is sub-
stantially contributing to patient’s stabilization on a number of levels, as well 
as societal reintegration. Substitution treatment is not an ‘instant drug-free 
means’.  
A discussion is needed about realistically achievable goals and step by step 
reachable targets regarding substitution treatment. 
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Prisoner’ denial of substitution treatment 
Prisoners have been socialized with the above described drug-free orienta-
tion and they themselves often do not question the unavailability of substitu-
tion programmes in prison. Or they don’t demand such a treatment because 
they associate disadvantages with being a patient in such a programme (e.g. 
‘lack of privacy in terms of being know as a “drug user” to staff with antici-
pated negative consequences for the current sentence). Some experts on the 
Prague conference also point out that prisoners do not want to become 
known as patients in a substitution treatment because they fear that other 
prisoners will know this and they are put under pressure by criminal and 
aggressive behaviour. As a contributor puts it on the conference in Prague: 
“There is again the thing that everybody in the prison knows who is on sub-
stitution, and the patient doesn’t want everyone to know this. It is again the 
discretion of the prison system.” This is an argument of strictly looking at 
the conditions and the procedure of administrating the drug which should be 
as discreet as possible. 
Another argument brought forward in several countries is that prisoners 
often are not completely informed about the status of the medical service and 
the degree of confidentiality guaranteed: “It should be very clear to the 
patient that the doctor or anyone from the medical staff is just coming for 
treatment, that he or she is not part of the prison system. It’s often one of the 
things you get as a doctor in the treatment, somebody tells you that it’s very 
clear that you are a part of the health system and not of the justice system (a 
contribution on the Prague conference).” 
In order not to stigmatise prisoners, procedures have to be thought of, which 
are aimed at not letting staff and other prisoners know what medication is 
given out. Several procedures have been practised in the prison visited to 
give substitution drugs out with other drugs etc. 
In some other countries (e.g. Switzerland) it is up to the prisoners themselves 
to take the substitution drug when it suits them most (although this requires a 
lot of flexibility with the nurse staff): “In community settings, patients are 
free to take the drug whenever they like. We’re trying to copy the situation in 
their life, and it appeared the time that suited them best was 12:30, however, 
a couple of weeks later, we received a petition from prisoners signed by them 
that stated that they wanted to be able to take the drug at a time that suited 
them best. We explained to them that this time was the best for them in order 
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not to be stigmatised, but they still had a problem with that.” (A contributor 
on the Prague conference) 
Another aspect is that substitution drugs (methadone, buprenorphine) are 
often seen as hedonistic drugs which are bought in the streets and not as 
drugs prescribed on therapeutic purposes, best in a therapeutic setting. For 
many prisoners the sentence advances (more or less) to the only drug free 
period and they either experience their ability being abstinent for the first 
time (after long periods of compulsory drug use) and/or are associate the 
prison sentence with ‘getting clear again’. For many prisoners, this expresses 
the wish to avoid relapses after release drug-abstinence is combined with 
rehabilitation. 
Finally it has to be said that one of the reasons of patients’ resistance against 
substitution treatment in prisons is that there is no free choice of doctors 
whereas outside in the community mostly there is a choice finding a doctor 
meeting the substitution treatment needs of the drug user. 
From other studies it is known that clients often do not equate ‘success’ on a 
methadone programme with becoming drug free. Success is defined as rela-
tive and much more complex state than a simple measure of abstinence. 
Often the stabilization and the absence of heroin craving is valued a success. 
Generally speaking, substitution treatment is often perceived to have a sub-
stantial impact on the quality of life in a number of areas. So it becomes nec-
essary that a discussion is led about the basic objectives of such a treatment. 
Informed consent for a detoxification treatment 
It has been stated by several experts on the conference in Prague and discus-
sions in some countries (The Netherlands, Germany) focused on the topic as 
well that it is problematic to stop a community-based, medically indicated 
substitution treatment, diagnosed, assessed and initiated in the community, 
without informed consent of the patient in the prison. In The Netherlands the 
debate is going on between the Ministry of Health, Welfare and Sport and 
‘The Health Council’ who states that according to the agreement between 
provider (medical doctor) and user of the provision of medical services stop-
ping a treatment is a form of medical treatment and therefore requires the 
informed consent of the patient/inmate, especially when a medical decision 
(from maintenance to detoxification treatment) is a fundamental change of 
treatment from care to cure. It is not an argument that people are shifted from 
460 
 
one treatment system to another (community-based to prison-based medical 
health care). This at least has to be justified from case to case. 
Prisoners who went to court in several cases were given right to receive sub-
stitution treatment also in prison despite the refusal of doctors (The Nether-
lands, Germany). 
Continuity of treatment: avoiding yo-yo -effects 
Applying substitution therapy solely in the form of detoxification is restrict-
ing it’s therapeutic potentials. Substitution maintenance treatment with the 
aim of health stabilization and social rehabilitation is aimed at longer time 
lines. As research indicates, for most opiate dependent persons “the thresh-
old of significant improvement is reached after about three months in treat-
ment, with further gains as treatment is continued. Because people often 
leave treatment prematurely, and premature departure is associated with high 
rates of relapse into drug use, programmes should include strategies to 
engage and keep patients in treatment. Many patients need several years in 
treatment”. (WHO/UNODC/UNAIDS, 2004, 18) 
Several prisoners interviewed who had a detoxification in prison said that 
they relapsed after release and after a while went into substitution treatment 
again. This yo-yo-process of substitution treatment, detoxification in prison, 
entering a treatment programme again, re-offending and entering a substitu-
tion treatment again is physically risky behaviour and absorbs much energy 
of those concerned. As previously stated, prisoners themselves opt for a ces-
sation of substitution treatment either to gain certain advantages or as an 
option in the self-management of their addiction. As it has been put by the 
director of a treatment unit in The Netherlands: 
“When they are over in that department they all think: I don’t use drugs out-
side. When they are outside, its a different story. When they are here it’s 
safe, they have work, they go to school, training courses, they really feel 
good and strong and healthy. It changes dramatically when they have the 
possibility to get outside the ward.” So sometimes it is the medical unit, the 
doctors themselves to present the disadvantages of a discontinuation (French 
doctor on the Prague Conference). 
Another aspect has been that a cessation of substitution treatment for those 
inmates with a long history of drug and methadone use is perceived as 
essential loss of an option of self-medication (to manage craving and adverse 
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effects of their drugs with methadone) which could have always been chosen 
as a last resort (because methadone has been served as a coping strategy in 
times of heroin scarcity), describable in terms of a ‘love and hate-relation-
ship’. 
As Michael Farrell puts it on the Prague Conference (2004) “… the issue is 
we’ve got people with chronic opiate dependence, we’re detoxifying them, 
and then sending them back at it, and we’re potentially adding to the burden 
the people already have with this process. My argument is chronic, long-term 
dependence should be maintained and not detoxified”. The process is not to 
be seen in its full consequences as a liaison is often missing between prison 
doctors, staff and community health care services. But as relapse in drug use 
is high, and re-offenders are not necessarily put into the same prison, the 
process of a steady interruption of treatment is only realized when a person is 
re-admitted to the same prison. 
Substitution treatment thus is a treatment with long-term potentials which 
demands a throughcare or a treatment started in the prison setting with con-
nection to the community. 
Many studies have shown that in particular, engagement in transitional after-
care has been proven as crucial for reducing post-prison recidivism (Simpson 
& Knight, 1999; Vigilante et al., 1999; Butzin et al, 2002). Effective and 
successful drug treatment in prison requires a continuum of care that takes 
the drug-using inmate from the correctional environment to the re-integrative 
processes of community-based treatment offers (see also Hiller et al., 1999). 
This applies not only to drug-free but also to substitution therapy. 
Low and/or high threshold substitution programmes 
Andrej Kastelic (2004) raised the question of low and high threshold substi-
tution programmes in prisons. Substitution in a low threshold option would 
mean emphasising harm reduction goals (e.g. prevention of relapse after 
release, prevention of infectious diseases, taking the pressure for dependent 
inmates to engage in illegal trafficking etc.). The low-threshold substitution 
treatment should then cover as many treatment demands and needs as possi-
ble, whereas high threshold programmes would be equipped with additional 
means and resources (e.g. psycho-social care and support), and would 
require more commitment and engagement from the patients and a higher 
therapeutic setting. Between both levels permeability has to be ensured. 
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This division is happening outside in the community in many countries 
already and worth thinking about in the prison setting as well. 
The needs of women must be treated specifically 
Mostly the different needs of women in prisons are not mentioned specifi-
cally. As Jan Plamer (2004) pointed out: “The complexity and severity of the 
drug use in women’s prisons is far greater than for the male counterparts, 
where there is a range of drug using problems, whereas for women, they 
tend to be very severe drug users. They tend to use between 6 and 9 sub-
stances at the time they’re admitted to prison. They have a lot of health 
related problems on top of that. Therefore the clinical management or over-
all management of women in prison needs addressing separately to the needs 
of men.” 
This requires a set of clinical protocols that act as a minimum standard of 
care for women. 
Drugs, dosage and duration 
Some experts (Farrell 2004) point out the particular value of buprenorphine 
with it’s reduced overdose risk which makes it valuable for the prison setting 
and for the release situation. But as discussed in the interview with Jan 
Palmer3 the safe use of substitution drugs is also a matter of accurate super-
vision and control. Nevertheless, those substitution drugs available in the 
community should be available as options and with different therapeutic 
agents so there is a choice for the patients. 
As it was reported from the US, in the prison in New Mexico, a pre-release 
buprenorphine pilot is about to be introduced. One of the advantages, despite 
the extra costs of the buprenorphine products is that it doesn’t have the 
‘stigma of methadone’. 
As shown in the literature review one of the crucial points of MMT to be 
effective is a moderately high dose of methadone and buprenorphine and the 
prescription lasting the entire period of imprisonment. A sufficiently high 
dosage (more than 50 mg) also seems to be important for an increase of the 
retention rate, which then can be used for additional health care services. So 
                                                          
3  See chapter “The need to treat women separately in substitution treatment”. 
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apart from timely entry into treatment, duration and continuity of treatment, 
and accompanying medical and psychosocial services the adequate medica-
tion dosage, is responsible for the effectiveness of opioid substitution main-
tenance therapy. However, these findings serve as a general orientation and 
are not to be seen as a binding principle. 
Bernhard Spitzer (2004), psychiatrist and doctor in a men’s prison in Stein/ 
Austria pointed out that substitution treatment is not a short term range 
intervention. Therefore success can only be seen and measured on a longer 
term basis. It’s success is amongst other factors dependent on the duration of 
the treatment, which has to be set up individually: “A patient is an individ-
ual, so you can’t have a one size fits all approach, you have to consider each 
person … Referring to the methadone, we also use retarding morphine, and 
we use that only in certain cases. But this reflects the situation in the com-
munity, if someone has started a treatment in the community, he should con-
tinue on the same stuff while in prison. These retarding morphine improve 
the quality of life considerably, not in all the cases, though. I just wish to say 
that we can’t only focus on methadone treatment, even though it has 
improved a lot, but we also have to talk about other substitutions, other 
medication. Substitution programs have to be developed on a case-by-case 
basis.” 
Supervision of intake 
Some debate has been going on how to best control the intake of substitution 
drugs. There is a consensus that the intake of substitution drugs (as well as 
the intake of other psychoactive substances, antidepressants etc.) has to be 
supervised in order to make sure the drug has been swallowed adequately 
and to avoid that other prisoners are blackmailing patients in methadone pro-
grammes to sell or provide their portion and finally to avoid overdoses from 
prisoners with no opiate tolerance. While this consensus counts for metha-
done, it is not the case regarding buprenorphine, where there is no risk of 
overdosing. Like in French prisons, the medication can be given to the pris-
oners for 3 days. As there is no risk of overdose with buprenorphine, it is 
argued that handing out the medication is part of a process initiating or sup-
porting the responsibility of the patient, which he/she has to achieve when 
leaving prison. Also the goal of avoiding any involvement in the traffic of 
other illegal (injectable) drugs is put high on the priority list: 
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“If everything is ok, then the prisoner can get medication for up to 3 days. 
Everyone who wants substitution treatment will get it, so then there is not 
reason for them to get it in illicit trading. Of course, there will always be 
people who are trying to sell things, and this is something we will not solve 
unless we solve the problem of poverty…Now we have Subutex substitution 
treatment, and we have to see to it that we take care of those patients who are 
problematic, who try to hide the pills and not swallow them. The nurse has to 
be alerted to these patients and monitor the situation so that she can be quite 
sure that the drug is gone.” (French speaker in Prague.) 
It has been said that the accurate supervision of intake of buprenorphine, 
which takes ten minutes before it dissolves on the tongue, requires quite 
some time, and the prisoner is monitored and observed by the nurse. If the 
number of inmates receiving buprenorphine is high, the administration of in 
a safe environment would need very many health professionals. So it be-
comes a policy of keeping the balance between prescribing the drug to those 
in need for it, within an environment which has scarce resources to control 
the whole procedure. Arrangements have to be organised in practice, as done 
in France, to give out the drug to reliable prisoners for several days. The 
danger remains that substitution drugs become part of the intra prison 
trafficking which then would discredit the whole programme. This has seri-
ous consequences for prison staff and everybody involved. 
The problem is described by a doctor responsible for health care in prison: 
“I have 4,500 prisoners and we would need 19 nurses taking into account 
40 per cent of drug users among the prison population. It was immediately 
clear to us. This would mean that you would not be able to launch substitu-
tion programs, or we would be able to distinguish between problematic and 
less problematic patients, so that problematic patients would be required to 
come to the surgery and get supervised intake so that 85 per cent of patients, 
and I’m speaking of methadone, which is administered by a nurse everyday 
including weekends, I’m talking about Subutex. Today we have 600 patients 
on Subutex and the vast majority of them get it in their cell once a day or 
twice per week. Then they get their supply of Subutex to last for two or three 
days. And if they can’t cope themselves, they will tell us. This is also part of 
the care for prisoners before they’re released so we can observe their needs 
and deal with them. I think it’s better than to absolutely supervise everything 
that’s going on because that rid them of responsibility.” 
 465 
 
Substitution treatment in prison as part of a broader local,  
regional and national strategy 
The study showed that substitution treatment in prison could only be under-
stood within the context of a national strategy regulating treatment modali-
ties and local/regional structures, implementing concrete treatment modali-
ties. One consensus found in most countries is that those being in substitu-
tion treatment in the community should be able to continue while in prison 
(see also WHO recommendation 1993). This indicates that the scope of sub-
stitution in prison (the number of places) is closely linked with community 
capacities (to re-integrate drug users in substitution programmes after 
release, e.g. Ireland). This means that substitution treatment as a whole could 
not be started within a country from the prison first, when structures are not 
to be found in the community, and even high threshold structures outside 
(e.g. Sweden and Poland), which are difficult to access coming for patients 
leaving prisons make it very difficult to start or continue substitution treat-
ment in prison. 
So, improvement of substitution treatment in prison in some countries also 
needs an improvement of equivalent structures in the community and even 
on a national level. Vice versa there are some countries where despite the 
fact that substitution treatment in the community is widespread, legal regula-
tions are facilitating substitution treatment (e.g. some states in Germany), 
this treatment in prisons is poor and confined to single cases (Keppler, Knorr 
& Stöver, 2004).Here efforts are needed both from the community and the 
prison service to harmonize treatment strategies in order to avoid treatment 
interruptions, yo-yo-effects (see above), complaints of the prisoners or 
transports to other regions and prisons when some prison doctors refuse to 
prescribe. 
Medical services of remand prisons, arrest houses, police arrest do play a 
central role in the process of interlinking community and sentenced prison’s 
policy and practice. They are often closely communicating and co-operating 
with community services, and their diagnosis and prescription policy is often 
decisive for the further treatment if remand prisoners are sentenced. 
Finally, international questions have to be raised when it comes to foreigners 
who are drug dependent, are receiving substitution treatment and are sup-
posed to be transferred to their home country where substitution treatment is 
not available. The same accounts for foreign prisoners with no health insur-
ance. 
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Lack of information and comprehension of drug dependence and 
substitution treatment 
Many doctors in our study expressed that more information is needed on the 
nature of drug dependence and the potential of substitution treatment. The 
practice of this treatment confirms that there are severe misunderstandings 
which may result in inadequate practice. Both the substitution treatment and 
the nature and dynamics of addiction require a long-term response. 
“It’s more difficult to talk to the prisoners,  
sometimes you have to change your mind”  
(Dr. Knud Christensen, chief medical doctor at Vaestre Faengsel, 
Copenhagen, Denmark) 
Acknowledgement and integration of prisoner’s experiences and 
expertise  
“Official reports scrutinising the needs of prisoners draw information from 
many sources, but the opinion of the prisoner is seldom sought.” Luke Bir-
mingham (1997) formulated this in his article “Should prisoners have a say 
in prison health care?” He stresses the valuable contribution of the patients to 
the quality improvement of health care in general: “Policies which are 
implemented without taking these views into consideration are one sided and 
are unlikely to be effective” (p.1). This was one of the reasons why in this 
study prisoner’s views have been given space to formulate their needs and 
perception regarding substitution treatment. Most prisoners have previous, 
personal experience of prison health care, substitution treatment inside 
prison and in the community (either detoxification or maintenance). They are 
able and willing to make substantial and valuable comments on the health 
care and service delivery. The prisoners interviewed also acknowledged 
improvements regarding substitution treatment over time. Their treatment 
needs regarding the choice of the substitution drug (e.g. received in the 
community), dosage, confidentiality, psycho-social support, detoxification 
steps, maintenance modalities regarding organization of substance delivery 
etc. could contribute substantially to the improvement of this form of treat-
ment. Moreover, prisoners in some focus groups said that they had not 
received sufficient help during detoxification and in some cases no services 
were provided. 
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We are used to integrating patient’s views, needs, even judgements to a high 
extent within the community in order to improve treatment, organization and 
to save costs. Inside prison, within prison health care, the value of patients 
integration is often underestimated, coincidentally but not systematically, or 
even excluded. 
“But many prisoners do have concerns which are valid, expectations that are 
realistic, and suggestions that if listened to could help resolve at least some 
of the problems that hamper the delivery of health care in prisons.” 
(Birmingham, p. 1) 
One of the reasons for the sometimes rigid doctor-patient-relationship may 
be the patronizing character of this relation: “It shows not only with the 
doctor, but also with the rest of the prison staff. We look at the prisoner as 
the bad guy saying, “You don’t know anything, we will tell you what you 
should do you, and I know better how you should be treated.” It was coming 
to little discussion, because in many cases, it’s the prisoner who knows bet-
ter, about substitution and how he was treated before and how he was feel-
ing with this dosage of methadone, and not a doctor who has no experience. 
In the beginning, they were not willing to accept that the patient has a much 
better expertise, and I think you should accept that the patient who is a drug 
user knows much better than you. This is very difficult to accept by many 
doctors.” 
Lack of confidentiality and prisoner’s rights 
Andrej Kastelic (2004) pointed to the ethical issues when working with pris-
oners “… such as the right to privacy, not letting everyone in the prison 
know that someone is using methadone, or for the privileges, like leaving 
prison for visits, or early release from the prison. This is the reason that 
many prisoners don’t want to accept substitution treatment, because they 
don’t feel they have rights. They should consider users involvement or 
prisoners’ involvement in policymaking, and something about informed 
consent. Every patient should know before getting any sort of treatment what 
is the primary physicians obligation to the state, to the prison, or to the 
prisoner. I hope that this can be a reality very soon.” 
Prison is a different setting than an outside addiction clinic and therefore cir-
cumstances have to be approximated to the ideal situation. This applies to the 
dispensing situation in prison when it comes to the point that for certain pris-
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oners, who for security reasons cannot be sent to rooms in the medical unit, 
substitution therapy has to be administered to them somehow, taking into 
account both their privacy, but also security and safety. 
Jan Palmer (2004) emphasized the necessity to build structures which guar-
antee confidentiality in order to protect inmates being dependent: “Because 
as long as we have this kind of stigmatisation, we have to protect inmates 
from being dependant, and would be prepared to do something about it and 
come forward to treatment. What they need is absolute confidentiality. They 
have an enormous anxiety for coming out. You have mentioned that, and we 
have exactly the same experience. They do not want to come out, even if they 
know the risks because the supreme interest is to avoid conflict with other 
inmates, and as long as they have to fear conflict with other inmates, they 
will not come out.” 
Auke van der Heide (2004) pointed out that in The Netherlands, inmates can 
complain about their medical treatment, and many of these complaints are 
regarding methadone treatment: “When they do that, they send a letter to us, 
and we try to mediate. Mostly, the result is that the patient and the doctor 
are satisfied. This way, the patient has an influence on the treatment. They 
use this possibility very intensively. Last year, we had almost 700 com-
plaints, and I think that about 50 of these complaints dealt with t he metha-
done treatment.” 
From the Uk it has been reported by Michael Farrell (2004) that a legal 
action group is fighting for inmates rights: “… in the UK … there’s a legal 
action group of people who’ve been in prison, after coming out for failure of 
duty to care, sort of not receiving proper withdrawal treatment. It’s interest-
ing that it is one way to get the system to move. Practitioners who previously 
weren’t prepared to take onboard policy directives now see themselves as 
potentially vulnerable by having legal action brought against them.” 
In many other countries possibilities do exist for prisoners to go to criminal 
court and to bring forward complains about wrong or insufficient therapy. 
However, this is a long lasting procedure and often it is not clear if prisoners 
are still in prison and could benefit from positive court decisions. So there is 
no user-friendly complaints procedure in place in prison in many countries, 
which also accounts for drug treatment services in the community (although 
there is a choice for the patient). Prisoners fear they would be victimised in 
one way or another. 
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Substitution treatment in prisons in Central and Eastern Europe 
As Morag MacDonald (2004) pointed out in her study of existing drug ser-
vices and strategies operating in prisons in ten countries from Central and 
Eastern Europe, substitution treatment was only available in Slovenia and in 
Poland. In the other eight sample countries substitution treatment was not 
available in prison, but detoxification was available in most of the countries, 
either at a Prison Hospital or provided by an external organization. Much 
debate is going on regarding that issue (see MacDonald 2004, 68ff). The 
implementation of substitution treatment in prison as it was done in Poland 
and Slovenia could serve as Good Practice as it has been done carefully 
including visits to other countries, training of the staff and doctors and in 
close co-operation and communication with community agencies and with 
accordance and support of key persons from the Ministry of Justice. 
The specific situation and requirements of prisons to introduce substitution 
treatment is described by Uchtenhagen (2004): “I think it’s very different if 
in a given prison, you want to introduce substitution treatment newly, where 
you didn’t have it before. I think that from the situation of a prison where 
methadone has been available and the practice of working with methadone is 
well known. So, a multitude or plurality of substances makes sense where 
there is already some experience. Whereas it is not advisable to introduce a 
range of new substances where there is no experience. I think there the 
methadone is the substance to start with.” 
Establishing good clinical practice 
Ambros Uchtenhagen (2004) expressed the need of establishing good clini-
cal practice in prisons, which is shared over the boarder. There are several 
good practice models (e.g. Palmer 2004) which may serve as good examples 
of how to design protocols of good clinical practice, containing descriptions 
of problems and suggestions to best solve them. These manuals are to be 
specified both to national, regional particularities and to target specific needs 
(e.g. women). 
Good clinical protocols and standards are one thing, it’s a different thing to 
accomplish them. As it was stated during the conference in Prague, the 
therapeutic freedom of the doctors has to be acknowledged but at the same 
time a communication about standards and policies derived from evidence-
based approaches should be communicated with doctors. This is often split: 
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The standards and protocols in the Ministries and the everyday prescription 
(or non-prescription) policy in practice. 
Facing the heterogeneity of substitution treatment identified during this 
research project not only in Europe, or on national, but also on a regional and 
local, standards and protocols of good clinical practice are necessary in order 
to standardize treatment conditions. 
Lack of data on substitution treatment in European prisons 
In many countries prison health care is not monitored properly, so that only 
rough estimations on scope and quality of substitution treatment are avail-
able. The EMCDDA is currently conducting an inventory project with the 15 
EU member states (Western countries) and Norway collecting figures on 
health care services in prison. 
For an improvement of substitution treatment in prisons more evaluation on 
patients needs, service provision and connection with community services 
has to be carried out. 
Training of doctors and medical staff 
“Also, prisoners have the right to receive state of the art medical care” (B. 
Spitzer 2004). This statement is a plea for (vocational) training for all 
involved in he substitution treatment. The manifold developments in the field 
of addiction medicine, psycho-social support need to be transferred to the 
medical and psycho-social services in prisons. Not only the introduction of 
‘new’ substitution drugs (e.g. buprenorphine), but also topics as the nature of 
addiction, comorbidity?, interactions with other drugs, have to be discussed 
permanently. Also the attitude of staff and heir relationship towards prison-
ers in substitution treatment has to be discussed in these vocational trainings. 
Manuela dos Santos Pardal (2004) emphasises, at least for the situation in 
Portugal, that she feels a lack of medical rules and training of health profes-
sionals in prisons, and a lack of specific information about substitution 
treatment. “If they know how important it was, they would understand why 
the treatment must be improved. Prison administrators and prison systems 
use all the arguments in order not to change routines. A methadone program 
is one thing more that disturbs the system. If prisoners would be really in-
formed about substitution treatment, about the importance for their health 
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and every thing that is about the treatment, I think that more and more pris-
oners would ask for this treatment.” 
As pointed out by Michel (2004) in their study on substitution treatment in 
French prisons, the vast majority of doctors interviewed prescribing substi-
tution drugs have not been educated in the area of drug addiction. Most of 
them were learning as they went along. In some countries a special training 
before employment as a doctor in prison is envisaged (The Netherlands), in 
some other countries (e.g. Germany, Keppler, 2004) a special training for 
doctors on addiction medicine is required (in the community and in the 
prison) before the start of substitution treatment. Michel (2004) stated on the 
background of their studies that “Doctors who work in prisons in contrast to 
community doctors have not chosen this program on purpose. Outside prison 
work, doctors started to proactively prescribe substitution therapy while 
prison doctors very often felt that substitution therapy was something that 
was imposed on them, that they were forced to do it.” 
Especially in those countries starting a new substitution programme informa-
tion and education on all aspects of this treatment is needed. 
Further research questions 
Regarding inconsistencies between the prison and the community, should 
healthcare in the prison be provided by community-based services?  
Prison is a supremely hierarchical organization - how do doctors get appro-
priate support from the top level? 
What is the need and what are the requirements for psycho-social care within 
the substitution treatment? 
Is there a need for clients’ satisfaction with substitution treatment services 
and a need for guidelines regarding prescription and concrete organization of 
dispensing etc.? 
How can the quality of treatment and development of integration with other 
services from the community be developed? 
What role, if any, do professional standards play (best practice models of 
substitution treatment) and ethical codes (for instance “United Nation’s 
Declaration ion the principles of Medical Ethics” or the “World Medical 
Association’s Declaration of Tokyo!” in the everyday practice and what 
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impact do they have for doctors and medical officers working in prisons who 
face difficult ethical decisions daily, also with regard to substitution treat-
ment (Reed and Lyne 1997). 
  
B Recommendations 
Introduction 
This study has shown the heterogeneity in how prison health care in general 
and substitution treatment for opiate dependent prisoners in particular are 
organised in Europe. This reflects the historical, cultural, social, economic 
and political differences to be found throughout Europe and even in one 
country. We found a diversity of settings and environments in which prison 
health care is provided and in which substitution treatment is either provided 
or at least discussed: in well-funded and severely under-funded prison sys-
tems, civilian and military prison systems, in institutions with drastically dif-
ferent physical arrangements for the housing of prisoners, in overcrowded 
systems, in men’s, women’s and juvenile’s institutions, and in prisons of all 
security classifications and all sizes. Sometimes substitution treatments are 
being operated as individual pilot projects, or as routinely part of health care 
and as an integrated component of overall prison health care policy and 
practice. 
In this background, it is not appropriate to make recommendations that are 
supposed to be suitable for all the different prison settings. Instead, we are 
providing recommendations that have already been made by international 
bodies, experts and guidance and suggestions for good clinical practice of 
substitution treatment in prisons. Recommendations have already been for-
mulated by the European Network on Drugs and HIV/AIDS in Prisons. The 
Network brought together expertise on various matters and also on how to 
manage best substitution treatment for opiate users in prisons. In the annual 
Conferences in Oldenburg (1998), Rome (2003) and Prague (2004) experts 
from various levels have been working on improvement of this treatment 
form in prisons and links with service providers in the community. So far, 
we are introducing the results of this work first, and then building them up 
further, taking into consideration the results of our own research. 
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1 Recommendations of international bodies 
The European Council recommendation (of 18 June 2003) on the prevention 
and reduction of health-related harm associated with drug dependence 
(2003/488/EC) recommends to its Member States that they should: 
… 
“6. provide, in accordance with the individual needs of the drug abuser, 
drug-free treatment as well as appropriate substitution treatment supported 
by adequate psycho-social care and rehabilitation taking into account the fact 
that a wide variety of different treatment options should be provided for the 
drug-abuser; 
7. establish measures to prevent diversion of substitution substances while 
ensuring appropriate access to treatment; 
8. consider making available to drug abusers in prison access to services 
similar to those provided to drug abusers not in prison, in a way that does not 
compromise the continuous and overall efforts of keeping drugs out of 
prison;” 
The World Health Organization (WHO), Regional Office Europe (2003) in 
its Moscow Declaration on “Prison Health as part of Public Health” recom-
mends to member Governments “… to develop close working links between 
the Ministry of Health and the ministry responsible for the penitentiary sys-
tem so as to ensure high standards of treatment for detainees, protection for 
personnel, joint training of professionals in modern standards of disease 
control, high levels of professionalism amongst penitentiary medical person-
nel, continuity of treatment between the penitentiary and outside society, and 
unification of statistics.” 
2 The “Oldenburg Recommendations” 
The ‘Prison and Drugs 1998 Conference’ in Oldenburg/Germany (European 
Network of Drug and HIV/AIDS Services in Prison/ENDSP, 12-14th March 
1998) gathered together 109 people to discuss prison drug services and to 
make recommendations on them. These participants included senior officials 
from prison administrations, prison doctors, prison officers, managers and 
staff of non-governmental organisations, probation officers, social workers 
and representatives of drug user organisations. They came from twelve 
member states of the European Union and three other countries. Recommen-
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dations were drawn up in workshops on topics like ‘harm reduction’, ‘drug-
free treatment’, ‘needle exchange’, ‘peer support’ and ‘substitution treat-
ment’ in prison. The recommendations regarding the latter are presented in 
the following: 
1. Substitution treatment includes both detoxification and maintenance. 
2. Substitution treatment offers an opportunity to regularly engage with the 
prisoner, but it is not the whole, or the only solution to drug problems. 
3. Although substitution is best used as one component of a comprehensive 
treatment regimen that includes psycho-social support, it may, by itself, 
provide prisoners with a period of stability that can help them to improve 
physical and mental health and social circumstances. 
4. Individuals on maintenance in the community must have the option to 
continue to be maintained on entry to prison, and those receiving substi-
tution treatment in prison must be able to continue with such treatment 
on release. Decisions on the continuity of treatment should be taken into 
consultation with the treatment programme in which the prisoner parti-
cipates outside prison. 
5. A clear treatment contract must be drawn up between the prisoner and 
the programme. 
6. A thorough, structured, ongoing assessment, leading to a cohesive treat-
ment plan is necessary. 
7. Adequate human resources and facilities for substitution treatment must 
be provided. 
3 From general recommendations to concrete policy and practice 
of substitution treatment in prison 
In Rome (2003) during the conference “'The reduction of negative health and 
social consequences of drug use in prison', (ENDSP, Rome, 22-24 May 
2003) a workshop has been organised entitled: “What is the role and value of 
substitution treatment in the process?” Several experts from several countries 
were presenting results of their studies and experiences and discussing the 
above mentioned Oldenburg recommendations. All present agreed that the 
recommendations from the 1998 ENDSPs are very good for the period and 
that they contribute to the overall goal of improving access to and continuity 
of substitution treatment. They are a baseline containing general and some 
particular recommendations on possibilities and limits of substitution treat-
ment. It became clear that once goals are formulated and agreed upon ener-
476 
 
gies have to be concentrated on the initiation and organisation, that means 
policy of substitution treatment in prison (from the introduction, circumstan-
ces, requirements regarding doctor’s and staff’s training, political and legal 
suppositions) to the clinical management of substitution treatment in the pri-
son setting. Clinical management focuses on all aspects of how substitution 
treatment (together with other pharmaco therapies) should be organised in 
practice (e.g. confidentiality, supervision of intake, urine tests, home leave, 
dosage increasing and reduction etc.).  
Good policy and practice of substitution treatment have been described for 
countries and community settings (like consensus conferences, guidelines, 
regulations; Henry-Edwards et al. 2003). Moreover European expertise has 
been brought together (e.g. the work of “Euromethwork”, see Verster/ 
Buning 2003; EMCDDA 2000, or Pompidou Group 2004). These guidelines 
can not simply be transferred to the prison setting, but need to take into 
account the specific prison conditions. Different treatment settings necessi-
tate different treatment options. The problems arising in prison are different 
to those outside in the community and require a flexible response: for 
instance admissions with multiple drug use arriving late the day and in high 
numbers require sufficient support and clear guidelines to guarantee a stan-
dard regime (see Palmer 2003, 5). 
Nevertheless, several attempts have already been made to elaborate guideli-
nes for good clinical practice in prison. Some of this work will be presented 
in the following. Keeping in mind the heterogeneity outlined above, these 
guidelines are not able to be generalized to all prison systems. So, basically, 
the introduction and organisation of prison-based substitution treatment 
reflects to a certain extent the way substitution treatment is organised and 
run in the specific country and/or community. 
During the Rome conference some points of the Oldenburg recommenda-
tions regarding substitution treatment were said to be elaborated: 
− It was felt that there needed to be a differentiation between different types 
of substitution (low and high threshold) and substitution drugs. 
− Protocols/guidelines for good clinical practice/management needs to be 
set up with the following objectives: 
− Bring about consistency in the management of inmates who are on a sub-
stitution programme when admitted to or released from prison; and 
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− Ensure that the provision of substitution drugs to inmates is managed 
safely and securely. 
− The term and requirement of a ‘contract’ should be defined and adapted to 
routines and practice in the community. 
− It was agreed that some information needed to be added in relation to an 
agreement for having treatment. There were also some issues raised 
around the guidelines given to patients about drugs that they would be 
given in terms of poly drug use and alcohol use. 
− Informed consent should be received from the patient and agreement 
which indicates rules and also dangers of certain types of behaviours. 
− Regarding Point 7 of the recommendations, suggestions have been made 
to implement multidisciplinary teams in place to support treatment. Multi 
disciplinary teams can contribute to the decision about continuing, starting 
or ending a substitution treatment for which the doctor always has ulti-
mate responsibility. With regard to the introduction of substitution treat-
ment in a given prison system, multi disciplinary teams should not be seen 
as an inevitable prerequisite or else substitution treatment could become 
too expensive. 
− Participants agreed to instigate that the physical, social, psychological 
needs of patients are met. There is a need to stress a comprehensive and 
cohesive approach to treatment. 
− Participants agreed that specific trainings for doctors in addiction medi-
cine are a valuable contribution to an improvement of the quality of sub-
stitution treatment in prisons 
4 Guidelines and protocols for clinical management and treatment 
of substance use 
The WHO/UNODC/UNAIDS position paper on “Substitution maintenance 
therapy in the management of opioids dependence and HIV/AIDS prevention 
(2004, 28) points out that “substitution therapy for opioid dependence must 
be subject to principles of good medical practice. Evidence-based guidelines 
are in place in many countries, and need to be elaborated where they are not. 
Such guidelines should include criteria to define who are considered eligible 
for substitution therapy, as well as contraindications, and should outline best 
practices in clinical management, as well as relevant government regulations. 
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Efforts should be made to ensure that guidelines are widely disseminated and 
programmes for monitoring treatment quality and outcomes are put in 
place.” 
However, most of general guidelines and recommendations do not contain a 
view on the specific conditions for substitution treatment in penitentiary 
institutions. In a general way, it is then stated that drug users in hospital, pri-
sons and on holidays need specific requirements (see Verster 2000). Only a 
few guidelines are targeted at the prison setting and describe in detail service 
provisions either specifically on substitution programmes, (like methadone 
treatment – programme guidelines for the Irish prison Service) or within a 
broader drug service and control strategy approach (e.g. “Strategy for intoxi-
cant abuse of the Finnish prison administration” etc.) for the respective 
country. 
In the following, some guidelines are presented which do have an important 
impact on prison-based substitution treatment or are already directed to the 
prison setting. 
Jan Palmer (2003) raises the issue of a gender specific view in the clinical 
management and of substance use and treatment needs when they are admit-
ted to prisons. She is setting up minimum clinical standards of care for 
women drug users entering prisons (for England and Wales). The standard 
regimes ensure that every prisoner receives at least a minimum baseline of 
care. Furthermore, she describes the process of continuous quality improve-
ment including induction process of nursing and medical staff, training and 
ongoing ‘professional’ nursing supervision. 
The United Kingdom (Department of Health 1999) published guidelines for 
maintenance treatment. One striking point is the outline of the model of 
‘shared care’, which means that the goals of substitution treatment (to help 
the patient to become or remain healthy) can only be achieved by a co-
operation of medical practitioners and other professionals. This is a form of 
best practice encountered in this study in several prison settings. 
The consensus statement of US-American “The National Institutes of 
Health” (NIH) explicitly stated that abstinence is not the most important goal 
of treatment. Moreover it states “Continuity of treatment is crucial – patients 
who are treated for fewer than 3 months generally show little or no 
improvement, and most, if not all, patients require continuous treatment over 
a period of years and perhaps for life. (NIH Consensus Statement 1997). 
Both the guidelines of the American Psychiatric Association (1995) and the 
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National Institutes on Drug Abuse (NIDA 1999) are supporting this view. 
They recommend a minimum treatment time of 12 months and even repeti-
tive treatment efforts. 
Other countries have elaborated quite detailed recommendations for clinical 
practice of substitution treatment (amongst others prescribing guidelines in 
UK, Germany and Belgium1). 
In Switzerland, for instance, a national substitution conference (NASUKO 
2001) has been held in order to improve the process of quality assurance. 
Some key issues have been named: 
− Dosage and treatment plan should be stronger and adapted to the individ-
ual needs. 
− Opiate dependent persons often show psychiatric diagnoses. This should 
taken into consideration more when developing new treatment modules. 
− Everyone prescribing substitutions means should ensure that the patient 
gets access to additional therapy and counselling facilities. 
The need to train practitioners on addiction medicine has been included in 
many guidelines. Training on the nature of dependency and pharmacother-
apy should be offered to all those involved in substitution treatment in order 
to assure the quality of this therapy: medical practitioners, alcohol and drug 
counsellors working with clients of substitution maintenance treatment pro-
grammes; health practitioners associated with infectious disease program-
mes; and general health professionals who may come into contact with 
clients on these programmes (nurses, medical officers). 
As an additional strategy for the improvement of quality, on a local level, 
quality circles either among prison doctors/nurses involved in substitution 
treatment or with doctors/nurses in the community are considered to be a 
helpful and useful arena in which to discuss practice and to share experien-
ces. 
Finally, it has to be stressed that the contribution of the patients are valuable 
in order to improve the quality of health care in general and substitution 
treatment in particular. Most prisoners have previous, personal experience of 
prison health care, substitution treatment inside prison and in the community 
                                                          
1  For Central and Eastern European Countries see www.ceehrn.lt  
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(either detoxification or maintenance). They are able and willing to make 
substantial and valuable comments on the service delivery. 
  
C. Prevention and treatment of blood-borne-viruses 
(HIV and Hepatitis) within Substitution Treatment  
in Prisons 
Substitution treatment in prisons offers a great opportunity to integrate HIV-
/Hepatitis prevention and treatment strategies. Daily contact between drug 
treatment service deliverers (doctor, nurses, health/social worker) and 
patients is the supposition for a continuous personal confidential relationship 
– important prerequisites for HIV-and Hepatitis preventive interventions. 
Improving the awareness for HIV/AIDS and Hepatitis risks both of prisoners 
and staff is a strategy to support a change of attitude. Specific methods – 
outlined here – have been successfully applied within HIV/AIDS strategies 
throughout the world. Counselling, practical training aim at enabling patients 
to initiate and/ or maintain safer behaviour in drug consumption, sexual 
activities and procedures of skin penetration. Further more the delivery of 
preventive material as a prerequisite for a change of behaviour can support 
HIV-preventive strategies and can be conducted within the setting of a drug 
treatment (Stöver & Trautmann 2001). 
1 Improving risk awareness of participants  
(Target: Change of attitude) 
− Identifying risk behaviour and risk situations with regard to the transmis-
sion of BBV in the everyday life and connected to consumption patterns 
of clients. 
− Identifying target, gender and culture specific risk situations and behavi-
our. 
− Transfer of knowledge on the nature and character and transmission 
routes of BBV, via injectable drug use with shared syringes or equipment, 
unprotected sex and unhygienic skin penetration: piercings, tattoos, acu-
puncture. 
2 Improving risk awareness of staff (Target: Change of attitude) 
Improving risk awareness is not only a target for the work with prisoners, but 
for staff of drug treatment services and/or medical units as well. Staff should 
be informed on transmission routes, character and nature of BBV’s in order 
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to improve knowledge and to get familiar with the specific settings drug 
users are in. Especially the so called “hidden-risks” of drug use have to be 
identified (i.e. “Is there a protocol for PEP (post-exposure prophylaxis) 
available in prison?” 
3 Improving risk awareness of clients of substitution clinics 
(Change of attitude/behaviour): Methods 
− Training of drug users in short intervals with refresher courses. The train-
ing has to be conducted interactively, with role games, exercises, quiz etc. 
instead of a confrontative structure (Stichting mainline 1999). 
− Discussion about controversial and confidential topics, taboos (e.g. risk 
behaviour, topping up drugs while in substitution treatment) with prison-
ers either in group sessions or in single face-to-face communications. 
− Peer driven – interventions: peer-support; peer education are methods 
which integrate the expertise of the concerned drug users into the strate-
gies of HIV/AIDS and Hepatitis prevention. Both participation of the tar-
get group and the high value of the transported information from peers are 
part of important strategies in HIV-prevention. Key persons (peer leader) 
are educated and given support in order to disseminate information (e.g. 
on risk reduction) to the target group. 
− Gender specific approach: e.g. female social and health worker should be 
employed in order to identify and discuss risk situations for women. This 
improves the confidentiality of the relationship. 
− Campaigning my be a useful strategy to reach numerous people within a 
certain target group. 
− Working on specific projects with clients: leaflets, brochures, newspapers, 
broadcasting etc. in order to stimulate peer-driven information. 
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Appendices 
  
  
A. Interview Schedule for Prisoners 
1 Personal experiences 
− Is substitution treatment (ST) provided in this prison? 
− Do you receive methadone or any other ST in this prison?  
If so, are you satisfied with the way it is done?  
If not, what are the reasons? Do you agree with these reasons?  
Is there transparency in the provision of ST (e.g. concerning the decision 
of who gets it or not)? 
− Did you have any experience with ST prior to this treatment (in another 
prison)? What are the differences? 
− Have you received ST in the community? What are the differences? 
− Do you think ST in prisons is a controversial issue? Is it outside in the 
community? 
− What do you think the key topics are in this debate? Who are the key peo-
ple, stakeholders, associations? 
2 Treatment aspects 
− Treatment options for ST in prisons:  
What specific procedures of ST have you experienced? (Detoxification, 
maintenance, relapse prevention, substitution treatment starting in prisons, 
low threshold substitution treatment, bridging the time until start of ther-
apy?) 
− What substances are offered (methadone, LAAM, buprenorphine 
(Subutex), codeine)?   
What is the average dosage? Are there additional drugs prescribed (i.e. 
benzodiazepines?) Are you satisfied with the form of treatment (urine 
analysis, dosage, detoxification scheme)? 
State the advantages and disadvantages you have experienced with these 
drugs?  
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− Diagnosis and indication  
Who decides about the start of a ST in prison?  
What do you think, which criteria are relevant?   
− When ST from the community is continued, what is the practical proce-
dure?  
In which way is your doctor in the community involved/contacted? 
− Psychosocial care   
Is psycho-social care provided for patients in ST in prisons? Are you sat-
isfied with psycho-social care?  
If so, what kind of psychosocial care or assistance is on offer?  
Is psycho-social care provided on a voluntarily basis, is it compulsory? 
Who provides the psycho-social care? How is this connected with the 
medical part of the treatment?  
− Integration and links of ST to other drug treatment offered (abstinence-
oriented treatment, (psychotherapy)?  
Do you receive ST as a basis for other medical treatments (e.g. interferon/ 
HIV/ TB-therapy)? 
− Are there self-help and/or peer-support groups in prisons dealing with 
patients who are or have been in ST (i.e., after detoxification)? Do you 
have experiences in that? 
− Practical procedure  
Who provides the medicine (e.g. the methadone)?  
What is the concrete procedure (time, location)? 
− Access to ST  
What are the difficulties for prisoners in receiving ST? 
− Referral and release  
What happens to prisoners in substitution treatment who are transferred to 
other prisons, e.g., from remand prison to another type of institution? 
How is ST continued after release? 
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3 Institutional aspects 
− What are the problematic areas of ST in prison? (e.g. adjustment of dos-
age, anonymity, confidentiality, daily practical problems, information 
policy, perception of procedure of substitution treatment, topping up 
drugs, system of less transparency for the patient, etc.) 
− What is the general perception of ST by the personnel in this prison? (As 
a means of detoxification, abstinence-orientation, gratification for well-
being/ good behaviour, or maintenance)? 
− What impact does participation in ST have on release or on the sentence 
(home leave etc.)? 
  
B. Interview Schedule for Professionals 
1 General situation of substitution treatment (ST) 
1.1 Historical, legal and political aspects of substitution treatment 
(ST) in prisons 
− Is substitution provided in this prison? (If yes, what type of substitution 
treatment?) 
− What is the history, development of ST in prisons in your country/region/ 
city and in your prison?   
When was ST introduced in the prison setting?  
What were the different stages in the progress of ST? 
− What is the legal framework for ST in prisons   
(Legal situation, laws and regulations, guidelines, health care standards, 
recommendations)  
Which laws and regulations are relevant? Who was developing them? 
Please describe the development of ST.  
− Provision of health care  
Who provides health care in prisons in your country?  
− Financial matters  
Who finances ST in prisons? Are financial aspects relevant for initiating 
or ending a ST? Is data available concerning costs per patient in ST? 
− What are the professional and/or political reasons for (not) implementing ST? 
− Is ST (still) a controversial issue of drug services in prisons (and partly 
outside as well)? What are the key topics in that debate? Who were the 
key people, stakeholder, associations (see above)? 
1.2 Recommendations, Standards, Best practice 
− Did you develop guidelines or “Best Practice” models for ST in prisons? 
(i.e. health care standards?) 
− If there are standards on ST, are they applied? If not, what are the rea-
sons? Is there any activity to facilitate the application of standards? 
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− Is the ST certified? 
2 Practical procedures 
2.1 Treatment aspects 
− What are the general aims of ST in prisons?  
(Health stabilisation, prevention of infectious diseases etc.)  
− Treatment options for ST in prisons 
What are the specific treatment options (Detoxification, maintenance, 
relapse prevention, substitution treatment starting in prisons, low 
threshold substitution treatment, bridging the time until start of ther-
apy?) 
Do you have/follow a particular concept for the ST? 
− Diagnosis and indication  
Who decides about the start of a ST in prison? Which criteria are rele-
vant? Which other professionals/organisations are involved?  
When ST from the community is continued: What is the practical proce-
dure? In which way are doctors in the community involved/contacted? 
− Which substances are applied (methadone, LAAM, buprenorphine 
(Subutex), codeine?) What are the experiences of advantages/disadvan-
tages with which drugs? What is the average dosage? Are there additional 
drugs prescribed (i.e. benzodiazepines?) 
− Medical and pharmacological aspects   
Is there a special scheme for urine analysis, dosage, detoxification scheme 
etc.? Who gives out the methadone (profession, qualification), what is the 
concrete procedure (time, location)? 
− Legal aspects  
Is there a contract between doctors and patients? 
− Psychosocial care  
Is psycho-social care provided for patients in ST in prisons? If so, what 
kind of psychosocial care or assistance (concepts)?   
Is psycho-social care an offer that can be taken voluntarily or is it obliga-
tory? Who provides the psycho-social care?  
How is this connected with the medical part of the treatment?  
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− Integration and links of ST to other treatment offers (abstinence-ori-
ented treatment, (psycho-therapy)?  
Is ST seen as a basis for other medical treatments (i.e. interferon/HIV/ TB 
–therapy) 
What is the value of ST in prisons for other drug services? Are they linked 
and are they part of a whole strategy of drug services (which one)? 
− Involvement of outside agencies in ST  
Are external social/psychological support groups or professionals in-
volved in the ST? What are the professional links between outside/inside? 
How is the cooperation/communication working? 
− Are there self-help and/or peer-support groups in prisons dealing with 
patients who are or have been in ST (i.e after detoxification)?  
2.2 Organisational aspects 
− Scope of ST inside prisons  
Is ST in prison only partly available (in your prison?) or covering a whole 
region/city or state/country?  
How many prisoners are in ST? What is the development?  
Is the number of places for ST limited? If so, for what reasons? 
− Access to and provision of ST  
What are the difficulties for prisoners to receive ST?   
What are the difficulties with providing ST? 
− Referral and release  
What happens to prisoners in ST, who are referred to other prisons? 
Transfer from remand prison to other type of institution?   
How is ST continued after release? 
− Quality of substitution treatment  
Are there concrete protocols of how to organise ST on a day-to-day basis? 
Is the procedure certified? 
− Evaluation  
Has ST been evaluated? Is there any evaluation report available?   
From your personal experience: do you perceive ST being as a successful 
tool? 
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2.3 Institutional aspects 
− What is the general perception of ST by the personnel in (your) prison(s) 
…  
as a mean of detoxification, abstinence-orientation, gratification for well-
being/ good-behaviour, maintenance? 
− What are the problematic areas of ST in prison? (e.g. adjustment of dos-
age, anonymity, confidentiality, daily practical problems, information 
policy, perception of procedure of substitution treatment, topping up 
drugs, less transparency for the patient, etc.) 
− What impact does the participation in ST have on release or on the sen-
tence (home leave etc.)? 
− Is training on ST for medical staff provided? 
  
C. Research Protocol and ethical issuses 
My name is Laetitia/Heino … I am a researcher. I am conducting a research 
on ‘Substitution Treatment in European Prisons’ funded by the European 
Commission (Directorate General of Health) in 18 countries (the 15 EU 
Member States, Poland, Czech Republic and Slovenia). 
This study is an overview study that aims to explore substitution treatments 
offered in prisons. This is not an evaluation, nor a comparative study, but 
rather an exploration (or snapshot study) into the procedure of the provision 
of substitution treatment in prisons. 
The importance of this report is that we aim to: 
− Elaborate an inventory of the substitution policy and practice in prisons – 
making the whole situation clearer and more transparent, 
− Point out issues related to the cessation or continuation of Substitution 
Treatment from the community into the prison setting and between differ-
ent prisons 
− Initialise an exchange of information of medical doctors and health care 
workers in charge of prison health care services 
− Identify ‘good practises’ of Substitution Treatment in prisons and make 
recommendations 
In each country providing substitution treatment in prisons, I will visit at 
least 2 prisons and will conduct interviews (one-to-one and in a group) with 
prison staff, prisoners, professionals working in the community, and minis-
tries.  
I will use a list of open-ended questions (no questionnaires to be completed) 
to gain more in-depth insight from your experiences. 
All of the information I get will then be analysed and presented in a report to 
the European Commission in the summer 2004. Findings and recommenda-
tions from the report will then be disseminated to relevant stakeholders 
across Europe. The report will also be presented at the “7th European Confe-
rence on Drug related Services in Prison” in Prague in April 2004. 
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Consent and Confidentiality Statement 
Have you heard and understood the ‘Explanation Sheet’ that describes the 
nature and purpose of the study? Is there anything you did not understand or 
want to have clarified? 
Participation in this study is anonymous. No names will be taken.  
All participants will have their anonymity assured and confidentiality main-
tained unless information shared with the researcher indicates a risk to the 
self or others. 
Participation in this study is voluntary – you do not have to take part and you 
have the right to withdraw from any stage of the study at any time.  
Your participation in the study will involve taking part in an interview (indi-
vidually or in group) with the researcher. Interviews and focus groups will be 
tape-recorded – only if you agree to it – in order to aid the researchers’ abil-
ity to record information and to allow her to focus on the interview (instead 
of the note-taking). These tapes will be destroyed six months after publica-
tion of the final report. The researcher is the only person that will listen to 
taped-interviews (and, when applicable, read notes made during interviews). 
All information gathered will be stored in a safe and secure environment.  
Have you understood: the nature and purpose of the study, that information 
will be dealt with in confidence unless it poses a risk to the self or others, 
participation in the study is voluntary and that you have the right to withdraw 
from it at anytime? 
Do you give your consent to participate in the study 
  
D. Useful Websites 
Aids Foundation East West: 
http://afew.org/english/index.php 
American Association for the Treatment of Opioid Dependence (AATOD) : 
http://www.aatod.org/ 
amnesty international : 
http://www.amnesty.org/ 
Archive and Documentations Centre for Drug Literature: 
www.archido.de 
Council of Europe/Pompidou Group: 
http://www.coe.int/T/E/Social_cohesion/Pompidou_Group/ 
Cranstoun Drug Service: 
http://www.cranstoun.org/ 
Canadian HIV/AIDS Legal Network: 
www.aidslaw.ca 
Central and Eastern European Network of Drug Services in Prison: 
http://www.ceendsp.net/ 
Drug Scope:  
http://www.drugscope.org.uk/ 
EC/Drug Coordination: 
http://www.europa.eu.int/comm/justice_home/fsj/drugs/fsj_drugs_intro_en.h
tm 
EMCDDA/Publications/National Reports: 
http://www.emcdda.eu.int/ 
EuroMethwork:  
http://www.q4q.nl/methwork/home2.html 
European Institute for Crime Prevention and Control affiliated with the  
United Nations: 
http://www.heuni.fi 
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European Network for Drugs and Infections Prevention in Prisons: 
www.endipp.net and former www.ceendsp.net 
European Network for the Target Group of Mobile Drug Users: 
http://www.ac-company.org/ 
Harm Reduction Coalition:  
http://www.harmreduction.org/ 
The International Center for Advancement of Addiction Treatment:  
http://www.drugaddictionrx.com/ 
International Centre for Prison Studies: 
http://www.kcl.ac.uk/depsta/rel/icps/worldbrief/europe.html 
International Harm Reduction Development Program: 
http://www.soros.org/initiatives/ihrd/articles_publications 
International Harm Reduction Association: 
http://ihra.net/ 
Justice Health (New South Wales/Australia): 
www.justicehealth.nsw.gov.au 
The Methadone Alliance:  
http://www.m-alliance.org.uk/ 
Moscow Center for Prison Reform: 
http://www.prison.org 
New Drug Policy – Russia (in Russian): 
http://www.drugpolicy.ru 
UNAIDS:  
http://www.unaids.org/en/default.asp 
World Health Organization (WHO): 
http://www.who.int 
WHO/Regional Office for Europe:  
http://www.euro.who.int 
WHO/Health in Prisons Project: 
http://www.hipp-europe.org/ 
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